PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Alter, MJ				Alter, MJ			The birth of serological testing for hepatitis B virus infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AUSTRALIA-ANTIGEN				Alter, MJ (corresponding author), CTR DIS CONTROL, HEPATITIS BRANCH, DIV VIRAL & RICKETTSIAL DIS, NATL CTR INFECT DIS, MAILSTOP G37, ATLANTA, GA 30333 USA.							ALTER HJ, 1975, AM J MED SCI, V270, P329, DOI 10.1097/00000441-197509000-00014; BARKER L F, 1970, Journal of the American Medical Association, V211, P1509, DOI 10.1001/jama.211.9.1509; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; DANE DS, 1970, LANCET, V1, P695; GILES JP, 1969, NEW ENGL J MED, V281, P119, DOI 10.1056/NEJM196907172810302; GOCKE DJ, 1972, J AMER MED ASSOC, V219, P1165, DOI 10.1001/jama.219.9.1165; KRUGMAN S, 1967, J AMER MED ASSOC, V200, P365, DOI 10.1001/jama.200.5.365	7	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					845	846		10.1001/jama.276.10.845	http://dx.doi.org/10.1001/jama.276.10.845			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769598				2022-12-28	WOS:A1996VF21900038
J	Lowry, R; Kann, L; Collins, JL; Kolbe, LJ				Lowry, R; Kann, L; Collins, JL; Kolbe, LJ			The effect of socioeconomic status on chronic disease risk behaviors among US adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR-DISEASE; HEALTH PROMOTION; BLOOD-PRESSURE; UNITED-STATES; EDUCATION; SMOKING; CHILDHOOD; ADULTHOOD; CANCER; DISPARITIES	Objective.-To examine the relationship between socioeconomic status and risk behaviors for chronic disease among a nationally representative sample of adolescents in the United States. Design.-Household survey, the Youth Risk Behavior Survey supplement to the 1992 National Health Interview Survey. Setting.-United States. Participants.-Nationally representative sample of 6321 adolescents aged 12 to 17 years. Main Outcome Measures.-Standardized prevalence rates and logistic and multiple regression models were used to examine the effect of educational level of the responsible adult and family income on 5 risk behaviors for chronic disease among adolescents-cigarette smoking, sedentary lifestyle, insufficient consumption of fruits and vegetables, excessive consumption of foods high in fat, and episodic heavy drinking of alcohol. Results.-Most adolescents (63%) reported 2 or more of the 5 risk behaviors. Controlling for age, sex, race/ethnicity, and school enrollment status of adolescents, as the educational level of the responsible adult increased, cigarette smoking, sedentary lifestyle, and insufficient consumption of fruits and vegetables were less likely among adolescents. Among girls, but not boys, consumption of foods high in fat decreased as education of the responsible adult increased. As family income increased, adolescents were less likely to smoke cigarettes, less likely to be sedentary, and less likely to engage in episodic heavy drinking. Conclusion.-Among adolescents, risk behaviors for chronic disease are common and inversely related to socioeconomic status. Improved community- and school-based programs to prevent such behaviors among adolescents are needed, especially among socially and economically disadvantaged youth.			Lowry, R (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV ADOLESCENT & SCH HLTH,ATLANTA,GA 30341, USA.							ADAMS PF, 1992, VITAL HLTH STAT, V10; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; *AM CANC SOC, 1990, REP PLANN ADV COUNC; *AM MED ASS, 1994, AMA GUID AD PREV SER; BACHMAN JG, 1991, AM J PUBLIC HEALTH, V81, P372, DOI 10.2105/AJPH.81.3.372; BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551; BECKETT LA, 1992, AM J EPIDEMIOL, V135, P1166, DOI 10.1093/oxfordjournals.aje.a116217; BENSON V, 1994, VITAL HLTH STAT, V10; BUNKER JP, 1989, PATHWAYS HLTH ROLE S, P15; *CHILDR DEF FUND, 1994, STAT AM CHILDR YB 19; CLARKE WR, 1993, CRIT REV FOOD SCI, V33, P423, DOI 10.1080/10408399309527641; Cohen S, 1985, SOCIAL SUPPORT HLTH; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; FREEMAN H, 1991, J NATL CANCER I, V83, P526, DOI 10.1093/jnci/83.8.526; FUCHS VR, 1979, MILBANK FUND Q, V57, P153, DOI 10.2307/3349761; GOREY KM, 1994, J NATL MED ASSOC, V86, P209; IGRA V, 1993, JAMA-J AM MED ASSOC, V269, P1408, DOI 10.1001/jama.269.11.1408; JACOBSEN BK, 1988, AM J EPIDEMIOL, V127, P923, DOI 10.1093/oxfordjournals.aje.a114895; JOHNSTON LD, 1991, US DEP HHS PUBL; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KELDER SH, 1994, AM J PUBLIC HEALTH, V84, P1121, DOI 10.2105/AJPH.84.7.1121; KLEIN JD, 1992, J ADOLESCENT HEALTH, V13, P162, DOI 10.1016/1054-139X(92)90084-O; KOLBE LJ, 1993, PUBLIC HEALTH REP, V108, P2; LAU RR, 1990, J HEALTH SOC BEHAV, V31, P240, DOI 10.2307/2136890; LAUER RM, 1989, PEDIATRICS, V84, P633; LYTLE LA, 1995, HEALTH EDUC RES, V10, P133, DOI 10.1093/her/10.2.133; MCINTOSH H, 1995, J NATL CANCER I, V87, P564, DOI 10.1093/jnci/87.8.564; MILLAR WJ, 1986, CAN MED ASSOC J, V134, P127; MILLSTEIN SG, 1993, JAMA-J AM MED ASSOC, V269, P1413, DOI 10.1001/jama.269.11.1413; Nader P.R., 1988, HLTH BEHAV, P107; NELSON DE, 1995, AM J PUBLIC HEALTH, V85, P34, DOI 10.2105/AJPH.85.1.34; NEWACHECK PW, 1988, PEDIATRICS, V82, P462; NUTBEAM D, 1989, SOC SCI MED, V29, P317, DOI 10.1016/0277-9536(89)90280-3; PAPPAS G, 1994, AM J PUBLIC HEALTH, V84, P892, DOI 10.2105/AJPH.84.6.892; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PATTERSON TL, 1989, J PEDIATR PSYCHOL, V14, P277, DOI 10.1093/jpepsy/14.2.277; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; SERDULA MK, 1995, AM J PUBLIC HEALTH, V85, P236, DOI 10.2105/AJPH.85.2.236; SHAH BV, 1991, SUDAAN USERS MANUAL; TERRE L, 1990, PREV MED, V19, P134, DOI 10.1016/0091-7435(90)90015-C; *US C, 1991, OFF TECHN ASS PUBL; *US DEP HHS, PREV TOB US YOUNG PE; *US DEP HHS, 1991, US DEP HHS PUBL; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; 1994, MMWR-MORBID MORTAL W, V43, P1	47	259	265	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					792	797		10.1001/jama.276.10.792	http://dx.doi.org/10.1001/jama.276.10.792			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF219	8769588				2022-12-28	WOS:A1996VF21900025
J	Bry, L; Falk, PG; Midtvedt, T; Gordon, JI				Bry, L; Falk, PG; Midtvedt, T; Gordon, JI			A model of host-microbial interactions in an open mammalian ecosystem	SCIENCE			English	Article							GERM-FREE; DIFFERENTIATION; MOUSE; INTESTINE; ECOLOGY; MICE; GLYCOSYLATION; EPITHELIUM; BACTERIA; ADHESION	The maintenance and significance of the complex populations of microbes present in the mammalian intestine are poorly understood. Comparison of conventionally housed and germ-free NMRI mice revealed that production of fucosylated glycoconjugates and an alpha 1,2-fucosyltransferase messenger RNA in the small-intestinal epithelium requires the normal microflora. Colonization of germ-free mice with Bacteroides thetaiotadmicron, a component of this flora, restored the fucosylation program, whereas an isogenic strain carrying a transposon insertion that disrupts its ability to use L-fucose as a carbon source did not. Simplified models such as this should aid the study of open microbial ecosystems.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; KAROLINSKA INST, DEPT MED, S-17177 STOCKHOLM, SWEDEN; KAROLINSKA INST, LAB MED MICROBIAL ECOL, S-17177 STOCKHOLM, SWEDEN	Washington University (WUSTL); Karolinska Institutet; Karolinska Institutet				Bry, Lynn/0000-0002-8792-8527	NIDDK NIH HHS [DK30292, DK37960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037960, R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIOL MC, 1994, BIOCHIMIE, V14, P13; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FALK P, 1994, METHOD CELL BIOL, V45, P165; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GRANHOLM T, 1992, CYTOKINE, V4, P545, DOI 10.1016/1043-4666(92)90017-L; GUSTAFSSON BE, 1959, ANN NY ACAD SCI, V78, P17, DOI 10.1111/j.1749-6632.1959.tb53092.x; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; LENOIR D, 1995, BBA-BIOMEMBRANES, V1234, P29, DOI 10.1016/0005-2736(94)00254-M; MIDTVEDT T, 1986, MICROECOL THER, V16, P121; NORIN KE, 1985, ACTA PAEDIATR SCAND, V74, P207, DOI 10.1111/j.1651-2227.1985.tb10951.x; PUSZTAI A, 1995, GLYCOCONJUGATE J, V12, P22, DOI 10.1007/BF00731865; SALYERS AA, 1989, APPL ENVIRON MICROB, V55, P2572, DOI 10.1128/AEM.55.10.2572-2578.1989; SAVAGE DC, 1989, WENNER-GR C, V52, P3; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SHINDO K, 1976, Gastroenterologia Japonica, V11, P167; STARK PL, 1982, J MED MICROBIOL, V15, P189, DOI 10.1099/00222615-15-2-189; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; USHIJIMA T, 1983, MICROBIOL IMMUNOL, V27, P985, DOI 10.1111/j.1348-0421.1983.tb02929.x; VANDERWAAIJ D, 1989, ANNU REV MICROBIOL, V43, P69, DOI 10.1146/annurev.micro.43.1.69; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	25	458	505	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1380	1383		10.1126/science.273.5280.1380	http://dx.doi.org/10.1126/science.273.5280.1380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703071				2022-12-28	WOS:A1996VF61000040
J	Salsberg, ES; Wing, P; Dionne, MG; Jemiolo, DJ				Salsberg, ES; Wing, P; Dionne, MG; Jemiolo, DJ			Graduate medical education and physician supply in New York state	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORKFORCE POLICY	Objectives.-To estimate the supply of physicians and residents in New York State and to assess the impact of state policies on the supply and distribution of physicians in the state. Design.-A comparison of the number of residents in New York State for 1988 and 1994 (from the American Medical Association Medical Education Database) and the number of active patient care physicians in New York by specialty and age (from the 1995 New York State Physician File). Main Outcome Measures.-Changes in the number of residents in New York State between 1988 and 1994 by specialty and medical school location-estimates of the numbers of physicians by age and specialty in New York for 1995; the migration of new physicians into and out of the state. Results.-The number of residents in New York State grew by nearly 21% between 1988 and 1994, despite a number of policies and programs encouraging maintenance of production levels. This growth is attributed to increases in the number of international medical graduates (IMGs) entering residency training through a widening ''IMG window.'' Projection models show that, if production of new physicians continues at current levels, the supply of physicians will grow substantially during the next 2 decades. Conclusions.-Past policies to influence the supply, production, and distribution of physicians in New York State have not had their desired effects. Future policies and incentives must be carefully framed and coordinated to avoid similar failures.	SUNY ALBANY,SCH PUBL HLTH,CTR HLTH WORKFORCE STUDIES,ALBANY,NY; PLANNING & RES SERV,DELMAR,NY; NEW YORK STATE DEPT HLTH,BUR HLTH RESOURCES DEV,ALBANY,NY	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System								COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; EISENBERG JM, 1994, INQUIRY-J HEALTH CAR, V31, P241; GAMLIEL S, 1995, HEALTH AFFAIR, V14, P131, DOI 10.1377/hlthaff.14.2.131; LOHR KN, 1996, NATIONS PHYSICIAN WO; *NEW YORK STAT DEP, 1996, SUPPL DISTR PHYS NEW; *NEW YORK STAT DEP, 1995, NEW DIR HLTH NEW YOR; *NY STAT DEP HLTH, 1996, INT PLANN DOC; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; *PEW HLTH PROF COM, 1995, STAT HLTH PERS HDB; SCHROEDER SA, 1994, JAMA-J AM MED ASSOC, V272, P239, DOI 10.1001/jama.272.3.239; SEIFER SD, 1995, JAMA-J AM MED ASSOC, V274, P685, DOI 10.1001/jama.274.9.685; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; WHITCOMB M, 1994, IMPACT NATL GRADUATE; 1995, JAMA-J AM MED ASSOC, V274, P758; 1995, JAMA-J AM MED ASSOC, V274, P756; 1989, JAMA-J AM MED ASSOC, V262, P1030	17	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					683	688		10.1001/jama.276.9.683	http://dx.doi.org/10.1001/jama.276.9.683			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE233	8769545				2022-12-28	WOS:A1996VE23300005
J	Girling, DJ; Thatcher, N; Clark, PI; Hopwood, P; Twiddy, S; Stephens, RJ; Bailey, AJ; Machin, D; Bleehen, NM; Bolger, JJ; Connolly, CK; Hasleton, PS; Macbeth, FR; Moghissi, K; Saunders, MI; White, RJ; Alcock, S; Burt, H; Crossley, E; Decker, E; English, J; Foster, G; Hannigan, K; Heron, D; Hutchinson, J; Lomax, L; Mercer, V; Page, S; Rothwell, T; Staines, K; TaylorNeal, P; Turnball, V; Axford, AT; Earl, HM; Glaholm, J; Falk, SJ; Graham, JD; Jones, DK; Coombes, RC; Epstein, RJ; Hanham, I; Lowdell, CP; Newlands, E; Smith, DB; Cookson, JB; Anderson, H; Gribbin, HR; Sinclair, DJM; Carmichael, J; Chan, SYT; Johnston, IDA; Morgan, SA; Dunn, KS; Manifold, IH; Radstone, DJ; Lamont, A; Robinson, ACR; Bissett, D; Nicolson, MC; Tang, OT; Sinnamon, DG; Varghese, G; Bibby, RJ; OReilly, JF; Bath, JCJ; Bredin, CP; Stewart, SJ; Whillis, D; Wiltshire, CR; McIllmurray, MB; Bond, MG; Wardman, AG; Bozzino, JM; Ferguson, GC; Macmillan, CH; Sugden, EM; Talbot, DC; Quigley, IG; Weatherstone, RM; Veale, D; ORegan, PF				Girling, DJ; Thatcher, N; Clark, PI; Hopwood, P; Twiddy, S; Stephens, RJ; Bailey, AJ; Machin, D; Bleehen, NM; Bolger, JJ; Connolly, CK; Hasleton, PS; Macbeth, FR; Moghissi, K; Saunders, MI; White, RJ; Alcock, S; Burt, H; Crossley, E; Decker, E; English, J; Foster, G; Hannigan, K; Heron, D; Hutchinson, J; Lomax, L; Mercer, V; Page, S; Rothwell, T; Staines, K; TaylorNeal, P; Turnball, V; Axford, AT; Earl, HM; Glaholm, J; Falk, SJ; Graham, JD; Jones, DK; Coombes, RC; Epstein, RJ; Hanham, I; Lowdell, CP; Newlands, E; Smith, DB; Cookson, JB; Anderson, H; Gribbin, HR; Sinclair, DJM; Carmichael, J; Chan, SYT; Johnston, IDA; Morgan, SA; Dunn, KS; Manifold, IH; Radstone, DJ; Lamont, A; Robinson, ACR; Bissett, D; Nicolson, MC; Tang, OT; Sinnamon, DG; Varghese, G; Bibby, RJ; OReilly, JF; Bath, JCJ; Bredin, CP; Stewart, SJ; Whillis, D; Wiltshire, CR; McIllmurray, MB; Bond, MG; Wardman, AG; Bozzino, JM; Ferguson, GC; Macmillan, CH; Sugden, EM; Talbot, DC; Quigley, IG; Weatherstone, RM; Veale, D; ORegan, PF			Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial	LANCET			English	Article							BIOAVAILABILITY; SCHEDULE	Background Single-drug oral etoposide daily for 5 days or more in 3 week cycles is commonly used as palliative chemotherapy for small-cell lung cancer (SCLC). However, there have been no randomised trials to compare this treatment with standard intravenous multidrug chemotherapy. Our objective was such a comparison in patients with poor performance status. However, before the planned intake of 450 patients had been completed the trial was stopped on the recommendation of an independent data monitoring committee, because of the inferiority of oral etoposide. We report the interim findings of the trial. Methods Patients of either sex and any age were entered into the trial if they had: previously untreated, microscopically confirmed SCLC; WHO grade performance status 2-4; no contraindications to either treatment regimen; normal renal function; and plasma bilirubin concentrations of less than 35 mu mol/L. Patients with grade 4 performance status were likely to benefit from chemotherapy. Between September, 1992, and August, 1995, 339 patients were randomly allocated four cycles of 50 mg oral etoposide twice daily for 10 days (171 patients) or a standard intravenous regimen of etoposide and vincristine (EV), or cyclophosphamide, doxorubicin, and vincristine (CAV, 168 controls). The intake was stopped in September, 1995. Patients were assessed by clinicians before the start of treatment, at each attendance for treatment, at 3 months after randomisation, every month to 6 months, every 2 months to 1 year, then every 3 months thereafter. The primary endpoint was the palliation of major symptoms at 3 months after randomisation-ie, a reduction in cough, pain, anorexia, and shortness of breath scores. Secondary endpoints were quality of life, clinical and radiographic tumour response, and survival. Findings The palliative effects of treatment were similar in the etoposide group and control group (41% vs 46%). Grade 2 or worse haematological toxicity occurred in 35 (29%) etoposide-treated patients and 26 (21%) controls. Controls had a higher overall response rate than etoposide-treated patients (51% vs 45%). There was a small disadvantage in survival associated with oral etoposide (hazard ratio 1.35 [95% CI 1.03-1.79], p=0.03). Median survival was 130 days in the etoposide group and 183 days in the controls; survival rates were 35% and 49% at 6 months and 11% and 13% at 12 months, respectively. Interpretation Oral etoposide 50 mg twice daily for 10 days every 3 weeks for four cycles is inferior to standard intravenous multidrug chemotherapy in the palliative treatment of patients with SCLC and poor performance status. Oral etoposide alone should no longer be used in the treatment of such patients.			Girling, DJ (corresponding author), MRC,CANC TRIALS OFF,CAMBRIDGE CB2 2BW,ENGLAND.		Varghese, George/AAQ-8219-2021	Coombes, Raoul Charles/0000-0002-4811-1100				[Anonymous], 1979, Br J Cancer, V40, P1; CLARK PI, 1992, SEMIN ONCOL, V19, P36; CLARK PI, 1989, P AN M AM SOC CLIN, V8, P257; DORWARD AJ, 1991, LUNG CANC S, V7, P111; HANDE KR, 1993, J CLIN ONCOL, V11, P374, DOI 10.1200/JCO.1993.11.2.374; HARVEY VJ, 1985, EUR J CANCER CLIN ON, V21, P1315, DOI 10.1016/0277-5379(85)90310-4; Ihde D C, 1984, Cancer, V54, P2722, DOI 10.1002/1097-0142(19841201)54:2+<2722::AID-CNCR2820541419>3.0.CO;2-P; MACHIN D, 1992, INTRO NEW TREATMENTS; MILLER AA, 1995, J CLIN ONCOL, V13, P1871, DOI 10.1200/JCO.1995.13.8.1871; Organization W.H, 1979, WHO HDB REP RES CANC; RAWSON NSB, 1990, BRIT J CANCER, V61, P597, DOI 10.1038/bjc.1990.133; SLEVIN ML, 1989, J CLIN ONCOL, V7, P1333, DOI 10.1200/JCO.1989.7.9.1333; SOUHAMI RL, 1986, CANC ITS MANAGEMENT, P2126; STEPHENS RJ, 1994, LUNG CANCER-J IASLC, V11, P259, DOI 10.1016/0169-5002(94)90546-0; 1996, BRIT J CANCER, V73, P406	15	166	167	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					563	566		10.1016/S0140-6736(96)02005-3	http://dx.doi.org/10.1016/S0140-6736(96)02005-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774567				2022-12-28	WOS:A1996VF18600008
J	Winer, KK; Yanovski, JA; Cutler, GB				Winer, KK; Yanovski, JA; Cutler, GB			Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism - Results of a short-term randomized crossover trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-D; BONE; 1,25-DIHYDROXYVITAMIN-D3; OSTEOPOROSIS; CHILDREN; FRAGMENT	Objective.-To test the hypothesis that treatment with human parathyroid hormone 1-34 (PTH 1-34) can maintain normal serum calcium without hypercalciuria in patients with hypoparathyroidism. Design.-Randomized crossover trial lasting 20 weeks. Each 10-week arm consisted of a 2-week inpatient dose-adjustment phase followed by an 8-week outpatient phase. Setting.-Tertiary care center. Patients.-A total of 10 patients with hypoparathyroidism were enrolled consecutively over a 15-month period. Half of the patients were prior National Institutes of Health patients, and the other 5 patients were referred from outside physicians. Interventions.-A dose of PTH 1-34 was administered each morning by subcutaneous injection. Calcitriol was given orally twice daily with supplemental calcium carbonate. Main Outcome Measures.-Serum and urine calcium and phosphorus levels. Results.-Once-daily treatment with PTH 1-34 maintained serum calcium in the normal range with decreased urine calcium excretion (P<.05 at 2 weeks and P<.01 at 10 weeks) compared with calcitriol treatment. Biochemical markers of bone turnover increased significantly (P<.01 at 10 weeks) during PTH 1-34 treatment. Conclusions.-Treatment of hypoparathyroidism with PTH 1-34 reduces urine calcium excretion compared with treatment with calcitriol and calcium.			Winer, KK (corresponding author), NICHHD,DEV ENDOCRINOL BRANCH,SDE,NIH,BLDG 10,ROOM 10N262,10 CTR DR,MSC 1862,BETHESDA,MD 20892, USA.		Winer, Karen K/HDO-6143-2022	Yanovski, Jack/0000-0001-8542-1637				Albright F, 1938, J CLIN INVEST, V17, P317, DOI 10.1172/JCI100956; ALLEN SH, 1992, HORM RES, V37, P68, DOI 10.1159/000182285; ARATA RO, 1974, MEDICINA-BUENOS AIRE, V34, P463; CHAN JCM, 1985, J PEDIATR-US, V106, P421, DOI 10.1016/S0022-3476(85)80668-5; CHAN JCM, 1983, PEDIATRICS, V72, P225; CHRISTIANSEN C, 1978, LANCET, V2, P700; Davies M, 1989, Int J Vitam Nutr Res Suppl, V30, P81; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P517; KUROKAWA K, 1987, KIDNEY INT, V32, P760, DOI 10.1038/ki.1987.272; MARKOWITZ ME, 1982, J CLIN ENDOCR METAB, V55, P727, DOI 10.1210/jcem-55-4-727; MELICK RA, 1967, NEW ENGL J MED, V276, P144, DOI 10.1056/NEJM196701192760304; PARFITT AM, 1972, J CLIN INVEST, V51, P1879, DOI 10.1172/JCI106990; PORTER RH, 1978, NEW ENGL J MED, V298, P577, DOI 10.1056/NEJM197803162981101; REEVE J, 1976, LANCET, V1, P1035; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; REEVE J, 1975, CALCIF TISSUE RES S, V21, P469; RIGGS BL, 1993, P 4 INT S OST HONG K, P13; SANTOS F, 1986, AM J DIS CHILD, V140, P139, DOI 10.1001/archpedi.1986.02140160057032; SLOVIK DM, 1986, J BONE MINER RES, V1, P377; SLOVIK DM, 1981, J CLIN INVEST, V68, P1261, DOI 10.1172/JCI110372; Strogmann W, 1990, MONATSSCHR KINDERH, V138, P141; UEBELHART D, 1990, BONE MINER, V8, P87, DOI 10.1016/0169-6009(91)90143-N; WEBER G, 1988, CHILD NEPHROL UROL, V89, P273; [No title captured]	26	136	146	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					631	636		10.1001/jama.276.8.631	http://dx.doi.org/10.1001/jama.276.8.631			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC853	8773636				2022-12-28	WOS:A1996VC85300030
J	McGill, KA; Busse, WW				McGill, KA; Busse, WW			Zileuton	LANCET			English	Article							ACTIVE 5-LIPOXYGENASE INHIBITOR; ALLERGEN CHALLENGE; BRONCHIAL-ASTHMA; NOCTURNAL ASTHMA; LEUKOTRIENE-C4; INFLAMMATION; AIRWAYS; ASPIRIN; EXCRETION; PRODUCTS				McGill, KA (corresponding author), UNIV WISCONSIN,SCH MED,CTR CLIN SCI,DEPT MED,SECT ALLERGY IMMUNOL,MADISON,WI 53792, USA.							BARNES PJ, 1988, PHARMACOL REV, V40, P49; BELL RL, 1992, INT J IMMUNOPHARMACO, V14, P505, DOI 10.1016/0192-0561(92)90182-K; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BUSSE WW, 1991, AM REV RESPIR DIS, V143, pS103, DOI 10.1164/ajrccm/143.5_Pt_2.S103; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203, DOI 10.1164/ajrccm.152.4.7551371; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; HACKSHAW KV, 1995, J RHEUMATOL, V22, P462; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; KNAPP HR, 1992, J LAB CLIN MED, V119, P48; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAURSEN LS, 1990, LANCET, V335, P683; LEE TH, 1992, AM REV RESPIR DIS, V145, P534; Lewis M. A., 1985, BIOCHEM PHARMACOL, V34, P3411; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; ORNING L, 1985, BIOCHEM BIOPH RES CO, V130, P214, DOI 10.1016/0006-291X(85)90404-8; PIACENTINI GL, 1991, AM REV RESPIR DIS, V143, pS96; RUBIN P, 1991, AGENT ACTION SUPPL, V35, P103; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SMITH CM, 1991, AM REV RESPIR DIS, V144, P1411, DOI 10.1164/ajrccm/144.6.1411; STPETER JV, 1995, CLIN PHARMACOL THER, V57, P299, DOI 10.1016/0009-9236(95)90155-8; SWEENY DJ, 1995, DRUG METAB DISPOS, V23, P149; WEINBLATT ME, 1992, J RHEUMATOL, V19, P1537; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112	38	74	76	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					519	524		10.1016/S0140-6736(95)12297-4	http://dx.doi.org/10.1016/S0140-6736(95)12297-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757156				2022-12-28	WOS:A1996VD42700014
J	Albright, TD				Albright, TD			An excellent lightness	SCIENCE			English	Editorial Material											Albright, TD (corresponding author), SALK INST BIOL STUDIES,POB 85800,SAN DIEGO,CA 92186, USA.							DAVINCI L, 1956, TREATISE PAINTING; FIORENTINI A, 1990, VISUAL PERCEPTION NE; HARTLINE HK, 1949, FED PROC, V8, P69; Hering E., 1964, OUTLINES THEORY LIGH; Koffka K, 1935, PRINCIPLES GESTALT P; Mach E, 1965, MACH BANDS QUANTITAT; Rossi AF, 1996, SCIENCE, V273, P1104, DOI 10.1126/science.273.5278.1104; VONHELMHOLTZ H, 1924, PHYSL OPTICS, V2	8	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1055	1056		10.1126/science.273.5278.1055	http://dx.doi.org/10.1126/science.273.5278.1055			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8711483				2022-12-28	WOS:A1996VD42800026
J	Zimmerman, LB; DeJesusEscobar, JM; Harland, RM				Zimmerman, LB; DeJesusEscobar, JM; Harland, RM			The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; EARLY XENOPUS EMBRYO; NEURAL INDUCTION; VENTRALIZING FACTOR; BETA FAMILY; RECEPTOR; MESODERM; BMP-4; CELLS; DIFFERENTIATION	Signals released by the Spemann organizer of the amphibian gastrula can directly induce neural tissue from ectoderm and can dorsalize ventral mesoderm to form muscle. The secreted polypeptide noggin mimics these activities and is expressed at the appropriate time and place to participate in the organizer signal. Neural induction and mesoderm dorsalization are antagonized by bone morphogenetic proteins (BMPs), which induce epidermis and ventral mesoderm instead. Here we report that noggin protein binds BMP4 with high affinity and can abolish BMP4 activity by blocking binding to cognate cell-surface receptors. These data suggest that noggin secreted by the organizer patterns the embryo by interrupting BMP signaling.			Zimmerman, LB (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015782, R01GM049346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 15782, GM 49346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; DALE L, 1992, DEVELOPMENT, V115, P573; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; ECONOMIDES AN, 1995, SCIENCE, V270, P1351, DOI 10.1126/science.270.5240.1351; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HOLLEY SA, 1996, CELL, V86; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; JONES CM, 1992, DEVELOPMENT, V115, P639; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEIN P, 1995, NEURON, V15, P597, DOI 10.1016/0896-6273(95)90148-5; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Moos M, 1995, DEVELOPMENT, V121, P4293; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; PLESSOW S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P280, DOI 10.1016/0167-4781(91)90026-I; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; VALENZUELA DM, 1995, J NEUROSCI, V15, P6077; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4	46	1313	1392	1	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					599	606		10.1016/S0092-8674(00)80133-6	http://dx.doi.org/10.1016/S0092-8674(00)80133-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752214	Bronze			2022-12-28	WOS:A1996VE23500010
J	Cabral, JHM; Petosa, C; Sutcliffe, MJ; Raza, S; Byron, O; Poy, F; Marfatia, SM; Chishti, AH; Liddington, RC				Cabral, JHM; Petosa, C; Sutcliffe, MJ; Raza, S; Byron, O; Poy, F; Marfatia, SM; Chishti, AH; Liddington, RC			Crystal structure of a PDZ domain	NATURE			English	Article							PROTEINS; GRAPHICS; PROGRAM; ORIGIN; DHR	PDZ domains (also known as DHR domains or GLGF repeats) are similar to 90-residue repeats found in a number of proteins implicated in ion-channel and receptor clustering, and the linking of receptors to effector enzymes(1). PDZ domains are protein-recognition modules; some recognize proteins containing the consensus carboxy-terminal tripeptide motif S/TXV with high specificity(2-4). Other PDZ domains form homotypic dimers: the PDZ domain of the neuronal enzyme nitric oxide synthase binds to the PDZ domain of PSD-95, an interaction that has been implicated in its synaptic association(5). Here we report the crystal structure of the third PDZ domain of the human homologue of the Drosophila discs-large tumour-suppressor gene product, DlgA. It consists of a five-stranded antiparallel beta-barrel flanked by three alpha-helices. A groove runs over the surface of the domain, ending in a conserved hydrophobic pocket and a buried arginine; we suggest that this is the binding site for the C-terminal peptide.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV LEICESTER,DEPT NCMH,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV LEICESTER,DEPT CHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; DANA FARBER CANC INST,BOSTON,MA 02115; TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,TUMOR CELL BIOL LAB,BOSTON,MA 02135	University of Leicester; University of Leicester; University of Leicester; Harvard University; Dana-Farber Cancer Institute; St. Elizabeth's Medical Center; Tufts University			Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716; Petosa, Carlo/0000-0002-9975-1167; Byron, Olwyn/0000-0001-7857-4520; Sutcliffe, Mike/0000-0003-0414-1700				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KNIGHT S, 1989, THESIS SWEDISH U AGR; KOMAU HC, 1995, SCIENCE, V269, P1737; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	28	277	288	2	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					649	652		10.1038/382649a0	http://dx.doi.org/10.1038/382649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757139				2022-12-28	WOS:A1996VC30300059
J	Cummings, DE; Brandon, EP; Planas, JV; Motamed, K; Idzerda, RL; McKnight, GS				Cummings, DE; Brandon, EP; Planas, JV; Motamed, K; Idzerda, RL; McKnight, GS			Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A	NATURE			English	Article							BROWN ADIPOSE-TISSUE; OBESE GENE; TRANSGENIC MICE; FAT; THERMOGENESIS; RECEPTORS; WHITE	CYCLIC AMP is an important second messenger in the coordinated regulation of cellular metabolism, Its effects are mediated by cAMP-dependent protein kinase (PKA), which is assembled from two regulatory (R) and two catalytic (C) subunits, In mice there are four R genes (encoding RI alpha, RI beta, RII alpha, and RII beta) and two C genes (encoding C alpha and C beta), expressed in tissue specific patterns(1). The RII beta isoform is abundant in brown and white adipose tissue and brain, with limited expression elsewhere. To elucidate its functions, we generated RII beta knockout mice, Here we report that mutants appear healthy but have markedly diminished white adipose tissue despite normal food intake, They are protected against developing diet-induced obesity and fatty livers, Mutant brown adipose tissue exhibits a compensatory increase in RI alpha, which almost entirely replaces lost RII beta, generating an isoform switch, The holoenzyme from mutant adipose tissue binds cAMP more avidly and is more easily activated than wild-type enzyme, This causes induction of uncoupling protein and elevations of metabolic rate and body temperature, contributing to the lean phenotype. Our results demonstrate a role for the RII beta holoenzyme in regulating energy balance and adiposity.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Planas, Josep/0000-0002-6525-9617				ARNER P, 1995, NEW ENGL J MED, V333, P382, DOI 10.1056/NEJM199508103330612; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CARNEHEIM C, 1988, AM J PHYSIOL, V254, pE155, DOI 10.1152/ajpendo.1988.254.2.E155; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; JEQUIER E, 1987, BAILLIERE CLIN ENDOC, V1, P911, DOI 10.1016/S0950-351X(87)80011-3; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; LAFONTAN M, 1993, J LIPID RES, V34, P1057; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SCHNEIDER A, 1993, NAT GENET, V5, P381, DOI 10.1038/ng1293-381; STEIN DT, 1995, INT J OBESITY, V19, P804; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	28	346	354	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					622	626		10.1038/382622a0	http://dx.doi.org/10.1038/382622a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757131				2022-12-28	WOS:A1996VC30300051
J	Young, GP; Wagner, MB; Kellermann, AL; Ellis, J; Bouley, D				Young, GP; Wagner, MB; Kellermann, AL; Ellis, J; Bouley, D			Ambulatory visits to hospital emergency departments - Patterns and reasons for use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC EMERGENCY; TELEPHONE ADVICE; REFUSING CARE; MEDICAL-CARE; TRIAGE; NEED	Objectives.-To characterize the reasons ambulatory patients use hospital emergency departments (EDs) for outpatient care and to determine the proportion of ED patients who initially are assessed as having nonurgent conditions, but subsequently are hospitalized. Design.-Cross-sectional survey during a single 24-hour period of time. Setting.-Fifty-six hospital EDs nationwide. Patients or Other Participants.-Consecutive ambulatory patients presenting for care, Patients who arrived by ambulance were excluded. Results.-Of 6441 ambulatory patients (79% of all ED visits) who were eligible for study, interviews were obtained from 6187 (96%). A total of 5323 patients (86%) had clinical reasons or preferences for seeking care at an ED, including 2799 (45%) who thought they had an emergency or an urgent condition or were too sick to go elsewhere, Nineteen percent (n=1199) reported that they were sent to the ED by a health care professional. Patients with a regular clinician or with insurance cited similar reasons for seeking care at an ED. A total of 3062 patients (50%) cited 1 or more nonfinancial barriers to care as an important reason for coming to the ED, and 949 (15%) cited financial considerations, A total of 3045 patients (49% of ambulatory patients and 37% of total ED visits) were assessed at triage as having a nonurgent condition; 166 of them (5.5%; 95% confidence interval, 4.7%-6.3%) were admitted to the hospital. Conclusions.-Most ambulatory patients seek care in an ED because of worrisome symptoms or nonfinancial barriers to care. Although many ambulatory patients appear to have nonurgent conditions based on triage classification, a small but disturbing percentage of nonurgent patients are hospitalized.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; BETH ISRAEL HOSP,DIV EMERGENCY MED,BOSTON,MA 02215; EMORY UNIV,DEPT SURG,DIV EMERGENCY MED,ATLANTA,GA 30322	University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center; Emory University	Young, GP (corresponding author), HIGHLAND GEN HOSP,DEPT EMERGENCY MED,1411 E 31ST,OAKLAND,CA 94602, USA.							ALBIN SL, 1975, AM J PUBLIC HEALTH, V65, P1063, DOI 10.2105/AJPH.65.10.1063; *AM HOSP ASS, 1994, HOSP STAT EM TRENDS; BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; BERMAN DA, 1989, ANN EMERG MED, V18, P141, DOI 10.1016/S0196-0644(89)80102-7; Birnbaum A, 1994, Acad Emerg Med, V1, P213; Brillman JC, 1996, ANN EMERG MED, V27, P493, DOI 10.1016/S0196-0644(96)70240-8; CHYBA MM, 1983, 2 NAT CTR HLTH STAT; DERLET RW, 1990, ANN EMERG MED, V19, P262, DOI 10.1016/S0196-0644(05)82041-4; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GADOMSKI AM, 1995, PEDIATRICS, V95, P170; GIFFORD MJ, 1980, ANN EMERG MED, V9, P502, DOI 10.1016/S0196-0644(80)80187-9; GLOTZER D, 1991, PEDIATRICS, V88, P674; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; GUTERMAN JJ, 1985, ANN EMERG MED, V14, P1191, DOI 10.1016/S0196-0644(85)81028-3; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; IGLEHART JK, 1993, NEW ENGL J MED, V328, P1208, DOI 10.1056/NEJM199304223281627; INGLEHART JK, 1992, NEW ENGL J MED, V327, P742; ISAACMAN DJ, 1992, PEDIATRICS, V89, P35; KELLERMANN A, 1993, VISITS HOSPITAL EMER; KELLERMANN AL, 1994, JAMA-J AM MED ASSOC, V271, P1953, DOI 10.1001/jama.271.24.1953; Lohr K N, 1986, Med Care, V24, pS1; LOWE RA, 1994, ANN EMERG MED, V23, P286, DOI 10.1016/S0196-0644(94)70042-7; McCaig L F, 1994, Adv Data, P1; Mills J, 1976, JACEP, V5, P877, DOI 10.1016/S0361-1124(76)80034-2; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; SHAW KN, 1990, ANN EMERG MED, V19, P59, DOI 10.1016/S0196-0644(05)82144-4; SHESSER R, 1991, ANN EMERG MED, V20, P743, DOI 10.1016/S0196-0644(05)80835-2; STEELE R, 1975, CAN MED ASSOC J, V112, P1096; Steinbrook R, 1996, NEW ENGL J MED, V334, P657, DOI 10.1056/NEJM199603073341010; *US DEP HHS, 1993, 069000181 US DEP HLT; *US DEP HHS, 1993, 069000180 US DEP HLT; *US GEN ACC OFF, 1993, HOSP EM DEP UN AFF G; VERDILE VP, 1989, ANN EMERG MED, V18, P278, DOI 10.1016/S0196-0644(89)80414-7; Warren B H, 1993, Arch Fam Med, V2, P523, DOI 10.1001/archfami.2.5.523; Williams RM, 1996, NEW ENGL J MED, V334, P642, DOI 10.1056/NEJM199603073341007; WILSON LO, 1981, ANN EMERG MED, V10, P427, DOI 10.1016/S0196-0644(81)80311-3; 1996, C Q REP, V6, P1; 1994, NEW ENGL J MED, V330, P1426	39	197	199	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					460	465		10.1001/jama.276.6.460	http://dx.doi.org/10.1001/jama.276.6.460			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691553				2022-12-28	WOS:A1996VA86300033
J	Munjanja, SP; Lindmark, G; Nystrom, L				Munjanja, SP; Lindmark, G; Nystrom, L			Randomised controlled trial of a reduced-visits programme of antenatal care in Harare, Zimbabwe	LANCET			English	Article							CLUSTER RANDOMIZATION	Background Many of the individual components of antenatal care have been studied in randomised controlled trials, but few studies have compared whole programmes of antenatal care. Our aim was to test the hypothesis that a new programme of antenatal care with fewer goal-oriented visits would give an equivalent or better result in the outcomes associated with pregnancy and delivery. Methods In a randomised clinical trial in Harare, Zimbabwe, we compared a new programme of antenatal care with the standard programme. The new programme consisted of fewer but more objectively oriented procedures per visit. Seven primary randomly assigned to the two programmes-three to the standard programme and four to the new programme. Findings Over a 2-year period, 15 994 women were recruited into the study at the time they booked antenatal cave, 97% of the women were followed up, 9394 who had followed the new programme, and 6138 from clinics with the standard one, Women allocated to the new programme made, as planned, fewer visits than those in the standard programme (median 4 vs 6 visits, respectively). The proportion of antenatal referrals was also lower (13.6 vs 15.3%: odds ratio 0.87 [95% CI 0.79-0.95]) because of fewer referrals for pregnancy-induced (2.5 vs 3.8%; 0.66 [0.55-0.79]). Nevertheless, there were significantly fewer labour referrals for severe hypertension or eclampsia (2.1 vs 2.6%; 0.81 [0.66-1.00]). The risk for preterm (<37 weeks) delivery was significantly lower for women on the new programme (10.1 vs 11.5%: 0.86 [0.78-0.96]). There were no other significant differences between the programmes in other major indices of pregnancy outcome, including antenatal referrals for other causes, labour referrals, obstetric interventions, low birthweight, and perinatal and maternal mortality and morbidity. Interpretation An antenatal care programme with fewer more objectively oriented visits can be introduced without adverse effects on the main intermediate outcome pregnancy variables.	UNIV UPPSALA,DEPT OBSTET & GYNAECOL,UPPSALA,SWEDEN; UMEA UNIV,DEPT EPIDEMIOL & PUBL HLTH,UMEA,SWEDEN	Uppsala University; Umea University	Munjanja, SP (corresponding author), UNIV ZIMBABWE,DEPT OBSTET & GYNAECOL,POB A178,AVONDALE,HARARE,ZIMBABWE.							BLONDEL B, 1985, BRIT J OBSTET GYNAEC, V92, P565, DOI 10.1111/j.1471-0528.1985.tb01393.x; *CENTR STAT OFF, 1994, IND MON SURV 1993; *CENTR STAT OFF, 1989, DEM HLTH SURV 1988; Central Statistical Office, 1992, CENS 1992; CHALMERS I, 1989, EFFECTIVE CARE PREGN, P1465; CROWTHER CA, 1986, J PERINAT MED, V14, P325, DOI 10.1515/jpme.1986.14.5.325; CROWTHER CA, 1986, S AFR MED J, V69, P180; CROWTHER CA, 1992, BRIT J OBSTET GYNAEC, V99, P13, DOI 10.1111/j.1471-0528.1992.tb14384.x; DAWSON AJ, 1989, BRIT J OBSTET GYNAEC, V96, P1319, DOI 10.1111/j.1471-0528.1989.tb03230.x; *DEP HLTH HUM SERV, 1989, CAR OUR FUT CONT PRE; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; DUFFY SW, 1992, STAT MED, V11, P307, DOI 10.1002/sim.4780110304; ENKIN M, 1982, EFFECTIVENESS SATISF, P266; GILES W, 1992, MED J AUSTRALIA, V156, P158; *GREAT BRIT MIN HL, 1930, MEM ANT CLIN THEIR C; HALL M, 1985, ANTENATAL CARE ASSES; Hall M, 1982, EFFECTIVENESS SATISF, P60; HALL MH, 1980, LANCET, V2, P78; *HAR CIT HLTH DEP, 1989, 1985 1988 HAR CIT HL; *HAR CIT HOSP, 1989, 1985 1988 MIN HLTH; MEIRIK O, 1992, INT J TECHNOL ASSESS, V1, P46; MUNJANJA SP, 1988, CENTR AFR J MED, V33, P29; MUNJANJA SP, 1990, CTR AFR J MED, V36, P146; Rooney C., 1992, ANTENATAL CARE MATER; SEN D K, 1991, Singapore Journal of Obstetrics and Gynaecology, V22, P83; Sikorski J, 1996, BRIT MED J, V312, P546, DOI 10.1136/bmj.312.7030.546; VILLAR J, 1993, CURR OPIN OBSTET GYN, V5, P688	27	106	110	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					364	369		10.1016/S0140-6736(96)01250-0	http://dx.doi.org/10.1016/S0140-6736(96)01250-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709734				2022-12-28	WOS:A1996VB42600010
J	Everard, ML				Everard, ML			Acute bronchiolitis - A perennial problem	LANCET			English	Editorial Material											Everard, ML (corresponding author), SHEFFIELD CHILDRENS HOSP,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND.							Geelhoed GC, 1995, PEDIATR PULM, V20, P355, DOI 10.1002/ppul.1950200604; GREEN M, 1989, PEDIATR INFECT DIS J, V8, P601, DOI 10.1097/00006454-198909000-00007; KAIRY SW, 1989, J PEDIATR, V115, P323; REYNOLDS EO, 1963, J PEDIATR-US, V63, P1205, DOI 10.1016/S0022-3476(63)80215-2; SILVERMAN M, 1995, NEW ENGL J MED, V332, P181, DOI 10.1056/NEJM199501193320309; 1993, PEDIATRICS, V92, P501	6	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					279	280		10.1016/S0140-6736(05)64467-4	http://dx.doi.org/10.1016/S0140-6736(05)64467-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709682				2022-12-28	WOS:A1996VA25000003
J	Labahn, J; Scharer, OD; Long, A; EzazNikpay, K; Verdine, GL; Ellenberger, TE				Labahn, J; Scharer, OD; Long, A; EzazNikpay, K; Verdine, GL; Ellenberger, TE			Structural basis for the excision repair of alkylation-damaged DNA	CELL			English	Article							ENZYME ENDONUCLEASE-III; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 3-METHYLADENINE-DNA GLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; CATALYTIC MECHANISM; ALKA GENE; CLONING; PROTEIN; CDNA	Base-excision DNA repair proteins that target alkylation damage act on a variety of seemingly dissimilar adducts, yet fail to recognize other closely related lesions. The 1.8 Angstrom crystal structure of the monofunctional DNA glycosylase AlkA (E. coli 9-methyladenine-DNA glycosylase II) reveals a large hydrophobic cleft unusually rich in aromatic residues. An Asp residue projecting into this cleft is essential for catalysis, and it governs binding specificity for mechanism-based inhibitors. We propose that AlkA recognizes electron-deficient methylated bases through pi-donor/acceptor interactions involving the electron-rich aromatic cleft. Remarkably, AlkA is similar in fold and active site location to the bifunctional glycosylase/lyase endonuclease III, suggesting the two may employ fundamentally related mechanisms for base excision.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University			Scharer, Orlando/B-8908-2008; Labahn, Jörg/G-9593-2013; Schärer, Orlando D./AAF-8613-2021	Scharer, Orlando/0000-0003-2425-2715; Labahn, Jörg/0000-0002-0648-8145; 				BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, X PLOR VERSION 3 1 S; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; *DAR LAB, 1979, SUIT PROGR PROT CRYS; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; EVANS R, 1990, VIA, V11, P134; FRIEDBERG EC, 1995, DNA REPAIR; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LAVAL J, 1977, NATURE, V269, P829, DOI 10.1038/269829a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAIN P, 1990, ACTA CRYSTALLOGR A, V46, P372, DOI 10.1107/S0108767389012146; Mattes WB, 1996, CARCINOGENESIS, V17, P643, DOI 10.1093/carcin/17.4.643; MEMISOGLU A, 1996, IN PRESS GENE; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; NASH HM, 1996, IN PRESS CURR BIOL; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANTERRE A, 1994, P NATL ACAD SCI USA, V91, P2240, DOI 10.1073/pnas.91.6.2240; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; THOMSON AJ, 1993, CURR BIOL, V3, P173, DOI 10.1016/0960-9822(93)90264-O; TRONRUD DE, 1995, USERS GUIDE TNT REFI; VANDUYNE GD, 1993, J MOL BIOL, V229, P104; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	52	228	233	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					321	329		10.1016/S0092-8674(00)80103-8	http://dx.doi.org/10.1016/S0092-8674(00)80103-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706136	Bronze			2022-12-28	WOS:A1996UZ97200017
J	Jacobs, GH; Neitz, M; Deegan, JF; Neitz, J				Jacobs, GH; Neitz, M; Deegan, JF; Neitz, J			Trichromatic colour vision in New World monkeys	NATURE			English	Article							CONE PIGMENTS; GENETIC-BASIS; PHOTOPIGMENTS; POLYMORPHISM; GREEN; SENSITIVITY; MARMOSET	TRICHROMATIC colour vision depends on the presence of three types of cone photopigment. Trichromacy is the norm for all Old World monkeys, apes and humans, but in several genera of New World monkeys, colour vision is strikingly polymorphic(1). The difference in colour vision between these New and Old World primates results from differing arrangements of the pigment genes on the X chromosome. In Old World primates the three photopigments required for routine trichromatic colour vision are encoded by two or more X-chromosome pigment genes and an autosomal pigment gene. New World monkeys typically have only one X-chromosome pigment gene; multiple alleles allow different types of dichromatic colour vision and, in females heterozygous at this locus, variant forms of trichromatic colour vision. Here we report that multiple X-chromosome pigment genes and trichromatic colour vision are the norm for one genus of platyrrhine monkey, the howler monkey, Alouatta.	UNIV CALIF SANTA BARBARA, DEPT PSYCHOL, SANTA BARBARA, CA 93106 USA; MED COLL WISCONSIN, DEPT OPHTHALMOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT CELLULAR BIOL, MILWAUKEE, WI 53226 USA; CALIF STATE UNIV BAKERSFIELD, DEPT PSYCHOL, BAKERSFIELD, CA 93311 USA	University of California System; University of California Santa Barbara; Medical College of Wisconsin; Medical College of Wisconsin; California State University System; California State University Bakersfield	Jacobs, GH (corresponding author), UNIV CALIF SANTA BARBARA, NEUROSCI RES INST, SANTA BARBARA, CA 93106 USA.			Neitz, Maureen/0000-0002-5404-3343				BOWMAKER JK, 1987, PROC R SOC SER B-BIO, V231, P383, DOI 10.1098/rspb.1987.0051; BOWMAKER JK, 1991, NATO ADV SCI I A-LIF, V203, P1; CHAN T, 1992, J BIOL CHEM, V267, P9478; COTTON RGH, 1995, CURR OPIN BIOTECH, V3, P1013; DULAI KS, 1994, VISION RES, V34, P2483, DOI 10.1016/0042-6989(94)90233-X; HAGSTROM SA, 1993, INVEST OPHTH VIS SCI, V34, P809; HUNT DM, 1993, VISION RES, V33, P147, DOI 10.1016/0042-6989(93)90153-N; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; JACOBS GH, 1993, VISION RES, V33, P269, DOI 10.1016/0042-6989(93)90083-9; Jacobs GH, 1996, J OPT SOC AM A, V13, P641, DOI 10.1364/JOSAA.13.000641; JACOBS GH, 1993, INVEST OPHTH VIS SCI, V34, P749; JACOBS GH, 1993, BIOL REV, V68, P413, DOI 10.1111/j.1469-185X.1993.tb00738.x; JACOBS GH, 1987, P NATL ACAD SCI USA, V84, P2545, DOI 10.1073/pnas.84.8.2545; JACOBS GH, 1994, AM J PRIMATOL, V33, P217; MERBS SL, 1992, PHOTOCHEM PHOTOBIOL, V56, P869, DOI 10.1111/j.1751-1097.1992.tb09708.x; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; MOLLON JD, 1991, EVOLUTION EYE VISUAL, P306; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1984, J OPT SOC AM A, V1, P1175, DOI 10.1364/JOSAA.1.001175; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; NEITZ M, 1995, SCIENCE, V267, P1013, DOI 10.1126/science.7863325; SCHNEIDER H, 1993, MOL PHYLOGENET EVOL, V2, P225, DOI 10.1006/mpev.1993.1022; SHYUE SK, 1995, SCIENCE, V269, P1265, DOI 10.1126/science.7652574; TOVEE MJ, 1992, VISION RES, V32, P867, DOI 10.1016/0042-6989(92)90029-I; WILLIAMS AJ, 1992, EMBO J, V11, P2039, DOI 10.1002/j.1460-2075.1992.tb05261.x	26	200	204	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					156	158		10.1038/382156a0	http://dx.doi.org/10.1038/382156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700203				2022-12-28	WOS:A1996UW67200046
J	Thierfelder, WE; vanDeursen, JM; Yamamoto, K; Tripp, RA; Sarawar, SR; Carson, RT; Sangster, MY; Vignali, DAA; Doherty, PC; Grosveld, GC; Ihle, JN				Thierfelder, WE; vanDeursen, JM; Yamamoto, K; Tripp, RA; Sarawar, SR; Carson, RT; Sangster, MY; Vignali, DAA; Doherty, PC; Grosveld, GC; Ihle, JN			Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells	NATURE			English	Article								SIGNAL transducers and activators of transcription (STATs) are activated by tyrosine phosphorylation in response to cytokines and mediate many of their functional responses(1-3). Statil was initially cloned as a result of its homology with Stat1 (refs 4, 5) and is widely expressed, although it is only tyrosine-phosphorylated after stimulation of T cells with interleukin (IL)-12 (refs 6, 7). IL-12 is required for the T-cell-independent induction of the cytokine interferon (IFN)-gamma, a keg step in the initial suppression of bacterial and parasitic infections. IL-12 is also important for the development of a Th1 response, which is critical for effective host defence against intracellular pathogens(8,9). To determine the function of Stat4 and its role in IL-12 signalling, we have produced mice that lack Stat4 by gene targeting. The mice were viable and fertile, with no detectable defects in haematopoiesis, However, all IL-12 functions tested were disrupted, including the induction of IFN-gamma, mitogenesis, enhancement of natural killer cytolytic function and Th1 differentiation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, SCH MED, DEPT PATHOL, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, SCH MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; TOKYO MED & DENT UNIV, DEPT INTERNAL MED 1, BUNKYO KU, TOKYO 113, JAPAN	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Tokyo Medical & Dental University (TMDU)			Tripp, Ralph/F-5218-2011; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph/0000-0002-2924-9956; Doherty, Peter Charles/0000-0002-5028-3489; Sangster, Mark/0000-0002-1599-5894				BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; DYBEDAL I, 1995, J IMMUNOL, V154, P4950; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SALCEDO TW, 1993, J IMMUNOL, V151, P2511; SARAWAR SR, 1994, J VIROL, V68, P3112, DOI 10.1128/JVI.68.5.3112-3119.1994; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WOLF SF, 1994, STEM CELLS, V12, P154, DOI 10.1002/stem.5530120203; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	20	931	951	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					171	174		10.1038/382171a0	http://dx.doi.org/10.1038/382171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700208				2022-12-28	WOS:A1996UW67200051
J	Donaldson, MDC				Donaldson, MDC			Jury still out on growth hormone for normal short stature and Turner's syndrome	LANCET			English	Editorial Material											Donaldson, MDC (corresponding author), ROYAL HOSP SICK CHILDREN,GLASGOW G3 8SJ,LANARK,SCOTLAND.							CHU CE, 1995, HORM RES S1, V44, pA73; LOCHE S, 1994, J PEDIATR-US, V125, P196, DOI 10.1016/S0022-3476(94)70192-X; LYON AJ, 1985, ARCH DIS CHILD, V60, P932, DOI 10.1136/adc.60.10.932; ROSENFELD RG, 1992, J PEDIATR-US, V121, P49, DOI 10.1016/S0022-3476(05)82540-5; VANDENBROECK J, 1995, J PEDIATR-US, V127, P729, DOI 10.1016/S0022-3476(95)70161-3	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					3	4		10.1016/S0140-6736(05)64348-6	http://dx.doi.org/10.1016/S0140-6736(05)64348-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691928				2022-12-28	WOS:A1996UV92300003
J	Berg, DT; Wiley, MR; Grinnell, BW				Berg, DT; Wiley, MR; Grinnell, BW			Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator	SCIENCE			English	Article							STRUCTURAL-CHANGES; THROMBOMODULIN; BINDING; SPECIFICITY; SITE; ANTICOAGULANT; AFFINITY; ENZYME	A modulator of the enzymatic activity of human thrombin, designated LY254603, was identified that enhances the thrombin-catalyzed generation of the anticoagulant factor activated protein C, yet inhibits thrombin-dependent fibrinogen clotting, By means of mutant substrates, it was shown that LY254603 mediates the change in enzymatic substrate specificity through an alteration in thrombin's S3 substrate recognition site, a mechanism that appeared to be independent of allosteric changes induced by either sodium ions or by thrombomodulin. This compound may represent the prototype of a class of agents that specifically modulates the balance between thrombin's procoagulant and anticoagulant functions.	LILLY RES LABS,CARDIOVASC RES DIV,INDIANAPOLIS,IN 46285	Eli Lilly								AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BERLINER LJ, 1977, BIOCHEMISTRY-US, V16, P4622, DOI 10.1021/bi00640a015; CONERY BG, 1983, BIOCHEMISTRY-US, V22, P369, DOI 10.1021/bi00271a021; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; GRINNELL BW, 1990, PROTEIN C RELATED AN, P13; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIU LW, 1991, J BIOL CHEM, V266, P16977; MUSCI G, 1987, J BIOL CHEM, V262, P13889; OWEN WG, 1981, J BIOL CHEM, V256, P5532; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; RICHARDSON MA, 1994, PROTEIN SCI, V3, P711; SADLER JE, 1993, HAEMOSTASIS, V23, P183; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; YE J, 1991, J BIOL CHEM, V266, P23016	24	44	46	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1389	1391		10.1126/science.273.5280.1389	http://dx.doi.org/10.1126/science.273.5280.1389			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703074				2022-12-28	WOS:A1996VF61000043
J	Dunn, MR; Miller, RS				Dunn, MR; Miller, RS			The shifting sands of graduate medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Each year the American Medical Association (AMA) surveys all programs in graduate medical education (GME) accredited by the Accreditation Council for Graduate Medical Education. Because of the importance of GME in the national workforce policy debate, this year's survey report has been expanded to provide more detailed GME data. The authors describe the historical basis of the current GME workforce dilemma and the multiple forces that now tend to neutralize efforts to adapt to a changing marketplace. For example, as resident physicians find it increasingly difficult to locate suitable employment, one would expect a reduction in hospital-based programs and in the number of their resident physician appointments. Yet, while US medical graduates (USMGs) did not pursue certain programs in this year's National Resident Matching Program, AMA data show that during the past 2 years the reduced number of residents in hospital-based programs was almost exactly offset by the increased number in new and expanded programs. Also, more USMGs are leaving residency training to enter practice after 3 years of basic training in primary care (internal medicine, pediatrics, and family practice). At the same time, an increasing number of international medical graduates are remaining in subspecialty programs. Other examples are cited to show the ebb and flow of GME activities that behave like ''shifting sands.''			Dunn, MR (corresponding author), AMER MED ASSOC,DIV GRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							*COUNC GRAD MED ED, 1994, 4 COUNC GRAD MED ED; *I MED, 1996, NAT PHYS WORKF OPT B; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; PHILIBERT I, 1995, STUDY GROUP FUTURE G	6	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					710	713		10.1001/jama.276.9.710	http://dx.doi.org/10.1001/jama.276.9.710			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769550				2022-12-28	WOS:A1996VE23300010
J	Bleul, CC; Farzan, M; Choe, H; Parolin, C; ClarkLewis, I; Sodroski, J; Springer, TA				Bleul, CC; Farzan, M; Choe, H; Parolin, C; ClarkLewis, I; Sodroski, J; Springer, TA			The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; RECEPTOR CDNA; GENE; INTERLEUKIN-8; INFECTION; SEQUENCE; PROTEINS; CELLS	CHEMOKINES are chemotactic cytokines that activate and direct the migration of leukocytes(1,2). There are two subfamilies, the CXC and the CC chemokines, We recently found that the CXC-chemokine stromal cell-derived factor-1 (SDF-1)(3,4) is a highly efficacious lymphocyte chemoattractant(5). Chemokines act on responsive leukocyte subsets through G-protein-coupled seven-transmembrane receptors', which are also used by distinct strains of HIV-1 as cofactors for viral entry. Laboratory-adapted and some T-cell-line-tropic (T-tropic) primary viruses use the orphan chemokine receptor LESTR/fusin (also known as fusin)(6-8), whereas macrophage-tropic primary HIV-1 isolates use CCR-5 and CCR-3 (refs 7-11), which are receptors for known CC chemokines, Testing of potential receptors demonstrated that SDF-1 signalled through, and hence 'adopted', the orphan receptor LESTR, which we therefore designate CXC-chemokine receptor-4 (CXCR-4). SDF-1 induced an increase in intracellular free Ca2+ and chemotaxis in CXCR-4-transfected cells. Because SDF-1 is a biological ligand for the HIV-1 entry cofactor LESTR, we tested whether it inhibited HIV-1, SDF-1 inhibited infection by T-tropic HIV-1 of HeLa-CD4 cells, CXCR-4 transfectants, and peripheral blood mononuclear cells (PBMCs), but did not affect CCR-5-mediated infection by macrophage-tropic (M-tropic) and dual-tropic primary HIV-1.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHO,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; UNIV PADUA,INST MICROBIOL,I-35121 PADUA,ITALY; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Padua; University of British Columbia				Farzan, Michael/0000-0002-2990-5319				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ASJO B, 1986, LANCET, V2, P660; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BLEUL CC, IN PRESS J EXP MED; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LOETSCHER M, IN PRESS J EXP MED; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; PAROLIN C, 1994, J VIROL, V68, P3888, DOI 10.1128/JVI.68.6.3888-3895.1994; PAROLIN C, IN PRESS J VIROL, V222; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; ROTH SJ, 1995, J IMMUNOL METHODS, V100, P97; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; YENUSH L, 1994, J BIOL CHEM, V269, P100	29	1700	1807	1	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					829	833		10.1038/382829a0	http://dx.doi.org/10.1038/382829a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752280				2022-12-28	WOS:A1996VE34700053
J	Hans, D; DargentMolina, P; Schott, AM; Sebert, JL; Cormier, C; Kotzki, PO; Delmas, PD; Pouilles, JM; Breart, G; Meunier, PJ				Hans, D; DargentMolina, P; Schott, AM; Sebert, JL; Cormier, C; Kotzki, PO; Delmas, PD; Pouilles, JM; Breart, G; Meunier, PJ			Ultrasonographic heel measurements to predict hip fracture in elderly women: The EPIDOS prospective study	LANCET			English	Article							X-RAY ABSORPTIOMETRY; ULTRASOUND MEASUREMENTS; BONE-DENSITY; OS CALCIS; OSTEOPOROSIS; RISK; MASS	Background The ability of ultrasonographic measurements to discriminate between patients with hip fracture and age-matched controls has until now been tested mainly through cross-sectional studies. We report the results of a prospective study to assess the value of measurements with ultrasound in predicting the risk of hip fracture. Methods 5662 elderly women (mean age 80 . 4 years) had both baseline calcaneal ultrasonography measurements and femoral radiography (dual-photon X-ray absorptiometry, DPXA) to assess their bone quality. Follow-up every 4 months enabled us to identify incident fractures, 115 hip fractures were recorded during a mean follow-up duration of 2 years. Findings Low calcaneal ultrasonographic variables (obtained from measurements of broadband ultrasound attenuation by, and speed of sound through the bone) were able to predict an increased risk of hip fracture, with similar accuracy to low femoral bone mineral density (BMD) obtained by DPXA. The relative risk of hip fracture for 1 SD reduction was 2 . 0 (95% CI 1 . 6-2 . 4) for ultrasound attenuation and 1 . 7 (1 . 4-2 . 1) for speed of sound, compared with 1 . 9 (1 . 6-2 . 4) for BMD. After control for the femoral neck BMD, ultrasonographic variables remained predictive of hip fracture. The incidence of hip fracture among women with values above the median for both calcaneal ultrasound attenuation and femoral neck BMD was 2 . 7 per 1000 woman-years, compared with 19 . 6 per 1000 woman-years for those with values below the median for both measures. Interpretation Ultrasonographic measurements of the os calcis predict the risk of hip fracture in elderly women living at home as well as DPXA of the hip does, and the combination of both methods makes possible the identification of women at very high or very low risk of fracture.	HOP EDOUARD HERRIOT, DEPT RHUMATOL & MALAD OSSEUSES, F-69437 LYON 03, FRANCE; INSERM, U149, VILLEJUIF, FRANCE; HOP NORD AMIENS, SERV RHUMATOL, AMIENS, FRANCE; HOP COCHIN, SERV RHUMATOL, F-75674 PARIS, FRANCE; HOP LAPEYRONIE, NUCL MED SERV, MONTPELLIER, FRANCE; HOP PURPAN, SERV ENDOCRINOL, TOULOUSE, FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier; CHU de Toulouse	Hans, D (corresponding author), HOP EDOUARD HERRIOT, INSERM, U403, PAVILLON F, F-69437 LYON 03, FRANCE.		Schott, Anne-Marie/V-7580-2018; Dargent-Molina, Patricia/N-3887-2017; Hans, Didier B/B-3208-2018	Schott, Anne-Marie/0000-0003-3337-4474; Dargent-Molina, Patricia/0000-0001-8596-6899; 				ASHMAN RB, 1984, J BIOMECH, V17, P349, DOI 10.1016/0021-9290(84)90029-0; BIOT MA, 1962, J ACOUST SOC AM, V34, P1254, DOI 10.1121/1.1918315; BOUXSEIN ML, 1995, J BONE MINER RES  S1, V10, P146; Chevalley T, 1991, Osteoporos Int, V1, P147, DOI 10.1007/BF01625444; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7; Duboeuf F, 1991, Osteoporos Int, V1, P242; HANS D, 1994, CALCIFIED TISSUE INT, V55, P94, DOI 10.1007/BF00297182; HANS D, 1995, BONE, V16, P295, DOI 10.1016/8756-3282(94)00041-7; KAUFMAN JJ, 1993, J BONE MINER RES, V8, P517; Langton C M, 1984, Eng Med, V13, P89, DOI 10.1243/EMED_JOUR_1984_013_022_02; Langton CM, 1991, OSTEOPOROSIS INT, V1, P194; MAUTALEN C, 1995, CALCIFIED TISSUE INT, V57, P165, DOI 10.1007/BF00310252; Melton L J 3rd, 1985, Clin Geriatr Med, V1, P525; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; PORTER RW, 1990, BMJ-BRIT MED J, V301, P638, DOI 10.1136/bmj.301.6753.638; SCHOTT AM, 1995, J BONE MINER RES, V10, P243; SCHOTT AM, 1995, J BONE MINER RES  S1, V10, P29; TURNER CH, 1995, OSTEOPOROSIS INT, V5, P130, DOI 10.1007/BF01623314; 1994, WHO TECHNICAL REPORT, V843, P1994	25	905	917	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	1996	348	9026					511	514		10.1016/S0140-6736(95)11456-4	http://dx.doi.org/10.1016/S0140-6736(95)11456-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757153				2022-12-28	WOS:A1996VD42700011
J	Bostom, AG; Cupples, LA; Jenner, JL; Ordovas, JM; Seman, LJ; Wilson, PWF; Schaefer, EJ; Castelli, WP				Bostom, AG; Cupples, LA; Jenner, JL; Ordovas, JM; Seman, LJ; Wilson, PWF; Schaefer, EJ; Castelli, WP			Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger - A prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRE-BETA LIPOPROTEIN; ENDOTHELIUM-DEPENDENT DILATION; LP(A) LIPOPROTEIN; MYOCARDIAL-INFARCTION; ARTERY DISEASE; HUMAN APOLIPOPROTEIN(A); GEL-ELECTROPHORESIS; LDL CHOLESTEROL; RISK; QUANTIFICATION	Objective.-To establish whether elevated lipoprotein(a) [Lp(a)], detected as a sinking pre-beta-lipoprotein band on electrophoresis of fresh plasma, is an independent risk factor for the development of premature coronary heart disease (CHD) in men. Design and Setting.-Prospective study of the Framingham offspring cohort. Participants.-A total of 2191 men aged 20 to 54 years old who were free of cardiovascular disease when they were examined between 1971 and 1975. Main Outcome Measures.-Incident CHD (myocardial infarction, coronary insufficiency, angina pectoris, or sudden cardiac death) occurring by age 55 years. Results.-After a median follow-up of 15.4 years, there were 129 CHD events. The relative risk (RR) estimates (with 95% confidence intervals [Cls]) for premature CHD derived from a proportional hazards model that included age, body mass index, and the dichotomized risk factor covariables elevated plasma Lp(a) level, total cholesterol level of 6.2 mmol/L (240 mg/dL) or more, high-density lipoprotein (HDL) level less than 0.9 mmol/L (35 mg/dL), smoking, glucose intolerance, and hypertension were as follows: elevated Lp(a) level, RR, 1.9 (95% Cl, 1.2-2.9), prevalence, 11.3%; total cholesterol level of 6.2 mmol/L or more, RR, 1.8 (95% Cl, 1.2-2.7), prevalence, 14.3%; HDL level of less than 0.9 mmol/L, RR, 1.8 (95% Cl, 1.2-2.6), prevalence, 19.2%; smoking, RR, 3.6 (95% Cl, 2.2-5.5), prevalence, 46.7%; glucose intolerance, RR, 2.7 (95% Cl, 1.4-5.3), prevalence, 2.6%; hypertension, RR, 1.2 (95% Cl, 0.8-1.8), prevalence, 26.3%. Conclusions.-Elevated plasma Lp(a) is an independent risk factor for the development of premature CHD in men, comparable in magnitude and prevalence (ie, attributable risk) to a total cholesterol level of 6.2 mmol/L (240 mg/dL) or more, or an HDL level less than 0.9 mmol/L (35 mg/dL).	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, EPIDEMIOL & BIOMETRY PROGRAM, FRAMINGHAM, MA USA; BOSTON UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL & BIOSTAT, BOSTON, MA USA; TUFTS UNIV, NEW ENGLAND MED CTR,LIPID METAB LAB,USDA, JEAN MAYER HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA	Framingham Heart Study; Boston University; Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA)	Bostom, AG (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, VITAMIN BIOAVAILABIL LAB, USDA, BOSTON, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016; Ordovas, Jose/B-8727-2013	Ordovas, Jose/0000-0002-7581-5680	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035243] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35243, HV-83-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1975, METABOLISM, V24, P1047, DOI 10.1016/0026-0495(75)90098-0; ALBERS JJ, 1974, LIPIDS, V9, P15, DOI 10.1007/BF02533209; Albers John J., 1994, Current Opinion in Lipidology, V5, P417, DOI 10.1097/00041433-199412000-00004; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ALVAREZ JJ, 1993, CLIN BIOCHEM, V26, P399, DOI 10.1016/0009-9120(93)90117-O; [Anonymous], 1990, SAS STAT US GUID VER; AVOGARO P, 1975, CLIN CHIM ACTA, V61, P239, DOI 10.1016/0009-8981(75)90413-1; BALLANTYNE D, 1973, J CLIN PATHOL, V26, P163, DOI 10.1136/jcp.26.3.163; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; BRECKENRIDGE WC, 1981, CLIN BIOCHEM, V14, P82, DOI 10.1016/S0009-9120(81)90755-4; BRUCKERT E, 1990, CLIN CHIM ACTA, V188, P71, DOI 10.1016/0009-8981(90)90147-K; CRAIG WY, 1992, CLIN CHEM, V38, P550; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; CUPPLES LA, NIH PUBLICATION; DAHLEN G, 1975, CLIN GENET, V8, P183; DAHLEN G, 1972, ACTA MED SCAND, P1; DAHLEN G, 1974, ACTA MED SCAND, V195, P341; EZRATTY A, 1993, BIOCHEMISTRY-US, V32, P4628, DOI 10.1021/bi00068a021; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; FRICK MH, 1974, ACTA MED SCAND, V195, P337; GALLE J, 1995, CIRCULATION, V92, P1582, DOI 10.1161/01.CIR.92.6.1582; GAMBERT P, 1980, CLIN CHIM ACTA, V100, P99, DOI 10.1016/0009-8981(80)90070-4; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HANSEN PR, 1994, EUR J CLIN INVEST, V24, P497, DOI 10.1111/j.1365-2362.1994.tb02381.x; HARVIE NR, 1970, P NATL ACAD SCI USA, V66, P99, DOI 10.1073/pnas.66.1.99; HEIBERG A, 1974, CLIN GENET, V5, P144; HERVIO L, 1993, BLOOD, V82, P392; HEWITT D, 1977, CLIN GENET, V11, P224; HEWITT D, 1982, CLIN GENET, V21, P301; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; KAWAKAMI K, 1989, CLIN CHIM ACTA, V185, P147, DOI 10.1016/0009-8981(89)90037-5; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LEERINK CB, 1992, THROMB HAEMOSTASIS, V68, P185; LINDEN L, 1976, SCAND J CLIN LAB INV, V36, P51, DOI 10.3109/00365517609068018; LOVEJOY K, 1994, CIRCULATION, V90, P504; MAHER VMG, 1995, JAMA-J AM MED ASSOC, V274, P1771, DOI 10.1001/jama.274.22.1771; MAHER VMG, 1995, CURR OPIN LIPIDOL, V6, P229, DOI 10.1097/00041433-199508000-00007; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MCNAMARA JR, 1989, J LIPID RES, V30, P747; MORTON NE, 1978, CLIN GENET, V14, P207; NAUCK M, 1995, CLIN CHEM, V41, P731; PAGAN A, 1982, GERONTOLOGY, V28, P381; PAGAN A, 1983, J CLIN CHEM CLIN BIO, V21, P267; PEARSON TA, 1989, CIRCULATION S2, V80, P102; PETEK W, 1972, CLIN CHIM ACTA, V38, P460, DOI 10.1016/0009-8981(72)90140-4; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RHOADS GG, 1978, AM J EPIDEMIOL, V108, P350, DOI 10.1093/oxfordjournals.aje.a112631; RIDER AK, 1970, CIRCULATION, V42, pII10; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; RIDKER PM, 1994, PRIMER PREVENTIVE CA, P205; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P86; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCANU AM, 1995, CLIN CHEM, V41, P170; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SCHULTZ JS, 1968, P NATL ACAD SCI USA, V61, P963, DOI 10.1073/pnas.61.3.963; SEMAN LJ, 1994, CLIN CHEM, V40, P400; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WAGENKNECHT LE, 1996, CIRCULATION, V93, P635; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WALDEN CE, 1983, ARTERIOSCLEROSIS, V3, P117, DOI 10.1161/01.ATV.3.2.117; WILLIAMS RR, 1990, ARCH INTERN MED, V150, P582, DOI 10.1001/archinte.150.3.582	70	340	355	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					544	548		10.1001/jama.276.7.544	http://dx.doi.org/10.1001/jama.276.7.544			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709403				2022-12-28	WOS:A1996VC10100030
J	Hagberg, M				Hagberg, M			Neck and arm disorders	BRITISH MEDICAL JOURNAL			English	Article							MUSCULOSKELETAL				Hagberg, M (corresponding author), NATL INST WORKING LIFE,SOLNA,SWEDEN.							AARAS A, 1994, ERGONOMICS, V37, P1679, DOI 10.1080/00140139408964945; BONGERS PM, 1993, SCAND J WORK ENV HEA, V19, P297, DOI 10.5271/sjweh.1470; GERR F, 1991, ANNU REV PUBL HEALTH, V12, P543; HAGBERG M, 1994, TXB OCCUPATIONAL ENV, P356; Kuorinka I, 1995, WORK RELATED MUSCULO	5	47	48	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					419	422						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD206	8761237				2022-12-28	WOS:A1996VD20600036
J	Watanabe, M				Watanabe, M			Reward expectancy in primate prefrontal neurons	NATURE			English	Article							UNIT-ACTIVITY; DELAYED-RESPONSE; MONKEY; CORTEX; MEMORY; PERFORMANCE; STIMULI; TASK	THE prefrontal cortex is important in the organization of goal-directed behaviour(1-3). When animals are trained to work for a particular goal or reward(4-7), reward 'expectancy' is processed by prefrontal neurons, Recent studies of the prefrontal cortex have concentrated on the role of working memory in the control of behaviour(8-10). In spatial delayed-response tasks, neurons in the prefrontal cortex shaw activity changes during the delay period between presentation of the cue and the reward(11-15), with some of the neurons being spatially specific (that is, responses vary with the cue position)(13-15). Here I report that the delay activity in prefrontal neurons is dependent also on the particular reward received for the behavioural response, and to the way the reward is given. It seems that the prefrontal cortex may monitor the outcome of goal-directed behaviour.			Watanabe, M (corresponding author), TOKYO METROPOLITAN INST NEUROSCI,DEPT PSYCHOL,MUSASHIDAI 2-6,FUCHU,TOKYO 183,JAPAN.							APICELLA P, 1992, J NEUROPHYSIOL, V68, P945, DOI 10.1152/jn.1992.68.3.945; CHATLOSH DL, 1992, LEARNING AND MEMORY : THE BEHAVIORAL AND BIOLOGICAL SUBSTRATES, P61; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster J.M., 1989, PREFRONTAL CORTEX; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; Luria A. R., 2012, HIGHER CORTICAL FUNC; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; NIKI H, 1974, BRAIN RES, V70, P346, DOI 10.1016/0006-8993(74)90324-2; NIKI H, 1976, BRAIN RES, V105, P79, DOI 10.1016/0006-8993(76)90924-0; NIKI H, 1979, BRAIN RES, V171, P213, DOI 10.1016/0006-8993(79)90328-7; Peterson G.B., 1984, P135; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; SAKAGAMI M, 1994, EXP BRAIN RES, V97, P423; SCHULTZ W, 1992, J NEUROSCI, V12, P4595, DOI 10.1523/jneurosci.12-12-04595.1992; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Tinklepaugh OL, 1928, J COMP PSYCHOL, V8, P197, DOI 10.1037/h0075798; TOLMAN EC, 1932, PURPOSIVE BEHAVIOR A; WATANABE M, 1992, EXP BRAIN RES, V89, P233; WATANABE M, 1989, NEUROSCI LETT, V101, P113, DOI 10.1016/0304-3940(89)90450-3; WATANABE M, 1990, EXP BRAIN RES, V80, P296	24	520	530	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					629	632		10.1038/382629a0	http://dx.doi.org/10.1038/382629a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757133				2022-12-28	WOS:A1996VC30300053
J	Yuasa, J; Hirano, S; Yamagata, M; Noda, M				Yuasa, J; Hirano, S; Yamagata, M; Noda, M			Visual projection map specified by topographic expression of transcription factors in the retina	NATURE			English	Article							FORK HEAD; CHICK; AXONS; GENE; ONCOGENE; FAMILY; ARBORIZATION; GRADIENTS; SYSTEM; BF-1	TOPOGRAPHICAL maps of neuronal connectivity occur in various brain regions(1). In the visual system of birds, retinal ganglion-cell axons from the anterior retina connect to a posterior part of the optic tectum, and posterior retinal axons connect to the anterior part, thereby establishing a point-to-point projection map(2,3). The chemoaffinity theory(4) predicts that the orderly retinotectal projection is generated by a topographical arrangement of molecules. We report here that me have found several genes topographically expressed along the nasotemporal (anterior-posterior) axis in the embryonic chicken retina. Among these, two transcriptional regulators, belonging to the winged-helix family(5) are expressed in a mutually exclusive manner in either the nasal or temporal part of the retina, Misexpression of each factor causes misprojection on the tectum along the rostrocaudal axis, showing that topographical expression of these transcription factors controls formation of the retinotectal map.	NATL INST BASIC BIOL,DIV MOL NEUROBIOL,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES,DEPT MOL BIOMECH,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Noda, Masaharu/D-7146-2016; Yamagata, Masahito/H-6695-2016	Noda, Masaharu/0000-0002-3796-524X; Yamagata, Masahito/0000-0001-8193-2931; Yuasa-Kawada, Junichi/0000-0002-1382-3159				CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DEITCHER DL, 1994, J NEUROSCI, V14, P486; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; DUTTING D, 1995, DEV BIOL, V167, P263, DOI 10.1006/dbio.1995.1022; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Homburger SA, 1996, DEV DYNAM, V206, P112, DOI 10.1002/(SICI)1097-0177(199605)206:1<112::AID-AJA10>3.0.CO;2-7; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ITASAKI N, 1991, DEVELOPMENT, V113, P1133; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; KAPRIELIAN Z, 1994, BIOESSAYS, V16, P1, DOI 10.1002/bies.950160102; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MEY J, 1992, J HIRNFORSCH, V33, P673; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, NEURON, V5, P733; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; WALTER J, 1987, DEVELOPMENT, V101, P909; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P1	30	111	117	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					632	635		10.1038/382632a0	http://dx.doi.org/10.1038/382632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757134				2022-12-28	WOS:A1996VC30300054
J	FleckPaladino, B				FleckPaladino, B			Welcome to Stone Harbour Mansion.	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					431	431						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691534				2022-12-28	WOS:A1996VA86300001
J	Shen, XT; Gorovsky, MA				Shen, XT; Gorovsky, MA			Linker histone H1 regulates specific gene expression but not global transcription in vivo	CELL			English	Article							TATA-BINDING PROTEIN; RNA POLYMERASE-II; TETRAHYMENA-THERMOPHILA; IN-VIVO; CRYSTAL-STRUCTURE; LARGEST SUBUNIT; CHROMATIN; SEQUENCE; CELLS; ORGANIZATION	In a linker histone H1 knockout strain (Delta H1) of Tetrahymena thermophila, the number of mature RNAs produced by genes transcribed by pol I and pol III and of most genes transcribed by pol II remains unchanged. However, H1 is required for the normal basal repression of a gene (ngoA) in growing cells but is not required for its activated expression in starved cells. Surprisingly, H1 is required for the activated expression of another gene (CyP) in starved cells but not for its repression in growing cells. Thus, H1 does not have a major effect on global transcription but can act as either a positive or negative gene-specific regulator of transcription in vivo.			Shen, XT (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.			Shen, Xuetong/0000-0002-4267-5298	NIGMS NIH HHS [GM21793] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021793] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIS CD, 1984, J CELL BIOL, V99, P1669, DOI 10.1083/jcb.99.5.1669; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; CALZONE FJ, 1983, J BIOL CHEM, V258, P6887; CECH TR, 1982, CELL NUCLEUS, P171; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKERT WA, 1978, EUR J BIOCHEM, V87, P607, DOI 10.1111/j.1432-1033.1978.tb12413.x; ENGBERG J, 1980, J MOL BIOL, V142, P289, DOI 10.1016/0022-2836(80)90274-0; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GOROVSKY MA, 1973, J PROTOZOOL, V20, P19, DOI 10.1111/j.1550-7408.1973.tb05995.x; GOROVSKY MA, 1980, ANNU REV GENET, V14, P203, DOI 10.1146/annurev.ge.14.120180.001223; GRIMES A, 1988, ANAL BIOCHEM, V172, P436, DOI 10.1016/0003-2697(88)90466-6; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KUCHINO Y, 1985, P NATL ACAD SCI USA, V82, P4758, DOI 10.1073/pnas.82.14.4758; LEWIN B, 1994, GENE, V5, P847; LI WB, 1989, NUCLEIC ACIDS RES, V17, P9621, DOI 10.1093/nar/17.23.9621; LINDER C, 1994, MOL CELL BIOL, V14, P2822, DOI 10.1128/MCB.14.4.2822; LOVE HD, 1988, MOL CELL BIOL, V8, P427, DOI 10.1128/MCB.8.1.427; MARTINDALE DW, 1983, MOL CELL BIOL, V3, P1857, DOI 10.1128/MCB.3.10.1857; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MILOSHEV G, 1994, P NATL ACAD SCI USA, V91, P11567, DOI 10.1073/pnas.91.24.11567; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PEDERSON DS, 1984, NUCLEIC ACIDS RES, V12, P3003, DOI 10.1093/nar/12.6.3003; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SIMPSON RT, 1993, COLD SPRING HARB SYM, V58, P237, DOI 10.1101/SQB.1993.058.01.028; STARGELL LA, 1990, NUCLEIC ACIDS RES, V18, P6637, DOI 10.1093/nar/18.22.6637; STARGELL LA, 1994, MOL CELL BIOL, V14, P723, DOI 10.1128/MCB.14.1.723; WHITE EM, 1988, MOL CELL BIOL, V8, P4780, DOI 10.1128/MCB.8.11.4780; Wolffe A., 1995, CHROMATIN STRUCTURE; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZLATANOVA J, 1992, J CELL SCI, V103, P889	49	266	268	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					475	483		10.1016/S0092-8674(00)80120-8	http://dx.doi.org/10.1016/S0092-8674(00)80120-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756729	hybrid			2022-12-28	WOS:A1996VC30900015
J	Willems, AR; Lanker, S; Patton, EE; Craig, KL; Nason, TF; Mathias, N; Kobayashi, R; Wittenberg, C; Tyers, M				Willems, AR; Lanker, S; Patton, EE; Craig, KL; Nason, TF; Mathias, N; Kobayashi, R; Wittenberg, C; Tyers, M			Cdc53 targets phosphorylated G1 cyclins for degradation by the ubiquitin proteolytic pathway	CELL			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; BUDDING YEAST; CONJUGATING ENZYME; GENE; MITOSIS; COMPLEX; INHIBITOR; DIVISION	In budding yeast, cell division is initiated in late Gf phase once the Cdc28 cyclin-dependent kinase is activated by the G1 cyclins Cln1, Cln2, and Cln3. The extreme instability of the Cln proteins couples environmental signals, which regulate Cln synthesis, to cell division. We isolated Cdc53 as a Cln2-associated protein and show that Cdc53 is required for Cln2 instability and ubiquitination in vivo. The Cln2-Cdc53 interaction, Cln2 ubiquitination, and Cln2 instability all depend on phosphorylation of Cln2. Cdc53 also binds the E2 ubiquitin-conjugating enzyme, Cdc34. These findings suggest that Cdc53 is a component of a. ubiquitin-protein ligase complex that targets phosphorylated G1 cyclins for degradation by the ubiquitin-proteasome pathway.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; SCRIPPS RES INST, DEPT MOL & CELL BIOL, LA JOLLA, CA 92037 USA; UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Scripps Research Institute; University of Toronto; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Cold Spring Harbor Laboratory			Tyers, Michael/ABE-3194-2021		NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043487] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline; NIGMS NIH HHS [GM43487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harlow E., 1988, ANTIBODIES LAB MANUA; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Kaiser C., 1994, METHODS YEAST GENETI; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MADURA K, 1993, J BIOL CHEM, V268, P12046; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SOPTA M, 1985, J BIOL CHEM, V260, P353; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1996, IN PRESS P NATL ACAD; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; YOON HJ, 1995, MOL CELL BIOL, V15, P4835	59	261	269	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					453	463		10.1016/S0092-8674(00)80118-X	http://dx.doi.org/10.1016/S0092-8674(00)80118-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756727	Bronze			2022-12-28	WOS:A1996VC30900013
J	Metzstein, MM; Hengartner, MO; Tsung, N; Ellis, RE; Horvitz, HR				Metzstein, MM; Hengartner, MO; Tsung, N; Ellis, RE; Horvitz, HR			Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces-2	NATURE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING SPECIFICITY; C-ELEGANS; CRYSTAL-STRUCTURE; BASIC REGION; PROTEIN; HLF; FUSION; E2A; DROSOPHILA	THE ces (for cell-death specification) genes of the nematode Caenorhabditis elegans the cell-death fate of individual cell types and are candidates for being the regulators of an evolutionarily conserved general pathway of programmed cell death(1-4). Here we present what we believe is the first molecular characterization of a ces gene. We cloned the gene ces-2, which is required to activate programmed cell death in the sister cells of the serotoninergic neurosecretory motor (NSM) neurons, and found that ces-2 encodes a basic region leucine-zipper (bZIP) transcription factor. The CES-2 protein is most similar to members of the PAR (proline- and acid-rich) subfamily of bZIP proteins and has DNA-binding specificity like that of PAR-family proteins. An oncogenic form of the mammalian PAR-family protein, hepatic leukaemia factor (HLF), is reported to effect programmed cell death in mammalian cells(5). On the basis of these observations, we suggest that some CES-2/PAR family transcription factors are evolutionarily conserved regulators of programmed cell death.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X				CAPOVILLA M, 1992, DEVELOPMENT, V114, P99; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLIS RE, 1991, DEVELOPMENT, V112, P591; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; HURST HC, 1994, TRANSCRIPTION FACTOR, V1; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; Sambrook J., 2002, MOL CLONING LAB MANU; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZHANG W, 1995, MOL CELL BIOL, V15, P6055	26	139	144	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					545	547		10.1038/382545a0	http://dx.doi.org/10.1038/382545a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700229				2022-12-28	WOS:A1996VB25800052
J	Stansfeld, S; Gallacher, J; Babisch, W; Shipley, M				Stansfeld, S; Gallacher, J; Babisch, W; Shipley, M			Road traffic noise and psychiatric disorder: Prospective findings from the Caerphilly study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									LLANDOUGH HOSP, MRC, EPIDEMIOL UNIT S WALES, PENARTH, S GLAM, WALES; BUNDESGESUNDHEITSAMT, INST WASSER & LUFTHYG, BERLIN, GERMANY; UNIV LONDON UNIV COLL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND	University of London; University College London; UCL Medical School	Stansfeld, S (corresponding author), UCL, SCH MED, DEPT PSYCHIAT, SOCIAL & COMMUNITY PSYCHIAT UNIT, LONDON W1N 8AA, ENGLAND.							Goldberg D.P, 1972, DETECTION PSYCHIAT I; STANSFELD SA, 1991, PSYCHOL MED, V21, P157, DOI 10.1017/S0033291700014744; STANSFELD SA, 1992, PSYCHOL MED, P1, DOI 10.1017/S0033291716002336; TARNOPOLSKY A, 1980, AIRCRAFT NOISE PREVA; 1984, J EPIDEMIOL COMMUNIT, V38, P259	5	58	60	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	1996	313	7052					266	267		10.1136/bmj.313.7052.266	http://dx.doi.org/10.1136/bmj.313.7052.266			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VA903	8704537	Green Published			2022-12-28	WOS:A1996VA90300026
J	Geelhoed, GC; Turner, J; Macdonald, WBG				Geelhoed, GC; Turner, J; Macdonald, WBG			Efficacy of a small single dose of oral dexamethasone for outpatient group: A double blind placebo controlled clinical trial	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED DOUBLE-BLIND; RACEMIC EPINEPHRINE; CROUP; LARYNGOTRACHEITIS; BUDESONIDE; CHILDREN	Objective-To assess the efficacy of a single dose of oral dexamethasone 0.15 mg/kg in children with mild croup not admitted to hospital. Design-Double blind, randomised, placebo controlled clinical trial. Setting-The emergency department of a tertiary paediatric hospital. Subjects-100 children aged 4-122 months presenting with mild croup, Intervention-A single oral dose of dexamethasone 0.15 mg/kg or placebo. Main outcome measure-Return to medical care with ongoing croup. Results-Baseline characteristics of the two treatment groups were similar. Eight children (all from the placebo group) returned to medical care with ongoing croup, one being admitted, There was no reported difference in duration of croup symptoms, duration of viral symptoms, or rate of return to medical care for other reasons. Conclusion-Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.			Geelhoed, GC (corresponding author), PRINCESS MARGARET HOSP CHILDREN,EMERGENCY DEPT,BOX D184 GPO,PERTH,WA 6001,AUSTRALIA.			Turner, Janette/0000-0003-3884-7875				CONNORS K, 1994, PEDIATR EMERG CARE, V4, P197; CRUZ MN, 1995, PEDIATRICS, V96, P220; GEELHOED GC, IN PRESS PEDIAT PULM; HUSBY S, 1993, ARCH DIS CHILD, V68, P352, DOI 10.1136/adc.68.3.352; JAMES JA, 1969, AM J DIS CHILD, V117, P511, DOI 10.1001/archpedi.1969.02100030513003; KAIRYS SW, 1989, PEDIATRICS, V83, P683; KLASSEN TP, 1994, NEW ENGL J MED, V331, P285, DOI 10.1056/NEJM199408043310501; KOREN G, 1983, AM J DIS CHILD, V137, P941, DOI 10.1001/archpedi.1983.02140360005002; KUUSELA AL, 1988, ACTA PAEDIATR SCAND, V77, P99, DOI 10.1111/j.1651-2227.1988.tb10606.x; LEIPZIG B, 1979, J PEDIATR-US, V94, P194, DOI 10.1016/S0022-3476(79)80821-5; MUHLENDAHL KE, 1982, HELV PAEDIATR ACTA, V37, P431; NOVIK A, 1960, Acta Otolaryngol Suppl, V158, P20; SUPER DM, 1989, J PEDIATR-US, V115, P323, DOI 10.1016/S0022-3476(89)80095-2; WESTLEY CR, 1978, AM J DIS CHILD, V132, P484, DOI 10.1001/archpedi.1978.02120300044008	14	57	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					140	142		10.1136/bmj.313.7050.140	http://dx.doi.org/10.1136/bmj.313.7050.140			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688774	Green Published			2022-12-28	WOS:A1996UY92100016
J	Henkemeyer, M; Orioli, D; Henderson, JT; Saxton, TM; Roder, J; Pawson, T; Klein, R				Henkemeyer, M; Orioli, D; Henderson, JT; Saxton, TM; Roder, J; Pawson, T; Klein, R			Nuk controls pathfinding of commissural axons in the mammalian central nervous system	CELL			English	Article							RECEPTOR-TYROSINE KINASE; PROTEIN; EPH; LIGAND; ELK; DROSOPHILA; CLONING; FAMILY; BRAIN; MICE	Eph family receptor tyrosine kinases have been proposed to control axon guidance and fasciculation. To address the biological functions of the Eph family member Nuk, two mutations in the mouse germline have been generated: a protein null allele (Nuk(1)) and an allele that encodes a Nuk-beta gal fusion receptor lacking the tyrosine kinase and C-terminal domains (Nuk(lacZ)). In Nuk(1) homozygous brains, the majority of axons forming the posterior tract of the anterior commissure migrate aberrantly to the floor of the brain, resulting in a failure of cortical neurons to link the two temporal lobes. These results indicate that Nuk, a receptor that binds transmembrane ligands, plays a critical and unique role in the pathfinding of specific axons in the mammalian central nervous system.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOL BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; European Molecular Biology Laboratory (EMBL)			Pawson, Tony J/E-4578-2013; Roder, John/G-6468-2013; Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163; Henkemeyer, Mark/0000-0002-7525-1061; ORIOLI, DONATA/0000-0002-3830-3408				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CALZONETTI T, 1995, DEV BIOL, V171, P615, DOI 10.1006/dbio.1995.1309; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLETCHER FA, 1994, ONCOGENE, V9, P3241; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; His W., 1889, ABHANDL D MATH PHY K, V15, P675; Johnston JB, 1913, J COMP NEUROL, V23, P371, DOI 10.1002/cne.900230502; KATZ MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5936, DOI 10.1073/pnas.80.19.5936; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; Langelaan JA, 1908, BRAIN, V31, P221, DOI 10.1093/brain/31.2.221; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; MIHALKOVICS VV, 1877, ENTWICKLUNGSGESCHICH; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; Probst M, 1901, ARCH PSYCHIAT NERVEN, V34, P709, DOI 10.1007/BF02680175; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; Suitsu N, 1920, J COMP NEUROL, V32, P35, DOI 10.1002/cne.900320103; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONSZILY A, 1912, A VONGRAEFES ARCH OP, V81, P67; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WURST W, 1993, GENE TARGETING PRACT; Xu QL, 1995, DEVELOPMENT, V121, P4005	40	458	468	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					35	46		10.1016/S0092-8674(00)80075-6	http://dx.doi.org/10.1016/S0092-8674(00)80075-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689685	Bronze			2022-12-28	WOS:A1996UX93400006
J	BarreSinoussi, F				BarreSinoussi, F			HIV as the cause of AIDS	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION; GENE; IDENTIFICATION; RETROVIRUS; DIVERSITY; SEQUENCES; PROTEIN; PRODUCT; REGION	The two known types of HIV are members of a family of primate lentiviruses. HIV, like other retroviruses, contains a virus capsid, which consists of the major capsid protein, the nucleocapsid protein, the diploid single-stranded RNA genome, and the viral enzymes protease, reverse transcriptase, and integrase. HIV isolates show extensive genetic variability, resulting from the relatively low fidelity of reverse transcriptase in conjunction with the extremely high turnover of virions in vivo. These features of HIVs may have strong implications for vaccine development. Simian immunodeficiency viruses from naturally infected animals differ from HIV in one fundamental respect: they do not cause disease in their natural hosts. Study of these viruses may therefore lead to information about the interaction between lentiviruses and host immune response that could be exploited to combat AIDS.			BarreSinoussi, F (corresponding author), INST PASTEUR,UNIT BIOL RETROVIRUS,25 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE.		Barre-Sinoussi, Françoise/G-8355-2011					BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENN S, 1985, SCIENCE, V230, P949, DOI 10.1126/science.2997922; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CALVEL F, 1986, SCIENCE, V233, P343; Coffin J. M., 1992, RETROVIRIDAE, V1, P19; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CULLEN BR, 1990, VIROLOGY, V178, P1, DOI 10.1016/0042-6822(90)90373-Y; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; EIGEN M, 1990, AIDS (London), V4, pS85; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; FUNG MSC, 1992, J VIROL, V66, P848, DOI 10.1128/JVI.66.2.848-856.1992; GAO F, 1994, J VIROL, V68, P7433, DOI 10.1128/JVI.68.11.7433-7447.1994; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HASELTINE WA, 1988, SCI AM, V259, P52, DOI 10.1038/scientificamerican1088-52; Hayami M, 1994, Curr Top Microbiol Immunol, V188, P1; HIRSCH VM, 1995, J VIROL, V69, P955, DOI 10.1128/JVI.69.2.955-967.1995; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLMES EC, 1995, J INFECT DIS, V171, P45, DOI 10.1093/infdis/171.1.45; JIN MJ, 1994, EMBO J, V13, P2935, DOI 10.1002/j.1460-2075.1994.tb06588.x; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kostrikis LG, 1996, J VIROL, V70, P445, DOI 10.1128/JVI.70.1.445-458.1996; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LOUSSERTAJAKA I, 1995, J VIROL, V69, P5640, DOI 10.1128/JVI.69.9.5640-5649.1995; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MCKNIGHT A, 1995, J VIROL, V69, P3167, DOI 10.1128/JVI.69.5.3167-3170.1995; MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MULLER MC, 1993, J VIROL, V67, P1227; MURPHY E, 1993, AIDS RES HUM RETROV, V9, P997, DOI 10.1089/aid.1993.9.997; MYERS G, 1994, AIDS RES HUM RETROV, V10, P1317, DOI 10.1089/aid.1994.10.1317; MYERS G, 1992, AIDS RES HUM RETROV, V8, P373, DOI 10.1089/aid.1992.8.373; MYERS G, 1994, HUMAN RETROVIRUSES 3; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PARK IW, 1995, J ACQ IMMUN DEF SYND, V8, P335; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; POPOVIC M, 1984, SCIENCE, V224, P500; RICHMAN DD, 1992, AIDS RES HUM RETROV, V8, P1065, DOI 10.1089/aid.1992.8.1065; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; Sharp P.M., 1994, AIDS S1, V8, pS27; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISS RA, 1993, RETROVIRIDAE, V2, P1; WENIGER BG, 1994, AIDS S2, V8, pS12; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	50	41	48	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					31	35		10.1016/S0140-6736(96)09058-7	http://dx.doi.org/10.1016/S0140-6736(96)09058-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691930				2022-12-28	WOS:A1996UV92300014
J	Block, SD; ClarkChiarelli, N; Peters, AS; Singer, JD				Block, SD; ClarkChiarelli, N; Peters, AS; Singer, JD			Academia's chilly climate for primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-SCHOOL; APPLICANTS	Objective.-To describe the attitudes toward and perceptions of primary care education and practice among academic health center constituents. Design and Participants.-Descriptive study using confidential telephone interviews (October 1993 to March 1994) of national stratified probability samples of first- and fourth-year medical students, residents, clinical faculty, internal medicine and pediatrics residency training directors and chairs, and deans (N=2293). Results.-Five areas were examined: respondents' specialty orientation, attitudes toward the competence of primary care physicians, encouragement and positive regard for primary care, exposure to primary care-related educational experiences, and socioemotional orientation. The response rate was 84%. Respondents generally perceive primary care tasks as not requiring high levels of expertise; nearly half believe that generalists are not the best physicians to manage patients with serious illness and that the quality of primary care research is inferior to that in other fields. Attitudes are more positive toward the quality of primary care teaching. Learners perceive little encouragement for generalist careers and negative attitudes toward generalists among faculty, and view the quality of their primary care training as inferior to that for specialty practice. Those who have progressed further in the academic medicine hierarchy generally report lower levels of socioemotional orientation than individuals at earlier phases of career development. Conclusions.-Despite changes in the health care system and in education, students and residents encounter an atmosphere that is chilly toward primary care. If medical educators seek to optimize enthusiasm and preparation for primary care careers, they must develop approaches to. changing the attitudes, values, and composition of their faculties.	HARVARD PILGRIM HLTH CARE,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV PSYCHIAT,BOSTON,MA 02115; HARVARD UNIV,GRAD SCH EDUC,CAMBRIDGE,MA 02138	Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University	Block, SD (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,BOSTON,MA 02215, USA.		Singer, Judith D/B-6846-2008	Singer, Judith D/0000-0002-5828-4961				ABBOTT LC, 1983, J FAM PRACTICE, V16, P1141; Allport G.W., 1954, NATURE PREJUDICE; BLAND CJ, 1995, ACAD MED, V70, P620, DOI 10.1097/00001888-199507000-00013; BLOOM SW, 1989, MED EDUC, V23, P228, DOI 10.1111/j.1365-2923.1989.tb01538.x; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; Funkenstein DH., 1978, MED STUDENTS MED SCH; Good DelVecchio., 1995, AM MED QUEST COMPETE, DOI [10.1525/california/9780520088962.001.0001, DOI 10.1525/CALIFORNIA/9780520088962.001.0001]; GRAUBARD BI, 1993, J AM STAT ASSOC, V88, P629, DOI 10.2307/2290345; Hunt DD, 1996, ACAD MED, V71, P665, DOI 10.1097/00001888-199606000-00022; Kalton G., 1983, INTRO SURVEY SAMPLIN, DOI DOI 10.4135/9781412984683; KASSLER WJ, 1991, ACAD MED, V66, P41, DOI 10.1097/00001888-199101000-00012; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; MARTINI CJM, 1994, JAMA-J AM MED ASSOC, V272, P661, DOI 10.1001/jama.272.9.661; PETERSDORF RG, 1992, NEW ENGL J MED, V326, P408, DOI 10.1056/NEJM199202063260610; PETERSDORF RG, 1993, ACAD MED, V68, P113, DOI 10.1097/00001888-199302000-00001; RABINOWITZ HK, 1993, NEW ENGL J MED, V328, P934, DOI 10.1056/NEJM199304013281307; Randlett RR, 1996, ACAD MED, V71, P697, DOI 10.1097/00001888-199606000-00028; Roos NP, 1980, EVAL HEALTH PROF, V3, P3, DOI [10.1177/016327878000300101, DOI 10.1177/016327878000300101]	19	78	78	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					677	682		10.1001/jama.276.9.677	http://dx.doi.org/10.1001/jama.276.9.677			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769544				2022-12-28	WOS:A1996VE23300004
J	Veloski, J; Barzansky, B; Nash, DB; Bastacky, S; Stevens, DP				Veloski, J; Barzansky, B; Nash, DB; Bastacky, S; Stevens, DP			Medical student education in managed care settings - Beyond HMOs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-MAINTENANCE-ORGANIZATIONS; PHYSICIAN WORKFORCE; PROMOTE QUALITY; SYSTEM; REFORM; PLAN; INSURANCE; BENEFITS; LESSONS; CENTERS	Objective.-To describe the educational experiences of students in managed care settings and to compare these with recommendations for preparing physicians to practice in managed care. Design.-We searched MEDLINE using the keywords ''medical education,'' ''managed care, ''health maintenance organization, and others; we manually checked the reference lists of identified articles and reports from 1969 to 1996. Survey information was obtained from all US medical schools in 1995 and 1996. Site visits were made to 6 managed care organizations selected according to size, geographic region, and involvement in education. Main Outcome Measures.-The extent to which schools use managed care settings for clinical education, the types of settings used, and the kinds of educational programs experienced. Results.-In 1995 and 1996, an average of 16% of schools required all students to have clerkships or other clinical experiences in a group/staff model HMO, and some students from another 46% of schools spent time in an HMO for clerkships or physical diagnosis/introduction to clinical medicine courses. About 85% of schools potentially exposed students to other types of managed care during 1 or more required clinical experiences in ambulatory, community-based settings. The learning objectives of these experiences did not explicitly address features unique to managed care such as cost containment and disease prevention. Conclusion.-The selection of managed care settings for undergraduate education is based on general clinical objectives rather than explicit goals tied to managed care. Whether these experiences in managed care settings help students to develop competencies for future practice in a managed care environment has not been demonstrated. While the feasibility of medical education in nonprofit group/staff model HMOs is well documented, it is not certain whether these models can be adapted to for-profit managed care settings.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, OFF HLTH POLICY & CLIN OUTCOMES, PHILADELPHIA, PA 19107 USA; AMER MED ASSOC, DIV UNDERGRAD MED EDUC, CHICAGO, IL 60610 USA; HLTH RESOURCES & SERV ADM, DIV MED, BUR HLTH PROFESS, US DEPT HHS, ROCKVILLE, MD USA; CASE WESTERN RESERVE UNIV, SCH MED, OFF DEAN, CLEVELAND, OH 44106 USA	Jefferson University; American Medical Association; United States Health Resources & Service Administration (HRSA); Case Western Reserve University	Veloski, J (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, CTR RES MED EDUC & HLTH CARE, 1025 WALNUT ST, PHILADELPHIA, PA 19107 USA.				PHS HHS [240-93-0040] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MD, 1987, HEALTH AFFAIR, V6, P71, DOI 10.1377/hlthaff.6.1.71; BARZANSKY B, 1995, JAMA-J AM MED ASSOC, V274, P716, DOI 10.1001/jama.274.9.716; BARZANSKY B, 1989, EVAL HEALTH PROF, V12, P300, DOI 10.1177/016327878901200305; Barzansky B, 1992, FLEXNER, P129; BOSCH SJ, 1973, J MED EDUC, V48, P144; BOSCH SJ, 1970, J AMER MED ASSOC, V212, P2101, DOI 10.1001/jama.212.12.2101; BRADLEY DW, 1988, J MED EDUC, V63, P611; BUCHANAN JR, 1987, J MED EDUC, V62, P100; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; CHRISTAKIS NA, 1995, JAMA-J AM MED ASSOC, V274, P706, DOI 10.1001/jama.274.9.706; COGGAN P, 1995, UNPUB FHP SCH MED; COLWILL JM, 1986, JAMA-J AM MED ASSOC, V255, P2643, DOI 10.1001/jama.255.19.2643; *COMM FUT PRIM CAR, 1994, DEF PRIM CAR; CORRIGAN JM, 1991, ACAD MED, V66, P656, DOI 10.1097/00001888-199111000-00002; *COUNC GRAD MED ED, 1995, 6 US DEP HLTH HUM SE; DANA B, 1969, MILBANK FUND Q, V47, P353; DARLING H, 1991, HEALTH AFFAIR, V10, P147, DOI 10.1377/hlthaff.10.4.147; Dorsey J L, 1973, Med Care, V11, P12, DOI 10.1097/00005650-197301000-00002; DORSEY JL, 1975, J MED EDUC, V50, P137; EMMONS D, 1995, SOCIOECONOMIC CHARAC; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FINOCCHIO LJ, 1995, ACAD MED, V70, P1023, DOI 10.1097/00001888-199511000-00021; FOREMAN S, 1986, J MED EDUC, V61, P11; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; GINZBERG E, 1995, JAMA-J AM MED ASSOC, V274, P1633, DOI 10.1001/jama.274.20.1633; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GREENLICK MR, 1992, JAMA-J AM MED ASSOC, V267, P1645, DOI 10.1001/jama.267.12.1645; GREENLICK MR, 1995, ACAD MED, V70, P179, DOI 10.1097/00001888-199503000-00007; *GROUP HLTH ASS AM, 1994, PRIM CAR PHYS REC RE; GROVER PL, 1977, J MED EDUC, V52, P338; GUMBINER R, 1994, INQUIRY-J HEALTH CAR, V31, P330; Hasan MM, 1996, NEW ENGL J MED, V334, P1055, DOI 10.1056/NEJM199604183341610; HOFT RH, 1982, NEW ENGL J MED, V307, P1681, DOI 10.1056/NEJM198212303072705; HUDSON JI, 1981, HLTH MAINTENANCE ORG; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; Inui TS, 1996, ACAD MED, V71, pS119, DOI 10.1097/00001888-199601000-00062; ISAACS JC, 1984, J MED EDUC, V59, P615; KAHN L, 1978, MED CARE, V16, P61, DOI 10.1097/00005650-197801000-00005; KIRZ HL, 1986, JAMA-J AM MED ASSOC, V256, P734, DOI 10.1001/jama.256.6.734; MILLER RH, 1994, ANNU REV PUBL HEALTH, V15, P437; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; Moore G T, 1986, Health Aff (Millwood), V5, P147, DOI 10.1377/hlthaff.5.1.147; MOORE GT, 1994, INQUIRY-J HEALTH CAR, V31, P276; MOORE GT, 1990, ACAD MED, V65, P427, DOI 10.1097/00001888-199007000-00001; MOORE GT, 1994, ACAD MED, V69, P983, DOI 10.1097/00001888-199412000-00017; MOORE GT, 1993, IMPACT MANAGED CARE; MOORE GT, 1988, HMO PRACT, V2, P122; Nudelman PM, 1996, NEW ENGL J MED, V334, P1057, DOI 10.1056/NEJM199604183341611; OLNESS K, 1975, J MED EDUC, V50, P687; PALSBO SE, 1993, RECRUITMENT EXPERIEN; PETERSDORF RG, 1995, ACAD MED, V70, pS41, DOI 10.1097/00001888-199507000-00019; REID WM, 1995, ACAD MED, V70, P662, DOI 10.1097/00001888-199508000-00005; RIVO ML, 1995, JAMA-J AM MED ASSOC, V274, P712, DOI 10.1001/jama.274.9.712; SHENKIN BN, 1995, JAMA-J AM MED ASSOC, V273, P1937, DOI 10.1001/jama.273.24.1937; STERN RS, 1977, NEW ENGL J MED, V297, P638, DOI 10.1056/NEJM197709222971205; Stevens DP, 1996, ACAD MED, V71, P133, DOI 10.1097/00001888-199602000-00014; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222	58	45	45	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					667	671		10.1001/jama.276.9.667	http://dx.doi.org/10.1001/jama.276.9.667			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE233	8769542				2022-12-28	WOS:A1996VE23300002
J	Pahor, M; Guralnik, JM; Ferrucci, L; Corti, MC; Salive, ME; Cerhan, JR; Wallace, RB; Havlik, RJ				Pahor, M; Guralnik, JM; Ferrucci, L; Corti, MC; Salive, ME; Cerhan, JR; Wallace, RB; Havlik, RJ			Calcium-channel blockade and incidence of cancer in aged populations	LANCET			English	Article							CELL-DEATH; DEPENDENT TISSUES; OLDER PERSONS; ANTAGONISTS; MORTALITY; DISEASE; RISK; APOPTOSIS; SURVIVAL; SERUM	Background Calcium-channel blockers can alter apoptosis, a mechanism for destruction of cancer cells. We examined whether the long-term use of calcium-channel blockers is associated with an increased risk of cancer. Methods Between 1988 and 1992 we carried out a prospective cohort study of 5052 people aged 71 years or more and who lived in three regions of Massachusetts, Iowa, and Connecticut USA. Those taking calcium-channel blockers (n=451) were compared with all other participants (n=4601). The incidence of cancer was assessed by survey of hospital discharge diagnoses and causes of death. These outcomes were validated by the cancer registry in the one region where it was available. Demographic variables, disability, cigarette smoking, alcohol consumption, blood pressure, body-mass index, use of other drugs, hospital admissions for other causes, and comorbidity were all assessed as possible confounding factors. Findings The hazard ratio for cancer associated with calcium-channel blockers (1549 person-years, 47 events) compared with those not taking calcium-channel blockers (17 225 person-years, 373 events) was 1 . 72 (95% CI 1 . 27-2 . 34, p=0 . 0005), after adjustment for confounding factors. A significant dose-response gradient was found. Hazard ratios associated with verapamil, diltiazem, and nifedipine did not differ significantly from each other. The results remained unchanged in community-specific analyses. The association between calcium-channel blockers and cancer was found with most of the common cancers. Interpretation Calcium-channel blockers were associated with a general increased risk of cancer in the study populations, which suggested a common mechanism. These observational findings should be confirmed by other studies.	CATHOLIC UNIV,DEPT INTERNAL MED & GERIATR,ROME,ITALY; NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; IST NAZL RIC & CURA PER GLI ANZIANI,DEPT GERIATR,FLORENCE,ITALY; UNIV IOWA,DEPT PREVENT MED & ENVIRONM HLTH,IOWA CITY,IA 52242	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Iowa				Cerhan, James/0000-0002-7482-178X	NATIONAL INSTITUTE ON AGING [N01AG002105, N01AG002107, N01AG002106] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-0-2107, N01-AG-0-2105, N01-AG-0-2106] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BATRA S, 1991, PROSTATE, V19, P299, DOI 10.1002/pros.2990190404; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CROWSON AN, 1995, NEW ENGL J MED, V333, P1429, DOI 10.1056/NEJM199511233332117; DALHOFF IK, 1991, EUR J CLIN PHARMACOL, V41, P313; DYER AR, 1975, LANCET, V1, P1051; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; FURBERG CD, 1995, J AM GERIATR SOC, V43, P1309, DOI 10.1111/j.1532-5415.1995.tb07411.x; Furberg CD, 1996, EUR HEART J, V17, P1142; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P94, DOI DOI 10.1001/JAMA.1963.03060120024016; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; *NIH, 1994, NIH PUBL; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PAHOR M, 1994, J AM GERIATR SOC, V42, P50, DOI 10.1111/j.1532-5415.1994.tb06073.x; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P638; RAY SD, 1993, FASEB J, V7, P453, DOI 10.1096/fasebj.7.5.8462787; RAYNOR WJ, 1981, AM J EPIDEMIOL, V113, P371, DOI 10.1093/oxfordjournals.aje.a113105; ROSE G. A., 1982, Monograph Series. World Health Organisation, V56; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STEIN G, 1990, ARCH TOXICOL, V64, P623, DOI 10.1007/BF01974690; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776; WHITFIELD J F, 1992, Critical Reviews in Oncogenesis, V3, P55; YUSUF S, 1995, CIRCULATION, V92, P1079, DOI 10.1161/01.CIR.92.5.1079; 1977, JAMA-J AM MED ASSOC, V237, P2385	36	299	302	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					493	497		10.1016/S0140-6736(96)04277-8	http://dx.doi.org/10.1016/S0140-6736(96)04277-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757150				2022-12-28	WOS:A1996VD42700008
J	Poulter, NR; Chang, CL; Farley, TMM; Meirik, O; Marmot, MG; DebertRibeiro, M; Medina, E; Artigas, J; Shen, H; Zhong, YH; Zhang, DW; Zhao, WJ; Rojas, O; Vessey, M; Heinemann, L; Donnan, S; Ho, S; Bartfai, G; Kisjanto, J; Wilks, R; Agwanda, R; Ruiz, R; KozuhNovak, M; Dusitsin, N; Virutamasen, P; Phanthumcinda, K; Koetsawang, S; PiyaAnant, M; Demirovic, J; Belkic, K; Mwandila, WS; Mutale, CM; Matenga, J; Wilson, A; Petitti, D; Perlman, J; Keleghan, J; Lawley, S; Smith, S; Shipley, M; Olsen, J; Thorogood, M				Poulter, NR; Chang, CL; Farley, TMM; Meirik, O; Marmot, MG; DebertRibeiro, M; Medina, E; Artigas, J; Shen, H; Zhong, YH; Zhang, DW; Zhao, WJ; Rojas, O; Vessey, M; Heinemann, L; Donnan, S; Ho, S; Bartfai, G; Kisjanto, J; Wilks, R; Agwanda, R; Ruiz, R; KozuhNovak, M; Dusitsin, N; Virutamasen, P; Phanthumcinda, K; Koetsawang, S; PiyaAnant, M; Demirovic, J; Belkic, K; Mwandila, WS; Mutale, CM; Matenga, J; Wilson, A; Petitti, D; Perlman, J; Keleghan, J; Lawley, S; Smith, S; Shipley, M; Olsen, J; Thorogood, M			Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study	LANCET			English	Article							BLOOD-PRESSURE; CEREBROVASCULAR-DISEASE; RISK; AGE	Background The association between use of oral contraceptives (OCs) and cerebral infarction was established in studies from northern Europe and the USA during the 1960s and 1970s. Since then, the constituents of hormonal OCs have changed and now contain lower doses of oestrogen and progestagen. Current recommendations restrict OC use to younger women who do not have other risk factors for cardiovascular disease, in this international study we assessed the risk of CC-associated first stroke in women from Europe and other countries throughout Vie world. Methods In this hospital-based, case-control study, we assessed the risk of ischaemic stroke in association with current use of combined OCs in 697 cases, aged 20-44 years, and 1962 age-matched hospital controls in 21 centres in Africa, Asia, Europe, and Latin America. The diagnosis of ischaemic stroke was almost exclusively based on computed tomography (CT), magnetic resonance imaging (MRI), or cerebral angiography carried out within 3 weeks of the clinical event. Ail cases and controls were interviewed while in hospital with the same questionnaire, which included information on medical and personal history, details of lifetime contraceptive use, and blood-pressure measurements before the most recent episode of OC use. Findings The overall odds ratio of ischaemic stroke was 2 . 99 (95% CI 1 . 65-5 . 40) in Europe and 2 . 93 (2 . 15-4 . 00) in the non-European (developing) countries, Odds ratios were lower in younger women and those who did not smoke, and less than 2 in women who did not have hypertension and who reported that their blood pressure had been checked before the current episode of OC use. By contrast, among current OC users with a history of hypertension, the odds ratio was 10 . 7 (2 . 04-56 . 6) in Europe and 14 . 5 (5 . 36-39 . 0) in the developing countries. In Europe, the odds ratio associated with current use of low-dose OCs (<50 mu g oestrogen) was 1 . 53 (0 . 71-3 . 31), whereas for higher-dose preparations it was 5 . 30 (2 . 56-11 . 0). In the developing countries, there was no significant difference between overall estimates of risk associated with use of low-dose or higher-dose OCs (3 . 26 [2 . 19-4 . 86] vs 2 . 71 [1 . 75-4 . 19]), This differential effect of dose in Europe and the developing countries is likely to be due to different levels of other risk factors among users of low-dose and higher-dose OCs in the two groups of countries. There was no significant increase in odds ratios with increasing duration of OC use among current users; odds ratios were not significantly increased after cessation of OC use. Interpretation The incidence of ischaemic stroke is low in women of reproductive age and any risk attributable to OC use is small. The risk can be further reduced if users are younger than 35 years, do not smoke, do not have a history of hypertension, and have blood pressure measured before the start of QC use. In such women OC preparations with low oestrogen doses may be associated with even lower risk.	WHO, UNDP UNFPA WHO WORLD BANK SPECIAL PROGRAMME RES D, CH-1211 GENEVA 27, SWITZERLAND; ESCOLA PAULISTA MED, DEPT PREVENT MED, SAO PAULO, BRAZIL; UNIV CHILE, ESCUELA SALUD PUBL, SANTIAGO, CHILE; ESCUELA MED, DEPT SALUD PUBL, VALPARAISO, CHILE; NATL RES INST FAMILY PLANNING, BEIJING, PEOPLES R CHINA; SICHUAN FAMILY PLANNING RES INST, CHENGDU, PEOPLES R CHINA; SHANGHAI INST PLANNED PARENTHOOD RES, SHANGHAI, PEOPLES R CHINA; UNIV VALLE, FAC SALUD, CALI, COLOMBIA; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; ZENTRUM EPIDEMIOL & GESUNDHEITSFORSCH, BERLIN, GERMANY; CHINESE UNIV HONG KONG, DEPT COMMUNITY MED, HONG KONG, HONG KONG; ALBERT SZENT GYORGYI MED UNIV, DEPT OBSTET & GYNAECOL, SZEGED, HUNGARY; UNIV INDONESIA, FAC MED, JAKARTA, INDONESIA; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; KENYA GOVT MED RES CTR, NAIROBI, KENYA; GRP INTERUNIV MEXICANO INVEST EPIDEMIOL SALUD REP, DURANGO, MEXICO; UNIV LJUBLJANA, INST PUBL HLTH, LJUBLJANA, SLOVENIA; CHULALONGKORN HOSP, DEPT OBSTET & GYNAECOL, BANGKOK, THAILAND; SIRIRAJ HOSP, SIRIRAJ FAMILY HLTH RES CTR, BANGKOK, THAILAND; UNIV BELGRADE, SCH MED, BELGRADE, YUGOSLAVIA; UNIV LUSAKA, TEACHING HOSP, LUSAKA, ZAMBIA; UNIV ZIMBABWE, DEPT MED, HARARE, ZIMBABWE; UCL, LONDON MED SCH, DEPT EPIDEMIOL & PUBL HLTH, LONDON, ENGLAND; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; KAISER PERMANENTE, PASADENA, CA USA; NIH, BETHESDA, MD 20892 USA; UNIV AARHUS, DANISH EPIDEMIOL SCI CTR, AARHUS, DENMARK; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND	United Nations Population Fund; World Health Organization; Universidade Federal de Sao Paulo (UNIFESP); Universidad de Chile; National Research Institute for Family Planning - China; Universidad del Valle; University of Oxford; Chinese University of Hong Kong; Szeged University; University of Indonesia; University West Indies Mona Jamaica; Kenya Medical Research Institute; University of Ljubljana; Chulalongkorn University; Mahidol University; University of Belgrade; University of Zimbabwe; University of London; University College London; University of Oxford; Kaiser Permanente; National Institutes of Health (NIH) - USA; Aarhus University; University of London; London School of Hygiene & Tropical Medicine	Poulter, NR (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002914] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1995, J Clin Epidemiol, V48, P1513; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; ARBUCKLE DD, 1982, PUBLIC HEALTH, V96, P96, DOI 10.1016/S0033-3506(82)80102-9; BICKERSTAFF E, 1975, NEUROLOGICAL COMPLIC; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BRITTON M, 1986, STROKE, V17, P861, DOI 10.1161/01.STR.17.5.861; CHANG KK, 1986, INT J GYNECOL OBSTET, V24, P421, DOI 10.1016/0020-7292(86)90032-9; FOGELHOLM R, 1973, ACTA NEUROL SCAND, V49, P415; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; JICK H, 1978, ANN INTERN MED, V89, P58, DOI 10.7326/0003-4819-89-1-58; KAY CR, 1981, LANCET, V1, P541; LAYDE PM, 1983, J ROY COLL GEN PRACT, V33, P75; LIDEGAARD O, 1986, STROKE, V17, P670, DOI 10.1161/01.STR.17.4.670; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LORENTZ IT, 1962, BRIT MED J, P1191; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MANN JI, 1976, BRIT J PREV SOC MED, V30, P94; MASI AT, 1970, ANN INTERN MED, V72, P111, DOI 10.7326/0003-4819-72-1-111; METTINGER KL, 1984, STROKE, V15, P795, DOI 10.1161/01.STR.15.5.795; METTINGER KL, 1984, ACTA NEUROL SCAND, V70, P415; Poulter NR, 1996, LANCET, V348, P505; POULTER NR, 1995, LANCET, V346, P1575; RAMCHARAN S, 1981, CTR POPULATION RES M; ROSENBERG L, 1985, JAMA-J AM MED ASSOC, V253, P2965, DOI 10.1001/jama.253.20.2965; Royal College of General Practitioners, 1974, OR CONTR HLTH; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; SHAH IH, 1994, WORLD HLTH STAT Q, V4, P1; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; THOROGOOD M, 1990, BRIT J FAMILY PLANNI, V0016; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; WHELTON PK, 1994, TXB HYPERTENSION; IN PRESS J EPIDEMIOL	36	297	302	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	1996	348	9026					498	505						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757151				2022-12-28	WOS:A1996VD42700009
J	Tang, MX; Jacobs, D; Stern, Y; Marder, K; Schofield, P; Gurland, B; Andrews, H; Mayeux, R				Tang, MX; Jacobs, D; Stern, Y; Marder, K; Schofield, P; Gurland, B; Andrews, H; Mayeux, R			Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; PARADIGM-BASED DIAGNOSIS; E ALLELE EPSILON-4; APOLIPOPROTEIN-E; HETEROGENEOUS POPULATION; DEMENTIA; RECEPTORS; NEURONS; WOMEN	Background Oestrogen use by postmenopausal women has many health benefits, but findings on the effect of oestrogen in Alzheimer's disease are conflicting. Oestrogen promotes the growth and survival of cholinergic neurons and could decrease cerebral amyloid deposition, both of which may delay the onset or prevent Alzheimer's disease. To investigate whether use of oestrogen during the postmenopausal period affects the risk of Alzheimer's disease, we studied 1124 elderly women who were initially free of Alzheimer's disease, Parkinson's disease, and stroke, and who were taking part in a longitudinal study of ageing and health in a New York City community. Methods Relative risks and age-at-onset distributions were calculated from simple and adjusted Cox proportional hazards models. Standard annual clinical assessments and criterion-based diagnoses were used in follow-up (range 1-5 years). Findings Overall, 156 (12.5%) women reported taking oestrogen after onset of menopause. The age at onset of Alzheimer's disease was significantly later in women who had taken oestrogen than in those who did not and the relative risk of the disease was significantly reduced (9/156 [5.8%] oestrogen users vs 158/968 [16.3%] non-users; 0.40 [95% CI 0.22-0.85], p<0.01), even after adjustment for differences in education, ethnic origin, and apolipoprotein-E genotype. Women who had used oestrogen for longer than 1 year had a greater reduction in risk; none of 23 women who were taking oestrogen at study enrolment has developed Alzheimer's disease. Interpretation Oestrogen use in postmenopausal women may delay the onset and decrease the risk of Alzheimer's disease. Prospective studies are needed to establish the dose and duration of oestrogen required to provide this benefit and to assess its safety in elderly postmenopausal women.	COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,TAUB CTR ALZHEIMERS DIS RES,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,DEPT PSYCHIAT,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute			Schofield, Peter/J-7133-2013	Stern, Yaakov/0000-0001-7542-3241; Jacobs, Diane/0000-0003-0886-6784	NATIONAL INSTITUTE ON AGING [P01AG007232, P50AG008702, R35AG010963] Funding Source: NIH RePORTER; NIA NIH HHS [AG08702, AG10963, AG07232] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P205; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; COLLET D, 1994, MODELLING SUVIVAL DA, P153; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HERBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354; HIXSON J, 1991, J LIPID RES, V31, P545; HONJO H, 1995, HORM METAB RES, V27, P204, DOI 10.1055/s-2007-979941; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRANDA RC, 1993, MOL CELL NEUROSCI, V4, P510, DOI 10.1006/mcne.1993.1063; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SIMPKINS JW, 1994, NEUROBIOL AGING, V15, pS195; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Singh M., 1993, Society for Neuroscience Abstracts, V19, P1254; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; TORANALLERAND CD, 1992, P NATL ACAD SCI USA, V89, P4668, DOI 10.1073/pnas.89.10.4668	28	1352	1392	2	88	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					429	432		10.1016/S0140-6736(96)03356-9	http://dx.doi.org/10.1016/S0140-6736(96)03356-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709781	Green Submitted, hybrid			2022-12-28	WOS:A1996VC67300009
J	Mirkin, CA; Letsinger, RL; Mucic, RC; Storhoff, JJ				Mirkin, CA; Letsinger, RL; Mucic, RC; Storhoff, JJ			A DNA-based method for rationally assembling nanoparticles into macroscopic materials	NATURE			English	Article							ORGANIC-SURFACES; MONOLAYERS; CATENANES; SILVER; SIZE	COLLOIDAL, particles of metals and semiconductors have potentially useful optical, optoelectronic and material properties(1-4) that derive from their small (nanoscopic) size. These properties might lead to applications including chemical sensors, spectroscopic enhancers, quantum dot and nanostructure fabrication, and microimaging methods(2-4). A great deal of control can now be exercised over the chemical composition, size and polydispersity(1,2) of colloidal particles, and many methods have been developed for assembling them into useful aggregates and materials, Here we describe a method for assembling colloidal gold nanoparticles rationally and reversibly into macroscopic aggregates. The method involves attaching to the surfaces of two batches of 13-nm gold particles non-complementary DNA oligonucleotides capped with thiol groups, which bind to gold, When we add to the solution an oligonucleotide duplex with 'sticky ends' that are complementary to the two grafted sequences, the nanoparticles self-assemble into aggregates, This assembly process can be reversed by thermal denaturation. This strategy should now make it possible to tailor the optical, electronic and structural properties of the colloidal aggregates by using the specificity of DNA interactions to direct the interactions between particles of different size and composition.			Mirkin, CA (corresponding author), NORTHWESTERN UNIV,DEPT CHEM,2145 SHERIDAN RD,EVANSTON,IL 60208, USA.		Mirkin, Chad A/E-3911-2010	Mirkin, Chad/0000-0002-6634-7627				BAIN CD, 1989, ANGEW CHEM INT EDIT, V28, P506, DOI 10.1002/anie.198905061; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; CHEN LQ, 1994, BIOCHEMISTRY-US, V33, P13540, DOI 10.1021/bi00250a005; COLVIN VL, 1992, J AM CHEM SOC, V114, P5221, DOI 10.1021/ja00039a038; CREIGHTON JA, 1979, J CHEM SOC FARAD T 2, V75, P790, DOI 10.1039/f29797500790; DUBOIS LH, 1992, ANNU REV PHYS CHEM, V43, P437, DOI 10.1146/annurev.pc.43.100192.002253; GRABAR KC, 1995, ANAL CHEM, V67, P735, DOI 10.1021/ac00100a008; Hayat MA, 1991, COLLOIDAL GOLD PRINC; HERRLEIN MK, 1995, J AM CHEM SOC, V117, P10151, DOI 10.1021/ja00145a042; HERRON N, 1990, J AM CHEM SOC, V112, P1322, DOI 10.1021/ja00160a004; LINNERT T, 1993, J PHYS CHEM-US, V97, P679, DOI 10.1021/j100105a024; MARSH TC, 1995, NUCLEIC ACIDS RES, V23, P696, DOI 10.1093/nar/23.4.696; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MUCIC RC, 1996, J CHEM SOC CHEM COMM, P555; Schmid G., 1994, CLUSTERS COLLOIDS; SEEMAN NC, 1993, NEW J CHEM, V17, P739; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SHEKHTMAN EM, 1993, NEW J CHEM, V17, P757; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WANG YL, 1991, BIOCHEMISTRY-US, V30, P5667, DOI 10.1021/bi00237a005; WELLS RD, 1988, J BIOL CHEM, V263, P1095	24	5362	5622	75	2690	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					607	609		10.1038/382607a0	http://dx.doi.org/10.1038/382607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757129				2022-12-28	WOS:A1996VC30300046
J	Jayson, MIV				Jayson, MIV			ABC of work related disorders - Back pain	BRITISH MEDICAL JOURNAL			English	Article											Jayson, MIV (corresponding author), UNIV MANCHESTER,HOPE HOSP,SALFORD BACK PAIN CTR,SALFORD M6 8HD,LANCS,ENGLAND.							BIGOS SJ, 1991, SPINE, V16, P1, DOI 10.1097/00007632-199101000-00001; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; CROFT PR, 1996, SPINE, V20, P2731; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; Health and Safety Executive, 1992, MAN HANDL GUID REG; HELIOVAARA M, 1991, SPINE, V16, P608, DOI 10.1097/00007632-199106000-00002; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002	7	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					355	358		10.1136/bmj.313.7053.355	http://dx.doi.org/10.1136/bmj.313.7053.355			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760750	Green Published			2022-12-28	WOS:A1996VC30000028
J	Strang, J; Sheridan, J; Barber, N				Strang, J; Sheridan, J; Barber, N			Prescribing injectable and oral methadone to opiate addicts: Results from the 1995 national postal survey of community pharmacies in England and Wales	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To establish the extent of prescribing injectable and oral methadone to opiate addicts and the practice characteristics and dispensing arrangements attached to these prescriptions. Design-National survey of 25% random sample of community (high street) pharmacies through postal questionnaire, with four mailings. Setting-England and Wales. Subjects-1 in 4 sample of all 10 616 community pharmacies, stratified by family health services authority. Main outcome measures-Data were collected on each prescription for controlled drugs currently being dispensed by pharmacies to misusers, describing the drug, form, dose, source (general practice or hospital; and NHS or private), and numbers of dispensing pick ups a week. Results-Methadone was the opiate most commonly dispensed to misusers (96.0% of 3846 opiate prescriptions). 79.6% of methadone prescriptions were for the oral liquid form, 11.0% for tablet, and 9.3% for injectable ampoules. More than one third of all methadone prescriptions were for weekly or fortnightly pick up, with a further third being for daily pick up. Tablets and ampoules were even less likely to be dispensed on a daily basis. Private prescriptions were significantly more likely than NHS ones to be for tablets or ampoules, to be for substantially higher daily doses, and to be collected on a weekly or fortnightly basis. Conclusions-The distinctively British practice of prescribing injectable methadone was found to be widespread and, contrary to guidance, to be as prevalent in non-specialist as specialist settings. In view of the frequent crushing and injecting of methadone tablets, clearer more authoritative guidance is needed on the contexts in which injectable methadone (tablets as well as ampoules) should be prescribed and on the responsibilities for monitoring and supervision which should be attached.	UNIV LONDON, SCH PHARM, LONDON WC1N 1AX, ENGLAND	University of London; University College London; University of London School of Pharmacy	Strang, J (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT, NATL ADDICT CTR, DE CRESPIGNY PK, DENMARK HILL, LONDON SE5 8AF, ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Sheridan, Janie/0000-0002-0312-3095				*ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; BALL JC, 1991, EFF METH MAIN TREATM; BAMMER G, 1993, ADDICTION, V88, P467; *DEP HLTH SCOTT HO, 1991, DRUG MIS DEP GUID CL; *DEP HLTH SOC SEC, 1984, GUID GOOD CLIN PRACT; DERKS JTM, 1990, DRUG MISUSE DEPENDEN, P85; *DRUG TREATM EFF T, 1996, REP DEP HLTH; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; *HOM OFF, 1994, STAT MIS DRUGS ADD N; LAUZON P, 1994, J SUBST ABUSE TREAT, V11, P457, DOI 10.1016/0740-5472(94)90099-X; MITCHESON M, 1994, HEROIN ADDICTION DRU, P178; POLKINGHORNE J, 1995, DRUG LINK        JAN, P1; Sheridan J, 1996, BRIT MED J, V313, P272, DOI 10.1136/bmj.313.7052.272; Strang J, 1994, HEROIN ADDICTION DRU, P192; Strang J., 1994, HEROIN ADDICTION DRU; STRANG J, 1989, INT REV PSYCHIATR, V1, P109; UCHTENHAGEN A, IN PRESS MED PRESCRI; WARD J, 1992, KEY ISSUES METHADONE	18	99	99	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	1996	313	7052					270	272		10.1136/bmj.313.7052.270	http://dx.doi.org/10.1136/bmj.313.7052.270			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VA903	8704540	Green Published			2022-12-28	WOS:A1996VA90300030
J	Stubbs, P; Collinson, P; Moseley, D; Greenwood, T; Noble, M				Stubbs, P; Collinson, P; Moseley, D; Greenwood, T; Noble, M			Prospective study of the role of cardiac troponin T in patients admitted with unstable angina	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; PROGNOSTIC VALUE; RISK; IDENTIFICATION; DEATH	Objective-To examine the prognostic significance and role in risk stratification of the biochemical marker troponin T in patients admitted with unstable angina. Design-Single centre, blinded, prospective study of patients admitted with chest pain. Setting-Coronary care unit of a district general hospital. Subjects-460 patients admitted with chest pain and followed up for a median of three years. 183 patients had a final diagnosis of unstable angina. Main outcome measures-Cardiac death, need for coronary revascularisation, or readmission with non-fatal myocardial infarction as first events. Results-62 (34%) unstable angina patients were troponin T positive. This group had significantly increased incidence rates of subsequent cardiac death (12 cases (19%) v 14 (12%)), coronary revascularisation (22 (35%) v 26 (21%)), death or revascularisation (33 (53%) v 40 (33%)), and death or non-fatal myocardial infarction (18 (29%) v 21 (17%)) compared with the troponin T negative group. In multiple logistic regression troponin T status was a highly significant predictor for the end points coronary revascularisation and cardiac death or revascularisation as first events. Conclusion-Troponin T in the serum of patients with unstable angina identifies a subgroup at higher risk of subsequent cardiac events and its measurement aids in risk factor stratification. The increased risk extends to two years after admission. Prospective randomised trials are required to identify optimum therapeutic strategies for this subgroup.	MAYDAY UNIV HOSP,LONDON CR7 7YE,ENGLAND; W MIDDLESEX UNIV HOSP,LONDON TW7 6AF,ENGLAND	Croydon University Hospital; Imperial College London	Stubbs, P (corresponding author), CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,ACAD UNIT CARDIOVASC MED,5TH FLOOR,S WING,LONDON W6 8RF,ENGLAND.							BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; COLLINSON PO, 1992, NEW ENGL J MED, V327, P1760; COLLINSON PO, 1993, ANN CLIN BIOCHEM, V30, P11, DOI 10.1177/000456329303000102; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DESERVI S, 1989, INT J CARDIOL, V22, P43, DOI 10.1016/0167-5273(89)90134-4; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GILLUM RF, 1984, AM HEART J, V108, P155; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HENG MK, 1976, BRIT HEART J, V38, P921; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; MULCAHY R, 1981, AM J CARDIOL, V48, P525, DOI 10.1016/0002-9149(81)90083-7; MURPHY JJ, 1992, BRIT HEART J, V67, P395; NORDLANDER R, 1979, BRIT HEART J, V41, P647; OLSON HG, 1981, CIRCULATION, V64, P674, DOI 10.1161/01.CIR.64.4.674; QUALE J, 1987, AM J CARDIOL, V58, P703; RAVKILDE J, 1993, SCAND J CLIN LAB INV, V53, P677, DOI 10.3109/00365519309092571; SEINO Y, 1993, LANCET, V342, P1236, DOI 10.1016/0140-6736(93)92216-G; *WHO, 1971, 82015 WHO EUR	20	166	168	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					262	264		10.1136/bmj.313.7052.262	http://dx.doi.org/10.1136/bmj.313.7052.262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704534	Green Published			2022-12-28	WOS:A1996VA90300023
J	Lee, JT; Strauss, WM; Dausman, JA; Jaenisch, R				Lee, JT; Strauss, WM; Dausman, JA; Jaenisch, R			A 450 kb transgene displays properties of the mammalian X-inactivation center	CELL			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; INSITU HYBRIDIZATION; DOSAGE COMPENSATION; STEM-CELLS; MOUSE; GENE; LOCUS; DIFFERENTIATION; CONSTRUCTION; EXPRESSION	X inactivation results in inactivation of one X chromosome to compensate for gene dosage differences between mammalian females and males. It requires the X-inactivation center (Xic) and Xist in cis. We report that introducing 450 kb of murine Xic/Xist sequences onto autosomes activates female dosage compensation in male ES cells. Xist is induced upon differentiation and can be expressed from both endogenous and ectopic loci, suggesting that elements for counting and choosing Xs are present in the transgene. Differentiating transgenic ES cells undergo excessive cell death. Postnatally, Xist is expressed only from the transgene. Ectopic Xist RNA structurally associates with the autosome and may inactivate a marker gene in cis. These results argue that the Xic is contained within 450 kb and that these sequences are sufficient for chromosome counting, choosing, and initiation of X inactivation.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lee, JT (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NCI NIH HHS [R35-CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BARR ML, 1962, ACTA CYTOL, V6, P34; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BELMONT AS, 1986, EXP CELL RES, V165, P165, DOI 10.1016/0014-4827(86)90541-0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CATTANACH BM, 1974, GENET RES, V23, P291, DOI 10.1017/S0016672300014932; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CLEMSON CM, 1996, J CELL BIOL, V132, P1; COOPER P, 1993, GENOMICS, V15, P570, DOI 10.1006/geno.1993.1109; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; GRAVES JAM, 1986, SOMAT CELL MOLEC GEN, V12, P275, DOI 10.1007/BF01570786; Heard E, 1996, HUM MOL GENET, V5, P441, DOI 10.1093/hmg/5.4.441; HEARD E, 1993, GENOMICS, V15, P559, DOI 10.1006/geno.1993.1108; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEE JT, 1992, GENOMICS, V12, P526, DOI 10.1016/0888-7543(92)90444-W; LEPPIG KA, 1993, HUM MOL GENET, V2, P883, DOI 10.1093/hmg/2.7.883; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MARTIN GR, 1978, NATURE, V271, P329, DOI 10.1038/271329a0; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Matsuura S, 1996, HUM MOL GENET, V5, P451, DOI 10.1093/hmg/5.4.451; MCGAHON AJ, 1995, CELL DEATH DIFFER, P153; MIGEON BR, 1994, TRENDS GENET, V10, P230, DOI 10.1016/0168-9525(94)90169-4; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; TAI HH, 1994, SOMAT CELL MOLEC GEN, V20, P171, DOI 10.1007/BF02254758; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4	42	269	280	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					83	94		10.1016/S0092-8674(00)80079-3	http://dx.doi.org/10.1016/S0092-8674(00)80079-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689690	Bronze			2022-12-28	WOS:A1996UX93400010
J	Kittner, SJ; Stern, BJ; Feeser, BR; Hebel, JR; Nagey, DA; Buchholz, DW; Earley, CJ; Johnson, CJ; Macko, RF; Sloan, MA; Wityk, RJ; Wozniak, MA				Kittner, SJ; Stern, BJ; Feeser, BR; Hebel, JR; Nagey, DA; Buchholz, DW; Earley, CJ; Johnson, CJ; Macko, RF; Sloan, MA; Wityk, RJ; Wozniak, MA			Pregnancy and the risk of stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUERPERIUM	Background It is widely believed that pregnancy increases the risk of stroke, but there are few data available to quantify that risk. Methods We identified all female patients 15 through 44 years of age in central Maryland and Washington, D.C., who were discharged from any of 46 hospitals in the study area in 1988 or 1991. Two neurologists reviewed each case, using data from the women's medical records. We determined whether the women had been pregnant at the time of the stroke or up to six weeks before it occurred. For purposes of this analysis, the six-week period after pregnancy could begin with an induced or spontaneous abortion or with the delivery of a live or stillborn child. Results Seventeen cerebral infarctions and 14 intracerebral hemorrhages occurred in women who were or had recently been pregnant (pregnancy-related strokes), and there were 175 cerebral infarctions and 48 intracerebral hemorrhages that were not related to pregnancy. For cerebral infarction, the relative risk during pregnancy, adjusted for age and race, was 0.7 (95 percent confidence interval, 0.3 to 1.6), but it increased to 8.7 for the postpartum period (after a live birth or stillbirth) (95 percent confidence interval, 4.6 to 16.7). For intracerebral hemorrhage, the adjusted relative risk was 2.5 during pregnancy (95 percent confidence interval, 1.0 to 6.4) but 28.3 for the postpartum period (95 percent confidence interval, 13.0 to 61.4). Overall, for either type of stroke during or within six weeks after pregnancy, the adjusted relative risk was 2.4 (95 percent confidence interval, 1.6 to 3.6), and the attributable, or excess, risk was 8.1 strokes per 100,000 pregnancies (95 percent confidence interval, 6.4 to 9.7). Conclusions The risks of both cerebral infarction and intracerebral hemorrhage are increased in the six weeks after delivery but nor during pregnancy itself. (C) 1996, Massachusetts Medical Society.	UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD 21201; UNIV MARYLAND,DEPT OBSTET & GYNECOL,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21218; SINAI HOSP,DIV NEUROL,BALTIMORE,MD 21215; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Sinai Hospital of Baltimore; Emory University	Kittner, SJ (corresponding author), UNIV MARYLAND,DEPT NEUROL,BRESSLER BLDG,RM 12-013,655 W BALTIMORE ST,BALTIMORE,MD 21201, USA.				NINDS NIH HHS [K08 NS001764-03, K08-NS01764-01A1, NS16332-11] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016332, P01NS016332, K08NS001764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIAS A G, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P100; ATRASH HK, 1995, OBSTET GYNECOL, V86, P700, DOI 10.1016/0029-7844(95)00200-B; Bureau of the Census, 1992, 1990 CENS POP GEN PO; CALABRESE LH, 1992, CLEV CLIN J MED, V59, P293, DOI 10.3949/ccjm.59.3.293; CROSS JN, 1968, BMJ-BRIT MED J, V3, P214, DOI 10.1136/bmj.3.5612.214; *CTR HLTH STAT, 1988, MAR VIT STAT ANN REP; CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P3; CUNNINGHAM FG, 1993, WILLIAMS OBSTET, P459; CUNNINGHAM FG, 1993, WILLIAMS OBSTET, P662; *DIV HLTH STAT, 1991, MAR VIT STAT ANN REP; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; GARNER BF, 1990, J RHEUMATOL, V17, P93; GROSSET DG, 1995, J NEUROL NEUROSUR PS, V58, P129, DOI 10.1136/jnnp.58.2.129; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; IREY NS, 1973, ARCH PATHOL, V96, P227; JOHNSON CJ, 1995, STROKE, V26, P46, DOI 10.1161/01.STR.26.1.46; KITTNER SJ, 1993, STROKE J CEREBRAL CI, V0024; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; *NATL CTR HLTH STA, 1991, 1988 VIT STAT US, V1; *NATL CTR HLTH STA, 1991, 1988 VIT STAT US A, V2; *NATL CTR HLTH STA, 1995, 1991 VIT STAT US A, V2; *NATL CTR HLTH STA, 1992, TRENDS PREGN PREGN R, V41; *NATL CTR HLTH STA, 1995, 1991 VIT STAT US, V1; NENCINI P, 1988, STROKE, V19, P977, DOI 10.1161/01.STR.19.8.977; Rohr J, 1996, ARCH NEUROL-CHICAGO, V53, P603, DOI 10.1001/archneur.1996.00550070041010; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHARSHAR T, 1995, STROKE, V26, P930, DOI 10.1161/01.STR.26.6.930; SIMOLKE GA, 1991, OBSTET GYNECOL, V78, P37; Stern B J, 1991, Md Med J, V40, P453; Stern B J, 1991, Md Med J, V40, P565; *US BUR CENS, 1992, CENS POP HOUS; WIEBERS DO, 1985, JAMA-J AM MED ASSOC, V254, P3055, DOI 10.1001/jama.254.21.3055	32	418	434	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					768	774		10.1056/NEJM199609123351102	http://dx.doi.org/10.1056/NEJM199609123351102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8703181	Green Accepted			2022-12-28	WOS:A1996VF78600002
J	Aapro, MS				Aapro, MS			Oral etoposide and palliative treatment for small-cell lung cancer	LANCET			English	Editorial Material											Aapro, MS (corresponding author), EUROPEAN INST ONCOL,DIV MED ONCOL,I-20141 MILAN,ITALY.							ARDIZZONI A, 1995, EUR J CANCER, V31, pS19; ARRIAGADA R, 1993, NEW ENGL J MED, V329, P1848, DOI 10.1056/NEJM199312163292504; CARNEY DN, 1994, CANCER CHEMOTH PHARM, V34, pS96, DOI 10.1007/BF00684871; DeJong RS, 1995, ANTICANCER RES, V15, P2319; HARPER C, 1996, P AM SOC CLIN ONCOL, V15, P27; MILLER AA, 1995, J CLIN ONCOL, V13, P1871, DOI 10.1200/JCO.1995.13.8.1871; PAYNE DG, 1994, CRIT REV ONCOL HEMAT, V16, P113, DOI 10.1016/1040-8428(94)90044-2; 1996, BRIT J CANCER, V73, P406	8	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					559	559		10.1016/S0140-6736(05)64791-5	http://dx.doi.org/10.1016/S0140-6736(05)64791-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774562				2022-12-28	WOS:A1996VF18600003
J	Vaidya, SG; Naik, UD; Vaidya, JS				Vaidya, SG; Naik, UD; Vaidya, JS			Effect of sports sponsorship by tobacco companies on children's experimentation with tobacco	BRITISH MEDICAL JOURNAL			English	Article									GOA CANC SOC,PANAJI 403001,GOA,INDIA; TATA MEM HOSP,BOMBAY 400012,MAHARASHTRA,INDIA	Tata Memorial Centre (TMC); Tata Memorial Hospital			Vaidya, Jayant S/F-7717-2010; Vaidya, Jayant S/A-7218-2008	Vaidya, Jayant S/0000-0003-1760-1278; Vaidya, Jayant S/0000-0003-1760-1278				CHARLTON A, 1992, BRIT J CANCER, V66, P1, DOI 10.1038/bjc.1992.207; CONEY S, 1990, LANCET, V335, P342; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; VAIDYA SG, 1993, ASSESSMENT EFFICACY	4	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					400	400						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761228				2022-12-28	WOS:A1996VD20600026
J	Lindbaek, M; Hjortdahl, P; Johnsen, ULH				Lindbaek, M; Hjortdahl, P; Johnsen, ULH			Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; INCIDENTAL ABNORMALITIES; MAXILLARY SINUSITIS; MANAGEMENT; SYMPTOMS; SURGERY	Objective-To compare the effectiveness of penicillin V and amoxycillin with placebo in treatment of adult patients with acute sinusitis. Design-Randomised, double blind, placebo controlled trial. Setting-Norwegian general practice. Subjects-130 adult patients with a clinical diagnosis of acute sinusitis confirmed by computed tomography. Main outcome measures-Subjective status after three and 10 days of treatment, difference in clinical severity score between day 0 and day 10 as evaluated by the general practitioner, difference in score from computed tomography on day 0 and day 10, and duration of sinusitis. Results-Amoxycillin and penicillin V led to significantly faster and better recovery than placebo. By day 10, 71 patients receiving antibiotic treatment (86%) considered themselves to be recovered or much better compared with 25 (57%) receiving placebo. The mean (95% confidence interval) reductions in clinical severity scores by day 10 were 5.4 (5.0 to 5.8) for penicillin V, 5.5 (4.9 to 6.0) for amoxycillin, and 3.4 (2.8 to 4.0) for placebo. For the antibiotic groups combined the number of patients with the greatest degree of improvement on computed tomography (scale 0-16)-that is, score 5-16 on day 10-was 31/83 (37%) compared with 10/44 (23%) receiving placebo. The median duration of the sinusitis was nine days in the amoxycillin group, 11 days in the penicillin V group, and 17 days in the placebo group. Conclusion-Penicillin V and amoxycillin are significantly more effective than placebo in the treatment of acute sinusitis.	UNIV OSLO, ULLEVAAL HOSP, DEPT NEURORADIOL, N-0407 OSLO, NORWAY	University of Oslo	Lindbaek, M (corresponding author), UNIV OSLO, DEPT GEN PRACTICE, BOX 1130, N-0317 OSLO, NORWAY.							AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BRETT AS, 1994, JAMA-J AM MED ASSOC, V271, P502, DOI 10.1001/jama.1994.03510310031023; COOKE LD, 1991, J LARYNGOL OTOL, V105, P278, DOI 10.1017/S0022215100115609; DEMELKER RA, 1991, BRIT J GEN PRACT, V41, P504; FACER GW, 1993, HEAD NECK SURG OTOLA, P366; GOODMAN AG, 1990, GOODMAN GILMANS PHAR; HANSEN JG, 1995, BRIT MED J, V311, P233, DOI 10.1136/bmj.311.6999.233; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; Hovelius B, 1986, INFEKTIONER PRIMARVA, P75; KALLINGS LO, 1983, SCAND J INFECT DIS, P9; LAINE FJ, 1992, AM J ROENTGENOL, V159, P849, DOI 10.2214/ajr.159.4.1529853; LINDBAEK M, 1996, IN PRESS ACTA RADIOL; LINDBAEK M, 1996, FAM MED, V28, P181; LINDBAEK M, 1995, TREATMENT ACUTE INFE, P125; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; MOSS AJ, 1986, CURRENT ESTIMATES NA, P667; POLLEI S, 1989, Postgraduate Radiology, V9, P242; Royal College of General Practitioners, 1986, MORB STAT GEN PRACT; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, P187; SODERSTROM M, 1991, SCAND J INFECT DIS, V23, P347, DOI 10.3109/00365549109024322; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; WALD ER, 1986, PEDIATRICS, V77, P795; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WINTHER B, 1990, OTOLARYNG HEAD NECK, V103, P876, DOI 10.1177/01945998901030S507; YLIKOSKI J, 1989, ORL J OTO-RHINO-LARY, V51, P175, DOI 10.1159/000276054; ZEIFER BA, 1993, HEAD NECK SURG OTOLA, P350	28	131	132	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1996	313	7053					325	329		10.1136/bmj.313.7053.325	http://dx.doi.org/10.1136/bmj.313.7053.325			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760738	Green Published			2022-12-28	WOS:A1996VC30000016
J	McDonald, IG; Daly, J; Jelinek, VM; Panetta, F; Gutman, JM				McDonald, IG; Daly, J; Jelinek, VM; Panetta, F; Gutman, JM			Opening Pandora's box: The unpredictability of reassurance by a normal test result	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS; ECHOCARDIOGRAPHY; ILLNESS; MURMURS	Objectives-To determine the rate of failure of patient reassurance after a normal test result and study the determinants of failure. Design-Replicated single case study with qualitative and quantitative data analysis. Setting-University teaching hospital. Subjects-40 consecutive patients referred for echocardiography either because of symptoms (10 patients) or because of a heart murmur (30), 39 were shown to have a normal heart. Interventions-Medical consultations and semistructured patient interviews were tape recorded. Structured interviews with consultant cardiologists were recorded in survey form. Main outcome measures-Patient recall of the explanation and residual understanding, doubt, and anxiety about the heart after the test and post-test consultation. Results-All 10 patients presenting with symptoms were left with anxiety about the heart despite a normal test result and reassurance by the consultant. Of 28 patients referred because of a murmur but shown to have no heart abnormality, 20 became anxious after detection of the murmur; 11 had residual anxiety despite the normal test result. Conclusions-Reassurance of the ''worried well''-anxious patients with symptoms or patients concerned by a health query resulting from a routine medical examination or from screening-constitutes a large part of medical practice, It seems to be widely assumed that explaining that tests have shown no abnormality is enough to reassure, The results of this study refute this and emphasise the importance of personal and social factors as obstacles to reassurance.	LA TROBE UNIV,SCH SOCIOL & ANTHROPOL,MELBOURNE,VIC 3065,AUSTRALIA; ALFRED HOSP,MELBOURNE,VIC 3181,AUSTRALIA	La Trobe University; Florey Institute of Neuroscience & Mental Health	McDonald, IG (corresponding author), ST VINCENTS HOSP,CTR STUDY CLIN PRACTICE,MELBOURNE,VIC 3065,AUSTRALIA.							BASS C, 1992, AM J MED S1A, V92, P125; CACERES CA, 1967, INNOCENT MURMUR PROB, P75; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; DALY J, 1989, SOCIOL HEALTH ILL, V11, P99, DOI 10.1111/1467-9566.ep10844255; DALY JM, 1993, HLTH CARE TECHNOLOGY, V9; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P544, DOI 10.7326/0003-4819-99-4-544; FITZPATRICK R, 1981, J NEUROL NEUROSUR PS, V44, P1061, DOI 10.1136/jnnp.44.12.1061; FLETCHER RH, 1982, CLIN EPIDEMIOLOGY ES, P54; HOWELL DC, 1987, STATISTICAL METHODS; HUNT LM, 1989, SOC SCI MED, V28, P945, DOI 10.1016/0277-9536(89)90324-9; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; MCDONALD IG, 1988, J CLIN EPIDEMIOL, V41, P151, DOI 10.1016/0895-4356(88)90089-3; MeKinlay JB, 1981, RELEVANCE SOCIAL SCI, P77; NEWBURGER JW, 1983, NEW ENGL J MED, V308, P61, DOI 10.1056/NEJM198301133080201; OAKLEY CM, 1987, J ANTIMICROB CHEMOTH, V20, P99, DOI 10.1093/jac/20.suppl_A.99; PILOWSKY I, 1969, BRIT J MED PSYCHOL, V42, P347, DOI 10.1111/j.2044-8341.1969.tb02089.x; Strauss AL., 1987, QUALITATIVE ANAL SOC, Vxv, P319; TUCKETT D, 1985, M EXP APPR SHAR IDE; 1992, LANCET, V339, P525	19	143	143	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					329	332		10.1136/bmj.313.7053.329	http://dx.doi.org/10.1136/bmj.313.7053.329			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VC300	8760739	Green Published			2022-12-28	WOS:A1996VC30000017
J	Walsh, LJ; Wong, CA; Pringle, M; Tattersfield, AE				Walsh, LJ; Wong, CA; Pringle, M; Tattersfield, AE			Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							INDUCED BONE LOSS; RHEUMATOID-ARTHRITIS; STEROID OSTEOPOROSIS; REPLACEMENT THERAPY; DEPENDENT ASTHMA; CALCITONIN; PATHOGENESIS; ETIDRONATE; MANAGEMENT; FRACTURES	Objective-To determine the prevalence of continuous use of oral steroids in the general population, the conditions for which they are prescribed, and the extent to which patients taking oral steroids are taking treatment to prevent osteoporosis. Design-A cross sectional study with a four year retrospective review of drug treatment. Setting-Eight large general practices in central and southern Nottinghamshire. Subjects-A population of 65 786 patients (52% women) registered with a general practitioner during 1995. Results-303 patients (65% (197) women) aged 12-94 years were currently taking ''continuous'' (for at least three months) oral corticosteroid treatment. This figure represents 0.5% of the total population and 1.4% (245/17 114) of patients aged 55 years or more (1.7% (166/9601) of women). The usual steroid was prednisolone (97% (294/303)), the mean dose was 8.0 mg/day, and the median duration of oral steroid treatment determined in 149 patients was three years. The most common conditions for which continuous oral steroids were prescribed were rheumatoid arthritis (23% (70)), polymyalgia rheumatica (22% (66)), and asthma or chronic obstructive airways disease (19% (59)). Only 41 (14%) of the 303 patients taking oral steroids had received treatment for the prevention of osteoporosis over the past four years. Although 37 of the 41 patients were women, only 10% (18/181) of the women over 45 years taking continuous oral corticosteroids were currently taking hormone replacement therapy. Conclusions-If our figures are typical then they suggest that over 250 000 people in the United Kingdom are taking continuous oral steroids and that most of these are taking no prophylaxis against osteoporosis.	QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Walsh, LJ (corresponding author), CITY HOSP NOTTINGHAM,DIV RESP MED,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.		Walsh, Laurence J/F-1210-2010	Walsh, Laurence J/0000-0001-5874-5687				ADACHI JD, 1994, J RHEUMATOL, V21, P1922; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49; DIAMOND T, 1995, AM J MED, V98, P459, DOI 10.1016/S0002-9343(99)80345-3; EASTELL R, 1995, J INTERN MED, V237, P439, DOI 10.1111/j.1365-2796.1995.tb00868.x; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; KANIS JA, 1993, OSTEOPOROSIS INT, V3, pS10; KHOSLA S, 1994, BONE, V15, P551, DOI 10.1016/8756-3282(94)90280-1; LUENGO M, 1994, THORAX, V49, P1099, DOI 10.1136/thx.49.11.1099; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; LUENGO M, 1990, AM REV RESPIR DIS, V142, P104, DOI 10.1164/ajrccm/142.1.104; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; LUKERT BP, 1994, CHEST, V105, P1640, DOI 10.1378/chest.105.6.1640; MULDER H, 1994, BRIT J RHEUMATOL, V33, P348; REID IR, 1988, LANCET, V2, P1144; REID IR, 1989, CLIN ENDOCRINOL, V30, P83, DOI 10.1111/j.1365-2265.1989.tb03730.x; REID IR, 1988, LANCET, V1, P143; RICE P, 1994, BRIT MED J, V309, P1069, DOI 10.1136/bmj.309.6961.1069; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; Sheldon TA, 1996, BRIT MED J, V312, P296; SPECTOR TD, 1993, BRIT MED J, V307, P519, DOI 10.1136/bmj.307.6903.519; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; WILSON S, 1995, AIMING HLTH YEAR 200	24	291	306	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					344	346		10.1136/bmj.313.7053.344	http://dx.doi.org/10.1136/bmj.313.7053.344			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760745	Green Published			2022-12-28	WOS:A1996VC30000023
J	Pollard, AJ; Isaacs, A; Lyall, EGH; Curtis, N; Lee, K; Walters, S; Levin, M				Pollard, AJ; Isaacs, A; Lyall, EGH; Curtis, N; Lee, K; Walters, S; Levin, M			Lesson of the Week - Potentially lethal bacterial infection associated with varicella zoster virus	BRITISH MEDICAL JOURNAL			English	Article							SHOCK-LIKE SYNDROME; TOXIC SHOCK; STAPHYLOCOCCAL ENTEROTOXINS; STREPTOCOCCAL BACTEREMIA; CHICKENPOX; CHILDREN		ST ALBANS & HEMEL HEMPSTEAD NHS TRUST,DEPT PAEDIAT,HEMEL HEMPSTEAD HP2 4AD,ESSEX,ENGLAND		Pollard, AJ (corresponding author), ST MARYS HOSP,SCH MED,PAEDIAT INFECT DIS UNIT,DEPT PAEDIAT,LONDON W2 1NY,ENGLAND.		Curtis, Nigel/B-3491-2012	Curtis, Nigel/0000-0003-3446-4594; Levin, Michael/0000-0003-2767-6919				ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; BARSON WJ, 1990, PEDIATR INFECT DIS J, V9, P146, DOI 10.1097/00006454-199002000-00019; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P77, DOI 10.1097/00006454-199101000-00017; BROGAN TV, 1995, PEDIATR INFECT DIS J, V14, P588, DOI 10.1097/00006454-199507000-00007; BROOK MG, 1991, POSTGRAD MED J, V67, P1013, DOI 10.1136/pgmj.67.793.1013; BROWN JL, 1983, CLIN PEDIATR, V22, P648; BRUNELL PA, 1992, TXB PEDIAT INFECTIOU, P1587; Bullowa JGM, 1935, AM J DIS CHILD, V49, P923; CHARATAN FB, 1995, BRIT MED J, V310, P824, DOI 10.1136/bmj.310.6983.824; CHRISTIE CDC, 1988, AM J DIS CHILD, V142, P559, DOI 10.1001/archpedi.1988.02150050097042; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; COWAN MR, 1994, ANN EMERG MED, V23, P818, DOI 10.1016/S0196-0644(94)70320-5; Curtis N, 1996, CURR OPIN INFECT DIS, V9, P191, DOI 10.1097/00001432-199606000-00012; CURTIS N, IN PRESS ADV PAEDIAT; DOCTOR A, 1995, PEDIATRICS, V96, P428; FISCHBACHER CM, 1987, SCAND J INFECT DIS, V19, P519, DOI 10.3109/00365548709032416; GELB LD, 1993, HUMAN HERPES VIRUSES, P287; GRIEBEL M, 1985, J PEDIATR ORTHOPED, V5, P101, DOI 10.1097/01241398-198501000-00020; GUESS HA, 1984, AM J DIS CHILD, V138, P1055, DOI 10.1001/archpedi.1984.02140490055013; JACKSON MA, 1992, PEDIATR INFECT DIS J, V11, P441, DOI 10.1097/00006454-199206000-00004; JACOBSON JA, 1983, JAMA-J AM MED ASSOC, V249, P922; Joseph Samuel G., 1993, Journal of the American Osteopathic Association, V93, P941; JOSEPH SG, 1993, J AM OSTEOPATH ASSOC, V93, P946; KOPEC J S, 1990, Pediatric Emergency Care, V6, P38, DOI 10.1097/00006565-199003000-00012; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KPOTB M, 1995, CLIN MICROBIOL REV, V8, P411; LEGGIADRO RJ, 1993, SOUTHERN MED J, V86, P615, DOI 10.1097/00007611-199306000-00004; LEVIN M, 1995, J PEDIATR-US, V127, P355, DOI 10.1016/S0022-3476(95)70063-3; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; Peterson CL, 1996, PEDIATR INFECT DIS J, V15, P151, DOI 10.1097/00006454-199602000-00012; RAPHAEL SA, 1989, PEDIATR INFECT DIS J, V8, P187; SMITH EWP, 1976, PEDIATRICS, V57, P306; STERNBACH G, 1994, PEDIATR EMERG CARE, V10, P377, DOI 10.1097/00006565-199412000-00019; TORRESMARTINEZ C, 1992, ARCH DIS CHILD, V67, P126, DOI 10.1136/adc.67.1.126; Vugia DJ, 1996, PEDIATR INFECT DIS J, V15, P146, DOI 10.1097/00006454-199602000-00011; WALD ER, 1973, J PEDIATR-US, V83, P1017, DOI 10.1016/S0022-3476(73)80538-4; WALSH M, 1994, AM J EMERG MED, V12, P602, DOI 10.1016/0735-6757(94)90280-1; WILEY JF, 1989, ANN EMERG MED, V18, P785, DOI 10.1016/S0196-0644(89)80021-6; WONG VK, 1988, AM J DIS CHILD, V142, P831, DOI 10.1001/archpedi.1988.02150080037016	40	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					283	285		10.1136/bmj.313.7052.283	http://dx.doi.org/10.1136/bmj.313.7052.283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704543	Green Published			2022-12-28	WOS:A1996VA90300033
J	Kolanus, W; Nagel, W; Schiller, B; Zeitlmann, L; Godar, S; Stockinger, H; Seed, B				Kolanus, W; Nagel, W; Schiller, B; Zeitlmann, L; Godar, S; Stockinger, H; Seed, B			alpha L beta 2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1, a cytoplasmic regulatory molecule	CELL			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; OUT SIGNAL-TRANSDUCTION; BRUTON TYROSINE KINASE; CELL-ADHESION; T-CELL; LYMPHOCYTE ADHESION; LIGAND-BINDING; GPIIB-IIIA; PH DOMAIN; PROTEIN	The avidity of integrin adhesion receptors for extracellular ligands is subject to dynamic regulation by intracellular programs that have yet to be elucidated. We describe here a protein, cytohesin-1, which specifically interacts with the intracellular portion of the integrin beta 2 chain (CD18). The molecule shows homology to the yeast SEC7 gene product and bears a pleckstrin homology (PH) domain. Overexpression of either the full-length cytohesin-1 or the SEC7 domain induces beta 2 integrin-dependent binding of Jurkat cells to ICAM-1, whereas expression of the isolated cytohesin-1 PH domain inhibits T cell receptor-stimulated adhesion. Similar inhibition is not exhibited by PH domains taken from other proteins, showing that the interaction is specific and that individual PH domains are capable of discriminating between alternative targets.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT BIOL MOL, BOSTON, MA 02114 USA; UNIV VIENNA, VIRCC, INST IMMUNOL, A-1235 VIENNA, AUSTRIA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Vienna	Kolanus, W (corresponding author), UNIV MUNICH, MOL BIOL LAB, GENZENTRUM, D-81375 MUNICH, GERMANY.		Zeitlmann, Lutz/AAF-3586-2019; Stockinger, Hannes/E-5173-2011	Stockinger, Hannes/0000-0001-6404-4430	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAZIL V, 1990, FOLIA BIOL-PRAGUE, V36, P41; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MEIJNE AML, 1994, J CELL SCI, V107, P2557; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	59	392	406	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1996	86	2					233	242		10.1016/S0092-8674(00)80095-1	http://dx.doi.org/10.1016/S0092-8674(00)80095-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706128	Bronze			2022-12-28	WOS:A1996UZ97200009
J	Raff, MC				Raff, MC			Size control: The regulation of cell numbers in animal development	CELL			English	Review							INHIBITORS; CYCLE		UCL, DEPT BIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	Raff, MC (corresponding author), UCL, MRC, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND.							Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FRANKHAUSER G, 1952, INT REV CYTOL, V1, P165; Hara E, 1996, MOL CELL BIOL, V16, P859; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; METCALF D, 1963, AUST J EXP BIOL MED, V41, P437, DOI 10.1038/icb.1963.64; METCALF D, 1964, TRANSPLANTATION, V2, P387, DOI 10.1097/00007890-196405000-00008; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WILLEMS AR, 1996, IN PRESS CELL, V86	20	168	172	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1996	86	2					173	175		10.1016/S0092-8674(00)80087-2	http://dx.doi.org/10.1016/S0092-8674(00)80087-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706120	Bronze			2022-12-28	WOS:A1996UZ97200001
J	Sanderson, J				Sanderson, J			The SWORD of Damocles	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR ARRHYTHMIAS; MORTALITY; AMIODARONE; PLACEBO; TRIAL				Sanderson, J (corresponding author), CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT MED, SHATIN, HONG KONG.							CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; NAVARROLOPEZ F, 1993, AM J CARDIOL, V72, P1243, DOI 10.1016/0002-9149(93)90291-J; PFISTERER ME, 1993, CIRCULATION, V87, P309, DOI 10.1161/01.CIR.87.2.309; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201	10	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1996	348	9019					2	3		10.1016/S0140-6736(05)64347-4	http://dx.doi.org/10.1016/S0140-6736(05)64347-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691925				2022-12-28	WOS:A1996UV92300002
J	Ginzberg, E				Ginzberg, E			The health care market - Theory and reality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Ginzberg, E (corresponding author), COLUMBIA UNIV,EISENHOWER CTR CONSERVAT HUMAN RESOURCES,MAIL CODE 7740,2960 BROADWAY,NEW YORK,NY 10027, USA.							*CAL HEALTHC ASS, 1996, CAL HLTH CAR 1996 20; Levit KR, 1996, HEALTH CARE FINANC R, V17, P205; US Bureau of the Census, 1995, STAT ABSTR US	3	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					777	778		10.1001/jama.276.10.777	http://dx.doi.org/10.1001/jama.276.10.777			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769580				2022-12-28	WOS:A1996VF21900011
J	Kang, HJ; Schuman, EM				Kang, HJ; Schuman, EM			A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity	SCIENCE			English	Article							LONG-TERM POTENTIATION; MESSENGER-RNA; DENTATE GYRUS; GRANULE CELLS; NITRIC-OXIDE; LATE-PHASE; CRITICAL PERIOD; NERVOUS-SYSTEM; OLFACTORY-BULB; NEURONS	Two neurotrophic factors,brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), are able to produce a long-lasting enhancement of synaptic transmission in the hippocampus. Unlike other forms of plasticity, neurotrophin-induced plasticity exhibited an immediate requirement for protein synthesis. Plasticity in rat hippocampal slices in which the synaptic neuropil was isolated from the principal cell bodies also required early protein synthesis. Thus, the neurotrophins may stimulate the synthesis of proteins in either axonal or dendritic compartments, allowing synapses to exert local control over the complement of proteins expressed at individual synaptic sites.	CALTECH,DIV BIOL 216 76,PASADENA,CA 91125	California Institute of Technology			Schuman, Erin M/D-6204-2011					ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; AMARAL D, COMMUNICATION; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS L, 1992, J NEUROSCI, V12, P4867; FEIG S, 1993, J NEUROSCI, V13, P1010; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GIOIO AE, 1994, J NEUROCHEM, V63, P13; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Harris K. M., 1995, Society for Neuroscience Abstracts, V21, P594; IP NY, 1993, J NEUROSCI, V13, P3394; JOHNSTON HM, 1995, MOL BRAIN RES, V31, P141, DOI 10.1016/0169-328X(95)00046-U; JOHNSTON HM, 1994, J NEUROCHEM, V63, P379; JOHNSTON HM, 1994, NEUROSCI LETT, V177, P5, DOI 10.1016/0304-3940(94)90031-0; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; KANG H, IN PRESS LEARN MEM; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KLEIMAN R, 1994, J NEUROSCI, V14, P1130, DOI 10.1523/JNEUROSCI.14-03-01130.1994; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; LAMBALLE F, 1994, J NEUROSCI, V14, P14; LAUTERBORN JC, 1993, NEUROREPORT, V5, P273, DOI 10.1097/00001756-199312000-00023; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MARSH HN, 1993, J NEUROSCI, V13, P4281; Marty S, 1996, J NEUROSCI, V16, P675; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIYASHIRO K, 1994, P NATL ACAD SCI USA, V91, P10800, DOI 10.1073/pnas.91.23.10800; MOHR E, 1991, EMBO J, V10, P786; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Osten P, 1996, J NEUROSCI, V16, P2444; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; RAO A, 1991, J NEUROSCI, V11, P2881; RASHID K, 1995, P NATL ACAD SCI USA, V92, P9495, DOI 10.1073/pnas.92.21.9495; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STANTON PK, 1984, J NEUROSCI, V4, P3080; STEWARD O, 1982, J NEUROSCI, V2, P284; TORRE ER, 1992, J NEUROSCI, V12, P762; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; WELCHER A, UNPUB; Zhou X.-G., COMMUNICATION COMMUNICATION; ZHOU XF, 1993, BRAIN RES, V621, P189, DOI 10.1016/0006-8993(93)90106-W	56	714	728	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1402	1406		10.1126/science.273.5280.1402	http://dx.doi.org/10.1126/science.273.5280.1402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703078				2022-12-28	WOS:A1996VF61000047
J	Meyer, GS; Jacoby, I; Krakauer, H; Powell, DW; Aurand, J; McCardle, P				Meyer, GS; Jacoby, I; Krakauer, H; Powell, DW; Aurand, J; McCardle, P			Gastroenterology workforce modeling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNAL-MEDICINE; UNITED-STATES; MANPOWER	Objective.-To examine the current supply and distribution of gastroenterologists and project future supply under various scenarios to provide a paradigm for workforce reform. Design.-An analysis of current practices and distribution of gastroenterologists and a demographic model, using the 1992 gastroenterology workforce as a baseline, Main Outcome Measure.-Comparison of current supply, distribution, and practice profiles with past data and future projections, using analyses of data from the 1993 Area Resource File, 1992 Medicare Part B file, age- and sex-specific death and retirement rates from the Bureau of Health Professions, managed care staffing patterns, the National Survey of Internal Medicine Manpower, and the Bureau of the Census. Results.-Rapid growth in the number of US gastroenterologists has resulted in a gastroenterologist-to-population ratio double that used on average by health maintenance organizations. In addition, the work profile of gastroenterologists is shared significantly by primary care physicians and other specialists, with the exception of a few specific and uncommon procedures, Conclusions.-Empirical evidence suggests that, even in the absence of detailed models to describe the desired supply/need balance for gastroenterology, the US health care system and clinicians may benefit from a reduction in gastroenterology training programs. The Gastroenterology Leadership Council endorsed a goal of 25% to 50% reduction in trainee numbers over 5 years, and recent National Resident Matching Program data indicate that a voluntary downsizing process is in full force, This study illustrates a paradigm for workforce planning that could be useful for other medical specialties.	UNIFORMED SERV UNIV HLTH SCI,DEPT PREVENT MED & BIOMETR,CTR HLTH CARE QUAL ASSESSMENT,BETHESDA,MD 20814; UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,GASTROENTEROL LEADERSHIP COUNCIL MANPOWER COMM,GALVESTON,TX 77550; NIH,BETHESDA,MD 20892	Uniformed Services University of the Health Sciences - USA; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA			Powell, Don W/K-4774-2014					ANDERSON RJ, 1995, AM J MED, V99, P74, DOI 10.1016/S0002-9343(99)80108-9; FARTHING MJG, 1993, GUT, V34, P1728, DOI 10.1136/gut.34.12.1728; FEIL EC, 1993, JAMA-J AM MED ASSOC, V269, P2659, DOI 10.1001/jama.269.20.2659; *I MED, 1996, NAT PHYS WORKF OPT B; JACOBY I, 1995, US DEP HLTH HUMAN SE; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V272, P37, DOI 10.1001/jama.272.1.37; Langdon LO, 1996, ANN INTERN MED, V124, P686, DOI 10.7326/0003-4819-124-7-199604010-00011; LYTTLE CS, 1994, ANN INTERN MED, V121, P435, DOI 10.7326/0003-4819-121-6-199409150-00008; *MAPINFO CORP, 1994, MAPINFO; MCGIL DB, 1976, GASTROENTEROLOGY, V72, P1345; MCGILL DW, 1981, GASTROENTEROLOGY, V80, P861; *MIDDL SER EST, 1991, CURR POP REP SER P, V25; MODLIN IM, 1989, GASTROENTEROLOGY, V96, P956; Mullan F, 1996, NEW ENGL J MED, V334, P916, DOI 10.1056/NEJM199604043341411; *NAT CTR HLTH STAT, 1991, US DEP HLTH HUM SERV; *PEW HLTH PROF COM, 1995, CRIT CHAL REV HLTH P; *PRATT MED GROUP N, 1994, SMLTREE VERS 2 6; *RAND CORP INC, 1978, RAND CORP RES MON VA; Rivo ML, 1996, NEW ENGL J MED, V334, P892, DOI 10.1056/NEJM199604043341405; ROSENBLATT RA, 1991, WESTERN J MED, V154, P43; *SAS I INC, 1994, SAS STAT SOFTW; STAMBLER HV, 1988, PUBLIC HEALTH REP, V103, P184; STILLMAN AE, 1995, NEW ENGL J MED, V333, P1086, DOI 10.1056/NEJM199510193331618; *US DHHS, 1980, US DEP HLTH HUM SERV; Weiner JP, 1996, ANN INTERN MED, V124, P681, DOI 10.7326/0003-4819-124-7-199604010-00009; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; 1993, GASTROENTEROLOGY, V105, P611	27	60	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					689	694		10.1001/jama.276.9.689	http://dx.doi.org/10.1001/jama.276.9.689			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769546				2022-12-28	WOS:A1996VE23300006
J	Simons, AJ; Beart, RW				Simons, AJ; Beart, RW			Glyceryl trinitrate for anal fissure	LANCET			English	Editorial Material											Simons, AJ (corresponding author), UNIV SO CALIF,SCH MED,DEPT SURG,DIV COLORECTAL SURG,LOS ANGELES,CA 90033, USA.							GORFINE SR, 1995, DIS COLON RECTUM, V38, P453, DOI 10.1007/BF02148842; KLOSTERHALFEN B, 1989, DIS COLON RECTUM, V32, P43, DOI 10.1007/BF02554725; LODER PB, 1994, BRIT J SURG, V81, P1386, DOI 10.1002/bjs.1800810949; Lund JN, 1996, BRIT J SURG, V83, P776, DOI 10.1002/bjs.1800830615; SCHOUTEN WR, 1994, DIS COLON RECTUM, V37, P664, DOI 10.1007/BF02054409; Watson SJ, 1996, BRIT J SURG, V83, P771, DOI 10.1002/bjs.1800830614	6	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					491	492		10.1016/S0140-6736(05)64667-3	http://dx.doi.org/10.1016/S0140-6736(05)64667-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757148				2022-12-28	WOS:A1996VD42700006
J	Brown, EJ; Schreiber, SL				Brown, EJ; Schreiber, SL			A signaling pathway to translational control	CELL			English	Review							RIBOSOMAL PROTEIN-S6; MESSENGER-RNAS; RAPAMYCIN; KINASE; PHOSPHORYLATION; GROWTH; TRACT		HARVARD UNIV,HOWARD HUGHES MED INST,PROGRAM IMMUNOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute	Brown, EJ (corresponding author), HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM & BIOL CHEM,12 OXFORD ST,CAMBRIDGE,MA 02138, USA.							Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; GRESSNER AM, 1974, BIOCHEM BIOPH RES CO, V60, P1482, DOI 10.1016/0006-291X(74)90365-9; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; IGNOTZ GG, 1981, BIOCHEMISTRY-US, V20, P2550, DOI 10.1021/bi00512a029; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOHNSON SP, 1987, MOL CELL BIOL, V7, P1338, DOI 10.1128/MCB.7.4.1338; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; Mendez R, 1996, MOL CELL BIOL, V16, P2857; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076	20	338	340	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					517	520		10.1016/S0092-8674(00)80125-7	http://dx.doi.org/10.1016/S0092-8674(00)80125-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752206	Bronze			2022-12-28	WOS:A1996VE23500002
J	Swann, PF; Waters, TR; Moulton, DC; Xu, YZ; Zheng, QG; Edwards, M; Mace, R				Swann, PF; Waters, TR; Moulton, DC; Xu, YZ; Zheng, QG; Edwards, M; Mace, R			Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine	SCIENCE			English	Article							NON-ENZYMATIC METHYLATION; ESCHERICHIA-COLI DNA; O-6-METHYLGUANINE RESIDUES; MUTATOR PHENOTYPE; DAMAGE TOLERANCE; CELLS TOLERANT; 6-THIOGUANINE; BINDING; MECHANISM; CANCER	It is proposed here that the delayed cytotoxicity of thioguanine involves the postreplicative DNA mismatch repair system. After incorporation into DNA, the thioguanine is chemically methylated by S-adenosylmethionine to form S-6-methylthioguanine. During DNA replication, the S-6-methylthioguanine directs incorporation of either thymine or cytosine into the growing DNA stand, and the resultant S-6-methylthioguanine-thymine nine-thymine pairs are recognized by the postreplicative mismatch repair system. pairs are recognized by the postreplicative mismatch repair system. Azathioprine, an immunosuppressant used in organ transplantation, is partly converted to thioguanine. Because the carcinogenicity of N-nitrosamines depends on formation of O-6-alkylguanine in DNA, the formation of the analog S-6-methylthioguanine during azathioprine treatment may partly explain the high incidence of cancer after transplantation.			Swann, PF (corresponding author), UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOL BIOL, CANC RES CAMPAIGN, NITROSAMINE INDUCED CANC GRP, LONDON WC1E 6BT, ENGLAND.		Xu, Yao/A-7700-2010	Xu, Yao/0000-0002-5713-8030				AQUILINA G, 1990, CANCER RES, V50, P4248; AQUILINA G, 1995, CANCER RES, V55, P2569; BARROWS LR, 1982, CARCINOGENESIS, V3, P349, DOI 10.1093/carcin/3.3.349; BODELL WJ, 1991, MUTAGENESIS, V6, P175, DOI 10.1093/mutage/6.3.175; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; HAWN MT, 1995, CANCER RES, V55, P3721; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JONES M, 1981, MOL GEN GENET, V184, P562, DOI 10.1007/BF00352542; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; LENNARD L, 1985, BRIT J DERMATOL, V113, P723, DOI 10.1111/j.1365-2133.1985.tb02408.x; PENN I, 1994, CANCER DETECT PREV, V18, P241; PLANT JE, 1971, CHEM-BIOL INTERACT, V3, P337, DOI 10.1016/0009-2797(71)90013-5; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAPPAPORT HP, 1993, BIOCHEMISTRY-US, V32, P3047, DOI 10.1021/bi00063a016; RASOULINIA A, 1994, MUTAT RES, V314, P99, DOI 10.1016/0921-8777(94)90074-4; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; TAN HB, 1994, BIOCHEMISTRY-US, V33, P5335, DOI 10.1021/bi00183a042; TIDD DM, 1974, CANCER RES, V34, P738; XU YZ, 1995, NUCLEOS NUCLEOT, V14, P929, DOI 10.1080/15257779508012504; XU YZ, 1992, TETRAHEDRON, V48, P1729, DOI 10.1016/S0040-4020(01)88731-7	25	329	337	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1109	1111		10.1126/science.273.5278.1109	http://dx.doi.org/10.1126/science.273.5278.1109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688098				2022-12-28	WOS:A1996VD42800039
J	McLellan, MF				McLellan, MF			Images of physicians in literature: From quacks to heroes	LANCET			English	Article							NONMEDICAL LITERATURE; PORTRAYAL		UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	McLellan, MF (corresponding author), UNIV TEXAS,MED BRANCH,DEPT ANESTHESIOL,GALVESTON,TX 77555, USA.			McLellan, Faith/0000-0003-0744-1450				ACKERKNECHT E, 1967, MED PARIS HOSPITAL 1; COLES P, 1989, CALL STORIES TEACHIN, P160; COLES R, 1985, AM POETRY REV, V14, P42; DONLEY C, 1991, LIT MED, V10, P18; ELIOT G, 1977, MIDDLEMARCH, P102; FISHER JH, 1977, COMPLETE POETRY PROS, P17; FRAME DM, 1968, MISANTHROPE OTHER PL, P479; JAYMES D, 1993, LIT MED, V12, P1; JONES AH, 1989, HDB AM POPULAR CULTU, P721; JONES AH, 1994, 8 JP MCGOV AW LECT 2; JONES AH, 1983, LIT MED, V2, P1; JONES AH, 1988, IMAGES NURSES PERSPE; Nussbaum Martha, 1990, LOVES KNOWLEDGE ESSA, P47; PELLEGRINO E, 1980, MED LIT, pR15; Peschel Enid Rhodes, 1980, MED LIT, P103; POSEN S, 1994, J ROY SOC MED, V87, P675; POSEN S, 1994, J ROY SOC MED, V87, P237; POSEN S, 1994, J ROY SOC MED, V87, P104; POSEN S, 1993, J ROY SOC MED, V86, P128; POSEN S, 1993, J ROY SOC MED, V86, P410; POSEN S, 1993, J ROY SOC MED, V86, P345; POSEN S, 1993, J ROY SOC MED, V86, P724; POSEN S, 1993, J ROY SOC MED, V86, P67; POSEN S, 1993, J ROY SOC MED, V86, P582; POSEN S, 1992, J ROY SOC MED, V85, P659; POSEN S, 1992, J ROY SOC MED, V85, P520; POSEN S, 1992, J ROY SOC MED, V85, P66; POSEN S, 1992, J ROY SOC MED, V85, P5; POSEN S, 1992, J R SOC MED, V5, P314; Reiser S., 1978, MED REIGN TECHNOLOGY; Rothfield Lawrence, 1992, VITAL SIGNS MED REAL; SNOW LF, 1983, LIT MED, V2, P45	32	13	13	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					458	460		10.1016/S0140-6736(96)02421-X	http://dx.doi.org/10.1016/S0140-6736(96)02421-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	VC673	8709790				2022-12-28	WOS:A1996VC67300018
J	Mitchell, SJ; Gray, J; Morgan, MEI; Hocking, MD; Durbin, GM				Mitchell, SJ; Gray, J; Morgan, MEI; Hocking, MD; Durbin, GM			Nosocomial infection with Rhizopus microsporus in preterm infants: Association with wooden tongue depressors	LANCET			English	Article							NECROTIZING CELLULITIS; ANTIBODIES; TRIMMERS	Background We report four cases of cutaneous infection with Rhizopus microsporus in vulnerable preterm infants in one neonatal nursery. Methods There was no overlap in hospital stay between the first two cases and an extensive programme of environmental sampling was therefore initiated, with special attention being paid to items that had close contact with infants' skin. Samples were cultured by standard techniques, including fungal culture with Sabouraud's medium. Filamentous fungi with non-septate hyphae were presumptively identified as agents of mucormycosis and referred to the Mycology Reference Laboratory, Bristol, UK, for speciation. Findings The source of infection was identified as wooden tongue depressors, which were used on the nursery to construct splints for intravenous and arterial cannulation sites. The outbreak was ended by the removal of these items from the nursery. Interpretation Wooden tongue depressors can be a vehicle for transmission of mucormycosis. The combination of warm, humid conditions in neonatal incubators, particularly in association with occlusive dressings, may favour cutaneous fungal invasion and put small, sick babies at risk of infection.	BIRMINGHAM WOMENS HOSP,DEPT MICROBIOL,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND	Birmingham Women's Hospital	Mitchell, SJ (corresponding author), BIRMINGHAM WOMENS HOSP,NEONATAL UNIT,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND.							ARISOY AE, 1993, PEDIATR INFECT DIS J, V12, P1029, DOI 10.1097/00006454-199312000-00016; BELIN L, 1987, INT ARCH ALLER A IMM, V82, P440, DOI 10.1159/000234248; BUTLER KM, 1988, PEDIATR CLIN N AM, V35, P543; CRI N, 1994, PEDIAT DERMATOL, V11, P346; DENNIS JE, 1980, J PEDIATR-US, V96, P824, DOI 10.1016/S0022-3476(80)80550-6; EDUARD W, 1992, INT ARCH ALLERGY IMM, V97, P274, DOI 10.1159/000236133; EDWARDS JE, 1980, ANN INTERN MED, V93, P93; GARTENBERG G, 1978, NEW ENGL J MED, V299, P1115, DOI 10.1056/NEJM197811162992007; HEDENSTIERNA G, 1986, INT ARCH OCC ENV HEA, V58, P167, DOI 10.1007/BF00432098; HUHE C, 1995, PEDIATR INFECT DIS J, V1, P36; KEYS TF, 1978, MMWR-MORBID MORTAL W, V27, P33; NG PC, 1989, ARCH DIS CHILD, V64, P862, DOI 10.1136/adc.64.6.862; ROWEN JL, 1995, PEDIATRICS, V95, P682; ROWEN JL, 1992, PEDIATR INFECT DIS J, V11, P576, DOI 10.1097/00006454-199207000-00012; SHELDON DL, 1979, JAMA-J AM MED ASSOC, V241, P1032, DOI 10.1001/jama.241.10.1032; WHITE CB, 1986, PEDIATRICS, V78, P100; 1996, COMMUNICAB DIS REP, V6, P145	17	96	98	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					441	443		10.1016/S0140-6736(96)05059-3	http://dx.doi.org/10.1016/S0140-6736(96)05059-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709784				2022-12-28	WOS:A1996VC67300012
J	Behrens, J; vonKries, JP; Kuhl, M; Bruhn, L; Wedlich, D; Grosschedl, R; Birchmeier, W				Behrens, J; vonKries, JP; Kuhl, M; Bruhn, L; Wedlich, D; Grosschedl, R; Birchmeier, W			Functional interaction of beta-catenin with the transcription factor LEF-1	NATURE			English	Article							PROTEIN-PROTEIN INTERACTIONS; TCR-ALPHA ENHANCER; XENOPUS EMBRYOS; E-CADHERIN; ACTIVATION DOMAIN; HMG DOMAIN; DNA; ARMADILLO; PLAKOGLOBIN; DROSOPHILA	THE cytoplasmic proteins beta-catenin of vertebrates and armadillo of Drosophila have two functions: they link the cadherin cell-adhesion molecules to the cytoskeleton(1-4), and they participate in the wnt/wingless signalling pathway(5-7). Here we show, in a yeast two-hybrid screen, that the architectural transcription factor LEF-1 (for lymphoid enhancer-binding factor)(8-10) interacts with beta-catenin. In mammalian cells, coexpressed LEF-1 and beta-catenin form a complex that is localized to the nucleus and can be detected by immunoprecipitation, Moreover, LEF-1 and beta-catenin form a ternary complex with DNA that displays an altered DNA bend. Microinjection of LEF-1 into Xenopus embryos induces axis duplication, which is augmented by interaction with beta-catenin. Thus beta-catenin regulates gene expression by direct interaction with transcription factors such as LEF-1, providing a molecular mechanism for the transmission of signals from cell-adhesion components or ant protein to the nucleus.	MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; UNIV ULM,D-89081 ULM,GERMANY; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ulm University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ABERLE H, 1994, J CELL SCI, V107, P3655; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kuhl M, 1996, MECH DEVELOP, V54, P71, DOI 10.1016/0925-4773(95)00462-9; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miller J.H., 1972, EXPT MOL GENETICS; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	30	2503	2590	1	135	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					638	642		10.1038/382638a0	http://dx.doi.org/10.1038/382638a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757136				2022-12-28	WOS:A1996VC30300056
J	Evans, I				Evans, I			Amorous inclinations	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					352	352		10.1016/S0140-6736(05)64989-6	http://dx.doi.org/10.1016/S0140-6736(05)64989-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709731				2022-12-28	WOS:A1996VB42600007
J	Ricciardolo, FLM; Geppetti, P; Mistretta, A; Nadel, JA; Sapienza, MA; Bellofiore, S; DiMaria, GU				Ricciardolo, FLM; Geppetti, P; Mistretta, A; Nadel, JA; Sapienza, MA; Bellofiore, S; DiMaria, GU			Randomised double-blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma	LANCET			English	Article							INDUCED BRONCHOCONSTRICTION; SYNTHASE; HYPERRESPONSIVENESS; INFLAMMATION; AIRWAYS; HUMANS; LUNG	Background Bronchoconstriction induced by bradykinin is reduced by the release oi nitric oxide (NO) in the airways of guineapigs. Inhaled NO is known to cause bronchodilatation in asthmatic patients. To find out the role of endogenous NO in airway response to bradykinin in asthma, we examined the effect of the NO synthase inhibitor N-G-monomethyl-L-arginine (L-MMMA) on broncho-constriction after bradykinin challenge in ten patients with mild asthma. Methods The study had a randomised, double-blind, placebo-controlled, cross-over design. Participants were studied during two phases, each consisting of 2 study days. After baseline measurements oi forced expiratory volume in 1 s (FEV(1)) participants inhaled an aerosol of L-NMMA or saline (placebo). After 5 min, saline and doubling doses of bradykinin (from 0.25 nmol) were inhaled until FEV(1) fell by at least 20% of the post-saline value. The effect of L-NMMA and placebo an airway response to doubling concentrations of methacholine (from 0.03 mg/mL) was then examined. We also assessed the effect of the inactive enantiomer of L-NMMA, D-NMMA, and placebo on bronchoconstriction after bradykinin or methacholine challenge in six of the participants. Findings The geometric mean of the provocative dose producing a 20% fall in FEV(1) to bradykinin was 138.0 nmol (range 48.2-475.2 nmol) after placebo and 11.2 nmol (range 0.9-51.3 nmol) after L-NMMA (p<0.01). L-NMMA also caused a decrease in the provocative concentration of methacholine producing a 20% fall in FEV(1) from 0.93 mg/mL (range 0.12-2.55 mg/mL) to 0.38 mg/mL (range 0.06-0.92 mg/mL; p<0.01). In contrast, D-NMMA did not affect airway response to bradykinin or methacholine. Interpretation The results suggest that bronchoconstriction after bradykinin inhalation is greatly inhibited by the formation of NO in airways of asthmatic patients and that NO could have a bronchoprotective role in asthma.	UNIV CATANIA, INST RESP DIS, I-95125 CATANIA, ITALY; UNIV FERRARA, INST PHARMACOL, I-44100 FERRARA, ITALY; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of Catania; University of Ferrara; University of California System; University of California San Francisco			Geppetti, Pierangelo/AHA-7897-2022; Ricciardolo, F. L. M./K-5330-2018	Ricciardolo, F. L. M./0000-0003-1826-5018				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BARNES PJ, 1992, THORAX, V47, P979, DOI 10.1136/thx.47.11.979; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900, DOI 10.1164/ajrccm/145.4_Pt_1.900; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Figini M, 1996, AM J RESP CRIT CARE, V153, P918, DOI 10.1164/ajrccm.153.3.8630573; FISCHER A, 1993, NEUROSCI LETT, V149, P157, DOI 10.1016/0304-3940(93)90760-I; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; ICHINOSE M, 1992, LANCET, V340, P1248, DOI 10.1016/0140-6736(92)92948-F; JORENS PG, 1993, EUR RESPIR J, V6, P258; Kacmarek RM, 1996, AM J RESP CRIT CARE, V153, P128, DOI 10.1164/ajrccm.153.1.8542105; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; NIJKAMP FP, 1993, AM REV RESPIR DIS, V148, P727, DOI 10.1164/ajrccm/148.3.727; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; RICCIARDOLO FLM, 1994, BRIT J PHARMACOL, V113, P1147, DOI 10.1111/j.1476-5381.1994.tb17117.x; SCHEMPER V, 1994, BRIT J PHARMACOL, V111, P83	21	133	135	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1996	348	9024					374	377		10.1016/S0140-6736(96)04450-9	http://dx.doi.org/10.1016/S0140-6736(96)04450-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709736				2022-12-28	WOS:A1996VB42600012
J	Skuse, D; Albanese, A; Stanhope, R; Gilmour, J; Voss, L				Skuse, D; Albanese, A; Stanhope, R; Gilmour, J; Voss, L			A new stress-related syndrome of growth failure and hyperphagia in children, associated with reversibility of growth-hormone insufficiency	LANCET			English	Article							REFERENCE CURVES; RETARDATION; DEFICIENCY; SECRETION; CHILDHOOD; STATURE; DISEASE; INDEX; UK	Background Growth failure without organic aetiology but associated with behavioural disturbance and psychosocial stress has been termed psychosocial short stature, This condition is not a valid diagnostic entity, but encompasses failure to thrive, stunting secondary to chronic malnutrition, and idiopathic hypopituitarism. Some children show spontaneous catch-up growth when removed from the source of stress, without further treatment, but until now precise definition of this subgroup for the purpose of clinical identification has not been possible. Methods Hospital-referred children with growth failure unrelated to organic pathology, who came from stressful homes, were compared with children of short-normal stature identifed from an epidemiological survey (n=31). Growth-hormone dynamics were studied in the hospital group by a combination of diurnal profiles and provocation tests, The tests were repeated after a hospital stay of 3 weeks away from familial stress, Standard behavioural measures were obtained from home and school. Findings In a distinctive subgroup (n=29), growth-hormone insufficiency was associated with characteristic behavioural features, especially hyperphagia and polydipsia, and a normal body-mass index. When the children were removed from their stressful home circumstances, growth-hormone insufficiency spontaneously resolved only in formerly hyperphagic subjects, 74% of the non-hyperphagic cases (n=23) were anorexic, with a low body-mass index and normal growth-hormone responses to provocation tests. Interpretation We present explicit behavioural and developmental criteria by which the novel syndrome of hyperphagic short stature may be recognised clinically. Such children have a capacity for spontaneous recovery of growth-hormone production on removal from or reduction of stress, Discriminant and predictive validity of the core symptoms are demonstrated. Preliminary familial studies indicate a possible genetic predisposition.	INST CHILD HLTH, MED UNIT, LONDON, ENGLAND; SOUTHAMPTON GEN HOSP, DEPT CHILD HLTH, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of London; University College London; University of Southampton	Skuse, D (corresponding author), INST CHILD HLTH, BEHAV SCI UNIT, 30 GUILFORD ST, LONDON WC1N 1EH, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLIZZARD RM, 1992, BAILLIERE CLIN ENDOC, V6, P687, DOI 10.1016/S0950-351X(05)80119-3; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; Cameron N., 1984, MEASUREMENT HUMAN GR; CHATFIELD C, 1984, ANAL TIME SERIES; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; DOWDNEY L, 1987, J CHILD PSYCHOL PSYC, V28, P529, DOI 10.1111/j.1469-7610.1987.tb00221.x; ELLIOTT CD, 1983, BRIT ABILITY SCALES; FRASIER SD, 1972, J PEDIATR-US, V80, P603, DOI 10.1016/S0022-3476(72)80057-X; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; GREEN WH, 1986, ADV CLIN CHILD PSYCH, V9, P245; HINDMARSH PC, 1988, CLIN ENDOCRINOL, V29, P35, DOI 10.1111/j.1365-2265.1988.tb00247.x; MARTIN JB, 1992, PROG BRAIN RES, V93, P31; MAYES LC, 1993, CHILD ADOLESCENT PSY, V2, P15; MONEY J, 1972, J AUTISM CHILD SCHIZ, V2, P127, DOI 10.1007/BF01537566; POWELL GF, 1967, NEW ENGL J MED, V276, P1279, DOI 10.1056/NEJM196706082762302; POWELL GF, 1967, NEW ENGL J MED, V276, P1271, DOI 10.1056/NEJM196706082762301; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; Rutter M., 1970, ED HLTH BEHAV PSYCHO, P412; SAMUEL AM, 1972, J CLIN ENDOCR METAB, V35, P863, DOI 10.1210/jcem-35-6-863; SCHACHAR R, 1981, J CHILD PSYCHOL PSYC, V22, P375, DOI 10.1111/j.1469-7610.1981.tb00562.x; SHAH A, 1992, BRIT MED J, V304, P173, DOI 10.1136/bmj.304.6820.173; SKORZEWSKA A, 1989, NEUROPSYCHOBIOLOGY, V21, P17, DOI 10.1159/000118545; Skuse D., 1993, CHILD ADOL PSYCH CL, V2, P37; SKUSE D, 1993, TXB CHILD ADOLESCENT, P209; SMITH M, 1993, TXB CHILD ADOLESCENT, P230; STANHOPE R, 1988, CLIN ENDOCRINOL, V28, P778; TAITZ LS, 1988, ACTA PAEDIATR SCAND, P62; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; VOSS LD, 1992, BMJ-BRIT MED J, V305, P1400, DOI 10.1136/bmj.305.6866.1400; Wechsler D., 1976, WECHSLER INTELLIGENC; WECHSLER D, 1990, WECHSLER PRESCHOOL P; WOOLSTON JL, 1991, BENIGN NUTR DWARFING, P65; YAMANAKA C, 1993, EUR J PEDIATR, V152, P99, DOI 10.1007/BF02072482	33	78	80	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1996	348	9024					353	358		10.1016/S0140-6736(96)01358-X	http://dx.doi.org/10.1016/S0140-6736(96)01358-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709732				2022-12-28	WOS:A1996VB42600008
J	Roberts, CW; Roberts, JW				Roberts, CW; Roberts, JW			Base-specific recognition of the nontemplate strand of promoter DNA by E-coli RNA polymerase	CELL			English	Article							AMINO-ACID SUBSTITUTIONS; -10 BINDING REGION; BACILLUS-SUBTILIS; SIGMA-FACTOR; TRANSCRIPTION INITIATION; START SITE; PROTEIN; ELONGATION; MECHANISM; COMPLEXES	RNA polymerase recognizes its promoters through base-specific interaction between defined segments of DNA and the sigma subunit of the enzyme. This interaction leads to separation of base pairs and exposure of the template strand for RNA synthesis. We show that base-specific recognition by the sigma(70) holoenzyme in this process involves primarily nontemplate strand bases in the -10 promoter region. We suggest that melting involves the persistence of these contacts as the bound duplex (closed) form is converted to the single-stranded (open) form of the enzyme-promoter complex.			Roberts, CW (corresponding author), CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUCKLE M, 1994, TRANSCRIPTION MECH R, P207; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHEN YF, 1995, J MOL BIOL, V249, P743, DOI 10.1006/jmbi.1995.0333; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; GUO HC, 1990, THESIS CORNELL U ITH; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Johnston D. E., 1976, RNA POLYMERASE, P413; JONES CH, 1992, J BACTERIOL, V174, P6815, DOI 10.1128/JB.174.21.6815-6821.1992; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; RING BZ, 1995, THESIS CORNELL U ITH; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; TATTI KM, 1995, J BACTERIOL, V177, P6506, DOI 10.1128/jb.177.22.6506-6509.1995; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	34	122	123	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					495	501						7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756731				2022-12-28	WOS:A1996VC30900017
J	Clark, JE; Cant, AJ				Clark, JE; Cant, AJ			Lesson of the week - Pitfalls in contact tracing and early diagnosis of childhood tuberculosis	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN		NEWCASTLE GEN HOSP,DEPT PAEDIAT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital			Clark, Julia/A-8214-2012	Clark, Julia/0000-0001-7746-0599				Hayward A C, 1995, Commun Dis Rep CDR Rev, V5, pR29; SMITH MHD, 1990, TXB PEDIAT INF DIS, P1344; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; STARKE JR, 1995, PEDIATR INFECT DIS J, V14, P455, DOI 10.1097/00006454-199506000-00001; STEINER P, 1980, AM J DIS CHILD, V134, P747, DOI 10.1001/archpedi.1980.02130200017007; 1994, THORAX, V49, P1193	6	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					221	222		10.1136/bmj.313.7051.221	http://dx.doi.org/10.1136/bmj.313.7051.221			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696203	Green Published			2022-12-28	WOS:A1996VA12600033
J	Helander, TS; Carpen, O; Turunen, O; Kovanen, PE; Vaheri, A; Timonen, T				Helander, TS; Carpen, O; Turunen, O; Kovanen, PE; Vaheri, A; Timonen, T			ICAM-2 redistributed by ezrin as a target for killer cells	NATURE			English	Article							MEMBRANE-CYTOSKELETAL LINKER; ERM FAMILY MEMBERS; PLASMA-MEMBRANE; MOLECULE; ADHESION; RECOGNITION; LYMPHOCYTES; MICROVILLI; PROTEIN; CYTOVILLIN	VERY little is known about the receptors and target molecules involved in natural killer (NK) cell activity. Here we present a model system in which interleukin-2-activated killing by NK cells depends on the intercellular adhesion molecule ICAM-2 and is regulated by the distribution of ICAM-2. The level of ICAM-2 expression in NK-sensitive and resistant cells is similar, but in sensitive cells ICAM-2 is concentrated into bud-like cellular projections known as uropods, whereas in resistant cells it is evenly distributed. The cytoskeletal-membrane linker protein ezrin is also localized in uropods. Transfection of human ezrin into NK-resistant cells induces uropod formation, redistribution of ICAM-2 and ezrin, and sensitizes target cells to interleukin-2-activated killing. These results reveal a new mechanism of target-cell recognition: cytotoxic cells recognize adhesion molecules that are already present on normal cells, but in diseased cells are concentrated into a biologically active cell-surface region by cytoskeletal reorganization. The results also highlight the importance of cytoskeletal interactions in the regulation of ICAM-2-mediated adhesive phenomena.	UNIV HELSINKI,DEPT VIROL,HAARTMANN INST,FIN-00014 HELSINKI,FINLAND	University of Helsinki	Helander, TS (corresponding author), UNIV HELSINKI,DEPT PATHOL,HAARTMANN INST,HAARTMANINKATU 3,POB 21,FIN-00014 HELSINKI,FINLAND.		Vaheri, Antti/AAV-1523-2020; Turunen, Ossi/HHN-4776-2022					ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CHAMBERS WH, 1995, CHEM BIOL, V2, P429, DOI 10.1016/1074-5521(95)90258-9; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; FREY JL, 1991, J EXP MED, V174, P1527, DOI 10.1084/jem.174.6.1527; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GIARDINA SL, 1995, J IMMUNOL, V154, P80; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HELANDER T, 1991, J IMMUNOL, V147, P2063; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; PAKKANEN R, 1988, EUR J CELL BIOL, V46, P435; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VALIANTE NM, 1993, J EXP MED, V178, P1397, DOI 10.1084/jem.178.4.1397; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	29	206	215	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					265	268		10.1038/382265a0	http://dx.doi.org/10.1038/382265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717043				2022-12-28	WOS:A1996UX79000053
J	Vasan, S; Zhang, X; Zhang, XN; Kapurniotu, A; Bernhagen, J; Teichberg, S; Basgen, J; Wagle, D; Shih, D; Terlecky, I; Bucala, R; Cerami, A; Egan, J; Ulrich, P				Vasan, S; Zhang, X; Zhang, XN; Kapurniotu, A; Bernhagen, J; Teichberg, S; Basgen, J; Wagle, D; Shih, D; Terlecky, I; Bucala, R; Cerami, A; Egan, J; Ulrich, P			An agent cleaving glucose-derived protein crosslinks in vitro and in vivo	NATURE			English	Article							GLYCOSYLATION END-PRODUCTS; DIABETES-MELLITUS; ALZHEIMER-DISEASE; MAILLARD REACTION; GLYCATION; COLLAGEN; COMPLICATIONS; AMYLOIDOSIS; MECHANISM; RATS	GLUCOSE and other reducing sugars react with proteins by a nonenzymatic, post-translational modification process called nonenzymatic glycosylation or glycation. The sugar-derived carbonyl group adds to a free amine, forming a reversible adduct which over time rearranges to produce a class of products termed advanced-glycation end-products (AGEs). These remain irreversibly bound to macromolecules and can covalently crosslink proximate amino groups(1,2). The formation of AGEs on long-lived connective tissue and matrix components accounts largely for the increase in collagen crosslinking that accompanies normal ageing and which occurs at an accelerated rate in diabetes(3,4) AGEs can activate cellular receptors and initiate a variety of pathophysiological responses(5-9). They modify an appreciable fraction of circulating low-density lipoproteins preventing uptake of these particles by their high-affinity tissue receptors(10,11) Advanced glycation has also been implicated in the pathology of Alzheimer's disease(12,13). Because AGEs may form by a pathway involving reactive alpha-dicarbonyl intermediates(1,2,14), we investigated a potential pharmacological strategy for selectively cleaving the resultant glucose-derived protein crosslinks, We now describe a prototypic AGE crosslink 'breaker', N-phenacylthiazolium bromide (PTB), which reacts with and cleaves covalent, AGE-derived protein crosslinks. The ability of PTB to break AGE crosslinks in vivo points to the importance of an alpha-dicarbonyl intermediate in the advanced glycation pathway and offers a potential therapeutic approach for the removal of established AGE crosslinks.	PICOWER INST MED RES, MANHASSET, NY 11030 USA; ALTEON INC, RAMSEY, NJ 07446 USA; N SHORE UNIV HOSP, MANHASSET, NY 11030 USA; UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA	Northwell Health; Northwell Health; North Shore University Hospital; University of Minnesota System; University of Minnesota Twin Cities								BOCHANTIN J, 1981, EXP GERONTOL, V16, P101, DOI 10.1016/0531-5565(81)90013-9; Bucala R, 1992, Adv Pharmacol, V23, P1; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; CHEN HJC, 1993, J CARBOHYD CHEM, V12, P731; COTRAN RS, 1994, ROBBINS PATHOLOGIC B, P231; DANZE PM, 1987, CLIN CHIM ACTA, V166, P143, DOI 10.1016/0009-8981(87)90416-5; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; EBLE AS, 1983, J BIOL CHEM, V258, P9406; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; ESTENDORFER S, 1990, ANGEW CHEM INT EDIT, V29, P536, DOI 10.1002/anie.199005361; ITAKURA M, 1991, LIFE SCI, V49, P889, DOI 10.1016/0024-3205(91)90174-A; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; UKAI OK, 1943, YAKUGAKU ZASSHI, V63, P296; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLASSARA H, 1995, MOL MED, V1, P447, DOI 10.1007/BF03401582; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VOVK AI, 1985, UKR KHIM ZH+, V51, P521	27	394	433	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1996	382	6588					275	278		10.1038/382275a0	http://dx.doi.org/10.1038/382275a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717046				2022-12-28	WOS:A1996UX79000056
J	Frangiskakis, JM; Ewart, AK; Morris, CA; Mervis, CB; Bertrand, J; Robinson, BF; Klein, BP; Ensing, GJ; Everett, LA; Green, ED; Proschel, C; Gutowski, NJ; Noble, M; Atkinson, DL; Odelberg, SJ; Keating, MT				Frangiskakis, JM; Ewart, AK; Morris, CA; Mervis, CB; Bertrand, J; Robinson, BF; Klein, BP; Ensing, GJ; Everett, LA; Green, ED; Proschel, C; Gutowski, NJ; Noble, M; Atkinson, DL; Odelberg, SJ; Keating, MT			LIM-kinase1 hemizygosity implicated in impaired visuospatial constructive cognition	CELL			English	Article							SUPRAVALVULAR AORTIC-STENOSIS; LONG-TERM POTENTIATION; GAMMA-MUTANT MICE; ELASTIN GENE; WILLIAMS-SYNDROME; PROTEIN; TRANSLOCATION; CHROMOSOME-7; HOMEODOMAIN; SEQUENCES	To identify genes important for human cognitive development, we studied Williams syndrome (WS), a developmental disorder that includes poor visuospatial constructive cognition. Here we describe two families with a partial WS phenotype; affected members have the specific WS cognitive profile and vascular disease, but lack other WS features. Submicroscopic chromosome 7q11.23 deletions cosegregate with this phenotype in both families. DNA sequence analyses of the region affected by the smallest deletion (83.6 kb) revealed two genes, elastin (ELN) and LIM-kinase-1 (LIMK1). The latter encodes a novel protein kinase with LIM domains and is strongly expressed in the brain. Because ELN mutations cause vascular disease but not cognitive abnormalities, these data implicate LIMK1 hemizygosity in impaired visuospatial constructive cognition.	UNIV UTAH, HLTH SCI CTR, ECCLES INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, HUNTSMAN CANC INST, DEPT ONCOL SCI, SALT LAKE CITY, UT 84112 USA; UNIV NEVADA, SCH MED, DEPT PEDIAT, LAS VEGAS, NV 89102 USA; UNIV NEVADA, SCH MED, DEPT PATHOL, LAS VEGAS, NV 89102 USA; EMORY UNIV, DEPT PSYCHOL, ATLANTA, GA 30322 USA; INDIANA UNIV, SCH MED, DEPT PEDIAT, DIV PEDIAT CARDIOL, INDIANAPOLIS, IN 46202 USA; NATL INST HLTH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA; UNIV LONDON, INST NEUROL, DEPT CLIN NEUROL, LONDON WC1N 3BG, ENGLAND	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of London; University College London	Frangiskakis, JM (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA.		Toland, Amanda Ewart/E-4202-2011; Robinson, Byron/G-6144-2012	Robinson, Byron/0000-0003-2618-5771	NHLBI NIH HHS [R01 HL4807] Funding Source: Medline; NICHD NIH HHS [R01 HD29957, R01 HD029957] Funding Source: Medline; NINDS NIH HHS [R01 NS035102, R01 NS35102] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035102] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bayley N, 1993, BAYLEY SCALES INFANT; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; Beery K. E, 1989, DEV TEST VISUAL MOTO, V3rd; Bellugi U., 1994, ATYPICAL COGNITIVE D, P23; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BUDARF ML, 1995, NAT GENET, V10, P269, DOI 10.1038/ng0795-269; Capruso D. X., 1995, CLIN NEUROPSYCHOL, P137; CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEAR S, 1992, DNA SEQUENCE, V3, P99; DILTS CV, 1990, AM J MED GENET, P126; Elliott C. D., 1990, DIFFERENTIAL ABILITY; ENSING GJ, 1989, J AM COLL CARDIOL, V13, P413, DOI 10.1016/0735-1097(89)90520-2; EWART AK, 1994, J CLIN INVEST, V93, P1071, DOI 10.1172/JCI117057; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; EWART AK, 1993, P NATL ACAD SCI USA, V90, P3226, DOI 10.1073/pnas.90.8.3226; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOSTER K, 1993, ANN HUM GENET, V57, P87, DOI 10.1111/j.1469-1809.1993.tb00890.x; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GILBERTDUSSARDIER B, 1995, AM J HUM GENET, V56, P542; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HWU HR, 1986, P NATL ACAD SCI USA, V83, P3875, DOI 10.1073/pnas.83.11.3875; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LOWERY MC, 1995, AM J HUM GENET, V57, P49; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARDIS ER, 1994, NUCLEIC ACIDS RES, V22, P2173, DOI 10.1093/nar/22.11.2173; MERVIS CB, 1996, IN PRESS NEURODEVELO; MERVIS CB, 1996, RES COMMUNICATION LA; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORRIS CA, 1993, AM J MED GENET, V46, P737, DOI 10.1002/ajmg.1320460634; MORRIS CA, 1988, J PEDIATR-US, V113, P318, DOI 10.1016/S0022-3476(88)80272-5; NUNOUE K, 1995, ONCOGENE, V11, P701; OLSON TM, 1995, HUM MOL GENET, V4, P1677, DOI 10.1093/hmg/4.9.1677; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; PREUS M, 1984, CLIN GENET, V25, P422, DOI 10.1111/j.1399-0004.1984.tb02011.x; PROSCHEL C, 1995, ONCOGENE, V11, P1271; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SLIGHTOM JL, 1994, GENOMICS, V20, P149, DOI 10.1006/geno.1994.1149; UDWIN O, 1987, J CHILD PSYCHOL PSYC, V28, P297, DOI 10.1111/j.1469-7610.1987.tb00212.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; WILKINSON DG, 1992, IN SITU HYBRIDISATIO; Xu Y, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P376	50	411	425	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					59	69		10.1016/S0092-8674(00)80077-X	http://dx.doi.org/10.1016/S0092-8674(00)80077-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689688	Bronze			2022-12-28	WOS:A1996UX93400008
J	Porcher, C; Swat, W; Rockwell, K; Fujiwara, Y; Alt, FW; Orkin, SH				Porcher, C; Swat, W; Rockwell, K; Fujiwara, Y; Alt, FW; Orkin, SH			The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages	CELL			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING MOTIF; SCL GENE-PRODUCT; CHROMOSOMAL TRANSLOCATION; FUSION TRANSCRIPT; ERYTHROID-DIFFERENTIATION; DROSOPHILA-TRITHORAX; ENHANCER-BINDING; GATA-BINDING; ES CELLS	The T cell leukemia oncoprotein SCL/tal-1, a basic-helix-loop-helix transcription factor, is required for production of embryonic red blood cells in the mouse yolk sac. To define roles in other lineages, we studied the hematopoietic potential of homozygous mutant SCL/tal-1 -/- embryonic stem cells upon in vitro differentiation and in vivo in chimeric mice. Here we show that in the absence of SCL/tal-1, hematopoiesis, including the generation of red cells, myeloid cells, megakaryocytes, mast cells, and both T and B lymphoid cells, is undetectable. These findings suggest that SCL/tal-1 functions very early in hematopoietic development, either in specification of ventral mesoderm to a blood cell fate, or in formation or maintenance of immature progenitors.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL & ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute			Porcher, Catherine/D-7026-2016					APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERGER CN, 1995, DEV BIOL, V170, P651, DOI 10.1006/dbio.1995.1244; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERICKSON P, 1992, BLOOD, V80, P1825; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAWLEY RG, 1994, GENE THER, V1, P136; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; Hoang T, 1996, BLOOD, V87, P102; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KELLER G, 1993, MOL CELL BIOL, V13, P472; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEAR WS, 1996, IN PRESS METHODS MOL; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBB L, 1995, ONCOGENE, V10, P205; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILES MV, 1991, DEVELOPMENT, V111, P259; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	69	583	589	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					47	57		10.1016/S0092-8674(00)80076-8	http://dx.doi.org/10.1016/S0092-8674(00)80076-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689686	Bronze			2022-12-28	WOS:A1996UX93400007
J	Ng, M; DiazBenjumea, FJ; Vincent, JP; Wu, J; Cohen, SM				Ng, M; DiazBenjumea, FJ; Vincent, JP; Wu, J; Cohen, SM			Specification of the wine by localized expression of wingless protein	NATURE			English	Article							HALTERE DEVELOPMENT; DROSOPHILA EMBRYO; DISC; MUTATION; SYSTEM; CELLS; GENES	LIMB development in Drosophila depends on subdivision of the limb primordia into functional units called compartments(1-4). Cell interactions across compartment boundaries establish pattern-organizing centres that control growth and specify cell fates along the anteroposterior (AP) and dorsoventral (DV) axes of the limbs(2,3,5-9). AP sub,division of the disc primordia is inherited from the embryonic ectoderm(10). DV subdivision of the wine; disc occurs during the second larval instar through localized expression of the apterous protein (Apterous) in dorsal cells(2,11). A third major subdivision of the wing disc into wing and body-wall compartments also occurs in the second instar(1). Here we show that specification of the wing primordium in early second instar depends on activity of the AP patterning system but not the DV system. These results define two distinct roles for the wingless gene: a primary role in specifying the wing primordium. and a subsequent role mediating the patterning activities of the DV compartment boundary(9,12,13).	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	European Molecular Biology Laboratory (EMBL); MRC Laboratory Molecular Biology; Baylor College of Medicine			Diaz-Benjumea, Fernando/K-7667-2014; Cohen, Stephen M/G-9930-2011	Diaz-Benjumea, Fernando/0000-0003-3007-2489; Cohen, Stephen M/0000-0003-2858-9163				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NG M, 1995, DEVELOPMENT, V121, P589; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; ZECCA M, 1995, DEVELOPMENT, V121, P2265	25	177	179	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					316	318		10.1038/381316a0	http://dx.doi.org/10.1038/381316a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692268				2022-12-28	WOS:A1996UM40300054
J	Yang, J; Zimmerly, S; Perlman, PS; Lambowitz, AM				Yang, J; Zimmerly, S; Perlman, PS; Lambowitz, AM			Efficient integration of an intron RNA into double-stranded DNA by reverse splicing	NATURE			English	Article							YEAST MITOCHONDRIA; INVITRO; RIBOZYME	SOME group introns are mobile elements as well as catalytic RNAs(1,2). Introns aI1 and aI2 found in the gene COX1 in yeast mitochondria encode reverse transcriptases which promote site-specific insertion of the intron into intronless alleles ('housing')(3-6). For aI2 this predominantly occurs by reverse transcription of unspliced precursor RNA st a break in double. strand DNA made by an endonuclease encoded by the intron(7). The aI2 endonuclease involves both the excised intron RNA, which cleaves the DNA's sense strand by partial reverse splicing; and the intron-encoded reverse transcriptase which cleaves the antisense strand(8). Here we show that aI1 encodes an analogous endonuclease specific for a different target site compatible with the different exon-binding sequences of the intron RNA. Over half of aI1 undergoes complete reverse splicing in vitro, thus integrating linear intron RNA directly into the DNA. This unprecedented reaction has implications for both intron mobility and evolution, and potential genetic engineering applications.	OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								HEBBAR SK, 1992, NUCLEIC ACIDS RES, V20, P1747, DOI 10.1093/nar/20.7.1747; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Sambrook J., 2002, MOL CLONING LAB MANU; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	17	133	148	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					332	335		10.1038/381332a0	http://dx.doi.org/10.1038/381332a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692273				2022-12-28	WOS:A1996UM40300059
J	Bradley, DC; Maxwell, M; Andersen, RA; Banks, MS; Shenoy, KV				Bradley, DC; Maxwell, M; Andersen, RA; Banks, MS; Shenoy, KV			Mechanisms of heading perception in primate visual cortex	SCIENCE			English	Article							PURSUIT EYE-MOVEMENTS; CORTICAL AREAS MT; MST NEURONS; MOTION; MONKEY; DIRECTION; POSITION; IMAGE; FLOW	When we move forward while walking or driving, what we see appears to expand. The center or focus of this expansion tells us our direction of self-motion, or heading, as long as our eyes are still. However, if our eyes move, as when tracking a nearby object on the ground, the retinal image is disrupted and the focus is shifted away from the heading. Neurons in primate dorso-medial superior temporal area responded selectively to an expansion focus in a certain part of the visual field, and this selective region shifted during tracking eye movements in a way that compensated for the retinal focus shift. Therefore, these neurons account for the effect of eye movements on what we see as we travel forward through the world.	CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV CALIF BERKELEY,SCH OPTOMETRY,BERKELEY,CA 94720	California Institute of Technology; University of California System; University of California Berkeley								DUFFY CJ, 1995, J NEUROSCI, V15, P5192; Freeman T. C. A., 1996, Investigative Ophthalmology and Visual Science, V37, pS454; Gibson JJ, 1950, PERCEPTION VISUAL WO; GRAZIANO MSA, 1994, J NEUROSCI, V14, P54; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; KOMATSU H, 1988, J NEUROPHYSIOL, V60, P580, DOI 10.1152/jn.1988.60.2.580; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; MACK A, 1978, VISION RES, V18, P55, DOI 10.1016/0042-6989(78)90077-9; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; ROYDEN CS, 1992, NATURE, V360, P583, DOI 10.1038/360583a0; SAITO H, 1986, J NEUROSCI, V6, P145; SAKATA H, 1983, J NEUROPHYSIOL, V49, P1364, DOI 10.1152/jn.1983.49.6.1364; SHENOY KS, SOC NEUR ABSTR; Warren W. H., 1995, HDB PERCEPTION COGNI, P263, DOI [10.1016/b978-012240530-3/50010-9, DOI 10.1016/B978-012240530-3/50010-9]; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	15	174	176	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1544	1547		10.1126/science.273.5281.1544	http://dx.doi.org/10.1126/science.273.5281.1544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703215				2022-12-28	WOS:A1996VG59700039
J	Geerts, WH; Jay, RM; Code, KI; Chen, EL; Szalai, JP; Saibil, EA; Hamilton, PA				Geerts, WH; Jay, RM; Code, KI; Chen, EL; Szalai, JP; Saibil, EA; Hamilton, PA			A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ELECTIVE HIP-SURGERY; SPINAL-CORD INJURY; PULMONARY-EMBOLISM; ORTHOPEDIC-SURGERY; MULTIPLE TRAUMA; PREVENTION; METAANALYSIS; COMPRESSION; TRIAL	Background Patients who have had major trauma are at very high risk for venous thromboembolism if they do not receive thromboprophylaxis. We compared low-dose heparin and a low-molecular-weight heparin with regard to efficacy and safety in a randomized clinical trial in patients with trauma. Methods Consecutive adult patients admitted to a trauma center who had Injury Severity Scores of at least 9 and no intracranial bleeding were randomly assigned to heparin (5000 units) or enoxaparin (30 mg), each given subcutaneously every 12 hours in a double-blind manner, beginning within 36 hours after the injury. The primary outcome was deep-vein thrombosis as assessed by contrast venography performed on or before day 14 after randomization. Results Among 344 randomized patients, 136 who received low-dose heparin and 129 who received enoxaparin had venograms adequate for analysis. Sixty patients given heparin (44 percent) and 40 patients given enoxaparin (31 percent) had deep-vein thrombosis (P=0.014). The rates of proximal-vein thrombosis were 15 percent and 6 percent, respectively (P=0.012). The reductions in risk with enoxaparin as compared with heparin were 30 percent (95 percent confidence interval, 4 to 50 percent) for all deep-vein thrombosis and 58 percent (95 percent confidence interval, 12 to 87 percent) for proximal-vein thrombosis. Only six patients (1.7 percent) had major bleeding (one in the heparin group and five in the enoxaparin group, P=0.12). Conclusions Low-molecular-weight heparin was more effective than low-dose heparin in preventing venous thromboembolism after major trauma. Both interventions were safe. (C) 1996, Massachusetts Medical Society.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT RES DESIGN & BIOSTAT,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT MED IMAGING,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,CLIN EPIDEMIOL & HLTH CARE RES PROGRAM,SUNNYBROOK UNIT,TORONTO,ON M4N 3M5,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Geerts, WH (corresponding author), UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT MED,RM D674,2075 BAYVIEW AVE,TORONTO,ON M4N 3M5,CANADA.							BRATHWAITE CEM, 1993, CHEST, V104, P718, DOI 10.1378/chest.104.3.718; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COMEROTA AJ, 1992, AM J SURG, V164, P265, DOI 10.1016/S0002-9610(05)81083-9; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; GREEN D, 1994, PHARMACOL REV, V46, P89; GREEN D, 1994, ARCH PHYS MED REHAB, V75, P290, DOI 10.1016/0003-9993(94)90031-0; GREENFIELD LJ, 1995, J AM COLL SURGEONS, V180, P725; HILL SL, 1994, AM SURGEON, V60, P405; HOSMER DW, 1989, APPL LOGISTIC REGRES; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; IMPERIALE TF, 1995, JAMA-J AM MED ASSOC, V273, P288; JONGBLOETS LMM, 1994, LANCET, V343, P1142, DOI 10.1016/S0140-6736(94)90240-2; KAKKAR VV, 1969, LANCET, V2, P230; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; KOOPMAN MMW, 1994, PROG CARDIOVASC DIS, V37, P1, DOI 10.1016/S0033-0620(05)80047-7; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; LAVERICK MD, 1991, BRIT MED J, V303, P549, DOI 10.1136/bmj.303.6802.549; LECLERC JR, 1992, THROMB HAEMOSTASIS, V67, P417; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LIEBERMAN JR, 1994, J BONE JOINT SURG AM, V76A, P1239, DOI 10.2106/00004623-199408000-00015; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; MAYNARD MJ, 1991, CLIN ORTHOP RELAT R, V273, P125; MERLI GJ, 1993, ARCH PHYS MED REHAB, V74, P1199; Moser, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; NAPOLITANO LM, 1995, J TRAUMA, V39, P651, DOI 10.1097/00005373-199510000-00006; NORCROSS ED, 1991, AM SURGEON, V57, P169; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Pellegrini V D Jr, 1993, J Arthroplasty, V8, P449; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; ROGERS FB, 1995, SURG CLIN N AM, V75, P279, DOI 10.1016/S0039-6109(16)46588-6; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SMITH RM, 1994, INJURY S2, V25, pB23; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	41	587	604	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					701	707		10.1056/NEJM199609053351003	http://dx.doi.org/10.1056/NEJM199609053351003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH266	8703169				2022-12-28	WOS:A1996VH26600003
J	McMahon, MJ; Luther, ER; Bowes, WA; Olshan, AF				McMahon, MJ; Luther, ER; Bowes, WA; Olshan, AF			Comparison of a trial of labor with an elective second cesarean section	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VAGINAL BIRTH; DELIVERY; EXPERIENCE; METAANALYSIS; MULTICENTER; SUCCESS	Background in an attempt to reduce the rate of cesarean section, obstetricians now offer a trial of labor to pregnant women who have had a previous cesarean section. Although a trial of labor is usually successful and is relatively safe, few studies have directly addressed the maternal and perinatal morbidity and mortality associated with this method of delivery. Methods We performed a population-based, longitudinal study of 6138 women in Nova Scotia who had previously undergone cesarean section and had delivered a singleton live infant in the period from 1986 through 1992. Results A total of 3249 women elected a trial of labor, and 2889 women chose to undergo a second cesarean section. There were no maternal deaths. The overall rate of maternal morbidity was 8.1 percent; 1.3 percent had major complications (a need for hysterectomy, uterine rupture, or operative injury) and 6.9 percent had minor complications (puerperal fever, a need for blood transfusion, or abdominal-wound infection). Although the overall rate of maternal complications did not differ significantly between the women who chose a trial of labor and the women who elected cesarean section (odds ratio for the trial-of-labor group, 0.9; 95 percent confidence interval, 0.8 to 1.1), major complications were nearly twice as likely among women undergoing a trial of labor (odds ratio, 1.8; 95 percent confidence interval, 1.1 to 3.0). Apgar scores, admission to the neonatal intensive care unit, and perinatal mortality were similar among the infants whose mothers had a trial of labor and those whose mothers underwent elective cesarean section. Conclusions Among pregnant women who have had a cesarean section, major maternal complications are almost twice as likely among those whose deliveries are managed with a trial of labor as among those who undergo an elective second cesarean section. (C) 1996, Massachusetts Medical Society.	UNIV N CAROLINA,SCH MED,DEPT EPIDEMIOL,CHAPEL HILL,NC 27599; DALHOUSIE UNIV,HALIFAX,NS B3H 3J5,CANADA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Dalhousie University	McMahon, MJ (corresponding author), UNIV N CAROLINA,SCH MED,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,CB 7570,214 MACNIDER BLDG,CHAPEL HILL,NC 27599, USA.							COWAN RK, 1994, OBSTET GYNECOL, V83, P933, DOI 10.1097/00006250-199406000-00006; ESKEW PN, 1994, J REPROD MED, V39, P809; FLAMM BL, 1990, OBSTET GYNECOL, V76, P750, DOI 10.1097/00006250-199011000-00004; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; GELLMAN E, 1983, JAMA-J AM MED ASSOC, V249, P2935, DOI 10.1001/jama.249.21.2935; GIBBS C E, 1980, Clinical Obstetrics and Gynecology, V23, P507, DOI 10.1097/00003081-198006000-00019; MILLER DA, 1994, OBSTET GYNECOL, V84, P255; *NIH, 1981, NIH PUBL, P351; PAUL RH, 1985, AM J OBSTET GYNECOL, V151, P297, DOI 10.1016/0002-9378(85)90290-X; ROSEN MG, 1991, OBSTET GYNECOL, V77, P465; ROSEN MG, 1990, OBSTET GYNECOL, V76, P865, DOI 10.1097/00006250-199011000-00029; SOLIMAN SRH, 1993, CAN MED ASSOC J, V148, P1315; TAFFEL SM, 1991, BIRTH-ISS PERINAT C, V18, P73, DOI 10.1111/j.1523-536X.1991.tb00063.x; TAFFEL SM, 1992, BIRTH-ISS PERINAT C, V19, P21, DOI 10.1111/j.1523-536X.1992.tb00367.x; THURNAU GR, 1991, AM J OBSTET GYNECOL, V165, P353, DOI 10.1016/0002-9378(91)90091-5; TROYER LR, 1992, AM J OBSTET GYNECOL, V167, P1099, DOI 10.1016/S0002-9378(12)80046-9; Weinstein D, 1996, AM J OBSTET GYNECOL, V174, P192, DOI 10.1016/S0002-9378(96)70393-9; 1986, CAN MED ASSOC J, V134, P1348; 1993, MMWR-MORBID MORTAL W, V42, P285	19	452	470	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					689	695		10.1056/NEJM199609053351001	http://dx.doi.org/10.1056/NEJM199609053351001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH266	8703167	Bronze, Green Published			2022-12-28	WOS:A1996VH26600001
J	Schuchter, L; Schultz, DJ; Synnestvedt, M; Trock, BJ; Guerry, D; Elder, DE; Elenitsas, R; Clark, WH; Halpern, AC				Schuchter, L; Schultz, DJ; Synnestvedt, M; Trock, BJ; Guerry, D; Elder, DE; Elenitsas, R; Clark, WH; Halpern, AC			A prognostic model for predicting 10-year survival in patients with primary melanoma	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIFACTORIAL ANALYSIS; THICKNESS; AREAS; RISK	Objective: To develop a prognostic model, based on clinical and pathologic data that are routinely available to the clinician, that would estimate the chance for survival of a patient with primary cutaneous melanoma after definitive surgical therapy. Design: Cohort analytical study. Setting: University medical center. Patients: 488 patients with primary cutaneous melanoma who had no apparent metastatic disease. Patients were followed prospectively for at least 10 years. An independent validation sample of 142 patients was used to assess the stability of the model. Measurements: Six clinical and pathologic variables that predict survival and are readily available to the clinician were used to develop a prediction model. The variables were tested for their association with death by using a univariate logistic regression model. Point estimates were generated for the probability of surviving melanoma at 10 years. Variables that were statistically significantly associated with survival were retained for testing in a logistic regression model. Results: 488 patients were followed prospectively for a median of 13.5 years (minimum, 10.0 years; maximum, 20.5 years). The overall 10-year survival of the study group was 78%. Four variables were found to be independent predictors of survival. Presented as adjusted odds ratios, from strongest to weakest relative predictive strength, these variables were tumor thickness (odds ratio, 50.8), site of primary melanoma (odds ratio, 4.4), age of the patient (odds ratio, 3.0), and sex of the patient (odds ratio, 2.0). The four-variable model was significantly more accurate than tumor thickness alone, particularly for predicting death. Overall, use of the model reduced the error rate of the prediction of death by 50%. Conclusions: A prognostic model that uses four readily accessible variables more accurately predicts outcome in patients with primary melanoma than does tumor thickness alone. This four-variable model can identify patients at high risk for the recurrence of disease, an identification that becomes increasingly important as adjuvant therapies are developed for treatment of melanoma.	UNIV PENN, BIOSTAT UNIT, PHILADELPHIA, PA 19104 USA; LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; BETH ISRAEL HOSP, DEPT PATHOL, BOSTON, MA 02215 USA	University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center				halpern, allan/0000-0001-7320-1901				BALCH CM, 1978, ANN SURG, V188, P732, DOI 10.1097/00000658-197812000-00004; BALCH CM, 1979, SURGERY, V86, P343; BERD D, 1993, ANN NY ACAD SCI, V690, P147; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Clark W H Jr, 1975, Semin Oncol, V2, P83; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; DAY CL, 1982, ANN SURG, V195, P35, DOI 10.1097/00000658-198201001-00006; Elwood J. Mark, 1994, Current Opinion in Oncology, V6, P179, DOI 10.1097/00001622-199403000-00011; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOSMER DW, 1989, APPL LOGISTIC REGRES; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; LIVINGSTON PO, 1994, J CLIN ONCOL, V12, P1036, DOI 10.1200/JCO.1994.12.5.1036; MASRI GD, 1990, J AM ACAD DERMATOL, V22, P1042, DOI 10.1016/0190-9622(90)70149-C; VELLEMAN PF, 1981, APPLICATIONS BASICS	17	136	136	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					369	375		10.7326/0003-4819-125-5-199609010-00003	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702087				2022-12-28	WOS:A1996VE07900003
J	McNamee, D; Horton, R				McNamee, D; Horton, R			Lies, damn lies, and reports of RCTs	LANCET			English	Editorial Material																			0	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					562	562						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774566				2022-12-28	WOS:A1996VF18600007
J	Eppert, K; Scherer, SW; Ozcelik, H; Pirone, R; Hoodless, P; Kim, H; Tsui, LC; Bapat, B; Gallinger, S; Andrulis, IL; Thomsen, GH; Wrana, JL; Attisano, L				Eppert, K; Scherer, SW; Ozcelik, H; Pirone, R; Hoodless, P; Kim, H; Tsui, LC; Bapat, B; Gallinger, S; Andrulis, IL; Thomsen, GH; Wrana, JL; Attisano, L			MADR2 maps to 18q21 and encodes a TGF beta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma	CELL			English	Article							GROWTH-FACTOR-BETA; RECEPTOR COMPLEX; KINASE RECEPTOR; II RECEPTOR; GENE; IDENTIFICATION; MUTATIONS; MESODERM; XENOPUS; EXPRESSION	The MAD-related (MADR) family of proteins are essential components in the signaling pathways of serine/threonine kinase receptors for the transforming growth factor beta (TGF beta) superfamily. We demonstrate that MADR2 is specifically regulated by TGF beta and not bone morphogenetic proteins. The gene for MADR2 was found to reside on chromosome 18q21, near DPC4, another MADR protein implicated in pancreatic cancer. Mutational analysis of MADR2 in sporadic tumors identified four missense mutations in colorectal carcinomas, two of which display a loss of heterozygosity. Biochemical and functional analysis of three of these demonstrates that the mutations are inactivating. These findings suggest that MADR2 is a tumor suppressor and that mutations acquired in colorectal carcinomas may function to disrupt TGF beta signaling.	HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; MT SINAI HOSP,DEPT LAB MED & PATHOL,TORONTO,ON M5G 1X8,CANADA; MT SINAI HOSP,DEPT SURG,TORONTO,ON M5G 1X8,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT ANAT & CELL BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT CELLULAR & MOL PATHOL,TORONTO,ON M5S 1A8,CANADA; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,INST CELL & DEV BIOL,STONY BROOK,NY 11794	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Eppert, K (corresponding author), HOSP SICK CHILDREN,PROGRAM DEV BIOL,DIV GASTROENTEROL,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		Scherer, Stephen W./B-3785-2013; Gallinger, Steven/E-4575-2013; Bapat, Bharati/B-5839-2014; Tsui, Lap-chee/A-1081-2010; Andrulis, Irene L./E-7267-2013; Wrana, Jeffrey/F-8857-2013	Scherer, Stephen W./0000-0002-8326-1999; Eppert, Kolja/0000-0001-9061-8856; Hoodless, Pamela/0000-0003-1371-0725				Attisano L, 1996, MOL CELL BIOL, V16, P1066; BHUSHAN A, 1994, MOL CELL BIOL, V14, P4280, DOI 10.1128/MCB.14.6.4280; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHUMAKOV IM, 1995, NATURE, V377, P175; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MAHONY D, 1995, P NATL ACAD SCI USA, V92, P6474, DOI 10.1073/pnas.92.14.6474; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SCHERER S, 1991, P33; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P213; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1996, IN PRESS TRENDS GENE; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	45	765	798	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					543	552		10.1016/S0092-8674(00)80128-2	http://dx.doi.org/10.1016/S0092-8674(00)80128-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752209	Bronze			2022-12-28	WOS:A1996VE23500005
J	Hall, DB; Holmlin, RE; Barton, JK				Hall, DB; Holmlin, RE; Barton, JK			Oxidative DNA damage through long-range electron transfer	NATURE			English	Article							CLEAVAGE; 8-HYDROXY-2'-DEOXYGUANOSINE; INTERCALATION; RIBOFLAVIN; COMPLEXES; RESIDUES; GUANINE; BASES; SITE	The possibility has been considered for almost forty years that the DNA double helix, which contains a pi-stacked array of heterocyclic base pairs, could be a suitable medium for the migration of charge over long molecular distances(1-11). This notion of high charge mobility is a critical consideration with respect to DNA damage. We have previously found(7-10) that the DNA double helix can serve as a molecular bridge for photo-induced electron transfer between metallointercalators, with fast rates (greater than or equal to 10(10) s(-1))(10) and with quenching over a long distance (>40 Angstrom)(8). Here we use a metallointercalator to introduce a photoexcited hole into the DNA pi-stacked at a specific site in order to evaluate oxidative damage to DNA from a distance. Oligomeric DNA duplexes were prepared with a rhodium intercalator covalently attached to one end and separated spatially from 5'-GG-3' doublet sites of oxidation. Rhodium-induced photo-oxidation occurs specifically at the 5'-G in the 5'-GG-3' doublets and is observed up to 37 Angstrom away from the site of rhodium intercalation. We find that the yield of oxidative damage depends sensitively upon oxidation potential and pi-stacking, but not on distance. These results demonstrate directly that oxidative damage to DNA may be promoted from a remote site as a result of hole migration through the DNA pi-stack.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology				Hall, Daniel B/0000-0002-5085-8334				ARKIN MR, IN PRESS SCIENCE; BARCISZEWSKI J, 1995, POL J CHEM, V69, P841; BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894; Breslin DT, 1996, J AM CHEM SOC, V118, P2311, DOI 10.1021/ja953714w; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; CHUNG MH, 1992, BIOCHEM BIOPH RES CO, V188, P1, DOI 10.1016/0006-291X(92)92341-T; CULLIS PM, 1990, J CHEM SOC FARADAY T, V86, P591, DOI 10.1039/ft9908600591; DAVID SS, 1993, J AM CHEM SOC, V115, P2984, DOI 10.1021/ja00060a060; FROMHERZ P, 1986, J AM CHEM SOC, V108, P5361, DOI 10.1021/ja00277a060; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; ITO K, 1993, J BIOL CHEM, V268, P13221; JOHANN TW, 1996, PHIL T R SOC LOND A, V354, P29; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; Kittler L., 1980, J ELECTROANAL CHEM I, V116, P503; MEADE TJ, 1995, ANGEW CHEM INT EDIT, V34, P352, DOI 10.1002/anie.199503521; MEI HY, 1988, P NATL ACAD SCI USA, V85, P1339, DOI 10.1073/pnas.85.5.1339; MELVIN T, 1995, PHOTOCHEM PHOTOBIOL, V61, P584, DOI 10.1111/j.1751-1097.1995.tb09873.x; MURPHY CJ, 1994, P NATL ACAD SCI USA, V91, P5315, DOI 10.1073/pnas.91.12.5315; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; PURUGGANAN MD, 1988, SCIENCE, V241, P1645, DOI 10.1126/science.3420416; RETEL J, 1993, MUTAT RES, V299, P165, DOI 10.1016/0165-1218(93)90094-T; SAITO I, 1995, J AM CHEM SOC, V117, P6406, DOI 10.1021/ja00128a050; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; SNART RS, 1968, BIOPOLYMERS, V6, P293, DOI 10.1002/bip.1968.360060304; Stemp EDA, 1996, MET IONS BIOL SYST, V33, P325; SZENTGYORGYI A, 1960, P NATL ACAD SCI USA, V46, P1444, DOI 10.1073/pnas.46.11.1444; Turro C, 1996, INORG CHIM ACTA, V243, P101, DOI 10.1016/0020-1693(95)04896-0; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; WACHTER L, 1986, NUCLEIC ACIDS RES, V14, P7985, DOI 10.1093/nar/14.20.7985	30	849	870	6	123	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					731	735		10.1038/382731a0	http://dx.doi.org/10.1038/382731a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751447				2022-12-28	WOS:A1996VD33300055
J	Bone, RC				Bone, RC			Why sepsis trials fail	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; TUMOR-NECROSIS-FACTOR; CONTROLLED CLINICAL-TRIAL; HUMAN MONOCLONAL-ANTIBODY; SEPTIC SHOCK; DOUBLE-BLIND; RECEPTOR ANTAGONIST; FACTOR-ALPHA; ENDOTOXIN; CYTOKINE				Bone, RC (corresponding author), RUSH UNIV, RUSH MED COLL,DEPT MED,OFF DEAN,600 S PAULINA, STE 202, CHICAGO, IL 60612 USA.							ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BRUNET F, 1995, AM J RESP CRIT CARE, V151, P1269; CARLET, 1995, CURR OPIN CRIT CARE, V1, P349; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CHRISTOU NV, 1979, J SURG RES, V26, P355, DOI 10.1016/0022-4804(79)90020-9; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; FAIST E, 1992, SURGERY, V112, P562; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V272, P1170; FUKUSHIMA R, 1994, CRIT CARE MED, V22, P114, DOI 10.1097/00003246-199401000-00022; GOLDIE AS, 1995, JAMA-J AM MED ASSOC, V274, P172, DOI 10.1001/jama.274.2.172; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; MALEFYT RD, 1991, J EXP MED, V174, P915; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; MILLS CD, 1989, J CLIN IMMUNOL, V9, P139, DOI 10.1007/BF00916942; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; PLATZER C, 1995, INT IMMUNOL, V7, P517, DOI 10.1093/intimm/7.4.517; REINHART, 1995, CURR OPIN CRIT CARE, V1, P349; SADOFF, 1995, CURR OPIN CRIT CARE, V1, P349; STEWART AG, 1994, IMMUNOLOGY, V82, P51; SZABO G, 1991, J CLIN IMMUNOL, V11, P326, DOI 10.1007/BF00918798; VOLK HD, 1992, MICROBIOLOGIST, V3, P20; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	29	169	187	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					565	566		10.1001/jama.276.7.565	http://dx.doi.org/10.1001/jama.276.7.565			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709407				2022-12-28	WOS:A1996VC10100034
J	Milunsky, A				Milunsky, A			Congenital defects, folic-acid, and homoeobox genes	LANCET			English	Editorial Material											Milunsky, A (corresponding author), BOSTON UNIV,SCH MED,CTR HUMAN GENET,BOSTON,MA 02118, USA.			Milunsky, Aubrey/0000-0003-2114-4823				CZEIZEL AE, 1996, NEW ENGL J MED, V62, P179; LI DK, 1995, EPIDEMIOLOGY, V6, P212, DOI 10.1097/00001648-199505000-00004; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MILUNSKY A, 1992, TERATOLOGY, V46, P341, DOI 10.1002/tera.1420460405; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					419	420		10.1016/S0140-6736(05)64532-1	http://dx.doi.org/10.1016/S0140-6736(05)64532-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709776	hybrid			2022-12-28	WOS:A1996VC67300003
J	Brook, RH; Kamberg, CJ; McGlynn, EA				Brook, RH; Kamberg, CJ; McGlynn, EA			Health system reform and quality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BYPASS GRAFT-SURGERY; MEDICAL-CARE; CLINICAL GUIDELINES; CONTROLLED TRIAL; UNITED-STATES; APPROPRIATENESS; SERVICES; RELIABILITY; INSURANCE; MORTALITY		UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA; RAND CORP,WASHINGTON,DC	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; RAND Corporation	Brook, RH (corresponding author), RAND CORP,1700 MAIN ST,SANTA MONICA,CA 90407, USA.							ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; BERZON RA, 1995, QUAL LIFE RES, V4, P53, DOI 10.1007/BF00434384; BROOK RH, 1988, HEALTH AFFAIR, V7, P150, DOI 10.1377/hlthaff.7.3.150; BROOK RH, 1990, HEALTH POLICY, V14, P225, DOI 10.1016/0168-8510(90)90037-E; BROOK RH, 1973, NEW ENGL J MED, V288, P1323, DOI 10.1056/NEJM197306212882504; BUNKER JP, 1970, NEW ENGL J MED, V282, P135, DOI 10.1056/NEJM197001152820306; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CHALMERS I, 1989, EFFECTIVE CARE PRE 1, V1; CHALMERS I, 1989, EFFECTIVE CARE PRE 4, V2; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; *COL HLTH DAT COMM, 1992, COL HOSP OUTC MORT L; Committee on Choices in Health Care, 1992, CHOIC HLTH CAR; *DEP PRACT PAR AM, 1996, DIR PRACT PAR TITL S; Donabedian, 1985, EXPLORATIONS QUALITY, V3; Donabedian A., 1982, EXPLORATIONS QUALITY, VII; Donabedian A, 1980, EXPLORATIONS QUALITY, V1; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; IEZZONI LI, 1993, INQUIRY-J HEALTH CAR, V30, P112; IEZZONI LI, 1992, MED CARE, V30, P428, DOI 10.1097/00005650-199205000-00005; Kahan JP, 1996, MED CARE, V34, P512, DOI 10.1097/00005650-199606000-00002; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KONSTAM M, 1994, 940612 AHCPR; KORAN LM, 1975, NEW ENGL J MED, V293, P695, DOI 10.1056/NEJM197510022931405; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; KRISTIANSEN IS, 1993, J EPIDEMIOL COMMUN H, V47, P481, DOI 10.1136/jech.47.6.481; LENNOX EL, 1979, BRIT MED J, V2, P567, DOI 10.1136/bmj.2.6190.567; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; Lohr K N, 1986, Med Care, V24, pS1; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; *MAR MERR DOW, 1994, MAN CAR DIG; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; *NAT COMM QUAL ASS, 1993, REP CARD PIL PROJ; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; *PENNS HLTH CAR CO, 1991, CONS GUID COR ART BY; SCOTT EA, 1991, J PUBLIC HEALTH MED, V13, P35, DOI 10.1093/oxfordjournals.pubmed.a042575; SIU AL, 1991, HLTH AFF MILLWOOD, V10, P63; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; Swedish Parliamentary Priorities Commission, 1995, PRIOR HLTH CAR ETH E, P5; *US GEN ACC OFF, 1994, GAOHEHS951 US GEN OF; *US GEN ACC OFF, 1994, GAOHEHS94219 US GEN; Weissman JS., 1994, FALLING SAFETY NET I; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445	60	82	82	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					476	480		10.1001/jama.276.6.476	http://dx.doi.org/10.1001/jama.276.6.476			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VA863	8691556				2022-12-28	WOS:A1996VA86300036
J	Nightingale, SL				Nightingale, SL			One-day course on clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691538				2022-12-28	WOS:A1996VA86300008
J	Richards, MA; Parrott, JC				Richards, MA; Parrott, JC			Tertiary cancer services in Britain: Benchmarking study of activity and facilities at 12 specialist centres	BRITISH MEDICAL JOURNAL			English	Article								Objective-To collate information on current activity and facilities in British hospitals to assist the planning of future cancer services. Design-12 hospitals delivering specialist cancer services provided information on the size of population served, activity levels related to non-surgical oncology for 1994-5, and facilities available. Inconsistencies in the recording of data were resolved through meetings of all participants. Setting-Five single specialty NHS trusts and seven specialist cancer facilities within multispecialty trusts, serving a combined population of 24.3 million. Main outcome measures-Activity levels and facilities per million population served. Results-The facilities available per million population served varied widely between centres. In contrast, the range in the number of new referrals per million population (seen either at the centre or in peripheral clinics) was relatively small. Considerable variations were observed in the number of attendances per patient and amount of radiotherapy and chemotherapy delivered. Overall it was estimated that 40-45% of all new cases of cancer are currently being referred to nonsurgical oncologists. For the seven hospitals which could provide data on trends in activity, the average increase in chemotherapy day case episodes between 1992-3 and 1994-5 was 83%. Conclusions-The results of this study provide a benchmark both for purchasers and providers of cancer care. The increase in the use of chemotherapy points to an urgent need for a unified system for monitoring both activity and outcomes of treatment.	GUYS & ST THOMAS HOSP NHS TRUST,CANC SERV,LONDON,ENGLAND; GUYS & ST THOMAS HOSP NHS TRUST,TERTIARY SERV,LONDON,ENGLAND									Expert Advisory Group on Cancer, 1995, POL FRAM COMM CANC S; *ROYAL COLL RAD, 1990, SURV NAT RAD WORKL M	2	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					347	349		10.1136/bmj.313.7053.347	http://dx.doi.org/10.1136/bmj.313.7053.347			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760746	Green Published			2022-12-28	WOS:A1996VC30000024
J	Sheridan, J; Strang, J; Barber, N; Glanz, A				Sheridan, J; Strang, J; Barber, N; Glanz, A			Role of community pharmacies in relation to HIV prevention and drug misuse: Findings from the 1995 national survey in England and Wales	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To establish activity levels of community (high street) pharmacies in the provision of HIV prevention services to drug misusers and to compare these findings with the levels identified in 1988. Design-Self completion questionnaire (four mailings) to a random 1 in 4 sample of all community pharmacies, stratified by family health services authority. Setting-England and Wales. Subjects-Data provided by pharmacist in charge of the dispensary, on service provision at the pharmacy. Main outcome measures-quantitative reports of current activity levels for (a) dispensing of controlled drugs to drug misusers, (b) sale of needles and syringes, (c) needle and syringe exchange. Results-74.8% response rate (1984/2654). In 1995, 50.1% (992/1980) of pharmacies were dispensing controlled drugs (mostly methadone), compared with 23.0% (562/2457) in 1988; 34.5% (677/1962) of pharmacies were selling injecting equipment, compared with 28.0% (676/2434) in 1988; 18.9% (366/1937) were providing a needle exchange service, compared with 3.0% (65/2415) in 1988. Conclusion-Activity levels increased substantially across all three service areas. Increased activity included greater individual activity as well as higher proportions of pharmacies participating. The network of community pharmacies represents an underused point of contact for this Health of the Nation target population.	UNIV LONDON,SCH PHARM,CTR PHARM PRACTICE,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London School of Pharmacy	Sheridan, J (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,NATL ADDICT CTR,DE CRESPIGNY PK, DENMARK HILL,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Sheridan, Janie/0000-0002-0312-3095				*ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; Advisory Council on the Misuse of Drugs, 1988, AIDS DRUG MIS 1; *DEP HLTH, 1993, HLTH NATION KEY AREA; GLANZ A, 1989, BRIT MED J, V299, P1076, DOI 10.1136/bmj.299.6707.1076; GLANZ A, 1990, PREVENTION AIDS DRUG; *HOM OFF, 1995, STAT DRUG ADD NOT HO; Home Office, 1995, TACKLING DRUGS TOGET; MOTT J, 1994, HEROIN ADDICTION DRU, P270; Strang J, 1996, BMJ-BRIT MED J, V313, P270, DOI 10.1136/bmj.313.7052.270; 1991, PHARM J, V247, P223; 1993, PHARM J, V251, P20; 1994, PHARM J, V252, P53; 1991, PHARM J, V247, P304	13	62	63	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					272	274		10.1136/bmj.313.7052.272	http://dx.doi.org/10.1136/bmj.313.7052.272			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704541	Green Published			2022-12-28	WOS:A1996VA90300031
J	Ansell, P; Bull, D; Roman, E				Ansell, P; Bull, D; Roman, E			Childhood leukaemia and intramuscular vitamin K: Findings from a case-control study	BRITISH MEDICAL JOURNAL			English	Article							CANCER		RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford				Roman, Eve/0000-0001-7603-3704				DRAPER G, 1994, BRIT MED J, V308, P867, DOI 10.1136/bmj.308.6933.867; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; STILLER CA, 1995, EUR J CANCER, V202, P8	5	36	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					204	205		10.1136/bmj.313.7051.204	http://dx.doi.org/10.1136/bmj.313.7051.204			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696197	Green Published			2022-12-28	WOS:A1996VA12600026
J	Coetzee, T; Fujita, N; Dupree, J; Shi, R; Blight, A; Suzuki, K; Suzuki, K; Popko, B				Coetzee, T; Fujita, N; Dupree, J; Shi, R; Blight, A; Suzuki, K; Suzuki, K; Popko, B			Myelination in the absence of galactocerebroside and sulfatide: Normal structure with abnormal function and regional instability	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BASIC-PROTEIN; RAT-BRAIN; CERAMIDE GALACTOSYLTRANSFERASE; MORPHOMETRIC ANALYSIS; PROTEOLIPID PROTEIN; GALACTOSYL CERAMIDE; DEFICIENT MICE; UDP-GALACTOSE; EXPRESSION	The vertebrate nervous system is characterized by ensheathment of axons with myelin, a multilamellar membrane greatly enriched in the galactolipid galactocerebroside (GalC) and its sulfated derivative sulfatide. We have generated mice lacking the enzyme UDP-galactose:ceramide galactosyltransferase (CGT), which is required for GalC synthesis. CGT-deficient mice do not synthesize GalC or sulfatide but surprisingly form myelin containing glucocerebroside, a lipid not previously identified in myelin. Microscopic and morphometric analyses revealed myelin of normal ultrastructural appearance, except for slightly thinner sheaths in the ventral region of the spinal cord. Nevertheless, these mice exhibit severe generalized tremoring and mild ataxia, and electrophysiological analysis showed conduction deficits consistent with reduced insulative capacity of the myelin sheath. Moreover, with age, CGT-deficient mice develop progressive hindlimb paralysis and extensive vacuolation of the ventral region of the spinal cord. These results indicate that GalC and sulfatide play important roles in myelin function and stability.	UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT SURG,DIV NEUROSURG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT NEUROL & PSYCHIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,PROGRAM MOL BIOL & BIOTECHNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Coetzee, T (corresponding author), UNIV N CAROLINA,CTR NEUROSCI,CHAPEL HILL,NC 27599, USA.			Popko, Brian/0000-0001-9948-2553	NINDS NIH HHS [NS24453, NS27336, NS24289] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027336, R01NS027336, R01NS024453, R01NS024289] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON MB, 1965, J BIOL CHEM, V240, P2389; ADACHI M, 1972, ACTA NEUROPATHOL, V20, P22, DOI 10.1007/BF00687899; ADLKOFER K, 1995, NAT GENET, V11, P274, DOI 10.1038/ng1195-274; ALEU FP, 1963, J NEUROPATH EXP NEUR, V22, P403, DOI 10.1097/00005072-196307000-00003; BANSAL R, 1989, P NATL ACAD SCI USA, V86, P6181, DOI 10.1073/pnas.86.16.6181; BARRETT EF, 1982, J PHYSIOL-LONDON, V323, P117, DOI 10.1113/jphysiol.1982.sp014064; BEAUDET AL, 1995, METABOLIC MOL BASIS, P4599; BENJAMINS JA, 1990, ANN NY ACAD SCI, V305, P90; BLACK JA, 1990, TRENDS NEUROSCI, V13, P48, DOI 10.1016/0166-2236(90)90068-L; BLIGHT AR, 1985, NEUROSCIENCE, V15, P13, DOI 10.1016/0306-4522(85)90119-8; BOISON D, 1994, P NATL ACAD SCI USA, V91, P11709, DOI 10.1073/pnas.91.24.11709; BUSCHARD K, 1994, DIABETOLOGIA, V37, P1000; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COETZEE T, 1996, IN PRESS GENOMICS; COSTANTI.E, 1973, J BIOL CHEM, V248, P8240; CURATOLO W, 1987, BIOCHIM BIOPHYS ACTA, V906, P137, DOI 10.1016/0304-4157(87)90009-8; DAVID G, 1995, J PHYSIOL-LONDON, V489, P141, DOI 10.1113/jphysiol.1995.sp021037; DEVRIES GH, 1972, SCIENCE, V175, P1370, DOI 10.1126/science.175.4028.1370; DORFMAN SH, 1979, BRAIN RES, V177, P105, DOI 10.1016/0006-8993(79)90921-1; DYER CA, 1989, J NEUROSCI RES, V24, P212, DOI 10.1002/jnr.490240212; DYER CA, 1988, J NEUROSCI, V8, P4307; DYER CA, 1990, J CELL BIOL, V111, P625, DOI 10.1083/jcb.111.2.625; DYER CA, 1991, J NEUROSCI RES, V30, P699, DOI 10.1002/jnr.490300414; DYER CA, 1993, MOL NEUROBIOL, V7, P1, DOI 10.1007/BF02780606; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANKENHAEUSER B, 1963, J PHYSIOL-LONDON, V169, P431, DOI 10.1113/jphysiol.1963.sp007269; FRY JM, 1974, SCIENCE, V183, P540, DOI 10.1126/science.183.4124.540; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; HAMMARST.S, 1971, EUR J BIOCHEM, V21, P388, DOI 10.1111/j.1432-1033.1971.tb01481.x; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; IGISU H, 1983, BIOCHEM BIOPH RES CO, V110, P940, DOI 10.1016/0006-291X(83)91053-7; JANSEN R, 1989, GENE ANAL TECH, V6, P79, DOI 10.1016/0735-0651(89)90020-4; KOYNOVA R, 1995, BBA-LIPID LIPID MET, V1255, P213, DOI 10.1016/0005-2760(94)00202-A; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; LITTLE GJ, 1994, J ANAT, V184, P387; LONG D, 1994, J VIROL, V68, P5890, DOI 10.1128/JVI.68.9.5890-5898.1994; LUNN KF, 1995, MICROSC RES TECHNIQ, V32, P183, DOI 10.1002/jemt.1070320303; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; Morell Pierre, 1994, P117; NESKOVIC NM, 1986, J NEUROCHEM, V47, P1412, DOI 10.1111/j.1471-4159.1986.tb00773.x; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; POPKO B, 1987, CELL, V48, P713, DOI 10.1016/0092-8674(87)90249-2; RANSCHT B, 1987, J NEUROSCI, V7, P2936; RATH EM, 1995, J NEUROSCI, V15, P7226; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; ROACH A, 1983, CELL, V34, P799, DOI 10.1016/0092-8674(83)90536-6; ROSENBLUTH J, 1994, J NEUROCYTOL, V23, P699, DOI 10.1007/BF01181644; SCHAERENWIEMERS N, 1995, J NEUROCHEM, V65, P2267; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SHINE HD, 1992, J NEUROCHEM, V58, P342, DOI 10.1111/j.1471-4159.1992.tb09316.x; STAHL N, 1994, J NEUROSCI RES, V38, P234, DOI 10.1002/jnr.490380214; SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7; SUZUKI K, 1969, AM J PATHOL, V54, P307; TOWFIGHI J, 1974, LAB INVEST, V31, P712; Towfighi J, 1980, EXPT CLIN NEUROTOXIC, P440; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Watanabe I., 1980, EXPT CLIN NEUROTOXIC, P545; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992	65	479	486	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					209	219		10.1016/S0092-8674(00)80093-8	http://dx.doi.org/10.1016/S0092-8674(00)80093-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706126	Bronze			2022-12-28	WOS:A1996UZ97200007
J	West, SC				West, SC			DNA helicases: New breeds of translocating motors and molecular pumps	CELL			English	Review							SINGLE-STRANDED-DNA; BRANCH MIGRATION; PROTEIN; COMPLEX; HEXAMER; RINGS; FORMS				West, SC (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			West, Stephen/0000-0001-8848-9418				BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; Jezewska MJ, 1996, J BIOL CHEM, V271, P4261; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	13	122	124	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					177	180		10.1016/S0092-8674(00)80088-4	http://dx.doi.org/10.1016/S0092-8674(00)80088-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706121	Bronze			2022-12-28	WOS:A1996UZ97200002
J	Porter, JA; Ekker, SC; Park, WJ; vonKessler, DP; Young, KE; Chen, CH; Ma, Y; Woods, AS; Cotter, RJ; Koonin, EV; Beachy, PA				Porter, JA; Ekker, SC; Park, WJ; vonKessler, DP; Young, KE; Chen, CH; Ma, Y; Woods, AS; Cotter, RJ; Koonin, EV; Beachy, PA			Hedgehog patterning activity: Role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain	CELL			English	Article							MEMBRANE-PROTEINS; DROSOPHILA-EMBRYO	Autocatalytic processing mediated by the carboxyterminal domain of the hedgehog (hh) protein precursor (Hh) generates an amino-terminal product that accounts for all known signaling activity. The role of autoprocessing in biogenesis of the hh signal has been unclear, since a truncated unprocessed protein lacking all carboxy-terminal domain sequences retains signaling activity. Here, we present evidence that the autoprocessing reaction proceeds via an internal thioester intermediate and results in a covalent modification that increases the hydrophobic character of the signaling domain and influences its spatial and subcellular distribution. We demonstrate that truncated unprocessed amino-terminal protein causes embryonic mispatterning, even when expression is localized to cells that normally express Hh, thus suggesting a role for autoprocessing in spatial regulation of hh signaling. This type of processing also appears to operate in the biogenesis of other novel secreted proteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; NATL INST HLTH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Porter, JA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA.			Ekker, Stephen/0000-0003-0726-4212				Alberts B., 1994, MOL BIOL CELL; BLACKLEDGE JA, 1995, ANAL CHEM, V67, P843, DOI 10.1021/ac00101a009; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; CHU CT, 1994, LAB INVEST, V71, P792; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HEUKESHOVEN J, 1985, J CHROMATOGR, V326, P91, DOI 10.1016/S0021-9673(01)87434-3; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P141, DOI 10.1016/S0968-0004(00)88989-6; Koonin EV, 1996, METHOD ENZYMOL, V266, P295; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEVINE RP, 1990, CURR TOP MICROBIOL, V153, P73; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Moore DD, 1995, GLOB MOB SURV; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	37	421	447	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					21	34		10.1016/S0092-8674(00)80074-4	http://dx.doi.org/10.1016/S0092-8674(00)80074-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689684	hybrid			2022-12-28	WOS:A1996UX93400005
J	Grubb, A; Walsh, P; Lambe, N; Murrells, T; Robinson, S				Grubb, A; Walsh, P; Lambe, N; Murrells, T; Robinson, S			Survey of British clinicians' views on management of patients in persistent vegetative state	LANCET			English	Article								Background The best care and management of patients in persistent vegetative slate (PVS) has been the subject of sustained moral and legal debate for a number of years. However, the views of clinicians in the UK involved in caring for patients in PVS are largely unknown. Methods A postal questionnaire was sent to 1882 consultant members of the British Association of Orthopaedic Surgeons, the Association of British Neurologists, the Society of British Neurosurgeons, and the British Society of Rehabilitation Medicine. Their views were sought on various aspects of the management and care of PVS, in particular the appropriateness of a decision not to treat and a decision to withdraw artificial nutrition and hydration (ANH). Findings 1027 doctors responded (55%) of whom 558 (54%) had experience of managing patients in PVS. Over 90% of responding doctors considered that it could be not to treat acute infections and other life-threatning conditions. 65% of doctors considered that withdrawal of ANH could be apporpriate. About two-thirds of doctors who thought treatment-limiting decisions could be appropriate thought that such decisions could be considered with the first 12 months of the patient being in PVS. Despite recent case law, less than half the doctors responding to the survey thought that an advance directive made by the patient should have a decisive influence in determining treatment-limiting decisions. Most doctors would like decisions about withdrawing ANH to be made in conjunction with family members and in accordance with agreed guidelines but without the need to go to court. Interpretation There is a broad consensus among doctors that treatment-limiting decisions are sometimes appropriate for patients in PVS, irrespective of whether they have experience of the condition or of the specialty to which they belong. However, two thirds of doctors said that such decisions can be considered al a time earlier than that recommended by the British Medical Association. It is not clear why some doctors thought a decision not to treat could be appropriate while a decision to withdraw ANH would not be.	UNIV LONDON KINGS COLL,NURSING RES UNIT,LONDON WC2R 2LS,ENGLAND	University of London; King's College London	Grubb, A (corresponding author), UNIV LONDON KINGS COLL,CTR MED LAW & ETH,LONDON WC2R 2LS,ENGLAND.							ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; ANDREWS K, 1993, BRIT MED J, V306, P1602; [Anonymous], 1989, NEUROLOGY, V39, P125; ASHWAL S, 1992, ANN NEUROL, V32, P570, DOI 10.1002/ana.410320414; *BRIT MED ASS, 1995, ADV STAT MED TREATM; CANTOR NL, 1989, AM J LAW MED, V15, P381; Cartwright A, 1983, HLTH SURVEYS PRACTIC; CELESIA GG, 1993, ANN NEUROL, V33, P391, DOI 10.1002/ana.410330410; Dworkin R., 1993, LIFES DOMINION; *GEZ, 1994, PUBL GEZ; GIACINO GT, 1995, J HEAD TRAUMA REHABI, V10, P40; HODGES MO, 1994, ARCH INTERN MED, V154, P1013, DOI 10.1001/archinte.154.9.1013; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1992, BRIT MED J, V305, P1305, DOI 10.1136/bmj.305.6865.1305; KENNEDY I, 1993, MED LAW REV, V1, P359; Kennedy I, 1991, TREAT ME RIGHT ESSAY; KENNEDY I, 1994, MED LAW; *LAW COMM ENGL WAL, 1995, 231 LAW COMM ENGL WA; RACHELS J., 1986, END LIFE EUTHANASIA; *SCOTT LAW COMM, 1995, 151 SCOTT LAW COMM; 1994, NEW ENGL J MED, V330, P1499; 1996, J R COLL PHYSNS, V30, P119; [No title captured]; [No title captured]; 1994, NEW ENGL J MED, V330, P1572	25	49	51	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					35	40		10.1016/S0140-6736(96)02030-2	http://dx.doi.org/10.1016/S0140-6736(96)02030-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691931				2022-12-28	WOS:A1996UV92300015
J	Taback, SP; Collu, R; Deal, CL; Guyda, HJ; Salisbury, S; Dean, HJ; VanVliet, G				Taback, SP; Collu, R; Deal, CL; Guyda, HJ; Salisbury, S; Dean, HJ; VanVliet, G			Does growth-hormone supplementation affect adult height in Turner's syndrome?	LANCET			English	Article								Background By comparison with historical controls, the effect of treatment with growth hormone on adult height in Turner's syndrome was initially reported as uniformly and strongly positive. Because randomised controlled trials are not near completion, we report our experiences in an open study. Methods We examined adult height, projected attained, in 31 patients (17 treated with subcutaneous recombinant human growth hormone, up to 15 mg a week, outside of a controlled trial and 14 untreated contemporaries). Findings Contingency table analysis of attained versus projected height showed significantly higher values in treated patients although only 4 of 17 had final heights of 5 cm or more over projection, Patients' and treatment variables (height, bone-age delay, oestrogen replacement) that interfere with adult height projection confounded the analysis of adult height data. Interpretation Girls with Turner's syndrome should be counselled cautiously about the expectation of a strongly positive effect of treatment on adult height. Completion of the randomised controlled trials to adult height is needed to establish the effect of growth-hormone supplementation on adult height in Turner's syndrome and the psychological effect of treatment.	HOP ST JUSTINE, MONTREAL, PQ H3T 1C5, CANADA; MONTREAL CHILDRENS HOSP, SERV ENDOCRINOL, MONTREAL, PQ H3H 1P3, CANADA; IZAAK WALTON KILLAM HOSP CHILDREN, HALIFAX, NS B3J 3G9, CANADA; WINNIPEG CHILDRENS HOSP, WINNIPEG, MB, CANADA	Universite de Montreal; McGill University; Dalhousie University; University of Manitoba; Children's Hospital Research Institute of Manitoba								CHU CE, 1995, HORM RES S1, V44, pA73; CIANFARANI S, 1994, LANCET, V344, P114, DOI 10.1016/S0140-6736(94)91288-2; Greulich WW., 1959, CALIF MED, V91, P53; LYON AJ, 1985, ARCH DIS CHILD, V60, P932, DOI 10.1136/adc.60.10.932; RANKE MB, 1983, EUR J PEDIATR, V141, P81, DOI 10.1007/BF00496795; ROSENFELD RG, 1995, P 8 ANN INV M NAT CO, P16; Ross JL, 1996, J CLIN ENDOCR METAB, V81, P926, DOI 10.1210/jc.81.3.926; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Taback SP, 1995, INT CONGR SER, V1089, P183; Tanner J., 1994, DIAGNOSIS TREATMENT, V4th ed., P154; VANDENBROECK, 1995, J PEDIATR, V127, P729	12	53	54	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1996	348	9019					25	27		10.1016/S0140-6736(96)01267-6	http://dx.doi.org/10.1016/S0140-6736(96)01267-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691926				2022-12-28	WOS:A1996UV92300011
J	Grey, AB; Stapleton, JP; Evans, MC; Tatnell, MA; Reid, IR				Grey, AB; Stapleton, JP; Evans, MC; Tatnell, MA; Reid, IR			Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; UNTREATED PRIMARY HYPERPARATHYROIDISM; POPULATION-BASED COHORT; FOLLOW-UP; CONSERVATIVE TREATMENT; BREAST-CANCER; ESTROGEN; OSTEOPOROSIS; PARATHYROIDECTOMY; FRACTURES	Background: Most patients with primary hyperparathyroidism are postmenopausal women. The presence of osteopenia in persons with mild primary hyperparathyroidism is considered an indication for parathyroidectomy. No prospective, controlled trials have assessed medical therapies for osteopenia in primary hyperparathyroidism. Objective: To examine the effects of estrogen-progestin therapy (hormone replacement therapy) on bone mineral density and biochemical indices in postmenopausal women with mild primary hyperparathyroidism. Design: Double-blind, randomized, placebo-controlled trial. Setting: University teaching hospital. Patients: 42 postmenopausal women with mild primary hyperparathyroidism. Intervention: Patients were randomly assigned to receive either conjugated estrogens, 0.625 mg/d, and medroxyprogesterone, 5 mg/d, or placebo. Measurements: Bone mineral densities of the total body, lumbar spine, proximal femur (femoral neck, Ward triangle, trochanter), and proximal forearm were measured every 6 months using dual-energy x-ray absorptiometry. Biochemical indices of bone turnover and calcium metabolism were measured at baseline, 6 months, and 2 years. Results: In the placebo group, bone mineral densities of the total body and the proximal forearm decreased significantly from baseline (mean +/- SE, -2.3% +/- 0.7% [P = 0.005] and -3.5% +/- 1.2% [P = 0.01], respectively). At the other sites, bone mineral density also tended to decline. In the hormone replacement therapy group, bone mineral density increased from baseline in the total body (1.3% +/- 0.4%; P = 0.004), lumbar spine (5.2% +/- 1.4%; P = 0.002), and femoral neck (3.4% +/- 1.5%; P = 0.05). The between-group differences in bone mineral density at the end of the study ranged from 3.6% to 6.6% and were significant at all sites (P > 0.001 and P < 0.05) except for the Ward triangle (P = 0.06). In the hormone replacement therapy group, serum alkaline phosphatase levels decreased by 22% (P = 0.0004 compared with baseline), urinary hydroxyproline excretion decreased by 42% (P = 0.0004), urinary N-telopeptide excretion decreased by 54% (P = 0.001), and urinary calcium excretion decreased by 45% (P = 0.007). Hormone replacement therapy did not change levels of serum ionized calcium or intact parathyroid hormone. Conclusions: Although hormone replacement therapy has little effect on serum calcium levels, it suppresses bone turnover, reduces urinary calcium excretion, and increases bone mineral density throughout the skeleton in postmenopausal women with mild primary hyperparathyroidism. This therapy is thus an important management option for these patients.	UNIV AUCKLAND, DEPT MED, AUCKLAND 1, NEW ZEALAND; YALE UNIV, SCH MED, DEPT ENDOCRINOL, NEW HAVEN, CT 06520 USA	University of Auckland; Yale University								ALHAVA EM, 1988, ACTA CHIR SCAND, V154, P345; ANGUS RM, 1989, J AM DIET ASSOC, V89, P209; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BLOCK MA, 1989, SURGERY, V106, P1063; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CLYDE JW, 1992, NEW ZEAL MED J, V105, P71; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; DAUPHINE RT, 1975, ANN INTERN MED, V83, P365, DOI 10.7326/0003-4819-83-3-365; DAVIES M, 1992, CLIN ENDOCRINOL, V36, P325, DOI 10.1111/j.1365-2265.1992.tb01454.x; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; GALLAGHER JC, 1972, LANCET, V1, P503; GARTON M, 1995, CLIN ENDOCRINOL, V42, P493, DOI 10.1111/j.1365-2265.1995.tb02668.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREY AB, 1994, CLIN ENDOCRINOL, V40, P671, DOI 10.1111/j.1365-2265.1994.tb03020.x; GREY AB, 1994, ANN INTERN MED, V121, P745, DOI 10.7326/0003-4819-121-10-199411150-00003; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; HOROWITZ M, 1987, ARCH INTERN MED, V147, P681, DOI 10.1001/archinte.147.4.681; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KOCHERSBERGER G, 1987, ARCH INTERN MED, V147, P1951, DOI 10.1001/archinte.147.11.1951; LAFFERTY FW, 1989, ARCH INTERN MED, V149, P789, DOI 10.1001/archinte.149.4.789; LARSSON K, 1993, J INTERN MED, V234, P585, DOI 10.1111/j.1365-2796.1993.tb01017.x; LEPPLA DC, 1982, INVEST RADIOL, V17, P604, DOI 10.1097/00004424-198211000-00013; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003-4819-100-5-633; MARTIN P, 1986, ARCH INTERN MED, V146, P689, DOI 10.1001/archinte.146.4.689; MAUTALEN C, 1986, ACTA ENDOCRINOL-COP, V111, P494, DOI 10.1530/acta.0.1110494; MCDERMOTT MT, 1994, J BONE MINER RES, V9, P509; MCKANE WR, 1995, J CLIN ENDOCR METAB, V80, P3458, DOI 10.1210/jc.80.12.3458; MELTON LJ, 1992, ARCH INTERN MED, V152, P2269, DOI 10.1001/archinte.152.11.2269; MOLE PA, 1992, BRIT J SURG, V79, P263, DOI 10.1002/bjs.1800790327; MUNDY GR, 1980, LANCET, V1, P1317, DOI 10.1016/S0140-6736(80)91783-3; NORDIN BEC, 1991, J CLIN ENDOCR METAB, V72, P401, DOI 10.1210/jcem-72-2-401; PALMER M, 1988, EUR J CLIN INVEST, V18, P39, DOI 10.1111/j.1365-2362.1988.tb01163.x; PALMER M, 1987, LANCET, V1, P59; PARFITT AM, 1991, J BONE MINER RES, V6, P95; POTTS JT, 1990, J CLIN ENDOCR METAB, V70, P1489, DOI 10.1210/jcem-70-6-1489; POTTS JT, 1991, ANN INTERN MED, V114, P593, DOI 10.7326/0003-4819-114-7-593; REID IR, 1994, J CLIN ENDOCR METAB, V79, P1595, DOI 10.1210/jc.79.6.1595; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RICHARDSON ML, 1986, SKELETAL RADIOL, V15, P85, DOI 10.1007/BF00350200; RUDNICKI M, 1992, J INTERN MED, V232, P421, DOI 10.1111/j.1365-2796.1992.tb00608.x; SEIBEL MJ, 1992, J CLIN ENDOCR METAB, V74, P481, DOI 10.1210/jc.74.3.481; SELBY PL, 1986, NEW ENGL J MED, V314, P1481, DOI 10.1056/NEJM198606053142304; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P723, DOI 10.1210/jc.80.3.723; SILVERBERG SJ, 1989, J BONE MINER RES, V4, P283, DOI 10.1002/jbmr.5650040302; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; STEINICHE T, 1995, BONE, V16, pS214; STEVENSON JC, 1988, BRIT MED J, V296, P1016, DOI 10.1136/bmj.296.6628.1016-a; WARNER J, 1991, Journal of Bone and Mineral Research, V6, pS91; WILSON RJ, 1988, ANN INTERN MED, V109, P959, DOI 10.7326/0003-4819-109-12-959; WISHART J, 1990, ARCH INTERN MED, V150, P1329, DOI 10.1001/archinte.150.6.1329	55	133	136	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					360	368		10.7326/0003-4819-125-5-199609010-00002	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702086				2022-12-28	WOS:A1996VE07900002
J	Yool, AJ; Stamer, WD; Regan, JW				Yool, AJ; Stamer, WD; Regan, JW			Forskolin stimulation of water and cation permeability in aquaporin1 water channels	SCIENCE			English	Article							XENOPUS OOCYTES; PROTEIN; CHIP; CDNA; CAMP	Aquaporin1, a six-transmembrane domain protein, is a water channel present in many fluid-secreting and -absorbing cells. In Xenopus oocytes injected with aquaporin1 complementary RNA, the application of forskolin or cyclic 8-bromo- adenosine 3',5'-monophosphate increased membrane permeability to water and triggered a cationic conductance. The cationic conductance was also induced by direct injection of protein kinase A (PKA) catalytic subunit, reduced by the kinase inhibitor H7, and blocked by HgCl2, an inhibitor of aquaporin1. The cationic permeability of the aquaporin1 channel is activated by a cyclic adenosine monophosphate-dependent mechanism that may involve direct or indirect phosphorylation by PKA.	UNIV ARIZONA,DEPT PHARMACOL,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT PHYSIOL,PROGRAM NEUROSCI,TUCSON,AZ 85721	University of Arizona; University of Arizona; University of Arizona	Yool, AJ (corresponding author), UNIV ARIZONA,DEPT PHYSIOL,TUCSON,AZ 85724, USA.		Yool, Andrea/AAK-9907-2020	Yool, Andrea/0000-0003-1283-585X	NATIONAL EYE INSTITUTE [R29EY009355] Funding Source: NIH RePORTER; NEI NIH HHS [EY09355] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CHANG XB, 1993, J BIOL CHEM, V268, P11304; FISCHBARG J, 1989, P NATL ACAD SCI USA, V86, P8397, DOI 10.1073/pnas.86.21.8397; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; RICH DP, 1993, J BIOL CHEM, V268, P20259; STAMER WD, 1994, INVEST OPHTH VIS SCI, V35, P3867; Stamer WD, 1995, CURR EYE RES, V14, P1095, DOI 10.3109/02713689508995815; YOOL AJ, UNPUB; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	20	143	145	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1216	1218		10.1126/science.273.5279.1216	http://dx.doi.org/10.1126/science.273.5279.1216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703053				2022-12-28	WOS:A1996VE47600036
J	Kletke, PR; Emmons, DW; Gillis, KD				Kletke, PR; Emmons, DW; Gillis, KD			Current trends in physicians' practice arrangements - From owners to employees	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVIVOR ANALYSIS; MANAGED CARE; 21ST-CENTURY; WORKFORCE; PATTERNS; MEDICINE	Objective.-To examine current trends in practice organization among postresident patient care physicians in the United States. Design and Setting.-The American Medical Association's Socioeconomic Monitoring System (SMS), a series of periodic surveys of nationally representative samples of nonfederal postresident patient care physicians. Physicians were divided into 3 categories based on the organization of their main practice. They were classified as employee physicians if they had no ownership interest in their practice, as self-employed solo physicians if they were in 1-physician practices in which they had an ownership interest, and as self-employed group physicians if they were in multiple-physician practices in which they had an ownership interest. Participants.-Nonfederal, postresident patient care physicians who provided more than 47 000 responses to SMS surveys between 1983 and 1994. Main Outcome Measure.-The proportion of nonfederal postresident patient care physicians who were employees between 1983 and 1994. Results.-Between 1983 and 1994, the proportion of patient care physicians practicing as employees rose from 24.2% to 42.3% (P<.001), the proportion self-employed in solo practices fell from 40.5% to 29.3% (P<.001), and the proportion self-employed in group practices fell from 35.3% to 28.4% (P<.001). Most of these changes occurred in the latter half of the 12-year period. These trends, which are evident in virtually every segment of the patient care physician population, are especially prominent among young physicians. The growing proportion of employee physicians is associated with increases in the earnings of employee physicians relative to those of self-employed solo physicians. Conclusions.-Current trends in the US health care system are rapidly changing the career opportunities of patient care physicians and, hence, physicians' choice of practice arrangement.	AMER MED ASSOC, CTR HLTH POLICY RES, CHICAGO, IL 60610 USA	American Medical Association	Kletke, PR (corresponding author), AMER MED ASSOC, POLICY DEV UNIT, 515 N STATE ST, CHICAGO, IL 60610 USA.							*AM MED ASS CTR HL, 1994, PROD EFF WORKF SIZ P; *AM MED ASS CTR HL, 1993, COMP SMS PHYS INC DA; Bureau of Labor Statistics, CPI DET REP; COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; Emmons D W, 1988, Med Care Rev, V45, P101, DOI 10.1177/107755878804500105; FRECH HET, 1974, J BUS, V47, P23; Freidson E., 1970, PROFESSION MED STUDY; GAMLIEL S, 1995, HEALTH AFFAIR, V14, P131, DOI 10.1377/hlthaff.14.2.131; GILLIS KD, 1989, SOCIOECONOMIC CHARAC, P23; GONZALEZ ML, 1995, PHYSICIAN MARKETPLAC; GREENLICK MR, 1995, ACAD MED, V70, P179, DOI 10.1097/00001888-199503000-00007; HAVLICEK PL, 1993, MED GROUPS US; MARDER WD, 1988, HEALTH AFFAIR, V7, P137, DOI 10.1377/hlthaff.7.5.137; MARDER WD, 1985, J HEALTH ECON, V4, P167, DOI 10.1016/0167-6296(85)90005-0; MCKINLAY JB, 1988, INT J HEALTH SERV, V18, P191, DOI 10.2190/YEVW-6C44-YCYE-CGEU; POPE GC, 1993, MARGINAL PRACTICE CO; REED RR, 1987, JAMA-J AM MED ASSOC, V258, P3279, DOI 10.1001/jama.258.22.3279; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; RELMAN AS, 1983, HLTH AFF MILLWOO SUM, V2, P26; SCHNEIDER JE, 1992, INTEGRATING RESULTS; SCHROEDER SA, 1988, J GEN INTERN MED, V3, P25, DOI 10.1007/BF02595753; SCOVERN H, 1985, NEW ENGL J MED, V319, P787; SHORTELL SM, 1994, HEALTH AFFAIR, V13, P46, DOI 10.1377/hlthaff.13.5.46; STARR P, 1978, DAEDALUS, V107, P175; Starr P, 1982, SOCIAL TRANSFORMATIO; TARLOV AR, 1983, NEW ENGL J MED, V308, P1235, DOI 10.1056/NEJM198305193082028; THRAN S, 1995, ADJUSTMENTS NONRESPO; Weinber JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WEINERMAN ER, 1968, B NEW YORK ACAD MED, V44, P1423; WILLKE RJ, 1991, MED CARE, V29, P977, DOI 10.1097/00005650-199110000-00004	30	96	96	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					555	560		10.1001/jama.276.7.555	http://dx.doi.org/10.1001/jama.276.7.555			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VC101	8709405				2022-12-28	WOS:A1996VC10100032
J	Forbes, A				Forbes, A			Caring for older people - Loneliness	BRITISH MEDICAL JOURNAL			English	Article											Forbes, A (corresponding author), CATHOLIC AGCY SOCIAL CONCERN,LONDON SW1V 1BX,ENGLAND.							MARRIOTT V, 1988, LONELINESS OVERCOME	1	19	19	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					352	354		10.1136/bmj.313.7053.352	http://dx.doi.org/10.1136/bmj.313.7053.352			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760749	Green Published			2022-12-28	WOS:A1996VC30000027
J	Ana, J				Ana, J			Launching the Nigerian edition of the BMJ: Implications for Nigeria's health care	BRITISH MEDICAL JOURNAL			English	Article											Ana, J (corresponding author), NIGERIAN MED FORUM,84 BISHOPSCOTE RD,LUTON LU3 1PB,BEDS,ENGLAND.							*FED MIN HLTH, 1993, NIG HLTH PROF 1992 1, P1; *NIG MED ASS, 1993, NAT MED DIR	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					105	106		10.1136/bmj.313.7049.105	http://dx.doi.org/10.1136/bmj.313.7049.105			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688715	Green Published			2022-12-28	WOS:A1996UX69800031
J	vonMuhlendahl, KE				vonMuhlendahl, KE			Suspected sexual abuse in a 10-year-old girl	LANCET			English	Article							SCLEROSUS-ET-ATROPHICUS; CHILDREN				vonMuhlendahl, KE (corresponding author), KINDERHOSP,IBURGER STR 187,D-49082 OSNABRUCK,GERMANY.							CLARK JA, 1967, ARCH DERMATOL, V95, P476, DOI 10.1001/archderm.95.5.476; HANDFIELDJONES SE, 1987, BRIT MED J, V294, P1404, DOI 10.1136/bmj.294.6584.1404; JENNY C, 1981, PEDIATRICS, V83, P597; LOENINGBAUCKE V, 1991, AM J DIS CHILD, V145, P1058, DOI 10.1001/archpedi.1991.02160090110035; Young SJ, 1993, AUST FAM PHYSICIAN, V22729, P732	5	3	3	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					30	30						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691929				2022-12-28	WOS:A1996UV92300013
J	White, NJ				White, NJ			The treatment of malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEVERE FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; AFRICAN CHILDREN; EXCHANGE-TRANSFUSION; CEREBRAL MALARIA; PHARMACOKINETIC PROPERTIES; PHARMACODYNAMIC PROPERTIES; INTRAVENOUS QUININE; GAMBIAN CHILDREN; CHLOROQUINE		CHO QUAN HOSP, WELLCOME TRUST CLIN RES UNIT, CTR TROP DIS, HO CHI MINH CITY, VIETNAM; JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, CTR TROP MED, OXFORD OX3 9DU, ENGLAND	University of Oxford	White, NJ (corresponding author), MAHIDOL UNIV, FAC TROP MED, 420-6 RAJVITHI RD, BANGKOK 10400, THAILAND.		White, Nicholas J/I-4629-2012; Torero, Rebeca/C-1703-2012; White, Nick/AAC-6527-2019	White, Nick/0000-0002-1897-1978	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; BREWER TG, 1994, T ROY SOC TROP MED H, V88, P33, DOI 10.1016/0035-9203(94)90469-3; BruceChwatt LJ, 1981, WHO MONOGRAPH SERIES, V27; DAVIS TME, 1990, J INFECT DIS, V161, P1305, DOI 10.1093/infdis/161.6.1305; FIELD J. W., 1941, TRANS ROY SOC TROP MED AND HYG, V34, P405, DOI 10.1016/S0035-9203(41)90026-3; HIEN TT, 1992, T ROY SOC TROP MED H, V86, P582, DOI 10.1016/0035-9203(92)90137-2; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; HIEN TT, 1993, LANCET, V341, P603; KARBWANG J, 1993, BRIT J CLIN PHARMACO, V35, P265; KREMSNER PG, 1990, J ANTIMICROB CHEMOTH, V25, P9, DOI 10.1093/jac/25.1.9; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; Looareesuwan S, 1994, Trans R Soc Trop Med Hyg, V88 Suppl 1, pS9; LOOAREESUWAN S, 1990, Q J MED, V75, P471; LOOAREESUWAN S, 1992, LANCET, V339, P821, DOI 10.1016/0140-6736(92)90276-9; LOOAREESUWAN S, 1985, LANCET, V2, P4, DOI 10.1016/S0140-6736(85)90056-X; MABEY DCW, 1987, J INFECT DIS, V155, P1319, DOI 10.1093/infdis/155.6.1319; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; MILLER KD, 1989, NEW ENGL J MED, V321, P65, DOI 10.1056/NEJM198907133210201; MOLYNEUX ME, 1989, Q J MED, V71, P441; MURPHY GS, 1993, LANCET, V341, P96, DOI 10.1016/0140-6736(93)92568-E; NOSTEN F, 1995, J INFECT DIS, V171, P519; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; NOSTEN F, 1993, LANCET, V341, P1054, DOI 10.1016/0140-6736(93)92412-M; OKITOLONDA W, 1987, BMJ-BRIT MED J, V295, P716, DOI 10.1136/bmj.295.6600.716; PALMER KJ, 1993, DRUGS, V45, P430, DOI 10.2165/00003495-199345030-00009; PASVOL G, 1991, AM J TROP MED HYG, V45, P702, DOI 10.4269/ajtmh.1991.45.702; PHILLIPSHOWARD PA, 1995, DRUG SAFETY, V12, P370, DOI 10.2165/00002018-199512060-00003; PHU NH, 1995, T ROY SOC TROP MED H, V89, P200, DOI 10.1016/0035-9203(95)90496-4; PUSSARD E, 1991, ANTIMICROB AGENTS CH, V35, P406, DOI 10.1128/AAC.35.3.406; RIECKMANN KH, 1989, LANCET, V2, P1183, DOI 10.1016/S0140-6736(89)91792-3; Severe and complicated malaria, 1990, T R SOC TROP MED S2, p[84, 1]; SILAMUT K, 1991, BRIT J CLIN PHARMACO, V32, P311, DOI 10.1111/j.1365-2125.1991.tb03904.x; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; TERKUILE FO, 1992, J INFECT DIS, V166, P1393, DOI 10.1093/infdis/166.6.1393; TERKUILE FO, 1993, LANCET, V341, P1044, DOI 10.1016/0140-6736(93)92409-M; TERKUILE FO, 1996, T R SOC TROP MED HYG, V73, P631; TRANG TTM, 1992, CLIN INFECT DIS, V15, P874, DOI 10.1093/clind/15.5.874; Udomsangpetch R, 1996, J INFECT DIS, V173, P691, DOI 10.1093/infdis/173.3.691; VANDENENDE J, 1994, TROP GEOGR MED, V46, P340; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WALLER D, 1990, T ROY SOC TROP MED H, V84, P488, DOI 10.1016/0035-9203(90)90009-4; WATKINS WM, 1984, LANCET, V1, P357; WATT G, 1992, AM J TROP MED HYG, V47, P108, DOI 10.4269/ajtmh.1992.47.108; WHITE NJ, 1988, NEW ENGL J MED, V319, P1493, DOI 10.1056/NEJM198812083192301; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; WHITE NJ, 1989, LANCET, V2, P1313, DOI 10.1016/S0140-6736(89)91918-1; WHITE NJ, 1987, LANCET, V1, P708; WHITE NJ, 1982, AM J MED, V73, P564, DOI 10.1016/0002-9343(82)90337-0; WHO, 1994, WHOMAL941067; WINSTANLEY P, 1993, T ROY SOC TROP MED H, V87, P201, DOI 10.1016/0035-9203(93)90494-B	50	335	348	0	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					800	806		10.1056/NEJM199609123351107	http://dx.doi.org/10.1056/NEJM199609123351107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8703186				2022-12-28	WOS:A1996VF78600007
J	McAlindon, TE; Felson, DT; Zhang, YQ; Hannan, MT; Aliabadi, P; Weissman, B; Rush, D; Wilson, PWF; Jacques, P				McAlindon, TE; Felson, DT; Zhang, YQ; Hannan, MT; Aliabadi, P; Weissman, B; Rush, D; Wilson, PWF; Jacques, P			Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study	ANNALS OF INTERNAL MEDICINE			English	Article							OSTEO-ARTHRITIS; RADIOGRAPHIC PROGRESSION; PHYSICAL-ACTIVITY; JOINT SPACE; BONE; HEALTH; QUESTIONNAIRE; DISEASE; WOMEN; HIP	Background: Evidence suggests that pathophysiologic processes in bone are important determinants of outcome in osteoarthritis of the knee. Low intake and low serum levels of vitamin D may compromise favorable responses of bone to osteoarthritis, predisposing patients to progression. Objective: To determine whether dietary intake and serum levels of vitamin D would predict the incidence and progression of osteoarthritis of the knee in participants of the Framingham Study. Design: Prospective observational study. Setting: The Framingham Study. Participants: Participants in the Framingham Heart Study who had knee radiography at examinations 18 (done between 1983 and 1985) and 22 (done between 1992 and 1993) and received interim assessments of vitamin D intake and serum levels. Measurements: Intake of vitamin D and serum levels of 25-hydroxyvitamin D, calculated on the basis of dietary habits and supplement use as reported on a questionnaire, were evaluated at examination 20 (1988 to 1989). Knee radiographs were given scores for global severity of osteoarthritis, using a modification of the scale of Kellgren and Lawrence (range, 0 to 4), and for the presence of osteophytes and joint-space narrowing (range, 0 to 3). Covariates measured at examinations 18 and 20 were age, sex, body mass index, weight change, injury, physical activity, health status, bone mineral density, and energy intake. Results: 556 participants (mean age at baseline +/- SD, 70.3 +/- 4.5 years) had complete assessments. Incident osteoarthritis occurred in 75 knees; progressive osteoarthritis occurred in 62 knees. Serum levels of vitamin D were modestly correlated with vitamin D intake (r = 0.24). Risk for progression increased threefold in participants in the middle and lower tertiles for both vitamin D intake (odds ratio for the lower compared with the upper tertile, 4.0 [95% Cl, 1.4 to 11.6]) and serum levels of vitamin D (odds ratio for the lower compared with the upper tertilee, 2.9 [Cl, 1.0 to 8.2]). Low serum levels of vitamin D also predicted loss of cartilage, as assessed by loss of joint space (odds ratio, 2.3 [Cl, 0.9 to 5.5]) and osteophyte growth (odds ratio, 3.1 [Cl, 1.3 to 7.5]). Incident osteoarthritis of the knee occurring after baseline was not consistently related to either intake or serum levels of vitamin D. Conclusions: Low intake and low serum levels of vitamin D each appear to be associated with an increased risk for progression of osteoarthritis of the knee.	FRAMINGHAM STUDY, FRAMINGHAM, MA 01701 USA; TUFTS UNIV, USDA, CTR HUMAN NUTR, BOSTON, MA 02111 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA	Tufts University; United States Department of Agriculture (USDA); Harvard University; Brigham & Women's Hospital	McAlindon, TE (corresponding author), BOSTON UNIV, MED CTR, ARTHRIT CTR, ROOM A203, 80 E CONCORD ST, BOSTON, MA 02118 USA.		Wilson, Peter W.F./J-2455-2016	Felson, David/0000-0002-2668-2447; Zhang, Yuqing/0000-0001-7954-1149	NATIONAL INSTITUTE ON AGING [R01AG009300] Funding Source: NIH RePORTER; NIAMS NIH HHS [ARZ0613] Funding Source: Medline; NIA NIH HHS [R0-1 AG09300] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS JS, 1982, NEW ENGL J MED, V306, P722, DOI 10.1056/NEJM198203253061206; ALTMAN RD, 1987, ARTHRITIS RHEUM-US, V30, P1214, DOI 10.1002/art.1780301103; [Anonymous], 1990, NUTR EPIDEMIOLGY; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; CORVOL MT, 1981, ANN ENDOCRINOL-PARIS, V42, P482; DEDRICK DK, 1993, ARTHRITIS RHEUM, V36, P1460, DOI 10.1002/art.1780361019; DEQUEKER J, 1995, J RHEUMATOL, V22, P98; DIEPPE P, 1993, ANN RHEUM DIS, V52, P557, DOI 10.1136/ard.52.8.557; FELSON DT, 1995, ARTHRITIS RHEUM-US, V38, P1500, DOI 10.1002/art.1780381017; FELSON DT, 1990, RHEUM DIS CLIN N AM, V16, P499; GRANT MD, 1995, J CLIN EPIDEMIOL, V48, P375, DOI 10.1016/0895-4356(94)00143-E; HANNAN MT, 1993, J RHEUMATOL, V20, P704; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HORDON LD, 1992, ANN RHEUM DIS, V51, P823, DOI 10.1136/ard.51.6.823; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; Kellgren JH, 1963, EPIDEMIOLOGY CHRONIC; KIEL DP, 1995, NUTR ASSESSMENT ELDE, P277; LAYTON MW, 1988, ARTHRITIS RHEUM-US, V31, P1400, DOI 10.1002/art.1780311109; LEDINGHAM J, 1995, ANN RHEUM DIS, V54, P53, DOI 10.1136/ard.54.1.53; LEDINGHAM J, 1993, ANN RHEUM DIS, V52, P263, DOI 10.1136/ard.52.4.263; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MCALINDON T, 1990, BRIT J RHEUMATOL, V29, P471; McAlindon TE, 1996, ARTHRITIS RHEUM-US, V39, P648, DOI 10.1002/art.1780390417; MILGRAM JW, 1983, CLIN ORTHOP RELAT R, V173, P293; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; PERRY GH, 1972, ANN RHEUM DIS, V31, P440, DOI 10.1136/ard.31.6.440; POTTENGER LA, 1990, ARTHRITIS RHEUM-US, V33, P853, DOI 10.1002/art.1780330612; RADIN EL, 1986, CLIN ORTHOP RELAT R, P34; RADIN EL, 1970, ARTHRITIS RHEUM, V13, P400, DOI 10.1002/art.1780130406; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SMYTHE HA, 1987, J RHEUMATOL, V14; SPECTOR TD, 1994, ANN RHEUM DIS, V53, P565, DOI 10.1136/ard.53.9.565; Willett W, 1990, NUTRITIONAL EPIDEMIO; Willett W, 1990, NUTR EPIDEMIOLOGY, P92; WRIGHT V, 1989, BRIT MED J, V299, P1476, DOI 10.1136/bmj.299.6714.1476; 1976, BRIT MED J, V2, P4	38	301	318	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					353	359		10.7326/0003-4819-125-5-199609010-00001	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702085				2022-12-28	WOS:A1996VE07900001
J	Rooke, J; Pan, D; Xu, T; Rubin, GM				Rooke, J; Pan, D; Xu, T; Rubin, GM			KUZ, a conserved metalloprotease-disintegrin protein with two roles in Drosophila neurogenesis	SCIENCE			English	Article							PLATELET-AGGREGATION INHIBITOR; SPERM-EGG FUSION; CELL FATE; SENSORY BRISTLES; VENOM; MELANOGASTER; NOTCH; RECOMBINASE; PRECURSOR; SEQUENCE	During neurogenesis in Drosophila both neurons and nonneuronal cells are produced from a population of initially equivalent cells. The kuzbanian (kuz) gene described here is essential for the partitioning of neural and nonneuronal cells during development of both the central and peripheral nervous systems in Drosophila. Mosaic analyses indicated that kuz is required for cells to receive signals inhibiting the neural fate. These analyses further revealed that the development of a neuron requires a kuz-mediated positive signal from neighboring cells. The kuz gene encodes a metalloprotease-disintegrin protein with a highly conserved bovine homolog, raising the possibility that kuz homologs may act in similar processes during mammalian neurogenesis.	YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT GENET, NEW HAVEN, CT 06536 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	Yale University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703				ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AU LC, 1991, BIOCHEM BIOPH RES CO, V181, P585, DOI 10.1016/0006-291X(91)91230-A; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J. A., 1993, DEV DROSOPHILA MELAN, VII, P1091; CHOU TB, 1992, GENETICS, V131, P643; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOWARD L, 1995, METHOD ENZYMOL, V248, P388; JAN YN, 1993, DEV DROSOPHILA MELAN, V2, P1207; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824; RICHELLE J, 1979, DEV BIOL, V70, P418, DOI 10.1016/0012-1606(79)90036-8; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; SHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SIMPSON P, 1990, DEVELOPMENT, V109, P509; STUTTEM I, 1991, DEVELOPMENT, P39; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VANDERVORST P, 1980, NATURE, V286, P65, DOI 10.1038/286065a0; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; XU T, 1993, DEVELOPMENT, V117, P1223; XU T, 1990, GENETICS, V126, P665; XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	36	295	306	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1996	273	5279					1227	1231		10.1126/science.273.5279.1227	http://dx.doi.org/10.1126/science.273.5279.1227			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703057				2022-12-28	WOS:A1996VE47600040
J	Oberlin, E; Amara, A; Bachelerie, F; Bessia, C; Virelizier, JL; ArenzanaSeisdedos, F; Schwartz, O; Heard, JM; ClarkLewis, I; Legler, DF; Loetscher, M; Baggiolini, M; Moser, B				Oberlin, E; Amara, A; Bachelerie, F; Bessia, C; Virelizier, JL; ArenzanaSeisdedos, F; Schwartz, O; Heard, JM; ClarkLewis, I; Legler, DF; Loetscher, M; Baggiolini, M; Moser, B			The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1	NATURE			English	Article							CHEMOTACTIC CYTOKINES; MOLECULAR-CLONING; RECEPTOR; INTERLEUKIN-8; MIP-1-ALPHA; MIP-1-BETA; SEQUENCE; PROTEINS; RANTES	A PUTATIVE chemokine receptor that we previously cloned and termed LESTR(1) has recently been shown to function as a co-receptor (termed fusin) for lymphocyte-tropic HIV-1 strains(2), Cells expressing CD4 became permissive to infection with T-cell-line-adapted HIV-1 strains of the syncytium-inducing phenotype after transfection with LESTR/fusin complementary DNA, We report here the identification of a human chemokine of the CXC type, stromal cell-derived factor 1 (SDF-1), as the natural ligand for LESTR/fusin, and we propose the term CXCR-4 for this receptor, in keeping with the new chemokine-receptor nomenclature, SDF-1 activates Chinese hamster ovary (CHO) cells transfected with CXCR-4 cDNA as well as blood leukocytes and lymphocytes. In cell lines expressing CXCR-4 and CD4, and in blood lymphocytes, SDF-1 is a powerful inhibitor of infection by lymphocyte-tropic HIV-1 strains, whereas the CC chemokines RANTES, MIP-1 alpha and MIP-1 beta, which were shown previously to prevent infection with primary, monocyte-tropic viruses(3), are inactive, In combination with CC chemokines, which block the infection with monocyte/macrophage-tropic viruses, SDF-1 could help to decrease virus load and prevent the emergence of the syncytium-inducing viruses which are characteristic of the late stages of AIDS(4).	INST PASTEUR,UNITE IMMUNOL VIRALE,F-75724 PARIS 15,FRANCE; INST PASTEUR,LAB RETROVIRUS & TRANSFERT GENET,F-75724 PARIS 15,FRANCE; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BERN,THEODOR KOCHER INST,BERN 9,SWITZERLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of British Columbia; University of Bern			AMARA, Ali/ABX-9903-2022; BACHELERIE, FRANCOISE/F-8823-2013; Oberlin, Estelle/M-4915-2018; Amara, Ali/E-8803-2017; Arenzana-Seisdedos, Fernando/E-5835-2016; Schwartz, Olivier/AAZ-3765-2021	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Oberlin, Estelle/0000-0002-8200-9548; Schwartz, Olivier/0000-0002-0729-1475; Moser, Bernhard/0000-0002-4354-4572; AMARA, Ali/0000-0002-0283-1815; Legler, Daniel F./0000-0001-8610-4764				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BLEUL CC, IN PRESS J EXP MED; CANN AJ, 1990, J VIROL, V64, P4735, DOI 10.1128/JVI.64.10.4735-4742.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLOTTA F, 1984, J IMMUNOL, V132, P936; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Jacque JM, 1996, J VIROL, V70, P2930; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANTSCHAMER V, 1986, NATURE, V324, P369; Weiss RA, 1996, SCIENCE, V272, P1885, DOI 10.1126/science.272.5270.1885; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564	26	1440	1511	0	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					833	835		10.1038/382833a0	http://dx.doi.org/10.1038/382833a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752281	Green Submitted			2022-12-28	WOS:A1996VE34700054
J	Palareti, G; Leali, N; Coccheri, S; Poggi, M; Manotti, C; DAngelo, A; Pengo, V; Erba, N; Moia, M; Ciavarella, N; Devote, G; Berrettini, M; Musolesi, S				Palareti, G; Leali, N; Coccheri, S; Poggi, M; Manotti, C; DAngelo, A; Pengo, V; Erba, N; Moia, M; Ciavarella, N; Devote, G; Berrettini, M; Musolesi, S			Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)	LANCET			English	Article							HEMORRHAGIC COMPLICATIONS; ATRIAL-FIBRILLATION; PROTHROMBIN TIME; RISK-FACTORS; THERAPY; WARFARIN; THROMBOEMBOLISM; OUTPATIENTS; PREDICTION; PREVENTION	Background Bleeding is the most serious complication of the use of oral anticoagulation in the prevention and treatment of thromoboembolic complications. We studied the frequency of bleeding complications in outpatients treated routinely in anticoagulation clinics. Methods In a prospective cohort from thirty-four Italian anticoagulation clinics, 2745 consecutive patients were studied from the start of their oral anticoagulation (warfarin in 64%, acenocourmarol in the rest). The target anticoagulation-intensity was low (international normalised ratio [INR] less than or equal to 2.8) in 71% of the patients and high (less than or equal to 2.8) in. the remainder. We recorded demographic details and the main indication for treatment and, every 3-4 months, INR and outcome events. Such events included all complications (bleeding, thrombosis, other), although only overdosing. bleeding events are reported here, and deaths. We divided bleeding into major and minor categories. Findings 43% of the patients were women. Nearly three-fifths of the patients were aged 60-79; 8% were over 80. The main indication for treatment was venous thrombolism (33%), followed by non-ischaemic heart disease (17%). Mean follow-up was 267 days. Over 2011 patient-years of follow-up, 153 bleeding complications occurred (7.6 per 100 patient-years). 5 were fatal (all cerebral haemorrhages, 0.25 per 100 patient-years), 23 were major (1.1), and 125 were minor (6.2). The rate of events was similar between sexes, coumarin type, size of enrolling centre, and target INR. The rate was higher in older patients: 10.5 per 100 patient-years in those aged 70 or over, 6.0 in those aged under 70 (relative risk 1.75, 95% CI 1.29-2.39, p<0.001). The rate was also higher when the indication was peripheral and/or cerebrovascular disease than venous thromboembolism plus other indications (12.5 vs 6.0 per 100 patient-years) (1.80, 1.2-2.7, p<0.01), and during the first 90 days of treatment compared with later (11.0 vs 6.3, 1.75, 1.27-2.44, p<0.001). A fifth of the bleeding events occurred at low anticoagulation intensity (INR<2, rate 7.7 per 100 patient-years of follow-up). The rates were 4.8, 9.5, 40.5, and 200 at INRs 2.9-2.9, 3-4.4, 4.5-6.9, and over 7, respectively (relative risks for INR>4.5, 7.91, 5.44-11.5, p<0.0001). Interpretation We saw fewer bleeding events than those recorded in other observational and experimental studies. Oral anticoagulation has become safer in recent years, especially if monitored in anticoagulation clinics. Caution is required in elderly patients and anticoagulation intensity should be closely monitored to reduce periods of overdosing.	OSPED REG PARMA,CTR EMOSTASI,PARMA,ITALY; UNIV PADUA,CETTEDRA CARDIOL,SERV PREVENZ TROMBOSI,I-35100 PADUA,ITALY; OSPED MERATE,AMBULATORIO EMOSTASI SEZ TRASFUS,MERATE,ITALY; UNIV MILAN,CTR EMOFILIA & TROMBOSI A BIANCHI BONOMI,I-20122 MILAN,ITALY; POLICLIN BARI,SERV COAGULAZ,BARI,ITALY; OSPED LAVAGNA,LAB ANAL,LAVAGNA,ITALY; UNIV PERUGIA,IST MED INTERNA & VASC,CTR EMOSTASI & TROMBOSI,I-06100 PERUGIA,ITALY; UNIV BOLOGNA,IST STAT,I-40126 BOLOGNA,ITALY; OSPED SAN RAFFAELE,IRCCS,AMBULATORIO EMOSTASI TROMBOSI,MILAN,ITALY	University of Padua; University of Milan; Universita degli Studi di Bari Aldo Moro; University of Perugia; University of Bologna; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Palareti, G (corresponding author), UNIV BOLOGNA,OSPED S ORSOLA,CATTEDRA & DIV ANGIOL & MALATTIE COAGULAZ,I-40138 BOLOGNA,ITALY.		Pengo, Vittorio/AAV-9491-2020; Pengo, Vittorio/GSE-5972-2022; Moia, Marco/J-2888-2015; D'Angelo, Armando/K-2583-2018	Pengo, Vittorio/0000-0003-2064-6071; Pengo, Vittorio/0000-0003-2064-6071; Moia, Marco/0000-0002-7041-7755; D'Angelo, Armando/0000-0002-9857-4509; Malcangi, Giuseppe/0000-0001-8107-0892				BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; BUSSEY HI, 1989, PHARMACOTHERAPY, V9, P214; DAHL T, 1995, J INTERN MED, V237, P323, DOI 10.1111/j.1365-2796.1995.tb01182.x; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; FORFAR JC, 1979, BRIT HEART J, V42, P128; GIRTER MJ, 1995, MAYO CLIN P, V70, P725; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HIRSH J, 1987, ARCH INTERN MED, V147, P769, DOI 10.1001/archinte.147.4.769; JAFFIN BW, 1987, AM J MED, V83, P269, DOI 10.1016/0002-9343(87)90697-8; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LAUNBJERG J, 1991, J INTERN MED, V229, P351, DOI 10.1111/j.1365-2796.1991.tb00358.x; LEVINE M, 1986, STROKE, V17, P111, DOI 10.1161/01.STR.17.1.111; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V53, P155; LUNDSTROM T, 1989, J INTERN MED, V225, P137, DOI 10.1111/j.1365-2796.1989.tb00053.x; MARIANI G, 1990, RES CLIN LAB, V20, P119; PALARETI G, 1987, THROMB HAEMOSTASIS, V58, P905; PETITTI DB, 1989, J CLIN EPIDEMIOL, V42, P759, DOI 10.1016/0895-4356(89)90073-5; PETITTI DB, 1986, AM J MED, V81, P255, DOI 10.1016/0002-9343(86)90260-3; PETTY GW, 1988, ANN NEUROL, V23, P570, DOI 10.1002/ana.410230607; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SCOTT PJW, 1988, BRIT MED J, V2, P1261; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; 1983, WHO TECH REP SER, V687, P81	29	1115	1147	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					423	428		10.1016/S0140-6736(96)01109-9	http://dx.doi.org/10.1016/S0140-6736(96)01109-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709780				2022-12-28	WOS:A1996VC67300008
J	Nightingale, SL				Nightingale, SL			FDA conference on human subject protection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691538				2022-12-28	WOS:A1996VA86300005
J	Sapolsky, RM				Sapolsky, RM			Why stress is bad for your brain	SCIENCE			English	Editorial Material							HIPPOCAMPAL; GLUCOCORTICOIDS; PRIMATES; DISORDER; VOLUME				Sapolsky, RM (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.		Winwood, Peter/A-6363-2008					BREMNER J, IN PRESS BIOL PSYCHI; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; GURVITS T, IN PRESS BIOL PSYCHI; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; ISSA AM, 1990, J NEUROSCI, V10, P3247; Magarinos AM, 1996, J NEUROSCI, V16, P3534; MCEWEN BS, 1992, PROG BRAIN RES, V93, P365; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; Sapolsky RM., 1994, SEMIN NEUROSCI, DOI 10.1006/smns.1994.1041; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; STARKMAN M, COMMUNICATION; STARKMAN MN, 1992, BIOL PSYCHIAT, V32, P756, DOI 10.1016/0006-3223(92)90079-F; UNO H, 1989, J NEUROSCI, V9, P1705, DOI 10.1523/jneurosci.09-05-01705.1989	15	927	972	1	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					749	750		10.1126/science.273.5276.749	http://dx.doi.org/10.1126/science.273.5276.749			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VB429	8701325				2022-12-28	WOS:A1996VB42900026
J	Drummond, MF; Jefferson, TO				Drummond, MF; Jefferson, TO			Guidelines for authors and peer reviewers of economic submissions to the BMJ	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; SENSITIVITY ANALYSIS; HEALTH-CARE; INFECTION; JOURNALS; UTILITY; QUALITY; DISEASE; THERAPY; POLICY		MINIST DEF,ARMY MED DIRECTORATE 5,ASH VALE GU12 5RR,HAMPSHIRE,ENGLAND; UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; [Anonymous], 1995, ANN INTERN MED, V123, P61; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; BIRCH S, 1994, HEALTH POLICY, V28, P133, DOI 10.1016/0168-8510(94)90031-0; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; BRIGGS A, 1995, HEALTH ECON, V4, P355, DOI 10.1002/hec.4730040502; Cairns J, 1992, Health Econ, V1, P76, DOI 10.1002/hec.4730010111; *CAN COORD OFF HLH, 1994, GUID EC EV PHARM CAN; CLEMENS K, 1995, PHARMACOECONOMICS, V8, P169, DOI 10.2165/00019053-199508020-00008; Commonwealth Department of Health Housing and Community Services, 1992, GUID PHARM IND PREP; *DEP HLTH ASS BRIT, 1994, GUID EC EV PHARM; Drummond M, 1993, Int J Technol Assess Health Care, V9, P26; DRUMMOND M, 1993, SOC SCI MED, V37, P33, DOI 10.1016/0277-9536(93)90315-U; Drummond M F, 1992, Int J Technol Assess Health Care, V8, P671; DRUMMONG MF, 1987, METHODS EC EVALUATIO; EGBERTS J, 1992, BIOL NEONATE, V61, P59; ELIXHAUSER A, 1993, MED CARE S, V31, pS1; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; FORDHAM R, 1992, J PUBLIC HEALTH MED, V14, P127; GERARD K, 1992, HEALTH POLICY, V21, P249, DOI 10.1016/0168-8510(92)90022-4; JEFFERSON T, 1994, HEALTH ECON, V3, P25, DOI 10.1002/hec.4730030105; JEFFERSON T, 1995, BRIT MED J, V311, P393, DOI 10.1136/bmj.311.7001.393c; JEFFERSON T, 1995, HEALTH ECON, V4, P383, DOI 10.1002/hec.4730040504; JOHANNESSON M, 1995, SOC SCI MED, V41, P483, DOI 10.1016/0277-9536(94)00353-U; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; Kind P., 1996, QUAL LIFE PHARMACOEC, V25, P3110, DOI [10.1097/00007632-200012150-00005, DOI 10.1097/00007632-200012150-00005]; KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; *MIN HLHT ONT, 1994, ONT GUID EC AN PHARM; MUGFORD M, 1989, BMJ-BRIT MED J, V299, P1003, DOI 10.1136/bmj.299.6706.1003; *NHS CTR REV CISS, 1996, NHS EC EV DAT; OBRIEN BJ, 1994, MED CARE, V32, P150, DOI 10.1097/00005650-199402000-00006; *ORG EC COOP DEV, 1993, PURCH POW PAR; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCHULMAN K, 1994, JAMA-J AM MED ASSOC, V272, P154, DOI 10.1001/jama.272.2.154; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCHULMAN KA, 1995, DRUG INF J, V29, P1405; SMITH R, 1994, BRIT MED J, V308, P4, DOI 10.1136/bmj.308.6920.4; UDVARHELYI S, 1992, ANN INTERN MED, V116, P238; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; WAKKER P, 1995, HEALTH ECON, V4, P373, DOI 10.1002/hec.4730040503; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WILLIAMS A, 1974, BRIT MED BULL, V30, P252, DOI 10.1093/oxfordjournals.bmb.a071211; *WORLD BANK, 1993, 1993 WORLD BANK; 1996, BRIT MED J, V312, P41	48	1315	1332	4	51	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					275	283		10.1136/bmj.313.7052.275	http://dx.doi.org/10.1136/bmj.313.7052.275			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VA903	8704542	Green Published			2022-12-28	WOS:A1996VA90300032
J	Miller, R				Miller, R			HIV-associated respiratory diseases	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; PARANASAL SINUS DISEASE; INFECTED PATIENTS; TRIMETHOPRIM-SULFAMETHOXAZOLE; INTERSTITIAL PNEUMONITIS; DNA AMPLIFICATION; POSITIVE PATIENTS; KAPOSIS-SARCOMA; AIDS	The lungs of individuals infected with HIV are often affected by opportunistic infections and tumours; over two-thirds of patients have at least one respiratory episode during the course of their disease. Despite the availability of effective prophylaxis, infection with the fungus Pneumocystis carinii remains a common cause of respiratory disease. Bacterial infections, which occur more frequently in HIV-infected persons than in the general population, and tuberculosis are increasing causes of morbidity and mortality. Kaposi's sarcoma, the commonest HIV-associated malignancy, may affect the lungs in addition to the skin. Pulmonary involvement by non-Hodgkin lymphoma is common in those with disseminated disease.	CAMDEN & ISLINGTON COMMUNITY HLTH SERV NHS TRUST, LONDON, ENGLAND		Miller, R (corresponding author), UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, DIV PATHOL & INFECT DIS, LONDON W1N 8AA, ENGLAND.			Miller, Robert/0000-0003-2067-4291				AFESSA B, 1992, J ACQ IMMUN DEF SYND, V5, P132; BACHMEYER C, 1995, AIDS, V9, P299, DOI 10.1097/00002030-199509030-00013; BANERJI S, 1995, J EUKARYOT MICROBIOL, V42, P26; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARON AD, 1993, AM REV RESPIR DIS, V148, P992, DOI 10.1164/ajrccm/148.4_Pt_1.992; BARTLETT MS, 1994, EUK MICROBIOL, V41, P755; BATUNGWANAYO J, 1994, AIDS, V8, P1271, DOI 10.1097/00002030-199409000-00008; BAUER NL, 1993, INFECT IMMUN, V61, P1315, DOI 10.1128/IAI.61.4.1315-1319.1993; BENNETT CL, 1995, J INFECT DIS, V172, P312, DOI 10.1093/infdis/172.1.312; CADRANEL J, 1995, THORAX, V50, P407, DOI 10.1136/thx.50.4.407; CHEIN SM, 1992, CHEST, V102, P1035; CHONG WK, 1993, CLIN RADIOL, V47, P166, DOI 10.1016/S0009-9260(05)81154-7; CLARK RA, 1990, J ACQ IMMUN DEF SYND, V3, P480; CUSHION MT, 1993, J CLIN MICROBIOL, V31, P1217, DOI 10.1128/JCM.31.5.1217-1223.1993; FOLEY NM, 1993, THORAX, V48, P996, DOI 10.1136/thx.48.10.996; GRANT A, 1993, GENITOURIN MED, V69, P208; GRIFFITHS MH, 1995, THORAX, V50, P1141, DOI 10.1136/thx.50.11.1141; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JUNG AC, 1994, ARCH INTERN MED, V154, P2402, DOI 10.1001/archinte.154.21.2402; KEELY SP, 1995, J INFECT DIS, V172, P595, DOI 10.1093/infdis/172.2.595; KHOO SH, 1994, CLIN INFECT DIS, V19, pS41, DOI 10.1093/clinids/19.Supplement_1.S41; KOOPMANS PP, 1995, AIDS, V9, P217, DOI 10.1097/00002030-199509030-00001; KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008; LEE CH, 1993, J CLIN MICROBIOL, V31, P754, DOI 10.1128/JCM.31.3.754-757.1993; MAGNENAT JL, 1991, AM REV RESPIR DIS, V144, P917, DOI 10.1164/ajrccm/144.4.917; MATUSIEWICZ SP, 1994, BRIT MED J, V308, P1206, DOI 10.1136/bmj.308.6938.1206; MILLER RF, 1994, THORAX, V49, P367, DOI 10.1136/thx.49.4.367; MILLER RF, 1989, THORAX, V44, P559, DOI 10.1136/thx.44.7.559; MILLER RF, 1995, GENITOURIN MED, V71, P280; MILLER RF, 1992, THORAX, V47, P721, DOI 10.1136/thx.47.9.721; MILLER RF, IN PRESS J ANTIMICRO; OGNIBENE FP, 1988, ANN INTERN MED, V109, P874, DOI 10.7326/0003-4819-109-11-874; OLDHAM SAA, 1989, RADIOLOGY, V170, P83, DOI 10.1148/radiology.170.1.2909125; ORMEROD LP, 1992, BRIT MED J, V304, P1231; PEGLOW SL, 1990, J INFECT DIS, V161, P296, DOI 10.1093/infdis/161.2.296; PETERS SE, 1992, J PATHOL, V166, P195, DOI 10.1002/path.1711660217; PITKIN AD, 1993, THORAX, V48, P204, DOI 10.1136/thx.48.3.204; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STRINGER JR, 1993, INFECT AGENT DIS, V2, P109; STRINGER JR, 1993, J EUKARYOT MICROBIOL, V40, P733, DOI 10.1111/j.1550-7408.1993.tb04468.x; TRAVIS WD, 1990, AM J SURG PATHOL, V14, P615, DOI 10.1097/00000478-199007000-00002; TU JV, 1993, AM REV RESPIR DIS, V148, P370, DOI 10.1164/ajrccm/148.2.370; UNSWORTH DJ, 1993, GENITOURIN MED, V69, P373; VARGAS SL, 1995, J INFECT DIS, V172, P506, DOI 10.1093/infdis/172.2.506; WAKEFIELD AE, 1994, J EUKARYOT MICROBIOL, V41, pS116; WAKEFIELD AE, 1990, LANCET, V336, P451, DOI 10.1016/0140-6736(90)92008-6; WAKEFIELD AE, 1994, J CLIN MICROBIOL, V32, P2959, DOI 10.1128/JCM.32.12.2959-2961.1994; WAKEFIELD AE, 1992, MOL MICROBIOL, V6, P1903, DOI 10.1111/j.1365-2958.1992.tb01363.x; WALLACE JM, 1993, AM REV RESPIR DIS, V148, P1523, DOI 10.1164/ajrccm/148.6_Pt_1.1523; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542	50	62	65	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					307	312		10.1016/S0140-6736(95)11037-2	http://dx.doi.org/10.1016/S0140-6736(95)11037-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709692				2022-12-28	WOS:A1996VA25000013
J	Eom, SH; Wang, JM; Steitz, TA				Eom, SH; Wang, JM; Steitz, TA			Structure of Taq polymerase with DNA at the polymerase active site	NATURE			English	Article							I KLENOW FRAGMENT; ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; PROTEIN	THE DNA polymerase from Thermus aquaticus (Tag polymerase) is homologous to Escherichia coli DNA polymerase I (Pol I) and likewise has domains responsible for DNA polymerase and 5' nuclease activities(1,2). The structures of the polymerase domains of Tag polymerase and of the Klenow fragment (KF) of Pol I are almost identical, whereas the structure of a vestigial editing 3'-5' exonuclease domain of Tag polymerase that lies between the other two domains is dramatically altered, resulting in the absence of this activity in the thermostable enzyme(2). The structures have been solved for editing complexes between KF and single-stranded DNA(3,4) and for duplex DNA with a 3' overhanging single strand(5), but not for a complex containing duplex DNA at the polymerase active-site, Here we present the co-crystal structure of Taq polymerase with a blunt-ended duplex DNA bound to the polymerase active-site cleft; the DNA neither bends nor goes through the large polymerase cleft, and the structural form of the bound DNA is between the B and A forms. A wide minor groove allows access to protein side chains that hydrogen-bond to the N3 of purines and the O2 of pyrimidines at the blunt-end terminus. Part of the DNA bound to the polymerase site shares a common binding site with DNA bound to the exonuclease site, but they are translated relative to each other by several angstroms along their helix axes.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520	Yale University; Yale University; Howard Hughes Medical Institute; Yale University			Steitz, Thomas A./C-6559-2009					ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUNGER AT, 1992, XPLOR VERSION 3 1; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CONNER BN, 1982, NATURE, V295, P294, DOI 10.1038/295294a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STEITZ TA, 1987, COLD SPRING HARB SYM, V52, P465, DOI 10.1101/SQB.1987.052.01.053; STEITZ TA, 1992, BIOL ORG MACROMOLECU, P45; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339	30	292	313	4	101	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					278	281		10.1038/382278a0	http://dx.doi.org/10.1038/382278a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717047				2022-12-28	WOS:A1996UX79000057
J	Guarente, L				Guarente, L			Do changes in chromosomes cause aging?	CELL			English	Review							DNA; GENE				Guarente, L (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Finch CE, 1990, LONGEVITY SENESCENCE; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GREIDER CW, 1996, CELLULAR AGING CELL, P123; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; JOHNSON TE, 1996, CELLULAR AGING CELL, P1; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; SALK D, 1985, WERNERS SYNDROME HUM; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WONG A, 1995, GENETICS, V139, P1247; WRIGHT WE, 1996, CELLULAR AGING CELL, P153; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	21	52	53	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					9	12		10.1016/S0092-8674(00)80072-0	http://dx.doi.org/10.1016/S0092-8674(00)80072-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689691	Bronze			2022-12-28	WOS:A1996UX93400003
J	Willard, HF				Willard, HF			X chromosome inactivation, XIST, and pursuit of the X-inactivation center	CELL			English	Review							GENE; NUCLEUS				Willard, HF (corresponding author), CASE WESTERN RESERVE UNIV HOSP,SCH MED,DEPT GENET,CTR HUMAN GENET,CLEVELAND,OH 44106, USA.							BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CLEMSON CM, 1996, J CELL BIOL, V132, P1; Heard E, 1996, HUM MOL GENET, V5, P441, DOI 10.1093/hmg/5.4.441; HEARD E, 1994, HUM MOL GENET, V3, P1481, DOI 10.1093/hmg/3.suppl_1.1481; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; LYON MF, 1961, NATURE, V190, P373; Matsuura S, 1996, HUM MOL GENET, V5, P451, DOI 10.1093/hmg/5.4.451; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1	13	50	50	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					5	7		10.1016/S0092-8674(00)80071-9	http://dx.doi.org/10.1016/S0092-8674(00)80071-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689687	Bronze			2022-12-28	WOS:A1996UX93400002
J	Lamaze, C; Chuang, TH; Terlecky, LJ; Bokoch, GM; Schmid, SL				Lamaze, C; Chuang, TH; Terlecky, LJ; Bokoch, GM; Schmid, SL			Regulation of receptor-mediated endocytosis by Rho and Rac	NATURE			English	Article							GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; CELLS	PINOCYTOSIS and membrane ruffling are among the earliest and most dramatic cellular responses to stimulation by growth factors or other mitogens(1). The small Ras-related G proteins Rho and Rac have a regulatory role in membrane ruffling(1-3) and activated Rho has been shown to stimulate pinocytosis when microinjected into Xenopus oocytes(4). In contrast to these well established effects of Rho and Rac on plasma membrane morphology and bulk pinocytosis, there has been no evidence for their involvement in the regulation of receptor-mediated endocytosis in clathrin-coated pits. Here we show that activated Rho and Rac inhibit transferrin-receptor-mediated endocytosis when expressed in intact cells. Furthermore, we have reconstituted these effects in a cell-free system and established that Rho and Rac can regulate clathrin-coated vesicle formation.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Lamaze, Christophe/M-4912-2017; Chuang, Tsung-Hsien/F-9679-2010	Schmid, Sandra/0000-0002-1690-7024; LAMAZE, Christophe/0000-0001-5430-2707				AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CLAQUE MJ, 1995, FEBS LETT, V367, P272; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; UEDA T, 1990, J BIOL CHEM, V265, P9373; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	30	326	330	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					177	179		10.1038/382177a0	http://dx.doi.org/10.1038/382177a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700210				2022-12-28	WOS:A1996UW67200053
J	Kumagai, A; Dunphy, WG				Kumagai, A; Dunphy, WG			Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts	SCIENCE			English	Article							CELL-CYCLE REGULATION; PROTEIN-KINASE; CDC25 PHOSPHATASE; MITOTIC SPINDLE; DROSOPHILA POLO; MITOSIS; PHOSPHORYLATION; ACTIVATION; PHOSPHOPROTEINS; LOCALIZATION	Cdc2, the cyclin-dependent kinase that controls mitosis, is negatively regulated by phosphorylation on its threonine-14 and tyrosine-15 residues, Cdc25, the phosphatase that dephosphorylates both of these residues, undergoes activation and phosphorylation by multiple kinases at mitosis. Plx1, a kinase that associates with and phosphorylates the amino-terminal domain of Cdc25, was purified extensively from Xenopus egg extracts. Cloning of its complementary DNA revealed that Plx1 is related to the Polo family of protein kinases. Recombinant Plx1 phosphorylated Cdc25 and stimulated its activity in a purified system. Cdc25 phosphorylated by Plx1 reacted strongly with MPM-2, a monoclonal antibody to mitotic phosphoproteins. These studies indicate that Plx1 may participate in control of mitotic progression.			Kumagai, A (corresponding author), CALTECH, HOWARD HUGHES MED INST, DIV BIOL, 216-76, PASADENA, CA 91125 USA.							BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; KUMAGAI A, UNPUB; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VANDRE DD, 1991, J CELL SCI, V98, P577; Wang Y., 1993, PROTEIN PHOSPHORYLAT, P121; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	32	473	483	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1996	273	5280					1377	1380		10.1126/science.273.5280.1377	http://dx.doi.org/10.1126/science.273.5280.1377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703070				2022-12-28	WOS:A1996VF61000039
J	Whitcomb, ME; Miller, RS				Whitcomb, ME; Miller, RS			Comparison of IMG-dependent and non-IMG-dependent residencies in the national resident matching program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-to provide insight into the dynamics that determine the pattern of participation of international medical graduates (IMGs) in graduate medical education (GME), Design.-Data on IMG-dependent programs (ie, those having at least 50% of first-year positions filled by IMGs) and non-IMG-dependent programs in 6 core specialties (internal medicine, family practice, obstetrics and gynecology, surgery, pediatrics, and psychiatry) were matched with application data from the 1989 and 1995 National Resident Matching Program (NRMP), Main Outcome Measures.-Participation of IMG-dependent and non-IMG-dependent programs in the 1995 NRMP and the pattern of US medical graduate (USMG) and IMG applications to these programs in 1989 and 1995. Results.-Of the 1634 programs in the 6 specialties, 93.5% participated in the 1995 NRMP, The 1165 non-IMG-dependent programs were significantly more likely to participate in the NRMP and were slightly more likely to fill their offered positions than were the 469 IMG-dependent programs. Specifically, IMGs constituted 76% of applicants to IMG-dependent programs and only 14% of applicants to non-IMG-dependent programs. Changes in NRMP data between 1989 and 1995 indicated that the number of IMG applications to IMG-dependent programs increased 88.7%, as did the number of applicants ranked. Conclusions.-Persistent differences exist in the mix of USMGs and IMGs applying through the NRMP to IMG-dependent and non-IMG-dependent programs. Over time, programs that enroll large numbers of IMGs are likely to experience an increase in the number and proportion of applications from IMGs and a decrease in the number and proportion of applications from USMGs, If policies are adopted to limit IMG access to GME, IMG-dependent programs may be unable to recruit USMGs unless the total number of GME programs or the quality of existing programs fundamentally changes.	AMER MED ASSOC,DEPT RES & DATA ANAL,DIV GRAD MED EDUC,CHICAGO,IL 60610; ASSOC AMER MED COLL,DIV MED EDUC,WASHINGTON,DC 20036	American Medical Association; Association of American Medical Colleges								*COUNC GRAD MED ED, 1994, 4 COUNC GRAD MED ED; *I MED, 1996, NAT PHYS WORKF OPT B; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; *NAT RES MATCH PRO, 1996, NAT RES MATCH PROGR; *PEW HLTH PROF COM, 1995, CRIT CHAL REV HLTH P; WHITCOMB ME, 1995, JAMA-J AM MED ASSOC, V274, P696, DOI 10.1001/jama.274.9.696	6	17	17	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					700	703						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769548				2022-12-28	WOS:A1996VE23300008
J	Walker, AM; Stampfer, MJ				Walker, AM; Stampfer, MJ			Observational studies of drug safety	LANCET			English	Editorial Material											Walker, AM (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.								0	39	39	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					489	489		10.1016/S0140-6736(05)64664-8	http://dx.doi.org/10.1016/S0140-6736(05)64664-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757145				2022-12-28	WOS:A1996VD42700003
J	Cuttler, L; Silvers, JB; Singh, J; Marrero, U; Finkelstein, B; Tannin, G; Neuhauser, D				Cuttler, L; Silvers, JB; Singh, J; Marrero, U; Finkelstein, B; Tannin, G; Neuhauser, D			Short stature and growth hormone therapy - A national study of physician recommendation patterns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHORT CHILDREN; FINAL HEIGHT; DEFICIENCY; CHILDHOOD; GH	Objective.-To determine current expert opinion and recommendations regarding the controversial issue of the use of growth hormone (GH) to treat short children who do not have classical GH deficiency (non-GHD children). Study Design.-Analysis of a national survey mailed to 534 US physician experts on the management of short stature (pediatric endocrinologists) with a response rate of 81.3%. Main Outcome Measure.-The experts' GH treatment recommendations. Results.-The physicians reported that approximately 58% of their current patients undergoing GH therapy have classical GH deficiency, while 42% have other conditions. The proportion of physicians who recommended GH treatment of short non-GHD children ranged from 1% to 74% over all case scenarios presented. The likelihood of GH being recommended depended on the physiological growth characteristics of the child tie, the child's height, growth rate, and predicted adult height), contingency factors tie, strong family wishes or a reduction in GH cost), and physician beliefs tie, the impact of short stature on well-being, the effectiveness of GH therapy), Each of these factors exerted highly significant, independent, and additive effects on decisions to recommend GH. Conclusion.-Our results indicate that many pediatric endocrinologists consider GH treatment appropriate for selected short non-GHD children, going beyond current Food and Drug Administration-approved indications for GH. Decisions to recommend GH for a non-GHD child rest on a combination of medical, social, and perceptual factors; variations in treatment patterns stem from variations in these influences. Future GH use will likely be determined not only by the results of controlled trials, but also by family preferences, producer pricing, and physician perceptions of the value of height and GH therapy.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PEDIAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, WEATHERHEAD SCH MANAGEMENT, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University								ALLEN DB, 1990, J PEDIATR-US, V117, P16, DOI 10.1016/S0022-3476(05)82438-2; [Anonymous], 1978, MAIL TELEPHONE SURVE; AUGUST GP, 1990, J PEDIATR-US, V116, P899, DOI 10.1016/S0022-3476(05)80647-X; BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; BIERICH JR, 1992, ACTA ENDOCRINOL-COP, V127, P392, DOI 10.1530/acta.0.1270392; CARA JF, 1990, PEDIATR CLIN N AM, V37, P1229; CHIPMAN JJ, 1993, HORM RES, V39, P18, DOI 10.1159/000182761; CUTTLER L, 1987, Pediatrician, V14, P109; DARENDELILER F, 1990, HORM RES, V128, P33; FRASIER SD, 1990, J CLIN ENDOCR METAB, V71, P269, DOI 10.1210/jcem-71-2-269; FURLANETTO RW, 1995, J PEDIATR-US, V127, P857; GERTNER JM, 1984, J PEDIATR-US, V104, P172, DOI 10.1016/S0022-3476(84)80987-7; GORMAN C, 1995, TIME            0410, P60; GUYDA HJ, 1994, TRENDS ENDOCRIN MET, V5, P334, DOI 10.1016/1043-2760(94)90163-5; HAMILTON J, 1990, BUSINESS WEEK   0730, P66; HAMILTON J, 1990, BUSINESS WEEK   0730, P69; HILTS PJ, 1992, NY TIMES        0514, pD7; HILTS PJ, 1992, NY TIMES        0514, pD4; HINTZ R, 1995, PEDIATR RES, V37, pA91; HINTZ RL, 1992, HORM RES, V38, P44, DOI 10.1159/000182569; HOPWOOD NJ, 1993, J PEDIATR-US, V123, P215, DOI 10.1016/S0022-3476(05)81691-9; Hosmer D, 1989, APPL LOGISTIC REGRES, P148; KAPLAN SL, 1993, ADV INTERNAL MED, V38, P287; KAPLOWITZ PB, 1995, J PEDIATR-US, V126, P478, DOI 10.1016/S0022-3476(95)70475-2; LANTOS J, 1989, JAMA-J AM MED ASSOC, V261, P1020, DOI 10.1001/jama.261.7.1020; LIN TH, 1989, J PEDIATR-US, V115, P57, DOI 10.1016/S0022-3476(89)80329-4; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; MOORE KC, 1993, J PEDIATR-US, V122, P687, DOI 10.1016/S0022-3476(06)80005-3; OMEARA JJ, 1994, NEW ENGL J MED, V330, P1864, DOI 10.1056/NEJM199406303302605; QUAID KA, 1993, AM J MED GENET, V45, P41, DOI 10.1002/ajmg.1320450112; RANKE MB, 1993, ACTA PAEDIATR, V82, P82, DOI 10.1111/j.1651-2227.1993.tb12936.x; ROSENBLOOM AL, 1990, CLIN PEDIATR, V29, P288, DOI 10.1177/000992289002900507; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; ROSENFELD RG, 1992, ACTA PAEDIATR, V81, P3; ROSENFIELD RL, 1995, ENDOCRINOLOGY, P2549; RUVALCABA RHA, 1993, CLIN PEDIATR, V32, P292, DOI 10.1177/000992289303200507; SILINK M, 1992, Journal of Pediatric Endocrinology, V5, P43; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; THOMSETT M, 1993, MED J AUSTRALIA, V158, P802, DOI 10.5694/j.1326-5377.1993.tb137664.x; UNDERWOOD LE, 1992, HOSP PRACT, V27, P192; VANVLIET G, 1983, NEW ENGL J MED, V309, P1016; VIMPANI GV, 1977, BMJ-BRIT MED J, V2, P427, DOI 10.1136/bmj.2.6084.427; WEISS R, 1994, WASHINGTON POST 0315; WENNBERG JE, 1991, JAMA-J AM MED ASSOC, V265, P1306, DOI 10.1001/jama.265.10.1306; ZADIK Z, 1992, J PEDIATR-US, V121, P44, DOI 10.1016/S0022-3476(05)82539-9; 1994, MED LETT        0902, V36, P77	47	83	84	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					531	537		10.1001/jama.276.7.531	http://dx.doi.org/10.1001/jama.276.7.531			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709401				2022-12-28	WOS:A1996VC10100028
J	Garfield, E				Garfield, E			How can impact factors be improved?	BRITISH MEDICAL JOURNAL			English	Article								Impact factors are widely used to rank and evaluate journals. They are also often used inappropriately as surrogates in evaluation exercises. The inventor of the Science Citation Index warns against the indiscriminate use of these data. Fourteen year cumulative impact data for 10 leading medical journals provide a quantitative indicator of their long term influence. In the final analysis, impact simply reflects the ability of journals and editors to attract the best papers available.			Garfield, E (corresponding author), THE SCIENTIST,3600 MARKET ST,SUITE 450,PHILADELPHIA,PA 19104, USA.		Garfield, Eugene/A-1009-2008					ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; FLEISCHMANN M, 1989, J ELECTROANAL CHEM, V261, P301, DOI 10.1016/0022-0728(89)80006-3; GARFIELD E, 1986, ANN INTERN MED, V105, P313, DOI 10.7326/0003-4819-105-2-313; GARFIELD E, 1955, SCIENCE, V122, P108, DOI 10.1126/science.122.3159.108; Garfield E., 1990, ESSAYS INFORM SCI, V13, P185; GARFIELD E, 1987, ESSAYS INFORMATION S, V10, P7; GARFIELD E, 1984, ESSAYS INFORMATION S, V6, P354; Gross P L, 1927, Science, V66, P385, DOI 10.1126/science.66.1713.385; LOCK SP, 1990, ESSAYS INFORMATION S, V13, P19; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL BJ, 1984, LANCET, V1, P1311; VANTRIGT AM, 1995, SOC SCI MED, V41, P893, DOI 10.1016/0277-9536(94)00389-B	12	376	387	5	95	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					411	413		10.1136/bmj.313.7054.411	http://dx.doi.org/10.1136/bmj.313.7054.411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761234	Green Published			2022-12-28	WOS:A1996VD20600032
J	Day, JH; Grant, AD; Doherty, JF; Chiodini, PL; Wright, SG				Day, JH; Grant, AD; Doherty, JF; Chiodini, PL; Wright, SG			Schistosomiasis in travellers returning from sub-Saharan Africa	BRITISH MEDICAL JOURNAL			English	Article									HOSP TROP DIS,LONDON NW1 0PE,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine								BLANCHARD TJ, 1993, LANCET, V341, P959, DOI 10.1016/0140-6736(93)91249-L; HARRIES AD, 1986, LANCET, V1, P86; JORDAN P, 1993, HUMAN SCHISTOSOMIASI, P16; WHITWORTH JAG, 1993, BRIT MED J, V307, P936, DOI 10.1136/bmj.307.6909.936-c	4	36	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					268	269		10.1136/bmj.313.7052.268	http://dx.doi.org/10.1136/bmj.313.7052.268			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704539	Green Published			2022-12-28	WOS:A1996VA90300028
J	Jones, CM				Jones, CM			ABC of work related disorders - Occupational hearing loss and vibration induced disorders	BRITISH MEDICAL JOURNAL			English	Article											Jones, CM (corresponding author), BRITISH STEELS ENGN STEELS,ROTHERHAM,S YORKSHIRE,ENGLAND.							*FAC OCC MED ROYAL, 1993, HAND TRANSM VIBR C 2; *FAC OCC MED ROYAL, 1993, HAND TRANSM VIBR C 1; 1990, NOISE WORK REGULATIO; [No title captured]	4	12	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					223	226		10.1136/bmj.313.7051.223	http://dx.doi.org/10.1136/bmj.313.7051.223			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696204	Green Published			2022-12-28	WOS:A1996VA12600035
J	Shaham, S; Horvitz, HR				Shaham, S; Horvitz, HR			An alternatively spliced C-elegans ced-4 RNA encodes a novel cell death inhibitor	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; BCL-2 HOMOLOG BAK; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; APOPTOSIS; PROTEIN; INDUCTION; SURVIVAL; PROTOONCOGENE; CLONING	The C. elegans gene ced-4 is essential for programmed cell death. We report that ced-4 encodes two transcripts and that whereas the major transcript can cause programmed cell death, the minor transcript can act oppositely and prevent programmed cell death, thus defining a novel class of cell death inhibitors. That ced-4 has both cell-killing and cell-protective functions is consistent with previous genetic studies. Our results suggest that the dual protective and killer functions of the C. elegans bcl-2-like gene ced-9 are mediated by inhibition of the killer and protective ced-4 functions, respectively. We propose that a balance between opposing ced-4 functions influences the decision of a cell to live or to die by programmed cell death and that both ced-9 and ced-4 protective functions are required to prevent programmed cell death.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)								BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRENNER S, 1974, GENETICS, V77, P71; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Cortazzo M, 1996, CANCER RES, V56, P1199; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EMMONS SW, 1988, NEMATODE CAENORHABDI, P47; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HORVITZ HR, 1979, MOL GEN GENET, V175, P129, DOI 10.1007/BF00425528; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Sambrook J., 2002, MOL CLONING LAB MANU; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRENT C, 1983, GENETICS, V104, P619; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	44	124	133	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					201	208		10.1016/S0092-8674(00)80092-6	http://dx.doi.org/10.1016/S0092-8674(00)80092-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706125	Bronze			2022-12-28	WOS:A1996UZ97200006
J	Chapman, S				Chapman, S			Recent advances - Tobacco control	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE CONSUMPTION; SMOKING CESSATION; METAANALYSIS; MINORS				Chapman, S (corresponding author), UNIV SYDNEY,DEPT PUBL HLTH & COMMUNITY MED,SYDNEY,NSW 2006,AUSTRALIA.							Arno PS, 1996, JAMA-J AM MED ASSOC, V275, P1258, DOI 10.1001/jama.275.16.1258; BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; CARDADOR MT, 1995, AM J PUBLIC HEALTH, V85, P1212, DOI 10.2105/AJPH.85.9.1212; Chapman S, 1994, Aust J Public Health, V18, P39; Chapman S, 1996, BRIT MED BULL, V52, P121, DOI 10.1093/oxfordjournals.bmb.a011520; CHAPMAN S, 1990, AM J PUBLIC HEALTH, V80, P537, DOI 10.2105/AJPH.80.5.537; CHAPMAN S, 1990, INT J HEALTH SERV, V20, P417, DOI 10.2190/YYKC-PGTC-VUMM-3A5P; Collishaw N. E., 1996, Tobacco Alert, P1; CUMMINGS KM, 1994, AM J PUBLIC HEALTH, V84, P300, DOI 10.2105/AJPH.84.2.300; Cunningham R, 1995, TOB CONTROL, V4, P80, DOI DOI 10.1136/TC.4.1.80; DIAMOND A, 1995, SMOKING SECONDARY SC; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; FEDER BJ, 1996, NY TIMES        0315, pA1; FEDER BJ, 1996, NY TIMES        0314, pD6; FEDER BJ, 1996, NY TIMES NEWS S 0412; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FREEDMAN AM, 1996, WALL STREET J   0319, pB1; Glantz S.A., 1996, CIGARETTE PAPERS; GOODIN RE, 1989, ETHICS, V99, P574, DOI 10.1086/293100; Hill D, 1995, AUST J PUBLIC HEALTH, V19, P445; JASON LA, 1991, JAMA-J AM MED ASSOC, V266, P3159, DOI 10.1001/jama.266.22.3159; JOOSSENS L, 1995, BRIT MED J, V310, P1393, DOI 10.1136/bmj.310.6991.1393; KESSLER DA, 1994, TOB CONTROL, V3, P362; Kessler David A., 1994, TOB CONTROL, V3, P150, DOI DOI 10.1136/TC.3.2.148; KYLE K, 1994, TOB CONTROL, V3, P3; Longo DR, 1996, JAMA-J AM MED ASSOC, V275, P1252, DOI 10.1001/jama.275.16.1252; MORGALL JM, PHARM HELPING SMOKER; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PIERCE JP, 1995, HEALTH PSYCHOL, V14, P500, DOI 10.1037/0278-6133.14.6.500; POLLAY RW, 1996, J MARKETING      APR, P1; PREY M, 1995, AM LAWYER        JUL, P86; RAMSTROM LM, 1994, P FUT DIR NIC REPL T; Rooney BL, 1996, HEALTH EDUC QUART, V23, P48, DOI 10.1177/109019819602300104; SILAGY C, 1992, BRIT MED J, V305, P871, DOI 10.1136/bmj.305.6858.871; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; SKOLNICK AA, 1995, JAMA-J AM MED ASSOC, V274, P199, DOI 10.1001/jama.1995.03530030021007; Stephens T, 1995, CHRONIC DIS CANADA, V16, P27; TOWNSEND J, 1994, BMJ-BRIT MED J, V309, P923, DOI 10.1136/bmj.309.6959.923; Townsend J, 1996, BRIT MED BULL, V52, P132, DOI 10.1093/oxfordjournals.bmb.a011521; WOODRUFF TJ, 1993, ARCH INTERN MED, V153, P1485, DOI 10.1001/archinte.153.12.1485; 1995, US FED REG, V60, P41314; 1996, LOS ANGELES TIM 0517; 1996, MMWR-MORBID MORTAL W, V45, P413; 1996, US FED REG, V61, P1491	44	22	22	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					97	100		10.1136/bmj.313.7049.97	http://dx.doi.org/10.1136/bmj.313.7049.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UX698	8688764	Green Published			2022-12-28	WOS:A1996UX69800028
J	Aramayo, R; Metzenberg, RL				Aramayo, R; Metzenberg, RL			Meiotic transvection in fungi	CELL			English	Article							DROSOPHILA-ZESTE PROTEIN; WHITE GENE-EXPRESSION; NEUROSPORA-CRASSA; TRANS-INACTIVATION; PAIRING DEPENDENCE; ULTRABITHORAX GENE; MOLECULAR ANALYSIS; BITHORAX COMPLEX; SELF-ASSOCIATION; BROWN GENE	The Neurospora crassa Asm-1(+) (ascospore maturation 1) gene encodes an abundant nucleus-localized protein required for formation of female structures and for ascospore maturation. Deletion mutants of Asm-1(+) are ''ascus-dominant,'' i.e., when crossed to wild type, neither Asm-1(+) nor Asm-1(Delta) spores mature. To explain this behavior, we considered three models: an effect of reduced dosage of the gene product, failure of internuclear communication, and failure of transvection (regulation dependent on pairing of alleles). We found that for proper regulation of subsequent sexual sporulation, Asm-1(+) must be in proximity, probably paired, to its allelic counterpart in the zygote: i.e., transvection must occur. Disruption of pairing causes failure of ascospore progeny to mature. Transvection in Neurospora, unlike in Drosophila, occurs immediately before meiosis, and can be demonstrated between wildtype alleles.	UNIV WISCONSIN,DEPT BIOMOL CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Aramayo, Rodolfo/0000-0001-9702-6204	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM008995, R01GM008995] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08995] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAMAYO R, 1996, IN PRESS FUNGAL GENE, V43; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BABU P, 1987, MOL GEN GENET, V210, P557, DOI 10.1007/BF00327212; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; BESTOR TH, 1994, DEV GENET, V15, P458, DOI 10.1002/dvg.1020150603; BICKEL S, 1990, EMBO J, V9, P2959, DOI 10.1002/j.1460-2075.1990.tb07488.x; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BISTIS GN, 1983, EXP MYCOL, V7, P292, DOI 10.1016/0147-5975(83)90051-8; BISTIS GN, 1981, MYCOLOGIA, V73, P959, DOI 10.2307/3759806; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; BROCKMAN HE, 1963, AM J BOT, V50, P709, DOI 10.2307/2440049; CHEN JD, 1992, MOL CELL BIOL, V12, P598, DOI 10.1128/MCB.12.2.598; CHEN JD, 1993, EMBO J, V12, P2061, DOI 10.1002/j.1460-2075.1993.tb05855.x; COEN ES, 1988, EMBO J, V7, P877, DOI 10.1002/j.1460-2075.1988.tb02891.x; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DAVISON D, 1985, GENETICS, V110, P479; de TERRA NOEL, 1963, AMER JOUR BOT, V50, P669; DREESEN TD, 1991, GENE DEV, V5, P331, DOI 10.1101/gad.5.3.331; ELLIS N, 1989, TRENDS GENET, V5, P406, DOI 10.1016/0168-9525(89)90199-6; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; GEYER PK, 1988, P NATL ACAD SCI USA, V85, P3938, DOI 10.1073/pnas.85.11.3938; GEYER PK, 1990, EMBO J, V9, P2247, DOI 10.1002/j.1460-2075.1990.tb07395.x; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GLASS NL, 1988, SCIENCE, V241, P570, DOI 10.1126/science.2840740; GLASS NL, 1990, P NATL ACAD SCI USA, V87, P4912, DOI 10.1073/pnas.87.13.4912; GRIFFITHS AJF, 1978, GENETICS, V88, P239; GUBB D, 1990, GENETICS, V126, P167; HAZELRIGG T, 1992, GENETICS, V130, P125; HENIKOFF S, 1989, P NATL ACAD SCI USA, V86, P6704, DOI 10.1073/pnas.86.17.6704; HENIKOFF S, 1994, GENETICS, V138, P1; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPMANN R, 1995, GENETICS, V139, P815; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; JACOBSON DJ, 1992, FUNGAL GENET NEWSL, V39, P24; JUDD BH, 1988, CELL, V53, P841, DOI 10.1016/S0092-8674(88)90209-7; KASSIS JA, 1991, GENETICS, V128, P751; KLAR AJS, 1980, GENETICS, V94, P597; LANEY JD, 1992, GENE DEV, V6, P1531, DOI 10.1101/gad.6.8.1531; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MARTINEZLABORDA A, 1992, EMBO J, V11, P3645, DOI 10.1002/j.1460-2075.1992.tb05449.x; MATHOG D, 1990, GENETICS, V125, P371; METZENBERG RL, 1988, FUNGAL GENET NEWSL, V35, P28; MICOL JL, 1988, P NATL ACAD SCI USA, V85, P1146, DOI 10.1073/pnas.85.4.1146; MICOL JL, 1990, GENETICS, V126, P365; Murray J. C., 1959, Proceedings of the IX International Botanical Congress, Montreal, August 19-29, 1959., V2, pp; MURRAY JAY C., 1962, CANADIAN JOUR BOT, V40, P337; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; PERKINS DD, 1962, NEUROSPORA NEWSL, V2, P14; PERKINS DD, 1984, NEUROSPORA NEWSL, V31, P41; Perkins DD., 1988, FUNGAL GENET NEWSL, V35, P29; PERKINS DD, 1966, NEUROSPORA NEWSL, V9, P11; PETERSON KM, 1994, MOL GEN GENET, V242, P717, DOI 10.1007/BF00283427; PHILLEY ML, 1994, GENETICS, V137, P715; QIAN S, 1992, GENETICS, V131, P79; RAJU NB, 1977, EXP MYCOL, V1, P152, DOI 10.1016/S0147-5975(77)80040-6; RAJU NB, 1980, EUR J CELL BIOL, V23, P208; RAJU NB, 1992, MYCOL RES, V96, P241, DOI 10.1016/S0953-7562(09)80934-9; RAJU NB, 1988, MYCOLOGIA, V80, P825, DOI 10.2307/3807561; RUSSELL PJ, 1972, GENETICS, V71, P233; Sambrook J., 2002, MOL CLONING LAB MANU; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SMOLIKUTLAUT SM, 1987, GENETICS, V116, P285; SPRINGER ML, 1993, BIOESSAYS, V15, P365, DOI 10.1002/bies.950150602; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TIMBERLAKE W E, 1986, P343; TURNER BC, 1977, GENETICS, V85, P439; WESTERGAARD M, 1947, AM J BOT, V34, P573, DOI 10.2307/2437339; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7; WU CT, 1993, J CELL BIOL, V120, P587, DOI 10.1083/jcb.120.3.587	72	146	155	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					103	113		10.1016/S0092-8674(00)80081-1	http://dx.doi.org/10.1016/S0092-8674(00)80081-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689677	Bronze			2022-12-28	WOS:A1996UX93400012
J	Kanter, MH; vanMaanen, D; Anders, KH; Castro, F; Mya, WW; Clark, K				Kanter, MH; vanMaanen, D; Anders, KH; Castro, F; Mya, WW; Clark, K			Preoperative autologous blood donations before elective hysterectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALLOGENEIC TRANSFUSION; SURGERY; CONTROVERSIES; SCHEDULE; MEDICINE	Objective.-To determine whether preoperative autologous blood donation is justified for patients undergoing elective abdominal or vaginal hysterectomy. Design.-Retrospective cohort study. Patients and Setting.-A total of 263 consecutive patients admitted for elective abdominal or vaginal hysterectomy to a community health maintenance organization hospital during 1993 and 1994. Main Outcome Measures.-Evaluation of transfusion rates for patients who did and did not donate autologous blood; determination of any risk factors that would predict the need for transfusion; and evaluation of the need for transfusion based on chart review. Results.-Of 263 patients, 26 received a blood transfusion. The major risk factor identified for transfusion was the donation of autologous blood. Of 140 patients who donated autologous blood, 25 were transfused, whereas just 1 patient of 123 who did not donate autologous blood was transfused (P<.001). Patients who donated autologous blood had significantly lower mean admission hemoglobin level than patients who did not donate (119 g/L vs 132 g/L; P<.05); logistic regression showed that autologous donation was an independent risk factor for transfusion. Conclusion.-For hysterectomy patients, donation of autologous blood causes anemia and is associated with a more liberal transfusion policy. These 2 factors result in a markedly increased incidence of transfusion with its associated risks. Elimination of preoperative autologous donation for these patients should not result in frequent exposure to allogeneic blood.	KAISER PERMANENTE MED CTR,PANORAMA CITY,CA; UNIV CALIF LOS ANGELES,DEPT PATHOL & LAB MED,LOS ANGELES,CA	Kaiser Permanente; University of California System; University of California Los Angeles	Kanter, MH (corresponding author), KAISER PERMANENTE MED CTR,DEPT PATHOL,5601 DE SOTO AVE,WOODLAND HILLS,CA 91365, USA.		kanter, michael howard/W-2753-2019					ATLAS SJ, 1994, TRANSFUSION, V34, P386, DOI 10.1046/j.1537-2995.1994.34594249048.x; AXELROD FB, 1989, TRANSFUSION, V29, P677, DOI 10.1046/j.1537-2995.1989.29890020438.x; COHEN JA, 1995, TRANSFUSION, V35, P640, DOI 10.1046/j.1537-2995.1995.35895357894.x; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FRIEDMAN BA, 1976, TRANSFUSION, V16, P380; GIORDANO GF, 1991, TRANSFUSION, V31, P509, DOI 10.1046/j.1537-2995.1991.31691306247.x; GOODNOUGH LT, 1992, VOX SANG, V63, P96, DOI 10.1111/j.1423-0410.1992.tb02493.x; GOULD SA, 1995, TRANSFUSION, V35, P446, DOI 10.1046/j.1537-2995.1995.35595259156.x; KRUSKALL MS, 1988, AUTOLOGOUS BLOOD TRA, P151; MILLER RD, 1995, TRANSFUSION, V35, P450, DOI 10.1046/j.1537-2995.1995.35595259157.x; OWINGS DV, 1989, JAMA-J AM MED ASSOC, V262, P1963; PARSLOE MRJ, 1990, BRIT J ANAESTH, V64, P634, DOI 10.1093/bja/64.5.634; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; POPOVSKY MA, 1992, AM J CLIN PATHOL, V97, P297, DOI 10.1093/ajcp/97.3.297; RENNER SW, 1992, ARCH PATHOL LAB MED, V116, P613; SILVERGLEID AJ, 1991, TRANSFUSION, V31, P99, DOI 10.1046/j.1537-2995.1991.31291142959.x; TOY PTCY, 1992, TRANSFUSION, V32, P562, DOI 10.1046/j.1537-2995.1992.32692367202.x; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TOY PTCY, 1992, TRANSFUSION, V32, P63, DOI 10.1046/j.1537-2995.1992.32192116435.x; WALKER RH, 1987, AM J CLIN PATHOL, V88, P374, DOI 10.1093/ajcp/88.3.374; WASMAN J, 1987, JAMA-J AM MED ASSOC, V258, P3135, DOI 10.1001/jama.258.21.3135; 1986, JAMA-J AM MED ASSOC, V256, P2378; 1995, TRANSFUSION, V35, P703	23	72	73	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					798	801		10.1001/jama.276.10.798	http://dx.doi.org/10.1001/jama.276.10.798			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769589				2022-12-28	WOS:A1996VF21900026
J	Oler, A; Whooley, MA; Oler, J; Grady, D				Oler, A; Whooley, MA; Oler, J; Grady, D			Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ANTITHROMBOTIC THERAPY; INTRAVENOUS HEPARIN; ACUTE-PHASE; ISCHEMIA; TRIAL; PECTORIS; PROGNOSIS; USERS; REST	Objective.-To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone. Data Sources.-Studies were retrieved using MEDLINE, bibliographies, and consultation with experts. Study Selection.-Only published trials that enrolled patients with unstable angina, randomized participants to aspirin plus heparin vs aspirin alone, and reported incidence of myocardial infarction or death were included in the meta-analysis. Data Extraction.-Patient outcomes including MI or death, recurrent ischemic pain, and major bleeding during randomized treatment; revascularization procedures after randomization; and MI or death during the 2 to 12 weeks following randomization were extracted by 2 authors, 1 of whom was blinded to the journal, institution, and author of each study. Data Synthesis.-Six randomized trials were included. The overall summary relative risk (RR) of MI or death during randomized treatment was 0.67 (95% confidence interval [CI], 0.44-1.02) in patients with unstable angina treated with aspirin plus heparin compared with those treated with aspirin alone. The summary RRs for secondary endpoints in patients treated with aspirin plus heparin compared with those treated with aspirin alone were 0.68 (95% CI, 0.40-1.17) for recurrent ischemic pain; 0.82 (95% CI, 0.56-1.20) for MI or death 2 to 12 weeks following randomization; 1.03 (95% CI, 0.74-1.43) for revascularization; and 1.99 (95% CI, 0.52-7.65) for major bleeding, We found no statistically significant heterogeneity among individual study findings. Conclusions.-Our findings are consistent with a 33% reduction in risk of MI or death in patients with unstable angina treated with aspirin plus heparin compared with those treated with aspirin alone. The bulk of evidence suggests that most patients with unstable angina should be treated with both heparin and aspirin.	VET ADM MED CTR,GEN INTERNAL MED SECT,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; DREXEL UNIV,DEPT QUANITAT METHODS,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Drexel University								AVERKOV OV, 1993, KARDIOLOGIYA, V33, P4; AVERKOV OV, 1993, KARDIOLOGIYA, V33, P16; BARROWCLIFFE TW, 1995, BRIT J HAEMATOL, V90, P1, DOI 10.1111/j.1365-2141.1995.tb03373.x; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; Bishop YM., 2007, DISCRETE MULTIVARIAT; *BMDP STAT SOFTW I, 1990, PC90; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Charvat J, 1990, Vnitr Lek, V36, P537; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; COHEN M, 1993, J AM COLL CARDIOL, V22, P1338, DOI 10.1016/0735-1097(93)90540-H; COHEN M, 1994, EUR HEART J, V15, P1196, DOI 10.1093/oxfordjournals.eurheartj.a060653; COHEN M, 1990, AM J CARDIOL, V66, P1287, DOI 10.1016/0002-9149(90)91155-Y; DUNCAN B, 1976, BRIT MED J, V1, P981, DOI 10.1136/bmj.1.6016.981; Fisher LD., 1997, BIOMETRICS, V53, P1182; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Fleiss JL, 1981, STAT METHODS RATES P; FUCHS J, 1995, CIRCULATION, V92, P727, DOI 10.1161/01.CIR.92.4.727; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GRANGER C, 1995, CIRCULATION, V92, P460; GURFINKEL EP, 1995, J AM COLL CARDIOL, V26, P313, DOI 10.1016/0735-1097(95)80001-W; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; HOLDRIGHT D, 1994, J AM COLL CARDIOL, V24, P39, DOI 10.1016/0735-1097(94)90539-8; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; Low-molecular-weight heparin during instability in coronary artery disease, 1996, LANCET, V347, P561; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; MOISE A, 1994, CIRCULATION, V90, P1107, DOI 10.1161/circ.90.2.8044926; RAHIMTOOLA SH, 1984, CIRCULATION, V69, P842, DOI 10.1161/01.CIR.69.4.842; ROSENBERG RD, 1975, NEW ENGL J MED, V292, P146; SERNER GGN, 1990, LANCET, V335, P868; SERNERI GGN, 1995, LANCET, V345, P1201; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1993, CIRCULATION, V88, P2045, DOI 10.1161/01.CIR.88.5.2045; *UNST ANG PAN, 1994, UNST ANG DIAGN MAN C; WALLIS DE, 1991, AM HEART J, V122, P949, DOI 10.1016/0002-8703(91)90456-R; WALTER SD, 1991, BIOMETRICS, V47, P795, DOI 10.2307/2532640; WILLIAMS DO, 1986, BRIT J CLIN PRACT, V40, P114; ZWERNER PL, 1987, CIRCULATION, V76, P180; 1995, CIRCULATION, V92, P416; 1990, LANCET, V336, P827	41	389	396	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					811	815		10.1001/jama.276.10.811	http://dx.doi.org/10.1001/jama.276.10.811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769591				2022-12-28	WOS:A1996VF21900028
J	Levinsky, NG				Levinsky, NG			The purpose of advance medical planning - Autonomy for patients or limitation of care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NURSING-HOME RESIDENTS; CARDIOPULMONARY-RESUSCITATION; PREFERENCES; LIFE; DIRECTIVES; PHYSICIANS; DECISIONS				Levinsky, NG (corresponding author), BOSTON UNIV,MED CTR,88 E NEWTON ST,BOSTON,MA 02118, USA.							ANGELL M, 1991, NEW ENGL J MED, V325, P511, DOI 10.1056/NEJM199108153250712; Annas GJ, 1995, HASTINGS CENT REP, V25, pS12, DOI 10.2307/3527850; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BROWN NK, 1979, NEW ENGL J MED, V300, P1246, DOI 10.1056/NEJM197905313002204; Callahan D., 1987, MED GOALS AGEING SOC; CAPRON AM, 1994, HASTINGS CENT REP, V24, P42; Finucane TE, 1996, AM J MED, V100, P126, DOI 10.1016/S0002-9343(97)89449-1; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIESINGER GO, 1995, AM J MED, V99, P13, DOI 10.1016/S0002-9343(99)80098-9; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; GILLICK MR, 1995, ANN INTERN MED, V123, P621, DOI 10.7326/0003-4819-123-8-199510150-00009; HIRSCH CH, 1995, GERIATRICS, V50, P26; KONG D, 1995, BOSTON GLOBE    1120, P10; LEVINSKY NG, 1990, NEW ENGL J MED, V322, P1813, DOI 10.1056/NEJM199006213222512; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; NOYES R, 1977, J AM GERIATR SOC, V25, P470, DOI 10.1111/j.1532-5415.1977.tb00810.x; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; RETTIG RA, 1991, KIDNEY FAILURE FEDER, P89; ROTHMAN D, 1991, STRANGERS BEDSIDE; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TENO JM, 1994, J CLIN ETHIC, V5, P23; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	42	42	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					741	743		10.1056/NEJM199609053351012	http://dx.doi.org/10.1056/NEJM199609053351012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VH266	8703178				2022-12-28	WOS:A1996VH26600012
J	Cui, W; Fowlis, DJ; Bryson, S; Duffie, E; Ireland, H; Balmain, A; Akhurst, RJ				Cui, W; Fowlis, DJ; Bryson, S; Duffie, E; Ireland, H; Balmain, A; Akhurst, RJ			TGF beta 1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice	CELL			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; HUMAN BREAST-CANCER; KERATIN GENE-EXPRESSION; FACTOR RECEPTOR LIGANDS; FACTOR TYPE-BETA; MOUSE SKIN; TGF-BETA; FACTOR-ALPHA; EPITHELIAL-CELLS; II RECEPTOR	TGF beta 1 has been implicated in cell cycle control and carcinogenesis. To address the exact function of TGF beta 1 in skin carcinogenesis in vivo, mice with TGF beta 1 expression targeted to keratinocytes were subjected to long-term chemical carcinogenesis treatment. TGF beta 1 showed biphasic action during multistage skin carcinogenesis, acting early as a tumor suppressor but later enhancing the malignant phenotype. The transgenics were more resistant to induction of benign skin tumors than controls, but the malignant conversion rate was vastly increased. There was also a higher incidence of spindle cell carcinomas, which expressed high levels of endogenous TGF beta 3, suggesting that TGF beta 1 elicits an epithelial-mesenchymal transition in vivo and that TGF beta 3 might be involved in maintenance of the spindle cell phenotype. The action of TGF beta 1 in enhancing malignant progression may mimic its proposed function in modulating epithelial cell plasticity during embryonic development.	UNIV GLASGOW, DEPT MED GENET, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV GLASGOW, DEPT MED ONCOL, CANC RES CAMPAIGN, BEATSON LABS, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of Glasgow; Beatson Institute; University of Glasgow			Cui, Wei/AAD-1690-2019	AKHURST, ROSEMARY/0000-0002-4474-9668; Cui, Wei/0000-0003-2019-380X				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; AKHURST RJ, 1990, DEVELOPMENT, V108, P645; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; ANZANO MA, 1982, CANCER RES, V42, P4776; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; BATTIFORA H, 1976, CANCER, V37, P2275, DOI 10.1002/1097-0142(197605)37:5<2275::AID-CNCR2820370518>3.0.CO;2-3; BERGMANN M, 1951, CANCER, V4, P919, DOI 10.1002/1097-0142(195109)4:5<919::AID-CNCR2820040505>3.0.CO;2-W; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; BURSCH W, 1993, BRIT J CANCER, V67, P531, DOI 10.1038/bjc.1993.98; Cano A, 1996, INT J CANCER, V65, P254; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624; CHANG HL, 1993, CANCER RES, V53, P4391; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHENG C, 1993, CELL GROWTH DIFFER, V4, P317; CUI W, 1995, GENE DEV, V9, P945, DOI 10.1101/gad.9.8.945; CUI W, 1994, CANCER RES, V54, P5831; CUI W, 1996, IN PRESS GROWTH FACT; DERYNCK R, 1987, CANCER RES, V47, P707; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIXON MJ, 1991, ANAT EMBRYOL, V184, P83, DOI 10.1007/BF01744264; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; EVANS HL, 1980, CANCER-AM CANCER SOC, V45, P2687, DOI 10.1002/1097-0142(19800515)45:10<2687::AID-CNCR2820451034>3.0.CO;2-R; FALCIONI R, 1994, EXP CELL RES, V210, P113, DOI 10.1006/excr.1994.1017; FITZPATRICK DR, 1990, DEVELOPMENT, V109, P585; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; Fowlis DJ, 1996, CELL GROWTH DIFFER, V7, P679; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; GOMELLA LG, 1989, CANCER RES, V49, P6972; GOMEZ M, 1992, EXP CELL RES, V201, P250, DOI 10.1016/0014-4827(92)90272-A; GORSCH SM, 1992, CANCER RES, V52, P6949; HADDOW S, 1991, ONCOGENE, V6, P1465; HEINO J, 1989, J BIOL CHEM, V264, P21806; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; JIRTLE RL, 1993, CANCER RES, V53, P3849; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1991, CANCER CELL-MON REV, V3, P525; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KEMP CJ, 1994, QUANT BIOL, V59, P427; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; KRIEG P, 1991, MOL CARCINOGEN, V4, P129, DOI 10.1002/mc.2940040208; LENVENTON GS, 1981, CANCER, V48, P994; LIN JK, 1992, CANCER RES, V52, P385; MANNING AM, 1991, ONCOGENE, V6, P1471; MAREEL M, 1993, INT J DEV BIOL, V37, P227; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; NELSON KG, 1982, CANCER RES, V42, P4176; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; PELTON RW, 1990, DEV BIOL, V141, P456, DOI 10.1016/0012-1606(90)90401-4; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; POTTS JD, 1989, DEV BIOL, V134, P392, DOI 10.1016/0012-1606(89)90111-5; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1990, TRANSFORMING GROWTH, P419; ROOP DR, 1988, CANCER RES, V48, P3245; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TENNENBAUM T, 1992, CANCER RES, V52, P2966; TENNENBAUM T, 1993, CANCER RES, V53, P4803; TERZAGHIHOWE M, 1989, CARCINOGENESIS, V10, P973, DOI 10.1093/carcin/10.6.973; TOFTGARD R, 1985, CANCER RES, V45, P5845; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VALLES AM, 1991, EXP SUPPL, V59, P17; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WINTER H, 1980, CARCINOGENESIS, V1, P391, DOI 10.1093/carcin/1.5.391; WU JE, 1994, DEV DYNAM, V199, P292, DOI 10.1002/aja.1001990405; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	93	497	537	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 23	1996	86	4					531	542		10.1016/S0092-8674(00)80127-0	http://dx.doi.org/10.1016/S0092-8674(00)80127-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752208	Bronze			2022-12-28	WOS:A1996VE23500004
J	Piccolo, S; Sasai, Y; Lu, B; DeRobertis, EM				Piccolo, S; Sasai, Y; Lu, B; DeRobertis, EM			Dorsoventral patterning in xenopus: Inhibition of ventral signals by direct binding of Chordin to BMP-4	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; GROWTH-FACTOR-BETA; DROSOPHILA EMBRYO; SPEMANN ORGANIZER; NEURAL INDUCTION; MARGINAL ZONE; RECEPTOR; MESODERM; NOGGIN; GENES	Chordin (Chd) is an abundant protein secreted by Spemann organizer tissue during gastrulation. Chd antagonizes signaling by mature bone morphogenetic proteins (BMPs) by blocking binding to their receptors. Recombinant Xenopus Chd binds to BMP-4 with high affinity (K-D 3 x 10(-10) M), binding specifically to BMPs but not to activin or TGF-beta 1. Chd protein is able to dorsalize mesoderm and to neuralize ectoderm in Xenopus gastrula explants at 1 nM. We propose that the noncell-autonomous effects of Spemann's organizer on dorsoventral patterning are executed in part by diffusible signals that directly bind to and neutralize ventral BMPs during gastrulation.			Piccolo, S (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.			De Robertis, Edward/0000-0002-7843-1869; PICCOLO, STEFANO/0000-0002-2037-0004	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021502, R37HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD021502, R01 HD021502, R37 HD021502-13, HD21502-11] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOUWMEESTER T, 1996, IN PRESS NATURE; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HAMBERGER V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HOLLEY SA, 1996, CELL, V86; JONES CM, 1992, DEVELOPMENT, V115, P639; JONS CM, 1996, DEVELOPMENT, V122, P1545; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASUHARA K, 1995, BONE, V16, P91, DOI 10.1016/S8756-3282(94)00014-X; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; ZIMMERMAN LB, 1996, CELL	48	905	943	2	54	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					589	598		10.1016/S0092-8674(00)80132-4	http://dx.doi.org/10.1016/S0092-8674(00)80132-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752213	Bronze, Green Accepted			2022-12-28	WOS:A1996VE23500009
J	Chang, RWS				Chang, RWS			How should cadaver kidneys be allocated?	LANCET			English	Editorial Material							SURVIVAL				Chang, RWS (corresponding author), ST GEORGE HOSP,LONDON SW17 0QT,ENGLAND.							FERGUSON RM, 1988, TRANSPLANT P S8, V6, P42; HALASZ NA, 1993, CLIN TRANSPLANT, V7, P357; MATAS AJ, 1992, TRANSPLANTATION, V54, P568, DOI 10.1097/00007890-199209000-00039; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; TURKA LA, 1989, TRANSPLANTATION, V47, P234, DOI 10.1097/00007890-198902000-00007	5	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					453	454		10.1016/S0140-6736(96)02051-X	http://dx.doi.org/10.1016/S0140-6736(96)02051-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709787				2022-12-28	WOS:A1996VC67300015
J	Conn, PM; Bowers, CY				Conn, PM; Bowers, CY			A new receptor for growth hormone-release peptide	SCIENCE			English	Editorial Material							HEXAPEPTIDE; ACTS; MEN		OREGON HLTH SCI UNIV,DEPT PHYSIOL & PHARMACOL,PORTLAND,OR 97201; TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112	Oregon Health & Science University; Tulane University	Conn, PM (corresponding author), OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006, USA.							BELLONE J, 1995, EUR J ENDOCRINOL, V133, P425, DOI 10.1530/eje.0.1330425; BOWERS CY, 1991, ENDOCRINOLOGY, V128, P2027, DOI 10.1210/endo-128-4-2027; BOWERS CY, 1990, J CLIN ENDOCR METAB, V70, P975, DOI 10.1210/jcem-70-4-975; BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; BOWERS CY, 1994, J CLIN ENDOCR METAB, V79, P940, DOI 10.1210/jc.79.4.940; BOWERS CY, 1980, ENDOCRINOLOGY, V108, P1071; FLEISHER D, 1995, LIFE SCI, V57, P1293, DOI 10.1016/0024-3205(95)02086-X; FRENKEL J, 1995, J PEDIATR ENDOCR MET, V8, P43; GUILLEMIN R, 1982, SCIENCE, V218, P585, DOI 10.1126/science.6812220; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; PATCHETT AA, 1995, P NATL ACAD SCI USA, V92, P7001, DOI 10.1073/pnas.92.15.7001; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SMITH RG, 1996, 10 INT C END 12 15 J, P26	13	15	16	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					923	923		10.1126/science.273.5277.923	http://dx.doi.org/10.1126/science.273.5277.923			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8711477				2022-12-28	WOS:A1996VC67000051
J	Nightingale, SL				Nightingale, SL			Quality of mammography facilities improved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V271, P179; 1995, JAMA-J AM MED ASSOC, V273, P1897	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691538				2022-12-28	WOS:A1996VA86300007
J	Stevenson, WG; Ridker, PM				Stevenson, WG; Ridker, PM			Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SIGNAL-AVERAGED ELECTROCARDIOGRAM; VENTRICULAR ENLARGEMENT TRIAL; THROMBOLYTIC THERAPY; PROGNOSTIC-SIGNIFICANCE; LATE POTENTIALS; PREDICTION; VARIABLES; EVENTS; TACHYCARDIA	Because survivors of myocardial infarction are at risk for ventricular arrhythmias and sudden death, physicians must decide whether to refer these patients to specialists for arrhythmia assessment and therapy, However, this decision is complex as few randomized data are available concerning either diagnostic or therapeutic options, Therefore, we modeled the potential impact of current arrhythmia detection and management strategies on mortality in survivors of myocardial infarction with reduced left ventricular function who are managed in a contemporary manner. Based on recent data we estimated that the mortality for myocardial infarction survivors with left ventricular ejection fraction less than 0.40 is 20% over 3.5 years and that half of the deaths are sudden. The sensitivity and specificity of a Holter electrocardiogram (EGG), a signal-averaged EGG, and an invasive electrophysiology study for predicting sudden death were obtained from a literature review of trials published after 1990 that included more than 300 patients, A series of models were constructed to predict mortality achieved by different arrhythmia management strategies that reduced sudden death by 50% and 75%-reductions estimated to be within the range for amiodarone and implantable defibrillators. We found that, when routinely applied to all infarct survivors with depressed ventricular function, a therapy that reduces sudden death by 50% with 1% fatal adverse effects (potentially amiodarone) saves approximately 1 life for every 25 patients treated. Therapy that reduces sudden death by 75% with 2% fatal adverse effects (potentially implantable defibrillators) saves 1 life for every 14 patients treated, Using Holter ECG recordings, a signal-averaged EGG, or an invasive electrophysiology study to select higher-risk groups, 1 life can be saved for every 4 to 11 patients treated, and the negative impact of adverse effects can be reduced, However, to achieve this benefit, additional and potentially invasive arrhythmia testing must be applied to 28 to 47 patients for each life saved. Thus, with contemporary management of acute myocardial infarction, the risk of sudden death for survivors is sufficiently low that broad application of available antiarrhythmic therapies has limited potential for further improving survival, particularly if therapy also has significant adverse effects, Thus, routine referral to arrhythmia specialists is not warranted for the majority of infarct survivors and should be largely reserved for patients with serious, symptomatic arrhythmias.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School								BOURKE JP, 1991, J AM COLL CARDIOL, V18, P780, DOI 10.1016/0735-1097(91)90802-G; DECHILLOU C, 1991, J AM COLL CARDIOL, V18, P1638, DOI 10.1016/0735-1097(91)90496-V; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; GANG ES, 1989, NEW ENGL J MED, V321, P712, DOI 10.1056/NEJM198909143211104; GREENE HL, 1989, AM J CARDIOL, V63, P1, DOI 10.1016/0002-9149(89)91065-5; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; KOSTIS JB, 1987, J AM COLL CARDIOL, V10, P231, DOI 10.1016/S0735-1097(87)80001-3; MAGGIONI AP, 1993, CIRCULATION, V87, P312, DOI 10.1161/01.CIR.87.2.312; MCCLEMENTS BM, 1993, J AM COLL CARDIOL, V21, P1419, DOI 10.1016/0735-1097(93)90319-V; MOYE LA, 1991, AM J CARDIOL, V68, pD70; NADEMANEE K, 1993, CIRCULATION, V88, P764, DOI 10.1161/01.CIR.88.2.764; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; ODEMUYIWA O, 1993, AM HEART J, V125, P1597, DOI 10.1016/0002-8703(93)90746-V; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDRETTI R, 1993, AM J CARDIOL, V71, P1131, DOI 10.1016/0002-9149(93)90635-P; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; RICHARDS DAB, 1991, CIRCULATION, V83, P756, DOI 10.1161/01.CIR.83.3.756; SAGER PT, 1988, J AM COLL CARDIOL, V12, P19, DOI 10.1016/0735-1097(88)90350-6; SOGAARD P, 1994, CIRCULATION, V90, P101; SWEENEY MO, 1994, CIRCULATION, V89, P1851, DOI 10.1161/01.CIR.89.4.1851; WHITE HD, 1994, CIRCULATION, V89, P61, DOI 10.1161/01.CIR.89.1.61; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; ZAREMBSKI DG, 1993, ARCH INTERN MED, V153, P2661, DOI 10.1001/archinte.153.23.2661; ZIPES DP, 1994, CIRCULATION, V89, P2934, DOI 10.1161/01.CIR.89.6.2934	26	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					481	485		10.1001/jama.276.6.481	http://dx.doi.org/10.1001/jama.276.6.481			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691557				2022-12-28	WOS:A1996VA86300037
J	Nakajima, T; Fukamizu, A; Takahashi, J; Gage, FH; Fisher, T; Blenis, J; Montminy, MR				Nakajima, T; Fukamizu, A; Takahashi, J; Gage, FH; Fisher, T; Blenis, J; Montminy, MR			The signal-dependent coactivator CBP is a nuclear target for pp90(RSK)	CELL			English	Article							NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR CREB; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; BINDING PROTEIN CREB; PC12 CELLS; KINASE-II; PHOSPHORYLATION; INSULIN; CAMP; ACTIVATION	We have examined the mechanism by which growth factor-mediated induction of the Ras pathway interferes with signaling via the second messenger cAMP. Activation of cellular Ras with insulin or NGF stimulated recruitment of the S6 kinase pp90(RSK) to the signal-dependent coactivator CBP. Formation of the pp90(RSK)-CBP complex occurred with high stoichiometry and persisted for 6-8 hr following growth factor addition. pp90(RSK) specifically recognized the E1A-binding domain of the coactivator CBP. In addition, like E1A, binding of pp90(RSK) to CBP was sufficient to repress transcription of cAMP-responsive genes via the cAMP-inducible factor CREB. By contrast with its effects on the cAMP pathway, formation of the pp90(RSK)-CBP complex was required for induction of Ras-responsive genes. These results provide a demonstration of cross-coupling between two signaling pathways that occurs at the level of a signal-dependent coactivator.	FDN MED RES,PEPTIDE BIOL LABS,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,GENET LAB,LA JOLLA,CA 92037	Salk Institute	Nakajima, T (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,JOSLIN DIABET CTR,BOSTON,MA 02215, USA.				NCI NIH HHS [CA 54418] Funding Source: Medline; NIA NIH HHS [AG 06088] Funding Source: Medline; NIGMS NIH HHS [GM 37828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037828, R37GM037828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARANY Z, 1995, NATURE, V374, P8184; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FISHER T, 1996, IN PRESS MOL CELL BI; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LUNBLAD JR, 1995, NATURE, V374, P85; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MONTMINY MR, 1986, J NEUROSCI, V6, P803; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; Parker D, 1996, MOL CELL BIOL, V16, P694; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1993, J BIOL CHEM, V268, P16999; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	39	231	243	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					465	474		10.1016/S0092-8674(00)80119-1	http://dx.doi.org/10.1016/S0092-8674(00)80119-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756728	Bronze			2022-12-28	WOS:A1996VC30900014
J	Madan, I				Madan, I			ABC of work related disorders - Occupational asthma and other respiratory diseases	BRITISH MEDICAL JOURNAL			English	Article							SURVEILLANCE; UK				Madan, I (corresponding author), SOUTHMEAD NHS TRUST,BRISTOL,AVON,ENGLAND.							ROSS DJ, 1995, OCCUP MED-OXFORD, V45, P175, DOI 10.1093/occmed/45.4.175; SALLIE BA, 1994, OCCUP MED-OXFORD, V44, P177, DOI 10.1093/occmed/44.4.177	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					291	294		10.1136/bmj.313.7052.291	http://dx.doi.org/10.1136/bmj.313.7052.291			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704547	Green Published			2022-12-28	WOS:A1996VA90300038
J	Stricker, T; Willi, UV; Pfyffer, GE; Nadal, D				Stricker, T; Willi, UV; Pfyffer, GE; Nadal, D			A school-girl with constipation	LANCET			English	Article									UNIV ZURICH,CHILDRENS HOSP,INFECT DIS UNIT,CH-8032 ZURICH,SWITZERLAND; UNIV ZURICH,CHILDRENS HOSP,DIV RADIOL,CH-8032 ZURICH,SWITZERLAND; UNIV ZURICH,SWISS NATL CTR MYCOBACTERIA,ZURICH,SWITZERLAND; UNIV ZURICH,DEPT MED MICROBIOL,ZURICH,SWITZERLAND	University Children's Hospital Zurich; University of Zurich; University Children's Hospital Zurich; University of Zurich; University of Zurich; University of Zurich								BONOMO RA, 1995, CLIN INFECT DIS, V20, P1576, DOI 10.1093/clinids/20.6.1576; COLES HMT, 1950, ARCH DIS CHILD, V25, P280, DOI 10.1136/adc.25.123.280; Pfyffer GE, 1996, J CLIN MICROBIOL, V34, P834, DOI 10.1128/JCM.34.4.834-841.1996; QUEREDA C, 1991, ARCH INTERN MED, V151, P2314, DOI 10.1001/archinte.151.11.2314; WARD AS, 1971, BRIT J SURG, V58, P540, DOI 10.1002/bjs.1800580719	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					306	306		10.1016/S0140-6736(96)04392-9	http://dx.doi.org/10.1016/S0140-6736(96)04392-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709691				2022-12-28	WOS:A1996VA25000012
J	Blair, PS; Fleming, PJ; Bensley, D; Smith, I; Bacon, C; Taylor, E; Berry, J; Golding, J; Tripp, J; Anson, L; Sodzi, R; Thompson, R; Wood, S; Ahronson, C; Cansfield, L; Davis, C; Griffin, M; Johnson, P; Lovelock, L; Middleton, L; Mueller, P; Stephenson, S; Taylor, D; Wright, L; Laws, C; McCabe, R				Blair, PS; Fleming, PJ; Bensley, D; Smith, I; Bacon, C; Taylor, E; Berry, J; Golding, J; Tripp, J; Anson, L; Sodzi, R; Thompson, R; Wood, S; Ahronson, C; Cansfield, L; Davis, C; Griffin, M; Johnson, P; Lovelock, L; Middleton, L; Mueller, P; Stephenson, S; Taylor, D; Wright, L; Laws, C; McCabe, R			Smoking and the sudden infant death syndrome: Results from 1993-5 case-control study for confidential inquiry into stillbirths and deaths in infancy	BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION; MATERNAL SMOKING; RISK	Objective-To investigate the effects of exposure to tobacco smoke and of parental consumption of alcohol and illegal drugs as risk factors for the sudden infant death syndrome after a national risk reduction campaign which included advice on prenatal and postnatal avoidance of tobacco smoke. Design-Two year population based case-control study. Parental interviews were conducted for each infant who died and four controls matched for age and date of interview. Setting-Three regions in England with a total population of 17 million people. Subjects-195 babies who died and 780 matched controls. Results-More index than control mothers (62.6% v 25.1%) smoked during pregnancy (multivariate odds ratio = 2.10; 95% confidence interval 1.24 to 3.54). Paternal smoking had an additional independent effect when other factors were controlled for (2.50; 1.48 to 4.22). The risk of death rose with increasing postnatal exposure to tobacco smoke, which had an additive effect among those also exposed to maternal smoking during pregnancy (2.93; 1.56 to 5.48). The population attributable risk was over 61%, which implies that the numbers of deaths from the syndrome could be reduced by almost two third if parents did not smoke. Alcohol use was higher among index than control mothers but was strongly correlated with smoking and on multivariate analysis was not found to have any additional independent effect. Illegal drug use was more common among the index parents, and paternal use of illegal drugs remained significant in the multivariate model (4.68; 1.56 to 14.05). Conclusions-This study confirms the increased risk of the sudden infant death syndrome associated with maternal smoking during pregnancy and shows evidence that household exposure to tobacco smoke has an independent additive effect. Parental drug misuse has an additional small but significant effect.	ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,FDN STUDY INFANT DEATHS RES UNIT,BRISTOL BS2 8BJ,AVON,ENGLAND; NHS EXECUT,OPERAT RES DIV,LEEDS LS2 9UA,W YORKSHIRE,ENGLAND; NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND; FRIARAGE HOSP,NORTHALLERTON DL6 1JG,N YORKSHIRE,ENGLAND; SHEFFIELD CHILDRENS HOSP,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND; UNIV BRISTOL,ST MICHAELS HOSP,BRISTOL BS2 8EG,AVON,ENGLAND; ROYAL DEVON & EXETER HOSP,POSTGRAD MED SCH,DEPT CHILD HLTH,EXETER EX2 5DW,DEVON,ENGLAND	Bristol Royal Hospital For Children; University of Bristol; University of Leeds; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Bristol; University of Exeter			Fleming, Peter J/A-9081-2010; Blair, Peter S/C-1213-2009; Fleming, Peter/O-3231-2019	Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Blair, Peter/0000-0002-7832-8087; Golding, Jean/0000-0003-2826-3307				BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; ENGELBERTS A, 1991, THSIS AMSTERDAM; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; GILBERT RE, 1990, BMJ-BRIT MED J, V300, P1237, DOI 10.1136/bmj.300.6734.1237; GILBERT RE, 1992, ARCH DIS CHILD, V67, P272; HAGLUND B, 1990, AM J PUBLIC HEALTH, V80, P29, DOI 10.2105/AJPH.80.1.29; HOFFMAN HJ, 1988, SUDDEN INFANT DEATH, P153; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P795, DOI 10.1001/jama.273.10.795; LI DK, 1991, AM J EPIDEMIOL, V134, P958, DOI 10.1093/oxfordjournals.aje.a116180; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MICHELL EA, 1992, J PAEDIAT CHILD HL S, V28, pS3; Mitchell E. A., 1995, P114; MITCHELL EA, 1993, PEDIATRICS, V91, P893; NAEYE RL, 1976, AM J DIS CHILD, V130, P1207, DOI 10.1001/archpedi.1976.02120120041005; *NAT ADV BODY CESD, 1996, 1994 NAT ADV BOD CES; NICHOLL J, 1992, EFFECTS SMOKING FETU; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; Wigfield R., 1995, P124; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282	20	232	239	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					195	198		10.1136/bmj.313.7051.195	http://dx.doi.org/10.1136/bmj.313.7051.195			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696194	Green Published			2022-12-28	WOS:A1996VA12600020
J	Fleming, PJ; Blair, PS; Bacon, C; Bensley, D; Smith, I; Taylor, E; Berry, J; Golding, J; Tripp, JZ; Anson, L; Sodzi, R; Thompson, R; Wood, S; Ahronson, C; Cansfield, L; Davis, C; Griffin, M; Johnson, P; Lovelock, L; Middleton, L; Mueller, P; Stephenson, S; Taylor, D; Wright, L; Laws, C; McCabe, R				Fleming, PJ; Blair, PS; Bacon, C; Bensley, D; Smith, I; Taylor, E; Berry, J; Golding, J; Tripp, JZ; Anson, L; Sodzi, R; Thompson, R; Wood, S; Ahronson, C; Cansfield, L; Davis, C; Griffin, M; Johnson, P; Lovelock, L; Middleton, L; Mueller, P; Stephenson, S; Taylor, D; Wright, L; Laws, C; McCabe, R			Environment of infants during sleep and risk of the sudden infant death syndrome: Results of 1993-5 case-control study for confidential inquiry into stillbirths and deaths in infancy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSITION	Objective-To investigate the role of sleeping arrangements as risk factors for the sudden infant death syndrome after a national risk reduction campaign. Design-Two year population based case-control study. Parental interviews were conducted for each infant who died and for four controls matched for age and date of interview. Setting-Three regions in England with a total population of 17 million people. Subjects-195 babies who died and 780 matched controls. Results-Prone and side sleeping positions both carried increased risks of death compared with supine when adjusted for maternal age, parity, gestation, birth weight, exposure to smoke, and other relevant factors in the sleeping environment (multivariate odds ratio = 9.00 (95% confidence interval 2.84 to 28.47) and 1.84 (1.02 to 3.31), respectively). The higher incidence of side rather than prone sleeping led to a higher population attributable risk (side 18.4%, prone 14.2%). More of the infants who died were found with bed covers over their heads (21.58; 6.21 to 74.99). The use of a dummy had an apparent protective effect (0.38; 0.21 to 0.70). Bed sharing for the whole night was a significant risk factor for infants whose mothers smoked (9.25; 2.31 to 34.02). No protective effect of breast feeding could be identified on multivariate analysis. Conclusions-This study confirms the importance of certain risk factors for the sudden infant death syndrome and identifies others-for example, covers over the head, side sleeping position-which may be amenable to change by educating and informing parents and health care professionals.	FRIARAGE HOSP, NORTHALLERTON DL6 1JG, N YORKSHIRE, ENGLAND; NHS EXECUT, OPERAT RES DIV, LEEDS LS2 9UA, W YORKSHIRE, ENGLAND; NUFFIELD INST HLTH, LEEDS LS2 9PL, W YORKSHIRE, ENGLAND; SHEFFIELD CHILDRENS HOSP, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND; UNIV BRISTOL, ST MICHAELS HOSP, BRISTOL BS2 8EG, AVON, ENGLAND; ROYAL DEVON & EXETER HOSP, POSTGRAD MED SCH, DEPT CHILD HLTH, EXETER EX2 5DW, DEVON, ENGLAND	University of Leeds; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Bristol; University of Exeter	Fleming, PJ (corresponding author), ROYAL HOSP SICK CHILDREN, INST CHILD HLTH, FDN STUDY INFANT DEATHS RES UNIT, BRISTOL BS2 8BJ, AVON, ENGLAND.		Blair, Peter S/C-1213-2009; Fleming, Peter/O-3231-2019; Fleming, Peter J/A-9081-2010	Fleming, Peter/0000-0003-2521-5764; Fleming, Peter J/0000-0003-2521-5764; Reis, AlessanRSS/0000-0001-8486-7469; Blair, Peter/0000-0002-7832-8087; Golding, Jean/0000-0003-2826-3307				BARROS FC, 1995, PEDIATRICS, V95, P497; BLAIR P, 1995, LANCET, V345, P720, DOI 10.1016/S0140-6736(95)90891-9; Blair PS, 1996, BRIT MED J, V313, P195, DOI 10.1136/bmj.313.7051.195; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CORDNER SM, 1992, SUDDEN INFANT DEATH; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FLEMING PJ, 1993, ACTA PAEDIATR, V82, P57, DOI 10.1111/j.1651-2227.1993.tb12878.x; FORD RPK, 1993, INT J EPIDEMIOL, V22, P885, DOI 10.1093/ije/22.5.885; GILBERT RE, 1995, BMJ-BRIT MED J, V310, P88, DOI 10.1136/bmj.310.6972.88; GILBERT RE, 1992, ARCH DIS CHILD, V67, P272; KLONOFFCOHEN H, 1995, BMJ-BRIT MED J, V311, P1269, DOI 10.1136/bmj.311.7015.1269; *MICR CORP, 1995, FOX PRO; MITCHELL EA, 1993, ARCH DIS CHILD, V68, P501, DOI 10.1136/adc.68.4.501; *NAT ADV BOD CESDI, 1996, 1994 NAT ADV BOD CES; Norvenius S G, 1987, Acta Paediatr Scand Suppl, V333, P1; SAS, 1989, SAS US GUID; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; TAYLOR EM, 1990, ARCH DIS CHILD, V65, P535, DOI 10.1136/adc.65.5.535; Wigfield R., 1995, P124; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282	20	309	314	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 27	1996	313	7051					191	195		10.1136/bmj.313.7051.191	http://dx.doi.org/10.1136/bmj.313.7051.191			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696193	Green Published			2022-12-28	WOS:A1996VA12600019
J	Bhanot, P; Brink, M; Samos, CH; Hsieh, JC; Wang, YS; Macke, JP; Andrew, D; Nathans, J; Nusse, R				Bhanot, P; Brink, M; Samos, CH; Hsieh, JC; Wang, YS; Macke, JP; Andrew, D; Nathans, J; Nusse, R			A new member of the frizzled family from Drosophila functions as a Wingless receptor	NATURE			English	Article							SEGMENT POLARITY GENE; HOMEOTIC GENES; SPATIAL EXPRESSION; ARMADILLO PROTEIN; CELL; EMBRYOS; HOMOLOG; ENCODES; SIGNAL; MELANOGASTER	Receptors for Wingless and other signalling molecules of the Wnt gene family have yet to be identified. We show here that cultured Drosophila cells transfected with a novel member of the frizzled gene family in Drosophila, Dfz2, respond to added Wingless protein by elevating the level of the Armadillo protein. Moreover, Wingless binds to Drosophila or human cells expressing Dfz2. These data demonstrate that Dfz2 functions as a Wingless receptor, and they imply, in general, that Frizzled proteins are receptors for the Wnt signalling molecules.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT BIOL,STANFORD,CA 94305	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Stanford University; Stanford University				Nathans, Jeremy/0000-0001-8106-5460				ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; EISENBERG LM, 1992, DEV BIOL, V154, P73, DOI 10.1016/0012-1606(92)90049-M; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRABA Y, 1995, DEVELOPMENT, V121, P209; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MATHIES LD, 1994, DEVELOPMENT, V120, P2799; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PEEL DJ, 1992, ROUX ARCH DEV BIOL, V201, P120, DOI 10.1007/BF00420423; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; REUTER R, 1990, DEVELOPMENT, V110, P1031; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RUSSELL J, 1992, DEVELOPMENT, V115, P475; Sambrook J., 2002, MOL CLONING LAB MANU; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; ZHENG L, 1995, DEVELOPMENT, V121, P3045	50	1179	1235	1	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					225	230		10.1038/382225a0	http://dx.doi.org/10.1038/382225a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717036				2022-12-28	WOS:A1996UX79000040
J	Ascherio, A; Rimm, EB; Giovannucci, EL; Spiegelman, D; Stampfer, M; Willett, WC				Ascherio, A; Rimm, EB; Giovannucci, EL; Spiegelman, D; Stampfer, M; Willett, WC			Dietary fat and risk of coronary heart disease in men: Cohort follow up study in the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE; FACTOR INTERVENTION TRIAL; SERUM-LIPIDS; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; ALCOHOL-CONSUMPTION; 10-YEAR MORTALITY; ACIDS; CHOLESTEROL; DEATH	Objective-To examine the association between fat intake and the incidence of coronary heart disease in men of middle age and older. Design-Cohort questionnaire study of men followed up for six years from 1956. Setting-The health professionals follow up study in the United States. Subjects-43 757 health professionals aged 40 to 75 years free of diagnosed cardiovascular disease or diabetes in 1956. Main outcome measure e-Incidence of acute myocardial infarction or coronary death. Results-During follow up 734 coronary events were documented, including 505 non-fatal myocardial infarctions and 229 deaths. After age and several corollary risk factors were controlled for significant positive associations were observed between intake of saturated far and risk of coronary disease. For men in the Pop versus the lowest fifth of saturated fat intake (median = 14.8% v 5.7% of energy) the multivariate relative risk for myocardial infarction was 1.22 (95% confidence interval 0.96 to 1.56) and for fatal coronary heart disease was 2.21 (1.38 to 3.54). After adjustment for intake of fibre the risks were 0.96 (0.73 to 1.27) and 1.72 (1.01 to 2.90), respectively. Positive associations between intake of cholesterol and risk of coronary heart disease were similarly attenuated after adjustment for fibre intake. intake; of linolenic acid was inversely associated with risk of myocardial infarction; this association became significant only after adjustment for non-dietary risk factors and was strengthened after adjustment for total fat intake (relative risk 0.41 for a 1% increase in energy, P for trend <0.01). Conclusions-These data do not support the strong association between intake of saturated fat and risk of coronary heart disease suggested by international comparisons. They are compatible, however, with the hypotheses that saturated fat and cholesterol intakes affect the risk of coronary heart disease as predicted by their effects on blood cholesterol concentration. They also support a specific preventive effect of linolenic acid intake.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Ascherio, A (corresponding author), HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA.				NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAYRON S, 1966, J LIPID RES, V7, P103; DAYTON S, 1969, CIRCULATION, V40, pII1; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; GABH Rose, 1982, WHO MONOGRAPH SERIES; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; Grundy S. M., 1982, CIRCULATION, V65, P839, DOI DOI 10.1161/01.CIR.65.5.839; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HJERMANN I, 1981, LANCET, V2, P1303; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; KATO H, 1973, AM J EPIDEMIOL, V97, P372, DOI 10.1093/oxfordjournals.aje.a121518; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KROMHOUT D, 1982, LANCET, V2, P518; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; MCKEIGUE P, 1994, LANCET, V343, P1445, DOI 10.1016/S0140-6736(94)92575-5; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; OWREN PA, 1965, ANN INTERN MED, V63, P167, DOI 10.7326/0003-4819-63-2-167; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rothman K, 1986, MODERN EPIDEMIOLOGY; SANDKER GW, 1993, EUR J CLIN NUTR, V47, P201; SCRIMSHA.NS, 1968, LAB INVEST, V18, P623; SHEKELLE RB, 1989, LANCET, V1, P1177; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; WILLETT WC, IN PRESS PREVENTION	58	529	548	0	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	1996	313	7049					84	90		10.1136/bmj.313.7049.84	http://dx.doi.org/10.1136/bmj.313.7049.84			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688759	Green Submitted, Green Published			2022-12-28	WOS:A1996UX69800022
J	Bates, P				Bates, P			Chemokine receptors and HIV-1: An attractive pair?	CELL			English	Review											Bates, P (corresponding author), UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104, USA.		Bates, Paul/F-8823-2011					ALKHATIB G, 1996, IN PRESS SCIENCE; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136	13	94	106	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					1	3		10.1016/S0092-8674(00)80070-7	http://dx.doi.org/10.1016/S0092-8674(00)80070-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689676	hybrid			2022-12-28	WOS:A1996UX93400001
J	Kaplan, MH; Sun, YL; Hoey, T; Grusby, MJ				Kaplan, MH; Sun, YL; Hoey, T; Grusby, MJ			Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice	NATURE			English	Article							STIMULATORY FACTOR	INTERACTIONS between cytokine and receptor lead to the activation of multiple signalling molecules, including the family of signal transducer and activator of transcription (STAT) proteins(1,2). Stat4 is one member of this family(3,4), and is activated only in response to the cytokine interleukin(IL)-12, (refs 5, 6). By gene targeting, we have generated mice deficient in Stat4 to determine whether the function of this transcription factor is redundant with other signalling molecules activated by IL-12. IL-12-induced increases in the production of interferon(IFN)-gamma cellular proliferation and natural killer (NK) cell cytotoxicity are abrogated in lymphocytes from Statil-deficient mice. The development of Th1 cells in response to either IL-12 or Listeria monocytogenes is also impaired in the absence of Stat4. Furthermore, Stat4-deficient lymphocytes demonstrate a propensity towards the development of Th2 cells. These results demonstrate that Stat4 is essential for mediating responses to IL-12 in lymphocytes, and regulating the differentiation of both Th1 and Th2 cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; TULARIK INC,S SAN FRANCISCO,CA 94080; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School				Kaplan, Mark/0000-0002-2923-8245				BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEBLAKERHOHE DF, 1995, CELL IMMUNOL, V165, P33, DOI 10.1006/cimm.1995.1184; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	22	1022	1052	2	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					174	177		10.1038/382174a0	http://dx.doi.org/10.1038/382174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700209				2022-12-28	WOS:A1996UW67200052
J	Kim, J; Sebring, A; Esch, JJ; Kraus, ME; Vorwerk, K; Magee, J; Carroll, SB				Kim, J; Sebring, A; Esch, JJ; Kraus, ME; Vorwerk, K; Magee, J; Carroll, SB			Integration of positional signals and regulation of wing formation and identity by Drosophila vestigial gene	NATURE			English	Article							HEDGEHOG; ENCODES; CELLS; DISC	Appendage formation is organized by signals from discrete sources that presumably act upon downstream genes to control growth and patterning. The Drosophila vestigial gene is selectively required for wing-cell proliferation, and is sufficient to induce outgrowths of wing tissue from eyes, legs and antennae. Different signals activate separate enhancers to control vestigial expression: first, in the dorsal/ventral organizer through the Notch pathway, and subsequently, in the developing wing blade by decapentaplegic and a signal from the dorsal/ventral organizer. Signal integration must be a general feature of genes like vestigial, that regulate growth or patterning along more than one axis.	UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V6, P715; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DIPASQUALE A, 1952, RO IST IONB SCI LE 3, V85, P241; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Meinhardt H., 1991, Seminars in Developmental Biology, V2, P129; MORIMURA S, IN PRESS DEV BIOL; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OUWENEEL WJ, 1970, GENETICA, V41, P1, DOI 10.1007/BF00958890; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; SANICOLA M, 1995, GENETICS, V139, P745; SIMPSON P, 1981, DEV BIOL, V84, P206, DOI 10.1016/0012-1606(81)90384-5; SPREICHER S, 1994, DEVELOPMENT, V120, P535; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	52	406	412	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					133	138		10.1038/382133a0	http://dx.doi.org/10.1038/382133a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700202				2022-12-28	WOS:A1996UW67200039
J	Rimm, EB; Katan, MB; Ascherio, A; Stampfer, MJ; Willett, WC				Rimm, EB; Katan, MB; Ascherio, A; Stampfer, MJ; Willett, WC			Relation between intake of flavonoids and risk for coronary heart disease in male health professionals	ANNALS OF INTERNAL MEDICINE			English	Article							POTENTIALLY ANTICARCINOGENIC FLAVONOIDS; FOOD FREQUENCY QUESTIONNAIRE; ALCOHOL-CONSUMPTION; MEN; REPRODUCIBILITY; NETHERLANDS; VALIDITY	Objective: Flavonols and flavones are subgroups of flavonoids and are found in tea, vegetables, fruits, and red wine. Because they have antioxidant properties, we investigated whether intake of these dietary compounds is associated with a lower risk for fatal and nonfatal coronary heart disease. Design: Prospective cohort study. Setting: United States. Patients: 34 789 male health professionals, 40 to 75 years of age, who responded to a questionnaire in 1986. Measurements: In 1986 and 1990, detailed, 131-item questionnaires were used to assess dietary intake of flavonols and flavones. Results: Between 1986 and 1992, 496 patients received a new diagnosis of nonfatal myocardial infarction. The relative risk for nonfatal myocardial infarction was 1.08 (95% Cl, 0.81 to 1.43) for the highest (median, 40.0 mg/d) compared with the lowest (median, 7.1 mg/d) quintiles for intake of flavonols and flavones after adjustment for age, obesity, smoking, intake of vitamin E, intake of alcohol, diabetes, hypertension, hypercholesterolemia, and family history of coronary heart disease. Among the 4814 men who reported that they had previously had coronary heart disease, we found a modest but nonsignificant inverse association between in-take of flavonols and flavones and subsequent coronary mortality rates (relative risk, 0.63 [Cl, 0.33 to 1.20] for the highest compared with the lowest quintile for intake of flavonoids). Conclusion: The data do not support a strong inverse association between intake of flavonoids and total coronary heart disease, but they do not exclude the possibility that flavonoids have a protective effect in men with established coronary heart disease.	AGR UNIV WAGENINGEN, DEPT HUMAN NUTR, NL-6703 HD WAGENINGEN, NETHERLANDS; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Wageningen University & Research; Harvard University; Brigham & Women's Hospital	Rimm, EB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ASCHERIO A, 1994, CIRCULATION, V89, P969, DOI 10.1161/01.CIR.89.3.969; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; *CONS FOOD EC I, 1989, COMP FOODS; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011; HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015; HOLLMAN PCH, 1995, AM J CLIN NUTR, V62, P1276, DOI 10.1093/ajcn/62.6.1276; KLEIJNEN J, 1992, LANCET, V340, P1136, DOI 10.1016/0140-6736(92)93158-J; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; LANDOLFI R, 1984, BIOCHEM PHARMACOL, V33, P1525, DOI 10.1016/0006-2952(84)90423-4; MIDDLETON E, 1992, BIOCHEM PHARMACOL, V43, P1167, DOI 10.1016/0006-2952(92)90489-6; NEGRESALVAYRE A, 1992, FREE RADICAL BIO MED, V12, P101, DOI 10.1016/0891-5849(92)90002-X; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; RIMM EB, 1992, ALCOHOL AND CARDIOVASCULAR DISEASE, P1; Rose G, 1982, CARDIOVASCULAR SURVE; Rothman K, 1986, MODERN EPIDEMIOLOGY; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366	30	433	446	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					384	389		10.7326/0003-4819-125-5-199609010-00005	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702089				2022-12-28	WOS:A1996VE07900005
J	Whitley, RJ; Weiss, H; Gnann, JW; Tyring, S; Mertz, GJ; Pappas, PG; Schleupner, CJ; Hayden, F; Wolf, J; Soong, SJ; Laughlin, C; Gnann, J; Sherrill, L; Pappas, P; Greenberg, S; Couch, R; Wolfe, J; Basler, E; Orengo, I; Liu, HC; Pollard, R; Savoia, M; Oxman, MN; Fine, D; Mangi, R; Kessler, H; Peacock, J; Tilles, J; Flowers, F; Beutner, K				Whitley, RJ; Weiss, H; Gnann, JW; Tyring, S; Mertz, GJ; Pappas, PG; Schleupner, CJ; Hayden, F; Wolf, J; Soong, SJ; Laughlin, C; Gnann, J; Sherrill, L; Pappas, P; Greenberg, S; Couch, R; Wolfe, J; Basler, E; Orengo, I; Liu, HC; Pollard, R; Savoia, M; Oxman, MN; Fine, D; Mangi, R; Kessler, H; Peacock, J; Tilles, J; Flowers, F; Beutner, K			Acyclovir with and without prednisone for the treatment of herpes zoster - A randomized, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ORAL ACYCLOVIR; POSTHERPETIC NEURALGIA; THERAPY; FAMCICLOVIR; EFFICACY	Objective: To determine the effect of acyclovir and prednisone treatment of herpes tester on chronic pain and quality-of-life outcomes. Design: Randomized, double-blind, placebo-controlled study with a 2 x 2 factorial design. Setting: 15 university hospitals or affiliated clinics. Patients: 208 immunocompetent patients older than 50 years of age who had localized herpes tester that developed less than 72 hours before study enrollment. Intervention: Acyclovir or a matched placebo was administered orally, 800 mg five times daily, for 21 days. Prednisone or a matched placebo was administered orally at 60 mg/d for the first 7 days, 30 mg/d for days 8 to 14, and 15 mg/d for days 15 to 21. The four treatments regimens given were acyclovir plus prednisone; acyclovir plus prednisone placebo; prednisone plus acyclovir placebo; and placebos for both acyclovir and prednisone. Measurements: Patients were monitored daily for the first 28 days for lesion healing, resolution of pain, return to usual activity, and return to uninterrupted sleep. Monitoring was then done monthly for 6 months. Patients documented analgesic requirements each day, and adverse events and laboratory abnormalities were recorded at each clinic visit. An intention-to-treat analysis was used. Results: Patients were randomly allocated to receive one of the four regimens. Demographic characteristics were similar for each group. Time to total crusting and healing was accelerated for patients receiving acyclovir plus prednisone compared with patients receiving two placebos; the risk ratios were 2.27 (95% CI, 1.46 to 3.55) for total crusting and 2.07 (Cl, 1.26 to 3.38) for healing. Similarly, compared with the placebo group, patients receiving acyclovir plus prednisone had accelerated time to cessation of acute neuritis (risk ratio, 3.02 [Cl, 1.42 to 6.41]), time to return to uninterrupted sleep (risk ratio, 2.12 [Cl, 1.25 to 3.58]); time to return to usual daily activity (risk ratio, 3.22 [Cl, 1.92 to 5.40]); and time to cessation of analgesic therapy (risk ratio, 3.15 [Cl, 1.69 to 5.89]). In the acyclovir plus prednisone group, resolution of pain during the 6 months after disease onset did not statistically differ from that in the other groups. No important clinical or laboratory adverse events occurred in any group. Conclusions: In relatively healthy persons older than 50 years of age who have localized herpes tester, combined acyclovir and prednisone therapy can improve quality of life.	NIAID, NIH, BETHESDA, MD 20892 USA; UNIV ALABAMA, DEPT PEDIAT, CENT UNIT, BIRMINGHAM, AL 35233 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV KANSAS, KANSAS CITY, KS USA; UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA; UNIV OKLAHOMA, OKLAHOMA CITY, OK USA; HOSP ST RAPHAEL, NEW HAVEN, CT USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL USA; WAKE FOREST UNIV, WINSTON SALEM, NC 27109 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; UNIV FLORIDA, GAINESVILLE, FL USA; SOLANO DERMATOL, SOLANO BEACH, CA USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA; INFECT DIS RES, FAIRFAX, VA USA; HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35233 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35233 USA; UNIV ALABAMA, CTR COMPREHENS CANC, BIRMINGHAM, AL 35294 USA; UNIV TEXAS, MED BRANCH, DEPT MICROBIOL, GALVESTON, TX 77550 USA; UNIV NEW MEXICO, SCH MED, ALBUQUERQUE, NM 87131 USA; UNIV VIRGINIA, SALEM, VA 24153 USA; VET AFFAIRS MED CTR, SALEM, VA 24153 USA; UNIV VIRGINIA, MED CTR, CHARLOTTESVILLE, VA 22908 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; University of Kansas; University of California System; University of California San Diego; University of Oklahoma System; University of Oklahoma Health Sciences Center; Hospital Saint Raphael; Rush University; Wake Forest University; University of California System; University of California Irvine; State University System of Florida; University of Florida; Burroughs Wellcome Fund; Hennepin County Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Medical Branch Galveston; University of New Mexico; University of Virginia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Salem Veterans Affairs Medical Center; University of Virginia			OXMAN, MICHAEL NEIL/AGB-4695-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015113, N01AI012667, N01AI062554] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-62554, N01-AI-12667, N01-AI-15113] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPELMAN DH, 1955, NEW ENGL J MED, V253, P693, DOI 10.1056/NEJM195510202531606; BENOLDI D, 1991, INT J DERMATOL, V30, P288, DOI 10.1111/j.1365-4362.1991.tb04642.x; BEUTNER KR, 1995, ANTIMICROB AGENTS CH, V39, P1546, DOI 10.1128/AAC.39.7.1546; CLEMMENSEN OJ, 1984, CLIN EXP DERMATOL, V9, P557, DOI 10.1111/j.1365-2230.1984.tb00859.x; DEGREEF H, 1994, INT J ANTIMICROB AG, V4, P241, DOI 10.1016/0924-8579(94)90024-8; EAGLSTEIN WH, 1970, J AMER MED ASSOC, V211, P1681, DOI 10.1001/jama.211.10.1681; ELLIOTT FA, 1964, LANCET, V2, P610; ESMANN V, 1987, LANCET, V2, P126; GELFAND ML, 1954, JAMA-J AM MED ASSOC, V154, P911; GILL KS, 1994, EXPT OPINIONS INVEST, V3, P791; HARDING SP, 1991, CURR EYE RES, V10, P177, DOI 10.3109/02713689109020376; HUFF JC, 1988, AM J MED, V85, P84; KECZKES K, 1980, BRIT J DERMATOL, V102, P551, DOI 10.1111/j.1365-2133.1980.tb07654.x; MORTON P, 1989, NEW ZEAL MED J, V102, P93; SAUER GC, 1955, ARCH DERMATOL, V71, P488, DOI 10.1001/archderm.1955.01540280064016; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; WELLER TH, 1992, J INFECT DIS, V166, pS1; WHITLEY RJ, 1982, NEW ENGL J MED, V307, P971, DOI 10.1056/NEJM198210143071602; WOOD MJ, 1988, AM J MED, V85, P79; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304	20	267	276	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					376	383		10.7326/0003-4819-125-5-199609010-00004	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702088				2022-12-28	WOS:A1996VE07900004
J	Wolf, SS; Jones, DW; Knable, MB; Gorey, JG; Lee, KS; Hyde, TM; Coppola, R; Weinberger, DR				Wolf, SS; Jones, DW; Knable, MB; Gorey, JG; Lee, KS; Hyde, TM; Coppola, R; Weinberger, DR			Tourette syndrome: Prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding	SCIENCE			English	Article							BASAL GANGLIA; IMAGING AGENT; DISORDER; LINKAGE; ABNORMALITIES; MRI	Tourette syndrome, a chronic tic disorder with autosomal dominant inheritance, exhibits considerable phenotypic variability even within monozygotic twin pairs. The origins of this variability remain unclear. Recent findings have implicated the caudate nucleus as a locus of pathology, and pharmacological evidence supports dopaminergic involvement. Within monozygotic twins discordant for Tourette syndrome severity, differences in D2 dopamine receptor binding in the head of the caudate nucleus predicted differences in phenotypic severity (r = 0.99); this relation was not observed in putamen. These data may link Tourette syndrome with a spectrum of neuropsychiatric disorders that involve associative striatal circuitry.	NIMH,CLIN BRAIN DISORDERS BRANCH,INTRAMURAL RES PROGRAM,NIH,NEUROSCI CTR ST ELIZABETHS,WASHINGTON,DC 20032	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)				Coppola, Richard/0000-0003-0273-0675				ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; BRETT P, 1993, LANCET, V341, P1225, DOI 10.1016/0140-6736(93)91064-S; BRETT PM, 1995, BIOL PSYCHIAT, V37, P533, DOI 10.1016/0006-3223(94)00161-U; DEVOR EJ, 1990, HUM HERED, V40, P105, DOI 10.1159/000153914; FAHN S, 1993, ARCH NEUROL-CHICAGO, V50, P1013; GALERNTER J, 1995, GENOMICS, V30, P495; GALERNTER J, 1993, AM J PSYCHIAT, V150, P449; GALERNTER J, 1990, ARCH GEN PSYCHIAT, V47, P1073; GEORGE MS, 1994, PSYCHIAT RES-NEUROIM, V55, P193, DOI 10.1016/0165-1781(95)91245-9; Gilles de la Tourette G., 1885, ARCH NEUROL-CHICAGO, V9, P158; HYDE TM, 1992, NEUROLOGY, V42, P652, DOI 10.1212/WNL.42.3.652; HYDE TM, 1995, NEUROLOGY, V45, P1176, DOI 10.1212/WNL.45.6.1176; HYDE TM, 1995, JAMA-J AM MED ASSOC, V273, P498, DOI 10.1001/jama.273.6.498; INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739; KNABLE MB, 1995, J NUCL MED, V36, P1216; KUNG HF, 1989, J NUCL MED, V30, P88; KUNG MP, 1989, J LABELLED COMPD RAD, V27, P691, DOI 10.1002/jlcr.2580270612; KURLAN R, 1994, ARCH NEUROL-CHICAGO, V51, P1145, DOI 10.1001/archneur.1994.00540230083017; LECKMAN JF, 1993, BIOL PSYCHIAT, V34, P425, DOI 10.1016/0006-3223(93)90232-3; MALISON RT, 1995, AM J PSYCHIAT, V152, P1359; MORIARTY J, 1995, BRIT J PSYCHIAT, V167, P249, DOI 10.1192/bjp.167.2.249; MURRAY AM, 1994, P NATL ACAD SCI USA, V91, P11271, DOI 10.1073/pnas.91.23.11271; PAULS DL, 1986, NEW ENGL J MED, V315, P993, DOI 10.1056/NEJM198610163151604; PETERSON B, 1993, NEUROLOGY, V43, P941, DOI 10.1212/WNL.43.5.941; PRICE RA, 1985, ARCH GEN PSYCHIAT, V42, P815; ROBERTSON MM, 1989, BRIT J PSYCHIAT, V154, P147, DOI 10.1192/bjp.154.2.147; SINGER HS, 1993, NEUROLOGY, V43, P950, DOI 10.1212/WNL.43.5.950; SINGER HS, 1992, ADV NEUROL, V58, P233; SINGER HS, 1991, ANN NEUROL, V30, P558, DOI 10.1002/ana.410300408; TURJANSKI N, 1994, J NEUROL NEUROSUR PS, V57, P688, DOI 10.1136/jnnp.57.6.688	31	188	193	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1225	1227		10.1126/science.273.5279.1225	http://dx.doi.org/10.1126/science.273.5279.1225			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703056				2022-12-28	WOS:A1996VE47600039
J	Geyer, S; Ledberg, A; Schleicher, A; Kinomura, S; Schormann, T; Burgel, U; Klingberg, T; Larsson, J; Zilles, K; Roland, PE				Geyer, S; Ledberg, A; Schleicher, A; Kinomura, S; Schormann, T; Burgel, U; Klingberg, T; Larsson, J; Zilles, K; Roland, PE			Two different areas within the primary motor cortex of man	NATURE			English	Article							OWL MONKEYS; 2 REPRESENTATIONS; ORGANIZATION; HAND; CONNECTIONS; MOVEMENTS; INPUT; M1	THE primary motor area (M1) of mammals has long been considered to be structurally and functionally homogeneous(1-5). This area corresponds to Brodmann's cytoarchitectural area 4. A few reports shoeing that arm and hand are doubly represented in M1 of macaque monkeys(6,7) and perhaps man(8) and that each subarea has separate connections from somatosensory areas, have, with a few exceptions(9-12), gone largely unnoticed, Here we show that area 4 in man can be subdivided into areas '4 anterior' (4a) and '4 posterior' (4p) on the basis of both quantitative cytoarchitecture and quantitative distributions of transmitter-binding sites. We also show by positron emission tomography that two representations of the fingers exist, one in area 4a and one in area 4p, Roughness discrimination activated area 4p significantly more than a control condition of self-generated movements, We therefore suggest that the primary motor area is subdivided on the basis of anatomy, neurochemistry and function.	UNIV DUSSELDORF, DEPT NEUROANAT, D-40001 DUSSELDORF, GERMANY; UNIV DUSSELDORF, C&O VOGT INST BRAIN RES, D-40001 DUSSELDORF, GERMANY; KAROLINSKA INST, DEPT NEUROSCI, DIV HUMAN BRAIN RES, S-17177 STOCKHOLM, SWEDEN	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Karolinska Institutet			Zilles, Karl/J-9704-2013; Zilles, Karl/Y-3784-2019	Zilles, Karl/0000-0001-9296-9959; Zilles, Karl/0000-0002-4705-4175; Ledberg, Anders/0000-0003-3827-8721; Klingberg, Torkel/0000-0002-3175-2171				Brodmann K, 1909, VERGLEICHENDE LOKALI; FOERSTER O, 1936, HDB NEUROLOGIE, P1; Fritsch G, 1870, ARCH ANAT PHYSL WISS, V37, P300, DOI 10.1007/bf01759916; KAWASHIMA R, 1995, NEUROREPORT, V6, P238, DOI 10.1097/00001756-199501000-00003; KUNESCH E, 1989, EXP BRAIN RES, V78, P539; MAHALANOBIS P. C., 1949, Sankhya. The Indian Journal of Statistics, V9, P89; MATELLI M, 1989, J COMP NEUROL, V280, P468, DOI 10.1002/cne.902800311; MERKER B, 1983, J NEUROSCI METH, V9, P235, DOI 10.1016/0165-0270(83)90086-9; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; ROLAND E, 1976, ARCH NEUROL-CHICAGO, V33, P551; Roland P. E., 1993, Human Brain Mapping, V1, P3, DOI 10.1002/hbm.460010103; Roland P E, 1994, Hum Brain Mapp, V1, P173, DOI 10.1002/hbm.460010303; ROLAND PE, 1994, TRENDS NEUROSCI, V17, P458, DOI 10.1016/0166-2236(94)90131-7; ROLAND PE, 1987, BRAIN RES REV, V12, P1, DOI 10.1016/0165-0173(87)90017-8; SCHLEICHER A, 1990, J MICROSC-OXFORD, V157, P367, DOI 10.1111/j.1365-2818.1990.tb02971.x; SCHORMANN T, 1995, IEEE T MED IMAGING, V14, P25, DOI 10.1109/42.370399; Schormann T., 1993, Bioimaging, V1, P119, DOI 10.1002/1361-6374(199306)1:2<119::AID-BIO6>3.3.CO;2-Y; SEITZ RJ, 1991, EUR J NEUROSCI, V3, P481, DOI 10.1111/j.1460-9568.1991.tb00835.x; STEPNIEWSKA I, 1993, J COMP NEUROL, V330, P238, DOI 10.1002/cne.903300207; STEPNIEWSKA I, 1994, J COMP NEUROL, V349, P558, DOI 10.1002/cne.903490405; STEPNIEWSKA I, 1994, J COMP NEUROL, V349, P536, DOI 10.1002/cne.903490404; STRICK PL, 1982, J NEUROPHYSIOL, V48, P150, DOI 10.1152/jn.1982.48.1.150; STRICK PL, 1982, J NEUROPHYSIOL, V48, P139, DOI 10.1152/jn.1982.48.1.139; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238; Zilles K, 1995, AUTORADIOGRAPHY CORR, P277	25	484	485	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1996	382	6594					805	807		10.1038/382805a0	http://dx.doi.org/10.1038/382805a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752272				2022-12-28	WOS:A1996VE34700045
J	Silver, R; LeSauter, J; Tresco, PA; Lehman, MN				Silver, R; LeSauter, J; Tresco, PA; Lehman, MN			A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms	NATURE			English	Article							NEURAL TRANSPLANT; HAMSTERS; RESTORATION; BEHAVIOR; LESIONS; SYSTEM; SCN	THE mammalian suprachiasmatic nuclei (SCN) transmit signals to the rest of the brain, organizing circadian rhythms throughout the body(1-4), Transplants of the SCN restore circadian activity rhythms to animals whose own SCN have been ablated(5-9). The nature of the coupling signal from the grafted SCN to the host brain is not known, although it has been presumed that functional recovery requires re-establishment of appropriate synaptic connections. We have isolated SCN tissue from hamsters within a semipermeable polymeric capsule before transplantation, thereby preventing neural outgrowth but allowing diffusion of humoral signals, Here we show that the transplanted SCN, like neural pacemakers of Drosophila(10) and silkmoths(11), can sustain circadian activity rhythms by means of a diffusible signal.	COLUMBIA UNIV,DEPT PSYCHOL,NEW YORK,NY 10027; UNIV UTAH,DEPT BIOENGN,SALT LAKE CITY,UT 84112; UNIV CINCINNATI,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,CINCINNATI,OH 45267	Columbia University; Utah System of Higher Education; University of Utah; University System of Ohio; University of Cincinnati	Silver, R (corresponding author), COLUMBIA UNIV BARNARD COLL,DEPT PSYCHOL,3009 BROADWAY,NEW YORK,NY 10027, USA.		Jansen, Heiko T./A-5770-2008; Lehman, Michael/ABC-9076-2020	Jansen, Heiko T./0000-0003-0178-396X; Silver, Rae/0000-0001-8633-739X; Lehman, Michael/0000-0002-9076-5108				AEBISCHER P, 1991, BIOMATERIALS, V12, P50, DOI 10.1016/0142-9612(91)90132-T; AGUILARROBLERO R, 1994, EXP NEUROL, V130, P250, DOI 10.1006/exnr.1994.1203; BITTMAN EL, 1993, NEUR ABSTR, V19; DECOURSEY PJ, 1989, BRAIN RES, V500, P263, DOI 10.1016/0006-8993(89)90322-3; HAKIM H, 1991, J BIOL RHYTHM, V6, P97, DOI 10.1177/074873049100600201; HANDLER AM, 1979, NATURE, V279, P236, DOI 10.1038/279236a0; HONMA K, 1984, AM J PHYSIOL, V246, P949; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LEHMAN MN, 1987, J NEUROSCI, V7, P1626; LESAUTER J, 1994, RESTOR NEUROL NEUROS, V6, P135, DOI 10.3233/RNN-1994-6207; MAHE V, 1995, PRESSE MED, V24, P1041; MORIN LP, 1994, BRAIN RES REV, V67, P102; MOSKO S, 1978, P NATL ACAD SCI USA, V75, P6243, DOI 10.1073/pnas.75.12.6243; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; RUSAK B, 1977, J COMP PHYSIOL, V118, P145, DOI 10.1007/BF00611819; SILVER R, 1990, BRAIN RES, V525, P45, DOI 10.1016/0006-8993(90)91319-C; SOLLARS PJ, 1995, J NEUROSCI, V15, P2109, DOI 10.1523/JNEUROSCI.15-03-02109.1995; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; Tresco P A, 1992, Cell Transplant, V1, P255; TRUMAN JW, 1970, SCIENCE, V167, P1624, DOI 10.1126/science.167.3925.1624; TUREK FW, 1995, NEUROSCI BIOBEHAV R, V19, P53, DOI 10.1016/0149-7634(94)00030-5; VOGELBAUM MA, 1992, J NEUROSCI, V12, P3619	24	552	569	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					810	813		10.1038/382810a0	http://dx.doi.org/10.1038/382810a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752274				2022-12-28	WOS:A1996VE34700047
J	Dargie, HJ				Dargie, HJ			Calcium-channel blockers and the clinician	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; NIFEDIPINE; TRIAL				Dargie, HJ (corresponding author), UNIV GLASGOW,CLIN RES INITIAT HEART FAILURE,GLASGOW G12 8QQ,LANARK,SCOTLAND.							Braun S, 1996, J AM COLL CARDIOL, V28, P7, DOI 10.1016/0735-1097(96)00109-X; Dargie HJ, 1996, EUR HEART J, V17, P104; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P920; Rehnqvist N, 1996, EUR HEART J, V17, P76; WILCOX RG, 1986, BRIT MED J, V293, P1204, DOI 10.1136/bmj.293.6556.1204; ZACHARSKI LR, 1990, CANCER INVEST, V8, P451, DOI 10.3109/07357909009012067; 1990, AM J CARDIOL, V66, P779; 1988, NEW ENGL J MED, V319, P385	12	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					488	489		10.1016/S0140-6736(05)64663-6	http://dx.doi.org/10.1016/S0140-6736(05)64663-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757144				2022-12-28	WOS:A1996VD42700002
J	McQuillan, PM; Hahn, MB				McQuillan, PM; Hahn, MB			Does location matter in ulnar and common peroneal nerve block?	LANCET			English	Editorial Material							SCIATIC-NERVE; POPLITEAL				McQuillan, PM (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT ANESTHESIA,HERSHEY,PA 17033, USA.							BRIDENBAUGH LD, 1988, NEURAL BLOCKADE CLIN, P408; Dupre LJ, 1992, ANN FR ANESTH, V11S, pR42; LOFSTROM B, 1966, ACTA ANAESTH SCAND, V10, P111, DOI 10.1111/j.1399-6576.1966.tb00336.x; LOFSTROM JB, ILLUSTRATED HDB LOCA, P111; MCLEOD DH, 1994, CAN J ANAESTH, V41, P673, DOI 10.1007/BF03015619; MOORE DC, 1994, BRIT J ANAESTH, V73, P435, DOI 10.1093/bja/73.4.435; RORIE DK, 1980, ANESTH ANALG, V59, P371	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					490	491		10.1016/S0140-6736(05)64666-1	http://dx.doi.org/10.1016/S0140-6736(05)64666-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757147				2022-12-28	WOS:A1996VD42700005
J	Yang, YM; Dowling, J; Yu, QC; Kouklis, P; Cleveland, DW; Fuchs, E				Yang, YM; Dowling, J; Yu, QC; Kouklis, P; Cleveland, DW; Fuchs, E			An essential cytoskeletal linker protein connecting actin microfilaments to intermediate filaments	CELL			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; BULLOUS PEMPHIGOID ANTIGEN; DYSTONIA-MUSCULORUM; AXONAL-TRANSPORT; MOUSE MODEL; GENE; IDENTIFICATION; NEUROFILAMENTS; EXPRESSION; PLECTIN	Typified by rapid degeneration of sensory neurons, dystonia musculorum mice have a defective BPAG1 gene, known to be expressed in epidermis. We report a neuronal splice form, BPAG1n, which localizes to sensory axons. Both isoforms have a coiled-coil rod, followed by a carboxy domain that associates with intermediate filaments. However, the amino terminus of BPAG1n differs from BPAG1e in that it contains a functional actin-binding domain. In transfected cells, BPAG1n coaligns neurofilaments and microfilaments, establishing this as a cytoskeletal protein interconnecting actin and intermediate filament cytoskeletons. In BPAG1 null mice, axonal architecture is markedly perturbed, consistent with a failure to tether neurofilaments to the actin cytoskeleton and underscoring the physiological relevance of this protein.	UNIV CALIF SAN DIEGO,DEPT MED,LUDWIG INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LUDWIG INST CANC RES,LA JOLLA,CA 92093	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Yang, YM (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637, USA.		Cleveland, Don/AAN-9783-2021; Fuchs, Elaine/G-1565-2016	Cleveland, Don/0000-0002-1934-3682; Kouklis, Panos/0000-0003-0378-5619	NIAMS NIH HHS [R01-AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; BROWN A, 1995, GENOMICS, V29, P777, DOI 10.1006/geno.1995.9936; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CAMPBELL RM, 1992, NEURON, V9, P693, DOI 10.1016/0896-6273(92)90032-9; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Duchen L W, 1976, Adv Neurol, V14, P353; DURHAM HD, 1992, J NEUROPATH EXP NEUR, V51, P287, DOI 10.1097/00005072-199205000-00007; FATH KR, 1988, J CELL BIOL, V107, P613, DOI 10.1083/jcb.107.2.613; Foisner R, 1995, J STRUCT BIOL, V115, P304, DOI 10.1006/jsbi.1995.1055; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; GRIFFITH LM, 1978, J CELL BIOL, V78, P958, DOI 10.1083/jcb.78.3.958; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HOPKINSON SB, 1994, BIOCHEM J, V300, P851, DOI 10.1042/bj3000851; KOTHARY R, 1988, NATURE, V335, P435, DOI 10.1038/335435a0; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; LASEK RJ, 1976, CELL MOTILITY, V3, P1021; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Minichiello L, 1995, DEVELOPMENT, V121, P4067; NEMHAUSER I, 1985, BRAIN RES, V334, P47, DOI 10.1016/0006-8993(85)90566-9; PAGGI P, 1987, J NEUROSCI, V7, P2397; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; SOTELO C, 1988, NEUROSCIENCE, V27, P403, DOI 10.1016/0306-4522(88)90277-1; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SUGI T, 1989, J CLIN INVEST, V84, P1050, DOI 10.1172/JCI114266; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; TSUKITA S, 1986, J CELL BIOL, V102, P1710, DOI 10.1083/jcb.102.5.1710; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang XW, 1996, DEVELOPMENT, V122, P555; ZELENA J, 1974, CELL TISSUE RES, V153, P115	38	263	267	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					655	665		10.1016/S0092-8674(00)80138-5	http://dx.doi.org/10.1016/S0092-8674(00)80138-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752219	Bronze			2022-12-28	WOS:A1996VE23500015
J	Carter, AM; OsseiGerning, N; Grant, PJ				Carter, AM; OsseiGerning, N; Grant, PJ			Platelet glycoprotein IIIa PIA polymorphism in young men with myocardial infarction	LANCET			English	Letter											Carter, AM (corresponding author), UNIV LEEDS,GEN INFIRM,RES SCH MED,UNIT MOL VASC MED,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.		Grant, Peter/HIR-3733-2022					GoldschmidtClermont PJ, 1996, LANCET, V347, P1833, DOI 10.1016/S0140-6736(96)91652-9; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	2	63	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					485	486		10.1016/S0140-6736(05)64592-8	http://dx.doi.org/10.1016/S0140-6736(05)64592-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709822				2022-12-28	WOS:A1996VC67300071
J	Alivisatos, AP; Johnsson, KP; Peng, XG; Wilson, TE; Loweth, CJ; Bruchez, MP; Schultz, PG				Alivisatos, AP; Johnsson, KP; Peng, XG; Wilson, TE; Loweth, CJ; Bruchez, MP; Schultz, PG			Organization of 'nanocrystal molecules' using DNA	NATURE			English	Article							QUANTUM DOTS; PARTICLES; CLUSTERS; CDS; COLLOIDS; STATE; TIO2	PATTERNING matter on the nanometre scale is an important objective of current materials chemistry and physics. It is driven by both the need to further miniaturize electronic components and the fact that at the nanometre scale, materials properties are strongly size-dependent and thus can be tuned sensitively(1). In nanoscale crystals, quantum size effects and the large number of surface atoms influence the, chemical, electronic, magnetic and optical behaviour(2-4). 'Top-down' (for example, lithographic) methods for nanoscale manipulation reach only to the upper end of the nanometre regime(5); but whereas 'bottom-up' wet chemical techniques allow for the preparation of monodisperse, defect-free crystallites just 1-10 nm in size(6-10), ways to control the structure of nanocrystal assemblies are scarce. Here we describe a strategy for the synthesis of 'nanocrystal molecules', in which discrete numbers of gold nanocrystals are organized into spatially defined structures based on Watson-Crick base-pairing interactions. We attach single-stranded DNA oligonucleotides of defined length and sequence to individual nanocrystals, and these assemble into dimers and trimers on addition of a complementary single-stranded DNA template, We anticipate that this approach should allow the construction of more complex two- and three-dimensional assemblies.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY NATL LAB,INST MOL DESIGN,BERKELEY,CA 94701	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Alivisatos, AP (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.		peng, xiaogang/R-6184-2016; johnsson, kai/P-4222-2014; Bruchez, Marcel P/C-2271-2009; Alivisatos, Paul/N-8863-2015	peng, xiaogang/0000-0002-5606-8472; johnsson, kai/0000-0002-8002-1981; Bruchez, Marcel P/0000-0002-7370-4848; Alivisatos, Paul/0000-0001-6895-9048				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Andres RP, 1996, SCIENCE, V272, P1323, DOI 10.1126/science.272.5266.1323; BAWENDI MG, 1990, ANNU REV PHYS CHEM, V41, P477, DOI 10.1146/annurev.pc.41.100190.002401; BENTZON MD, 1989, PHILOS MAG B, V60, P169, DOI 10.1080/13642818908211188; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; COVIN VL, 1992, J AM CHEM SOC, V114, P5221; FENDLER JH, 1995, ADV MATER, V7, P607, DOI 10.1002/adma.19950070703; GOPIDAS KR, 1990, J PHYS CHEM-US, V94, P6435, DOI 10.1021/j100379a051; Guzelian AA, 1996, J PHYS CHEM-US, V100, P7212, DOI 10.1021/jp953719f; HANEDA K, 1987, CAN J PHYS, V65, P1233, DOI 10.1139/p87-198; HERRON N, 1993, SCIENCE, V259, P1426, DOI 10.1126/science.259.5100.1426; Klein DL, 1996, APPL PHYS LETT, V68, P2574, DOI 10.1063/1.116188; LAWLESS D, 1995, J PHYS CHEM-US, V99, P10329, DOI 10.1021/j100025a040; LITTAU KA, 1993, J PHYS CHEM-US, V97, P1224, DOI 10.1021/j100108a019; Maniatis T, 1989, DECONTAMINATION DILU; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; NIEMEYER CM, 1994, NUCLEIC ACIDS RES, V22, P5530, DOI 10.1093/nar/22.25.5530; PAG X, UNPUB ANGEW CHEM; PENG XG, 1992, J PHYS CHEM-US, V96, P3412, DOI 10.1021/j100187a043; PESCHEL S, 1995, ANGEW CHEM INT EDIT, V34, P1442, DOI 10.1002/anie.199514421; SCHMID G, 1992, CHEM REV, V92, P1709, DOI 10.1021/cr00016a002; SEEMAN NC, 1993, MATER RES SOC SYMP P, V292, P123; SPANHEL L, 1987, J AM CHEM SOC, V109, P6632, DOI 10.1021/ja00256a012; TOLBERT SH, 1995, ANNU REV PHYS CHEM, V46, P595, DOI 10.1146/annurev.pc.46.100195.003115; VOSSMEYER T, 1995, SCIENCE, V267, P1476, DOI 10.1126/science.267.5203.1476; WAUGH FR, 1995, PHYS REV LETT, V75, P705, DOI 10.1103/PhysRevLett.75.705; WELLER H, 1993, ANGEW CHEM INT EDIT, V32, P41, DOI 10.1002/anie.199300411; Whetten RL, 1996, ADV MATER, V8, P428, DOI 10.1002/adma.19960080513; ZUCKERMANN R, 1987, NUCLEIC ACIDS RES, V15, P5305, DOI 10.1093/nar/15.13.5305	30	2496	2630	16	999	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					609	611		10.1038/382609a0	http://dx.doi.org/10.1038/382609a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757130	Green Submitted			2022-12-28	WOS:A1996VC30300047
J	Sperling, MR; OConnor, MJ; Saykin, AJ; Plummer, C				Sperling, MR; OConnor, MJ; Saykin, AJ; Plummer, C			Temporal lobectomy for refractory epilepsy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURGICAL-TREATMENT; LOBE EPILEPSY; RESECTIVE SURGERY; FOLLOW-UP; SEIZURES; PREDICTION; RISK; AGE	Objective.-To examine the long-term effectiveness of anterior temporal lobectomy for refractory epilepsy with regard to seizure control and related medical and psychosocial measures and to determine how patterns of early seizure recurrence relate to long-term prognosis. Design.-cohort of patients prospectively followed up for 5 years after surgery. Setting.-Tertiary care comprehensive epilepsy center. Patients.-Eighty-nine patients with medically refractory epilepsy who were consecutively treated with anterior temporal lobectomy between 1986 and 1990. All patients had noninvasive preoperative evaluations, and 31 were evaluated with intracranial electrodes prior to surgery. Main Outcome Measures.-Postoperative seizure frequency, neuropsychologic function, mortality, and postoperative employment status. Results.-Five years after surgery, 62 patients (70%) were seizure free, 8 (9%) had seizures on fewer than 3 days per year or exclusively had nocturnal seizures, 10 (11%) had greater than 80% reduction in seizure frequency, 5 (6%) had less than 80% reduction in seizure frequency, and 4 (4%) died of causes unrelated to surgery. The proportion of patients in each outcome class remained stable throughout the 5-year period, Fifty-five percent of seizure recurrences happened within 6 months of surgery, and 93% occurred within 2 years after surgery. Outcome at 1 year related only moderately well to outcome at 5 years, No significant cognitive or linguistic deficits occurred. All patients who died had persistent seizures after surgery, Underemployment and unemployment declined significantly after surgery, with improvement noted in seizure-free patients. Conclusions.-Temporal lobectomy provides sustained seizure relief over 5 years to most patients who have surgery. Outcome at 2 years predicts long-term outcome. A seizure-free state is associated with reduced mortality and increased employment. Mere reduction in seizure frequency is not associated with improvement in those measures.	UNIV PENN,GRAD HOSP,DEPT NEUROL,PHILADELPHIA,PA 19146; UNIV PENN,GRAD HOSP,DIV NEUROSURG,PHILADELPHIA,PA 19146; DARTMOUTH COLL,DEPT PSYCHIAT,HANOVER,NH	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Dartmouth College	Sperling, MR (corresponding author), UNIV PENN,GRAD HOSP,COMPREHENS EPILEPSY CTR,1800 LOMBARD ST,PHILADELPHIA,PA 19146, USA.		Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NINDS NIH HHS [NS28813, NS14867] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014867, R01NS028813, P50NS014867] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENGZON ARA, 1968, NEUROLOGY, V18, P717, DOI 10.1212/WNL.18.8.717; BERKOVIC SF, 1995, NEUROLOGY, V45, P1358, DOI 10.1212/WNL.45.7.1358; Bonis A, 1980, Acta Neurochir Suppl (Wien), V30, P55; CAHAN LD, 1984, CLEVELAND CLIN Q, V51, P313, DOI 10.3949/ccjm.51.2.313; CHOVAZ CJ, 1994, SEIZURE, V3, P171, DOI 10.1016/S1059-1311(05)80185-2; DIKMEN S, 1980, J NERV MENT DIS, V168, P236, DOI 10.1097/00005053-198004000-00008; Dodrill Carl B., 1993, P263; DODRILL CB, 1986, ANN NEUROL, V20, P2, DOI 10.1002/ana.410200103; ELWES RDC, 1991, J NEUROL NEUROSUR PS, V54, P200, DOI 10.1136/jnnp.54.3.200; ELWES RDC, 1991, J NEUROL NEUROSUR PS, V54, P949, DOI 10.1136/jnnp.54.11.949; Engel Jerome Jr., 1993, P23; Engel Jr J., 1987, SURG TREATMENT EPILE, P553; FALCONER MA, 1963, J NEUROL NEUROSUR PS, V26, P154, DOI 10.1136/jnnp.26.2.154; GOLDRING S, 1984, J NEUROSURG, V60, P457, DOI 10.3171/jns.1984.60.3.0457; GULDVOG B, 1994, EPILEPSIA, V35, P540, DOI 10.1111/j.1528-1157.1994.tb02474.x; GULDVOG B, 1994, EPILEPSIA, V35, P554, DOI 10.1111/j.1528-1157.1994.tb02475.x; Hauser W, 1990, EPILEPSY FREQUENCY C; JENSEN I, 1976, ACTA NEUROL SCAND, V53, P335, DOI 10.1111/j.1600-0404.1976.tb04353.x; JOHNSTON SC, 1995, ANN NEUROL, V37, P531, DOI 10.1002/ana.410370416; KING DW, 1986, NEUROLOGY, V36, P334, DOI 10.1212/WNL.36.3.334; MIZRAHI EM, 1990, EPILEPSIA, V31, P302, DOI 10.1111/j.1528-1157.1990.tb05380.x; PAILLAS JE, 1983, SURG NEUROL, V20, P189, DOI 10.1016/0090-3019(83)90051-4; RASMUSSEN TB, 1983, EPILEPSIA, V24, pS65, DOI 10.1111/j.1528-1157.1983.tb04645.x; RODIN E, 1972, EPILEPSIA, V13, P149, DOI 10.1111/j.1528-1157.1972.tb04562.x; ROUGIER A, 1992, J NEUROL NEUROSUR PS, V55, P762, DOI 10.1136/jnnp.55.9.762; SAYKIN AJ, 1995, EPILEPSIA, V36, P1071, DOI 10.1111/j.1528-1157.1995.tb00464.x; SAYKIN AJ, 1992, NEUROPSYCHOLOGY EPIL, P63; SMITH DF, 1991, EPILEPSY RES, V9, P231, DOI 10.1016/0920-1211(91)90057-M; SPERLING MR, 1986, ANN NEUROL, V20, P57, DOI 10.1002/ana.410200110; SPERLING MR, 1995, NEUROLOGY, V45, P970, DOI 10.1212/WNL.45.5.970; SPERLING MR, 1994, NEUROLOGY, V44, P2325, DOI 10.1212/WNL.44.12.2325; SPERLING MR, 1992, NEUROLOGY, V42, P416, DOI 10.1212/WNL.42.2.416; SPERLING MR, 1989, NEUROLOGY, V39, P1487; STAFINIAK P, 1990, NEUROLOGY, V40, P1509, DOI 10.1212/WNL.40.10.1509; TAYLOR DC, 1987, SURG TREATMENT EPILE, P485; Van Buren J M, 1975, Adv Neurol, V8, P155; VICKREY BG, 1995, ANN NEUROL, V37, P158, DOI 10.1002/ana.410370205; WALCZAK TS, 1990, NEUROLOGY, V40, P413, DOI 10.1212/WNL.40.3_Part_1.413; WINGKUN EC, 1991, EPILEPSIA, V32, P851, DOI 10.1111/j.1528-1157.1991.tb05541.x	39	234	238	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					470	475		10.1001/jama.276.6.470	http://dx.doi.org/10.1001/jama.276.6.470			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691555				2022-12-28	WOS:A1996VA86300035
J	Lee, DH; Granja, JR; Martinez, JA; Severin, K; Ghadiri, MR				Lee, DH; Granja, JR; Martinez, JA; Severin, K; Ghadiri, MR			A self-replicating peptide	NATURE			English	Article							COILED-COILS; HEXADEOXYNUCLEOTIDE; PROTEINS; SYSTEM; ARCHITECTURE; STABILITY; MECHANISM; LINKAGE; MODEL	THE production of amino acids and their condensation to polypeptides under plausibly prebiotic conditions have long been known(1,2). But despite the central importance of molecular self-replication in the origin of life, the feasibility of peptide self-replication has not been established experimentally(3-6). Here we report an example of a self-replicating peptide. We show that a 32-residue alpha-helical peptide based on the leucine-zipper domain of the yeast transcription factor GCN4 can act autocatalytically in templating its own synthesis by accelerating the thioester-promoted amide-bond condensation of 15- and 17-residue fragments in neutral, dilute aqueous solutions. The self-replication process displays parabolic growth pattern with the initial rates of product formation correlating with the square-root of initial template concentration.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Granja, Juan R/P-7646-2014	Granja, Juan R/0000-0002-5842-7504; Severin, Kay/0000-0003-2224-7234				BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DYSON FJ, 1982, J MOL EVOL, V18, P344, DOI 10.1007/BF01733901; Fox S. W., 1977, MOL EVOLUTION ORIGIN; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; KAUFFMAN SA, 1986, J THEOR BIOL, V119, P1, DOI 10.1016/S0022-5193(86)80047-9; KOBAYASHI K, 1995, ANGEW CHEM INT EDIT, V34, P95, DOI 10.1002/anie.199500951; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; Miller S. L., 1974, ORIGINS LIFE EARTH; NOWICK JS, 1991, J AM CHEM SOC, V113, P8831, DOI 10.1021/ja00023a036; OPARIN A. I., 1965, ADVANCE ENZYMOL, V27, P347; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; PITSCH S, 1995, HELV CHIM ACTA, V78, P1621, DOI 10.1002/hlca.19950780702; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; VONKIEDROWSKI G, 1989, ANGEW CHEM INT EDIT, V28, P1235, DOI 10.1002/anie.198912351; WINTNER EA, 1995, J ORG CHEM, V60, P7997, DOI 10.1021/jo00129a046; WINTNER EA, 1994, J AM CHEM SOC, V116, P8877, DOI 10.1021/ja00099a003; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0	25	481	500	4	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1996	382	6591					525	528		10.1038/382525a0	http://dx.doi.org/10.1038/382525a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700225				2022-12-28	WOS:A1996VB25800045
J	Treue, S; Maunsell, JHR				Treue, S; Maunsell, JHR			Attentional modulation of visual motion processing in cortical areas MT and MST	NATURE			English	Article							POSTERIOR PARIETAL CORTEX; SUPERIOR TEMPORAL SULCUS; FUNCTIONAL-PROPERTIES; FOCAL ATTENTION; MACAQUE MONKEY; NEURONS; V1; CONNECTIONS; RESPONSES; FIELD	THE visual system is constantly inundated with information received by the eyes, only a fraction of which seems to reach visual awareness. This selection process is one of the functions ascribed to visual attention(1-6). Although many studies have investigated the role of attention in shaping neuronal representations in the visual cortex, few have focused on attentional modulation of neuronal signals related to visual motion. Here we report that the responses of direction-selective neurons in monkey visual cortex are greatly influenced by attention, and that this modulation occurs as early in the cortical hierarchy as the level of the middle temporal visual area (MT). Our finding demonstrates a stronger and earlier influence of attention on motion processing along the dorsal visual pathway than previously recognized.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine	Treue, S (corresponding author), UNIV TUBINGEN,DEPT NEUROL,COGNIT NEUROSCI LAB,MORGENSTELLE 15,D-72076 TUBINGEN,GERMANY.		Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439	NEI NIH HHS [R01 EY005911] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN R, 1990, Society for Neuroscience Abstracts, V16, P7; ASSAD JA, 1995, NATURE, V373, P518, DOI 10.1038/373518a0; BROADBENT DE, 1982, ACTA PSYCHOL, V50, P253, DOI 10.1016/0001-6918(82)90043-9; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DUBNER R, 1971, BRAIN RES, V35, P528, DOI 10.1016/0006-8993(71)90494-X; FERRERA VP, 1994, J NEUROSCI, V14, P6171; James W., 1980, PRINCIPLES PSYCHOL, V1st; JULESZ B, 1984, DYNAMIC ASPECTS NEOC, P585; LOGOTHETIS NK, 1994, VISUAL DETECTION MOT, P177; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2178; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; MOUNTCASTLE VB, 1981, J NEUROSCI, V1, P1218; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; OCRAVEN KM, 1995, INVEST OPHTH VIS SCI, V36, pS856; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Recanzone G. H., 1993, Society for Neuroscience Abstracts, V19, P973; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P147, DOI 10.1002/cne.902480202; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302	26	763	775	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					539	541		10.1038/382539a0	http://dx.doi.org/10.1038/382539a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700227	Green Published			2022-12-28	WOS:A1996VB25800050
J	Ahmed, FB; Hodgson, HJF; Oakley, CM; Scott, J; Friedland, JS; Ind, PW				Ahmed, FB; Hodgson, HJF; Oakley, CM; Scott, J; Friedland, JS; Ind, PW			Grand rounds - Hammersmith Hospital - Tuberculous enteritis - A serious possibility in some	BRITISH MEDICAL JOURNAL			English	Editorial Material							ABDOMINAL TUBERCULOSIS; PERITONITIS; DISEASE				Ahmed, FB (corresponding author), HAMMERSMITH HOSP,DEPT GASTROENTEROL,LONDON W12 0HS,ENGLAND.							ADDISON NV, 1983, ANN ROY COLL SURG, V65, P105; BASTANI B, 1985, Q J MED, V56, P549; COOKE NJ, 1985, BRIT MED J, V291, P497, DOI 10.1136/bmj.291.6494.497; DAS P, 1976, BRIT J SURG, V63, P941, DOI 10.1002/bjs.1800631213; HADDAD FS, 1987, DIS COLON RECTUM, V30, P724, DOI 10.1007/BF02561699; SAKAI Y, 1979, Materia Medica Polona, V11, P275; SCULLY RE, 1980, NEW ENGL J MED, V303, P445; SHELDON CD, 1993, TUBERCLE LUNG DIS, V74, P12, DOI 10.1016/0962-8479(93)90061-2; SHERMAN S, 1980, ARCH INTERN MED, V140, P506, DOI 10.1001/archinte.140.4.506; TABRISKY J, 1975, AM J GASTROENTEROL, V63, P49; VAIDYA MG, 1978, CLIN RADIOL, V29, P189, DOI 10.1016/S0009-9260(78)80230-X; VOIGT MD, 1989, LANCET, V1, P751	12	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					215	217						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696201				2022-12-28	WOS:A1996VA12600031
J	Sirigu, A; Duhamel, JR; Cohen, L; Pillon, B; Dubois, B; Agid, Y				Sirigu, A; Duhamel, JR; Cohen, L; Pillon, B; Dubois, B; Agid, Y			The mental representation of hand movements after parietal cortex damage	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; MOTOR IMAGERY; APRAXIA; MODEL	Recent neuroimagery findings showed that the patterns of cerebral activation during the mental rehearsal of a motor act are similar to those produced by its actual execution. This concurs with the notion that part of the distributed neural activity taking place during movement involves internal simulations, but it is not yet clear what specific contribution the different brain areas involved bring to this process. Here, patients with lesions restricted to the parietal cortex were found to be impaired selectively at predicting, through mental imagery, the time necessary to perform differentiated finger movements and visually guided pointing gestures, in comparison to normal individuals and to a patient with damage to the primary motor area, These results suggest that the parietal cortex is important for the ability to generate mental movement representations.	COLL FRANCE, CNRS, LAB PHYSIOL PERCEPT ACT, F-75006 PARIS, FRANCE; HOP LA PITIE SALPETRIERE, F-75013 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Sirigu, A (corresponding author), INSERM, U289, 47 BLVD HOP, F-75013 PARIS, FRANCE.		Sirigu, Angela/L-4683-2017; Duhamel, Jean-René/M-4723-2017	Duhamel, Jean-René/0000-0003-0210-1027; cohen, laurent/0000-0002-5010-9085				ANNETT J, 1995, NEUROPSYCHOLOGIA, V33, P1395, DOI 10.1016/0028-3932(95)00072-B; CLARK MA, 1994, BRAIN, V117, P1093, DOI 10.1093/brain/117.5.1093; DECETY J, 1989, BRAIN COGNITION, V11, P87, DOI 10.1016/0278-2626(89)90007-9; DECETY J, 1989, BEHAV BRAIN RES, V34, P35, DOI 10.1016/S0166-4328(89)80088-9; DECETY J, 1991, BEHAV BRAIN RES, V42, P1, DOI 10.1016/S0166-4328(05)80033-6; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; DOMINEY P, 1995, NEUROPSYCHOLOGIA, V33, P727, DOI 10.1016/0028-3932(95)00008-Q; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FITTS PM, 1954, J EXP PSYCHOL, V47, P381, DOI 10.1037/h0055392; FUJITA M, 1982, BIOL CYBERN, V45, P195, DOI 10.1007/BF00336192; GESCHWIN.N, 1965, BRAIN, V88, P585, DOI 10.1093/brain/88.3.585; HEILMAN KM, 1982, NEUROLOGY, V32, P342, DOI 10.1212/WNL.32.4.342; INGVAR DH, 1977, ANN NEUROL, V2, P230, DOI 10.1002/ana.410020309; Ito M, 1984, CEREBELLUM NEURAL CO; JEANNEROD M, 1986, BEHAV BRAIN RES, V19, P99, DOI 10.1016/0166-4328(86)90008-2; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; Kosslyn S. M., 1994, IMAGE BRAIN; LANG W, 1994, NEUROREPORT, V5, P921, DOI 10.1097/00001756-199404000-00017; LEONE AP, 1995, J NEUROPHYSIOL, V67, P1114; MacKenzie C. L., 1994, THE GRASPING HAND; MELVILLJONES G, 1985, ADAPTIVE MECH GAZE C; OPTICAN LM, 1982, FUNCTIONAL BASIS OCU, P423; PARSONS LM, 1994, J EXP PSYCHOL HUMAN, V20, P709, DOI 10.1037/0096-1523.20.4.709; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; ROTHI LJG, 1991, COGN NEUROPSYCHOL, V8, P443, DOI 10.1080/02643299108253382; Sakata Hideo, 1994, Current Opinion in Neurobiology, V4, P847, DOI 10.1016/0959-4388(94)90133-3; SIRIGU A, 1995, CORTEX, V31, P41, DOI 10.1016/S0010-9452(13)80104-9; SIRIGU A, 1995, NEUROREPORT, V6, P997, DOI 10.1097/00001756-199505090-00012; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373, DOI 10.1152/jn.1995.73.1.373; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931	30	607	622	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1996	273	5281					1564	1568		10.1126/science.273.5281.1564	http://dx.doi.org/10.1126/science.273.5281.1564			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VG597	8703221				2022-12-28	WOS:A1996VG59700045
J	Delbanco, TL; Rubenstein, AH				Delbanco, TL; Rubenstein, AH			A 64-year-old man with adult-onset diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONVERTING ENZYME-INHIBITION; MELLITUS		UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago	Delbanco, TL (corresponding author), BETH ISRAEL HOSP, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, LY310, BOSTON, MA 02215 USA.							BALFOUR JA, 1993, DRUGS, V46, P1025, DOI 10.2165/00003495-199346060-00007; Clark CM, 1996, ANN INTERN MED, V124, P81, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00001; COWIE CC, 1996, AM DIABETES ASS DIAB, P71; DALY A, 1994, AM DIABETES ASS CLIN, P95; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; *DIAB STAT, 1996, AM DIAB ASS DIAB 199, P13; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; Diabet Control Complications Trial Res Grp, 1996, DIABETES CARE, V19, P195; Henry RR, 1996, ANN INTERN MED, V124, P175, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00019; HORTON ES, 1994, AM DIABETES ASS CLIN, P107; Laakso M, 1996, ANN INTERN MED, V124, P127, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00009; LEBOVITZ HE, 1994, AM DIABETES ASS CLIN, P116; LEBOVITZ HE, 1994, AM DIABETES MELLITUS, P1; Leibowitz G, 1996, DIABETOLOGIA, V39, P503, DOI 10.1007/BF00403296; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Mogensen CE, 1994, CURR OPIN ENDOCRINOL, V1, P239; OLEFSKY JM, 1995, CURR OPIN ENDOCRINOL, V2, P290; PETERS AL, 1995, CURR OPIN ENDOCRINOL, V2, P325; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; SALTIEL AR, 1995, CURR OPIN ENDOCRINOL, V2, P341; SCHNEIDER SH, 1992, PATIENT CARES CL SEP, P5; TESTA MA, 1996, 56TH ANN M SCI SESS; TURNER R, 1996, ANN INTERN MED 2 S1, V124, P137; WHITE NH, 1995, CURR OPIN ENDOCRINOL, V2, P45; 1993, NEW ENGL J MED, V329, P304; 1970, DIABETES, V25, P1129	26	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					816	822						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769592				2022-12-28	WOS:A1996VF21900029
J	Fiedler, K; Veit, M; Stamnes, MA; Rothman, JE				Fiedler, K; Veit, M; Stamnes, MA; Rothman, JE			Bimodal interaction of coatomer with the p24 family of putative cargo receptors	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; TRANSPORT VESICLES; COATED VESICLES; INTRACELLULAR-TRANSPORT; BETA-COP; GOLGI; MEMBRANE; GLYCOPROTEIN; RETENTION	Cytoplasmic domains of members of the p24 family of putative cargo receptors were shown to bind to coatomer, the coat protein of COPI-coated transport vesicles. Domains that contained dilysine endoplasmic reticulum retrieval signals bound the alpha-, beta'-, and epsilon-COP subunits of coatomer, whereas other p24 domains bound the beta-, gamma-, and zeta-COP subunits and required a phenylalanine-containing motif, Transit of a CD8-p24 chimera from the endoplasmic reticulum through the Golgi complex was slowed when the phenylalanine motif was mutated, suggesting that this motif may function as an anterograde transport signal. The either-or bimodal binding of coatomer to p24 tails suggests models for how coatomer can potentially package retrograde-directed and anterograde-directed cargo into distinct COPI-coated vesicles.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center			Veit, Michael/G-6492-2010	Fiedler, Klaus/0000-0001-9398-1116; Stamnes, Mark/0000-0002-5869-7985; Veit, Michael/0000-0002-7638-1829				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DUDEN R, 1994, J BIOL CHEM, V269, P24486; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; WADA I, 1991, J BIOL CHEM, V266, P19599; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	32	278	281	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1996	273	5280					1396	1399		10.1126/science.273.5280.1396	http://dx.doi.org/10.1126/science.273.5280.1396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703076				2022-12-28	WOS:A1996VF61000045
J	Olsen, EJ; Davis, AM; Clayton, RN; Mayeda, TK; Moore, CB; Steele, IM				Olsen, EJ; Davis, AM; Clayton, RN; Mayeda, TK; Moore, CB; Steele, IM			A silicate inclusion in Puente del Zacate, a IIIA iron meteorite	SCIENCE			English	Article							IAB	The IIIA and IIIB iron meteorites are considered to have formed in the cores of asteroids. A silicate inclusion within the IIIA meteorite Puente del Zacate consisting of olivine (Fa(4)), low-calcium pyroxene (Fs(6)Wo(1)), chromium diopside (Fs(3)Wo(47)), plagioclase (An(14)Or(4)), graphite, troilite, chromite, daubreelite, and iron metal resembles inclusions in IAB iron meteorites. The oxygen isotopic composition of the Puente del Zacate inclusion is like chromite and phosphate inclusions in other IIIA and IIIB irons. The Puente del Zacate inclusion may have been derived from the lower mantle of the IIIAB parent asteroid.	UNIV CHICAGO,ENRICO FERMI INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637; ARIZONA STATE UNIV,CTR METEORITE STUDIES,TEMPE,AZ 85287; UNIV CHICAGO,DEPT GEOPHYS SCI,ENRICO FERMI INST,CHICAGO,IL 60637	University of Chicago; University of Chicago; Arizona State University; Arizona State University-Tempe; University of Chicago	Olsen, EJ (corresponding author), UNIV CHICAGO,DEPT GEOPHYS SCI,5734 S ELLIS AVE,CHICAGO,IL 60637, USA.			Davis, Andrew/0000-0001-7955-6236				Buchwald V., 1975, HDB IRON METEORITES, P1426; BUNCH TE, 1970, CONTRIB MINERAL PETR, V25, P297, DOI 10.1007/BF00399290; CHOI BG, 1995, GEOCHIM COSMOCHIM AC, V59, P593, DOI 10.1016/0016-7037(94)00384-X; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; KRACHER A, 1985, P LUNAR PLANET SCI C, V15, pC689; MEIBOM A, 1995, METEORITICS, V30, P544; OLSEN E, 1966, GEOCHIM COSMOCHIM AC, V30, P459, DOI 10.1016/0016-7037(66)90057-3; OLSEN E, 1994, LUNAR PLANET SCI, V25, P1025; OSLEN E, 1993, METEORITICS, V28, P415; ZINNER E, 1986, INT J MASS SPECTROM, V69, P17, DOI 10.1016/0168-1176(86)87039-2	10	4	4	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1365	1367		10.1126/science.273.5280.1365	http://dx.doi.org/10.1126/science.273.5280.1365			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703065				2022-12-28	WOS:A1996VF61000034
J	Jabbour, S				Jabbour, S			Training too many, training too few	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Jabbour, Samer/0000-0002-7150-6856					0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					729	729		10.1001/jama.276.9.729	http://dx.doi.org/10.1001/jama.276.9.729			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769554				2022-12-28	WOS:A1996VE23300014
J	Rose, PG				Rose, PG			Medical progress: Endometrial carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PAPILLARY SEROUS CARCINOMA; BREAST-CANCER PATIENTS; CLINICAL STAGE-I; NONPOLYPOSIS COLORECTAL-CANCER; PRIMARY RADIATION-THERAPY; PROGNOSTIC-SIGNIFICANCE; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; MYOMETRIAL INVASION; ADJUVANT TAMOXIFEN		CASE WESTERN RESERVE UNIV,IRELAND CANC CTR,CLEVELAND,OH 44106	Case Western Reserve University	Rose, PG (corresponding author), UNIV HOSP CLEVELAND,DEPT REPROD BIOL,DIV GYNECOL ONCOL,11100 EUCLID AVE,CLEVELAND,OH 44107, USA.							AALDERS J, 1980, OBSTET GYNECOL, V56, P419; ABELER VM, 1991, CANCER, V67, P3093, DOI 10.1002/1097-0142(19910615)67:12<3093::AID-CNCR2820671226>3.0.CO;2-L; *AM COLL OBST GYN, 1992, ACOG TECHN B, V166; *AM COLL OBST GYN, 1996, ACOG COMM GYN PRACT; *AM COLL OBST GYN, 1991, ACOG TECHN B, V162; *AM COLL OBST GYN, 1993, ACOG COMM GYN PRACT; ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; ARCHER DF, 1991, AM J OBSTET GYNECOL, V165, P317, DOI 10.1016/0002-9378(91)90084-5; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; AZIZ H, 1993, INT J RADIAT ONCOL, V27, P293, DOI 10.1016/0360-3016(93)90240-V; Ball H. G., 1995, Gynecologic Oncology, V56, P120; BARRETT RJ, 1995, AM J OBSTET GYNECOL, V173, P414, DOI 10.1016/0002-9378(95)90261-9; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P15, DOI 10.1016/0002-9378(91)90615-X; BIGSBY RM, 1992, OBSTET GYNECOL, V79, P95; BJORKHOLM E, 1980, ACTA OBSTET GYN SCAN, V59, P361; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; BOKHMAN JV, 1985, GYNECOL ONCOL, V20, P139, DOI 10.1016/0090-8258(85)90135-0; BUR ME, 1992, AM J CLIN PATHOL, V98, P81, DOI 10.1093/ajcp/98.1.81; CANDIANI GB, 1990, GYNECOL ONCOL, V37, P6, DOI 10.1016/0090-8258(90)90297-X; CARCANGIU ML, 1992, GYNECOL ONCOL, V47, P298, DOI 10.1016/0090-8258(92)90130-B; CHEN MD, 1992, 40 ANN CLIN M APR 27, P13; CHILDERS JM, 1993, OBSTET GYNECOL, V82, P741; CHILDERS JM, 1993, GYNECOL ONCOL, V51, P33, DOI 10.1006/gyno.1993.1242; CHRISTOPHERSON WM, 1983, CANCER-AM CANCER SOC, V51, P1705, DOI 10.1002/1097-0142(19830501)51:9<1705::AID-CNCR2820510924>3.0.CO;2-C; CHRISTOPHERSON WM, 1982, AM J CLIN PATHOL, V77, P534; CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8; CREASMAN WT, 1993, CANCER, V71, P1467, DOI 10.1002/cncr.2820710411; DOERING DL, 1989, OBSTET GYNECOL, V74, P930; Dubeau L, 1993, SYNOPSIS GYNECOLOGIC, P1; FARHI DC, 1986, OBSTET GYNECOL, V68, P741; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FLEISCHER AC, 1986, J ULTRAS MED, V5, P445; *FOOD DRUG ADM, 1976, FDA DRUG B, V6, P18; FORNANDER T, 1989, LANCET, V1, P117; GALLUP DG, 1984, OBSTET GYNECOL, V64, P417; Gibson L E, 1996, Cancer J Sci Am, V2, P35; GIMPELSON RJ, 1988, AM J OBSTET GYNECOL, V158, P489, DOI 10.1016/0002-9378(88)90011-7; GITSCH G, 1995, OBSTET GYNECOL, V85, P504, DOI 10.1016/0029-7844(95)00001-8; GOFF BA, 1994, GYNECOL ONCOL, V54, P264, DOI 10.1006/gyno.1994.1208; GOLDCHMIT R, 1993, OBSTET GYNECOL, V82, P727; GORDON AN, 1989, GYNECOL ONCOL, V34, P175, DOI 10.1016/0090-8258(89)90136-4; GRANBERG S, 1991, AM J OBSTET GYNECOL, V164, P47, DOI 10.1016/0002-9378(91)90622-X; GRIMES DA, 1982, AM J OBSTET GYNECOL, V142, P1; GRONROOS M, 1993, CANCER, V71, P1279, DOI 10.1002/1097-0142(19930215)71:4<1279::AID-CNCR2820710418>3.0.CO;2-4; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; HANSON MB, 1985, CANCER, V55, P1753, DOI 10.1002/1097-0142(19850415)55:8<1753::AID-CNCR2820550823>3.0.CO;2-P; HAROUNY VR, 1988, OBSTET GYNECOL, V72, P394; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; Hawwa Z M, 1970, Lahey Clin Found Bull, V19, P61; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; HILL HA, 1995, GYNECOL ONCOL, V56, P154, DOI 10.1006/gyno.1995.1024; HOULSTON RS, 1990, BRIT MED J, V301, P366, DOI 10.1136/bmj.301.6748.366; HOULSTON RS, 1990, BRIT MED J, V301, P446; HUNTER RE, 1989, OBSTET GYNECOL, V73, P813; IVERSEN OE, 1986, AM J OBSTET GYNECOL, V155, P770, DOI 10.1016/S0002-9378(86)80018-7; JUDD HL, 1982, OBSTET GYNECOL, V59, P680; KADAR N, 1992, OBSTET GYNECOL, V80, P655; KARLSSON B, 1995, AM J OBSTET GYNECOL, V172, P1488, DOI 10.1016/0002-9378(95)90483-2; KAUPPILA A, 1984, ACTA OBSTET GYN SCAN, V63, P441, DOI 10.3109/00016348409156700; KILGORE LC, 1995, GYNECOL ONCOL, V56, P29, DOI 10.1006/gyno.1995.1005; KILLACKEY MA, 1985, CANCER TREAT REP, V69, P237; KOHLER MF, 1992, CANCER RES, V52, P1622; KOSARY CL, 1995, NIH PUBLICATION, P171; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; LEE RB, 1990, GYNECOL ONCOL, V36, P189, DOI 10.1016/0090-8258(90)90171-G; LESKO SM, 1985, NEW ENGL J MED, V313, P593, DOI 10.1056/NEJM198509053131001; LEWIS B V, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P343; LIU JR, 1995, OBSTET GYNECOL, V86, P486, DOI 10.1016/S0029-7844(95)80002-6; LOFFER FD, 1989, OBSTET GYNECOL, V73, P16; LUKES AS, 1994, CANCER, V73, P2380, DOI 10.1002/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G; LURAIN JR, 1989, OBSTET GYNECOL, V74, P175; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MCGONIGLE KF, 1994, GYNECOL ONCOL, V55, P126, DOI 10.1006/gyno.1994.1261; MECKLIN JP, 1993, DIS COLON RECTUM, V36, P927, DOI 10.1007/BF02050627; MECKLIN JP, 1991, CANCER, V68, P1109, DOI 10.1002/1097-0142(19910901)68:5<1109::AID-CNCR2820680535>3.0.CO;2-S; MOORE TD, 1991, J CLIN ONCOL, V9, P1071, DOI 10.1200/JCO.1991.9.6.1071; MORROW CP, 1991, GYNECOL ONCOL, V40, P55, DOI 10.1016/0090-8258(91)90086-K; NILOFF JM, 1984, AM J OBSTET GYNECOL, V148, P1057, DOI 10.1016/S0002-9378(84)90444-7; PARAZZINI F, 1989, EUR J CANCER CLIN ON, V25, P1451, DOI 10.1016/0277-5379(89)90103-X; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PATSNER B, 1988, AM J OBSTET GYNECOL, V158, P399, DOI 10.1016/0002-9378(88)90163-9; PETERSON EP, 1968, OBSTET GYNECOL, V31, P702, DOI 10.1097/00006250-196805000-00018; PISANI AL, 1995, OBSTET GYNECOL, V85, P729, DOI 10.1016/0029-7844(95)00037-R; PLATZ CE, 1995, CANCER, V75, P270, DOI 10.1002/1097-0142(19950101)75:1+<270::AID-CNCR2820751312>3.0.CO;2-D; ROSE PG, 1994, OBSTET GYNECOL, V84, P12; ROSE PG, 1993, INT J RADIAT ONCOL, V27, P585, DOI 10.1016/0360-3016(93)90383-7; SCHINK JC, 1987, OBSTET GYNECOL, V70, P216; SCHOTTENFELD D, 1995, GYNECOL ONCOL, V56, P151, DOI 10.1006/gyno.1995.1023; SHIM JU, 1992, AM J OBSTET GYNECOL, V166, P1335, DOI 10.1016/0002-9378(92)91600-F; Thigpen T, 1993, P AN M AM SOC CLIN, V12, P261; THIGPEN T, 1991, P AN M AM SOC CLIN, V10, P185; TSUDA H, 1995, AM J OBSTET GYNECOL, V172, P1494, DOI 10.1016/0002-9378(95)90484-0; VANDENBOSCH T, 1995, OBSTET GYNECOL, V85, P349, DOI 10.1016/0029-7844(94)00421-9; VARIA M, 1987, INT J RADIAT ONCOL, V13, P11, DOI 10.1016/0360-3016(87)90253-7; VERGOTE I, 1989, CANCER, V64, P1011, DOI 10.1002/1097-0142(19890901)64:5<1011::AID-CNCR2820640507>3.0.CO;2-7; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Zaino RJ, 1996, CANCER-AM CANCER SOC, V77, P1115, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1115::AID-CNCR17>3.0.CO;2-4; ZAINO RJ, 1991, CANCER-AM CANCER SOC, V68, P2293, DOI 10.1002/1097-0142(19911115)68:10<2293::AID-CNCR2820681032>3.0.CO;2-V; ZAINO RJ, 1983, GYNECOL ONCOL, V16, P196, DOI 10.1016/0090-8258(83)90094-X; 1983, JAMA-J AM MED ASSOC, V249, P1600	101	425	439	1	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					640	649		10.1056/NEJM199608293350907	http://dx.doi.org/10.1056/NEJM199608293350907			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8692240				2022-12-28	WOS:A1996VD42500007
J	Bassuk, EL; Weinreb, LF; Buckner, JC; Browne, A; Salomon, A; Bassuk, SS				Bassuk, EL; Weinreb, LF; Buckner, JC; Browne, A; Salomon, A; Bassuk, SS			The characteristics and needs of sheltered homeless and low-income housed mothers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY HOMELESSNESS; UNITED-STATES; PREVALENCE; WOMEN; LIFETIME; VIOLENCE; TRAUMA	Objective.-To compare characteristics of homeless and low-income housed mothers across economic, psychosocial, and physical health domains. Design.-Case-control study. Setting.-Community of worcester, Mass. Participants.-A cross-sectional sample of 220 sheltered homeless mothers and 216 low-income housed (never homeless) mothers receiving welfare. Main outcome Measures.-Income, housing, life events, social support, history of abuse and assault, and mental and physical health. Results.-Comparison of homeless and housed mothers revealed some important similarities and differences. The proportion of homeless mothers with annual incomes of less than $7000 was 46% vs 17% for housed mothers (P<.01). Homeless mothers experienced more residential instability than the housed mothers (3.8 moves vs 1.8 moves; P<.001) and had smaller support networks (P<.001). More homeless mothers reported severe physical and sexual assault over the lifespan than housed mothers (91.6% vs 81.1%; P<.003). No significant differences were found between the groups in mental and physical health. However, the lifetime prevalence of major depressive disorder, posttraumatic stress disorder, and substance use disorders was overrepresented compared to the general female population. Both groups had lower physical functioning compared to the general population and a higher prevalence of chronic health conditions. Conclusion.-Sheltered homeless mothers had fewer economic resources and social supports and higher cumulative rates of violent abuse and assault over their lifespans than their housed counterparts. However, both groups faced extreme adversity that compromised family well-being. Practitioners and social policymakers need to be cognizant of the multiple economic, psychosocial, and physical health needs of these mothers in providing treatment and developing program interventions.	UNIV MASSACHUSETTS, MED CTR, DEPT FAMILY & COMMUNITY MED, WORCESTER, MA USA; HARVARD UNIV, SCH MED, DEPT PSYCHIAT, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Bassuk, EL (corresponding author), BETTER HOMES FUND, 181 WELLS AVE, NEWTON, MA 02159 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051479, R01MH047312] Funding Source: NIH RePORTER; NIMH NIH HHS [MH47312, MH51479] Funding Source: Medline; PHS HHS [MCJ250809] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Barrow S, 1985, PERSONAL HIST FORM; BASSUK EL, 1986, AM J PUBLIC HEALTH, V76, P1097, DOI 10.2105/AJPH.76.9.1097; BASSUK EL, 1988, AM J PUBLIC HEALTH, V78, P783, DOI 10.2105/AJPH.78.7.783; BASSUK EL, 1991, SCI AM, V265, P66, DOI 10.1038/scientificamerican1291-66; BASSUK EL, 1995, MENTAL HLTH RACISM S, P237; BAUM AS, 1993, NATION DENIAL; Bernard J., 1982, LIVES STRESS WOMEN D, V45; BLANK RM, 1993, BROOKINGS PAPERS EC, V2, P285; BROWN R, 1992, JAMA-J AM MED ASSOC, V267, P3184; BROWNE A, 1993, AM PSYCHOL, V48, P1077, DOI 10.1037/0003-066X.48.10.1077; BROWNE A, 1993, AM J ORTHOPSYCHIAT, V63, P370, DOI 10.1037/h0079444; CHOMITZ VR, 1995, FUTURE CHILD, V5, P121, DOI 10.2307/1602511; COOK JT, 1995, ASSET DEV AM POOR TR; Davidson J. R., 1993, POSTTRAUMATIC STRESS; DEARBORN PM, 1994, INTERGOVERN PERSPECT, P20; DUNST CJ, 1987, CHILD CARE HLTH DEV, V13, P111, DOI 10.1111/j.1365-2214.1987.tb00528.x; DUNST CJ, 1988, PERSONAL ASSESSMENT; GOODMAN LA, 1991, AM J ORTHOPSYCHIAT, V61, P489, DOI 10.1037/h0079287; GOODMAN LA, 1991, J COMMUNITY PSYCHOL, V19, P321, DOI 10.1002/1520-6629(199110)19:4<321::AID-JCOP2290190404>3.0.CO;2-8; Handler Joel F., 1995, POVERTY WELFARE REFO; Herman Judith, 2001, TRAUMA RECOVERY; HOBFOLL SE, 1993, HDB STRESS THEORETIC; Jencks C., 1992, RETHINKING SOCIAL PO; Karoly LA, 1996, OXFORD REV ECON POL, V12, P76, DOI 10.1093/oxrep/12.1.76; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KNICKMAN JR, 1989, STUDY HOMELESS FAMIL, V3; LINK BG, 1994, AM J PUBLIC HEALTH, V84, P1907, DOI 10.2105/AJPH.84.12.1907; MAY R, 1995, 1993 POVERTY INCOME; MCLANAHAN S, 1986, SINGLE MOTHERS THEIR, P11; Miller B A, 1987, Violence Vict, V2, P157; MILLER BA, 1993, J STUD ALCOHOL, P109, DOI 10.15288/jsas.1993.s11.109; MOLNAR J, 1991, FARES LAND CONSEQUEN; *NAT CTR HLTH STAT, 1994, VIT STAT US SER, V10; *NAT CTR HLTH STAT, 1983, VIT STAT US SER, V1; *NAT I MENT HLTH, 1988, EP CATCHM AR STUD PU; RESNICK HS, 1993, J CONSULT CLIN PSYCH, V61, P984, DOI 10.1037/0022-006X.61.6.984; ROG DJ, 1995, AM J ORTHOPSYCHIAT, V65, P514, DOI 10.1037/h0079675; SHINN M, 1991, AM PSYCHOL, V46, P1180, DOI 10.1037/0003-066X.46.11.1180; Spitzer RL, 1990, STRUCTURED CLIN INTE; Stack C.B., 1974, ALL OUR KIN STRATEGI; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; *US BUR CENS, 1994, 1990 CENS POP; *US BUR CENS, 1995, STAT BRIEF MOTH REC; *US C MAYO, 1995, STAT REP HUNG HOM AM; WAGNER JK, 1994, PSYCHOL REP, V75, P1671, DOI 10.2466/pr0.1994.75.3f.1671; WALTER SD, 1977, AM J EPIDEMIOL, V105, P387, DOI 10.1093/oxfordjournals.aje.a112395; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 1993, SF36 HLTH SURVEY MAN; WOOD D, 1990, AM J PUBLIC HEALTH, V80, P1049, DOI 10.2105/AJPH.80.9.1049; *WORC DEP PUBL WEL, 1990, CHAR	51	249	252	0	48	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					640	646						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VC853	8773638				2022-12-28	WOS:A1996VC85300032
J	Poulter, NR; Chang, CL; Farley, TMM; Meirik, O; Marmot, MG				Poulter, NR; Chang, CL; Farley, TMM; Meirik, O; Marmot, MG			Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, multicentre, case-control study	LANCET			English	Article							CEREBROVASCULAR-DISEASE; SUBARACHNOID HEMORRHAGE; EPIDEMIOLOGY; SMOKING; AGE	Background The risk of haemorrhagic stroke associated with use of oral contraceptives (OCs) is less well-established than that for ischaemic stroke. We assessed the risk of haemorrhagic stroke associated with current use of modern OCs as now used throughout the world. Methods In this WHO collaborative, case-control study, we assessed the association between risk of haemorrhagic stroke and use of combined OCs in 1068 cases, 20-44 years, and 2910 age-matched controls. We also assessed risks for all strokes combined (haemorrhagic, ischaemic, and unclassified) based on 2198 cases and 6086 controls. Findings Overall, current use of combined OCs was associated with slightly increased risk of haemorrhagic stroke; the increase was significant in the developing countries (odds ratio 1 . 76 [95% CI 1 . 34-2 . 30]) but not in Europe (1 . 38 [0 . 84-2 . 25]). Use of OCs in women younger than 35 years did not affect risk of haemorrhagic stroke in either group of countries, whereas in women aged older than 35 years, odds ratios were greater than 2. Women who were current users of OCs and had a history of hypertension (detected before current episode of OC use, but not during pregnancy) had a substantially increased risk (ten-fold to 15-fold) of haemorrhagic stroke compared with women who did not use OCs and had no history of hypertension. Odds ratios among current OC users who were also current cigarette smokers were greater than 3. In both groups of countries, past use of OCs, dose of oestrogen, and dose and type of progestagen had no effect on risk, and risks were similar for subarachnoid and intracerebral haemorrhage. The odds ratios for any type of stroke associated with current use of low-dose (<50 mu g oestrogen) and higher-dose OCs were 1 . 41 (0 . 90-2 . 20) and 2 . 71 (1 . 70-4 . 32), respectively, in Europe and 1 . 86 (1 . 49-2 . 33) and 1 . 92 (1 . 48-2 . 50) in the developing countries. From these data we estimated that about 13% and 8% of all strokes in women aged 20-44 in Europe and the developing countries, respectively, are attributable to the use of OCs. Interpretation The risk of haemorrhagic stroke attributable to OC use is not increased in younger women and is only slightly increased in older women. The estimated excess risk of all stroke types associated with use of low-oestrogen and higher-oestrogen dose OCs in Europe was about two and eight, respectively, per 100 000 woman-years of OC use. However, findings need to be considered in the context of other risks and benefits associated with OC use, as well as those associated with the use of other forms of contraception.	WHO, UNDP UNFPA WHO WORLD BANK SPECIAL PROGRAMME RES D, CH-1211 GENEVA 27, SWITZERLAND; ESCOLA PAULISTA MED, DEPT PREVENT MED, SAO PAULO, BRAZIL; UNIV CHILE, ESCUELA SALUD PUBL, SANTIAGO, CHILE; ESCUELA MED, DEPT SALUD PUBL, VALPARAISO, CHILE; NATL RES INST FAMILY PLANNING, BEIJING, PEOPLES R CHINA; SICHUAN FAMILY PLANNING RES INST, CHENGDU, PEOPLES R CHINA; SHANGHAI INST PLANNED PARENTHOOD RES, SHANGHAI, PEOPLES R CHINA; UNIV VALLE, FAC SALUD, CALI, COLOMBIA; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; ZENTRUM EPIDEMIOL & GESUNDHEITSFORSCH, BERLIN, GERMANY; CHINESE UNIV HONG KONG, DEPT COMMUNITY MED, HONG KONG, HONG KONG; ALBERT SZENT GYORGYI MED UNIV, DEPT OBSTET & GYNAECOL, H-6701 SZEGED, HUNGARY; UNIV INDONESIA, FAC MED, JAKARTA, INDONESIA; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; KENYA GOVT MED RES CTR, NAIROBI, KENYA; GRP INTERUNIV MEXICANO INVEST EPIDEMIOL SALUD REP, DURANGO, MEXICO; UNIV LJUBLJANA, INST PUBL HLTH, LJUBLJANA, SLOVENIA; CHULALONGKORN HOSP, DEPT OBSTET & GYNAECOL, BANGKOK, THAILAND; SIRIRAJ HOSP, SIRIRAJ FAMILY HLTH RES CTR, BANGKOK, THAILAND; UNIV BELGRADE, SCH MED, BELGRADE, YUGOSLAVIA; UNIV LUSAKA, TEACHING HOSP, LUSAKA, ZAMBIA; UNIV ZIMBABWE, DEPT MED, HARARE, ZIMBABWE; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; KAISER PERMANENTE, PASADENA, CA USA; NIH, BETHESDA, MD 20892 USA; UNIV AARHUS, DANISH EPIDEMIOL SCI CTR, AARHUS, DENMARK; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND	United Nations Population Fund; World Health Organization; Universidade Federal de Sao Paulo (UNIFESP); Universidad de Chile; National Research Institute for Family Planning - China; Universidad del Valle; University of Oxford; Chinese University of Hong Kong; Szeged University; University of Indonesia; University West Indies Mona Jamaica; Kenya Medical Research Institute; University of Ljubljana; Chulalongkorn University; Mahidol University; University of Belgrade; University of Zimbabwe; University of Oxford; Kaiser Permanente; National Institutes of Health (NIH) - USA; Aarhus University; University of London; London School of Hygiene & Tropical Medicine	Poulter, NR (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; CHANG KK, 1986, INT J GYNECOL OBSTET, V24, P421, DOI 10.1016/0020-7292(86)90032-9; FISCH IR, 1974, WALNUT CREEK CONTRAC, V1, P105; FOGELHOLM R, 1973, ACTA NEUROL SCAND, V49, P415; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; INMAN WHW, 1979, BRIT MED J, V2, P1468, DOI 10.1136/bmj.2.6203.1468; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; JICK H, 1978, ANN INTERN MED, V89, P58, DOI 10.7326/0003-4819-89-1-58; KAY CR, 1981, LANCET, V1, P541; LAYDE PM, 1983, J ROY COLL GEN PRACT, V33, P75; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; METTINGER KL, 1984, STROKE, V15, P795, DOI 10.1161/01.STR.15.5.795; METTINGER KL, 1984, ACTA NEUROL SCAND, V70, P415; PETITTI DB, 1978, LANCET, V2, P234; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; PRENTICE RL, 1988, AM J EPIDEMIOL, V127, P213, DOI 10.1093/oxfordjournals.aje.a114797; RAMCHARAN S, 1981, CTR POPULATION RES M; RAMCHARAN S, 1976, WALNUT CREEK CONTRAC, V2, P1; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; Schlesselman JJ, 1982, CASE CONTROL STUDIES; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; VESSEY MP, 1990, ORAL CONTRACEPTIVES; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; WEIR RJ, 1994, TXB HYPERTENSION; 1977, LANCET, V2, P727; 1995, J CLIN EPIDEMIOL S12, V48, P1513	32	181	183	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	1996	348	9026					505	510						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757152				2022-12-28	WOS:A1996VD42700010
J	Walt, RP				Walt, RP			Metronidazole-resistant H-pylori - Of questionable clinical importance	LANCET			English	Editorial Material											Walt, RP (corresponding author), BIRMINGHAM HEARTLANDS HOSP,DEPT GASTROENTEROL,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND.							BANATVALA N, 1994, GUT, V35, P1562, DOI 10.1136/gut.35.11.1562; Ching CK, 1996, GUT, V38, P675, DOI 10.1136/gut.38.5.675; DeKoster E, 1996, GASTROENTEROLOGY, V110, pA93; Lopez-Brea M., 1995, Gut, V37, pA97; REDDY R, 1966, GASTROENTEROLOGY, V110, pA238; WALT R, 1986, LANCET, V1, P489	6	26	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					489	490		10.1016/S0140-6736(05)64665-X	http://dx.doi.org/10.1016/S0140-6736(05)64665-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757146				2022-12-28	WOS:A1996VD42700004
J	Atkins, MC; Carlin, EM; Emery, VC; Griffiths, PD; Boag, F				Atkins, MC; Carlin, EM; Emery, VC; Griffiths, PD; Boag, F			Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases	BRITISH MEDICAL JOURNAL			English	Article									ROYAL CHELSEA & WESTMINSTER HOSP,DEPT GENITOURINARY MED,LONDON SW10 9TH,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT VIROL,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Emery, Vincent/G-8928-2013	Emery, Vincent/0000-0001-5893-9756				ERON J, 1996, JAMA-J AM MED ASSOC, V275, P38; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607	5	52	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					341	342		10.1136/bmj.313.7053.341	http://dx.doi.org/10.1136/bmj.313.7053.341			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760742	Green Published			2022-12-28	WOS:A1996VC30000020
J	Jiang, J; Struhl, G				Jiang, J; Struhl, G			Complementary and mutually exclusive activities of Decapentaplegic and Wingless organize axial patterning during Drosophila leg development	CELL			English	Article							SEGMENT-POLARITY GENE; PROTEIN-KINASE-A; SIGNALING PATHWAY; IMAGINAL DISKS; LIMB DEVELOPMENT; VERTEBRATE LIMB; THICK VEINS; I RECEPTORS; WNT GENES; HEDGEHOG	Growth and patterning of the Drosophila leg are organized by three secreted proteins: Hedgehog (Hh), Wingless (Wg), and Decapentaplegic (Dpp). Hh is secreted by posterior cells; it acts at short range to induce dorsal anterior cells to secrete Dpp and ventral anterior cells to secrete Wg. Here we show that the complementary patterns of dpp and wg expression are maintained by mutual repression: Dpp signaling blocks wg transcription, whereas Wg signaling attenuates dpp transcription. We also show that this mutual repression is essential for normal axial patterning because it ensures that the dorsalizing and ventralizing activities of Dpp and Wg are restricted to opposite sides of the leg primordium and meet only at the center of the primordium to distalize the appendage.			Jiang, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT GENET & DEV,NEW YORK,NY 10032, USA.							BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL G, 1995, DEVELOPMENT, V121, P619; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHOU TB, 1992, GENETICS, V131, P643; COHEN B, 1993, DEVELOPMENT, V117, P597; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GUILLEN I, 1995, DEVELOPMENT, V121, P3447; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; ROELINK H, 1995, CURR OPIN NEUROBIOL, V6, P33; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THEISEN H, 1994, DEVELOPMENT, V120, P347; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; XU T, 1993, DEVELOPMENT, V117, P1223; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	60	152	153	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					401	409		10.1016/S0092-8674(00)80113-0	http://dx.doi.org/10.1016/S0092-8674(00)80113-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756722	hybrid			2022-12-28	WOS:A1996VC30900008
J	Galaktionov, K; Chen, XC; Beach, D				Galaktionov, K; Chen, XC; Beach, D			Cdc25 cell-cycle phosphatase as a target of c-myc	NATURE			English	Article							DNA-BINDING; ORNITHINE DECARBOXYLASE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; MAX; PROTEIN; TRANSFORMATION; ACTIVATION; EXPRESSION; ONCOGENES	The product of the proto-oncogene c-myc, in partnership with Max, forms a transcription factor that can promote either oncogenic transformation or apoptosis. The Myc/Max heterodimer binds to elements in the cdc25A gene and activates transcription. Like myc, cdc25A, itself a proto-oncogene, can induce apoptosis in cells depleted of growth factor, and Myc-induced apoptosis also requires cdc25A. These findings indicate that cdc25A is a physiologically relevant transcriptional target of c-myc.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute								ALBRECHT M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOMKAMM GW, 1987, ADV VIRAL ONCOL, V7, P173; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, REV BIOCH, V61, P809; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WATERS CM, 1991, ONCOGENE, V6, P797	50	640	666	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1996	382	6591					511	517		10.1038/382511a0	http://dx.doi.org/10.1038/382511a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700224				2022-12-28	WOS:A1996VB25800041
J	Inaba, T; Inukai, T; Yoshihara, T; Seyschab, H; Ashmun, RA; Canman, CE; Laken, SJ; Kastan, MB; Look, AT				Inaba, T; Inukai, T; Yoshihara, T; Seyschab, H; Ashmun, RA; Canman, CE; Laken, SJ; Kastan, MB; Look, AT			Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor	NATURE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; PROGRAMMED CELL-DEATH; DNA-BINDING; E2A GENE; BCL-2; SURVIVAL; ELEGANS; PROTEIN; FUSION; HLF	THE E2A-HLF (for hepatic leukaemia factor) fusion gene, formed by action of the t(17;19) (q22;p13) chromosomal translocation, drives the leukaemic transformation of early B-cell precursors(1-4), but the mechanism of this activity remains unknown. Here we report that human leukaemia cells carrying the translocation t(17;19) rapidly died by apoptosis when programmed to express a dominant-negative suppressor of the fusion protein E2A-HLF, indicating that the chimaeric oncoprotein probably affects cell survival rather than cell growth. Moreover, when introduced into murine pro-B lymphocytes, the oncogenic E2A-HLF fusion protein reversed both interleukin-3-dependent and p53-mediated apoptosis. The close homology of the basic region/leucine zipper (bZIP) DNA-binding and dimerization domain of HLF to that of the CES-2 cell death specification protein of Caenorhabditis elegans(5) suggests a model of leukaemogenesis in which E2A-HLF blocks an early step within an evolutionarily conserved cell-death pathway(6-9).	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21287 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Johns Hopkins Medicine				, Christine/0000-0001-8892-7430				ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; KORSMEYER SJ, 1992, BLOOD, V80, P879; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	26	115	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					541	544		10.1038/382541a0	http://dx.doi.org/10.1038/382541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700228				2022-12-28	WOS:A1996VB25800051
J	Rosenberg, J; Overgaard, H; Andersen, M; Rasmussen, V; Schulze, S				Rosenberg, J; Overgaard, H; Andersen, M; Rasmussen, V; Schulze, S			Double blind randomised controlled trial of effect of metoprolol on myocardial ischaemia during endoscopic cholangiopancreatography	BRITISH MEDICAL JOURNAL			English	Article							UPPER-GASTROINTESTINAL ENDOSCOPY; SUPPLEMENTAL OXYGEN; BETA-BLOCKADE; HYPOXEMIA; ISCHEMIA; SEDATION; ANXIETY	Objective-To evaluate the effect of metoprolol, a beta adrenergic blocking drug, on the occurrence of myocardial ischaemia during endoscopic cholangiopancreatography. Design-Double blind, randomised, controlled trial. Setting-University Hospital. Subjects-38 (two groups of 19) patients scheduled for endoscopic cholangiopancreatography. Interventions-Metoprolol 100 mg or placebo as premedication two hours before endoscopy. Main outcome measures-Heart rate, arterial oxygen saturation by continuous pulse oximetry, ST segment changes during endoscopic cholangiopancreatography (an ST segment deviation >1 mV was defined as myocardial ischaemia), electrocardiogram monitored continuously with a Holter tape recorder. Results-All patients had increased heart rate during endoscopy compared with rate before endoscopy, but heart rate during endoscopy was significantly lower in the metoprolol group compared with the placebo group (P = 0.0002). Twenty one patients (16 placebo, 5 metoprolol; P = 0.0008) developed tachycardia (heart rate > 100/min) during the procedure, and 11 patients (10 placebo, 1 metoprolol; P = 0.003) developed myocardial ischaemia. One patient in the placebo group had an acute inferolateral myocardial infarction. In the 10 other patients with signs of myocardial ischaemia during endoscopy the ST deviation disappeared when the endoscope was retracted. In all patients myocardial ischaemia was related to increases in heart rate, and 10 of the 11 patients had tachycardia coherent with myocardial ischaemia. Conclusions-Metoprolol prevented myocardial ischaemia during endoscopic cholangiopancreatography, probably through lowering the heart rate. Thus, tachycardia seems to be a key pathogenic factor in the development of myocardial ischaemia during endoscopy.	SUNDBY HOSP,DEPT SURG,DK-2300 COPENHAGEN S,DENMARK; HVIDOVRE UNIV HOSP,DEPT CARDIOL,HOLTER LAB,DK-2650 HVIDOVRE,DENMARK	University of Copenhagen								BELL GD, 1987, LANCET, V1, P1022; BELL GD, 1991, GUT, V32, P823, DOI 10.1136/gut.32.7.823; BOWLING TE, 1993, GUT, V34, P1492, DOI 10.1136/gut.34.11.1492; FUJITA R, 1974, AM J GASTROENTEROL, V64, P44; GRIFFIN SM, 1990, BRIT MED J, V300, P83, DOI 10.1136/bmj.300.6717.83; GROSS JB, 1990, GASTROINTEST ENDOSC, V36, P26, DOI 10.1016/S0016-5107(90)70917-0; HAINES DJ, 1992, GUT, V33, P973, DOI 10.1136/gut.33.7.973; HOLM C, IN PRESS ENDOSCOPY; JAKOBSEN CJ, 1992, EUR J ANAESTH, V9, P209; JAKOBSEN CJ, 1989, ANAESTHESIA, V44, P249, DOI 10.1111/j.1365-2044.1989.tb11236.x; JAKOBSEN CJ, 1990, ANAESTHESIA, V45, P40, DOI 10.1111/j.1365-2044.1990.tb14502.x; JURELL KR, 1994, GASTROINTEST ENDOSC, V40, P665, DOI 10.1016/S0016-5107(94)70106-7; MACKENZIE JW, 1989, BRIT MED J, V298, P363, DOI 10.1136/bmj.298.6670.363; MURRAY AW, 1991, ANAESTHESIA, V46, P181, DOI 10.1111/j.1365-2044.1991.tb09404.x; PASTERNACK PF, 1989, AM J SURG, V158, P113, DOI 10.1016/0002-9610(89)90357-7; REED MWR, 1993, SCAND J GASTROENTERO, V28, P319, DOI 10.3109/00365529309090249; ROSENBERG J, 1990, BRIT J ANAESTH, V65, P684, DOI 10.1093/bja/65.5.684; Rosenberg J, 1996, SCAND J GASTROENTERO, V31, P200, DOI 10.3109/00365529609031986; ROSENBERG J, 1992, SCAND J GASTROENTERO, V27, P717, DOI 10.3109/00365529209000147; ROSENBERG J, 1995, DAN MED BULL, V42, P40; WESSLEN O, 1992, J THORAC CARDIOV SUR, V104, P1672; 1991, GASTROINTEST ENDOSC, V37, P120; 1985, LANCET, V2, P193	23	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					258	261		10.1136/bmj.313.7052.258	http://dx.doi.org/10.1136/bmj.313.7052.258			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704533	Green Published			2022-12-28	WOS:A1996VA90300021
J	Wanklyn, P				Wanklyn, P			Caring for older people - Homes and housing for elderly people	BRITISH MEDICAL JOURNAL			English	Article								Most elderly people in Britain live independently in their own homes. Moving to alternative accommodation may be necessary for some people but requires careful consideration. A multidisciplinary assessment should be performed when a person plans to move into residential care; this should include the input of a doctor trained in geriatric medicine. A range of housing options is open to elderly people and these options are discussed here.			Wanklyn, P (corresponding author), LEEDS GEN INFIRM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.							*BRIT GER SOC, 1990, POL STAT 4 PRIV VOL; DAVIES K, 1991, MORE EVERYDAY AIDS A, P39; *DEP ENV, 1993, ENGL HOUS COND SURV; 1993, CARE ELDERLY PEOPLE	4	11	11	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					218	221		10.1136/bmj.313.7051.218	http://dx.doi.org/10.1136/bmj.313.7051.218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696202	Green Published			2022-12-28	WOS:A1996VA12600032
J	Wessely, S				Wessely, S			The rise of counselling and the return of alienism	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRIMARY CARE	Current services for those with mental disorders show two trends. Psychiatric services are becoming concentrated on the care of those with ''severe mental illness,'' largely (but unjustifiably) synonymous with chronic psychosis. The retreat of psychiatry from the care of those with nonpsychotic mental disorders has helped the growth of counselling services for these patients. However, there is no evidence that non-directive counselling is effective for such disorders, in contrast to the evidence for the effectiveness of other treatments that are usually delivered by psychologists or community psychiatric nurses. By retreating from the concerns of general practice and general medicine, psychiatry is returning to the days of alienism: in Victorian terms, the care of ''the mad.'' Possible consequences include increasing expectations of psychiatric services that cannot be met, a loss of skills within psychiatry, and increased demoralisation in the mental health services.	INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	Wessely, S (corresponding author), UNIV LONDON KINGS COLL,SCH MED,DEPT PSYCHOL MED,LONDON WC2R 2LS,ENGLAND.		Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929				AITKENHEAD D, 1995, INDEPENDENT SUN 1210, P5; BOOT D, 1994, PATIENT EDUC COUNS, V24, P79, DOI 10.1016/0738-3991(94)90028-0; British Association for Counselling, 1993, COD ETH PRACT COUNS; BURTON MV, 1995, J ROY SOC MED, V88, P97; CORNEY R, 1994, J ROY SOC MED, V87, P408; Corney Roslyn, 1992, International Review of Psychiatry, V4, P331, DOI 10.3109/09540269209066337; *DEP HLTH, 1995, KEY AR HDB MENT ILLN, P99; DRYDEN W, 1995, ISSUES PROFESSIONAL; Eastman N, 1996, INQUIRIES HOMICIDE, P147; Fallowfield L., 1992, PSYCHOL HEALTH, V6, P107; FINK P, 1992, PSYCHOL MED, V22, P173, DOI 10.1017/S0033291700032827; FLETCHER J, 1995, BRIT J GEN PRACT, V45, P467; GARFIELD SL, IN PRESS CLIN PSYCHO; HOLDEN J, 1989, BRIT MED J, V298, P222; KING M, 1994, BRIT J GEN PRACT, V44, P229; KING M, 1994, PSYCHIAT B, V18, P65; Lelliot P., 1995, PSYCHIAT B, V19, P273; MARI JJ, 1995, SCHIZOPHRENIA MODULE; MARKS IM, 1987, FEARS PHOBIAS; ONYETT S, 1995, MAKING COMMUNITY CAR; PHAROAH P, 1995, J PRIM CARE PSYCHIAT, V1, P263; PRINGLE M, 1995, BRIT MED J, V311, P1382, DOI 10.1136/bmj.311.7017.1382; PRINGLE M, 1993, BRIT MED J, V306, P2, DOI 10.1136/bmj.306.6869.2; *ROYAL COLL PHYS R, 1995, PSYCH CAR MED PAT RE; SCOTT AIF, 1992, BRIT MED J, V304, P883, DOI 10.1136/bmj.304.6831.883; Shah Ajit, 1992, International Review of Psychiatry, V4, P243, DOI 10.3109/09540269209066324; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; Sibbald B, 1996, BRIT J GEN PRACT, V46, P63; SIBBALD B, 1993, BMJ-BRIT MED J, V306, P29, DOI 10.1136/bmj.306.6869.29; STRATHDEE G, 1984, J ROY COLL GEN PRACT, V34, P615; *U LEEDS, 1993, EFF HLTH CAR; WEISZ JR, 1995, J CONSULT CLIN PSYCH, V63, P688, DOI 10.1037/0022-006X.63.5.688; WESSELY S, 1994, PSYCHOL MED, V24, P483, DOI 10.1017/S0033291700027458	33	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					158	160		10.1136/bmj.313.7050.158	http://dx.doi.org/10.1136/bmj.313.7050.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UY921	8688780	Green Published			2022-12-28	WOS:A1996UY92100028
J	Campbell, S; McLaren, EH; Danesh, BJ				Campbell, S; McLaren, EH; Danesh, BJ			Rapidly reversible increase in insulin requirement with interferon	BRITISH MEDICAL JOURNAL			English	Letter											Campbell, S (corresponding author), STOBHILL NHS TRUST,DEPT MED,GLASGOW G21 3UW,LANARK,SCOTLAND.							FABRIS P, 1992, LANCET, V340, P548, DOI 10.1016/0140-6736(92)91744-S; KOIVISTO VA, 1989, DIABETES, V38, P641, DOI 10.2337/diabetes.38.5.641; LOPES EPA, 1994, LANCET, V343, P224	3	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					92	92		10.1136/bmj.313.7049.92a	http://dx.doi.org/10.1136/bmj.313.7049.92a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688762	Green Published			2022-12-28	WOS:A1996UX69800025
J	Hindmarsh, PC; Brook, CGD				Hindmarsh, PC; Brook, CGD			Final height of short normal children treated with growth hormone	LANCET			English	Article							DEFICIENCY; SECRETION; THERAPY; GH	Background. Short-term studies have demonstrated acceleration of growth rate following administration of biosynthetic human growth hormone (r-hGH) to short normal children. We describe the effect of such treatment on final height. Methods This was an open study of consecutive referrals to a growth disorder clinic from which 16 short children (height standard deviation score [SDS] -2.17 [range -1.8 to -3.3]; height velocity SDS -0.44 [0.33]; peak serum GH response to stimulation 27.9 mU/L [9.2] were treated with r-hGH, and 7 short children who declined treatment (height SDS -2.34 [0.61]; height velocity SDS -0.36 [0.28]; peak serum GH response 28.2 mU/L [6.8]) acted as an observation group. Subcutaneous r-hGH dose ranged between 12.2 and 21.0 U/m(2) per week (0.02-0.04 mg/kg per day) for the first 2 years of treatment and 20 U/m(2) per week thereafter. 3 untreated children were lost to long-term follow-up. Findings r-hGH significantly increased the difference in final height compared with pretreatment predicted height (+0.42 SDS [0.79], p=0.03) but this change was not significantly greater than that of the observation group (+0.16 SDS [0.20]). Treatment had no effect on the timing of puberty. Boys progressed slightly faster through puberty, associated with an acceleration in bone-age maturation. No untoward effects on glucose metabolism were observed. Long-term therapy did not alter body-fat distribution or blood pressure. Interpretation Long-term therapy in this group of children appears safe but the small increment in final height, approximately 2.8 cm in boys and 2.5 cm in girls, does not justify the widespread use of r-hGH for short normal children.	MIDDLESEX HOSP, LONDON CTR PAEDIAT ENDOCRINOL & METAB, LONDON W1N 8AA, ENGLAND	University of London; University College London			Hindmarsh, P C/C-4964-2008					[Anonymous], 1987, PEDIATRICS, V79, P1; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BERCU BB, 1986, J CLIN ENDOCR METAB, V63, P709, DOI 10.1210/jcem-63-3-709; BUNDAK R, 1988, J PEDIATR-US, V112, P875, DOI 10.1016/S0022-3476(88)80207-5; HINDMARSH P, 1987, CLIN ENDOCRINOL, V27, P581, DOI 10.1111/j.1365-2265.1987.tb01188.x; HINDMARSH PC, 1987, BRIT MED J, V295, P573, DOI 10.1136/bmj.295.6598.573; JOB JC, 1994, HORM RES, V41, P177, DOI 10.1159/000183889; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; LOCHE S, 1994, J PEDIATR-US, V125, P196, DOI 10.1016/S0022-3476(94)70192-X; Marshall WQ, 1978, HUMAN GROWTH, P141; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; SKUSE D, 1994, ACTA PAEDIATR, V83, P11, DOI 10.1111/j.1651-2227.1994.tb13413.x; TANNER JM, 1971, ARCH DIS CHILD, V46, P745, DOI 10.1136/adc.46.250.745; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; Tanner JM., 1983, ASSESSMENT SKELETAL; VOSS LD, 1994, GROWTH STATURE ADAPT, P47; ZADIK Z, 1992, HORM RES, V37, P150, DOI 10.1159/000182300; ZADIK Z, 1992, J PEDIATR-US, V121, P44, DOI 10.1016/S0022-3476(05)82539-9	18	88	91	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1996	348	9019					13	16		10.1016/S0140-6736(96)01038-0	http://dx.doi.org/10.1016/S0140-6736(96)01038-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691923				2022-12-28	WOS:A1996UV92300009
J	Okada, F				Okada, F			Kampo medicine, a source of drugs waiting to be exploited	LANCET			English	Editorial Material											Okada, F (corresponding author), OKAJIMA NEUROPSYCHIAT CLIN,HIGASHI KU,SAPPORO,HOKKAIDO 065,JAPAN.							BABA S, 1995, CLIN OTOLARYNGOL, V88, P389; HIRAYAMA C, 1989, Gastroenterologia Japonica, V24, P715; HIZAWA N, 1994, INTERNAL MED, V33, P337, DOI 10.2169/internalmedicine.33.337; *JAP MIN HLTH WELF, 1992, STAT PROD PHARM IND; *JAP MIN HLTH WELF, 1992, 15 JAP MIN HLTH WELF; KIMURA I, 1993, ANN NY ACAD SCI, V685, P529, DOI 10.1111/j.1749-6632.1993.tb35916.x; Miyoshi A, 1994, GASTROENTEROLOGY, V18, P299; WOMIOKA H, 1992, SAISHIN IGAKU, V47, P1342; 1991, NIHON KEIZAI SH 1214	9	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					5	6		10.1016/S0140-6736(05)64351-6	http://dx.doi.org/10.1016/S0140-6736(05)64351-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691936				2022-12-28	WOS:A1996UV92300006
J	Muchmore, SW; Sattler, M; Liang, H; Meadows, RP; Harlan, JE; Yoon, HS; Nettesheim, D; Chang, BS; Thompson, CB; Wong, SL; Ng, SC; Fesik, SW				Muchmore, SW; Sattler, M; Liang, H; Meadows, RP; Harlan, JE; Yoon, HS; Nettesheim, D; Chang, BS; Thompson, CB; Wong, SL; Ng, SC; Fesik, SW			X-ray and NMR structure of human Bcl-x(L), an inhibitor of programmed cell death	NATURE			English	Article							DIPHTHERIA-TOXIN; ASSIGNMENTS; MODELS	THE Bcl-2 family of proteins regulate programmed cell death by an unknown mechanism(1). Here we describe the crystal and solution structures of a Bcl-2 family member, Bcl-x(L) (ref. 2). The structures consist of two central, primarily hydrophobic alpha-helices, which are surrounded by amphipathic helices. A 60-residue loop connecting helices alpha 1 and alpha 2 was found to be flexible and non-essential for anti-apoptotic activity. The three functionally important Bcl-2 homology regions (BH1, BH2 and BH3)(3-5) are in close spatial proximity and form an elongated hydrophobic cleft that may represent the binding site for other Bcl-2 family members. The arrangement of the alpha-helices in Bcl-x(L) is reminiscent of the membrane translocation domain of bacterial toxins, in particular diphtheria toxin and the colicins(6). The structural similarity may provide a clue to the mechanism of action of the Bcl-2 family of proteins.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,PROT CRYSTALLOG,ABBOTT PK,IL 60064; ABBOTT LABS,DIV PHARMACEUT DISCOVERY,NMR RES,ABBOTT PK,IL 60064; ABBOTT LABS,DIV PHARMACEUT DISCOVERY,RES COMP & INFORMAT SCI,ABBOTT PK,IL 60064; ABBOTT LABS,DIV PHARMACEUT DISCOVERY,AGING & DEGENERAT DIS RES,ABBOTT PK,IL 60064; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,CHICAGO,IL 60637	Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Muchmore, SW (corresponding author), ABBOTT LABS,PROT CRYSTALLOG,ABBOTT PK,IL 60064, USA.		Yoon, Ho Sup/A-2193-2011; Sattler, Michael/C-1169-2010; Sattler, Michael/A-2407-2012	Yoon, Ho Sup/0000-0002-8243-3904; Sattler, Michael/0000-0002-1594-0527				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bomer C, 1994, J CELL BIOL, V126, P1059; BOYD JM, 1995, ONCOGENE, V11, P1921; BRUNGER AT, 1992, X PLOR 3 1; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; FANG W, 1994, J IMMUNOL, V153, P4388; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOGAN TM, 1992, FEBS LETT, V314, P413, DOI 10.1016/0014-5793(92)81517-P; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; *SERC DAR LAB, 1979, CCP4 SUIT PROGR PROT; VUISTER GW, 1994, J AM CHEM SOC, V116, P9206, DOI 10.1021/ja00099a041; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	30	1251	1341	1	100	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					335	341		10.1038/381335a0	http://dx.doi.org/10.1038/381335a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692274	Green Accepted			2022-12-28	WOS:A1996UM40300060
J	Best, S; LeTissier, P; Towers, G; Stoye, JP				Best, S; LeTissier, P; Towers, G; Stoye, JP			Positional cloning of the mouse retrovirus restriction gene Fv1	NATURE			English	Article							MURINE LEUKEMIA VIRUSES; LOCUS AFFECTING RESISTANCE; HOST-RANGE; WILD MOUSE; MOLECULAR CLONES; CELL-CULTURES; HUMAN DNA; FV-1; YEAST; INVITRO	VERTEBRATE evolution has taken place against a background of constant retrovirus infection, and much of the mammalian genome consists of endogenous retrovirus-like elements(1). Several host genes have evolved to control retrovirus replication(3), including Friend-virus-susceptibility-1, Fv1, on mouse chromosome 4 (refs 3, 4). The Fv1 gene acts on murine leukaemia virus at a stage after entry into the target cell but before integration and formation of the provirus(5). Although restriction is not absolute, Fv1 prevents or delays spontaneous or experimentally induced viral tumours(2), In vitro, Fv1 restriction leads to an apparent 50-1,000 fold reduction in viral titre(6). Genetic evidence implicates a direct interaction between the Fv1 gene product and a component of the viral preintegration complex, the capsid protein CA (refs 7-9), We have now cloned Fv1: the gene appears to be derived from the gag region of an endogenous retrovirus unrelated to murine leukaemia virus, implying that the Fv1 protein and its target mag share functional similarities despite the absence of nucleotide-sequence homology.	NATL INST MED RES, DIV VIROL, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research			Best, Steve/A-7531-2012; Towers, Greg J/H-8892-2012; Le Tissier, Paul/G-3079-2011	Towers, Gregory/0000-0002-7707-0264; Le Tissier, Paul/0000-0002-7220-5705; Stoye, Jonathan/0000-0003-3377-323X	Medical Research Council [MC_U117570590] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BOONE LR, 1983, J VIROL, V48, P110, DOI 10.1128/JVI.48.1.110-119.1983; BOONE LR, 1989, J VIROL, V63, P2592, DOI 10.1128/JVI.63.6.2592-2597.1989; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CORDONNIER A, 1995, J VIROL, V69, P5890, DOI 10.1128/JVI.69.9.5890-5897.1995; DURANTROISE G, 1981, VIROLOGY, V112, P795, DOI 10.1016/0042-6822(81)90329-9; FRANKEL WN, 1989, J VIROL, V63, P1763, DOI 10.1128/JVI.63.4.1763-1774.1989; GARDNER MB, 1991, TRENDS GENET, V7, P22, DOI 10.1016/0168-9525(91)90017-K; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GUIGO R, 1992, J MOL BIOL, V226, P141, DOI 10.1016/0022-2836(92)90130-C; HARTLEY JW, 1970, J VIROL, V5, P221, DOI 10.1128/JVI.5.2.221-225.1970; HOLLAND CA, 1985, J VIROL, V53, P152, DOI 10.1128/JVI.53.1.152-157.1985; Jolicoeur P, 1979, Curr Top Microbiol Immunol, V86, P67; KOZAK CA, 1987, J VIROL, V61, P3082, DOI 10.1128/JVI.61.10.3082-3088.1987; KOZAK CA, 1985, J VIROL, V55, P281, DOI 10.1128/JVI.55.2.281-285.1985; LANDER MR, 1984, J VIROL, V52, P695, DOI 10.1128/JVI.52.2.695-698.1984; LILLY F, 1970, J NATL CANCER I, V45, P163; Morgan BA, 1996, P NATL ACAD SCI USA, V93, P2801, DOI 10.1073/pnas.93.7.2801; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PINCUS T, 1975, VIROLOGY, V65, P333, DOI 10.1016/0042-6822(75)90039-2; PRYCIAK PM, 1992, J VIROL, V66, P5959, DOI 10.1128/JVI.66.10.5959-5966.1992; REIN A, 1982, VIROLOGY, V120, P251, DOI 10.1016/0042-6822(82)90024-1; ROMMELAERE J, 1979, CELL, V16, P43, DOI 10.1016/0092-8674(79)90186-7; ROWE WP, 1973, J EXP MED, V137, P850, DOI 10.1084/jem.137.3.850; SRIVASTAVA AK, 1991, GENE, V103, P53, DOI 10.1016/0378-1119(91)90390-W; STEEVES R, 1977, ANNU REV GENET, V11, P277, DOI 10.1146/annurev.ge.11.120177.001425; STOYE JP, 1995, MAMM GENOME, V6, P31, DOI 10.1007/BF00350890	30	377	382	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1996	382	6594					826	829		10.1038/382826a0	http://dx.doi.org/10.1038/382826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752279				2022-12-28	WOS:A1996VE34700052
J	Feldman, HI; Kinosian, M; Bilker, WB; Simmons, C; Holmes, JH; Pauly, MV; Escarce, JJ				Feldman, HI; Kinosian, M; Bilker, WB; Simmons, C; Holmes, JH; Pauly, MV; Escarce, JJ			Effect of dialyzer reuse on survival of patients treated with hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY; MORBIDITY; DIALYSIS	Objective-To evaluate the impact of dialyzer reuse on the survival of US hemodialysis patients. Study Design and Participants.-Nonconcurrent cohort study of 27938 patients beginning hemodialysis in the United Stales in 1986 and 1987. Main Outcome Measure.-Patient survival. Results-Dialysis in freestanding facilities reprocessing dialyzers with the combination of peracetic and acetic acids was associated with greater mortality than treatment in facilities not reprocessing dialyzers (rate ratio [RR], 1.10, 95% confidence interval [CI], 1.02-1.18; P=.02) In contrast, there was no significant difference between survival in freestanding facilities reprocessing dialyzers with either formaldehyde (RR, 1.03, 95% CI, 0.96-1.10; P=.45) or glutaraldehyde (RR, 1.13, 95% CI, 0.95-1.35; P=.18) and survival in freestanding facilities not reprocessing dialyzers. Among freestanding facilities reprocessing dialyzers, use of peracetic/acetic acid was associated with a higher rate of death than use of formaldehyde (RR=1.08, 95% CI, 1.01-1.14, P=.02). There was no statistical difference between survival in hospital-based facilities reprocessing dialyzers with either peracetic/acetic acid (RR=0.95, 95% CI, 0.85-1.06; P=.40), formaldehyde (RR=1.06, 95% CI, 0.98-1.15; P=.12), or glutaraldehyde (RR=1.09, 95% CI, 0.71-1.67; P=.70) and survival in hospital-based facilities not reprocessing dialyzers. In addition, choice of sterilant was not associated with a statistically significant difference in survival among hospital-based facilities reprocessing dialyzers. Conclusions.-Dialysis in freestanding facilities reprocessing dialyzers with peracetic/acetic acid may be associated with worse survival than dialysis in freestanding facilities not reprocessing dialyzers or in those reprocessing with formaldehyde. We were unable to determine whether these relationships arose from greater comorbidity among patients treated in facilities using peracetic/acetic acid, poor quality of dialysis procedures in these facilities, or direct toxicity of peracetic/acetic acid. These findings raise important concerns about potentially avoidable mortality among US hemodialysis patients treated in dialysis facilities reprocessing hemodialyzers.	UNIV PENN,MED CTR,CTR CLIN EPIDEMIOL & BIOSTAT,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MED,RENAL ELECTROLYTE & HYPERTENS DIV,PHILADELPHIA,PA 19104; UNIV PENN,WHARTON SCH,DEPT HLTH CARE SYST,PHILADELPHIA,PA 19104; UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Feldman, HI (corresponding author), UNIV PENN,MED CTR,DEPT BIOSTAT & EPIDEMIOL,423 SERV DR,720 BLOCKLEY HALL,PHILADELPHIA,PA 19104, USA.		Bilker, Warren/AAS-3515-2021		NIDDK NIH HHS [DK-97006, DK-45191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COX DR, 1972, J R STAT SOC B, V34, P187; DOR A, 1992, MED CARE, V30, P879, DOI 10.1097/00005650-199210000-00001; EFRON B, 1992, MONOGRAPH SOC IND AP, V38; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HAKIM RM, 1980, T AM SOC ART INT ORG, V26, P159; HELD PJ, 1994, AM J KIDNEY DIS, V23, P692, DOI 10.1016/S0272-6386(12)70280-9; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELD PJ, 1992, OP M FOOD DRUG ADM O; *HLTH CAR FIN ADM, 1989, HCFA PUBL; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEE ET, 1980, STAT MODELS SURVIVAL, P250; POLLAK VE, 1986, NEPHRON, V42, P217, DOI 10.1159/000183670; Rettig RA, 1991, KIDNEY FAILURE FEDER; SHUSTERMAN NH, 1989, AM J KIDNEY DIS, V14, P81, DOI 10.1016/S0272-6386(89)80181-7; THOMSEN BL, 1992, STAT MED, V11, P1528; THOMSEN BL, 1991, STAT MED, V10, P733, DOI 10.1002/sim.4780100508; TOKARAS JI, 1992, NATL SURVEILLANCE DI; Tokars J I, 1993, ASAIO J, V39, P71, DOI 10.1097/00002480-199301000-00016; WING AJ, 1978, BRIT MED J, V2, P853, DOI 10.1136/bmj.2.6141.853	19	81	83	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					620	625		10.1001/jama.276.8.620	http://dx.doi.org/10.1001/jama.276.8.620			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC853	8773634				2022-12-28	WOS:A1996VC85300028
J	Maly, P; Thall, AD; Petryniak, B; Rogers, GE; Smith, PL; Marks, RM; Kelly, RJ; Gersten, KM; Cheng, GY; Saunders, TL; Camper, SA; Camphausen, RT; Sullivan, FX; Isogai, Y; Hindsgaul, O; vonAndrian, UH; Lowe, JB				Maly, P; Thall, AD; Petryniak, B; Rogers, GE; Smith, PL; Marks, RM; Kelly, RJ; Gersten, KM; Cheng, GY; Saunders, TL; Camper, SA; Camphausen, RT; Sullivan, FX; Isogai, Y; Hindsgaul, O; vonAndrian, UH; Lowe, JB			The alpha(1,3)Fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis	CELL			English	Article							SIALYL-LEWIS-X; ELAM-1-DEPENDENT CELL-ADHESION; ENDOTHELIAL-DERIVED LIGAND; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; MONOCLONAL-ANTIBODY; MESENTERIC VENULES; EXPRESSION CLONING; MOLECULAR-CLONING; DEFICIENT MICE; MOUSE	alpha(1,3)Fucosylated oligosaccharides represent components of leukocyte counterreceptors for E- and P-selectins and of L-selectin ligands expressed by lymph node high endothelial venules (HEV). The identity of the alpha(1,3)fucosyltransferase(s) required for their expression has been uncertain, as has a requirement for alpha(1,3)fucosylation in HEV L-selectin ligand activity. We demonstrate here that mice deficient in alpha(1,3)fucosyltransferase Fuc-TVII exhibit a leukocyte adhesion deficiency characterized by absent leukocyte E- and P-selectin ligand activity and deficient HEV L-selectin ligand activity. Selectin ligand deficiency is distinguished by blood leukocytosis, impaired leukocyte extravasation in inflammation, and faulty lymphocyte homing. These observations demonstrate an essential role for Fuc-TVII in E-, P-, and L-selectin ligand biosynthesis and imply that this locus can control leukocyte trafficking in health and disease.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; GENET INST INC,CAMBRIDGE,MA 02140; LA JOLLA CANC RES CTR,BURNHAM INST,LA JOLLA,CA 92119	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Sanford Burnham Prebys Medical Discovery Institute	Maly, P (corresponding author), UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109, USA.		von Andrian, Ulrich H/A-5775-2008; Malý, Petr/H-5962-2014	Malý, Petr/0000-0001-8118-0581; Camper, Sally/0000-0001-8556-3379; Saunders, Thom/0000-0003-2015-101X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47455] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIGNER S, 1995, INT IMMUNOL, V7, P1557, DOI 10.1093/intimm/7.10.1557; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BARRESI F, 1995, J CARBOHYD CHEM, V14, P1043, DOI 10.1080/07328309508005396; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HART PH, 1986, INFECT IMMUN, V51, P936, DOI 10.1128/IAI.51.3.936-941.1986; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HESTDAL K, 1991, J IMMUNOL, V147, P22; ITO K, 1994, GLYCOCONJUGATE J, V11, P232, DOI 10.1007/BF00731223; JOHNSONTIDEY RR, 1994, AM J PATHOL, V144, P952; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; LEY K, 1991, BLOOD, V77, P2553; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOWE JB, 1996, IN PRESS SELECTINS I; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; OBESO J, 1990, LAB INVEST, V63, P259; PALCIC MM, 1994, METHOD ENZYMOL, V247, P215; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PEMBERTON M, 1993, J IMMUNOL, V150, P5104; Phillips ML, 1995, J CLIN INVEST, V96, P2898, DOI 10.1172/JCI118361; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; PRIES AR, 1988, INT J MICROCIRC, V7, P327; ROSEN SD, 1989, J IMMUNOL, V142, P1985; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WATT SM, 1980, J HISTOCHEM CYTOCHEM, V28, P934, DOI 10.1177/28.9.7410816; WELLER A, 1992, J BIOL CHEM, V267, P15176; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176	54	640	660	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					643	653		10.1016/S0092-8674(00)80137-3	http://dx.doi.org/10.1016/S0092-8674(00)80137-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752218	Bronze			2022-12-28	WOS:A1996VE23500014
J	Halevy, A; Brody, BA				Halevy, A; Brody, BA			A multi-institution collaborative policy on medical futility	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RESUSCITATION		BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CTR MED ETH & HLTH POLICY, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine								[Anonymous], 1990, CRIT CARE MED, V18, P1435; BRODY BA, 1995, J MED PHILOS, V20, P123, DOI 10.1093/jmp/20.2.123; DAAR JF, 1995, AM J LAW MED, V21, P221; Gewirtz P, 1996, YALE LAW J, V105, P1023, DOI 10.2307/797245; Grant Edward R, 1992, Law Med Health Care, V20, P330; Halevy A, 1996, ARCH INTERN MED, V156, P100, DOI 10.1001/archinte.156.1.100; *HAST CTR, 1987, GUID TERM LIF SUST T; JECKER NS, 1992, AM J MED, V92, P189, DOI 10.1016/0002-9343(92)90111-N; LANKEN PN, 1991, AM REV RESPIR DIS, V144, P726, DOI 10.1164/ajrccm/144.3_Pt_1.726; Murphy D J, 1994, New Horiz, V2, P326; Sachdeva RC, 1996, J PEDIATR-US, V128, P742, DOI 10.1016/S0022-3476(96)70323-2; Sadler J Z, 1993, HEC Forum, V5, P35, DOI 10.1007/BF01454916; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TOMLINSON T, 1995, HASTINGS CENT REP, V25, P28, DOI 10.2307/3562112; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; WAISEL DB, 1995, ANN INTERN MED, V122, P304, DOI 10.7326/0003-4819-122-4-199502150-00011; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1993, MED ETHICS ADVISO S, P9; 1992, ANN INTERN MED, V117, P947	20	120	121	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					571	574		10.1001/jama.276.7.571	http://dx.doi.org/10.1001/jama.276.7.571			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VC101	8709410				2022-12-28	WOS:A1996VC10100037
J	Schmidt, SA				Schmidt, SA			When you come into my room	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					512	512		10.1001/jama.276.7.512	http://dx.doi.org/10.1001/jama.276.7.512			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709385				2022-12-28	WOS:A1996VC10100001
J	Ryan, RM; Maduako, K; White, C; East, CA				Ryan, RM; Maduako, K; White, C; East, CA			Routine monitoring of all postoperative outcomes at one year: Longitudinal study at the royal national throat, nose and ear hospital	BRITISH MEDICAL JOURNAL			English	Article									ROYAL NATL THROAT NOSE & EAR HOSP,LONDON WC1X 8DA,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London								FRATER A, 1995, OUTCOMES BRIEFING, V3, P25; MCDOWELL I, 1987, GUIDE RATING SCALES; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; RYAN RM, 1994, ANN R COLL SURG ENGL, V76, P75	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					403	403						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761231				2022-12-28	WOS:A1996VD20600029
J	deVries, EGE; tenVergert, EM; Mastenbroek, CG; Dalesio, O; Rodenhuis, S				deVries, EGE; tenVergert, EM; Mastenbroek, CG; Dalesio, O; Rodenhuis, S			Breast cancer studies in the Netherlands	LANCET			English	Letter											deVries, EGE (corresponding author), UNIV GRONINGEN HOSP,DEPT MED ONCOL,DUTCH WORK PARTY AUT BONE MARROW TRANS SOLID TUM,NL-9700 RB GRONINGEN,NETHERLANDS.			de Vries, Elisabeth/0000-0002-8949-7425				McCarthy M, 1996, LANCET, V347, P1617, DOI 10.1016/S0140-6736(96)91102-2	1	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					407	408		10.1016/S0140-6736(05)65026-X	http://dx.doi.org/10.1016/S0140-6736(05)65026-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709754				2022-12-28	WOS:A1996VB42600047
J	Berman, DM; Wilkie, TM; Gilman, AG				Berman, DM; Wilkie, TM; Gilman, AG			GAIP and RGS4 are GTPase-activating proteins for the G(i) subfamily of G protein alpha subunits	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FACTOR PHEROMONES; CRYSTAL-STRUCTURE; CHOLERA-TOXIN; HUMAN GENE; A-FACTOR; TRANSDUCIN; HYDROLYSIS; MECHANISM	A novel class of regulators of G protein signaling (RGS) proteins has been identified recently. Genetic evidence suggests that RGS proteins inhibit G protein-mediated signaling at the level of the receptor-G protein interaction or the G protein alpha subunit itself. We have found that two RGS family members, GAlP and RGS4, are GTPase-activating proteins (GAPs), accelerating the rate of GTP hydrolysis by G(i alpha 1) at least 40-fold. All G(i) subfamily members assayed were substrates for these GAPs; (s alpha)was not. RGS4 activates the GTPase activity of certain G(i alpha 1) mutants (e.g., R178C), but not others (e.g., Q204L). The GAP activity of RGS proteins is consistent with their proposed role as negative regulators of G protein-mediated signaling.			Berman, DM (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NIDDK NIH HHS [DK47890] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HONG JX, 1993, J IMMUNOL, V150, P3895; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAGES F, 1993, J BIOL CHEM, V268, P26358; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOP C, 1984, J BIOL CHEM, V259, P696; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WILKIE T M, 1991, Methods (Orlando), V2, P32, DOI 10.1016/S1046-2023(05)80123-9	49	648	657	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					445	452		10.1016/S0092-8674(00)80117-8	http://dx.doi.org/10.1016/S0092-8674(00)80117-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756726	Bronze			2022-12-28	WOS:A1996VC30900012
J	Bilwes, AM; denHertog, J; Hunter, T; Noel, JP				Bilwes, AM; denHertog, J; Hunter, T; Noel, JP			Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization	NATURE			English	Article							CRYSTAL-STRUCTURE; RECOGNITION; LIGAND; PHOSPHORYLATION; ENVIRONMENT; SYSTEM; 1B	RECEPTOR-LIKE protein-tyrosine phosphatases (RPTPs), like their non-receptor counterparts, regulate the level of phosphotyrosine-containing proteins derived from the action of protein-tyrosine kinases(1). RPTPs are type-I integral membrane proteins which contain one or two catalytic domains in their cytoplasmic region(2). It is not known whether extracellular ligands regulate the activity of RPTPs. Here we describe the crystal structure of the membrane-proximal catalytic domain (D1) of a typical RPTP, murine RPTP alpha. Significant structural deviations from the PTP1B fold reside within the amino-terminal hells-turn-helix segment of RPTP alpha D1 (residues 214 to 242) and a distinctive two stranded beta-sheet formed between residues 211-213 and 458-461. The turn of the N-terminal segment inserts into the active site of a dyad-related D1 monomer. On the basis of two independent crystal structures, sequence alignments, and the reported biological activity of EGF receptor/CD45 chimaeras(3), we propose that dimerization and active-site blockage is a physiologically important mechanism for downregulating the catalytic activity of RPTP alpha and other RBTPs.	SALK INST BIOL STUDIES,STRUCT BIOL LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOL BIOL & VIROL LAB,LA JOLLA,CA 92037; NETHERLANDS INST DEV BIOL,NL-3584 CT UTRECHT,NETHERLANDS	Salk Institute; Salk Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)			Noel, Joseph P/A-9459-2009	Bilwes Crane, Alexandrine/0000-0001-9922-0692				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRUNGER AT, 1992, XPLOR VERSION 3 1; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GOLDSTEIN BJ, 1995, PHOSPHOPROTEIN PHOSP, V1; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; Schmitz K. S., 1990, INTRO DYNAMIC LIGHT; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WILD DL, 1995, J MOL GRAPHICS, V13, P291, DOI 10.1016/0263-7855(95)00068-2; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	28	282	288	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					555	559		10.1038/382555a0	http://dx.doi.org/10.1038/382555a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700232				2022-12-28	WOS:A1996VB25800055
J	Morris, JZ; Tissenbaum, HA; Ruvkun, G				Morris, JZ; Tissenbaum, HA; Ruvkun, G			A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans	NATURE			English	Article							CONTROLLING DAUER FORMATION; PROTEIN-KINASE; INTERACTING GENES; 3-KINASE; WORTMANNIN; CELLS; INHIBITION; RECEPTOR; SUBUNIT; DAF-2	A PHEROMONE-INDUCED neurosecretory pathway in Caenorhabditis elegans triggers developmental arrest and an increase in longevity at the dauer diapause stage. The gene age-1 is required for non-dauer development and normal senescence. age-1 encodes a homologue of mammalian phosphatidylinositol-3-OH kinase (PI(3)K) catalytic subunits. Lack of both maternal and zygotic age-1 activity causes dauer formation, whereas animals with maternal but not zygotic age-1 activity develop as non-dauers that live more than twice as long as normal. These data suggest that phosphatidylinositol signalling mediated by AGE-1 protein controls lifespan and the dauer diapause decision.	MASSACHUSETTS GEN HOSP,DEPT MOL BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DORMAN JB, 1995, GENETICS, V141, P1399; Finch CE, 1990, LONGEVITY SENESCENCE; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRIEDMAN DB, 1988, GENETICS, V118, P75; GOTTLIEB S, 1994, GENETICS, V137, P107; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; OKADA T, 1994, J BIOL CHEM, V269, P3563; PONS S, 1995, MOL CELL BIOL, V15, P4453; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; RIDDLE DL, 1988, DAUER LARVA NEMATODE, P393; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SATO Y, 1994, GEN COMP ENDOCR, V96, P27, DOI 10.1006/gcen.1994.1156; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMAS JH, 1993, GENETICS, V134, P1105; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VOWELS JJ, 1992, GENETICS, V130, P105; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	30	659	688	1	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					536	539		10.1038/382536a0	http://dx.doi.org/10.1038/382536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700226				2022-12-28	WOS:A1996VB25800049
J	Bai, C; Sen, P; Hofmann, K; Ma, L; Goebl, M; Harper, JW; Elledge, SJ				Bai, C; Sen, P; Hofmann, K; Ma, L; Goebl, M; Harper, JW; Elledge, SJ			SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ANAPHASE TRANSITION; BUDDING YEAST; PROTEIN; KINASE; DESTRUCTION; INHIBITOR; PATHWAY; MITOSIS; COMPLEX	We have identified the yeast and human homologs of the SKP1 gene as a suppressor of cdc4 mutants and as a cyclin F-binding protein. Skp1p indirectly binds cyclin A/Cdk2 through Skp2p, and directly binds Skp2p, cyclin F, and Cdc4p through a novel structural motif called the F-box. SKP1 is required for ubiquitin-mediated proteolysis of Cln2p, Clb5p, and the Cdk inhibitor Sic1p, and provides a link between these molecules and the proteolysis machinery. A large number of proteins contain the F-box motif and are thereby implicated in the ubiquitin pathway. Different skp1 mutants arrest cells in either G1 or G2, suggesting a connection between regulation of proteolysis in different stages of the cycle.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; SWISS INST EXPTL CANC RES,BIOINFORMAT GRP,CH-1066 LAUSANNE,SWITZERLAND; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Swiss Institute Experimental Cancer Research; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute			Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG11085] Funding Source: Medline; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BANERJEE A, 1993, J BIOL CHEM, V270, P26209; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CONNELLY C, 1996, IN PRESS CELL, V86; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LIU HP, 1992, GENETICS, V132, P665; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	38	1148	1236	7	67	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					263	274		10.1016/S0092-8674(00)80098-7	http://dx.doi.org/10.1016/S0092-8674(00)80098-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706131	Bronze			2022-12-28	WOS:A1996UZ97200012
J	Yamagata, Y; Kato, M; Odawara, K; Tokuno, Y; Nakashima, Y; Matsushima, N; Yasumura, K; Tomita, K; Ihara, K; Fujii, Y; Nakabeppu, Y; Sekiguchi, M; Fujii, S				Yamagata, Y; Kato, M; Odawara, K; Tokuno, Y; Nakashima, Y; Matsushima, N; Yasumura, K; Tomita, K; Ihara, K; Fujii, Y; Nakabeppu, Y; Sekiguchi, M; Fujii, S			Three-dimensional structure of a DNA repair enzyme, 3-methyladenine DNA glycosylase II, from Escherichia coli	CELL			English	Article							BASE-EXCISION-REPAIR; TATA-BINDING PROTEIN; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ALKA GENE; ENDONUCLEASE-III; 3-DIMENSIONAL STRUCTURE; STACKING INTERACTION; ADAPTIVE RESPONSE; ALKYLATING-AGENTS	The three-dimensional structure of Escherichia coli 3-methyladenine DNA glycosylase II, which removes numerous alkylated bases from DNA, was solved at 2.3 Angstrom resolution. The enzyme consists of three domains: one alpha + beta fold domain with a similarity to one-half of the eukaryotic TATA box-binding protein, and two all alpha-helical domains similar to those of Escherichia coli endonuclease III with combined N-glycosylase/abasic lyase activity. Mutagenesis and model-building studies suggest that the active site is located in a cleft between the two helical domains and that the enzyme flips the target base out of the DNA duplex into the active-site cleft. The structure of the active site implies broad substrate specificity and simple N-glycosylase activity.	KYUSHU UNIV,MED INST BIOREGULAT,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University	Yamagata, Y (corresponding author), OSAKA UNIV,FAC PHARMACEUT SCI,SUITA,OSAKA 565,JAPAN.		Yamagata, Yoshiki/T-6489-2019; Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X; Ihara, Kenji/0000-0002-8831-1991				ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BJORAS M, 1995, BIOCHEMISTRY-US, V34, P4577, DOI 10.1021/bi00014a010; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUNGER AT, 1993, X PLOR VERSION 3 1; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; FINNIN MS, 1994, P NATL ACAD SCI USA, V91, P10972, DOI 10.1073/pnas.91.23.10972; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; FRIEDBERG EC, 1995, DNA REPAIR; IHARA K, 1994, MOL GEN GENET, V243, P379; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOW YW, 1994, ANN NY ACAD SCI, V726, P178, DOI 10.1111/j.1749-6632.1994.tb52812.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MATIJASEVIC Z, 1992, P NATL ACAD SCI USA, V89, P9331, DOI 10.1073/pnas.89.19.9331; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3723; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; SAKUMI K, 1986, J BIOL CHEM, V261, P5761; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANTERRE A, 1994, P NATL ACAD SCI USA, V91, P2240, DOI 10.1073/pnas.91.6.2240; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; STEIGEMANN W, 1985, PROTEIN; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; XIAO W, 1994, YEAST, V10, P687, DOI 10.1002/yea.320100513; YAMAGATA Y, 1988, J MOL BIOL, V204, P1055, DOI 10.1016/0022-2836(88)90063-0; YAMAGATA Y, 1994, CHEM PHARM BULL, V42, P2385; YAMAMOTO Y, 1979, MOL GEN GENET, V171, P251, DOI 10.1007/BF00267579	58	131	133	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					311	319		10.1016/S0092-8674(00)80102-6	http://dx.doi.org/10.1016/S0092-8674(00)80102-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706135	Bronze			2022-12-28	WOS:A1996UZ97200016
J	Wattis, J				Wattis, J			Caring for older people - What an old age psychiatrist does .1.	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL ANXIETY; DEPRESSION; SCALE; VALIDATION; INPATIENTS				Wattis, J (corresponding author), LEEDS COMMUNITY & MENTAL HLTH TRUST,LEEDS LS6 4QB,W YORKSHIRE,ENGLAND.		Wattis, John/J-7703-2019	Wattis, John/0000-0003-2991-3789				ADSHEAD F, 1992, BRIT MED J, V305, P397, DOI 10.1136/bmj.305.6850.397; Herrmann N, 1996, INT J GERIATR PSYCH, V11, P457, DOI 10.1002/(SICI)1099-1166(199605)11:5<457::AID-GPS325>3.0.CO;2-2; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; KENN C, 1987, INT J GERIATR PSYCH, V2, P189, DOI 10.1002/gps.930020309; WATTIS JP, 1994, INT J GERIATR PSYCH, V9, P61, DOI 10.1002/gps.930090113; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	6	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					101	104		10.1136/bmj.313.7049.101	http://dx.doi.org/10.1136/bmj.313.7049.101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UX698	8688714	Green Published			2022-12-28	WOS:A1996UX69800030
J	Jacobson, JL; Jacobson, SW				Jacobson, JL; Jacobson, SW			Intellectual impairment in children exposed to polychlorinated biphenyls in utero	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-MILK; YOUNG-CHILDREN; LEAD-EXPOSURE; PCB EXPOSURE; CONTAMINANTS; DIOXINS; DDE; AGE	Background In utero exposure to polychlorinated biphenyls, a ubiquitous environmental contaminant, has been linked to adverse effects on neurologic and intellectual function in infants and young children. We assessed whether these effects persist through school age and examined their importance in the acquisition of reading and arithmetic skills. Methods We tested 212 children, recruited as newborns to overrepresent infants born to women who had eaten Lake Michigan fish contaminated with polychlorinated biphenyls, A battery of IQ and achievement tests was administered when the children were 11 years of age, Concentrations of polychlorinated biphenyls in maternal serum and milk at delivery were slightly higher than in the general population. A composite measure of prenatal exposure was derived from concentrations in umbilical-cord serum and maternal serum and milk. Results Prenatal exposure to polychlorinated biphenyls was associated with tower full-scale and verbal IQ scores after control for potential confounding variables such as socioeconomic status (P = 0.02). The strongest effects related to memory and attention. The most highly exposed children were three times as likely to have low average IQ scores (P < 0.001) and twice as likely to be at least two years behind in reading comprehension (P = 0.03). Although larger quantities of polychlorinated biphenyls are transferred by breast-feeding than in utero, there were deficits only in association with transplacental exposure, suggesting that the developing fetal brain is particularly sensitive to these compounds. Conclusions In utero exposure to polychlorinated biphenyls in concentrations slightly higher than those in the general population can have a long-term impact on intellectual function. (C) 1996, Massachusetts Medical Society.			Jacobson, JL (corresponding author), WAYNE STATE UNIV,DEPT PSYCHOL,71 W WARREN AVE,DETROIT,MI 48202, USA.		Fahimifar, Sepideh/M-5303-2019		NIEHS NIH HHS [R01-ES05843] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANNAU Z, 1986, NEUROBEHAVIORAL TOXI, P153; BELLINGER DC, 1992, PEDIATRICS, V90, P855; CHEN YCJ, 1992, JAMA-J AM MED ASSOC, V268, P3213, DOI 10.1001/jama.268.22.3213; DIETRICH KN, 1993, NEUROTOXICOL TERATOL, V15, P37, DOI 10.1016/0892-0362(93)90043-N; DOBSON S, 1993, POLYCHLORINATED BIPH; DVORCHIK BH, 1981, DRUG METABOLISM IMMA, P145; FEIN GG, 1984, J PEDIATR-US, V105, P315, DOI 10.1016/S0022-3476(84)80139-0; GLADEN BC, 1988, J PEDIATR-US, V113, P991, DOI 10.1016/S0022-3476(88)80569-9; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; JACOBSON JL, 1990, NEUROTOXICOL TERATOL, V12, P319, DOI 10.1016/0892-0362(90)90050-M; JACOBSON JL, 1989, AM J PUBLIC HEALTH, V79, P1401, DOI 10.2105/AJPH.79.10.1401; JACOBSON JL, IN PRESS NEUROTOXICO; JACOBSON SW, 1985, CHILD DEV, V56, P853, DOI 10.2307/1130097; JENSEN AA, 1987, SCI TOTAL ENVIRON, V64, P259, DOI 10.1016/0048-9697(87)90250-6; KAUFMAN AS, 1975, J CONSULT CLIN PSYCH, V43, P135, DOI 10.1037/h0076502; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOOPMANESSEBOOM C, 1994, PEDIATR RES, V36, P468, DOI 10.1203/00006450-199410000-00009; KUZMA JW, 1981, NEUROBEH TOXICOL TER, V3, P211; LEVIN ED, 1988, ARCH TOXICOL, V62, P267, DOI 10.1007/BF00332486; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LILIENTHAL H, 1991, FUND APPL TOXICOL, V17, P368, DOI 10.1016/0272-0590(91)90226-T; NEEDHAM LL, 1981, J ASSOC OFF ANA CHEM, V64, P1131; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; ROGAN WJ, 1988, SCIENCE, V241, P334, DOI 10.1126/science.3133768; ROGAN WJ, 1986, AM J PUBLIC HEALTH, V76, P172, DOI 10.2105/AJPH.76.2.172; ROGAN WJ, 1986, J PEDIATR-US, V109, P335, DOI 10.1016/S0022-3476(86)80397-3; Sattler JM, 1992, ASSESSMENT CHILDRENS; SAWYER LD, 1978, J ASSOC OFF ANA CHEM, V61, P272; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Swain W. R., 1983, PCBS HUMAN ENV CONSE, P11; TANABE S, 1988, ENVIRON POLLUT, V50, P5, DOI 10.1016/0269-7491(88)90183-2; Weschler D., 1991, WECHSLER INTELLIGENC; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; WOODBURY DM, 1974, DRUGS DEV BRAIN, V8, P259	34	849	872	0	66	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					783	789		10.1056/NEJM199609123351104	http://dx.doi.org/10.1056/NEJM199609123351104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8703183				2022-12-28	WOS:A1996VF78600004
J	Chen, JY; Clifford, J; Zusi, C; Starrett, J; Tortolani, D; Ostrowski, J; Reczek, PR; Chambon, P; Gronemeyer, H				Chen, JY; Clifford, J; Zusi, C; Starrett, J; Tortolani, D; Ostrowski, J; Reczek, PR; Chambon, P; Gronemeyer, H			Two distinct actions of retinoid-receptor ligands	NATURE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; LIGATION-MEDIATED PCR; PML-RAR-ALPHA; T(1517) TRANSLOCATION; RESPONSE PATHWAYS; INVIVO; TRANSACTIVATION; TRANSCRIPTION; CELLS	SIGNALLING by all-trans retinoic acid is mediated through RXR-RAR retinoid receptor heterodimers(1,2), in which RXR has been considered to act as a transcriptionally silent partner(3-5), However, we show here that in cultured NB4 (ref. 6) human acute promyelocytic leukaemia(7-9) cells treated with either an RAR-alpha-selective agonist alone, or certain RAR-alpha antagonists in combination with an RXR agonist, receptor-DNA binding is induced in vivo, resulting in expression of the target genes of retinoic acid as well as acute promyelocytic leukaemia protein (PML) relocation to nuclear bodies(10-12) and differentiation before apoptosis, These results indicate that RAR-alpha ligands can induce two separate events: one enables RXR-RAR-alpha heterodimers to bind to DNA in vivo and allows RXR agonists to act; the other induces transcriptional activity of RAR-alpha. The availability of receptor-specific synthetic retinoids that can induce distinct receptor functions has potential in extending the therapeutic repertoire of retinoids.	COLL FRANCE, INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM, ULP, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, BUFFALO, NY 14213 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Bristol-Myers Squibb			Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; Blanco JCG, 1996, GENES CELLS, V1, P209, DOI 10.1046/j.1365-2443.1996.d01-229.x; CHAMBON P, IN PRESS FASEB J; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CLIFFORD J, IN PRESS EMBO J; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GRONEMEYER H, 1985, PROTIEN PROFILE, V2, P1173; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGY L, 1995, MOL CELL BIOL, V15, P3540; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	28	178	183	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1996	382	6594					819	822		10.1038/382819a0	http://dx.doi.org/10.1038/382819a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752277				2022-12-28	WOS:A1996VE34700050
J	Ho, SN; Biggar, SR; Spencer, DM; Schreiber, SL; Crabtree, GR				Ho, SN; Biggar, SR; Spencer, DM; Schreiber, SL; Crabtree, GR			Dimeric ligands define a role for transcriptional activation domains in reinitiation	NATURE			English	Article							RNA-POLYMERASE-II; PREINITIATION COMPLEX; FACTOR ATF; IN-VIVO; PROTEIN; PROMOTER; BINDING; RECRUITMENT; CALCINEURIN; INITIATION	EUKARYOTIC transcriptional activators mediate transcriptional induction through stabilization of the preinitiation complex(1-4), probably through direct interactions with basal transcription factors(5-7). In vitro studies on the role of an activator in the maintenance of on-going transcription (reinitiation) hare been contradictory, suggesting that, after formation of a preinitiation complex, an activator may(8) or may not(9) be necessary for transcription to be maintained, We have developed a means of regulating transcription in living cells through the use of both homodimeric and heterodimerizing synthetic ligands that allow the ligand-dependent association and disassociation of a transcriptional activation domain with a promoter. Here we report that maintaining the transcription of endogenous genes in vivo, in both yeast and human cells, requires the continuous presence of the activation domain. The use of synthetic ligands as a transcriptional on-off switch represents a powerful means of controlling the transcription in vitro and in vivo for both experimental and therapeutic purposes.	STANFORD UNIV,SCH MED,BECKMAN CTR MOL & GENET MED,HOWARD HUGHES MED INST,DEPT PATHOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,BECKMAN CTR MOL & GENET MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Harvard University								BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231; RIVERA, IN PRESS NATURE MED; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SZENTIRMAY MN, 1993, EMBO J, V12, P4677, DOI 10.1002/j.1460-2075.1993.tb06156.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TIJIAN R, 1994, CELL, V77, P5; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	31	215	245	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					822	826		10.1038/382822a0	http://dx.doi.org/10.1038/382822a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752278				2022-12-28	WOS:A1996VE34700051
J	Norris, JM; Beaty, B; Klingensmith, G; Yu, LP; Hoffman, M; Chase, HP; Erlich, HA; Hamman, RF; Eisenbarth, GS; Rewers, M				Norris, JM; Beaty, B; Klingensmith, G; Yu, LP; Hoffman, M; Chase, HP; Erlich, HA; Hamman, RF; Eisenbarth, GS; Rewers, M			Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity - Diabetes autoimmunity study in the young (DAISY)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECALL BIAS; IDENTICAL-TWINS; IDDM; ANTIBODIES; MELLITUS; RISK; PREDICTION; POPULATION; PREGNANCY; ACCURACY	Objective.-To examine whether infant dietary exposure to cow's milk is associated with beta-cell autoimmunity (BCA), an early predictor of insulin-dependent diabetes mellitus (IDDM). Setting.-Denver, Cole. Design.-Cross-sectional with retrospective analysis. Participants.-Between January 1994 and December 1995, 253 children from 171 families of persons with IDDM were screened for BCA, All children were between the ages of 9 months and 7 years. Main Outcome Measures.-BCA was defined as elevated levels of insulin autoantibody, glutamic acid decarboxylase autoantibody, or insulinoma-associated islet tyrosine phosphatases autoantibody (IA-2) above the 99th percentile of 198 normal subjects. Results.-Eighteen cases of BCA were detected; 153 unrelated autoantibody-negative children were selected from the cohort as controls, There were no differences in the proportion of cases and controls who were exposed to cow's milk or foods containing cow's milk or to cereal, fruit and vegetable, or meat protein by 3 months or by 6 months of age. Children with BCA were breast-fed for a slightly longer duration than controls (median duration 10 vs 8 months, P=.07). Conclusions.-These data suggest that early exposure to cow's milk or other dietary protein is not associated with BCA, This calls into question the importance of cow's milk avoidance as a preventive measure for IDDM.	BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO; ROCHE MOL SYST INC,DEPT HUMAN GENET,ALAMEDA,CA	Roche Holding	Norris, JM (corresponding author), UNIV COLORADO,SCH MED,DEPT PREVENT MED & BIOMETR,4200 E 9TH AVE,BOX C-245,DENVER,CO 80262, USA.				NIDDK NIH HHS [R01 DK-32493] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032493] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON MA, 1993, NEW ENGL J MED, V329, P1853, DOI 10.1056/NEJM199312163292505; BINGLEY PJ, 1994, DIABETES, V43, P1304, DOI 10.2337/diabetes.43.11.1304; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BRANDT LPA, 1992, AM J EPIDEMIOL, V135, P302, DOI 10.1093/oxfordjournals.aje.a116284; DAHLQUIST GG, 1995, DIABETES CARE, V18, P852, DOI 10.2337/diacare.18.6.852; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; DORMAN JS, 1995, NIH PUBLICATION, P165; DREWS CD, 1990, INT J EPIDEMIOL, V19, P405, DOI 10.1093/ije/19.2.405; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GIANANI R, 1995, DIABETES, V44, P1340, DOI 10.2337/diabetes.44.11.1340; GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469; HAMMAN RF, 1990, DIABETES CARE, V13, P499, DOI 10.2337/diacare.13.5.499; HUTTLY SRA, 1990, AM J EPIDEMIOL, V132, P572, DOI 10.1093/oxfordjournals.aje.a115693; JOHNSTON C, 1989, DIABETOLOGIA, V32, P382, DOI 10.1007/BF00277263; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; KHOURY MJ, 1993, AM J EPIDEMIOL, V137, P1241, DOI 10.1093/oxfordjournals.aje.a116626; KOSTRABA JN, 1993, DIABETES, V42, P288, DOI 10.2337/diabetes.42.2.288; KOSTRABA JN, 1992, DIABETES CARE, V15, P626, DOI 10.2337/diacare.15.5.626; MARTIKAINEN A, 1996, P 1 WORLD C PREV DIA; Norris JM, 1996, EPIDEMIOLOGY, V7, P87, DOI 10.1097/00001648-199601000-00015; OLEARY LA, 1991, DIABETES RES CLIN PR, V14, P183, DOI 10.1016/0168-8227(91)90019-A; PILCHER C C, 1991, Diabetes Research and Clinical Practice, V14, pS82; Rewers M, 1996, DIABETOLOGIA, V39, P807, DOI 10.1007/s001250050514; Vaarala O, 1996, DIABETES, V45, P178, DOI 10.2337/diabetes.45.2.178; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6; VARDI P, 1987, DIABETES, V36, P1286, DOI 10.2337/diabetes.36.11.1286; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; VERGE CF, 1995, DIABETES, V44, P1176, DOI 10.2337/diabetes.44.10.1176; WERLER MM, 1989, AM J EPIDEMIOL, V129, P415, DOI 10.1093/oxfordjournals.aje.a115145	30	131	133	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					609	614		10.1001/jama.276.8.609	http://dx.doi.org/10.1001/jama.276.8.609			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC853	8773632				2022-12-28	WOS:A1996VC85300026
J	Yan, SD; Chen, X; Fu, J; Chen, M; Zhu, HJ; Roher, A; Slattery, T; Zhao, L; Nagashima, M; Morser, J; Migheli, A; Nawroth, P; Stern, D; Schmidt, AM				Yan, SD; Chen, X; Fu, J; Chen, M; Zhu, HJ; Roher, A; Slattery, T; Zhao, L; Nagashima, M; Morser, J; Migheli, A; Nawroth, P; Stern, D; Schmidt, AM			RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease	NATURE			English	Article							GLYCATION END-PRODUCTS; CELL-ADHESION MOLECULE-1; NEURITE OUTGROWTH; BINDING-PROTEINS; OXIDANT STRESS; NEUROLOGICAL DISEASE; ENDOTHELIAL-CELLS; MICROGLIAL CELLS; TAU-PROTEIN; RECEPTOR	Amyloid-beta peptide is central to the pathology of Alzheimer's disease, because it is neurotoxic-directly by inducing oxidant stress, and indirectly by activating microglia. A specific cell-surface acceptor site that could focus its effects on target cells has been postulated but not identified. Here we present evidence that the receptor for advanced glycation end products' (RAGE) is such a receptor, and that it mediates effects of the peptide on neurons and microglia. increased expression of RAGE in Alzheimer's disease brain indicates that it is relevant to the pathogenesis of neuronal dysfunction and death.	COLUMBIA UNIV COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & MED,NEW YORK,NY 10032; SUN HLTH RES INST,SUN CITY,AZ 85372; BERLEX BIOSCI,RICHMOND,CA 94804; UNIV TURIN,I-10126 TURIN,ITALY; UNIV HEIDELBERG,DEPT MED,D-69115 HEIDELBERG,GERMANY	Columbia University; Columbia University; Banner Research; Banner Health; Banner Sun Health Research Institute; University of Turin; Ruprecht Karls University Heidelberg	Yan, SD (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		Fu, Jin/A-3510-2012					ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; BRETT J, 1993, AM J PATHOL, V143, P1699; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; DENNERY PA, 1990, AM J RESP CELL MOL, V3, P137, DOI 10.1165/ajrcmb/3.2.137; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; HAASS C, 1994, CELL, V7, P1039; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P7508, DOI 10.1073/pnas.90.16.7508; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; KOSIK KS, 1994, J CELL BIOL, V127, P1501, DOI 10.1083/jcb.127.6.1501; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; NEEPER M, 1992, J BIOL CHEM, V267, P14998; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIKE CJ, 1993, J NEUROSCI, V13, P1676; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; STRITTMATTER WJ, 1993, EXP NEUROL, V122, P327, DOI 10.1006/exnr.1993.1132; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; YAN SD, 1994, J BIOL CHEM, V269, P9889; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540	45	1688	1799	4	140	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					685	691		10.1038/382685a0	http://dx.doi.org/10.1038/382685a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751438				2022-12-28	WOS:A1996VD33300040
J	Guttmann, RD				Guttmann, RD			Cadaver kidneys: The rules of rationing	LANCET			English	Editorial Material											Guttmann, RD (corresponding author), MCGILL UNIV,CTR CLIN IMMUNOBIOL & TRANSPLANTAT,MONTREAL,PQ H3A 1A1,CANADA.							CALLAND CH, 1972, NEW ENGL J MED, V287, P334, DOI 10.1056/NEJM197208172870705; Chang RWS, 1996, LANCET, V348, P453, DOI 10.1016/S0140-6736(96)02051-X; GJERTSON DW, 1992, TRANSPLANTATION, V53, P357, DOI 10.1097/00007890-199202010-00018; GUTTMANN RD, 1992, TRANSPLANT P, V24, P2407; GUTTMANN RD, 1991, ORGAN REPLACEMENT TH, P410; LOWY I, 1990, HIST STUD PHYS BIOL, V21, P87; MYTILINEOS J, 1990, TRANSPLANTATION, V50, P870, DOI 10.1097/00007890-199011000-00024; THIEL G, 1991, ORGAN REPLACEMENT TH, P353; THOROGOOD DJ, 1992, STAT MODELING RENAL; *WHO, 1991, WHA4425 WHO	10	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					456	457		10.1016/S0140-6736(96)04010-X	http://dx.doi.org/10.1016/S0140-6736(96)04010-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709789				2022-12-28	WOS:A1996VC67300017
J	Price, RW				Price, RW			Neurological complications of HIV infection	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; AIDS DEMENTIA COMPLEX; IMMUNE-DEFICIENCY-SYNDROME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ZIDOVUDINE TREATMENT; CEREBROSPINAL-FLUID; VACUOLAR MYELOPATHY; NEUROPATHY; ENCEPHALITIS	Neurological complications of HIV infection cause considerable morbidity and are often associated with high mortality. These complications include not only the more common opportunistic diseases affecting the brain (cerebral toxoplasmosis, primary central nervous system lymphoma, progressive multifocal leucoencephalopathy, and cryptococcal meningitis) but also the AIDS dementia complex, with its characteristic cognitive and motor dysfunction, which is caused by HIV itself. Additionally, the peripheral nervous system is the target of several disorders, including a common painful neuropathy. Because these and other, less common, central and peripheral nervous system complications of HIV can often be specifically treated or effectively palliated, their accurate and timely diagnosis is important.			Price, RW (corresponding author), SAN FRANCISCO GEN HOSP, DEPT NEUROL, ROOM 4M62, 1001 POTRERO AVE, SAN FRANCISCO, CA 94110 USA.				NINDS NIH HHS [NS-25701] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025701] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BERGER AR, 1993, NEUROLOGY, V43, P358, DOI 10.1212/WNL.43.2.358; BERGER JR, 1989, NEUROLOGY, V39, P324, DOI 10.1212/WNL.39.3.324; BERGER JR, 1987, ANN INTERN MED, V107, P78, DOI 10.7326/0003-4819-107-1-78; BREW BJ, 1993, NEUROLOGY, V43, P1098, DOI 10.1212/WNL.43.6.1098; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; BREW BJ, 1992, AIDS, V6, P461, DOI 10.1097/00002030-199205000-00004; BREW BJ, 1989, AUST NZ J MED, V19, P700, DOI 10.1111/j.1445-5994.1989.tb00339.x; BROWNE MJ, 1993, J INFECT DIS, V167, P21, DOI 10.1093/infdis/167.1.21; CINQUE P, 1992, J INFECT DIS, V166, P1408, DOI 10.1093/infdis/166.6.1408; CORNBLATH DR, 1991, ANN NEUROL, V30, P104, DOI 10.1002/ana.410300119; DALPAN GJ, 1994, NEUROLOGY, V44, P2159; DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736; DEGANS J, 1990, AIDS, V4, P421, DOI 10.1097/00002030-199005000-00007; DICKSON DW, 1994, RES P ARNMD, V72, P99; ENGSTROM JW, 1989, AM J MED, V86, P528, DOI 10.1016/0002-9343(89)90379-3; GRAY F, 1994, BRAIN, V117, P987, DOI 10.1093/brain/117.5.987; GRIFFIN JW, 1994, RES P ARNMD, V72, P159; HAIR LS, 1992, HUM PATHOL, V23, P663, DOI 10.1016/0046-8177(92)90322-T; HOLLAND NR, 1994, NEUROLOGY, V44, P507, DOI 10.1212/WNL.44.3_Part_1.507; HOLLANDER H, 1987, AM J MED, V83, P813, DOI 10.1016/0002-9343(87)90635-8; JANSSEN RS, 1991, NEUROLOGY, V41, P778; KIEBURTZ KD, 1992, J ACQ IMMUN DEF SYND, V5, P60; KIOUMEHR F, 1994, NEURORADIOLOGY, V36, P93, DOI 10.1007/BF00588067; LIPKIN WI, 1985, NEUROLOGY, V35, P1479, DOI 10.1212/WNL.35.10.1479; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; MAJ M, 1990, AIDS, V4, P935; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; MEILLET D, 1993, EUR J CLIN CHEM CLIN, V31, P609; NAVIA BA, 1986, ANN NEUROL, V19, P224, DOI 10.1002/ana.410190303; NEATON JD, 1994, STAT MED, V13, P2107, DOI 10.1002/sim.4780131919; NUOVO GJ, 1994, AM J PATHOL, V144, P659; OBRIEN WA, 1994, RES P ARNMD, V72, P47; POST MJD, 1986, AM J ROENTGENOL, V146, P1229, DOI 10.2214/ajr.146.6.1229; Price R W, 1995, AIDS, V9 Suppl A, pS221; Price R W, 1996, J NeuroAIDS, V1, P1; PRICE RW, 1994, RES P ARNMD, V72, P1; PRICE RW, 1995, MED MANAGEMENT AIDS, P261; ROULLET E, 1994, NEUROLOGY, V44, P2174, DOI 10.1212/WNL.44.11.2174; SAAG MS, 1995, MED MANAGEMENT AIDS, P437; SAID G, 1991, ANN NEUROL, V29, P139, DOI 10.1002/ana.410290205; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; SIDTIS JJ, 1990, NEUROLOGY, V40, P323, DOI 10.1212/WNL.40.2.323; SIGURDSSON B, 1957, J NEUROPATH EXP NEUR, V16, P389, DOI 10.1097/00005072-195707000-00010; SIMPSON DM, 1992, NEUROL CLIN, V10, P685, DOI 10.1016/S0733-8619(18)30204-4; SIMPSON DM, 1993, NEUROLOGY, V43, P971, DOI 10.1212/WNL.43.5.971; SO YT, 1986, ANN NEUROL, V20, P566, DOI 10.1002/ana.410200503; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; VAGO L, 1993, J ACQ IMMUN DEF SYND, V6, P42	50	192	195	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					445	452		10.1016/S0140-6736(95)11035-6	http://dx.doi.org/10.1016/S0140-6736(95)11035-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709786				2022-12-28	WOS:A1996VC67300014
J	Nagasawa, T; Hirota, S; Tachibana, K; Takakura, N; Nishikawa, S; Kitamura, Y; Yoshida, N; Kikutani, H; Kishimoto, T				Nagasawa, T; Hirota, S; Tachibana, K; Takakura, N; Nishikawa, S; Kitamura, Y; Yoshida, N; Kikutani, H; Kishimoto, T			Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1	NATURE			English	Article							MURINE EMBRYO; RXR-ALPHA; C-KIT; GENE; MORPHOGENESIS; REQUIREMENT; RECEPTORS; LINEAGES; CLONING; HEART	THE chemokines are a large family of small, structurally related cytokines(1,2). The physiological importance of most members of this family has yet to be elucidated, although some are inducible inflammatory mediators that determine leukocyte chemotaxis(1-5). Pre-B-cell growth-stimulating factor/stromal cell-derived factor-1 (PBSF/SDF-1) is a member of the CXC group of chemokines(6,7). PBSF/SDF-1 stimulates proliferation of B-cell progenitors in vitro(6) and is constitutively expressed in bone-marrow-derived stromal cells(6,7). Here we investigate the physiological roles of PBSF/SDF-1 by generating mutant mice with a targeted disruption of the gene encoding PBSF/SDF-1, We found that mite lacking PBSF/SDF-1 died perinatally and that although the numbers of B-cell progenitors in mutant embryos were severely reduced in fetal liver and bone marrow, myeloid progenitors were reduced only in the hone marrow but not in the fetal liver, indicating that PBSF/SDF-1 is responsible for B-cell lymphopoiesis and bone-marrow myelopoiesis. In addition, the mutants had a cardiac ventricular septal defect, Hence, we have shown that the chemokine PBSF/SDF-1 has several essential functions in development.	OSAKA UNIV,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,FAC MED,DEPT MOL GENET,SAKYO KU,KYOTO 606,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Kyoto University; Osaka University	Nagasawa, T (corresponding author), OSAKA MED CTR MATERNAL & CHILD HLTH,RES INST,DEPT IMMUNOL,840 MURODO CHO,IZUMI,OSAKA 59002,JAPAN.		Kishimoto, Tadamitsu/C-8470-2009; Kikutani, Hitoshi/C-9525-2009	Nagasawa, Takashi/0000-0002-1085-0960				CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; FREEDENJEFFRY U, 1995, J EXP MED, V181, P1519; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; HARDY RR, 1991, P NATL ACAD SCI USA, V88, P11550, DOI 10.1073/pnas.88.24.11550; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KUNKEL SL, 1995, IMMUNOL TODAY, V16, P559, DOI 10.1016/0167-5699(95)80076-X; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; MOORE MW, 1995, SCIENCE, V269, P1591, DOI 10.1126/science.269.5230.1591; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; OGAWA M, 1993, DEVELOPMENT, V117, P1089; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PESHON J, 1994, J EXP MED, V180, P1955; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TAVASSOLI M, 1991, BLOOD CELLS, V1, P269; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	25	1904	2017	0	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					635	638		10.1038/382635a0	http://dx.doi.org/10.1038/382635a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757135				2022-12-28	WOS:A1996VC30300055
J	Nightingale, SL				Nightingale, SL			T-PA approved for acute ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691538				2022-12-28	WOS:A1996VA86300006
J	Cairns, A; Roberts, ISD; Benbow, EW				Cairns, A; Roberts, ISD; Benbow, EW			Characteristics of fatal methadone overdose in Manchester, 1985-94	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAINTENANCE TREATMENT; DEPENDENCE		UNIV MANCHESTER, DEPT PATHOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; MANCHESTER ROYAL INFIRM, DEPT HISTOPATHOL, MANCHESTER M13 9WL, LANCS, ENGLAND	University of Manchester; University of Manchester								CAPLEHORN J, 1995, BMJ-BRIT MED J, V310, P463, DOI 10.1136/bmj.310.6977.463; Clark J C, 1995, J Clin Forensic Med, V2, P143, DOI 10.1016/1353-1131(95)90082-9; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; FARRELL M, 1994, BRIT MED J, V308, P609, DOI 10.1136/bmj.308.6929.609; *OFF POP CENS SURV, 1987, MORT STAT INJ POIS	5	64	65	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	1996	313	7052					264	265		10.1136/bmj.313.7052.264	http://dx.doi.org/10.1136/bmj.313.7052.264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704535	Green Published			2022-12-28	WOS:A1996VA90300024
J	Sherer, R				Sherer, R			Delta in the real world	LANCET			English	Editorial Material											Sherer, R (corresponding author), COOK CTY HOSP,HIV PRIMARY CARE CTR,CHICAGO,IL 60612, USA.							Brun-Vezinet F., 1996, P21; Bryson Yvonne J., 1996, P214; Cameron D. W., 1996, P24; Coffin John M., 1996, P208; HAMMER S, 1995, EACS 5 EUR C CLIN AS; Katzenstein David A., 1996, P21; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; MAYERS D, 1996, 11 INT C AIDS VANC J, P16; Saravolatz L., 1996, P161; Sherer Renslow, 1996, P231; THOMPSON M, 1996, 3 C RETR OPP INF WAS, P202	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					278	279		10.1016/S0140-6736(05)64466-2	http://dx.doi.org/10.1016/S0140-6736(05)64466-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709681				2022-12-28	WOS:A1996VA25000002
J	DuranTauleria, E; Rona, RJ; Chinn, S; Burney, P				DuranTauleria, E; Rona, RJ; Chinn, S; Burney, P			Influence of ethnic group on asthma treatment in children in 1990-1: National cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; HOSPITAL ADMISSIONS; HEALTH; TRENDS; POPULATION; INCREASE; SEVERITY; GROWTH; HEIGHT; RATES	Objective-To examine the extent to which the prescription of drugs for asthma adhered to recommended guidelines in 1990-1 and to assess the influence of ethnic group on prescription. Design-Cross sectional. Setting-Primary schools in England and Scotland in 1990-1. Subjects-Children aged mainly 5-11 years. The representative samples included 10 628 children. The inner city sample included 7049 children, 4866 (69%) from ethnic minority groups. For the prevalence estimation 14 490 children were included in the analysis (82% of the eligible children). For the treatment analysis a subgroup of 5494 children with respiratory symptoms was selected. Main outcome measures-Prevalence of respiratory symptoms and drugs commonly prescribed for asthma, method of administration, inappropriate treatment, and odds ratios to assess the effect of ethnic group on rate of prescription and method of administration. Results-Children with respiratory symptoms in the inner city sample were less likely to be diagnosed as having asthma. Of children with reported asthma attacks, those in inner city areas had a higher risk of not having been prescribed any drug for asthma (odds ratio 1.87 (95% confidence interval 1.26 to 2.77). Overall, 773 (75%) of these children had received a beta(2) agonist, 259 (25%) had received steroids, 148 (14%) had received sodium cromoglycate, and 194 (19%) had received no drug treatment in the previous year. When prescribed, beta(2) agonists were inhaled in 534 (69%) of cases, and this percentage was even lower in ethnic minority groups. Children of Afro-Caribbean and Indian subcontinent origin who had asthma were less likely to receive beta(2) agonists, and those from the Indian subcontinent were less likely to receive anti-inflammatory drugs. Antibiotics were less prescribed and antitussives more prescribed in children from ethnic minority groups than in white children. Conclusion-In 1990-1 the risk of underdiagnosis and undertreatment of asthma was higher in children from ethnic minority groups. The implementation of indicators and targets to monitor inequalities in the treatment of asthma in ethnic groups could improve equity and effectiveness in the NHS.			DuranTauleria, E (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND.		Rona, Roberto J/C-2348-2011	Rona, Roberto/0000-0003-3739-5571; Burney, Peter/0000-0001-8635-5678				ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BOSCO LA, 1993, CHEST, V104, P1727, DOI 10.1378/chest.104.6.1727; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; BURNEY PGJ, 1991, BRIT MED J, V303, P571, DOI 10.1136/bmj.303.6802.571; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; GARRETT JE, 1989, NEW ZEAL MED J, V102, P121; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GILL PS, 1995, BRIT MED J, V310, P890, DOI 10.1136/bmj.310.6984.890; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; KUN HY, 1993, MED J AUSTRALIA, V159, P312, DOI 10.5694/j.1326-5377.1993.tb137867.x; MITCHELL EA, 1991, SOC SCI MED, V32, P831, DOI 10.1016/0277-9536(91)90309-Z; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; Osborn A.F., 1984, SOCIAL LIFE BRITAINS; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; PHIN S, 1993, MED J AUSTRALIA, V159, P662, DOI 10.5694/j.1326-5377.1993.tb138080.x; RONA RJ, 1986, ANN HUM BIOL, V13, P453, DOI 10.1080/03014468600008631; RONA RJ, 1977, ANN HUM BIOL, V4, P501, DOI 10.1080/03014467700002511; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; THOMPSON R, 1993, NEW ZEAL MED J, V106, P81; VOLLMER WM, 1993, AM REV RESPIR DIS, V147, P347, DOI 10.1164/ajrccm/147.2.347; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1995, BRIT MED J, V311, P663, DOI 10.1136/bmj.311.7006.663; WILSON SR, 1993, MED CARE, V31, pMS49; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1992, ARCH DIS CHILD, V67, P240	28	54	54	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					148	152		10.1136/bmj.313.7050.148	http://dx.doi.org/10.1136/bmj.313.7050.148			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688777	Green Published			2022-12-28	WOS:A1996UY92100020
J	Stratford, KJ; TarczyHornoch, K; Martin, KAC; Bannister, NJ; Jack, JJB				Stratford, KJ; TarczyHornoch, K; Martin, KAC; Bannister, NJ; Jack, JJB			Excitatory synaptic inputs to spiny stellate cells in cat visual cortex	NATURE			English	Article							ORIENTATION SELECTIVITY; GENICULOCORTICAL AFFERENTS; NEURONS; TRANSMISSION; PROJECTIONS; MONKEY	IN layer 4 of cat visual cortex, the monocular, concentric receptive fields of thalamic neurons, which relay retinal input to the cortex, are transformed into 'simple' cortical receptive fields that are binocular and selective for the precise orientation, direction of motion, and size of the visual stimulus(1). These properties are thought to arise from the pattern of connections from thalamic neurons(1-6), although anatomical studies show that most excitatory inputs to layer 4 simple cells are from recurrently connected circuits of cortical neurons(7-9). We examined single fibre inputs to spiny stellate neurons in slices of cat visual cortex, and conclude that thalamocortical synapses are powerful and the responses they evoke are unusually invariant for central synapses. However, the responses to intracortical inputs, although less invariant, are strong enough to provide most of the excitation to simple tells in vivo. Our results suggest that the recurrent excitatory circuits of cortex may amplify the initial feedforward thalamic signal, subserving dynamic modifications of the functional properties of cortical neurons(10-12).	ETH ZURICH,INST NEUROINFORMAT,CH-8006 ZURICH,SWITZERLAND; UNIV ZURICH,CH-8006 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Stratford, KJ (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.			Tarczy-Hornoch, Kristina/0000-0001-6881-0382	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; ANDERSON JC, 1994, J COMP NEUROL, V341, P25, DOI 10.1002/cne.903410104; ANDREASEN M, 1994, J NEUROPHYSIOL, V72, P326, DOI 10.1152/jn.1994.72.1.326; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; Das A, 1996, NEURON, V16, P477, DOI 10.1016/S0896-6273(00)80067-7; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; Everitt B. S., 1993, CLUSTER ANAL; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P233, DOI 10.1113/jphysiol.1985.sp015822; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; GAREY LJ, 1971, PROC R SOC SER B-BIO, V179, P41, DOI 10.1098/rspb.1971.0080; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GRIEVE KL, 1991, EXP BRAIN RES, V87, P521; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HIRSCH JA, 1995, J PHYSIOL-LONDON, V483, P183, DOI 10.1113/jphysiol.1995.sp020577; Hubel D, 1996, NATURE, V380, P197, DOI 10.1038/380197a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JACK JJB, 1975, ELECTRIC CURRENT FLO; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; LUND JS, 1979, J COMP NEUROL, V184, P599, DOI 10.1002/cne.901840402; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MASON A, 1991, J NEUROSCI, V11, P72; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SCLAR G, 1982, EXP BRAIN RES, V46, P457; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; STEVENS CF, 1994, LARGE SCALE NEURONAL, P239; VOLGUSHEV M, 1995, EUR J NEUROSCI, V7, P1751, DOI 10.1111/j.1460-9568.1995.tb00695.x	29	325	328	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					258	261		10.1038/382258a0	http://dx.doi.org/10.1038/382258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717041				2022-12-28	WOS:A1996UX79000051
J	Charatan, FB				Charatan, FB			Revisiting the Medicare crisis	BRITISH MEDICAL JOURNAL			English	News Item																		1995, BRIT MED J      0415, P961	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					74	74		10.1136/bmj.313.7049.74a	http://dx.doi.org/10.1136/bmj.313.7049.74a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688756				2022-12-28	WOS:A1996UX69800018
J	Wyttenbach, RA; May, ML; Hoy, RR				Wyttenbach, RA; May, ML; Hoy, RR			Categorical perception of sound frequency by crickets	SCIENCE			English	Article							FLYING CRICKETS; SPEECH-PERCEPTION; TELEOGRYLLUS-OCEANICUS; CALLING SONG; DISCRIMINATION; ULTRASOUND; PHONOTAXIS; ATTRACTION; AVOIDANCE; STIMULI	Partitioning continuously varying stimuli into categories is a fundamental problem of perception. One solution to this problem, categorical perception, is known primarily from human speech, but also occurs in other modalities and in some mammals and birds. Categorical perception was tested in crickets by using two paradigms of human psychophysics, labeling and habituation-dishabituation. The results show that crickets divide sound frequency categorically between attractive (<16 kilohertz) and repulsive (>16 kilohertz) sounds. There is sharp discrimination between these categories but no discrimination between different frequencies of ultrasound. This demonstration of categorical perception in an invertebrate suggests that categorical perception may be a basic and widespread feature of sensory systems, from humans to invertebrates.	CORNELL UNIV,NEUROBIOL & BEHAV SECT,ITHACA,NY 14853	Cornell University			Galantucci, Bruno/E-5770-2010	Wyttenbach, Robert/0000-0002-1681-9729	NIMH NIH HHS [K05-MH1148] Funding Source: Medline; OMHHE CDC HHS [T32-MN15793] Funding Source: Medline; ODCDC CDC HHS [R01-CD00103] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001148] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); OMHHE CDC HHS; ODCDC CDC HHS; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Boynton Robert M, 1975, HDB PERCEPTION, V5, P301; DOOLING RJ, 1990, PERCEPT PSYCHOPHYS, V47, P568, DOI 10.3758/BF03203109; EHRET G, 1987, CATEGORICAL PERCEPTI, pCH10; Herrnstein R. J., 1984, ANIMAL COGNITION, P233; KUHL PK, 1978, J ACOUST SOC AM, V63, P905, DOI 10.1121/1.381770; KUHL PK, 1981, J ACOUST SOC AM, V70, P340, DOI 10.1121/1.386782; LIBERMAN AM, 1961, J EXP PSYCHOL, V61, P379, DOI 10.1037/h0049038; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; LIBERSAT F, 1994, J COMP PHYSIOL A, V174, P485, DOI 10.1007/BF00191714; MATTINGLY IG, 1972, AM SCI, V60, P327; MAY ML, 1990, J EXP BIOL, V151, P485; MAY ML, 1988, J COMP PHYSIOL A, V164, P243, DOI 10.1007/BF00603954; MAY ML, 1991, J EXP BIOL, V159, P489; MILLER CL, 1976, J SPEECH HEAR RES, V19, P578, DOI 10.1044/jshr.1903.578; MILLER JD, 1976, J ACOUST SOC AM, V60, P410, DOI 10.1121/1.381097; MOISEFF A, 1978, P NATL ACAD SCI USA, V75, P4052, DOI 10.1073/pnas.75.8.4052; MORSE PA, 1975, PERCEPT PSYCHOPHYS, V17, P9, DOI 10.3758/BF03203991; NELSON DA, 1989, SCIENCE, V244, P976, DOI 10.1126/science.2727689; NOLEN TG, 1986, J COMP PHYSIOL A, V159, P423, DOI 10.1007/BF00604163; PASTORE RE, 1977, J EXP PSYCHOL HUMAN, V3, P686, DOI 10.1037/0096-1523.3.4.686; POLLACK GS, 1982, J COMP PHYSIOL, V146, P207, DOI 10.1007/BF00610239; POLLACK GS, 1981, J COMP PHYSIOL, V144, P367, DOI 10.1007/BF00612568; Rosch E., 1978, COGNITION CATEGORIZA, P27, DOI DOI 10.1037/0012-1649.16.5.391; STUDDERTKENNEDY M, 1970, PSYCHOL REV, V77, P234, DOI 10.1037/h0029078	24	146	149	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1542	1544		10.1126/science.273.5281.1542	http://dx.doi.org/10.1126/science.273.5281.1542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703214				2022-12-28	WOS:A1996VG59700038
J	Radford, RG; Holley, KE; Grande, JP; Larson, TS; Wagoner, RD; Donadio, JV; McCarthy, JT				Radford, RG; Holley, KE; Grande, JP; Larson, TS; Wagoner, RD; Donadio, JV; McCarthy, JT			Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE INTERSTITIAL NEPHRITIS; RHEUMATOID-ARTHRITIS; DICLOFENAC; GLOMERULONEPHRITIS; GLOMERULOPATHY	Objective.-To investigate the frequency of membranous nephropathy associated with nonsteroidal anti-inflammatory drug (NSAID) use and identify associated clinical characteristics. Design.-Retrospective chart review. Setting.-A large group practice that staffs 2 large teaching hospitals. Patients.-All patients diagnosed as having stage I or early stage II membranous nephropathy by renal biopsy between January 1975 and May 1995. Main Outcome Measures.-Nephrotic syndrome was said to be associated with NSAID use if patients developed nephrotic syndrome while taking an NSAID and if other causes of membranous nephropathy were excluded and a rapid remission of the nephrotic syndrome followed withdrawal of the drug. Results.-Of 125 patients identified with early membranous nephropathy, 29 were taking NSAIDs at the time symptoms of nephrotic syndrome developed. Thirteen of these patients met the criteria for NSAID-associated membranous nephropathy. None of these patients had any evidence of renal insufficiency or significant proteinuria after follow-up periods ranging from 5 months to 13 years. In addition to diclofenac and fenoprofen, which have previously been implicated, ibuprofen, nabumetone, naproxen, and tolmetin were found to be associated. Conclusions.-Nephrotic syndrome due to membranous nephropathy should be recognized as an idiosyncratic drug reaction to many NSAIDs. Because withdrawal of the drug may result in prompt and complete recovery of normal renal function, a history of NSAID intake should be sought in patients with membranous nephropathy.	MAYO CLIN & MAYO GRAD SCH MED,DIV NEPHROL & INTERNAL MED,ROCHESTER,MN; MAYO CLIN & MAYO FDN,DIV ANAT PATHOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic			Grande, Joseph P./AAG-2128-2020	Grande, Joseph P./0000-0001-5674-1682				ADU D, 1993, BRIT J RHEUMATOL, V32, P1008; Cahen R, 1988, Nephrol Dial Transplant, V3, P705; CAMPISTOL JM, 1989, NEPHROL DIAL TRANSPL, V4, P393, DOI 10.1093/oxfordjournals.ndt.a091897; DECRESPIGNY PJC, 1988, CLIN NEPHROL, V30, P52; DELIGNY BH, 1984, NEPHROLOGIE, V5, P135; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; DUCRET F, 1980, Nephrologie, V1, P143; FIGUEROA JE, 1982, SOUTHERN MED J, V75, P480, DOI 10.1097/00007611-198204000-00028; GARROUSTE O, 1990, ANN MED INTERNE, V141, P627; HAY NM, 1992, NEW ZEAL MED J, V105, P489; HEANEY DJ, 1978, SOUTHERN MED J, V71, P467, DOI 10.1097/00007611-197804000-00034; MIATELLO VR, 1959, PRENSA MED ARGENT, V46, P2551; PORILE JL, 1990, J CLIN PHARMACOL, V30, P468, DOI 10.1002/j.1552-4604.1990.tb03487.x; SCHILLINGER F, 1987, KIDNEY INT, V32, P428; SENNESAEL J, 1986, CLIN NEPHROL, V26, P213; TATTERSALL J, 1992, POSTGRAD MED J, V68, P392, DOI 10.1136/pgmj.68.799.392; WARREN GV, 1989, AM J KIDNEY DIS, V13, P127, DOI 10.1016/S0272-6386(89)80130-1	17	73	79	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					466	469						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691554				2022-12-28	WOS:A1996VA86300034
J	Greer, DL				Greer, DL			Treatment of symptom-free carriers in management of tinea capitis	LANCET			English	Editorial Material							STATE; EPIDEMIOLOGY; SCALP				Greer, DL (corresponding author), LOUISIANA STATE UNIV,DEPT DERMATOL,NEW ORLEANS,LA 70112, USA.							BABEL DE, 1989, J AM ACAD DERMATOL, V21, P1209, DOI 10.1016/S0190-9622(89)70331-5; BABEL DE, 1990, MYCOPATHOLOGIA, V109, P69, DOI 10.1007/BF00436787; FRIEDEN IJ, 1994, J AM ACAD DERMATOL, V31, pS42, DOI 10.1016/S0190-9622(08)81266-2; HOWARD R, 1995, SEMIN DERMATOL, V14, P2, DOI 10.1016/S1085-5629(05)80032-X; MACKENZIE D.W.R., 1961, SABOURAUDIA, V1, P58; NEIL G, 1990, PEDIATR INFECT DIS J, V9, P57, DOI 10.1097/00006454-199001000-00013; WILLIAMS JV, 1995, PEDIATRICS, V96, P265	7	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					350	351		10.1016/S0140-6736(05)64987-2	http://dx.doi.org/10.1016/S0140-6736(05)64987-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709729				2022-12-28	WOS:A1996VB42600005
J	Hedstrom, J; Sainio, V; Kemppainen, E; Haapiainen, R; Kivilaakso, E; Schroder, T; Leinonen, J; Stenman, UH				Hedstrom, J; Sainio, V; Kemppainen, E; Haapiainen, R; Kivilaakso, E; Schroder, T; Leinonen, J; Stenman, UH			Serum complex of trypsin 2 and alpha(1) antitrypsin as diagnostic and prognostic marker of acute pancreatitis: Clinical study in consecutive patients	BRITISH MEDICAL JOURNAL			English	Article							PERITONEAL-LAVAGE; SEVERITY; ASSAYS; TRIAL	Objective-To estimate the usefulness of serum concentrations of the complex of trypsin 2 and alpha(1) antitrypsin in diagnosing and assessing the severity of acute pancreatitis in comparison with serum C reactive protein, amylase, and trypsinogen 2 concentrations (reference markers). Design-Markers were measured in consecutive patients admitted with acute abdominal pain that was either due to pancreatitis or to other disease unrelated to the pancreas (controls). Setting-Department of surgery of a teaching hospital in Helsinki. Subjects-110 patients with acute pancreatitis and 66 with acute abdominal diseases of extrapancreatic origin. On the basis of the clinical course, acute pancreatitis was classified as mild (82 patients) or severe (28 patients). Main outcome measures-Clinical diagnosis of acute pancreatitis and severity of the disease. Results-At admission all patients with acute pancreatitis had clearly raised concentrations of trypsin 2-alpha(1) antitrypsin complex (32 mu g/l), whereas only three of the controls had such values. Of the markers studied, trypsin 2-alpha(1) antitrypsin complex had the largest area under the receiver operating curve, both in differentiating acute pancreatitis from extrapancreatic disease and in differentiating mild from severe disease. Conclusions-Of the markers studied, trypsin 2-alpha(1) antitrypsin complex was the most accurate in differentiating between acute pancreatitis and extrapancreatic disease and in predicting a severe course for acute pancreatitis.	HELSINKI UNIV,CENT HOSP,DEPT CLIN CHEM,FIN-00290 HELSINKI,FINLAND; HELSINKI UNIV,CENT HOSP,DEPT SURG 2,FIN-00290 HELSINKI,FINLAND; HELSINKI UNIV,CENT HOSP,DEPT SURG,FIN-00290 HELSINKI,FINLAND	University of Helsinki; University of Helsinki; University of Helsinki								BLOCK S, 1986, GUT, V27, P1035, DOI 10.1136/gut.27.9.1035; BORGSTROM A, 1978, EUR J CLIN INVEST, V8, P379, DOI 10.1111/j.1365-2362.1978.tb00868.x; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; DAMMANN HG, 1980, LANCET, V2, P860; DURIE PR, 1982, J PEDIATR GASTR NUTR, V1, P337, DOI 10.1097/00005176-198201030-00010; FISCHER CL, 1976, AM J CLIN PATHOL, V66, P840; GUDGEON AM, 1990, LANCET, V335, P4, DOI 10.1016/0140-6736(90)90135-R; HEDSTROM J, 1994, CLIN CHEM, V40, P1761; IMRIE CW, 1978, BRIT J SURG, V65, P337, DOI 10.1002/bjs.1800650514; ITKONEN O, 1990, J LAB CLIN MED, V115, P712; KIVISAARI L, 1984, GASTROINTEST RADIOL, V9, P27, DOI 10.1007/BF01887796; KOIVUNEN E, 1990, CANCER RES, V50, P2375; LASSON A, 1984, SCAND J GASTROENTERO, V19, P779, DOI 10.1080/00365521.1984.12005808; LEVITT RG, 1978, RADIOLOGY, V126, P149, DOI 10.1148/126.1.149; MAYER AD, 1985, NEW ENGL J MED, V312, P399, DOI 10.1056/NEJM198502143120703; OHISSON K, 1988, ACTA GASTROENTEROL B, V51, P3; OHLSSON K, 1975, GASTROENTEROLOGY, V69, P668; RANSON JHC, 1978, ANN SURG, V187, P565, DOI 10.1097/00000658-197805000-00016; SALT WB, 1976, MEDICINE, V55, P269, DOI 10.1097/00005792-197607000-00001; STEINBERG WM, 1985, ANN INTERN MED, V102, P576, DOI 10.7326/0003-4819-102-5-576; WILLIAMSON RCN, 1984, GUT, V25, P1331, DOI 10.1136/gut.25.12.1331; ZWEIG MH, 1993, CLIN CHEM, V39, P561	22	73	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					333	337		10.1136/bmj.313.7053.333	http://dx.doi.org/10.1136/bmj.313.7053.333			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760740	Green Published			2022-12-28	WOS:A1996VC30000018
J	Smith, IE				Smith, IE			Prophylactic cranial irradiation for small-cell lung cancer	LANCET			English	Editorial Material											Smith, IE (corresponding author), ROYAL MARSDEN NHS TRUST,LUNG UNIT,DOWNS RD,SUTTON SM2 5PT,SURREY,ENGLAND.							GREGOR A, 1996, P AN M AM SOC CLIN, V15, P381; HARDY J, 1990, BRIT J CANCER, V62, P684, DOI 10.1038/bjc.1990.357; JOHNSON BE, 1985, J CLIN ONCOL, V3, P1659, DOI 10.1200/JCO.1985.3.12.1659; KOMAKI R, 1993, P AN M AM SOC CLIN, V12, P1084; LUCAS CF, 1986, CANCER TREAT REP, V70, P565; Work E, 1996, EUR J CANCER, V32A, P772, DOI 10.1016/0959-8049(95)00597-8	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					350	350		10.1016/S0140-6736(05)64986-0	http://dx.doi.org/10.1016/S0140-6736(05)64986-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709728				2022-12-28	WOS:A1996VB42600004
J	Linde, K; Ramirez, G; Mulrow, CD; Pauls, A; Weidenhammer, W; Melchart, D				Linde, K; Ramirez, G; Mulrow, CD; Pauls, A; Weidenhammer, W; Melchart, D			St John's wort for depression - An overview and meta-analysis of randomised clinical trials	BRITISH MEDICAL JOURNAL			English	Article							HYPERICUM EXTRACT; UNITED-STATES; DISORDERS	Objective-To investigate if extracts of Hypericum perforatum (St John's wort) are more effective than placebo in the treatment of depression, are as effective as standard antidepressive treatment, and have fewer side effects than standard antidepressant drugs. Design-Systematic review and meta-analysis of trials revealed by searches. Trials-23 randomised trials including a total of 1757 outpatients with mainly mild or moderately severe depressive disorders: 15 (14 testing single preparations and one a combination with other plant extracts) were placebo controlled, and eight (six testing single preparations and two combinations) compared hypericum with another drug treatment. Main outcome measures-A pooled estimate of the responder rate ratio (responder rate in treatment group/responder rate in control group), and numbers of patients reporting and dropping out for side effects. Results-Hypericum extracts were significantly superior to placebo (ratio = 2.67; 95% confidence interval 1.78 to 4.01) and similarly effective as standard antidepressants (single preparations 1.10; 0.93 to 1.31, combinations 1.52; 0.78 to 2.94). There were two (0.8%) drop outs for side effects with hypericum and seven (3.0%) with standard antidepressant drugs. Side effects occurred in 50 (19.8%) patients on hypericum and 84 (52.8%) patients on standard antidepressants. Conclusion-There is evidence that extracts of hypericum are more effective than placebo for the treatment of mild to moderately severe depressive disorders. Further studies comparing extracts with standard antidepressants in well defined groups of patients and comparing different extracts and doses are needed.	AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO COCHRANE CTR,SAN ANTONIO,TX 78284; PRIVATE PRACTICE NEUROL & PSYCHIAT,D-80796 MUNICH,GERMANY	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Linde, K (corresponding author), UNIV MUNICH,PROJEKT MUNCHENER MODELL,KAISERSTR 9,D-80801 MUNICH,GERMANY.			Linde, Klaus/0000-0002-2902-970X				ALBERTINI H, 1986, RECHERCHE HOMEOPATHI, P75; *ASS METH DOC PSYC, 1990, RAT SCAL PSYCH; BENDRE VV, 1980, HAHNEMANN GLEANINGS, V47, P70; BERGMANN R, 1993, THERAPIEWOCHE NEUROL, V7, P235; DITTMER TLJ, 1992, NATURHEILPRAXIS NATU, V45, P118; DITZLER K, 1994, COMPLEMENT THER MED, V2, P5; Ernst E, 1995, PHYTOMEDICINE, V2, P67, DOI 10.1016/S0944-7113(11)80051-6; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; HALAMA P, 1991, NERVENHEILKUNDE, V10, P250; HANSGEN KD, 1994, J GERIATR PSYCHIA S1, V7, P15; HARRER G, 1993, NERVENHEILKUNDE, V12, P271; HARRER G, 1991, TW NEUROL PSYCHIATR, V5, P710; HARRER G, 1994, J GERIATR PSYCHIA S1, V7, P24; Hedges L, 1985, STATISTICAL METHODS; Hoffmann J, 1979, ZFA (Stuttgart), V55, P776; HOLZL J, 1993, Z PHYTOTHER, V14, P255; HUBNER WD, 1994, J GERIATR PSYCHIA S1, V7, P12; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOHNSON D, 1992, NEUROL PSYCHIATR, V6, P436; Johnson D, 1994, J GERIATR PSYCH NEUR, V7, P44; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KNIEBEL R, 1988, Z ALLG MED, V64, P689; KONIG CD, 1993, THESIS U BASEL; KUGLER J, 1990, Z ALLGEMEINMEDIZIN, V66, P13; KUGLER J, 1990, Z ALLG MED, V66, P21; LEHRL S, 1993, NERVENHEILKUNDE, V12, P281; LOHSE MJ, 1994, ARZNIEVERORDNUNGSREP, P354; MARTINEZ B, 1994, J GERIATR PSYCHIA S1, V7, P29; OSTERHEIDER M, 1992, FORTSCHR NEUROL PSYC, V60, P210; PANIJEL J, 1985, THERAPIEWOCHE, V41, P4659; QUANDT J, 1994, THERAPIEWOCHE, V44, P292; QUANDT J, 1993, ALLGEMEINARZT, V2, P97; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; REH C, 1992, THERAPIEWOCHE, V42, P1576; Schlich D, 1987, PSYCHO, V13, P440; Schmidt U, 1993, Fortschr Med, V111, P339; SCHMIDT U, 1993, NERVENHEILKUNDE, V12, P314; SCHMIDT U, 1989, PSYCHO, V15, P665; Schulz H, 1994, J GERIATR PSYCHIAT, V7, P39; SIEGERS CP, 1993, NERVENHEILKUNDE, V12, P320; SIEGERS CP, 1994, ALLGEMEINARZT, V16, P448; SOMMER H, 1994, J GERIATR PSYCHIA S1, V7, P9; SPIELBERGER E, 1985, ARZTLICHE PRAXIS, V37, P2546; Staffeldt B., 1994, J GERIATR PSYCHIA S1, V7, P47; STEGER W, 1985, Z ALLG MED, V61, P914; UPMEYER HJ, 1990, Z ALLGEMEINMEDIZI S1, V66, P33; VORBACH EU, 1994, J GERIATR PSYCHIA S1, V7, P19; WAGNER H, 1994, J GERIATR PSYCHIA S1, V7, P65; WARNECKE G, 1986, Z ALLGEMEINMED, V62, P1111; WENZEL P, 1993, HEILKUNST, V106, P21; WERTH W, 1989, KASSENARZT, V15, P64; WOELK H, 1994, J GERIATR PSYCHIA S1, V7, P34	52	747	779	0	109	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					253	258		10.1136/bmj.313.7052.253	http://dx.doi.org/10.1136/bmj.313.7052.253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704532	Green Published			2022-12-28	WOS:A1996VA90300020
J	Kardar, M				Kardar, M			Which came first, protein sequence or structure?	SCIENCE			English	Article											Kardar, M (corresponding author), MIT,DEPT PHYS,CAMBRIDGE,MA 02139, USA.			Kardar, Mehran/0000-0002-1112-5912				Li H, 1996, SCIENCE, V273, P666, DOI 10.1126/science.273.5275.666; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PANDE VS, 1995, J CHEM PHYS, V103, P9482, DOI 10.1063/1.470009; SHAKHNOVICH E, 1990, J CHEM PHYS, V93, P59637; YEE DP, 1994, J MOL BIOL, V241, P557, DOI 10.1006/jmbi.1994.1531	6	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					610	610		10.1126/science.273.5275.610	http://dx.doi.org/10.1126/science.273.5275.610			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8701315				2022-12-28	WOS:A1996VA24900035
J	Ahima, RS; Prabakaran, D; Mantzoros, C; Qu, DQ; Lowell, B; MaratosFlier, E; Flier, JS				Ahima, RS; Prabakaran, D; Mantzoros, C; Qu, DQ; Lowell, B; MaratosFlier, E; Flier, JS			Role of leptin in the neuroendocrine response to fasting	NATURE			English	Article							FOOD-DEPRIVATION; SECRETION; RAT	A TOTAL deficiency in or resistance to the protein leptin causes severe obesity(1-4). As leptin levels rise with increasing adiposity in rodents(5) and man(6,7), it is proposed to act as a negative feedback 'adipostatic signal' to brain centres controlling energy homeostasis, limiting obesity in times of nutritional abundance(1,3). Starvation is also a threat to homeostasis that triggers adaptive responses(8-12), but whether leptin plays a role in the physiology of starvation is unknown. Leptin concentration falls during starvation(13) and totally leptin-deficient ob/ob mice have neuroendocrine abnormalities similar to those of starvation(14), suggesting that this may be the case. Here we show that preventing the starvation-induced fall in leptin with exogenous leptin substantially blunts the changes in gonadal, adrenal and thyroid axes in male mice, and prevents the starvation-induced delay in ovulation in female mice. In contrast, leptin repletion during this period of starvation has little or no effect on body weight, blood glucose or ketones. We propose that regulation of the neuroendocrine system during starvation could be the main physiological role of leptin.	BETH ISRAEL HOSP,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Mantzoros, Christos/Y-2902-2019; Flier, jeffrey/AAG-6223-2019; Ahima, Rexford/W-1394-2019					BATES GW, 1985, CLIN OBSTET GYNECOL, V28, P632; BRAY GA, 1990, FRONT NEUROENDOCRIN, V11, P128; BRONSON FH, 1985, BIOL REPROD, V33, P660, DOI 10.1095/biolreprod33.3.660; CAHILL GF, 1966, J CLIN INVEST, V45, P1751, DOI 10.1172/JCI105481; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHEBAB FF, 1996, NAT GENET, V12, P318; CONNORS JM, 1985, ENDOCRINOLOGY, V117, P900, DOI 10.1210/endo-117-3-900; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; COOPER RL, 1984, ENDOCRINOLOGY, V114, P391, DOI 10.1210/endo-114-2-391; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Pierroz DD, 1996, ENDOCRINOLOGY, V137, P3, DOI 10.1210/en.137.1.3; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; SCHREIHOFER DA, 1993, ENDOCRINOLOGY, V132, P1890, DOI 10.1210/en.132.5.1890; SCHWARTZ MW, 1995, AM J PHYSIOL-REG I, V269, pR949, DOI 10.1152/ajpregu.1995.269.5.R949; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WHITE J D, 1990, Molecular and Cellular Neuroscience, V1, P41; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	24	2523	2580	5	166	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					250	252		10.1038/382250a0	http://dx.doi.org/10.1038/382250a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717038				2022-12-28	WOS:A1996UX79000048
J	Dernburg, AF; Sedat, JW; Hawley, RS				Dernburg, AF; Sedat, JW; Hawley, RS			Direct evidence of a role for heterochromatin in meiotic chromosome segregation	CELL			English	Article							DROSOPHILA-MELANOGASTER FEMALES; KINESIN-LIKE PROTEIN; SYNAPTONEMAL COMPLEX; ACHIASMATE SEGREGATION; RECOMBINATION NODULES; WILD-TYPE; DISTRIBUTIVE SEGREGATION; GENETIC-ANALYSIS; SATELLITE DNA; MICROSCOPY	We have investigated the mechanism that enables achiasmate chromosomes to segregate from each other at meiosis I in D. melanogaster oocytes. Using novel cytological methods, we asked whether nonexchange chromosomes are paired prior to disjunction. Our results show that the heterochromatin of homologous chromosomes remains associated throughout prophase until metaphase I regardless of whether they undergo exchange, suggesting that homologous recognition can lead to segregation even in the absence of chiasmata. However, partner chromosomes lacking homology do not pair prior to disjunction. Furthermore, euchromatic synapsis is not maintained throughout prophase. These observations provide a physical demonstration that homologous and heterologous achiasmate segregations occur by different mechanisms and establish a role for heterochromatin in maintaining the alignment of chromosomes during meiosis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF DAVIS, SECT MOL & CELLULAR BIOL, DEPT GENET, DAVIS, CA 95616 USA	University of California System; University of California San Francisco; University of California System; University of California Davis				Hawley, R. Scott/0000-0002-6478-0494; Dernburg, Abby/0000-0001-8037-1079				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Bridges CB, 1925, GENETICS, V10, P418; BRITTNACHER JG, 1989, GENETICS, V121, P739; CARMENA M, 1993, J CELL SCI, V105, P41; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1975, CHROMOSOMA, V51, P157, DOI 10.1007/BF00319833; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1981, CHROMOSOMA, V83, P59, DOI 10.1007/BF00286016; CARPENTER ATC, 1979, GENETICS, V92, P511; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; COMINGS DE, 1980, HUM GENET, V53, P131, DOI 10.1007/BF00273484; DEMBURG AF, 1996, CELL, V85, P745; DREIBIN RA, 1986, COMPUT GRAPH, V22, P65; GERSHENSON S, 1940, VIDENSK AKAD NAUK UR, V3, P3; Grell R. F., 1976, GENET BIOL DROSOPHIL, VIa, P435; GRELL RF, 1962, P NATL ACAD SCI USA, V48, P165, DOI 10.1073/pnas.48.2.165; GRELL RF, 1962, GENETICS, V50, P150; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HAWLEY RS, 1992, DEV GENET, V13, P440, DOI 10.1002/dvg.1020130608; Heitz E., 1928, JAHRB WISS BOT, V69, P762; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HSIEH T, 1979, J MOL BIOL, V135, P465, DOI 10.1016/0022-2836(79)90447-9; King R. C., 1970, OVARIAN DEV DROSOPHI; LINDSLEY DL, 1992, GENOME DROSOPHILIA M; LOHE AR, 1993, GENETICS, V134, P1149; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MAHOWALD AP, 1970, ROUX ARCH DEV BIOL, V165, P8; MAHOWALD AP, 1980, GENET BIOL DROSOPHIL, P141; MAKUNIN IV, 1995, DOKL AKAD NAUK+, V344, P266; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; Merriam J., 1968, DROS INFORM SERV, V43, P64; NICKLAS RB, 1977, PHILOS T ROY SOC B, V277, P267, DOI 10.1098/rstb.1977.0017; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; NOKKALA S, 1976, HEREDITAS, V83, P265; NOVITSKI E, 1964, GENETICS, V50, P1449; NOVITSKI E, 1981, GENETICS, V98, P257; NOVITSKI E, 1976, GENET BIOL DROSOPHIL, P562; OTOUSA J, 1982, GENETICS, V102, P503; PARDUE ML, 1977, CHROMOSOMA, V63, P135, DOI 10.1007/BF00292726; PARDUE ML, 1990, CHROMOSOMA, V100, P3, DOI 10.1007/BF00337597; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PIMPINELLI S, 1989, GENETICS, V121, P765; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; PURO J, 1977, CHROMOSOMA, V63, P273, DOI 10.1007/BF00327454; Rabl C, 1885, MORPHOL JB, V10, P214; SANDLER L, 1956, GENETICS, V41, P189; Sturtevant AH, 1936, GENETICS, V21, P554; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Weinstein A, 1936, GENETICS, V21, P155; WHYTE WL, 1993, GENETICS, V134, P825; WOLF KW, 1994, BIOESSAYS, V16, P107, DOI 10.1002/bies.950160207; WU CI, 1988, CELL, V54, P179, DOI 10.1016/0092-8674(88)90550-8; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZITRON AE, 1989, GENETICS, V122, P801	60	293	297	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					135	146		10.1016/S0092-8674(00)80084-7	http://dx.doi.org/10.1016/S0092-8674(00)80084-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689681	Bronze			2022-12-28	WOS:A1996UX93400015
J	Penton, A; Hoffmann, FM				Penton, A; Hoffmann, FM			Decapentaplegic restricts the domain of wingless during Drosophila limb patterning	NATURE			English	Article							IMAGINAL DISKS; GENE; EXPRESSION	SIGNALLING proteins in the BMP-decapentaplegic (dpp), WNT-wingless (wg) and Shh-hedgehog (hh) families have been implicated in Limb and appendage development in both invertebrates and vertebrates(1-3), In Drosophila, dpp protein (Dpp) induces distal outgrowth and patterning of legs and wings, but the molecular responses to Dpp are not well characterized(4-9). Analysis of clones mutant for the Dpp receptors encoded by punt or thickveins (tkv) reveals that repression of wg expression is one critical function of Dpp signalling in leg and wing discs. Distal clones that lie on the anterior edge of the anterior-posterior compartment boundary ectopically express wg and cause pattern abnormalities, suggesting that Dpp represses Hh activation of wg in the distal primordia of the leg and wing. By repressing Hg expression in the leg, Dpp signalling limits the region that responds to high levels of Wg and Dpp to the site of distal outgrowth. Such negative regulatory feedback loops between signalling molecules are likely to be critical for limb patterning in other species.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,GENET LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Hoffmann, F. Michael/0000-0002-2770-9656				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL G, 1995, DEVELOPMENT, V121, P619; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; INGHAM PW, 1993, DEVELOPMENT, V117, P283; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; XU T, 1993, DEVELOPMENT, V117, P1223; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	29	92	93	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					162	165		10.1038/382162a0	http://dx.doi.org/10.1038/382162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700205				2022-12-28	WOS:A1996UW67200048
J	Bergqvist, D; Benoni, G; Bjorgell, O; Fredin, H; Hedlundh, U; Nicolas, S; Nilsson, P; Nylander, G				Bergqvist, D; Benoni, G; Bjorgell, O; Fredin, H; Hedlundh, U; Nicolas, S; Nilsson, P; Nylander, G			Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; PULMONARY-EMBOLISM; PERIOPERATIVE THROMBOSIS; UNFRACTIONATED HEPARIN; ORTHOPEDIC-SURGERY; STANDARD HEPARIN; PREVENTION; ARTHROPLASTY; METAANALYSIS	Background The risk of venous thromboembolism in patients undergoing total hip replacement is known to be high. However, the optimal duration of prophylaxis with anticoagulant agents after this procedure is unknown. We sought to determine whether one month of anticoagulant therapy with the low-molecular-weight heparin enoxaparin is more effective than enoxaparin therapy given only during the hospitalization for surgery. Methods Two hundred sixty-two patients undergoing total hip replacement received enoxaparin during their hospitalizations (average stay, 10 to 11 days). They were then randomly assigned to receive enoxaparin or placebo (131 patients each). Blinded outpatient therapy (or placebo) was continued long enough that the total treatment period, inpatient plus outpatient, was one month for each patient. Bilateral ascending phlebography was performed 19 to 23 days after discharge, with deep-vein thrombosis as the primary end point. Distal and proximal thrombosis, pulmonary embolism, and hemorrhage were also recorded, as were deaths. Results Venography was adequate in 116 patients in the placebo group and 117 in the enoxaparin group. We observed 43 episodes of deep-vein thrombosis and 2 episodes of pulmonary embolism in the placebo group, but only 21 episodes of deep-vein thrombosis and no episodes of pulmonary embolism in the enoxaparin group (incidence of thromboembolism, 39 percent and 18 percent, respectively; P<0.001). The difference in the incidence of proximal deep-vein thrombosis was also significant (24 percent and 7 percent in the placebo and enoxaparin groups, respectively; P<0.001). Six patients in the enoxaparin group and one patient in the placebo group had hematomas at their injection sites. No patients died or had major complications. Conclusions There were significantly fewer venous thromboembolic complications in patients undergoing elective hip replacement when prophylaxis with enoxaparin was given for a total of one month, rather than only during the hospitalization. (C) 1996, Massachusetts Medical Society.	MALMO UNIV HOSP, DEPT ORTHOPED SURG, MALMO, SWEDEN; MALMO UNIV HOSP, DEPT DIAGNOST RADIOL, MALMO, SWEDEN; RHONE POULENC RORER, DEPT RES & DEV, PARIS, FRANCE	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Sanofi-Aventis	Bergqvist, D (corresponding author), ACAD HOSP, DEPT SURG, S-75185 UPPSALA, SWEDEN.							AGNELLI G, 1992, THROMB HAEMOSTASIS, V68, P257; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; BERGQVIST D, 1991, ACTA CHIR-EUR J SURG, V157, P571; BERGQVIST D, 1992, ACTA ANAESTH SCAND, V36, P605, DOI 10.1111/j.1399-6576.1992.tb03529.x; Bergqvist D, 1996, DISORDERS THROMBOSIS, P228; BORRIS LC, 1994, INT J CLIN PHARM TH, V32, P262; DAHL OE, 1995, THROMB HAEMOSTASIS, V73, P1094; ERIKSSON BI, 1988, BRIT J SURG, V75, P1053, DOI 10.1002/bjs.1800751104; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HAMPSON WGJ, 1974, LANCET, V2, P795; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; JORGENSEN LN, 1993, BRIT J SURG, V80, P689, DOI 10.1002/bjs.1800800607; KRISTIANSEN P, 1981, ACTA RADIOL DIAGN, V22, P577, DOI 10.1177/028418518102200511; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; LEYVRAZ PF, 1991, BRIT MED J, V303, P1243; MANNUCCI PM, 1976, THROMB HAEMOSTASIS, V36, P157; MCNALLY MA, 1993, J BONE JOINT SURG BR, V75, P640, DOI 10.1302/0301-620X.75B4.8331123; MOHR DN, 1993, ARCH INTERN MED, V153, P2221, DOI 10.1001/archinte.153.19.2221; NICOLAIDES AN, 1992, INT ANGIOL, V11, P151; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; Paiement G D, 1992, J Arthroplasty, V7, P471, DOI 10.1016/S0883-5403(05)80220-7; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; PLANES A, 1990, J BONE JOINT SURG BR, V72, P9, DOI 10.1302/0301-620X.72B1.2298803; PLANES A, IN PRESS LANCET; SCHRODER HM, 1993, CLIN ORTHOP RELAT R, V293, P196; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; TROWBRIDGE A, 1994, CLIN ORTHOP RELAT R, V299, P203; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; VANDERMEULEN EP, 1994, ANESTH ANALG, V79, P1165; WARWICK D, 1995, J BONE JOINT SURG BR, V77B, P6, DOI 10.1302/0301-620X.77B1.7822397; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	35	402	408	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					696	700		10.1056/NEJM199609053351002	http://dx.doi.org/10.1056/NEJM199609053351002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH266	8703168				2022-12-28	WOS:A1996VH26600002
J	Scheffer, H				Scheffer, H			Search for genes predisposing to atopic diseases	LANCET			English	Editorial Material							HYPERRESPONSIVENESS; LINKAGE; MARKERS				Scheffer, H (corresponding author), UNIV GRONINGEN, DEPT MED GENET, NL-9713 AW GRONINGEN, NETHERLANDS.		Scheffer, Hans/E-4644-2012	Scheffer, Hans/0000-0002-2986-0915				AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; COOKSON WOCM, 1989, LANCET, V1, P1292; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125	7	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					560	561		10.1016/S0140-6736(05)64793-9	http://dx.doi.org/10.1016/S0140-6736(05)64793-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774564				2022-12-28	WOS:A1996VF18600005
J	Moazed, D; Johnson, AD				Moazed, D; Johnson, AD			A deubiquitinating enzyme interacts with SIR4 and regulates silencing in S-cerevisiae	CELL			English	Article							UBIQUITIN-PROTEASOME PATHWAY; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; CHROMOSOME SEGREGATION; TRANSCRIPTIONAL STATES; MULTIPROTEIN COMPLEX; BINDING-PROTEIN; MATING LOCI; HISTONE H3	The SIR2, SIR3, and SIR4 proteins are required for silencing of transcription at the silent mating type loci and at telomeres in yeast. Using protein affinity chromatography, we show that SIR2, SIR3, and two proteins of 69 and 110 kDa tightly associate with SIR4. Surprisingly, the 110 kDa SIR4-binding protein is identical to UBP3, one of several previously described yeast enzymes that deubiquitinate target proteins. Deletion of the UBP3 gene results in markedly improved silencing of genes inserted either near a telomere or at one of the silent mating type loci, indicating that UBP3 is an inhibitor of silencing. We discuss possible roles for UBP3 in controlling the activity or assembly of the SIR protein complex.			Moazed, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143, USA.							ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GALL JG, 1971, CHROMOSOMA, V33, P319; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KELLUM R, 1995, J CELL SCI, V108, P1419; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LOO S, 1995, GENETICS, V141, P889; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; RINE J, 1987, GENETICS, V116, P9; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SHEI GJ, 1995, MOL CELL BIOL, V15, P3496; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spofford J., 1976, GENET BIOL DROSOPHIL, VVolume 1, P955; SPRADLING A, 1987, ANNU REV GENET, V21, P373, DOI 10.1146/annurev.ge.21.120187.002105; SPRAGUE G F JR, 1991, P77; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; VARSHAVSKY A, 1987, BIOCHEM SOC T, V15, P815, DOI 10.1042/bst0150815; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WILEY EA, 1995, GENETICS, V139, P67	65	211	215	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					667	677		10.1016/S0092-8674(00)80139-7	http://dx.doi.org/10.1016/S0092-8674(00)80139-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752220	Bronze			2022-12-28	WOS:A1996VE23500016
J	Sowers, MF; Hollis, BW; Shapiro, B; Randolph, J; Janney, CA; Zhang, DW; Schork, MA; Crutchfield, M; Stanczyk, F; RussellAulet, M				Sowers, MF; Hollis, BW; Shapiro, B; Randolph, J; Janney, CA; Zhang, DW; Schork, MA; Crutchfield, M; Stanczyk, F; RussellAulet, M			Elevated parathyroid hormone-related peptide associated with lactation and bone density loss	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTPARTUM WOMEN; MINERAL CONTENT; MAMMARY TISSUE; MILK CALCIUM; PROTEIN; PREGNANCY; TURNOVER; HYPERCALCEMIA; CONSERVATION; METABOLISM	Objective.-To investigate the hypothesis that parathyroid hormone-related peptide (PTHrP) may be involved with bone loss and recovery as a means of providing adequate calcium and phosphate to infants. Design.-An 18-month prospective cohort study. Setting.-General community setting with recruitment occurring at birthing education classes. Participants.-Volunteer sample of 115 postpartum healthy women aged 20 to 40 years, and 0 or 1 parity prior to parturition with no intent to breast-feed or intent to breast-feed at least 6 months. Main Outcome Measures.-Parathyroid hormone-related peptide, prolactin, estradiol, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, femoral bone mineral density, and bone turnover markers were measured in 115 postpartum women at 2 weeks, 2 months, 4 months, 6 months, 12 months, and 18 months postpartum. Lumbar bone mineral density was measured at 2 weeks, 6 months, 12 months, and 18 months postpartum. Results.-Elevated PTHrP values were significantly associated (P<.001) with breast-feeding status, elevated prolactin levels, and lower serum estradiol levels, conditions occurring during lactation, Furthermore, elevated PTHrP levels were negatively and significantly associated (P<.01) over time with bone mineral density change at both the spine and the femoral neck, even after accounting for prolactin levels, breast-feeding status, return of menstruation, estradiol levels, PTH levels, 1,25-dihydroxyvitamin D levels, dietary calcium intake, physical activity, and body size. Conclusion.-These data clearly support the hypothesis that PTHrP is an alternative mechanism associated with bone loss and recovery during and subsequent to lactation.	UNIV MICHIGAN, DEPT BIOSTAT, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT OBSTET & GYNECOL, ANN ARBOR, MI 48109 USA; MED UNIV S CAROLINA, DEPT PEDIAT, CHARLESTON, SC 29425 USA; UNIV SO CALIF, SCH MED, DEPT OBSTET & GYNECOL, LOS ANGELES, CA 90033 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Medical University of South Carolina; University of Southern California	Sowers, MF (corresponding author), UNIV MICHIGAN, SCH PUBL HLTH,DEPT EPIDEMIOL,109 OBSERV,ROOM 3037, SPH-1, ANN ARBOR, MI 48109 USA.			Randolph, John/0000-0003-4901-7711	NIAMS NIH HHS [R29 AR39651, R01 AR41310] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041310, R29AR039651] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATKINSON P J, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P555; BAIRD DT, 1979, J CLIN ENDOCR METAB, V49, P500, DOI 10.1210/jcem-49-4-500; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BROMMAGE R, 1985, AM J PHYSIOL, V248, pE182, DOI 10.1152/ajpendo.1985.248.2.E182; BUDAYR AA, 1989, P NATL ACAD SCI USA, V86, P7183, DOI 10.1073/pnas.86.18.7183; CAIRD LE, 1994, CLIN ENDOCRINOL, V41, P739, DOI 10.1111/j.1365-2265.1994.tb02788.x; CANALIS E, 1990, ENDOCRINOLOGY, V126, P1806, DOI 10.1210/endo-126-4-1806; CHAN GM, 1987, AM J CLIN NUTR, V46, P319, DOI 10.1093/ajcn/46.2.319; CROSS NA, 1995, AM J CLIN NUTR, V61, P514, DOI 10.1093/ajcn/61.3.514; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DOBNIG H, 1995, J CLIN ENDOCR METAB, V80, P3699, DOI 10.1210/jc.80.12.3699; DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E; GARNER SC, 1990, J BONE MINER RES, V5, P69, DOI 10.1002/jbmr.5650050111; GREER FR, 1982, AM J CLIN NUTR, V86, P431; GRILL V, 1992, CLIN ENDOCRINOL, V37, P405, DOI 10.1111/j.1365-2265.1992.tb02350.x; HAYSLIP CC, 1989, OBSTET GYNECOL, V73, P588; KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409; KENT GN, 1991, MINER ELECTROL METAB, V17, P1; KHOSLA S, 1990, MAYO CLIN PROC, V65, P1408, DOI 10.1016/S0025-6196(12)62164-8; LAMKE B, 1977, ACTA OBSTET GYN SCAN, V56, P217, DOI 10.3109/00016347709162123; LAW FMK, 1991, J ENDOCRINOL, V128, P21, DOI 10.1677/joe.0.1280021; PRENTICE A, 1995, AM J CLIN NUTR, V62, P58, DOI 10.1093/ajcn/62.1.58; RATCLIFFE WA, 1992, J ENDOCRINOL, V133, P87, DOI 10.1677/joe.0.1330087; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; *SAS I INC, 1992, P229 SAS; SAS Institute, 1990, SAS STAT US GUID VER; SOWERS M, 1995, J CLIN ENDOCR METAB, V80, P2210, DOI 10.1210/jc.80.7.2210; SOWERS M, 1995, OBSTET GYNECOL, V85, P285, DOI 10.1016/0029-7844(94)00351-D; SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130; SPECKER BL, 1994, AM J CLIN NUTR, V59, P593, DOI 10.1093/ajcn/59.3.593; STIEGLER C, 1995, J BONE MINER RES, V10, P751; THIEDE MA, 1989, MOL ENDOCRINOL, V3, P1443, DOI 10.1210/mend-3-9-1443; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; THOMAS ML, 1991, P SOC EXP BIOL MED, V196, P214, DOI 10.3181/00379727-196-43182; UZAWA T, 1995, BONE, V16, P477; VARGAS SJ, 1992, J BONE MINER RES, V7, P971; WADA S, 1992, INTERNAL MED, V31, P968, DOI 10.2169/internalmedicine.31.968; ZARATE A, 1987, J STEROID BIOCHEM, V27, P1023, DOI 10.1016/0022-4731(87)90185-3; ZHANG D, 1996, INT BIOM SOC E N AM; ZINAMAN MJ, 1995, J CLIN ENDOCR METAB, V80, P2088, DOI 10.1210/jc.80.7.2088	41	170	174	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					549	554		10.1001/jama.276.7.549	http://dx.doi.org/10.1001/jama.276.7.549			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709404				2022-12-28	WOS:A1996VC10100031
J	McKeganey, N; Forsyth, A; Barnard, M; Hay, G				McKeganey, N; Forsyth, A; Barnard, M; Hay, G			Designer drinks and drunkenness amongst a sample of Scottish schoolchildren	BRITISH MEDICAL JOURNAL			English	Article											McKeganey, N (corresponding author), UNIV GLASGOW,CTR DRUG MISUSE RES,GLASGOW G12 8RT,LANARK,SCOTLAND.		Forsyth, Alasdair John/ABG-3968-2021; Hay, Gordon/K-3310-2015	Hay, Gordon/0000-0002-8346-9618				Barnard M, 1996, DRUG-EDUC PREV POLIC, V3, P81, DOI 10.3109/09687639609019313; Carstairs V., 1991, DEPRIVATION HLTH SCO; *HLTH ED AUT, 1995, YOUNG AD HLTH LIF AL; *ROYAL COLL PHYS R, 1995, ALC YOUNG	4	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					401	401						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761229				2022-12-28	WOS:A1996VD20600027
J	Finter, NB				Finter, NB			The naming of cats - And alpha-interferons	LANCET			English	Editorial Material							CARCINOID-TUMORS; ANTIBODIES				Finter, NB (corresponding author), TIDESWELL,9 BURNTWOOD RD,SEVENOAKS TN13 1PS,KENT,ENGLAND.							Allen G, 1996, J INTERF CYTOK RES, V16, P181, DOI 10.1089/jir.1996.16.181; ANTONELLI G, 1991, J INFECT DIS, V163, P882, DOI 10.1093/infdis/163.4.882; Bacon B. R., 1995, Hepatology, V22, p152A; FINTER N B, 1991, Journal of Interferon Research, P185; GRANDER D, 1990, LANCET, V336, P337, DOI 10.1016/0140-6736(90)91879-F; HAWKINS MJ, 1984, J CLIN ONCOL, V2, P221, DOI 10.1200/JCO.1984.2.3.221; HENCO K, 1985, J MOL BIOL, V185, P227, DOI 10.1016/0022-2836(85)90401-2; Hopps H. E., 1985, INTERFERON, V4, P121; OBERG KE, 1994, J INTERFERON RES, V14, P215, DOI 10.1089/jir.1994.14.215; PESTKA S, 1995, EPIDERMAL GROWTH FAC, P163; Phillips, 1985, LARGE SCALE MAMMALIA, P87, DOI 10.1016/B978-0-12-250430-3.50012-X; STRANDER H, 1966, ANN MED EXP BIOL FEN, V44, P265; VONWUSSOW P, 1994, J INTERFERON RES, V14, P217, DOI 10.1089/jir.1994.14.217	13	10	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					348	349		10.1016/S0140-6736(05)64985-9	http://dx.doi.org/10.1016/S0140-6736(05)64985-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709727				2022-12-28	WOS:A1996VB42600003
J	Odeh, M; Oliven, A				Odeh, M; Oliven, A			Man who coughed for 15 years before a doctor took his pulse	LANCET			English	Article									TECHNION ISRAEL INST TECHNOL,FAC MED,IL-31063 HAIFA,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Odeh, M (corresponding author), BNAI ZION MED CTR,POB 6477,IL-31063 HAIFA,ISRAEL.							IRWIN RS, 1977, ARCH INTERN MED, V137, P1186, DOI 10.1001/archinte.137.9.1186; IRWIN RS, 1994, TXB RESPIRATORY MED, P529; JOSEPHSON ME, HARRISONS PRINCIPLES; SIMON SR, 1992, ARCH INTERN MED, V152, P1698, DOI 10.1001/archinte.152.8.1698	4	4	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					378	378		10.1016/S0140-6736(96)03432-0	http://dx.doi.org/10.1016/S0140-6736(96)03432-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709737				2022-12-28	WOS:A1996VB42600013
J	ToozsHobson, P; Cardozo, L				ToozsHobson, P; Cardozo, L			Controversies in management - Hormone replacement therapy for all? Universal prescription is desirable	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; ESTROGEN THERAPY; BREAST-CANCER; DISEASE; METAANALYSIS; RISK		UNIV LONDON KINGS COLL, SCH MED & DENT, DEPT OBSTET & GYNAECOL, UROGYNAECOL UNIT, LONDON SE5 8RX, ENGLAND	University of London; King's College London				Toozs-Hobson, Philip/0000-0002-1859-9934				ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; COWAN WK, 1991, BRIT J CANCER, V64, P780, DOI 10.1038/bjc.1991.398; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; FERGUSON KJ, 1989, ARCH INTERN MED, V149, P133, DOI 10.1001/archinte.149.1.133; GRADY D, 1991, AM J EPIDEMIOL, V134, P1396, DOI 10.1093/oxfordjournals.aje.a116043; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRIFFITHS F, 1995, FAM PRACT, V12, P54, DOI 10.1093/fampra/12.1.54; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; KLEMI PJ, 1992, BRIT MED J, V304, P467, DOI 10.1136/bmj.304.6825.467; Leather A. T., 1993, P291; LEATHER AT, 1990, BRIT J OBSTET GYNAEC, V97, P1071, DOI 10.1111/j.1471-0528.1990.tb02491.x; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P982, DOI 10.1016/0002-9378(95)90247-3; NACHIGALL RG, 1989, OBSTET GYNECOL, V75, P77; NORMAN SG, 1994, BRIT J OBSTET GYNAEC, V101, P879, DOI 10.1111/j.1471-0528.1994.tb13549.x; OHKURA T, 1995, DEMENTIA, V6, P99, DOI 10.1159/000106929; Paganini-Hill A, 1995, Int J Fertil Menopausal Stud, V40 Suppl 1, P54; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PURDIE DW, 1995, BRIT J OBSTET GYNAEC, V102, P735, DOI 10.1111/j.1471-0528.1995.tb11433.x; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; *US DEPT HHS, 1980, VIT STAT US	21	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1996	313	7053					350	351		10.1136/bmj.313.7053.350	http://dx.doi.org/10.1136/bmj.313.7053.350			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760747	Green Published			2022-12-28	WOS:A1996VC30000025
J	Harrison, SC				Harrison, SC			Peptide-surface association: The case of PDZ and PTB domains	CELL			English	Review							AFFINITY PHOSPHOTYROSYL PEPTIDE; BINDING; PROTEIN		HARVARD UNIV, CAMBRIDGE, MA 02138 USA	Harvard University	Harrison, SC (corresponding author), CHILDRENS HOSP, HOWARD HUGHES MED INST, 320 LONGWOOD AVE, BOSTON, MA 02115 USA.							BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Niethammer M, 1996, J NEUROSCI, V16, P2157; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V92, P7784	17	152	158	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					341	343		10.1016/S0092-8674(00)80105-1	http://dx.doi.org/10.1016/S0092-8674(00)80105-1			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756715	Bronze			2022-12-28	WOS:A1996VC30900001
J	Townsend, J; Frank, A; Piper, M				Townsend, J; Frank, A; Piper, M			Continuing rise in emergency admissions - Visiting elderly patients at home immediately after discharge reduces emergency readmissions	BRITISH MEDICAL JOURNAL			English	Letter									NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; HM PRISON SERV,DIRECTORATE HLTH CARE,LONDON SW1P 4LN,ENGLAND	Imperial College London	Townsend, J (corresponding author), UNIV HERTFORDSHIRE,CTR RES PRIMARY & COMMUNITY CARE,HATFIELD AL10 9AB,HERTS,ENGLAND.							Capewell S, 1996, BRIT MED J, V312, P991; *N THAM REG HLTH A, 1994, N THAM RES DEV PLAN, P16; Townsend J, 1992, Health Trends, V24, P136; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					302	302		10.1136/bmj.313.7052.302	http://dx.doi.org/10.1136/bmj.313.7052.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704567	Green Published			2022-12-28	WOS:A1996VA90300068
J	Ronsmans, C; Islam, T; Bennish, ML				Ronsmans, C; Islam, T; Bennish, ML			Medical practitioners' knowledge of dysentery treatment in Bangladesh	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		INT CTR DIARRHOEAL DIS RES,DHAKA,BANGLADESH; GONOSHASTHAYA KENDRA,SAVAR,BANGLADESH; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT PAEDIAT,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT MED,BOSTON,MA 02111	International Centre for Diarrhoeal Disease Research (ICDDR); Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University								BENNISH ML, 1992, CLIN INFECT DIS, V14, P1055, DOI 10.1093/clinids/14.5.1055; GUYON AB, 1994, B WORLD HEALTH ORGAN, V72, P265; RONSMANS C, 1988, LANCET, V2, P552; RONSMANS C, 1991, REV INFECT DIS, V13, pS351; 1994, UPDATE, V16, P1	5	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					205	206		10.1136/bmj.313.7051.205	http://dx.doi.org/10.1136/bmj.313.7051.205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696198	Green Published			2022-12-28	WOS:A1996VA12600027
J	Brown, JR; Ye, H; Bronson, RT; Dikkes, P; Greenberg, ME				Brown, JR; Ye, H; Bronson, RT; Dikkes, P; Greenberg, ME			A defect in nurturing in mice lacking the immediate early gene fosB	CELL			English	Article							OLFACTORY BULB REMOVAL; MEDIAL PREOPTIC AREA; MATERNAL-BEHAVIOR; C-FOS; POSTPARTUM RATS; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAYS; OXYTOCIN; BINDING; MOUSE	Although expression of the Fos family of transcription factors is induced by environmental stimuli that trigger adaptive neuronal responses, evidence that Fos family members mediate these responses is lacking. To address this issue, mice were generated with an inactivating mutation in the fosB gene. fosB mutant mice are profoundly deficient in their ability to nurture young animals but are normal with respect to other cognitive and sensory functions. The nurturing defect is likely due to the absence of FosB in the preoptic area, a region of the hypothalamus that is critical for nurturing. These observations suggest that a transcription factor controls a complex behavior by regulating a specific neuronal circuit and indicate that nurturing in mammals has a genetic component.	HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH VET MED, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Tufts University	Brown, JR (corresponding author), HARVARD UNIV, SCH MED, CHILDRENS HOSP, DIV NEUROSCI, BOSTON, MA 02115 USA.				NCI NIH HHS [CA43855] Funding Source: Medline; NICHD NIH HHS [P30-HD18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ANUMAN M, 1995, BEH NEUROSCI, V109, P135; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARNETT SA, 1970, REPRODUCTION BREEDIN; BRIDGES RS, 1994, PSYCHONEUROENDOCRINO, V19, P611, DOI 10.1016/0306-4530(94)90045-0; BRIDGES RS, 1994, ACTA PAEDIATR, V83, P33, DOI 10.1111/j.1651-2227.1994.tb13263.x; CALAMANDREI G, 1994, BEHAV NEUROSCI, V108, P113, DOI 10.1037/0735-7044.108.1.113; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEMMER J, 1993, MOL BRAIN RES, V17, P279, DOI 10.1016/0169-328X(93)90012-E; FAHRBACH SE, 1985, NEUROENDOCRINOLOGY, V40, P526, DOI 10.1159/000124125; FLEMING AS, 1994, BEHAV NEUROSCI, V108, P724, DOI 10.1037/0735-7044.108.4.724; FLEMING AS, 1990, BEHAV NEURAL BIOL, V53, P64, DOI 10.1016/0163-1047(90)90814-M; FLEMING AS, 1992, BEHAV NEURAL BIOL, V57, P177, DOI 10.1016/0163-1047(92)90122-K; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P221, DOI 10.1037/h0035937; FLEMING AS, 1980, PHYSIOL BEHAV, V25, P731, DOI 10.1016/0031-9384(80)90377-7; FLEMING AS, 1994, PSYCHONEUROENDOCRINO, V19, P429, DOI 10.1016/0306-4530(94)90030-2; FLEMING AS, 1983, PHYSIOL BEHAV, V31, P503, DOI 10.1016/0031-9384(83)90073-2; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GANDELMA.R, 1971, SCIENCE, V171, P210, DOI 10.1126/science.171.3967.210; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GRIFF IC, 1995, CELL, V83, P407, DOI 10.1016/0092-8674(95)90118-3; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JIRIKBABB P, 1984, BEHAV NEURAL BIOL, V40, P170, DOI 10.1016/S0163-1047(84)90267-X; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEPRI JJ, 1985, PHYSIOL BEHAV, V35, P809, DOI 10.1016/0031-9384(85)90416-0; LEREA LS, 1993, NEURON, V10, P31, DOI 10.1016/0896-6273(93)90239-N; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LUCKMAN SM, 1995, BRAIN RES, V669, P115, DOI 10.1016/0006-8993(94)01271-I; MALENFANT SA, 1991, PHYSIOL BEHAV, V49, P289, DOI 10.1016/0031-9384(91)90045-P; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Moore DD, 1995, GLOB MOB SURV; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NOIROT E, 1969, ANIM BEHAV, V17, P542, DOI 10.1016/0003-3472(69)90161-4; NOIROT E, 1969, ANIM BEHAV, V17, P547, DOI 10.1016/0003-3472(69)90162-6; NUMAN M, 1994, ACTA PAEDIATR, V83, P19, DOI 10.1111/j.1651-2227.1994.tb13261.x; NUMAN M, 1988, BEHAV NEUROSCI, V102, P381, DOI 10.1037/0735-7044.102.3.381; ORPEN BG, 1987, PHYSIOL BEHAV, V40, P47, DOI 10.1016/0031-9384(87)90184-3; PEDERSEN CA, 1985, NEUROPEPTIDES, V6, P175, DOI 10.1016/0143-4179(85)90108-8; PEDERSEN CA, 1982, SCIENCE, V216, P648, DOI 10.1126/science.7071605; PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROSENBLATT JS, 1988, PSYCHONEUROENDOCRINO, V13, P29, DOI 10.1016/0306-4530(88)90005-4; ROSENBLATT JS, 1994, ACTA PAEDIATR, V83, P3, DOI 10.1111/j.1651-2227.1994.tb13259.x; ROZEN F, 1995, P NATL ACAD SCI USA, V92, P200, DOI 10.1073/pnas.92.1.200; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SIDIS Y, 1994, ENDOCRINOLOGY, V134, P1979, DOI 10.1210/en.134.4.1979; SMOTHERMAN WP, 1974, BEHAV BIOL, V12, P55, DOI 10.1016/S0091-6773(74)91026-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANLEENGOED E, 1987, J ENDOCRINOL, V112, P275, DOI 10.1677/joe.0.1120275; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Watanabe Y, 1996, J NEUROSCI, V16, P3827; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; WYSOCKI CJ, 1977, BEHAV GENET, V7, P171, DOI 10.1007/BF01066005; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHUGE R, 1995, MOL REPROD DEV, V41, P20, DOI 10.1002/mrd.1080410105	61	263	268	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1996	86	2					297	309		10.1016/S0092-8674(00)80101-4	http://dx.doi.org/10.1016/S0092-8674(00)80101-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706134	Bronze			2022-12-28	WOS:A1996UZ97200015
J	Crompton, T; Gilmour, KC; Owen, MJ				Crompton, T; Gilmour, KC; Owen, MJ			The MAP kinase pathway controls differentiation from double-negative to double-positive thymocyte	CELL			English	Article							RECEPTOR-BETA-CHAIN; ACTIVATED PROTEIN-KINASE; T-CELL DEVELOPMENT; NIH 3T3 CELLS; ALLELIC EXCLUSION; DEFICIENT MICE; ALPHA-BETA; SIGNAL-TRANSDUCTION; MUTANT MICE; LYMPHOCYTES	T cell development is regulated at two major control points where maturation, proliferation, and antigen receptor gene rearrangement are coordinated. Progression through these developmental control points is dependent upon the expression of different forms of the T cell receptor. Here we show that the MAP kinase cascade is a regulator of the differentiation of immature thymocytes from double-negative to double-positive cell, most probably acting as a transducer of pre-T cell receptor signaling. Furthermore, this study demonstrates the use of retrovirus-mediated gene transfer in fetal thymic organ culture in the analysis of thymic development in mutant mice, an alternative to transgenesis by oocyte injection.			Crompton, T (corresponding author), IMPERIAL CANC RES FUND,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Crompton, Tessa/0000-0002-8973-4021				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON SJ, 1994, ADV IMMUNOL, V56, P151, DOI 10.1016/S0065-2776(08)60451-4; ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROMPTON T, 1994, EUR J IMMUNOL, V25, P1903; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; Jenkinson E J, 1990, Semin Immunol, V2, P51; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVELT CN, 1995, EUR J IMMUNOL, V25, P1257, DOI 10.1002/eji.1830250519; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; VONBOEHMER H, 1995, CLIN IMMUNOL IMMUNOP, V76, P145; WALLACE VA, 1995, EUR J IMMUNOL, V25, P1312, DOI 10.1002/eji.1830250527	44	183	184	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					243	251		10.1016/S0092-8674(00)80096-3	http://dx.doi.org/10.1016/S0092-8674(00)80096-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706129	Bronze			2022-12-28	WOS:A1996UZ97200010
J	Zambrano, MM; Kolter, R				Zambrano, MM; Kolter, R			GASPing for life in stationary phase	CELL			English	Review							ESCHERICHIA-COLI; ADAPTIVE MUTATION; SELECTION; SIGMA(S)		HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	Zambrano, MM (corresponding author), CORPOGEN,CALLE 26A 37-28,BOGOTA,COLOMBIA.		Zambrano, Maria Mercedes/AAD-2805-2019	Zambrano, Maria Mercedes/0000-0002-0796-4473				BOHRINGER J, 1995, J BACTERIOL, V177, P413; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; EBERHARD A, 1991, ARCH MICROBIOL, V155, P294, DOI 10.1007/BF00252215; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; HUISMAN GW, 1994, SCIENCE, V265, P537, DOI 10.1126/science.7545940; HUISMAN GW, 1996, ESCHERICHIA COLI SAL, P1672; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; More MI, 1996, SCIENCE, V272, P1655, DOI 10.1126/science.272.5268.1655; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; Pratt LA, 1996, P NATL ACAD SCI USA, V93, P2488, DOI 10.1073/pnas.93.6.2488; ROSENBERG SM, 1994, GENOME, V37, P893, DOI 10.1139/g94-127; SCHAEFER AL, 1996, IN PRESS P NATL ACAD; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; ZAMBRANO MM, 1993, SCIENCE, V259, P1757, DOI 10.1126/science.7681219	16	154	154	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					181	184		10.1016/S0092-8674(00)80089-6	http://dx.doi.org/10.1016/S0092-8674(00)80089-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706122	Bronze			2022-12-28	WOS:A1996UZ97200003
J	Grubb, NR; OCarroll, R; Cobbe, SM; Sirel, J; Fox, KAA				Grubb, NR; OCarroll, R; Cobbe, SM; Sirel, J; Fox, KAA			Chronic memory impairment after cardiac arrest outside hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEARTSTART SCOTLAND; DEFIBRILLATION; SURVIVAL; EMERGENCY; IMPACT	Objectives-To evaluate the nature, prevalence, and severity of chronic memory deficit in patients resuscitated after cardiac arrest outside hospital and to determine whether such deficits are related to duration of cardiac arrest. Design-Case-control study. Subjects-35 survivors of cardiac arrest outside hospital and 35 controls matched for age and sex who had had acute myocardial infarction without cardiac arrest. Main outcome measures-Subjects assessed at least two months after index event for affective state (hospital anxiety and depression scale), premorbid intelligence (national adult reading test), short term recall (digit recall test), and episodic long term memory (Rivermead behavioural memory test). Results-Cases and controls showed no difference in short term recall. Cases scored lower on Rivermead test than controls (mean (SD) score out of 24 points: 17.4 (5.4) v 21.8 (2.0), P<0.001), particularly in subtests relating to verbal and spatial memory. Moderate or severe impairment was found in 37% of cases and in no controls. Severity of impairment of memory correlated significantly with measures of duration of cardiac arrest. This deficit was not significantly associated with subjects' age, interval from index event to assessment, occupation, measures of comorbidity, social deprivation, anxiety or depression scores, or estimated premorbid intelligence. Conclusions-Clinically important impairment of memory was common after cardiac arrest outside hospital. Improvement in response times of emergency services could reduce the severity of such deficits. With an increasing numbers of people expected to survive cardiac arrest outside hospital, rehabilitation of those with memory deficit merits specific attention.	UNIV EDINBURGH, CARDIOVASC RES UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP, MRC, BRAIN METAB UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND; GLASGOW ROYAL INFIRM, DEPT MED CARDIOL, GLASGOW G4 0SF, LANARK, SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Glasgow			O'Carroll, Ronan E/A-5040-2009; Fox, keith A A/I-3742-2013	O'Carroll, Ronan E/0000-0002-5130-291X; Fox, Keith/0000-0002-0140-2752				[Anonymous], 1991, NEUROPSYCHOL REHABIL, DOI DOI 10.1080/09602019108401386; BASS E, 1985, ANN INTERN MED, V103, P920, DOI 10.7326/0003-4819-103-6-920; BEURET P, 1993, RESUSCITATION, V25, P171, DOI 10.1016/0300-9572(93)90093-6; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Carstairs V., 1991, DEPRIVATION HLTH SCO; COBB LA, 1992, CIRCULATION, V85, P98; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COLQUHOUN M, 1995, ABC RESUSCITATION, P56; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; DILLER L, 1976, CLIN PSYCHOL, V19, P13; Dougherty C M, 1994, Am J Crit Care, V3, P145; FRICCHIONE GL, 1989, AM HEART J, V117, P1411, DOI 10.1016/0002-8703(89)90457-2; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; GULY UM, 1995, BRIT MED J, V310, P1091, DOI 10.1136/bmj.310.6987.1091; HAMER DW, 1993, RESUSCITATION, V26, P31, DOI 10.1016/0300-9572(93)90160-R; HERLITZ J, 1994, EUR HEART J, V15, P1628, DOI 10.1093/oxfordjournals.eurheartj.a060445; Hillis Michael, 1993, Journal of Emergency Medicine, V11, P245; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; POWELL J, 1993, BRIT J CLIN PHARMACO, V35, P105, DOI 10.1111/j.1365-2125.1993.tb05675.x; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; STERN TA, 1987, AM J CARDIOL, V60, P59; TORPPEDERSEN C, 1991, RESUSCITATION, V21, P283, DOI 10.1016/0300-9572(91)90053-2; TOWNES BD, 1989, J THORAC CARDIOV SUR, V98, P774; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WECHSLE D, 1987, WECHSLER MEMORY SCAL; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson B., 1992, CLIN MANAGEMENT MEMO; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	29	90	92	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	1996	313	7050					143	146		10.1136/bmj.313.7050.143	http://dx.doi.org/10.1136/bmj.313.7050.143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UY921	8688775	Green Published			2022-12-28	WOS:A1996UY92100018
J	Snashall, D				Snashall, D			ABC of work related disorders - Hazards of work	BRITISH MEDICAL JOURNAL			English	Article											Snashall, D (corresponding author), GUYS & ST THOMAS HOSP,NHS TRUST,OCCUPAT HLTH SERV,LONDON SE1 9RT,ENGLAND.							*CENTR STAT OFF, 1992, ANN ABSTR STAT 1992; *DEP SOC SEC, 1993, NOT DIAGN PRESCR DIS; *HLTH SAF EX, 1996, GUID REP INJ DIS DAN; *WHO, 1985, 174 WHO	4	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					161	163		10.1136/bmj.313.7050.161	http://dx.doi.org/10.1136/bmj.313.7050.161			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688781	Green Published			2022-12-28	WOS:A1996UY92100029
J	BrashersKrug, T; Shadmehr, R; Bizzi, E				BrashersKrug, T; Shadmehr, R; Bizzi, E			Consolidation in human motor memory	NATURE			English	Article							LONG-TERM POTENTIATION; AMNESIA; MONKEYS; LESIONS	LEARNING a motor skill sets in motion neural processes that continue to evolve after practice has ended, a phenomenon known as consolidation(1-4). Here we present psychophysical evidence for this, and show that consolidation of a motor skill was disrupted when a second motor task was learned immediately after the first. There was no disruption if four hours elapsed between learning the two motor skills, with consolidation occuring gradually over this period. Previous studies in humans and other primates have found this time-dependent disruption of consolidation only in explicit memory tasks(5-12), which rely on brain structures in the medial temporal lobe(9,13,14). Our results indicate that motor memories, which do not depend on the medial temporal lobe(8,15), can be transformed by a similar process of consolidation. By extending the phenomenon of consolidation to motor memory, our results indicate that distinct neural systems share similar characteristics when encoding and storing new information.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; JOHNS HOPKINS UNIV,DEPT BIOMED ENGN,BALTIMORE,MD 21205	Massachusetts Institute of Technology (MIT); Johns Hopkins University								BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; Bailey Craig H., 1995, P19; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; FAYE IC, 1986, THESIS MIT; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; Ito M., 1993, CAN J NEUROL SCI, V20, P70; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KIM JJ, 1995, BEHAV NEUROSCI, V109, P195, DOI 10.1037/0735-7044.109.2.195; KIMURA A, 1994, NEUROREPORT, V5, P2372, DOI 10.1097/00001756-199411000-00040; LEWIS D, 1952, J EXP PSYCHOL, V44, P247; MALAMUT BL, 1984, BEHAV NEUROSCI, V98, P759, DOI 10.1037/0735-7044.98.5.759; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCGEOCH J, 1952, PSYCHOL HUMAN LEARNI, P299; McGeoch JA, 1931, AM J PSYCHOL, V43, P579, DOI 10.2307/1415159; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; Muller G. E., 1900, Z PSYCHOLOGIE, V1, P1; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; SHEA JB, 1993, J MOTOR BEHAV, V25, P264, DOI 10.1080/00222895.1993.9941647; SISSON DE, 1939, J EXP PSYCHOL, V25, P228; SKAGGS EB, 1925, PSYCHOL MONOGR, V34; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; SQUIRE LR, 1975, SCIENCE, V187, P77, DOI 10.1126/science.1109228; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Weingartner H., 1984, MEMORY CONSOLIDATION; ZOLAMORGAN S, 1985, BEHAV NEUROSCI, V99, P22, DOI 10.1037/0735-7044.99.1.22; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	30	691	697	0	56	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					252	255		10.1038/382252a0	http://dx.doi.org/10.1038/382252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UX790	8717039				2022-12-28	WOS:A1996UX79000049
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes: Measurement error proportional to the mean .23.	BRITISH MEDICAL JOURNAL			English	Article									INST HLT SCI,IMPERIAL CANC RES FUND,MED STAT GRP,CTR STAT MED,OXFORD OX3 7LF,ENGLAND	University of Oxford	Bland, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							Bland JM, 1996, BRIT MED J, V312, P700; Bland JM, 1996, BRIT MED J, V313, P41, DOI 10.1136/bmj.313.7048.41; Bland JM, 1996, BRIT MED J, V312, P770	3	404	407	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					106	106		10.1136/bmj.313.7049.106	http://dx.doi.org/10.1136/bmj.313.7049.106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688716	Green Published, Bronze			2022-12-28	WOS:A1996UX69800032
J	Gornick, ME; Eggers, PW; Reilly, TW; Mentnech, RM; Fitterman, LK; Kucken, LE; Vladeck, BC				Gornick, ME; Eggers, PW; Reilly, TW; Mentnech, RM; Fitterman, LK; Kucken, LE; Vladeck, BC			Effects of race and income on mortality and use of services among Medicare beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; OF-VETERANS-AFFAIRS; RACIAL-DIFFERENCES; CARDIOVASCULAR PROCEDURES; HEALTH-CARE; OUTCOMES; DISEASE; WOMEN	Background There are wide disparities between blacks and whites in the use of many Medicare services. We studied the effects of race and income on mortality and use of services. Methods We linked 1990 census data on median income according to ZIP Code with 1993 Medicare administrative data for 26.3 million beneficiaries 65 years of age or older (24.2 million whites and 2.1 million blacks). We calculated age-adjusted mortality rates and age- and sex-adjusted rates of various diagnoses and procedures according to race and income and computed black:white ratios. The 1993 Medicare Current Beneficiary Survey was used to validate the results and determine rates of immunization against influenza. Results For mortality, the black:white ratios were 1.19 for men and 1.16 for women (P<0.001 for both). For hospital discharges, the ratio was 1.14 (P<0.001), and for visits to physicians for ambulatory care it was 0.89 (P<0.001). For every 100 women, there were 26.0 mammograms among whites and 17.1 mammograms among blacks. As compared with mammography rates in the respective most affluent group, rates in the least affluent group were 33 percent lower among whites and 22 percent lower among blacks. The black:white rate ratio was 2.45 for bilateral orchiectomy and 3.64 for amputations of all or part of the lower limb (P<0.001 for both). For every 1000 beneficiaries, there were 515 influenza immunizations among whites and 313 among blacks. As compared with immunization rates in the respective most affluent group, rates in the least affluent group were 26 percent lower among whites and 39 percent lower among blacks. Adjusting the mortality and utilization rates for differences in income generally reduced the racial differences, but the effect was relatively small. Conclusions Race and income have substantial effects on mortality and use of services among Medicare beneficiaries. Medicare coverage alone is not sufficient to promote effective patterns of use by all beneficiaries. (C) 1996, Massachusetts Medical Society.			Gornick, ME (corresponding author), HLTH CARE FINANCING ADM,US DEPT HHS,OFF RES & DEMOSTRAT,7500 SECUR BLVD,C-3-24-07,BALTIMORE,MD 21244, USA.							Adler G S, 1994, Health Care Financ Rev, V15, P153; *AM MED ASS, 1993, PHYS CURR PROC TERM; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BENSON V, 1994, VITAL HLTH STAT, V10; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; DAVIS K, 1991, MILBANK Q, V69, P253, DOI 10.2307/3350204; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; FORD ES, 1995, HEALTH SERV RES, V30, P237; Geronimus A. T., 1993, 93269 U MICH POP STU; Geronimus A. T., 1995, 189 NAT BUR EC RES; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GRANICK MB, 1992, SCI AM MED; GUADAGNOLI E, 1995, ARCH SURG-CHICAGO, V130, P381; *HLTH CAR FIN ADM, 1994, HCFA PUBL, V3358; *HLTH CAR FIN ADM, 1995, HCFA PUBL, V3379; *HLTH CAR FIN ADM, 1993, MON CHANG US ACC A B; *HLTH CAR FIN ADM, 1986, HCFA PUBL, V3301; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; LONG SH, 1984, MILBANK FUND Q, V62, P609, DOI 10.2307/3349839; LOOKER AC, 1995, J BONE MINER RES, V10, P796; McBean A M, 1994, Health Care Financ Rev, V15, P77; MCBEAN AM, 1995, COMP INCOME INFORMAT; MONTGOMERY LE, 1993, TOXICOL IND HEALTH, V9, P729, DOI 10.1177/074823379300900505; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PAPPAS G, 1993, NEW ENGL J MED, V329, P1139; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Ries L, 1994, NIH PUBLICATION, V94-2789; Ruther M, 1981, Health Care Financ Rev, V2, P55; *SOC SEC ADM, 1975, MED HLTH INS AG 1967; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; 1993, MMWR-MORBID MORTAL W, V42, P1	33	645	648	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					791	799		10.1056/NEJM199609123351106	http://dx.doi.org/10.1056/NEJM199609123351106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF786	8703185				2022-12-28	WOS:A1996VF78600006
J	Kehoe, DM; Grossman, AR				Kehoe, DM; Grossman, AR			Similarity of a chromatic adaptation sensor to phytochrome and ethylene receptors	SCIENCE			English	Article							CYANOBACTERIUM FREMYELLA-DIPLOSIPHON; RESOLVED ENERGY-TRANSFER; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; 2-COMPONENT REGULATORS; PORPHYRIDIUM-CRUENTUM; GENE; ARABIDOPSIS; PHYCOBILISOMES; PROTEINS	Complementary chromatic adaptation in cyanobacteria acts through photoreceptors to control the biosynthesis of light-harvesting complexes. The mutant FdBk, which appears black, cannot chromatically adapt and may contain a lesion in the apparatus that senses light quality, The complementing gene identified here, rcaE, encodes a deduced protein in which the amino-terminal region resembles the chromophore attachment domain of phytochrome photoreceptors and regions of plant ethylene receptors; the carboxyl-terminal half is similar to the histidine kinase domain of two-component sensor kinases.			Kehoe, DM (corresponding author), CARNEGIE INST WASHINGTON,DEPT PLANT BIOL,290 PANAMA ST,STANFORD,CA 94305, USA.							ALLEN MM, 1968, J BACTERIOL, V96, P836, DOI 10.1128/JB.96.3.836-841.1968; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRUNS BU, 1989, J BACTERIOL, V171, P901, DOI 10.1128/jb.171.2.901-908.1989; CASEY E, 1996, THESIS STANFORD U; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHIANG GG, 1992, PLANT PHYSIOL BIOCH, V30, P315; CHIANG GG, 1992, P NATL ACAD SCI USA, V89, P9415, DOI 10.1073/pnas.89.20.9415; CLACK T, 1994, PLANT MOL BIOL, V25, P413, DOI 10.1007/BF00043870; COBLEY JG, 1993, PLASMID, V30, P90, DOI 10.1006/plas.1993.1037; COBLEY JG, 1983, J BACTERIOL, V153, P1486, DOI 10.1128/JB.153.3.1486-1492.1983; DEMARSAC NT, 1993, FEMS MICROBIOL LETT, V104, P119; DEMARSAC NT, 1983, B I PASTEUR, V81, P201; Engelmann T.W., 1902, ARCH ANAT PHYSL, P333; FAY P, 1987, CYANOBACTERIA, P69; FEDERSPIEL NA, 1990, J BACTERIOL, V172, P4072, DOI 10.1128/jb.172.7.4072-4081.1990; Gaidukov N., 1903, BER DEUT BOT GES, V21, P517; GAIDUKOV N, 1904, BER DEUT BOT GES, V22, P23; GLAZER AN, 1985, ANNU REV BIOPHYS BIO, V14, P47, DOI 10.1146/annurev.bb.14.060185.000403; GLAZER AN, 1989, J BIOL CHEM, V264, P1; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Kehoe David M., 1994, Seminars in Cell Biology, V5, P303, DOI 10.1006/scel.1994.1037; KEHOE DM, UNPUB; KEHOE DM, 1995, PHOTOSYNTHESIS LIGHT, V3, P501; KENDRICK RE, 1994, PHOTOMORPHOGENEIS PL; LOMAX TL, 1987, J BACTERIOL, V169, P2675, DOI 10.1128/jb.169.6.2675-2684.1987; OELMULLER R, 1988, PLANT PHYSIOL, V88, P1084, DOI 10.1104/pp.88.4.1084; OELMULLER R, 1988, PLANT PHYSIOL, V88, P1077, DOI 10.1104/pp.88.4.1077; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PORTER G, 1978, BIOCHIM BIOPHYS ACTA, V501, P232, DOI 10.1016/0005-2728(78)90029-4; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SEARLE GFW, 1978, BIOCHIM BIOPHYS ACTA, V501, P246, DOI 10.1016/0005-2728(78)90030-0; SEKI T, 1987, J BACTERIOL, V169, P2913, DOI 10.1128/jb.169.7.2913-2916.1987; THUMMLER F, 1995, FEBS LETT, V357, P149, DOI 10.1016/0014-5793(94)01327-W; WANNER BL, 1994, PHOSPHATE IN MICROORGANISMS, P215; WANNER BL, 1992, J BACTERIOL, V174, P2124, DOI 10.1128/JB.174.7.2124-2130.1992; WANNER BL, 1992, FEMS MICROBIOL LETT, V100, P133, DOI 10.1111/j.1574-6968.1992.tb05694.x; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807	40	299	314	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1409	1412		10.1126/science.273.5280.1409	http://dx.doi.org/10.1126/science.273.5280.1409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703080				2022-12-28	WOS:A1996VF61000049
J	Hall, WJ				Hall, WJ			Update in geriatrics	ANNALS OF INTERNAL MEDICINE			English	Article							POSTMENOPAUSAL WOMEN				Hall, WJ (corresponding author), UNIV ROCHESTER, SCH MED & DENT, DEPT MED, 601 ELMWOOD AVE, BOX MED, ROCHESTER, NY 14642 USA.							CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; HARRIS ST, 1993, J CLIN ENDOCR METAB, V76, P1399, DOI 10.1210/jcem.76.6.8501142	2	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					390	397		10.7326/0003-4819-125-5-199609010-00006	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702090				2022-12-28	WOS:A1996VE07900006
J	Lipp, MM; Lee, KYC; Zasadzinski, JA; Waring, AJ				Lipp, MM; Lee, KYC; Zasadzinski, JA; Waring, AJ			Phase and morphology changes in lipid monolayers induced by SP-B protein and its amino-terminal peptide	SCIENCE			English	Article							AIR-WATER-INTERFACE; PULMONARY SURFACTANT; LUNG SURFACTANT; SP-C; DIPALMITOYLPHOSPHATIDYLCHOLINE; TRANSITIONS; DOMAINS; SHAPES; FILM	Both human lung surfactant protein, SP-B, and its amino-terminal peptide, SP-B-1-25, inhibit the formation of condensed phases in monolayers of palmitic acid, resulting new fluid phase. This fluid phase forms a network, separating condensed-phase domains at coexistence. The network persists to high surface pressures, altering the nucleation, growth, and morphology of monolayer collapse structures, leading to lower surface tensions on compression and more reversible respreading on expansion. The network is stabilized by the low line tension between the fluid phase and the condensed phase as confirmed by the formation of ''stripe'' phases.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; UNIV CALIF LOS ANGELES,HARBOR MED CTR,PERINATAL LABS,LOS ANGELES,CA 90059; MARTIN LUTHER KING JR DREW UNIV MED CTR,LOS ANGELES,CA 90059	University of California System; University of California Santa Barbara; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NHLBI NIH HHS [HL55534, HL51177-02] Funding Source: Medline; NIGMS NIH HHS [GM 50483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S15GM050483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON AW, 1990, PHYSICAL CHEM SURFAC; AVERY ME, 1959, AM J DIS CHILD, V97, P917; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CHUNG JB, 1990, LANGMUIR, V6, P1647, DOI 10.1021/la00101a005; COCKSHUTT AM, 1991, BIOCHIM BIOPHYS ACTA, V1085, P248, DOI 10.1016/0005-2760(91)90101-M; DICKSTEIN AJ, 1993, SCIENCE, V261, P1012, DOI 10.1126/science.261.5124.1012; FIELDS C G, 1991, Peptide Research, V4, P95; Gordon LM, 1996, PROTEIN SCI, V5, P1662, DOI 10.1002/pro.5560050820; HAGWOOD S, 1987, P NATL ACAD SCI USA, V84, P66; HUNTER RJ, 1992, FDN COLLOID SCI, V1, pCH5; KNOBLER CM, 1992, ANNU REV PHYS CHEM, V43, P207, DOI 10.1146/annurev.pc.43.100192.001231; Lee K. T., UNPUB; LEE KYC, 1993, J PHYS CHEM-US, V97, P9532, DOI 10.1021/j100139a044; LONGO ML, 1993, SCIENCE, V261, P453, DOI 10.1126/science.8332910; LONGO ML, 1992, BIOPHYS J, V63, P760, DOI 10.1016/S0006-3495(92)81643-0; LONGO ML, 1993, THESIS U CALIFORNIA; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MCCONNELL HM, 1988, J PHYS CHEM-US, V92, P4520, DOI 10.1021/j100326a053; MCCONNELL HM, 1984, NATURE, V310, P47; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; Nag K, 1996, BIOPHYS J, V71, P246, DOI 10.1016/S0006-3495(96)79221-4; PEREZGIL J, 1995, BIOCHEMISTRY-US, V34, P3964, DOI 10.1021/bi00012a014; PEREZGIL J, 1992, BIOPHYS J, V63, P197, DOI 10.1016/S0006-3495(92)81582-5; POST A, 1995, MOL MEMBR BIOL, V12, P93, DOI 10.3109/09687689509038502; SARIN VK, 1990, P NATL ACAD SCI USA, V87, P2633, DOI 10.1073/pnas.87.7.2633; SEEGER W, 1992, AM J PHYSIOL, V262, pL286, DOI 10.1152/ajplung.1992.262.3.L286; SEELIG J, 1995, MOL MEMBR BIOL, V12, P51, DOI 10.3109/09687689509038495; SEUL M, 1995, SCIENCE, V267, P476, DOI 10.1126/science.267.5197.476; SEUL M, 1990, PHYS REV LETT, V64, P1903, DOI 10.1103/PhysRevLett.64.1903; SEUL M, 1993, PHYS REV LETT, V70, P1658, DOI 10.1103/PhysRevLett.70.1658; Shapiro D. L, 1989, SURFACTANT REPLACEME; SMITH RD, 1980, J COLLOID INTERF SCI, V74, P273, DOI 10.1016/0021-9797(80)90190-3; SOLL RF, 1992, RESIDENT STAFF PHYSI, V38, P19; STINE KJ, 1992, LANGMUIR, V8, P2509, DOI 10.1021/la00046a026; WHITSETT JA, 1986, PEDIATR RES, V20, P460, DOI 10.1203/00006450-198605000-00016; XU S, 1982, J COLLOID INTERF SCI, V89, P581, DOI 10.1016/0021-9797(82)90213-2; YU SH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P26, DOI 10.1016/0005-2760(92)90212-E; YU SH, 1986, BIOCHEM J, V236, P85, DOI 10.1042/bj2360085	39	163	167	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1196	1199		10.1126/science.273.5279.1196	http://dx.doi.org/10.1126/science.273.5279.1196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703046				2022-12-28	WOS:A1996VE47600029
J	Sarraf, D; Ernest, JT				Sarraf, D; Ernest, JT			AIDS and the eyes	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; OCULAR MANIFESTATIONS; OPHTHALMOLOGIC FINDINGS; AMBULATORY PATIENTS; INFECTION; CYTOMEGALOVIRUS; INVOLVEMENT; GANCICLOVIR; RIFABUTIN	The eye is affected in 50-75% of adult AIDS patients. This rate of ocular involvement is much higher than that in symptom-free HIV-seropositive patients, and seems to increase in Incidence with severity of disease. These observations indicate that regular screening of HIV-positive patients is warranted to allow early identification of potential vision and life threatening disease.	UNIV CHICAGO,CTR VISUAL SCI,DEPT OPHTHALMOL & VISUAL SCI,CHICAGO,IL 60637	University of Chicago								Althaus C., 1996, Investigative Ophthalmology and Visual Science, V37, pS370; ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027; DENNEHY PJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P978, DOI 10.1001/archopht.1989.01070020040025; FREEMAN WR, 1984, AM J OPHTHALMOL, V97, P133, DOI 10.1016/S0002-9394(14)76082-9; FRIEDMAN DI, 1991, NEUROL CLIN, V9, P55, DOI 10.1016/S0733-8619(18)30303-7; HAMED LM, 1988, AM J OPHTHALMOL, V106, P437, DOI 10.1016/0002-9394(88)90880-X; HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025; HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859; HOLLAND GN, 1982, AM J OPHTHALMOL, V93, P393, DOI 10.1016/0002-9394(82)90127-1; HUMPHRY RC, 1987, BRIT J OPHTHALMOL, V71, P565, DOI 10.1136/bjo.71.8.565; JABS DA, 1989, OPHTHALMOLOGY, V96, P1092; KATZ DA, 1989, ARCH NEUROL-CHICAGO, V46, P895, DOI 10.1001/archneur.1989.00520440085024; KEANE JR, 1991, NEUROLOGY, V97, P196; KHADEM M, 1984, ARCH OPHTHALMOL-CHIC, V102, P201; KREIGER AE, 1988, EYE, V2, P496, DOI 10.1038/eye.1988.99; Kuppermann B. D., 1996, Investigative Ophthalmology and Visual Science, V37, pS898; MCLEISH WM, 1990, OPHTHALMOLOGY, V97, P196; NEWSOME DA, 1989, INT OPHTHALMOL CLIN, V29, P95, DOI 10.1097/00004397-198902920-00006; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PALESTINE AG, 1992, OPHTHALMOL CLIN N AM, V5, P319; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; ROSENBERG PR, 1983, OPHTHALMOLOGY, V90, P874; RUMMELT V, 1994, OPHTHALMOLOGY, V101, P270; SARAN BR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1159, DOI 10.1001/archopht.1994.01090210043015; Schimkat M., 1996, Investigative Ophthalmology and Visual Science, V37, pS370; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; SHULER JD, 1989, INT OPHTHALMOL CLIN, V29, P98, DOI 10.1097/00004397-198902920-00007; Steinberg E. P., 1996, Investigative Ophthalmology and Visual Science, V37, pS899; Taskintuna I., 1996, Investigative Ophthalmology and Visual Science, V37, pS669; 1992, NEW ENGL J MED, V326, P213	30	18	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					525	528		10.1016/S0140-6736(96)05209-9	http://dx.doi.org/10.1016/S0140-6736(96)05209-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757157				2022-12-28	WOS:A1996VD42700015
J	Fullner, KJ; Lara, JC; Nester, EW				Fullner, KJ; Lara, JC; Nester, EW			Pilus assembly by Arobacterium T-DNA transfer genes	SCIENCE			English	Article							AGROBACTERIUM-TUMEFACIENS; BACTERIAL CONJUGATION; VIRULENCE; PLANT; MUTATIONS; OPERON	Agrobacterium tumefaciens can genetically transform eukaryotic cells, In many bacteria, pill are required for interbacterial DNA transfer. The formation of pill by Agrobacterium required induction of tumor-inducing (Ti) plasmid-encoded virulence genes and growth at low temperature, Agenetic analysis demonstrated that virA, virG, virB1 through virB11, and virD4 are the only Ti plasmid genes necessary for pilus assembly, The loss and gain of pill in various mutants correlated with the loss and gain of transferred DNA (T-DNA) transfer functions, which is consistent with the view that Agrobacterium pill are required for transfer of DNA to plant cells in a process similar to that of conjugation.	UNIV WASHINGTON, DEPT MICROBIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BOT, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Satchell, Karla/GSN-3100-2022		NIGMS NIH HHS [GM32618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; BERGER BR, 1994, J BACTERIOL, V176, P3646, DOI 10.1128/JB.176.12.3646-3660.1994; BINNS KJ, 1995, UNPUB, V177, P4890; BRADLEY DE, 1978, PLASMID, V1, P376, DOI 10.1016/0147-619X(78)90053-7; BRADLEY DE, 1980, PLASMID, V4, P155, DOI 10.1016/0147-619X(80)90005-0; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; CANGELOSI GA, 1991, METHOD ENZYMOL, V204, P384; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; DALE EM, 1993, J BACTERIOL, V175, P887, DOI 10.1128/JB.175.3.887-891.1993; DEFEYTER R, 1990, GENE, V88, P65, DOI 10.1016/0378-1119(90)90060-5; Frost LS., 1993, BACTERIAL CONJUGATIO, P189; Fullner KJ, 1996, J BACTERIOL, V178, P1498, DOI 10.1128/jb.178.6.1498-1504.1996; FULLNER KJ, 1994, MOL GEN GENET, V245, P705; GRIMSLEY N, 1989, MOL GEN GENET, V217, P309, DOI 10.1007/BF02464898; HAASE J, 1995, J BACTERIOL, V177, P4779, DOI 10.1128/jb.177.16.4779-4791.1995; Heath J.D., 1995, 2 COMPONENT SIGNAL T, P367; LESSL M, 1994, CELL, V77, P321, DOI 10.1016/0092-8674(94)90146-5; MAHER D, 1993, J BACTERIOL, V175, P2175, DOI 10.1128/JB.175.8.2175-2183.1993; MATTHYSSE AG, 1983, J BACTERIOL, V154, P906, DOI 10.1128/JB.154.2.906-915.1983; PAZOUR GJ, 1992, J BACTERIOL, V174, P4169, DOI 10.1128/jb.174.12.4169-4174.1992; Piers KL, 1996, P NATL ACAD SCI USA, V93, P1613, DOI 10.1073/pnas.93.4.1613; POHLMAN RF, 1994, MOL MICROBIOL, V14, P655, DOI 10.1111/j.1365-2958.1994.tb01304.x; Riker AJ, 1926, J AGRIC RES, V32, P0083; SCIAKY D, 1978, PLASMID, V1, P238, DOI 10.1016/0147-619X(78)90042-2; SHIRASU K, 1993, FEMS MICROBIOL LETT, V111, P287, DOI 10.1111/j.1574-6968.1993.tb06400.x; STEPHENS KM, 1995, J BACTERIOL, V177, P27, DOI 10.1002/path.1711770106; Sundberg C, 1996, J BACTERIOL, V178, P1207, DOI 10.1128/jb.178.4.1207-1212.1996; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; WATERS VL, 1992, J BACTERIOL, V174, P6666, DOI 10.1128/JB.174.20.6666-6673.1992; WATSON B, 1975, J BACTERIOL, V123, P255, DOI 10.1128/JB.123.1.255-264.1975; WILLETTS N, 1981, GENET RES, V37, P311, DOI 10.1017/S0016672300020310; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7; WINANS SC, 1987, NUCLEIC ACIDS RES, V15, P825, DOI 10.1093/nar/15.2.825; ZAMBRYSKI P, 1991, MOBILE DNA, P309; ZUPAN JR, 1995, PLANT PHYSIOL, V107, P1041, DOI 10.1104/pp.107.4.1041	35	181	211	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1996	273	5278					1107	1109		10.1126/science.273.5278.1107	http://dx.doi.org/10.1126/science.273.5278.1107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688097				2022-12-28	WOS:A1996VD42800038
J	Kaldis, P; Sutton, A; Solomon, MJ				Kaldis, P; Sutton, A; Solomon, MJ			The Cdk-activating kinase (CAK) from budding yeast	CELL			English	Article							CYCLIN-DEPENDENT KINASES; TRANSCRIPTION FACTOR TFIIH; RING FINGER PROTEIN; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; IN-VITRO; COMPLEX; PHOSPHORYLATION; KIN28; CDC28	Activation of the cyclin-dependent kinases to promote cell cycle progression requires their association with cyclins as well as phosphorylation of a threonine (residue 161 in human p34(cdc2)). This phosphorylation is carried out by CAK, the Cdk-activating kinase. We have purified and cloned CAK from S. cerevisiae. Unlike CAKs from other organisms, Cak1p is active as a monomer, has full activity when expressed in E. coli, and is not a component of the basal transcription factor, TFIIH. A temperature-sensitive mutation in CAK1 confers a G2 delay accompanied by low Cdc28p protein kinase activity and shows genetic interactions with altered expression of the gene for the major mitotic cyclin, CLB2. Our data raise the intriguing possibility that p40(MO15)-cyclin H-MAT1, identified as the predominant CAK in vertebrate cell extracts, may not function as a physiological CAK.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kaldis, P (corresponding author), YALE UNIV, SCH MED, DEPT MOL BIOPHYS & BIOCHEM, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.		Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47830] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESHAIES RJ, 1995, P NATL ACAD SCI USA, V92, P1182, DOI 10.1073/pnas.92.4.1182; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HADWIGER JA, 1988, MOL CELL BIOL, V8, P2976, DOI 10.1128/MCB.8.7.2976; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Moore DD, 1995, GLOB MOB SURV; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SCLAFANI RA, 1994, MOL MICROBIOL, V11, P805, DOI 10.1111/j.1365-2958.1994.tb00358.x; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587	54	185	190	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 23	1996	86	4					553	564		10.1016/S0092-8674(00)80129-4	http://dx.doi.org/10.1016/S0092-8674(00)80129-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752210	hybrid			2022-12-28	WOS:A1996VE23500006
J	Mohammadi, M; Schlessinger, J; Hubbard, SR				Mohammadi, M; Schlessinger, J; Hubbard, SR			Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism	CELL			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR-3; SIGNAL TRANSDUCTION; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; INSULIN-RECEPTOR; POINT MUTATION; REPLACEMENT; RECOGNITION; MITOGENESIS	The crystal structure of the tyrosine kinase domain of fibroblast growth factor receptor 1 (FGFR1K) has been determined in its unliganded form to 2.0 Angstrom resolution and in complex with an ATP analog to 2.3 Angstrom resolution. Several features distinguish the structure of FGFR1K from that of the tyrosine kinase domain of the insulin receptor. Residues in the activation loop of FGFR1K appear to interfere with substrate peptide binding but not with ATP binding, revealing a second and perhaps more general autoinhibitory mechanism for receptor tyrosine kinases. In addition, a dimeric form of FGFR1K observed in the crystal structure may provide insights into the molecular mechanisms by which FGF receptors are activated. Finally, the structure provides a basis for rationalizing the effects of kinase mutations in FGF receptors that lead to developmental disorders in nematodes and humans.	NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016	New York University	Mohammadi, M (corresponding author), NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Hubbard, Stevan/0000-0002-2707-9383				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRUNGER AT, 1992, XPLOR VERSION 31 MAN; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HENDRICKSON WA, 1979, ACTA CRYSTALLOGR A, V35, P158, DOI 10.1107/S0567739479000279; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	37	328	344	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					577	587		10.1016/S0092-8674(00)80131-2	http://dx.doi.org/10.1016/S0092-8674(00)80131-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752212	hybrid			2022-12-28	WOS:A1996VE23500008
J	Thuret, JY; Valay, JG; Faye, G; Mann, C				Thuret, JY; Valay, JG; Faye, G; Mann, C			Civ1 (CAK in vivo), a novel Cdk-activating kinase	CELL			English	Article							TRANSCRIPTION FACTOR TFIIH; DEPENDENT PROTEIN-KINASES; CELL-CYCLE REGULATION; RING FINGER PROTEIN; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SCHIZOSACCHAROMYCES-POMBE; RANDOM MUTAGENESIS; ASSEMBLY FACTOR; DOMAIN KINASE	Cyclin-dependent protein kinases (Cdks) play key roles in regulating cell division and gene expression. Most Cdks require binding of a cyclin and phosphorylation by a Cdk-activating kinase (CAK) to be active. We report the identification of Civ1 (CAK in vivo), a novel CAK activity in S. cerevisiae. Civ1 is most similar in sequence to the Cdks, but unlike them is active as a monomer and may thus be the founding member of a novel family of kinases. Civ1 binds tightly to and phosphorylates Cdc28, thereby allowing its subsequent activation by the binding of a cyclin. The CIV1 gene is essential for yeast cell viability, and Cdc28 phosphorylation and activity are conditionally inhibited in a civ1-4 temperature-sensitive mutant. Civ1 is the only CAK for which there are genetic data indicating that its activity is physiologically relevant in vivo.	CTR UNIV ORSAY,INST CURIE,SECT RECH,CNRS UMR 216,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Thuret, JY (corresponding author), CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE.			Thuret, Jean-Yves/0000-0001-5385-7620; Mann, Carl/0000-0001-7212-1512				BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DARBON JM, 1994, ONCOGENE, V9, P3127; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FOREMAN PK, 1994, GENE, V144, P63, DOI 10.1016/0378-1119(94)90204-6; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KREK W, 1992, NEW BIOL, V4, P323; LABBE JC, 1994, EMBO J, V14, P5027; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MANN C, 1992, MOL CELL BIOL, V125, P4314; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1993, CELL CYCLE; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POON RYC, 1995, CURR BIOL, V5, P1243; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIMON M, 1984, P NATL ACAD SCI-BIOL, V81, P8, DOI 10.1073/pnas.81.1.8; SIMON M, 1993, GENE, V127, P139, DOI 10.1016/0378-1119(93)90629-H; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Valay JG, 1996, CR ACAD SCI III-VIE, V319, P183; VALAY JG, 1994, THESIS U PARIS 6 PAR; WU LT, 1994, ONCOGENE, V9, P2089; YEE A, 1995, CANCER RES, V55, P6058; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	61	155	159	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					565	576		10.1016/S0092-8674(00)80130-0	http://dx.doi.org/10.1016/S0092-8674(00)80130-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752211	Bronze			2022-12-28	WOS:A1996VE23500007
J	ElKhoury, J; Hickman, SE; Thomas, CA; Cao, L; Silverstein, SC; Loike, JD				ElKhoury, J; Hickman, SE; Thomas, CA; Cao, L; Silverstein, SC; Loike, JD			Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils	NATURE			English	Article							ALZHEIMER-DISEASE; FLUOROMETRIC ASSAY; BASEMENT-MEMBRANE; END-PRODUCTS; CONGO RED; MACROPHAGES; NEUROTOXICITY; ACTIVATION; PROTEIN; REGION	A PATHOLOGICAL hallmark of Alzheimer's disease is the senile plaque, containing beta-amyloid fibrils, microglia and astrocytes(1). beta-amyloid fibrils exert a cytotoxic effect on neurons(2), and stimulate microglia to produce neurotoxins, such as reactive oxygen species(3,4). Mononuclear phagocytes, including microglia, express scavenger receptors that mediate endocytosis of oxidized low-density lipoproteins(5), and adhesion to glucose-modified extracellular matrix proteins(6). Here we report that class A scavenger receptors mediate adhesion of rodent microglia and human monocytes to beta-amyloid fibril-coated surfaces leading to secretion of reactive oxygen species and cell immobilization. Thus, class A scavenger receptors are potential therapeutic targets in Alzheimer's disease.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University	ElKhoury, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032, USA.			El Khoury, Joseph/0000-0003-1498-1703				AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; AUSUBEL FM, 1993, CURR PROT MOL BIOL, V1, P921; BELL MD, 1994, J NEUROCYTOL, V23, P605, DOI 10.1007/BF01191555; Christie RH, 1996, AM J PATHOL, V148, P399; ELGHETANY MT, 1989, ANN CLIN LAB SCI, V19, P190; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GIULIAN D, 1986, J NEUROSCI, V6, P2163; HARTUNG HP, 1986, LAB INVEST, V55, P209; JIANG HX, 1994, J IMMUNOL, V152, P5050; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LOIKE JD, 1995, J EXP MED, V181, P1763, DOI 10.1084/jem.181.5.1763; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; NARINDRASORASAK S, 1995, LAB INVEST, V72, P272; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022-1759(93)90150-6; WISNIEWSKI HM, 1989, J NEUROPATH EXP NEUR, V48, P606	23	626	649	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					716	719						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751442				2022-12-28	WOS:A1996VD33300050
J	Nelson, JR; Lawrence, CW; Hinkle, DC				Nelson, JR; Lawrence, CW; Hinkle, DC			Deoxycytidyl transferase activity of yeast REV1 protein	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE; MUTAGENESIS	MUTAGENESIS induced by DNA damage in Sacchalamyces cerevisiae requires the products of the REV1, REV3 and REV7 genes(1), The Rev3 and Rev7 proteins are subunits of DNA polymerase-zeta(2) (Pol-zeta), an enzyme whose sole function appears to be translesion synthesis(3). Rev1 protein has weak homology with UmuC protein(4), which facilitates translesion synthesis in Escherichia coli by an unknown mechanism. We show here that Rev1 protein has a deoxycytidyl transferase activity which transfers a dCMP residue from dCTP to the 3' end of a DNA primer in a template-dependent reaction. Efficient transfer occurred opposite a template abasic site, but similar to 20% transfer also occurred opposite a template guanine and similar to 10% opposite adenine or uracil; less than or equal to 1% was seen opposite thymine or cytosine. Insertion of cytosine opposite an abasic site produced a terminus that was extended efficiently by Pol-zeta, but not by yeast Poi-alpha.	UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642	University of Rochester; University of Rochester								ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; GIBBS PEM, 1995, NUCLEIC ACIDS RES, V23, P1919, DOI 10.1093/nar/23.11.1919; GIBBS PEM, 1993, J BACTERIOL, V175, P2607, DOI 10.1128/JB.175.9.2607-2612.1993; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ratliff R.L., 1981, ENZYMES, VXIV, P105	10	499	504	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					729	731		10.1038/382729a0	http://dx.doi.org/10.1038/382729a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751446				2022-12-28	WOS:A1996VD33300054
J	Samson, M; Libert, F; Doranz, BJ; Rucker, J; Liesnard, C; Farber, CM; Saragosti, S; Lapoumeroulie, C; Cognaux, J; Forceille, C; Muyldermans, G; Verhofstede, C; Burtonboy, G; Georges, M; Imai, T; Rana, S; Yi, YJ; Smyth, RJ; Collman, RG; Doms, RW; Vassart, G; Parmentier, M				Samson, M; Libert, F; Doranz, BJ; Rucker, J; Liesnard, C; Farber, CM; Saragosti, S; Lapoumeroulie, C; Cognaux, J; Forceille, C; Muyldermans, G; Verhofstede, C; Burtonboy, G; Georges, M; Imai, T; Rana, S; Yi, YJ; Smyth, RJ; Collman, RG; Doms, RW; Vassart, G; Parmentier, M			Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELLS; ACTIVATION; CLONING	HIV-1 and related viruses require co-receptors, in addition to CD4, to infect target cells. The chemokine receptor CCR-5 (ref. 1) was recently demonstrated to be a co-receptor for macrophage-tropic (M-tropic) HIV-1 strains(2-6), and the orphan(7) receptor LESTR (also called fusin) allows infection by strains adapted for growth in transformed T-cell lines (T-tropic strains). Here we show that a mutant allele of CCR-5 is present at a high frequency in caucasian populations (allele frequency, 0.092), but is absent in 'black populations from Western and Central Africa and Japanese populations. A 32-base-pair deletion within the coding region results in a frame shift, and generates a non-functional receptor that does not support membrane fusion or infection by macrophage- and dual-tropic HIV-1 strains. In a cohort of HIV-1-infected caucasian subjects, no individual homozygous for the mutation was found, and the frequency of heterozygotes was 35% lower than in the general population. White blood cells from an individual homozygous for the null allele were found to be highly resistant to infection by M-tropic HIV-1 viruses, confirming that CCR-5 is the major cc-receptor for primary HIV-1 strains, The lower frequency of heterozygotes in seropositive patients may indicate partial resistance.	FREE UNIV BRUSSELS,IRIBHN,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SERV GENET MED,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SERV VIROL,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SERV IMMUNODEFICIENCES,B-1070 BRUSSELS,BELGIUM; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; HOP COCHIN,INST COCHIN GENET MOL,F-75014 PARIS,FRANCE; HOP ROBERT DEBRE,INSERM,U120,F-75935 PARIS,FRANCE; UNIV LIEGE,BELGIAN AIDS REFERENCE LABS,B-4000 LIEGE,BELGIUM; UNIV LIEGE,FAC VET MED,DEPT GENET,B-4000 LIEGE,BELGIUM; NAGOYA UNIV,SCH MED,DEPT SURG 2,NAGOYA,AICHI 466,JAPAN; UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Pennsylvania; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Liege; University of Liege; Nagoya University; University of Pennsylvania			Muyldermans, Gaetan/AAE-7235-2020; Lapoumeroulie, Claudine/P-3515-2018; Samson, Michel/F-8356-2013	LAPOUMEROULIE, Claudine/0000-0001-6665-3598; Parmentier, Marc/0000-0001-8081-4685				AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DETELS R, 1994, J ACQ IMMUN DEF SYND, V7, P1263; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DRAJIC T, 1996, NATURE, V381, P667; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAYLOR R, 1994, J NIH RES, V6, P29; WAINBERG MA, 1987, CLIN EXP IMMUNOL, P136; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E	24	2323	2455	2	158	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					722	725		10.1038/382722a0	http://dx.doi.org/10.1038/382722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751444				2022-12-28	WOS:A1996VD33300052
J	Beelman, CA; Stevens, A; Caponigro, G; LaGrandeur, TE; Hatfield, L; Fortner, DM; Parker, R				Beelman, CA; Stevens, A; Caponigro, G; LaGrandeur, TE; Hatfield, L; Fortner, DM; Parker, R			An essential component of the decapping enzyme required for normal rates of mRNA turnover	NATURE			English	Article							TRANSLATIONAL TERMINATION CODON; MESSENGER-RNA DECAY; SACCHAROMYCES-CEREVISIAE; YEAST; DEADENYLATION; DEGRADATION; TRANSCRIPT; PROTEIN; GENE; IDENTIFICATION	A MAJOR pathway of messenger RNA degradation in eukaryotic cells is initiated by shortening of the poly(A) tail, which, at least in yeast, triggers a decapping reaction, thereby exposing the mRNA to 5' --> 3' degradation(1-4). Decapping is the key step in this decay pathway because the transcript body is rapidly degraded following decapping. Accordingly, decapping is the site of numerous controls, including inhibition of decapping by the poly(A) tail(3,4) and modulation of mRNA decapping rate by specific sequences(3-5). Moreover, a specialized decay pathway that degrades aberrant transcripts triggers rapid mRNA decapping independently of poly(A)-tail shortening(6). We have identified a yeast gene, termed DCP1, that encodes the decapping enzyme, or an essential component of a decapping complex. The protein Dcp1 is required for the normal decay of many unstable and stable yeast mRNAs, as well as mRNAs that are decapped independently of deadenylation. These results indicate that mRNA-specific rates of decapping, and thus decay, will result from differences in the interaction of the DCP1 decapping enzyme with individual transcripts.	UNIV ARIZONA,HOWARD HUGHES MED INST,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831	Howard Hughes Medical Institute; University of Arizona; University of Arizona; United States Department of Energy (DOE); Oak Ridge National Laboratory								BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; HATFIELD L, IN PRESS MOL CELL BI; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; MANDART E, 1995, MOL CELL BIOL, V15, P6979; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; STEVENS A, 1988, MOL CELL BIOL, V8, P2005, DOI 10.1128/MCB.8.5.2005	21	272	277	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					642	646		10.1038/382642a0	http://dx.doi.org/10.1038/382642a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757137				2022-12-28	WOS:A1996VC30300057
J	Saigal, S; Feeny, D; Rosenbaum, P; Furlong, W; Burrows, E; Stoskopf, B				Saigal, S; Feeny, D; Rosenbaum, P; Furlong, W; Burrows, E; Stoskopf, B			Self-perceived health status and health-related quality of life of extremely low-birth-weight infants at adolescence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AGE 8 YEARS; CHILDHOOD-CANCER; UTILITIES INDEX; OF-LIFE; SOCIAL PREFERENCES; INTENSIVE-CARE; SCHOOL-AGE; CHILDREN; SURVIVORS; DISABILITIES	Objectives.-To estimate and to compare the self-assessed health status and health-related quality of life of extremely low-birth-weight (ELBW) and control infants during adolescence. Design.-Prospective, observational study of an inception cohort with a concurrent control group. Setting.-Geographically defined region in central-west Ontario. Participants.-We interviewed 141 (83%) of 169 ELBW survivors born between 1977 and 1982 and 124 (86%) of 145 controls aged between 12 and 16 years. In addition, proxy responses obtained from parents were used for 9 severely impaired teenagers. Main Outcome Measures.-Assessments of health status (6 attributes), measured with the Health Utilities Index Mark 2 classification system, and health-related quality of life (utilities), quantified with 2 preference measurement techniques, were used to quantify each participant's self-reported, subjectively defined health state and 4 preselected hypothetical health states. Results.-Adolescents who were ELBW infants reported a higher number of attributes affected, as well as more complex and severe limitations in cognition, sensation, self-care, and pain, compared with controls, Statistically significant differences for the teenagers' health-related quality of life were noted between ELBW and control teenagers in the mean utility scores (0.87+/-0.26 vs 0.93+/-0.11; P=.02 on a conventional scale where 0=dead and 1.00=perfect health), However, a similar percentage of ELBW and control teenagers (71% vs 73%) gave utility ratings of more than 0.95 for their health status. Conclusions.-Direct measures of self-reported health status and utility scores indicated that, as a cohort, adolescents who were ELBW infants suffer from a greater burden of morbidity and rate their health-related quality of life as significantly lower than control teenagers, Nevertheless, the vast majority of ELBW respondents view their health-related quality of life as quite satisfactory and are difficult to distinguish from controls.	MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,CTR HLTH ECON & POLICY ANAL,HAMILTON,ON L8N 3Z5,CANADA	McMaster University; McMaster University	Saigal, S (corresponding author), MCMASTER UNIV,DEPT PEDIAT,ROOM 3C20,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.		Furlong, William J/A-1077-2008; Rosenbaum, Peter/AAW-7913-2021	Rosenbaum, Peter/0000-0001-6751-5613				ALLEN MC, 1993, NEW ENGL J MED, V329, P1597, DOI 10.1056/NEJM199311253292201; APPLETON PL, 1994, DEV MED CHILD NEUROL, V36, P198; BARR RD, 1993, AM J PEDIAT HEMATOL, V15, P284; BARR RD, 1995, INT J PEDIAT HEM ONC, V2, P305; BARR RD, 1994, INT J ONCOL, V4, P639; BERTHELOT JM, 1993, COLLOQ INSE, V226, P161; BILLSON AL, 1994, ARCH DIS CHILD, V70, P200, DOI 10.1136/adc.70.3.200; BOYLE MH, 1995, QUAL LIFE RES, V4, P249, DOI 10.1007/BF02260864; CADMAN D, 1986, J CHRON DIS, V39, P643, DOI 10.1016/0021-9681(86)90189-X; EFFER SB, 1992, J SOC OBSTET GYNECOL, V14, P39; FEENY D, 1993, BRIT J CANCER, V67, P1047, DOI 10.1038/bjc.1993.192; FEENY D, 1992, J CLIN ONCOL, V10, P923, DOI 10.1200/JCO.1992.10.6.923; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; FEENY DH, 1994, P SOC STAT SECT SESS, P161; FURLONG W, 1995, QUAL LIFE NEWSLETT, V13, P3; FURLONG W, 1995, QUAL LIFE NEWSLETT, V13, P10; FURLONG W, 1990, CHEPA WORKING PAPER, V909; GEMKE RJBJ, 1995, ARCH DIS CHILD, V73, P196, DOI 10.1136/adc.73.3.196; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HACK M, 1993, NEW ENGL J MED, V329, P1649, DOI 10.1056/NEJM199311253292210; HARRISON H, 1986, BIRTH-ISS PERINAT C, V13, P165, DOI 10.1111/j.1523-536X.1986.tb01038.x; HARRISON H, 1993, PEDIATRICS, V92, P643; Hollingshead A.B., 4 FACTOR INDEX SOCIA; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; KANABAR DJ, 1995, PEDIATR HEMAT ONCOL, V12, P29, DOI 10.3109/08880019509029525; KING GA, 1993, AM J OCCUP THER, V47, P132, DOI 10.5014/ajot.47.2.132; LAINE C, 1994, J PEDIATR, V125, P411; MCCORMICK MC, 1992, JAMA-J AM MED ASSOC, V267, P2204, DOI 10.1001/jama.267.16.2204; *NY STAT TASK FORC, 1988, FET EXTR SURV; Patrick D. L., 1993, HLTH STATUS HLTH POL; ROBERGE R, 1995, 11008E STAT CAN; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; SAIGAL S, 1991, J DEV BEHAV PEDIATR, V12, P294; SAIGAL S, 1984, J PEDIATR-US, V105, P969, DOI 10.1016/S0022-3476(84)80093-1; SAIGAL S, 1989, J PEDIATR-US, V114, P839, DOI 10.1016/S0022-3476(89)80150-7; SAIGAL S, 1994, J PEDIATR-US, V125, P418, DOI 10.1016/S0022-3476(05)83289-5; SAIGAL S, 1995, PEDIATR RES, V37, pA271; STAHLMAN MT, 1990, J PEDIATR-US, V116, P167, DOI 10.1016/S0022-3476(05)82869-0; TORRANCE GW, 1976, SOCIO ECON PLAN SCI, V10, P129, DOI 10.1016/0038-0121(76)90036-7; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; TOWNSEND M, 1991, ANN ALLERGY, V67, P403; 1994, CAN MED ASSOC J, V151, P547	44	246	248	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					453	459		10.1001/jama.276.6.453	http://dx.doi.org/10.1001/jama.276.6.453			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VA863	8691552				2022-12-28	WOS:A1996VA86300032
J	Ring, BZ; Yarnell, WS				Ring, BZ; Yarnell, WS			Function of E-coli RNA polymerase sigma factor sigma(70) in promoter-proximal pausing	CELL			English	Article							ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; TERNARY COMPLEXES; DNA; SUBUNIT; SPECIFICITY; RECOGNITION; ELONGATION; SEQUENCES; BINDING	The sigma factor sigma(70) of E. coli RNA polymerase acts not only in initiation, but also at an early stage of elongation to induce a transcription pause, and simultaneously to allow the phage lambda gene Q transcription antiterminator to act. We identify the signal in DNA that induces early pausing to be a version of the sigma(70) -10 promoter consensus, and we show that sigma(70) is both necessary for pausing and present in the paused transcription complex. Regions 2 and 3 of sigma(70) suffice to induce pausing. Since pausing is induced by the nontemplate DNA strand of the open transcription bubble, we conclude that RNA polymerase containing sigma(70) carries out base-specific recognition of the nontemplate strand as single stranded DNA. We suggest that sigma(70) remains bound to core RNA polymerase when the -10 promoter contacts are broken, and then moves to the pause-inducing sequence.			Ring, BZ (corresponding author), CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853, USA.				PHS HHS [21941] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIYAR SE, 1994, J BIOL CHEM, V269, P13179; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1969, J BIOL CHEM, V244, P6160; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEBOER HA, 1979, CELL, V17, P201, DOI 10.1016/0092-8674(79)90308-8; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; GUO HC, 1990, J BACTERIOL, V173, P1554; GUO HC, 1990, THESIS CORNELL U ITH; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Johnston D. E., 1976, RNA POLYMERASE, P413; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; RING BZ, 1995, THESIS CORNELL U ITH; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SHIMAMOTO N, 1986, J BIOL CHEM, V261, P1859; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRANEY DC, 1987, J MOL BIOL, V193, P279, DOI 10.1016/0022-2836(87)90219-1; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	41	173	179	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					485	493		10.1016/S0092-8674(00)80121-X	http://dx.doi.org/10.1016/S0092-8674(00)80121-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756730	hybrid			2022-12-28	WOS:A1996VC30900016
J	Selby, P; Gillis, C; Haward, R				Selby, P; Gillis, C; Haward, R			Benefits from specialised cancer care	LANCET			English	Review							BREAST-CANCER; CENTRALIZED TREATMENT; COMMUNITY HOSPITALS; PROGNOSTIC FACTORS; PATIENT SURVIVAL; RECTUM-CARCINOMA; CLINICAL-TRIALS; OVARIAN-CANCER; GASTRIC-CANCER; LUNG-CANCER	The Expert Advisory Group's recommendations to establish cancer centres, cancer units, and a network involving primary care for the treatment of cancer patients in the UH is based on the view that specialisation in cancer care will improve outcomes. Evidence to support the various aspects of specialisation (eg, training, caseload, and the formation of multidisciplinary teams) is strongest for breast cancer, ovarian cancer, and some haematological malignant diseases. There is evidence to support the view that some specialised care can be successfully delivered by a network of district hospitals and main general or teaching hospitals and does not always require referral to cancer centres.	RUCHILL HOSP, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW, LANARK, SCOTLAND; COOKRIDGE HOSP, YORKSHIRE CANC ORG, LEEDS LS16 6QB, W YORKSHIRE, ENGLAND; UNIV LEEDS, LEEDS RES SCH MED, CTR CANC RES, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Glasgow; Cookridge Hospital; University of Leeds	Selby, P (corresponding author), ST JAMES UNIV HOSP, IMPERIAL CANC RES FUND, CANC MED RES UNIT, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.							AASS N, 1991, J CLIN ONCOL, V9, P818, DOI 10.1200/JCO.1991.9.5.818; *ASS CANC PHYS, 1994, REV PATT CANC SERV E; BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; BEGG CB, 1982, NEW ENGL J MED, V306, P1076, DOI 10.1056/NEJM198205063061803; BOFFETTA P, 1993, CANCER CAUSE CONTROL, V4, P209; BONENKAMP JJ, 1995, LANCET, V345, P745, DOI 10.1016/S0140-6736(95)90637-1; BYRNE MJ, 1993, AUST NZ J SURG, V63, P624, DOI 10.1111/j.1445-2197.1993.tb00470.x; DAVIS S, 1987, JNCI-J NATL CANCER I, V78, P471; DAVIS S, 1985, CANCER-AM CANCER SOC, V56, P1710, DOI 10.1002/1097-0142(19851001)56:7<1710::AID-CNCR2820560741>3.0.CO;2-T; DVIES M, 1995, 4 NOTT BREAST C; EDGE SB, 1993, CANCER-AM CANCER SOC, V71, P3502, DOI 10.1002/1097-0142(19930601)71:11<3502::AID-CNCR2820711107>3.0.CO;2-N; Expert Advisory Group on Cancer, 1995, POL FRAM COMM CANC S; GILLIS CR, 1991, LANCET, V337, P611, DOI 10.1016/0140-6736(91)91673-I; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; GORDON TA, 1995, ANN SURG, V221, P43, DOI 10.1097/00000658-199501000-00005; GREENBERG ER, 1991, J CLIN EPIDEMIOL, V44, P505; Gulliford M C, 1993, Qual Health Care, V2, P17, DOI 10.1136/qshc.2.1.17; GUSTAFSON P, 1994, ACTA ORTHOP SCAND, V65, P47, DOI 10.3109/17453679408993717; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; Hakama M, 1989, Int J Technol Assess Health Care, V5, P619; HAM C, 1995, BRIT MED J, V310, P71, DOI 10.1136/bmj.310.6972.71; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; HARDING MJ, 1993, LANCET, V341, P999, DOI 10.1016/0140-6736(93)91082-W; HERMANEK P, 1995, TUMORI, V81, P60; JOHNSON TP, 1994, J CLIN ONCOL, V12, P1783, DOI 10.1200/JCO.1994.12.9.1783; JUNOR EJ, 1994, BRIT J CANCER, V70, P363, DOI 10.1038/bjc.1994.307; KARJALAINEN S, 1989, BMJ-BRIT MED J, V299, P1069, DOI 10.1136/bmj.299.6707.1069; KARJALAINEN S, 1990, J EPIDEMIOL COMMUN H, V44, P210, DOI 10.1136/jech.44.3.210; KEHOE S, 1994, BRIT J CANCER, V70, P1014, DOI 10.1038/bjc.1994.440; Kingston R D, 1992, J R Coll Surg Edinb, V37, P235; LAUNOY G, 1992, J EPIDEMIOL COMMUN H, V46, P365, DOI 10.1136/jech.46.4.365; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; MATTHEWS HR, 1986, BRIT J SURG, V73, P621, DOI 10.1002/bjs.1800730811; McArdle CS, 1996, GI CANCER, V1, P171; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; McArdle CS, 1996, GI CANCER, V1, P177; MOHNER M, 1990, ZBL CHIR, V115, P801; NORUM J, 1995, EUR J CANCER, V31, P361; ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332; *ROYAL COLL RAD, 1991, MED MANP WORKL CLIN; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Sant M., 1995, SURVIVAL CANC PATIEN; SONTAG S, 1983, ILLNESS AS METAPHOR; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; STILLER CA, 1989, ARCH DIS CHILD, V64, P657, DOI 10.1136/adc.64.5.657; SUELING HM, 1993, BMJ-BRIT MED J, V307, P591, DOI 10.1136/bmj.307.6904.591; THORNHILL JA, 1988, BRIT J UROL, V61, P244, DOI 10.1111/j.1464-410X.1988.tb06388.x; Timothy A R, 1995, Clin Oncol (R Coll Radiol), V7, P213, DOI 10.1016/S0936-6555(05)80601-6; WHEELER S, 1993, CONFRONTING CANC CAU; Winstanley J H, 1995, Eur J Surg Oncol, V21, P140, DOI 10.1016/S0748-7983(95)90138-8; WOLFE C, 1993, J EPIDEMIOL COMMUN H, V46, P400	52	121	123	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 3	1996	348	9023					313	318		10.1016/S0140-6736(96)02482-8	http://dx.doi.org/10.1016/S0140-6736(96)02482-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709693				2022-12-28	WOS:A1996VA25000014
J	Aylin, P; Majeed, FA; Cook, DG				Aylin, P; Majeed, FA; Cook, DG			Home visiting by general practitioners in England and Wales	BRITISH MEDICAL JOURNAL			English	Article							NORMAL WORKING HOURS; PATIENT; WORKLOAD; SERVICES; RATES; CARE	Objective-To use data from the fourth national survey of morbidity in general practice to investigate the association between home visiting rates and patients' characteristics. Design-Survey of diagnostic data on all home visits by general practitioners. Setting-60 general practices in England and Wales. Subjects-502 493 patients visited at home between September 1991 and August 1992. Main outcome measures-Home visiting rates per 1000 patient years and home visiting ratios standardised for age and sex. Results-10.1% (139 801/1 378 510) of contacts with general practitioners took place in patients' homes. The average annual home visiting rate was 299/1000 patient years. Rates showed a J shaped relation with age and were lowest in people aged 16-24 years (103/1000) and highest in people aged greater than or equal to 85 years (3009/1000). 1.3% of patients were visited five or more times and received 39% of visits. Age and sex standardised home visiting ratios increased from 69 (95% confidence interval 68 to 70) in social class I to 129 (128 to 130) in social class V. The commonest diagnostic group was diseases of the respiratory system. In older age groups, diseases of the circulatory system was also a common diagnostic group. Standardised home visiting ratios for the 60 practices in the study varied nearly eightfold, from 28 to 218 (interquartile range 67 to 126). Conclusions-Home visits remain an important component of general practitioners' workload. As well as the strong associations between home visiting rates and patient characteristics, there were also large differences between practices in home visiting rates. A small number of patients received a disproportionately high number of home visits. Further investigation of patients with high home visiting rates may help to explain the large differences in workload between general practices and help in allocation of resources to practices.	ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	Aylin, P (corresponding author), OFF NATL STAT,LONDON WC2B 6JP,ENGLAND.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743; Majeed, Azeem/0000-0002-2357-9858; Cook, Derek/0000-0002-9723-5759				BALARAJAN R, 1992, BRIT MED J, V304, P529, DOI 10.1136/bmj.304.6826.529; BEALE N, 1991, BRIT J GEN PRACT, V41, P16; BUCQUET D, 1985, BRIT MED J, V290, P14803; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; *CENTR STAT OFF, 1995, 25 YEARS SOC TRENDS; Fry J, 1972, J R Coll Gen Pract, V22, P521; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; Hennekens CH, 1987, EPIDEMIOLOGY MED, P66; Humphreys R C, 1981, Br Med J (Clin Res Ed), V282, P115; HURWITZ B, 1994, BRIT MED J, V309, P1593, DOI 10.1136/bmj.309.6969.1593; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT J GEN PRACT, V45, P531; MARSH GN, 1972, BRIT MED J, V1, P487, DOI 10.1136/bmj.1.5798.487; MCCORMICK A, 1995, MORBIDITY STAT GEN P; MCKENZIE KJ, 1994, BRIT MED J, V309, P286, DOI 10.1136/bmj.309.6950.286; MORRIS JA, 1989, STAT CONFIDENCE, P50; MORTONJONES TJ, 1993, BRIT MED J, V306, P1244, DOI 10.1136/bmj.306.6887.1244; *ROYAL COLL GEN PR, 1986, MORB STAT GEN PRACTI; WHEWELL J, 1983, BRIT MED J, V286, P1259, DOI 10.1136/bmj.286.6373.1259	20	44	44	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					207	210		10.1136/bmj.313.7051.207	http://dx.doi.org/10.1136/bmj.313.7051.207			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696199	Green Published			2022-12-28	WOS:A1996VA12600028
J	Lykkesfeldt, J; Prieme, H; Loft, S; Poulsen, HE				Lykkesfeldt, J; Prieme, H; Loft, S; Poulsen, HE			Effect of smoking cessation on plasma ascorbic acid concentration	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-C; NONSMOKERS; SMOKERS		UNIV COPENHAGEN, DEPT PHARMACOL, DK-2200 COPENHAGEN N, DENMARK	University of Copenhagen			Lykkesfeldt, Jens/A-1072-2011	Lykkesfeldt, Jens/0000-0002-6514-8407; Poulsen, Henrik Enghusen/0000-0003-4242-9924; Loft, Steffen/0000-0001-9552-8518				BOLTONSMITH C, 1993, ANN NY ACAD SCI, V686, P347, DOI 10.1111/j.1749-6632.1993.tb39199.x; LYKKESFELDT J, 1995, ANAL BIOCHEM, V229, P329, DOI 10.1006/abio.1995.1421; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503	5	65	67	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	1996	313	7049					91	91		10.1136/bmj.313.7049.91	http://dx.doi.org/10.1136/bmj.313.7049.91			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UX698	8688760	Green Published			2022-12-28	WOS:A1996UX69800023
J	Chamovitz, DA; Wei, N; Osterlund, MT; vonArnim, AG; Staub, JM; Matsui, M; Deng, XW				Chamovitz, DA; Wei, N; Osterlund, MT; vonArnim, AG; Staub, JM; Matsui, M; Deng, XW			The COP9 complex, a novel multisubunit nuclear regulator involved in light control of a plant developmental switch	CELL			English	Article							MEDIATED DEVELOPMENT; ARABIDOPSIS; PROTEIN; GENE; ENCODES	Arabidopsis COP9 is a component of a large protein complex that is essential for the light control of a developmental switch and whose conformation or size is modulated by light. The complex is acidic, binds heparin, and is localized within the nucleus. Biochemical purification of the complex to near homogeneity revealed that it contains 12 distinct subunits. One of the other subunits is COP11, mutations in which result in a phenotype identical to cop9 mutants. The COP9 complex may act to regulate the nuclear abundance of COP1, an established repressor of photomorphogenic development. During the biogenesis of the COP9 complex, a certain degree of prior subunit association is a prerequisite for proper nuclear translocation. Since both COP9 and COP11 have closely related human counterparts, the COP9 complex probably represents a conserved developmental regulator in higher eukaryotes.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA; RIKEN, LAB PHOTOPERCEPT & SIGNAL TRANSDUCT, WAKO, SAITAMA 35101, JAPAN	Yale University; RIKEN			Deng, Xing Wang/ABF-4107-2020; Matsui, Minami/A-5235-2016; Chamovitz, Daniel/S-5021-2019	Matsui, Minami/0000-0001-5162-2668; Chamovitz, Daniel/0000-0002-2815-2909; von Arnim, Albrecht/0000-0003-3472-3357				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHAMOVITZ DA, 1995, CELL, V82, P353, DOI 10.1016/0092-8674(95)90423-9; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Kwok SF, 1996, PLANT PHYSIOL, V110, P731, DOI 10.1104/pp.110.3.731; MATSUI M, 1995, P NATL ACAD SCI USA, V92, P4239, DOI 10.1073/pnas.92.10.4239; MCNELLIS TW, 1995, PLANT CELL, V7, P1749, DOI 10.1105/tpc.7.11.1749; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MCNELLIS TW, 1994, PLANT CELL, V6, P1391, DOI 10.1105/tpc.6.10.1391; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9	18	255	271	2	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					115	121		10.1016/S0092-8674(00)80082-3	http://dx.doi.org/10.1016/S0092-8674(00)80082-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689678	hybrid			2022-12-28	WOS:A1996UX93400013
J	Lin, K; Rath, VL; Dai, SC; Fletterick, RJ; Hwang, PK				Lin, K; Rath, VL; Dai, SC; Fletterick, RJ; Hwang, PK			A protein phosphorylation switch at the conserved allosteric site in GP	SCIENCE			English	Article							YEAST GLYCOGEN-PHOSPHORYLASE; ACTIVATION; MECHANISM; EVOLUTION	A phosphorylation-initiated mechanism of local protein refolding activates yeast glycogen phosphorylase (GP). Refolding of the phosphorylated amino-terminus was shown to create a hydrophobic cluster that wedges into the subunit interface of the enzyme to trigger activation, The phosphorylated threonine is buried in the allosteric site, The mechanism implicates glucose 6-phosphate, the allosteric inhibitor, in facilitating dephosphorylation by dislodging the buried covalent phosphate through binding competition, Thus, protein phosphorylation-dephosphorylation may also be controlled through regulation of the accessibility of the phosphorylation site to kinases and phosphatases. In mammalian glycogen phosphorylase, phosphorylation occurs at a distinct locus. The corresponding allosteric site binds a ligand activator, adenosine monophosphate, which triggers activation by a mechanism analogous to that of phosphorylation in the yeast enzyme.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; PFIZER INC,DIV CENT RES,GROTON,CT 06340	University of California System; University of California San Francisco; Pfizer					NIDDK NIH HHS [DK32822] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032822] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BROWN SL, 1994, MED PSYCHIATRY, V1, P317; BRUNGER AT, 1992, X PLOR VERSION 3 1; COHEN P, 1985, EUR J BIOCHEM, V151, P439, DOI 10.1111/j.1432-1033.1985.tb09121.x; FOSSET M, 1971, BIOCHEMISTRY-US, V10, P4105, DOI 10.1021/bi00798a015; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; GRAVES DJ, 1983, METHOD ENZYMOL, V99, P268; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JOHNSON LN, 1994, PROTEIN SCI, V3, P1726, DOI 10.1002/pro.5560031011; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LEONIDAS DD, 1990, FEBS LETT, V261, P23, DOI 10.1016/0014-5793(90)80627-U; LERCH K, 1975, BIOCHEMISTRY-US, V14, P2009, DOI 10.1021/bi00680a031; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; Lin K., UNPUB; RATH VL, 1994, NAT STRUCT BIOL, V1, P681, DOI 10.1038/nsb1094-681; RICKENBERG HV, 1986, ENZYMES, V18, P419; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STALMANS W, 1970, EUR J BIOCHEM, V15, P9, DOI 10.1111/j.1432-1033.1970.tb00968.x; Stroud RM, 1991, CURR OPIN STRUC BIOL, V1, P826, DOI 10.1016/0959-440X(91)90186-W	25	79	80	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1539	1541		10.1126/science.273.5281.1539	http://dx.doi.org/10.1126/science.273.5281.1539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703213				2022-12-28	WOS:A1996VG59700037
J	Weissman, J				Weissman, J			Uncompensated hospital care - Will it be there if we need it?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; MASSACHUSETTS; INSURANCE; COST; REFORM; ACCESS; STATE; POOR	The debates over health care system reform continue, but they rarely mention the enduring need for free or reduced-cost hospital care as a safety net for uninsured and underinsured individuals. Policy changes on numerous fronts threaten the ability or willingness of hospitals to provide uncompensated care. These changes include the decline of Hill-Burton funds, the closings or mergers of not-for-profit and public hospitals, the dominance of competitive forces, and the redirection of funds intended for disproportionate share hospitals or uncompensated pools. Federal and state governments lack coordinated approaches toward uncompensated care, and health system reforms may not have the expected effects on reducing hospitals' burden of paying for services to indigents. Furthermore, measurement of uncompensated care is inconsistent. In light of the persistent growth in the number of persons with inadequate health insurance coverage and the central role that uncompensated care will continue to play in ensuring access to care for the poor and uninsured, these policies need to be reexamined. Guidelines for policy based on past experience are presented herein.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, SECT HLTH SERV RES, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Weissman, J (corresponding author), HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B, 1ST FLOOR, BOSTON, MA 02115 USA.							ASHBY J, 1991, I9104 PROPAC; ASHBY J, I9505 PROSP PAYM ASS; Ashby J L Jr, 1992, Healthc Financ Manage, V46, P70; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P1113, DOI 10.1001/jama.267.8.1113; BLENDON RJ, 1994, JAMA-J AM MED ASSOC, V271, P949, DOI 10.1001/jama.271.12.949; *BUR NAT AFF, 1995, HLTH CAR POL, V3, P703; BURDA D, 1994, MOD HEALTHCARE, V24, P12; BURDA D, 1992, MOD HEALTHCARE, V22, P22; BURDA D, 1994, MOD HEALTHCARE, V24, P16; BUTLER PA, 1994, ROADBLOCK REFORM ERI; *C BUDG OFF, 1993, RESP UNC CAR PUBL PR; *CATH HLTH ASS US, 1992, COMM BEN STAND NOT F; COTTON P, 1995, FAULKNER GRAYS MED H, V47, P1; Cutler DM, 1996, Q J ECON, V111, P391, DOI 10.2307/2946683; *EMPL BEN RES I, 170 EMPL BEN RES I; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; EPSTEIN AM, 1993, DO FREE CARE POOLS A; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; FRANK RG, 1990, HEALTH POLICY, V14, P1, DOI 10.1016/0168-8510(90)90294-N; GRAY PE, 1992, IEEE CIRCUIT DEVIC, V8, P3; HELMS WD, 1992, HEALTH AFFAIR, V11, P7, DOI 10.1377/hlthaff.11.2.7; HERZLINGER RE, 1987, HARVARD BUS REV, V65, P93; *HLTH RES SERV ADM, 1994, HILL UNC SERV PROGR; HOLAHAN J, 1996, HLTH AFF MILLWOOD, V14, P253; HOLOHAN J, 1995, HEALTH AFFAIR, V14, P199, DOI 10.1377/hlthaff.14.1.199; KU L, 1995, HEALTH CARE FINANC R, V16, P27; Kurland R J, 1993, Health Care Law Newsl, V8, P13; LEWIN LS, 1988, NEW ENGL J MED, V318, P1212, DOI 10.1056/NEJM198805053181829; Long SH, 1996, INQUIRY-J HEALTH CAR, V33, P85; Longo D R, 1994, J Health Adm Educ, V12, P291; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; *NEW YORK U RF WAG, 1990, HOSP COMM BEN STAND; PARMET WE, 1993, AM J LAW MED, V19, P121; *PROSP PAYM ASS CO, 1995, MED AM HLTH CAR SYST; SCHLESINGER M, 1987, MILBANK Q, V65, P25, DOI 10.2307/3350012; Schroeder SA, 1996, NEW ENGL J MED, V334, P1130, DOI 10.1056/NEJM199604253341713; Seay J D, 1994, J Health Adm Educ, V12, P373; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; STEINBROOK R, 1992, NEW ENGL J MED, V326, P340, DOI 10.1056/NEJM199201303260511; THORPE KE, 1992, JAMA-J AM MED ASSOC, V267, P945, DOI 10.1001/jama.267.7.945; THORPE KE, 1991, J HEALTH POLIT POLIC, V16, P363, DOI 10.1215/03616878-16-2-363; THORPE KE, 1987, J HEALTH POLIT POLIC, V12, P313, DOI 10.1215/03616878-12-2-313; TUCKMAN HP, 1991, MILBANK Q, V69, P113, DOI 10.2307/3350123; United States General Accounting Office, 1990, NONPR HOSP BETT STAN; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WEISSMAN JS, 1992, HEALTH AFFAIR, V11, P148, DOI 10.1377/hlthaff.11.2.148; WELCH WP, 1995, HEALTH AFFAIR, V14, P212, DOI 10.1377/hlthaff.14.2.212; 1994, FED REG         0201, V59, P4717	48	30	30	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					823	828		10.1001/jama.276.10.823	http://dx.doi.org/10.1001/jama.276.10.823			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF219	8769594				2022-12-28	WOS:A1996VF21900031
J	Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P				Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P			Symptoms of chronic bronchitis and the risk of coronary disease	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE INFECTION; HEART-DISEASE; EASTERN FINLAND; STRAIN TWAR; ASSOCIATION; INFLAMMATION; MORTALITY; CELLS	Background Experimental and epidemiological studies show a positive association between coronary various infections in different organs, both bacterial and both acute and chronic. Most attention has been paid to dental infections and infections in the respiratory tract. We have studied how chronic respiratory infection predicts coronary disease. Methods We defined chronic respiratory infection by the occurrence of symptoms of chronic bronchitis. We also analysed whether any association with coronary disease incidence and mortality is independent of the known major cardiovascular risk factors and whether it is similar among persons in different occupations. Our cohort study was a 13-year follow-up of 19 444 randomly selected eastern Finnish men and women born between 1913 and 1947 and examined in either 1972 or 1977. Findings During follow-up, there were 1419 first coronary events, either fatal or non-fatal, and 614 coronary deaths. Among men, the age-adjusted and study-year-adjusted risk ratio of long lasting-symptoms of chronic bronchitis (during as much as 3 months in a year) was 1.52 (95% CI 1.33-1.75) for coronary disease and 1.74 (CI 1.43-2.11) for coronary death. Among women the risk ratios were 1.38 (1.07-1.78) and 1.49 (0.98-2.27), respectively. Inclusion of smoking, serum cholesterol, and systolic blood pressure into the models decreased risk ratios to 1.36 (1.17-1.56) and 1.55 (1.26-1.90) in men and to 1.34 (1.04-1.74) and 1.41 (0.92-2.16) in women, respectively. The risk of coronary disease associated with the symptoms of chronic bronchitis was similar among blue-collar and white-collar workers but the association was not found among farmers. Interpretation Symptoms of chronic bronchitis predicted the risk of coronary disease independently from the known major cardiovascular risk factors. If the observed association is causal, prevention and improved management of chronic infections may have played a role in the decrease in coronary disease mortality observed in eastern Finland in the past two decades.			Jousilahti, P (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, MANNERHEIMINTIE 166, FIN-00300 HELSINKI, FINLAND.							[Anonymous], COMMUNITY CONTROL CA; GODZIK KL, 1995, J CLIN MICROBIOL, V33, P2411, DOI 10.1128/JCM.33.9.2411-2414.1995; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; HUBBARD RC, 1991, LUNG SCI F, P2059; JANG IK, 1993, EUR HEART J, V14, P2; JOUSILAHTI P, 1995, AM J EPIDEMIOL, V141, P50, DOI 10.1093/oxfordjournals.aje.a117345; KARVONEN M, 1993, EPIDEMIOL INFECT, V110, P349, DOI 10.1017/S0950268800068291; KHAW KT, 1995, BRIT MED J, V310, P1559, DOI 10.1136/bmj.310.6994.1559; MATTHAY RA, 1988, CECIL TXB MED, P410; MATTILA K, 1989, THROMB RES, V56, P325, DOI 10.1016/0049-3848(89)90174-6; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; MENDALL MA, 1994, BRIT HEART J, V71, P437; MENDALL MA, 1995, J INFECTION, V30, P121, DOI 10.1016/S0163-4453(95)80006-9; NIEMINEN MS, 1993, EUR HEART J, V14, P12; ODEH M, 1992, EUR J CLIN MICROBIOL, V11, P885, DOI 10.1007/BF01962368; RICHARDSON SGN, 1979, BRIT J HAEMATOL, V42, P469, DOI 10.1111/j.1365-2141.1979.tb01155.x; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rose G, 1968, CARDIOVASCULAR SURVE; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAMMALKORPI K, 1989, J INTERN MED, V225, P15, DOI 10.1111/j.1365-2796.1989.tb00030.x; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; SZCZEKLIK A, 1993, CORONARY ARTERY DIS, V4, P1029, DOI 10.1097/00019501-199311000-00012; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; TOTANI L, 1994, ARTERIOSCLER THROMB, V14, P125, DOI 10.1161/01.ATV.14.1.125; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; *WHO, 1994, WHO TECH REP SER, V841	30	202	219	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					567	572		10.1016/S0140-6736(96)02374-4	http://dx.doi.org/10.1016/S0140-6736(96)02374-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774568				2022-12-28	WOS:A1996VF18600009
J	Kable, ML; Seiwert, SD; Heidmann, S; Stuart, K				Kable, ML; Seiwert, SD; Heidmann, S; Stuart, K			RNA editing: A mechanism for gRNA-specified uridylate insertion into precursor mRNA	SCIENCE			English	Article							MESSENGER-RNA; TRYPANOSOMA-BRUCEI; LEISHMANIA-TARENTOLAE; CRITHIDIA-FASCICULATA; GUIDE RNAS; KINETOPLASTID MITOCHONDRIA; CHIMERA FORMATION; IN-VITRO; DOMAINS; LIGASE	In the mitochondria of trypanosomatid protozoa the precursors of messenger RNAs (pre-mRNAs) have their coding information remodeled by the site-specific insertion and deletion of uridylate (U) residues. Small trans-acting guide RNAs (gRNAs) supply the genetic information for this RNA editing. An in vitro system was developed to study the mechanism of U insertion into pre-mRNA. U-insertion editing occurs through a series of enzymatic steps that begin with gRNA-directed pre-mRNA cleavage. Inserted U's are derived from free uridine triphosphate and are added to the 3' terminus of a 5' pre-mRNA cleavage product. gRNA specifies edited RNA sequence at the subsequent ligation step by base pairing-mediated juxtaposition of the 3' cleavage product and the processed 5' cleavage product. gRNA/pre-mRNA chimeras, purported intermediates, seem to be abortive end products of the same reaction.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	Center for Infectious Disease Research; University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM42188, GM08347] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER BK, 1994, CURR OPIN GENET DEV, V4, P316, DOI 10.1016/S0959-437X(05)80060-7; ARTS GJ, 1993, EMBO J, V12, P1523, DOI 10.1002/j.1460-2075.1993.tb05796.x; ARTS GJ, 1995, MOL BIOCHEM PARASIT, V73, P211, DOI 10.1016/0166-6851(95)00119-L; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1994, EUR J BIOCHEM, V221, P9, DOI 10.1111/j.1432-1033.1994.tb18710.x; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; Corell RA, 1996, MOL CELL BIOL, V16, P1410; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; KABLE ML, UNPUB; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; MASLOV DA, 1994, MOL BIOCHEM PARASIT, V68, P155, DOI 10.1016/0166-6851(94)00160-X; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; PILLER KJ, 1995, MOL CELL BIOL, V15, P2916; Piller KJ, 1996, J BIOL CHEM, V271, P4613, DOI 10.1074/jbc.271.9.4613; PILLER KJ, 1995, MOL CELL BIOL, V15, P2925; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, J BIOL CHEM, V267, P1123; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; RUSCHE LN, 1995, MOL CELL BIOL, V15, P2933; SABATINI R, 1995, J BIOL CHEM, V270, P7233, DOI 10.1074/jbc.270.13.7233; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SEIWERT SD, 1995, PARASITOL TODAY, V11, P362, DOI 10.1016/0169-4758(95)80004-2; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Simpson L, 1993, RNA EDITING ALTERATI, P53; Sollner-Webb B, 1991, CURR OPIN CELL BIOL, V3, P1056, DOI 10.1016/0955-0674(91)90129-M; STUART K, 1993, RNA EDITING ALTERATI, P26; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	37	157	161	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1189	1195		10.1126/science.273.5279.1189	http://dx.doi.org/10.1126/science.273.5279.1189			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703045				2022-12-28	WOS:A1996VE47600028
J	Zhang, JP; Normark, S				Zhang, JP; Normark, S			Induction of gene expression in Escherichia coli after pilus-mediated adherence	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PROTEINS; URINARY-TRACT INFECTION; OUTER-MEMBRANE PROTEINS; VIRULENCE FACTORS; AEROBACTIN; TRANSPORT; SEQUENCES; RNA	The induction of cascades of virulence factors after contact between bacteria and host cells was investigated. P-pili mediate the binding of uropathogenic Escherichia coli to its host cell receptor, After P-pili binding there was transcriptional activation of a sensor-regulator protein that is essential for the bacterial iron-starvation response, An insertion mutation of the sensor-regulator gene eliminated the ability of uropathogenic E, coli to produce siderophores and their iron-regulated membrane receptors, thereby abolishing their ability to grow in urine, These results suggest that P-pilus-mediated attachment may be an important part of the sensor-regulatory process involved in uropathogenic E. coli urinary tract infection.	WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; KAROLINSKA INST,MICROBIOL & TUMORBIOL CTR,S-10521 STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,S-10521 STOCKHOLM,SWEDEN	Washington University (WUSTL); Karolinska Institutet; Swedish Institute for Infectious Disease Control					NIGMS NIH HHS [5RO1GM44655-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; DEAN CR, 1993, MOL MICROBIOL, V8, P1095, DOI 10.1111/j.1365-2958.1993.tb01654.x; FREE AH, 1975, URINALYSIS CLIN LABO, P13; GIARDINA PC, 1995, J BACTERIOL, V177, P6058, DOI 10.1128/jb.177.21.6058-6063.1995; GRIFFITHS E, 1985, INFECT IMMUN, V47, P808, DOI 10.1128/IAI.47.3.808-813.1985; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MELTON AR, 1989, J BACTERIOL, V170, P6206; MONTGOMERIE JZ, 1984, INFECT IMMUN, V46, P835, DOI 10.1128/IAI.46.3.835-838.1984; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; NEILANDS JB, 1992, CAN J MICROBIOL, V38, P728, DOI 10.1139/m92-119; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OPAL SM, 1990, J INFECT DIS, V161, P794, DOI 10.1093/infdis/161.4.794; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; ROBLEDO JA, 1990, J UROLOGY, V143, P386, DOI 10.1016/S0022-5347(17)39971-8; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; WILLIS DK, 1990, MOL PLANT MICROBE IN, V1, P80; WONG KK, 1994, P NATL ACAD SCI USA, V91, P639, DOI 10.1073/pnas.91.2.639	26	144	149	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1234	1236		10.1126/science.273.5279.1234	http://dx.doi.org/10.1126/science.273.5279.1234			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703059				2022-12-28	WOS:A1996VE47600042
J	Gerber, GS; Thisted, RA; Scardino, PT; Frohmuller, HGW; Schroeder, FH; Paulson, DF; Middleton, AW; Rukstalis, DB; Smith, JA; Schellhammer, PF; Ohori, M; Chodak, GW				Gerber, GS; Thisted, RA; Scardino, PT; Frohmuller, HGW; Schroeder, FH; Paulson, DF; Middleton, AW; Rukstalis, DB; Smith, JA; Schellhammer, PF; Ohori, M; Chodak, GW			Results of radical prostatectomy in men with clinically localized prostate cancer - Multi-institutional pooled analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDIVIDUAL PATIENT DATA; MANAGEMENT; METAANALYSIS	Objective.-To assess the results of radical prostatectomy in men with early prostate cancer. Design.-Retrospective, nonrandomized, multi-institutional pooled analysis. Setting.-Eight university medical centers in the United States and Europe. Patients.-A total of 2758 men with stage T1 and T2 prostatic cancer. Main Outcome Measures.-Disease-specific and metastasis-free survival rates. Results.-Tumor grade was the most important preoperative factor in determining outcome. Disease-specific survival 10 years following surgery and associated 95% confidence intervals were 94% (range, 87%-98%), 80% (range, 74%-85%), and 77% (range, 65%-86%) for those men with grade 1, 2, and 3 tumors, respectively, Metastasis-free survival at 10 years was 87% (range, 78%-92%), 68% (range, 62%-73%), and 52% (range, 38%-64%) for patients with grade 1, 2, and 3 cancers, respectively. Conclusions.-Radical prostatectomy leads to high 10-year disease-specific survival rates in men with all tumor grades. However, caution is needed in comparing these results with similar studies of alternative treatment strategies, such as watchful waiting, due to the inherent potential biases in uncontrolled trials, Nevertheless, these results offer the best currently available estimates of 10-year outcome of radical prostatectomy in men with clinically localized prostate cancer and may be useful in counseling patients with early malignancy.	UNIV CHICAGO,PRITZKER SCH MED,DEPT STAT,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,DEPT ANESTHESIA & CRIT CARE,CHICAGO,IL 60637; BAYLOR COLL MED,DEPT UROL,HOUSTON,TX 77030; UNIV WURZBURG,DEPT UROL,D-8700 WURZBURG,GERMANY; ERASMUS UNIV ROTTERDAM,INST UROL,ROTTERDAM,NETHERLANDS; DUKE UNIV,SCH MED,DEPT SURG,DIV UROL,DURHAM,NC; UNIV UTAH,SCH MED,DEPT UROL,SALT LAKE CITY,UT; VANDERBILT UNIV,SCH MED,DEPT UROL,NASHVILLE,TN 37212; EASTERN VIRGINIA MED SCH,DEPT UROL,NORFOLK,VA 23501	University of Chicago; University of Chicago; Baylor College of Medicine; University of Wurzburg; Erasmus University Rotterdam; Duke University; Utah System of Higher Education; University of Utah; Vanderbilt University; Eastern Virginia Medical School	Gerber, GS (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT SURG,UROL SECT,MC6038,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.		Thisted, Ronald A/B-1985-2008					ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; AUSTENFELD MS, 1994, J UROLOGY, V152, P1866, DOI 10.1016/S0022-5347(17)32403-5; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COX DR, 1972, J R STAT SOC B, V34, P187; GIBBONS RP, 1986, J UROLOGY, V135, P65, DOI 10.1016/S0022-5347(17)45519-4; HARMER MH, 1978, TNM CLASSIFICATION M; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1959, J NATL CANCER I, V22, P719; MIDDLETON RG, 1995, J UROLOGY, V154, P2144, DOI 10.1016/S0022-5347(01)66718-1; OHORI M, 1994, J UROLOGY, V152, P1843, DOI 10.1016/S0022-5347(17)32398-4; OXMAN AD, 1995, JAMA-J AM MED ASSOC, V274, P845, DOI 10.1001/jama.274.10.845; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; PROUT GR, 1973, CANCER-AM CANCER SOC, V32, P1096, DOI 10.1002/1097-0142(197311)32:5<1096::AID-CNCR2820320514>3.0.CO;2-K; SPIESSL B, 1982, TNM ATLAS ILLUSTRATE; *STATA, 1992, STATA REF MAN REL 3; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WILT TJ, 1994, J UROLOGY, V152, P1910, DOI 10.1016/S0022-5347(17)32413-8; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6	21	173	177	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					615	619						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC853	8773633				2022-12-28	WOS:A1996VC85300027
J	OKeefe, RT; Norman, C; Newman, AJ				OKeefe, RT; Norman, C; Newman, AJ			The invariant U5 snRNA loop 1 sequence is dispensable for the first catalytic step of pre-mRNA splicing in yeast	CELL			English	Article							BASE-PAIRING INTERACTION; SMALL NUCLEAR-RNA; MESSENGER-RNA; SITE SELECTION; U1 SNRNA; U6 SNRNA; ACTIVE-SITE; SPLICEOSOME; MUTATIONS; INVITRO	We have developed an in vitro reconstitution system to investigate the role of U5 snRNA in the two catalytic steps of pre-mRNA splicing. The invariant U5 loop 1 is known to interact with exon sequences at the 5' splice site before the first catalytic step. Remarkably, analysis of U5 mutations in vitro reveals that the first transesterification occurs accurately in the absence of the U5 loop. Therefore this sequence is not an essential component of the spliceosomal active site for the first catalytic step. The second catalytic step, although strongly dependent on the presence of a U5 loop to tether the exon 1 splicing intermediate, is surprisingly tolerant of mutations in the invariant sequence.			OKeefe, RT (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCPHEETERS DS, 1989, GENE DEV, V3, P2124, DOI 10.1101/gad.3.12b.2124; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Moore M., 1993, RNA WORLD, P303; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; Newman AJ, 1995, RNA, V1, P968; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; Reyes J, 1996, RNA, V2, P213; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P143; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SEGAULT V, 1995, EMBO J, V14, P4010, DOI 10.1002/j.1460-2075.1995.tb00072.x; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; Umen JG, 1995, RNA, V1, P869; VARANI G, 1991, BIOCHEMISTRY-US, V30, P320; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WINKELMANN G, 1989, EMBO J, V8, P3105, DOI 10.1002/j.1460-2075.1989.tb08462.x; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	46	107	108	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					679	689		10.1016/S0092-8674(00)80140-3	http://dx.doi.org/10.1016/S0092-8674(00)80140-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752221	Bronze			2022-12-28	WOS:A1996VE23500017
J	Oelgeschlager, T; Chiang, CM; Roeder, RG				Oelgeschlager, T; Chiang, CM; Roeder, RG			Topology and reorganization of a human TFIID-promoter complex	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; TATA-BOX; PREINITIATION COMPLEX; CRYSTAL-STRUCTURE; MINOR-GROOVE; EUKARYOTIC GENES; BINDING PROTEIN; DNA COMPLEX; ELEMENT	TRANSCRIPTION factor TFIID is a multiprotein complex composed of a TATA-box-binding subunit, TBP, and several tightly associated factors (TAFs)(1,2). Human TFIID-promoter interactions are restricted to the TATA-box region on most core promoters(3,4) but extend over a large promoter region downstream of the TATA box and the transcription start site on the Ad2ML promoter(3-6). TFIID downstream interactions are thought to be functionally relevant because they can be induced by transcriptional activators(7-10), which in some cases requires TFIIA(9,10), result in stabilization of the TFIID-promoter complex(9,10), and correlate with increased recruitment of the remaining general transcription factors(8,10). Here we examine the topological organization of human TFIID complexes bound to the Ad2ML promoter. Our data provide insight into the relative disposition of DNA and several TFIID subunits, as well as evidence for DNA wrapping by TFIID, and suggest a direct role of TFIIA in the stable positioning of promoter DNA relative to TAFs.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University				Oelgeschlager, Thomas/0000-0002-4086-719X				BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BARTHOLOMEW B, 1994, J BIOL CHEM, V269, P18090; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; GE H, IN PRESSMETH ENZYM; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LORCH Y, 1993, MOL CELL BIOL, V13, P1872, DOI 10.1128/MCB.13.3.1872; MIZUTANI M, 1991, NUCLEIC ACIDS RES, V19, P2907, DOI 10.1093/nar/19.11.2907; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1996, P NATL ACAD SCI USA, V93, P4956; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TABUCHI H, 1993, BIOCHEM BIOPH RES CO, V192, P1432, DOI 10.1006/bbrc.1993.1576; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	30	151	151	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					735	738		10.1038/382735a0	http://dx.doi.org/10.1038/382735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751448				2022-12-28	WOS:A1996VD33300056
J	Kaddoura, S; PooleWilson, PA				Kaddoura, S; PooleWilson, PA			Endothelin-1 in heart failure: A new therapeutic target?	LANCET			English	Editorial Material							PLASMA ENDOTHELIN; HYPERTENSION		ROYAL BROMPTON HOSP,LONDON SW3 6LY,ENGLAND	Royal Brompton Hospital	Kaddoura, S (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.							CODY RJ, 1992, CIRCULATION, V85, P504, DOI 10.1161/01.CIR.85.2.504; HIROE M, 1991, AM J CARDIOL, V68, P1114, DOI 10.1016/0002-9149(91)90511-I; KIOWSKI W, 1995, LANCET, V346, P732, DOI 10.1016/S0140-6736(95)91504-4; KRUM H, 1995, AM J CARDIOL, V75, P1282, DOI 10.1016/S0002-9149(99)80783-8; Krum H, 1996, AM HEART J, V131, P337, DOI 10.1016/S0002-8703(96)90363-4; MARGULIES KB, 1990, CIRCULATION, V82, P2226, DOI 10.1161/01.CIR.82.6.2226; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; PACHER R, 1993, AM J CARDIOL, V71, P1293, DOI 10.1016/0002-9149(93)90543-L; Pacher R, 1996, J AM COLL CARDIOL, V27, P633, DOI 10.1016/0735-1097(95)00520-X; STEWART DJ, 1992, CIRCULATION, V85, P510, DOI 10.1161/01.CIR.85.2.510; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; TSUTAMOTO T, 1994, J AM COLL CARDIOL, V23, P1427, DOI 10.1016/0735-1097(94)90387-5; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580	13	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					418	419		10.1016/S0140-6736(05)64531-X	http://dx.doi.org/10.1016/S0140-6736(05)64531-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709775				2022-12-28	WOS:A1996VC67300002
J	While, D; Kelly, S; Huang, WY; Charlton, A				While, D; Kelly, S; Huang, WY; Charlton, A			Cigarette advertising and onset of smoking in children: Questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate uptake of smoking in a cohort of 11 to 12 year olds related to awareness of advertised cigarette brands named. Design-Self completed questionnaires administered to whole classes of schoolchildren in June 1993 and June 1994. Setting-Primary, middle, and secondary schools in the north and south of England. Subjects-1450 pupils aged 11 and 12 years at the time of the first survey. Main outcome measures-Onset of smoking and brands smoked by the second survey related to cigarette brands named in the first one. Less advertised brands were used as the: base for calculating odds ratios. Results-Girls who named the most advertised brands-namely, Benson and Hedges alone (odds ratio = 2.50, 95% confidence interval = 1.18 to 5.30) or Benson and Hedges and Silk Cut (2.15, 1.04 to 4.42) in the first survey were at greatest risk of taking up smoking by the second one. The difference was similar but not significant for boys. Boys and girls who named the least advertised brands in the first survey were at no greater risk of taking up smoking by the second survey than those who named no brands (boys odds ratio = 0.49 (0.24 to 1.01); girls 0.79 (0.38 to 1.62)). New smokers were more Likely to smoke any available brand (29.5%) or a less advertised brand such as Embassy (24.6%) than the most advertised ones, Benson and Hedges (19.7%) and Silk Cut (14.8%). Established smokers were more selective, only 15% smoking any available brand and 38.3% smoking Benson and Hedges. Conclusions-Cigarette advertising appears to increase children's awareness of smoking at a generic level and encourages them to take up the behaviour, beginning with any cigarettes which are available and affordable.	UNIV MANCHESTER,SCH EPIDEMIOL & HLTH SCI,CRC EDUC & CHILD STUDIES RES GRP,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester								AITKEN PP, 1990, BRIT J ADDICT, V85, P399; Aitken PP, 1987, HLTH PROMOTION, V2, P219; CHAPMAN S, 1982, AM J PUBLIC HEALTH, V72, P491, DOI 10.2105/AJPH.72.5.491; CHARLTON A, 1989, SOC SCI MED, V29, P813, DOI 10.1016/0277-9536(89)90080-4; Department of Health, 1992, POL REQ AV COMP SPEC; GODDARD E, 1990, WHY CHILDREN START S; GOLDSTEIN AO, 1987, J PEDIATR-US, V110, P488, DOI 10.1016/S0022-3476(87)80523-1; HASTINGS GB, 1994, BRIT MED J, V309, P933, DOI 10.1136/bmj.309.6959.933; MCNEILL AD, 1985, LANCET, V2, P271; *NEILS REG MEAL, 1994, 1993 94 MEAL NIELS R; *TOB ADV COUNC, 1985, CAS TOB ADV; *US SURG GEN, 1994, PREV TOB US YOUNG PE	12	34	34	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					398	399						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD206	8761227				2022-12-28	WOS:A1996VD20600025
J	Feig, SA				Feig, SA			Mammographic screening of elderly women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							AGED 40-49 YEARS; BREAST-CANCER				Feig, SA (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT RADIOL,PHILADELPHIA,PA 19107, USA.							BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; COSTANZA ME, 1992, CANCER, V69, P1925, DOI 10.1002/1097-0142(19920401)69:7+<1925::AID-CNCR2820691709>3.0.CO;2-U; COSTANZA ME, 1992, J GERONTOL, V47, P7; DODD GD, 1992, CA-CANCER J CLIN, V42, P177, DOI 10.3322/canjclin.42.3.177; FAULK RM, 1995, RADIOLOGY, V194, P193, DOI 10.1148/radiology.194.1.7997552; FEIG SA, 1995, CANCER, V75, P2412, DOI 10.1002/1097-0142(19950515)75:10<2412::AID-CNCR2820751005>3.0.CO;2-4; ROSENQUIST CJ, 1994, RADIOLOGY, V191, P647, DOI 10.1148/radiology.191.3.8184041; SHAPIRO S, 1994, CANCER, V74, P231, DOI 10.1002/cncr.2820741306; *US BUR CENS, 1995, VIT STAT STAT ABSTR; Vanchieri C, 1989, J Natl Cancer Inst, V81, P1126, DOI 10.1093/jnci/81.15.1126; WILSON TE, 1994, RADIOLOGY, V190, P203, DOI 10.1148/radiology.190.1.8259405; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; 1984, JAMA-J AM MED ASSOC, V252, P3008	13	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					446	446						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691541				2022-12-28	WOS:A1996VA86300011
J	Ptacek, JT; Eberhardt, TL				Ptacek, JT; Eberhardt, TL			Breaking bad news - A review of the literature	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CANCER-PATIENTS; PATIENTS VIEWS; COMMUNICATION; PARENTS; DEATH; EXPERIENCES; PHYSICIANS; DIFFICULT; EDUCATION; DIAGNOSIS	Objective.-To review the literature on breaking bad news while highlighting its limitations and describing a theoretical model from which Vie bad news process can be understood and studied. Data Sources.-Sources were obtained through the MEDLINE database, using ''bad news'' as the primary descriptor and limiting the sources to English-language articles published since 1985. Study Selection and Extraction.-All articles dealing specifically with bad news were examined, These works included letters, opinions, reviews, and empirical studies. Recommendations from these articles were examined, sorted into discrete categories, and summarized. Data Synthesis.-The 13 most consistently mentioned recommendations (eg, delivering the news at the patient's pace, conveying some hope, and giving the news with empathy) were examined. Conclusion.-Although much has been written on the topic of breaking bad news, the literature is in need of empirical work, Research should begin with the simple question of whether how the news is conveyed accounts for variance in adjustment before moving to more specific questions about which aspects of conveying bad news are most beneficial. It is suggested that the bad news process can be understood from the transactional approach to stress and coping.			Ptacek, JT (corresponding author), BUCKNELL UNIV, DEPT PSYCHOL, LEWISBURG, PA 17837 USA.							BACON AK, 1989, ANAESTHESIA, V44, P245, DOI 10.1111/j.1365-2044.1989.tb11235.x; Beasley N W, 1993, Va Med Q, V120, P90; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; BOND CF, 1987, J EXP SOC PSYCHOL, V23, P176, DOI 10.1016/0022-1031(87)90030-8; Bor R., 1993, COUNS PSYCHOL Q, V6, P69, DOI [10.1080/09515079308254494, DOI 10.1080/09515079308254494]; BORISH IM, 1975, OPTOM MANAGE, V11, P13; BREWIN TB, 1991, LANCET, V337, P1207, DOI 10.1016/0140-6736(91)92870-8; BUCKMAN R, 1984, BRIT MED J, V288, P1597, DOI 10.1136/bmj.288.6430.1597; BUIS C, 1991, FAM PRACT, V8, P303, DOI 10.1093/fampra/8.4.303; Bulkin W, 1991, Am J Hosp Palliat Care, V8, P10, DOI 10.1177/104990919100800213; BULLER MK, 1987, J HEALTH SOC BEHAV, V28, P375, DOI 10.2307/2136791; Campbell M L, 1994, JAMA, V271, P1052, DOI 10.1001/jama.271.13.1052; CHARLTON R, 1995, FAM PRACT, V12, P70, DOI 10.1093/fampra/12.1.70; CHARLTON R, 1993, MED J AUSTRALIA, V159, P72, DOI 10.5694/j.1326-5377.1993.tb137734.x; CHARLTON RC, 1992, MED J AUSTRALIA, V157, P615, DOI 10.5694/j.1326-5377.1992.tb137405.x; COLON K, 1995, MINN MED, V78, P10; CREAGAN ET, 1994, MAYO CLIN PROC, V69, P1015, DOI 10.1016/S0025-6196(12)61833-3; Davidhizar R M, 1985, Nursing, V15, P58; DAVIS H, 1991, PRACTITIONER, V235, P522; Davis H., 1993, COUNSELLING PARENTS; Doring L A, 1992, Aust Fam Physician, V21, P791; Eden O. B., 1994, Palliative Medicine, V8, P105, DOI 10.1177/026921639400800203; FALKNER A, 1994, PALIAT MED, V8, P145; FALLOWFIELD L, 1993, LANCET, V341, P476, DOI 10.1016/0140-6736(93)90219-7; FALLOWFIELD LJ, 1994, AM J GASTROENTEROL, V89, P473; FALVO DR, 1983, J FAM PRACTICE, V17, P479; FISHER B, 1993, BRIT J GEN PRACT, V43, P52; FOLKMAN S, 1984, J PERS SOC PSYCHOL, V46, P839, DOI 10.1037/0022-3514.46.4.839; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; FORD S, 1994, BRIT J CANCER, V70, P767, DOI 10.1038/bjc.1994.393; GILLARD JH, 1993, BRIT MED J, V307, P1176, DOI 10.1136/bmj.307.6913.1176; GIRGIS A, 1995, J CLIN ONCOL, V13, P2449, DOI 10.1200/JCO.1995.13.9.2449; GOLDFIELD N, 1987, SOC SCI MED, V24, P483, DOI 10.1016/0277-9536(87)90337-6; GOLDSTEIN S, 1984, DIVORCE YOUR CHILD P; GOODMAN JF, 1988, STRATEGIES GENETIC C, V1; GRAHAM JR, 1991, LANCET, V337, P1608, DOI 10.1016/0140-6736(91)93305-S; Harris L, 1988, Community Outlook, P15; HINDS C, 1995, CANCER NURS, V18, P374; HOGBIN B, 1989, BRIT J HOSP MED, V41, P330; HOGSHEAD HP, 1976, J FLA MED ASSOC, V63, P807; HOLDAWAY J, 1985, NEW ZEAL MED J, V98, P639; HOLLAND JC, 1989, J CLIN ONCOL, V7, P557, DOI 10.1200/JCO.1989.7.5.557; HOPPER SV, 1989, PATIENT EDUC COUNS, V14, P69, DOI 10.1016/0738-3991(89)90008-6; HOY AM, 1985, BRIT J HOSP MED, V34, P96; KAISER RM, 1993, HOSP PRACT      1020, P13; Klein S D, 1987, J Am Optom Assoc, V58, P660; KLEIN SD, 1993, J DEV BEHAV PEDIATR, V14, P184; KNOX JDE, 1989, MED EDUC, V23, P258, DOI 10.1111/j.1365-2923.1989.tb01541.x; KORSCH BM, 1968, PEDIATRICS, V42, P855; KRAHN GL, 1993, PEDIATRICS, V91, P578; KRAUSSMARS AH, 1994, CHILD CARE HLTH DEV, V20, P101, DOI 10.1111/j.1365-2214.1994.tb00857.x; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; Lazarus RS., 1984, STRESS APPRAISAL COP; LINKS M, 1994, SUPPORT CARE CANCER, V2, P91, DOI 10.1007/BF00572089; MAGUIRE P, 1988, BRIT MED J, V297, P907, DOI 10.1136/bmj.297.6653.907; MCHUGH P, 1995, BRIT J CANCER, V71, P388, DOI 10.1038/bjc.1995.79; MICHAELS E, 1983, CAN MED ASSOC J, V129, P1307; MIRANDA J, 1992, WESTERN J MED, V156, P83; MYERS BA, 1983, AM J DIS CHILD, V137, P572, DOI 10.1001/archpedi.1983.02140320048011; O'Brien Tony, 1993, Palliative Medicine, V7, P69; PARATHIAN AR, 1993, J ADV NURS, V18, P801, DOI 10.1046/j.1365-2648.1993.18050801.x; PERSAUD R, 1993, LANCET, V341, P832, DOI 10.1016/0140-6736(93)90611-J; PETEET JR, 1991, J FAM PRACTICE, V32, P577; PTACEK JT, 1994, J PSYCHOSOC ONCOL, V12, P47, DOI 10.1300/J077V12N03_04; QUILL TE, 1991, ARCH INTERN MED, V151, P463; RAPPAPORT W, 1993, SURGERY, V113, P163; SEALE C, 1991, SOC SCI MED, V32, P943, DOI 10.1016/0277-9536(91)90249-C; SELL L, 1993, RESP MED, V87, P61, DOI 10.1016/S0954-6111(05)80315-4; SHORT D, 1993, BRIT J HOSP MED, V50, P548; SNYDER CR, 1987, COPING NEGATIVE LIFE; Speck P, 1991, Nurs Times, V87, P24; STANTON AL, 1987, J BEHAV MED, V10, P377, DOI 10.1007/BF00846477; STATHAM H, 1992, BIRTH-ISS PERINAT C, V19, P103, DOI 10.1111/j.1523-536X.1992.tb00389.x; STRAUSS RP, 1995, PEDIATRICS, V96, P82; SWANSON RW, 1993, ANN EMERG MED, V22, P350, DOI 10.1016/S0196-0644(05)80464-0; SYKES N, 1989, LANCET, V2, P564; Taylor SE, 1995, HLTH PSYCHOL; TESSER A, 1973, J COMMUN, V23, P267, DOI 10.1111/j.1460-2466.1973.tb00948.x; TESSER A, 1975, ADV EXPT SOCIAL PSYC, V8; WALLSTON BS, 1984, HDB PSYCHOL HLTH, V4; 1994, NURS TIMES        S1, V90, P1; 1994, NURS TIMES        S3, V90, P9; 1994, NURS TIMES S2, V90, P5	83	454	460	1	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					496	502						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VA863	8691562				2022-12-28	WOS:A1996VA86300042
J	Huang, Z; Kunes, S				Huang, Z; Kunes, S			Hedgehog, transmitted along retinal axons, triggers neurogenesis in the developing visual centers of the Drosophila brain	CELL			English	Article							CELL-CELL COMMUNICATION; 1ST OPTIC GANGLION; POLARITY GENE; EARLY DIFFERENTIATION; PATTERN-FORMATION; PATCHED GENE; GLIAL-CELLS; MELANOGASTER; PROTEIN; SEGMENT	The development of the visual centers of the Drosophila brain is tightly regulated by the ingrowth of retinal axons from the developing eye. In the first optic ganglion, the lamina, arriving retinal axons trigger the precursors of their synaptic partners to complete a final cell division and commence neural differentiation. The secreted product of the hedgehog gene regulates the temporal assembly of photoreceptor precursor cells into ommatidial clusters in the compound eye. Here, we show that Hedgehog is transmitted along the retinal axons to serve as the inductive signal in the brain. Hedgehog acts in the first of two retinal axon-mediated steps in the assembly of lamina synaptic cartridges. These observations provide a novel insight into the molecular interactions that orchestrate the assembly of neural precursor cells into precise synaptic circuits.			Huang, Z (corresponding author), HARVARD UNIV,DEPT MOL & CELL BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL EYE INSTITUTE [R01EY010112] Funding Source: NIH RePORTER; NEI NIH HHS [EY10112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; DUNINBORKOWSKI OM, 1995, DEV BIOL, V168, P689, DOI 10.1006/dbio.1995.1115; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; GONG QH, 1995, NEURON, V14, P91, DOI 10.1016/0896-6273(95)90243-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KAPHINGST K, 1994, CELL, V78, P437, DOI 10.1016/0092-8674(94)90422-7; KOLLROS JJ, 1982, J COMP NEUROL, V205, P171, DOI 10.1002/cne.902050208; KUNES S, 1993, J NEUROSCI, V13, P752; Kunes Samuel, 1993, Current Opinion in Neurobiology, V3, P53, DOI 10.1016/0959-4388(93)90035-W; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MACAGNO ER, 1979, DEV BIOL, V73, P206, DOI 10.1016/0012-1606(79)90064-2; MARDON G, 1994, DEVELOPMENT, V120, P3473; Marigo V, 1996, DEVELOPMENT, V122, P1225; Meinertzhagen Ian A., 1993, P1363; MEYEROWITZ EM, 1978, DEV BIOL, V62, P112, DOI 10.1016/0012-1606(78)90096-9; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MOZER BA, 1994, DEVELOPMENT, V120, P1049; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Perez SE, 1996, J NEUROBIOL, V30, P359, DOI 10.1002/(SICI)1097-4695(199607)30:3<359::AID-NEU5>3.0.CO;2-3; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Power ME, 1943, J EXP ZOOL, V94, P33, DOI 10.1002/jez.1400940103; RAYMOND PA, 1983, J NEUROSCI, V3, P1092; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SELLECK SB, 1992, NATURE, V355, P253, DOI 10.1038/355253a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TOLBERT LP, 1990, EXP NEUROL, V109, P19, DOI 10.1016/S0014-4886(05)80005-6; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WINBERG ML, 1992, DEVELOPMENT, V115, P903; Wolff Tanya, 1993, P1277; ZECCA M, 1995, DEVELOPMENT, V121, P2265	54	221	223	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					411	422		10.1016/S0092-8674(00)80114-2	http://dx.doi.org/10.1016/S0092-8674(00)80114-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756723	Bronze			2022-12-28	WOS:A1996VC30900009
J	Hilton, PJ; White, RW; Lord, GA; Garner, GV; Gordon, DB; Hilton, MJ; Forni, LG; McKinnon, W; Ismail, FMD; Keenan, M; Jones, K; Morden, WE				Hilton, PJ; White, RW; Lord, GA; Garner, GV; Gordon, DB; Hilton, MJ; Forni, LG; McKinnon, W; Ismail, FMD; Keenan, M; Jones, K; Morden, WE			An inhibitor of the sodium pump obtained from human placenta	LANCET			English	Article							DIGITALIS-LIKE-FACTOR; ESSENTIAL-HYPERTENSION; TRANSPORT; SUBSTANCE; OUABAIN; PURIFICATION; PLASMA; SERUM; CELLS	Background Much effort has been expended in the search for an endogenous inhibitor of the cellular sodium/potassium pump, a compound of major physiological importance, which has been implicated in the mechanism of essential hypertension. Others have suggested that ouabain or an isomer of ouabain may be the endogenous pump inhibitor. Neonatal cord serum contains an inhibitor of the sodium pump; we attempted to isolate and characterise this substance from human placentas. Methods Homogenised placentas were dialysed and the resulting solutes were trapped on octadecylsilyl silica and then separated by high-performance liquid chromatography. Measurement of the activity of the sodium pump of human leucocytes was used to test each fraction for the presence of the inhibitor. Findings An inhibitor of the sodium pump was obtained by this technique in a mass spectrometrically pure form with a mass of 370 Da, an empirical formula of C24H34O3 and only one hydroxyl group. The characteristic fragmentation pattern observed in negative-ion mass spectrometry was compared with those of various model compounds; this comparison suggested that the active material was a dihydropyrone-substituted steroid. Interpretation These results suggest that a dihydropyrone-substituted steroid is an endogenous regulator of the sodium pump in humans and, presumably, other mammals. Proof of the endogenous origin will require the demonstration of a previously unrecognised biosynthetic pathway.	UNIV MANCHESTER,INST SCI & TECHNOL,MICHAEL BARBER CTR MASS SPECTROMETRY,MANCHESTER M13 9PL,LANCS,ENGLAND; MANCHESTER METROPOLITAN UNIV,MANCHESTER M15 6BH,LANCS,ENGLAND; UNIV HERTFORDSHIRE,DEPT CHEM SCI,HATFIELD AL10 9AB,HERTS,ENGLAND; UNIV LONDON KINGS COLL,DEPT CHEM,LONDON WC2R 2LS,ENGLAND	University of Manchester; Manchester Metropolitan University; University of Hertfordshire; University of London; King's College London	Hilton, PJ (corresponding author), ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.		Keenan, Mary Ann/ABB-1551-2020; Lord, Gwyn A/F-6969-2012; Ismail, fyaz/AAX-4387-2020; Ismail, Fyaz/E-7864-2010; Ismail, fyaz/ABH-4570-2020; Jones, Keith/R-7629-2016	Lord, Gwyn A/0000-0002-4300-9051; Ismail, fyaz/0000-0002-3595-6665; Ismail, Fyaz/0000-0002-3595-6665; Ismail, fyaz/0000-0002-3595-6665; Jones, Keith/0000-0002-9440-4094				BAGROV AY, 1996, CARDIOVASC RES, V207, P296; Cole C H, 1968, Trans Assoc Am Physicians, V81, P213; DEBOLD AJ, 1982, P SOC EXP BIOL MED, V170, P133; DEWARDENER H, 1961, CLIN SCI, V21, P249; DEWARDENER HE, 1980, KIDNEY INT, V18, P1, DOI 10.1038/ki.1980.104; DORIS PA, 1994, HYPERTENSION, V23, P632, DOI 10.1161/01.HYP.23.5.632; EDMONDSON RPS, 1975, CLIN SCI MOL MED, V49, P213, DOI 10.1042/cs0490213; EDMONDSON RPS, 1975, LANCET, V1, P1003; FAGOO M, 1985, FEBS LETT, V184, P150, DOI 10.1016/0014-5793(85)80672-4; GLITSCH HG, 1990, N-S ARCH PHARMACOL, V342, P598; GOTO A, 1988, BIOCHEM BIOPH RES CO, V154, P847, DOI 10.1016/0006-291X(88)90217-3; GRAY HH, 1986, CLIN SCI, V70, P583, DOI 10.1042/cs0700583; GRUBER KA, 1980, NATURE, V287, P743, DOI 10.1038/287743a0; HILTON PJ, 1981, J CELL PHYSIOL, V109, P323, DOI 10.1002/jcp.1041090216; HILTON PJ, 1995, HYPERTENSION, V25, P460; KRAMER HJ, 1977, KIDNEY INT, V13, P214; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; LEWIS LK, 1994, HYPERTENSION, V24, P49; LICHTSTEIN D, 1993, EUR J BIOCHEM, V216, P261, DOI 10.1111/j.1432-1033.1993.tb18141.x; MATHEWS WR, 1991, HYPERTENSION, V17, P930, DOI 10.1161/01.HYP.17.6.930; MORGAN K, 1985, J BIOL CHEM, V260, P3595; MORRIS JF, 1987, CLIN SCI, V73, P291, DOI 10.1042/cs0730291; POSTON L, 1981, BMJ-BRIT MED J, V282, P847, DOI 10.1136/bmj.282.6267.847; STACHE U, Patent No. 2033590; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189	25	90	93	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					303	305		10.1016/S0140-6736(96)02257-X	http://dx.doi.org/10.1016/S0140-6736(96)02257-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709690				2022-12-28	WOS:A1996VA25000011
J	Buchan, J				Buchan, J			Characteristics of orf in a farming community in mid-Wales	BRITISH MEDICAL JOURNAL			English	Article											Buchan, J (corresponding author), THE SURGERY,CAEHERBERT LANE,POWYS LD6 5ED,WALES.							HIGHET AS, 1992, TXB DERMATOLOGY, P873; Peterkin GAG, 1937, BRIT J DERMATOL SYPH, V49, P492, DOI 10.1111/j.1365-2133.1937.tb11664.x; WILKINSON JD, 1977, BRIT J DERMATOL, V97, P447, DOI 10.1111/j.1365-2133.1977.tb14256.x; YIRRELL DL, 1994, BRIT J DERMATOL, V130, P438, DOI 10.1111/j.1365-2133.1994.tb03375.x	4	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					203	204		10.1136/bmj.313.7051.203	http://dx.doi.org/10.1136/bmj.313.7051.203			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696196	Green Published			2022-12-28	WOS:A1996VA12600025
J	deSmet, PAGM; vandenEertwegh, AJM; Sticker, BHC				deSmet, PAGM; vandenEertwegh, AJM; Sticker, BHC			Hepatotoxicity associated with herbal tablets	BRITISH MEDICAL JOURNAL			English	Letter									MERWEDE HOSP,DORDRECHT,NETHERLANDS; NETHERLANDS CTR MONITORING ADVERSE DRUG REACT,RIJSWIJK,NETHERLANDS		deSmet, PAGM (corresponding author), ROYAL DUTCH ASSOC ADVANCEMENT PHARM,THE HAGUE,NETHERLANDS.							BISSET NG, 1994, HERBAL DRUGS PYTOPHA, P326; TAKEGOSHI K, 1986, Gastroenterologia Japonica, V21, P62	3	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					92	92		10.1136/bmj.313.7049.92	http://dx.doi.org/10.1136/bmj.313.7049.92			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688761	Green Published			2022-12-28	WOS:A1996UX69800024
J	Miklos, GLG; Rubin, GM				Miklos, GLG; Rubin, GM			The role of the genome project in determining gene function: Insights from model organisms	CELL			English	Review							CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; PROTEIN-PHOSPHORYLATION; HAEMOPHILUS-INFLUENZAE; VERTEBRATE GENOME; NERVOUS-SYSTEM; EXPRESSION; MOUSE; COMPLEXITY; DISRUPTION		UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Miklos, GLG (corresponding author), INST NEUROSCI,10640 JOHN JAY HOPKINS DR,SAN DIEGO,CA 92121, USA.			Rubin, Gerald/0000-0001-8762-8703				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Ashburner M., 1989, DROSOPHILA LAB HDB; Bard J. B. L., 1990, MORPHOGENESIS CELLUL; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRANDON EP, 1995, CURR BIOL, V5, P1; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; BRENNER SE, 1995, NATURE, V378, P140, DOI 10.1038/378140a0; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CAPANO CP, 1986, J NEUROCHEM, V46, P1517, DOI 10.1111/j.1471-4159.1986.tb01770.x; CLARK DV, 1988, GENETICS, V119, P345; COLLINS FS, 1995, P NATL ACAD SCI USA, V92, P10821, DOI 10.1073/pnas.92.24.10821; Cool D E, 1993, Semin Cell Biol, V4, P443, DOI 10.1006/scel.1993.1052; CROSSIN KL, 1994, PERSPECT DEV NEUROBI, V2, P21; DATTA S, 1993, J NEUROBIOL, V24, P824, DOI 10.1002/neu.480240609; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DOVE WF, 1987, GENETICS, V116, P5; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; Edelman G. M., 1988, TOPOBIOLOGY INTRO MO; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; EDELMAN GM, 1993, CELL ADHES COMMUN, V1, P1, DOI 10.3109/15419069309095677; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; FISCHER EH, 1993, ANGEW CHEM INT EDIT, V32, P1130, DOI 10.1002/anie.199311301; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GARCIABELLIDO A, 1994, EUR REV, V2, P15; GIBSON S, 1993, TRENDS BIOTECHNOL, V11, P306, DOI 10.1016/0167-7799(93)90019-6; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GOODMAN HM, 1995, P NATL ACAD SCI USA, V92, P10831, DOI 10.1073/pnas.92.24.10831; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRAY S, 1995, PHILOS T ROY SOC B, V349, P257, DOI 10.1098/rstb.1995.0111; GREENSPAN RJ, 1995, NEURON, V15, P747, DOI 10.1016/0896-6273(95)90165-5; GRUNEBERG H, 1952, GENETICS MOUSE; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HARTWELL LH, 1991, GENETICS, V129, P975; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; HOLDEN C, 1996, SCIENCE, V271, P1061; HOLLAND PWH, 1994, DEVELOPMENT, P125; HOWELL AM, 1990, GENETICS, V126, P583; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter Tony, 1994, Seminars in Cell Biology, V5, P367, DOI 10.1006/scel.1994.1044; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JOHN B, 1988, DEV EVOLUTION; JOHNSEN RC, 1991, GENETICS, V129, P735; JORDAN BR, 1996, GENOME DIGEST, V3, P11; KAMALAY JC, 1980, CELL, V19, P935, DOI 10.1016/0092-8674(80)90085-9; KAMPIS G, 1987, J THEOR BIOL, V124, P111, DOI 10.1016/S0022-5193(87)80256-4; KOONIN EV, 1995, P NATL ACAD SCI USA, V92, P11921, DOI 10.1073/pnas.92.25.11921; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LEVY LS, 1981, DEV BIOL, V85, P141, DOI 10.1016/0012-1606(81)90243-8; Lewin B, 1994, GENES V; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MALESZKA R, 1993, CURR GENET, V24, P548, DOI 10.1007/BF00351721; MARONI G, 1994, DNA SEQUENCE, V4, P347, DOI 10.3109/10425179409010184; MARONI G, 1996, EVOL BIOL, V129, P1; Meinke DW, 1994, ARABIDOPSIS THALIANA, P253; MIKLOS GLG, 1993, J NEUROBIOL, V24, P842, DOI 10.1002/neu.480240610; MIKLOS GLG, 1993, MEMOIRS AUSTRALASIAN, V15, P7; MIKLOS GLG, 1994, EARLY LIFE EARTH, P501; MIKLOS GLG, 1994, FLEXIBILITY CONSTRAI, P269; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; MULVIHILL JT, 1995, NAT GENET, V9, P101, DOI 10.1038/ng0295-101; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1994, SCIENCE, V266, P572, DOI 10.1126/science.7939708; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; PERRIMON N, 1989, GENETICS, V121, P333; PICKETT FB, 1995, PLANT CELL, V7, P1347, DOI 10.1105/tpc.7.9.1347; RAVETCH JV, 1980, P NATL ACAD SCI-BIOL, V77, P6734, DOI 10.1073/pnas.77.11.6734; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SHUBIN N, 1996, IN PRESS NATURE; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; THAKER HM, 1992, GENETICS, V131, P883; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; Tononi G, 1996, P NATL ACAD SCI USA, V93, P3422, DOI 10.1073/pnas.93.8.3422; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WATERSTON R, 1995, P NATL ACAD SCI USA, V92, P10836, DOI 10.1073/pnas.92.24.10836; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XU T, 1993, DEVELOPMENT, V117, P1223; [No title captured]	94	356	376	0	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					521	529		10.1016/S0092-8674(00)80126-9	http://dx.doi.org/10.1016/S0092-8674(00)80126-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752207	Bronze			2022-12-28	WOS:A1996VE23500003
J	Dalmak, S; Erek, E; Altiparmak, MR; Ulku, U				Dalmak, S; Erek, E; Altiparmak, MR; Ulku, U			A porter with pain in his neck	LANCET			English	Article							BRUCELLOSIS				Dalmak, S (corresponding author), CERRAHPASA TIP FAK,1C HASTALIKARI ANA BILIM DALI,NEFROL BILIM DALI,TR-34200 AKSARAY,ISTANBUL,TURKEY.		Altiparmak, Mehmet Riza/AAC-2508-2021	Altiparmak, Mehmet Riza/0000-0002-3579-1100				GOODHART GL, 1987, SPINE, V12, P414, DOI 10.1097/00007632-198705000-00026; LIFESO RM, 1985, J BONE JOINT SURG BR, V67, P345, DOI 10.1302/0301-620X.67B3.3997939; SAPICO FL, 1979, REV INFECT DIS, V1, P754; SERRE H, 1973, REV RHUM, V40, P243; TEKKOK IH, 1993, NEUROSURGERY, V33, P838, DOI 10.1227/00006123-199311000-00008	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					444	444		10.1016/S0140-6736(96)04123-2	http://dx.doi.org/10.1016/S0140-6736(96)04123-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709785				2022-12-28	WOS:A1996VC67300013
J	Dayan, M; Turner, B; McGhee, C				Dayan, M; Turner, B; McGhee, C			Acute angle closure glaucoma masquerading as systemic illness	BRITISH MEDICAL JOURNAL			English	Article									SUNDERLAND EYE INFIRM,SUNDERLAND SR2 9HP,DURHAM,ENGLAND; UNIV SUNDERLAND,SCH HLTH SCI,SUNDERLAND SR2 7EE,DURHAM,ENGLAND	University of Sunderland				McGhee, Charles NJ/0000-0001-7048-0706				*AM AC OPHTH, 1993, BAS CLIN SCI COURS; BERDY GJ, 1991, ARCH INTERN MED, V151, P1658, DOI 10.1001/archinte.151.8.1658; CAMPBELL DG, 1980, PERSPECT OPHTHALMOL, V4, P123; CLARK CV, 1986, DIABETIC MED, V3, P226, DOI 10.1111/j.1464-5491.1986.tb00749.x; KANSKI JJ, 1989, GLAUCOMA COLOUR MANU; RENNIE IG, 1993, DRUG SAFETY, V9, P196, DOI 10.2165/00002018-199309030-00005; REUSER T, 1992, J ROY SOC MED, V85, P499; RITCH R, 1994, ARCH OPHTHALMOL-CHIC, V112, P67, DOI 10.1001/archopht.1994.01090130077021	8	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					413	415						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761235				2022-12-28	WOS:A1996VD20600033
J	Roper, TA; Mulley, GP				Roper, TA; Mulley, GP			Public transport	BRITISH MEDICAL JOURNAL			English	Article								Most older people are mobile and able to use public transport without any problems. Those who are hard of hearing or have poor vision and those with mobility problems need not be deterred from using public transport. Though the design and provision of suitable buses, taxis, and trains is not always optimum, many now have imaginative features to help older passengers. Travel by air and sea needs extra planning for disabled elderly people, but helpful advice is available and much can be done to enable even the most disabled traveller to make long journeys confidently and in comfort.	LADYWELL HOSP,SALFORD M5 2AA,LANCS,ENGLAND; ST JAMES UNIV HOSP,DEPT MED ELDERLY,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital									0	3	3	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					415	418						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761236				2022-12-28	WOS:A1996VD20600034
J	Vasen, HFA; vanderLuijt, RB; Slors, JFM; Buskens, E; deRuiter, P; Baeten, CGM; Schouten, WR; Oostvogel, HJM; Kuijpers, JHC; Tops, CMJ; Khan, PM				Vasen, HFA; vanderLuijt, RB; Slors, JFM; Buskens, E; deRuiter, P; Baeten, CGM; Schouten, WR; Oostvogel, HJM; Kuijpers, JHC; Tops, CMJ; Khan, PM			Molecular genetic tests as a guide to surgical management of familial adenomatous	LANCET			English	Article							GERM-LINE MUTATIONS; APC GENE; POLYPOSIS; CANCER; IDENTIFICATION	Background In familial adenomatous polyposis the only curative treatment is colectomy, and the choice of operation lies between restorative proctocolectomy (RPC) and colectomy with ileorectal anastomosis (IRA). The RPC procedure carries a higher morbidity but, unlike IRA, removes the risk of subsequent rectal cancer. Since the course of familial adenomatous polyposis is influenced by the site of mutation in the polyposis gene, DNA analysis might be helpful in treatment decisions. Methods We evaluated the incidence of rectal cancer in polyposis patients who had undergone IRA, and examined whether the requirement for subsequent rectal excision because of cancer or uncontrollable polyps was related to the site of mutation. Findings Between 1956 and mid-1995, 225 patients registered at the Netherlands Polyposis Registry had undergone IRA. In 87 of them, a pathogenetic mutation was detected. 72 patients had a mutation located before codon 1250 and 15 patients after this codon. The cumulative risk of rectal cancer 20 years after surgery was 12%, and at that time 42% had undergone rectal excision. The risk of secondary surgery was higher in patients with mutations in the region after codon 1250 than in patients with mutations before this codon (relative risk 2.7, p<0.05). Interpretation On this evidence, IRA should be the primary treatment for polyposis in patients with mutations before codon 1250, and RPC in those with mutations after this codon.	LEIDEN UNIV HOSP,DEPT GASTROENTEROL,NL-2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT HUMAN GENET,MGC,NL-2300 RA LEIDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTRECHT HOSP,DEPT CLIN EPIDEMIOL,UTRECHT,NETHERLANDS; MED CTR,DEPT SURG,ALKMAAR,NETHERLANDS; UNIV LIMBURG HOSP,DEPT SURG,MAASTRICHT,NETHERLANDS; ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT SURG,ROTTERDAM,NETHERLANDS; ST ELIZABETH HOSP,DEPT SURG,TILBURG,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT SURG,NL-6500 HB NIJMEGEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC); Erasmus University Rotterdam; Erasmus MC; Elisabeth-TweeSteden Ziekenhuis (ETZ); Radboud University Nijmegen	Vasen, HFA (corresponding author), LEIDEN UNIV HOSP,NETHERLANDS FDN DETECT HEREDITARY TUMOURS,RIJNSBURGERWEG 10,BLDG 50,NL-2333 AA LEIDEN,NETHERLANDS.			Vasen, Hans/0000-0003-2682-2603				BESS MA, 1980, ARCH SURG-CHICAGO, V115, P460; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; BUSSEY HJR, 1985, BRIT J SURG, V72, pS29, DOI 10.1002/bjs.1800721318; CASPARI R, 1994, LANCET, V343, P629, DOI 10.1016/S0140-6736(94)92634-4; DECOSSE JJ, 1992, BRIT J SURG, V79, P1372, DOI 10.1002/bjs.1800791245; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GAYTHER SA, 1994, HUM MOL GENET, V3, P53, DOI 10.1093/hmg/3.1.53; GIARDIELLO FM, 1994, GASTROENTEROLOGY, V106, P1542, DOI 10.1016/0016-5085(94)90408-1; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; IWAMA T, 1993, ANN SURG, V217, P101, DOI 10.1097/00000658-199302000-00002; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; NAGASE H, 1992, CANCER RES, V52, P4055; NUGENT KP, 1994, GUT, V35, P1622, DOI 10.1136/gut.35.11.1622; NUGENT KP, 1992, BRIT J SURG, V79, P1204, DOI 10.1002/bjs.1800791136; PAUL P, 1993, HUM MOL GENET, V2, P925, DOI 10.1093/hmg/2.7.925; SPIGELMAN AD, 1994, FAMILIAL ADENOMATOUS; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VASEN HFA, 1990, DIS COLON RECTUM, V33, P227, DOI 10.1007/BF02134185	20	149	151	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					433	435		10.1016/S0140-6736(96)01340-2	http://dx.doi.org/10.1016/S0140-6736(96)01340-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709782	Green Submitted			2022-12-28	WOS:A1996VC67300010
J	Weaver, SC; Salas, R; RicoHesse, R; Ludwig, GV; Oberste, MS; Boshell, J; Tesh, RB				Weaver, SC; Salas, R; RicoHesse, R; Ludwig, GV; Oberste, MS; Boshell, J; Tesh, RB			Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America	LANCET			English	Article							ENCEPHALITIS COMPLEX; VIRUSES; IDENTIFICATION; ALPHAVIRUSES; ANTIBODY; VACCINE	Background Venezuelan equine encephalomyelitis (VEE) virus has caused periodic epidemics among human beings and equines in Latin America from the 1920s to the early 1970s. The first major outbreak since 1973 occurred in Venezuela and Colombia during 1995, and involved an estimated 75 000 to 100 000 people. We report an and virological investigation of this epidemic. Methods Virus isolates were made in cell culture from human serum, human throat swabs, and brain tissue from aborted and stillborn human fetuses, as well as from horse brain tissue and pooled mosquito collections. Human sera were also tested for VEE-specific antibodies. The serotypes of VEE isolates were identified by antigen assays, and viruses were characterised genetically by sequencing PCR products generated from the E3 and E2 genes. Phylogenetic analyses were done to determine evolutionary relations with respect to previous epidemic/epizootic and enzootic VEE virus isolates. Mosquito collections were made to identify possible vectors, and clinical findings were determined by direct observation of patients visiting hospitals and clinics in affected regions, and by inspecting patient records. Equine vaccination and vector control were used in an attempt to halt the spread of the outbreak. Findings Most affected people had an acute, self-limited febrile illness of 3 to 4 days duration. However, convulsions were often seen in children, and abortions and fetal deaths occurred in pregnant women infected with VEE virus. Antigenic characterisation of 12 virus isolates spanning the temporal and spatial range of the outbreak indicated that all are VEE serotype IC. Phylogenetic analysis revealed that all of the 1995 viruses were closely related to serotype IC viruses isolated during a large VEE outbreak that occurred in the same regions of Colombia and Venezuela from 1962-1964. A 1983 mosquito isolate from north central Venezuela was also closely related to the 1995 isolates. Interpretation This outbreak was remarkably similar to one that occurred in same regions of Venezuela and Colombia during 1962-1964. Symptoms of infected patients, estimated mortality rates, meteorological conditions preceding the epidemic, and seasonal patterns of transmission were all very similar to those reported in the previous outbreak. In addition, viruses isolated during 1995 were antigenically and genetically nearly identifical to those obtained during 1962-1964. These findings suggest that the epidemic resulted from the re-emergence of an epizootic serotype IC VEE virus. Identification of a similar virus isolate in mosquitoes in Venezuela in 1983, 10 years after epidemic/epizootic VEE activity ceased, raises the possibility of a serotype IC enzootic transmission cycle in northern Venezuela.	UNIV TEXAS,MED BRANCH,DEPT PATHOL,GALVESTON,TX 77555; INST NACL HIGIENE RAFAEL RANGEL,CARACAS,VENEZUELA; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,YALE ARBOVIRUS RES UNIT,NEW HAVEN,CT 06510; USA,MED RES INST INFECT DIS,DIV VIROL,FT DETRICK,MD 21702; INST NACL SALUD,BOGOTA,COLOMBIA	University of Texas System; University of Texas Medical Branch Galveston; Yale University; Instituto Nacional de Salud (Colombia)	Weaver, SC (corresponding author), UNIV TEXAS,MED BRANCH,CTR TROP DIS,GALVESTON,TX 77555, USA.		Rico-Hesse, Rebeca/C-5294-2011; Weaver, Scott C/D-6490-2011; Rico-Hesse, Rebecca/AAW-9501-2021	Rico-Hesse, Rebeca/0000-0001-6216-1000; Weaver, Scott C/0000-0001-8016-8556; 	NIAID NIH HHS [AI 33983, AI 39508, AI 10894] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039508] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOWEN GS, 1976, J CLIN MICROBIOL, V4, P22; BUNDO K, 1985, J VIROL METHODS, V11, P15, DOI 10.1016/0166-0934(85)90120-X; Calisher C. H., 1988, The arboviruses: epidemiology and ecology. Volume I., P19; ESCALANA AS, 1969, INVEST CLIN, V31, P45; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 1990, PHYLIP MANUAL VERSIO; Johnson K M, 1974, Adv Vet Sci Comp Med, V18, P79; KINNEY RM, 1989, VIROLOGY, V170, P19, DOI 10.1016/0042-6822(89)90347-4; KINNEY RM, 1992, J GEN VIROL, V73, P3301, DOI 10.1099/0022-1317-73-12-3301; KINNEY RM, 1983, J GEN VIROL, V64, P135, DOI 10.1099/0022-1317-64-1-135; MARTIN DH, 1972, AM J EPIDEMIOL, V95, P565, DOI 10.1093/oxfordjournals.aje.a121426; RICOHESSE R, 1995, P NATL ACAD SCI USA, V92, P5278, DOI 10.1073/pnas.92.12.5278; RICOHESSE R, 1988, AM J TROP MED HYG, V38, P187, DOI 10.4269/ajtmh.1988.38.187; ROEHRIG JT, 1991, J CLIN MICROBIOL, V29, P630, DOI 10.1128/JCM.29.3.630-631.1991; Rossi A L, 1967, Prog Med Virol, V9, P176; ROVIRA JA, 1964, REV VENEZ SANIDAD AS, V29, P231; Sudia W. D., 1972, Venezuelan encephalitis-proceedings of the workshop-symposium on Venezuelan encephalitis virus., P157; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053; Walton T. E., 1989, The arboviruses: epidemiology and ecology. Volume IV., P203; WALTON TE, 1973, J INFECT DIS, V128, P271, DOI 10.1093/infdis/128.3.271; WEAVER SC, 1992, VIROLOGY, V191, P282, DOI 10.1016/0042-6822(92)90190-Z; WEAVER SC, 1992, CURR TOP MICROBIOL, V176, P99; WEGNER F, 1978, TERAROLOGY, V16, P359; 1995, MMWR-MORBID MORTAL W, V44, P775; 1995, MMWR-MORBID MORTAL W, V44, P721	26	211	219	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					436	440		10.1016/S0140-6736(96)02275-1	http://dx.doi.org/10.1016/S0140-6736(96)02275-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709783	hybrid			2022-12-28	WOS:A1996VC67300011
J	deCraen, AJM; DiGiulio, G; LampeSchoenmaeckers, AJEM; Kessels, AGH; Kleijnen, J				deCraen, AJM; DiGiulio, G; LampeSchoenmaeckers, AJEM; Kessels, AGH; Kleijnen, J			Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: A systematic review	BRITISH MEDICAL JOURNAL			English	Article							ACETAMINOPHEN PLUS CODEINE; ORAL-SURGERY PAIN; PHOSPHATE 60 MG; POSTOPERATIVE PAIN; DOUBLE-BLIND; 1000 MG; DENTAL PAIN; PLACEBO; FLURBIPROFEN; RELIEF	Objectives-To assess whether adding codeine to paracetamol has an additive analgesic effect; to assess the safety of paracetamol-codeine combinations versus paracetamol alone. Design-Systematic literature review with meta-analysis, methodological quality of published trials being scored by means of 13 predefined criteria. Trials-24 of 29 trials that met the inclusion criteria. Models studied in the trials were postsurgical pain (21), postpartum pain (one), osteoarthritic pain (one), and experimentally induced pain (one). Interventions-Dosages ranged from 400 to 1000 mg paracetamol and 10 to 60 mg codeine. Main outcome measures-The sum pain intensity difference (efficacy analysis) and the proportion of patients reporting a side effect (safety analysis). Results-Most trials were considered of good to very good quality. Only the single dose studies could be combined for analysis of analgesic efficacy. Pooled efficacy results indicated that codeine added to paracetamol provided a 5% increase in analgesia on the sum pain intensity difference. This effect was comparable to the difference in analgesic effect between codeine and placebo. The cumulative incidence of side effects with each treatment was comparable in the single dose trials. In the multidose studies a significantly higher proportion of side effects occurred with paracetamol-codeine preparations. Conclusion-The difference in analgesic effect between paracetamol-codeine combinations and paracetamol alone was small but statistically significant. In the multidose studies the proportion of patients reporting a side effect was significantly higher with paracetamol-codeine combinations. For occasional pain relief a paracetamol-codeine combination might be appropriate but repeated use increases the occurrence of side effects.	UNIV LIMBURG,DEPT EPIDEMIOL,NL-6200 MD MAASTRICHT,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT ANAESTHESIOL,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DUTCH COCHRANE CTR,NL-1105 AZ AMSTERDAM,NETHERLANDS	Hasselt University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	deCraen, AJM (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,POB 22700,NL-1100 DE AMSTERDAM,NETHERLANDS.							ADAM D, 1994, EUR J PEDIATR, V153, P394; ARENDTNIELSEN L, 1991, EUR J CLIN PHARMACOL, V40, P241, DOI 10.1007/BF00315203; BEAVER WT, 1984, AM J MED, V77, P38, DOI 10.1016/S0002-9343(84)80101-1; BEAVER WT, 1978, CLIN PHARMACOL THER, V23, P108; BECKER J, 1990, DEUT ZAHNAERZTL Z, V45, P36; BENTLEY KC, 1987, CLIN PHARMACOL THER, V42, P634, DOI 10.1038/clpt.1987.211; BJORKMAN R, 1994, PAIN, V57, P259, DOI 10.1016/0304-3959(94)90001-9; COOPER S A, 1991, Journal of Clinical Dentistry, V2, P70; Cooper S A, 1988, J Clin Dent, V1, P31; COOPER SA, 1984, CLIN PHARMACOL THER, V35, P232; COOPER SA, 1976, CLIN PHARMACOL THER, V20, P241; COOPER SA, 1981, J ORAL SURG, V39, P21; COOPER SA, 1984, AM J MED, V9, P70; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIONNE RA, 1994, J ORAL MAXIL SURG, V52, P919, DOI 10.1016/S0278-2391(10)80068-0; EISENBERG E, 1994, J CLIN ONCOL, V12, P2756, DOI 10.1200/JCO.1994.12.12.2756; FORBES JA, 1990, PHARMACOTHERAPY, V10, pS94; FORBES JA, 1989, PHARMACOTHERAPY, V9, P322; FORBES JA, 1982, JAMA-J AM MED ASSOC, V248, P2139, DOI 10.1001/jama.248.17.2139; FORBES JA, 1983, PHARMACOTHERAPY, V3, pS47; GERTZBEIN SD, 1986, PHARMACOTHERAPY, V6, P104; HONIG S, 1984, J CLIN PHARMACOL, V24, P96, DOI 10.1002/j.1552-4604.1984.tb02771.x; JACKSON CH, 1984, CAN MED ASSOC J, V131, P25; Jaffe JH., 1985, GOODMAN GILMANS PHAR, P491; Kjaersgaard-Andersen P, 1991, Nurs Times, V87, P52; KJAERSGAARDANDERSEN P, 1990, PAIN, V43, P309, DOI 10.1016/0304-3959(90)90028-C; LEVIN HM, 1974, CURR THER RES CLIN E, V16, P921; MAX MB, 1991, ADV PAIN RES THER, V18, P55; MEADOWS BJ, 1984, CURR THER RES CLIN E, V35, P501; PILETTA P, 1991, CLIN PHARMACOL THER, V49, P350, DOI 10.1038/clpt.1991.40; QUIDING H, 1982, EUR J CLIN PHARMACOL, V23, P315, DOI 10.1007/BF00613612; QUIDING H, 1983, EUR J CLIN PHARMACOL, V24, P475, DOI 10.1007/BF00609889; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SINDRUP SH, 1990, CLIN PHARMACOL THER, V48, P686, DOI 10.1038/clpt.1990.212; SKJELBRED P, 1982, BRIT J CLIN PHARMACO, V14, P539, DOI 10.1111/j.1365-2125.1982.tb02025.x; SKOGLUND LA, 1991, PHARMACOTHERAPY, V11, P364; SNYDER J, 1988, CLIN PHARMACOL THER, V43, P141; SOMOGYI A, 1991, EUR J CLIN PHARMACOL, V41, P379, DOI 10.1007/BF00314972; SONNE J, 1988, EUR J CLIN PHARMACOL, V35, P109, DOI 10.1007/BF00555519; STEWART PK, 1991, DESIGN ANALGESIC CLI, P137; SUNSHINE A, 1986, AM J MED, V80, P50, DOI 10.1016/0002-9343(86)90111-7; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TORABINEJAD M, 1994, J ENDODONT, V20, P427, DOI 10.1016/S0099-2399(06)80031-2; TORABINEJAD M, 1994, J ENDODONT, V20, P345, DOI 10.1016/S0099-2399(06)80098-1; VANDERLOO WJC, 1992, NED TIJDSCHR GENEES, V136, P1409	45	87	93	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					321	325		10.1136/bmj.313.7053.321	http://dx.doi.org/10.1136/bmj.313.7053.321			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760737	Green Published			2022-12-28	WOS:A1996VC30000015
J	Sharpstone, D; Gazzard, B				Sharpstone, D; Gazzard, B			Gastrointestinal manifestations of HIV infection	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VASOACTIVE-INTESTINAL-PEPTIDE; CRYPTOSPORIDIUM-PARVUM; HOMOSEXUAL MEN; NATURAL-HISTORY; JEJUNAL MUCOSA; SYNDROME AIDS; DIARRHEA; INFLAMMATION; PREVALENCE	The harrowing picture of emaciated terminally ill AIDS patients is a reminder of our lack of understanding of immunological mechanisms that normally control opportunistic infections. Many gastrointestinal pathogens in patients with AIDS are resistant to treatment and lead inexorably to weight loss and death. Although knowledge of the pathogenesis and clinical significance of weight loss has improved considerably, this has not yet led to a sustained effort to improve nutritional status during early stages of disease.			Sharpstone, D (corresponding author), CHELSEA & WESTMINSTER HOSP,KOBLER CTR,DEPT HIV GUM,369 FULHAM RD,LONDON SW10 9TH,ENGLAND.							ANTONY MA, 1988, DIGEST DIS SCI, V33, P1141, DOI 10.1007/BF01535791; AnwarBruni DM, 1996, AIDS, V10, P619, DOI 10.1097/00002030-199606000-00007; BATMAN PA, 1991, AIDS, V5, P1247, DOI 10.1097/00002030-199110000-00015; BELITSOS PC, 1992, J INFECT DIS, V166, P277, DOI 10.1093/infdis/166.2.277; BLANSHARD C, 1995, J INFECT DIS, V172, P622, DOI 10.1093/infdis/172.3.622; BLANSHARD C, 1991, GUT, V32, pA1225; BLANSHARD C, 1995, GUT, V36, P283, DOI 10.1136/gut.36.2.283; BLANSHARD C, IN PRESS GUT; BLEWETT DA, 1993, WATER SCI TECHNOL, V27, P61, DOI 10.2166/wst.1993.0322; BUDHRAJA M, 1987, AM J GASTROENTEROL, V82, P427; COMPEAN DG, 1994, AIDS, V8, P1563, DOI 10.1097/00002030-199411000-00007; CUNNINGHAM AL, 1988, J INFECT DIS, V158, P386, DOI 10.1093/infdis/158.2.386; DIETERICH DT, 1991, J ACQ IMMUN DEF SYND, V4, pS29; DIETERICH DT, 1994, J INFECT DIS, V169, P178, DOI 10.1093/infdis/169.1.178; DRYDEN MS, 1988, J INFECTION, V17, P107, DOI 10.1016/S0163-4453(88)91515-0; DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304; FORBES A, 1993, GUT, V34, P116, DOI 10.1136/gut.34.1.116; FRANCIS N, 1990, BAILLIERE CLIN GASTR, V4, P495, DOI 10.1016/0950-3528(90)90014-8; GILMAN RH, 1988, GASTROENTEROLOGY, V94, P1308, DOI 10.1016/0016-5085(88)90668-3; GOODGAME RW, 1995, GASTROENTEROLOGY, V108, P1075, DOI 10.1016/0016-5085(95)90205-8; GOTTE L, 1993, J ACQ IMMUN DEF SYND, V6, P1024; GUARINO A, 1994, GASTROENTEROLOGY, V106, P28, DOI 10.1016/S0016-5085(94)94093-2; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; KEATING J, 1995, GUT, V37, P623, DOI 10.1136/gut.37.5.623; KELLY P, 1993, GUT S69, V34, pF274; KOTLER DP, 1994, AM J GASTROENTEROL, V89, P1998; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KOTLER DP, 1993, DIGEST DIS SCI, V38, P1119, DOI 10.1007/BF01295730; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LIM SG, 1993, CLIN EXP IMMUNOL, V92, P448, DOI 10.1111/j.1365-2249.1993.tb03419.x; LIONETTI P, 1993, GASTROENTEROLOGY, V105, P373, DOI 10.1016/0016-5085(93)90710-T; LUNA VA, 1995, AM J CLIN PATHOL, V103, P656; MACALLAN DC, 1993, AM J CLIN NUTR, V58, P417, DOI 10.1093/ajcn/58.3.417; MANFREDI R, 1993, AIDS, V7, P223, DOI 10.1097/00002030-199302000-00010; MCDONALD V, 1994, PARASITE IMMUNOL, V16, P315, DOI 10.1111/j.1365-3024.1994.tb00354.x; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; NELSON JA, 1988, LANCET, V1, P259; NELSON MR, 1992, AIDS, V12, P1495; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P1218; SHARPSTONE D, 1995, AIDS, V9, P658, DOI 10.1097/00002030-199506000-00025; SHARPSTONE D, 1995, GUT               S1, V36, pF278; SHARPSTONE D, 1995, 5 EUR C CLIN ASP TRE; SHARPSTONE D, 1994, GUT, V35, pT159; SHARPSTONE D, IN PRESS AIDS; SNIJDERS F, 1995, AIDS, V9, P367, DOI 10.1097/00002030-199509040-00008; ULLRICH R, 1992, GASTROENTEROLOGY, V102, P1483, DOI 10.1016/0016-5085(92)91705-9; ULLRICH R, 1992, GUT, V33, P1080, DOI 10.1136/gut.33.8.1080; UNGAR BLP, 1991, J IMMUNOL, V147, P1014; VELJKOVIC V, 1992, BIOCHEM BIOPH RES CO, V189, P705, DOI 10.1016/0006-291X(92)92258-Y; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	50	73	78	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					379	383		10.1016/S0140-6736(96)01034-3	http://dx.doi.org/10.1016/S0140-6736(96)01034-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709738	Bronze, Green Published			2022-12-28	WOS:A1996VB42600014
J	Spoor, PA; Airey, M; Bennett, C; Greensill, J; Williams, R				Spoor, PA; Airey, M; Bennett, C; Greensill, J; Williams, R			Use of the capture-recapture technique to evaluate the completeness of systematic literature searches	BRITISH MEDICAL JOURNAL			English	Article											Spoor, PA (corresponding author), UNIV LEEDS, NUFFIELD INST HLTH, DIV PUBL HLTH, LEEDS LS2 9PL, W YORKSHIRE, ENGLAND.		Bennett, Cathy/A-2386-2016; Spoor, Pat A/B-9838-2009	Bennett, Cathy/0000-0002-9112-5698; 				AIREY CM, 1995, DIABETIC MED, V12, P375, DOI 10.1111/j.1464-5491.1995.tb00497.x; [Anonymous], 1951, U CALIFORNIA PUBLICA; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; HOOK EB, 1992, AM J EPIDEMIOL, V135, P1060, DOI 10.1093/oxfordjournals.aje.a116400; LAPORTE RE, 1994, BRIT MED J, V308, P5, DOI 10.1136/bmj.308.6920.5	5	27	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					342	343		10.1136/bmj.313.7053.342	http://dx.doi.org/10.1136/bmj.313.7053.342			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760743	Green Submitted, Green Published			2022-12-28	WOS:A1996VC30000021
J	Wang, TW; Li, BY; Danielson, PD; Shah, PC; Rockwell, S; Lechleider, RJ; Martin, J; Manganaro, T; Donahoe, PK				Wang, TW; Li, BY; Danielson, PD; Shah, PC; Rockwell, S; Lechleider, RJ; Martin, J; Manganaro, T; Donahoe, PK			The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; SERINE-THREONINE KINASE; PEPTIDYL-PROLYL ISOMERASE; ACTIVIN RECEPTOR; IMMUNOSUPPRESSANT FK506; EXPRESSION CLONING; MAMMALIAN PROTEIN; COMPLEX; CALCINEURIN; RAPAMYCIN	The immunophilin FKBP12 is an evolutionarily conserved abundant protein; however, its physiological roles remain poorly defined. Here we report that FKBP12 is a common cytoplasmic interactor of TGF beta family type I receptors. FKBP12 binds to ligand-free TGF beta type I receptor, from which it is released upon a ligand-induced, type II receptor mediated phosphorylation of the type I receptor. Blocking FKBP12/type I receptor interaction with FK506 nonfunctional derivatives enhances the ligand activity, indicating that FKBP12 binding is inhibitory to the signaling pathways of the TGF beta family ligands. Overexpression of a myristylated FKBP12 in Mv1Lu cell specifically inhibits two separate pathways activated by TGF beta, and two point mutations on FKBP12 (G89P, 190K) abolish the inhibitory activity of FKBP12, suggesting that FKBP12 may dock a cytoplasmic protein to the type I receptors to inhibit TGF beta family mediated signaling.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, TW (corresponding author), HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT SURG,PEDIAT SURG RES LAB,BOSTON,MA 02114, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053710] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 32112, P-30 HD07396] Funding Source: Medline; NIGMS NIH HHS [R29 GM53710] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BECKER JW, 1993, J BIOL CHEM, V268, P11335; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DONAHOE PK, 1977, J SURG RES, V23, P141, DOI 10.1016/0022-4804(77)90202-5; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PRICE JM, 1977, AM J ANAT, V149, P353, DOI 10.1002/aja.1001490304; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TRELSTAD RL, 1982, DEV BIOL, V92, P27, DOI 10.1016/0012-1606(82)90147-6; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	47	308	320	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					435	444		10.1016/S0092-8674(00)80116-6	http://dx.doi.org/10.1016/S0092-8674(00)80116-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756725	Bronze			2022-12-28	WOS:A1996VC30900011
J	vandenHeuvel, M; Ingham, PW				vandenHeuvel, M; Ingham, PW			smoothened encodes a serpentine protein required for hedgehog signalling	NATURE			English	Article							DROSOPHILA PATCHED GENE; WINGLESS TRANSCRIPTION; POLARITY GENE; EXPRESSION; MUTATIONS; EMBRYOS; LARVAL; PATTERN; CUTICLE; FAMILY	MEMBERS of the Hedgehog family of secreted proteins control a number of important inductive interactions in the development of both vertebrates and Drosophila(1), but little is known about the ways in which their signalling activities are transduced. In Drosophila, hedgehog is one of the segment-polarity genes, mutations of which disrupt the pattern and polarity of individual embryonic segments(2) and their adult derivatives(3); several of these genes have been implicated in transduction of the hedgehog signal(4-6). Here we show that the segment-polarity gene smoothened is required for the response of cells to hedgehog signalling during the development of both the embryonic segments and imaginal discs. Sequence analysis of the smoothened transcription unit reveals a single open reading frame encoding a protein with seven putative transmembrane domains. This structure is typical of G-protein-coupled receptors, suggesting that the Smoothened protein may act as a receptor for the Hedgehog ligand.	IMPERIAL CANC RES FUND,MOL EMBRYOL LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Ingham, Philip W/G-9903-2011; Ingham, Philip W/E-6710-2010; Ingham, Philip William/AAH-5884-2020	Ingham, Philip W/0000-0001-8224-9958; Ingham, Philip William/0000-0001-8224-9958				BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOU TB, 1992, GENETICS, V131, P643; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FORBES AJ, 1993, DEVELOPMENT, P115; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; Wang YS, 1996, J BIOL CHEM, V271, P4468; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; XU T, 1993, DEVELOPMENT, V117, P1223	32	403	420	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					547	551		10.1038/382547a0	http://dx.doi.org/10.1038/382547a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700230				2022-12-28	WOS:A1996VB25800053
J	Greenwood, B				Greenwood, B			Fever and malaria	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; TOXINS				Greenwood, B (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1E 7HT,ENGLAND.							BATE CAW, 1994, INFECT IMMUN, V62, P3086, DOI 10.1128/IAI.62.8.3086-3091.1994; JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x; KARUNAWEERA ND, 1992, P NATL ACAD SCI USA, V89, P3200, DOI 10.1073/pnas.89.8.3200; KWIATKOWSKI D, 1993, Q J MED, V86, P91; MILLER M. J., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P152, DOI 10.1016/0035-9203(58)90036-1; Rogier C, 1996, AM J TROP MED HYG, V54, P613, DOI 10.4269/ajtmh.1996.54.613; SMITH T, 1994, PARASITOLOGY, V109, P539, DOI 10.1017/S0031182000076411; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					280	281		10.1016/S0140-6736(05)64468-6	http://dx.doi.org/10.1016/S0140-6736(05)64468-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709683				2022-12-28	WOS:A1996VA25000004
J	Connelly, C; Hieter, P				Connelly, C; Hieter, P			Budding yeast SKP1 encodes an evolutionarily conserved kinetochore protein required for cell cycle progression	CELL			English	Article							SACCHAROMYCES-CEREVISIAE KINETOCHORE; CHROMOSOME SEGREGATION; CENTROMERE DNA; CHECKPOINT; SEQUENCE; COMPLEX; GENES; IDENTIFICATION; LOCALIZATION; POLYMERASE	The budding yeast SKP1 gene, identified as a dosage suppressor of a known kinetochore protein mutant, encodes an intrinsic 22.3 kDa subunit of CBF3, a multi-protein complex that binds centromere DNA in vitro. Temperature-sensitive mutations in SKP1 define two distinct phenotypic classes. skp1-4 mutants arrest predominantly as large budded cells with a G2 DNA content and short mitotic spindle, consistent with a role in kinetochore function, skp1-3 mutants, however, arrest predominantly as multiply budded cells with a G1 DNA content, suggesting an additional role during the G1/S phase. Identification of Skp1p homologs from C. elegans, A. thaliana, and H. sapiens indicates that SKP1 is evolutionarily highly conserved. Skp1p therefore represents an intrinsic kinetochore protein conserved throughout eukaryotic evolution and may be directly involved in linking kinetochore function with the cell cycle-regulatory machinery.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA016519, CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOGUSKI MS, 1994, SCIENCE, V265, P1993, DOI 10.1126/science.8091218; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CHEN H, 1995, GENOMICS, V27, P389, DOI 10.1006/geno.1995.1068; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEHN B, 1991, MOL CELL BIOL, V11, P5212, DOI 10.1128/MCB.11.10.5212; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LU ZQ, 1995, VIROLOGY, V206, P339, DOI 10.1016/S0042-6822(95)80049-2; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NIEDENTHAL RK, 1993, NUCLEIC ACIDS RES, V21, P4413, DOI 10.1093/nar/21.18.4413; PANGILINAN F, 1996, IN PRESS MOL BIOL CE; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; STEMMANN O, 1996, IN PRESS EMBO J; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; WANG YC, 1995, MOL CELL BIOL, V15, P6838; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WEST CM, 1995, J BIOL CHEM, V270, P3022; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	50	232	249	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					275	285		10.1016/S0092-8674(00)80099-9	http://dx.doi.org/10.1016/S0092-8674(00)80099-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706132	Green Published, hybrid			2022-12-28	WOS:A1996UZ97200013
J	Felsenfeld, G				Felsenfeld, G			Chromatin unfolds	CELL			English	Review							LOCUS-CONTROL REGION; NUCLEOSOME DISRUPTION; GENE-EXPRESSION; YEAST; TRANSCRIPTION; COMPLEX; BINDING; REPRESSION; TELOMERE; DNA				Felsenfeld, G (corresponding author), NIDDK,NATL INST HLTH,BETHESDA,MD 20892, USA.							ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; BARTON MC, 1994, GENE DEV, V8, P2453, DOI 10.1101/gad.8.20.2453; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MOON AM, 1991, BLOOD, V77, P2272; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PIROTTA V, 1995, CURR OPIN GENET DEV, V5, P466; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; STANWORTH SJ, 1995, MOL CELL BIOL, V15, P3969; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TARTOF KD, 1990, DEVELOPMENT S, V110, P35; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZINK D, 1995, EMBO J, V14, P5600	52	249	253	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					13	19		10.1016/S0092-8674(00)80073-2	http://dx.doi.org/10.1016/S0092-8674(00)80073-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689680	Bronze			2022-12-28	WOS:A1996UX93400004
J	Cyster, JG; Healy, JI; Kishihara, K; Mak, TW; Thomas, ML; Goodnow, CC				Cyster, JG; Healy, JI; Kishihara, K; Mak, TW; Thomas, ML; Goodnow, CC			Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45	NATURE			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; TRANSGENIC MICE; PHOSPHORYLATION; ELIMINATION; ACTIVATION; EXPRESSION	ELIMINATION of self-reactive B cells must be balanced against the need for B-cell diversity for antibody responses to pathogens. To analyse factors that determine the extent of B cell negative selection, we crossed CD45-deficient mice(1) with mice carrying immunoglobulin transgenes specific for hen egg lysozyme (HEL). CD45 positively regulates antigen-receptor signallingt(2-9) and CD45-deficient HEL-specific B cells gave diminished signalling in response to HEL. Significantly, few mature CD45(-/-) B cells accumulated, despite normal immature B-cell production. Circulating HEL autoantigen mediates negative selection of mature CD45(+/+) HEL binding B cells(10) but, in striking contrast, the autoantigen positively selected CD45(-/-) HEL-binding B cells, promoting their accumulation as long-lived IgD(hi) cells. These findings are consistent with a signal-threshold model for B-cell selection and demonstrate that changes in antigen receptor signalling can cause high-affinity self-reactive B cells to be actively retained instead of eliminated, thus revealing a potential mechanism for inherited susceptibility to autoimmune disease.	STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; KYUSHU UNIV,MED RES INST BIOREGULAT,DEPT IMMUNOL,HIGASHI KU,FUKUOKA 812,JAPAN; UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS & BIOREGULAT,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,AMGEN INST,TORONTO,ON M4X 1K9,CANADA; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,ST LOUIS,MO 63110	Stanford University; Howard Hughes Medical Institute; Stanford University; Kyushu University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Howard Hughes Medical Institute; Washington University (WUSTL)			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1994, INT IMMUNOL, V6, P1417, DOI 10.1093/intimm/6.9.1417; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MALYNN BA, 1990, J EXP MED, V171, P843, DOI 10.1084/jem.171.3.843; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; OGIMOTO M, 1995, EUR J IMMUNOL, V25, P2265, DOI 10.1002/eji.1830250823; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835	27	207	208	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					325	328		10.1038/381325a0	http://dx.doi.org/10.1038/381325a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692271				2022-12-28	WOS:A1996UM40300057
J	Becraft, PW; Stinard, PS; McCarty, DR				Becraft, PW; Stinard, PS; McCarty, DR			CRINKLY4: A TNFR-like receptor kinase involved in maize epidermal differentiation	SCIENCE			English	Article							SEQUENCE; CELLS; GENE	The maize crinkly4 (cr4) mutation affects leaf epidermis differentiation such that cell size and morphology are altered, and surface functions are compromised, allowing graft-like fusions between organs. In the seed, loss of cr4 inhibits aleurone formation in a pattern that reflects the normal progression af differentiation over the developing endosperm surface. The cr4 gene was Isolated by transposon tagging and found to encode a putative receptor kinase. The extracellular domain contains a cysteine-rich region similar to the ligand binding domain in mammalian tumor necrosis factor receptors (TNFRs) and seven copies of a previously unknown 39-amino acid repeat. The results suggest a role for cr4 in a differentiation signal.	IOWA STATE UNIV,DEPT AGRON,AMES,IA 50011; ARS,USDA,URBANA,IL 61801; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611	Iowa State University; United States Department of Agriculture (USDA); State University System of Florida; University of Florida	Becraft, PW (corresponding author), IOWA STATE UNIV,DEPT ZOOL & GENET,AMES,IA 50011, USA.			Becraft, Philip/0000-0002-3299-2126				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARKER RF, 1984, NUCLEIC ACIDS RES, V12, P5955, DOI 10.1093/nar/12.15.5955; BECRAFT PW, UNPUB; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; BRUCK DK, 1985, AM J BOT, V72, P1602, DOI 10.2307/2443311; BRUCK DK, 1988, CAN J BOT, V67, P303; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Freeling Michael, 1994, P17; KOHORN BD, 1992, P NATL ACAD SCI USA, V89, P10989, DOI 10.1073/pnas.89.22.10989; Lee HS, 1996, PLANT J, V9, P613, DOI 10.1046/j.1365-313X.1996.9050613.x; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOLLE SJ, 1992, DEV BIOL, V152, P383, DOI 10.1016/0012-1606(92)90145-7; McClintock B., 1978, CLONAL BASIS DEV, P217; MOORE R, 1984, CAN J BOT, V62, P2476, DOI 10.1139/b84-338; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; Randolph LF, 1936, J AGRIC RES, V53, P0881; SATINA S, 1940, AM J BOT, V44, P311; SIEGEL BA, 1989, SCIENCE, V244, P580, DOI 10.1126/science.244.4904.580; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; STEWART RN, 1979, AM J BOT, V66, P47, DOI 10.2307/2442624; Stinard P. S., 1987, Maize Genetics Cooperation Newsletter, P7; STINARD PS, 1992, MAIZE GENET COOP NEW, V66, P3; STINARD PS, 1991, MAIZE GENET COOP NEW, V65, P17; Tilney-Bassett RA., 1986, PLANT CHIMERAS; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALKER DB, 1985, CAN J BOT, V63, P2129, DOI 10.1139/b85-300	29	283	313	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1406	1409		10.1126/science.273.5280.1406	http://dx.doi.org/10.1126/science.273.5280.1406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703079				2022-12-28	WOS:A1996VF61000048
J	ColeStrauss, A; Yoon, KG; Xiang, YF; Byrne, BC; Rice, MC; Gryn, J; Holloman, WK; Kmiec, EB				ColeStrauss, A; Yoon, KG; Xiang, YF; Byrne, BC; Rice, MC; Gryn, J; Holloman, WK; Kmiec, EB			Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide	SCIENCE			English	Article							BETA-S-GLOBIN; ERYTHROID-CELLS; GENE; LOCUS	A chimeric oligonucleotide composed of DNA and modified RNA residues was used to direct correction of the mutation in the hemoglobin beta(S) allele. After introduction of the chimeric molecule into lymphoblastoid cells homozygous for the beta(S) mutation, there was a detectable level of gene conversion of the mutant allele to the normal sequence. The efficient and specific conversion directed by chimeric molecules may hold promise as a therapeutic method for the treatment of genetic diseases.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19107; COOPER HOSP UNIV MED CTR,UNIV MED CTR,DEPT MED,DIV HEMATOL ONCOL,CAMDEN,NJ 08103; CORNELL UNIV,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10021	Jefferson University; Rutgers State University Camden; Cornell University								ALLISON AC, 1954, BRIT MED J, V1, P290, DOI 10.1136/bmj.1.4857.290; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; GREEVER RF, 1981, P NATL ACAD SCI USA, V78, P5081; INGRAM VM, 1956, NATURE, V178; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; KMIEC EB, 1994, MOL CELL BIOL, V14, P7163, DOI 10.1128/MCB.14.11.7163; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; MAROTTA CA, 1977, J BIOL CHEM, V252, P5040; MILLER JL, 1994, P NATL ACAD SCI USA, V91, P10183, DOI 10.1073/pnas.91.21.10183; NEEL JV, 1956, ANN HUM GENET, V21, P1, DOI 10.1111/j.1469-1809.1971.tb00262.x; ORKIN SH, 1982, NEW ENGL J MED, V307, P32, DOI 10.1056/NEJM198207013070106; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PLAVEC I, 1993, BLOOD, V81, P1384; SHESELY EG, 1991, P NATL ACAD SCI USA, V88, P4294, DOI 10.1073/pnas.88.10.4294; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS, P66; WILSON JT, 1982, P NATL ACAD SCI-BIOL, V79, P3628, DOI 10.1073/pnas.79.11.3628; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071	18	285	352	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1386	1389		10.1126/science.273.5280.1386	http://dx.doi.org/10.1126/science.273.5280.1386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703073				2022-12-28	WOS:A1996VF61000042
J	Meyer, GS; Blumenthal, D				Meyer, GS; Blumenthal, D			TennCare and academic medical centers - The lessons from Tennessee	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE SYSTEM; TEACHING HOSPITALS; RAPID CHANGES; MANAGED CARE; REFORM	Objective.-To ascertain the potential impact of public-sector-driven health system reform (Medicaid and Medicare programs) on academic medical centers (AMCs). Design.-A qualitative, case-study investigation of how 2 of Tennessee's 4 AMCs were affected by the TennCare program, which enrolled all of the state's Medicaid recipients and a sizable portion of its uninsured in managed care organizations (MCOs) in January 1994. Methods.-We reviewed pertinent documents related to the AMCs' response to TennCare; interviewed AMC executives and staff, state officials, and representatives of MCOs serving TennCare beneficiaries; and conducted site visits at both AMCs. Main Outcome Measures.-Changes in clinical revenues, clinical volume, patient selection, support for the AMCs' teaching and research missions, and the AMCs' response to these changes, Results.-Both AMCs studied experienced large revenue shortfalls, the closure of some specialty services, adverse patient selection, and loss of the patient volume needed to do clinical research, and had to reduce the number of training program positions. Longer-term consequences of TennCare for AMCs may include the integration of community-based services into academic missions, the acceleration of clinical diversification, and the attainment of experience in managed care, anticipating the evolution of the private-sector market. Conclusions.-The consequences of public-sector health system reform for AMCs are similar to, and equally as challenging as, the effects of private-sector changes in health care delivery, Important differences include the rapidity with which public-sector reforms can transform the AMC market, the vulnerability of special payments to AMCs, such as graduate medical education funding, and the accountability of managers of public-sector initiatives to the political process, It remains to be seen whether public-sector reforms will afford some competitive advantage to AMCs over the long term.	UNIFORMED SERV UNIV HLTH SCI,SCH MED,DEPT MED,BETHESDA,MD 20814; MASSACHUSETTS GEN HOSP,HLTL POLICY RES & DEV UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Uniformed Services University of the Health Sciences - USA; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; BROWN D, 1996, WASHINGTON POST 0609, P1; *COUNC GRAD MED ED, 1995, 6 COUNC GRAD MED ED; EPSTEIN AM, 1995, JAMA-J AM MED ASSOC, V273, P1203, DOI 10.1001/jama.273.15.1203; ERNST, 1995, TENNCARE FINANCIAL A; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; GOLD M, 1995, MANAGED CARE LOW INC; HUGHES R, 1995, GAOHEHS95186 US GEN; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1052, DOI 10.1056/NEJM199309303291428; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; JOHNSON S, 1995, J FAM PRACTICE, V40, P244; Miles M., 2013, QUALITATIVE DATA ANA; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; *NAT ASS PUBL HOSP, 1995, TENN FAIL HLTH CAR R; *NAT ASS PUBL HOSP, 1994, ASS DES IMPL TENNC N; RILEY T, 1995, JAMA-J AM MED ASSOC, V274, P267, DOI 10.1001/jama.274.3.267; Schear S, 1995, Natl J (Wash), V27, P294; STAMBLER HV, 1988, PUBLIC HEALTH REP, V103, P184; WALKER LM, 1995, MED EC          0626, P88; WINSLOW R, 1995, WALL STREET J   0412, P1; Yin R. K., 1984, CASE STUDY RES DESIG; 1995, HLTH CARE REFORM WEE, V24, P1; 1995, AM MED NEWS     1127	25	34	34	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					672	676		10.1001/jama.276.9.672	http://dx.doi.org/10.1001/jama.276.9.672			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769543				2022-12-28	WOS:A1996VE23300003
J	Kelley, DJ; Shah, JP				Kelley, DJ; Shah, JP			Management of Barrett's oesophagus	LANCET			English	Editorial Material							PHOTODYNAMIC THERAPY; ESOPHAGEAL; ABLATION; MUCOSA				Kelley, DJ (corresponding author), MEM SLOAN KETTERING CANC CTR, HEAD & NECK SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.							BERENSON MM, 1993, GASTROENTEROLOGY, V104, P1686, DOI 10.1016/0016-5085(93)90646-T; ERTAN A, 1995, AM J GASTROENTEROL, V90, P2201; FALK GW, 1994, GASTROINTEST ENDOSC, V40, P207, DOI 10.1016/S0016-5107(94)70168-7; MCBRIDE MA, 1995, AM J GASTROENTEROL, V90, P2029; OVERHOLT BF, 1995, SEMIN SURG ONCOL, V11, P372, DOI 10.1002/ssu.2980110508; Panjehpour M, 1996, GASTROENTEROLOGY, V111, P93, DOI 10.1053/gast.1996.v111.pm8698231; REGULA J, 1995, GUT, V36, P67, DOI 10.1136/gut.36.1.67; SAMPLINER RE, 1993, AM J GASTROENTEROL, V88, P2092; Wang Kenneth K., 1994, Comprehensive Therapy, V20, P36	9	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					561	562		10.1016/S0140-6736(05)64794-0	http://dx.doi.org/10.1016/S0140-6736(05)64794-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774565				2022-12-28	WOS:A1996VF18600006
J	Pierce, C; Goldstein, M; Suozzi, K; Gallaher, M; Dietz, V; Stevenson, J				Pierce, C; Goldstein, M; Suozzi, K; Gallaher, M; Dietz, V; Stevenson, J			The impact of the standards for pediatric immunization practices on vaccination coverage levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN; OPPORTUNITIES; PRESCHOOL; MEASLES	Objective.-To assess the impact on clinic-specific vaccination coverage of implementing the Standards for Pediatric immunization Practices. Design.-A nonrandomized intervention trial conducted for I year, Setting.-Two public health clinics in Albuquerque, NM: 1 intervention site and 1 control site, each serving 1 of 4 city quadrants. Participants.-All children enrolled in the 2 city public health clinics, Interventions.-Implementation of the Standards for Pediatric immunization Practices. Outcome Measures.-Assessment of up-to-date vaccination coverage levels prior to and at the conclusion of the project. The impact on the proportion of children who dropped out of vaccination services after receiving 1 dose by 3 months of age. Results.-At the intervention site, up-to-date coverage at 12 months of age rose from 57.5% to 80.4%, while levels at the control site decreased from 42.1% to 41.9%. Before the intervention, 24% of children at the intervention site who received the first dose of diphtheria and tetanus toxoids and pertussis vaccine (DTP 1) by 3 months of age failed to receive the third dose of DTP (DTP 3) by 12 months of age vs 5% after the intervention. At the control site, the proportion of children who received DTP 1 by 3 months of age, but not DTP 3 by 12 months of age, increased from 39% to 51%. Conclusion.-Implemenlation of the Standards for Pediatric Immunization Practices in a public health clinic was associated with important increases in vaccination coverage levels and a reduction in the proportion of children who dropped out of vaccination services.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30333; NEW MEXICO DEPT HLTH,PUBL HLTH DIV,DIST 1,ALBUQUERQUE,NM; NEW MEXICO DEPT HLTH,DIV EPIDEMIOL,SANTA FE,NM	Centers for Disease Control & Prevention - USA; New Mexico Department of Health; New Mexico Department of Health								ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; *CDCP, 1992, CASA CLIN ASS SOFTW; DIETZ VJ, 1994, ARCH PEDIAT ADOL MED, V148, P943, DOI 10.1001/archpedi.1994.02170090057008; KING GE, 1991, PEDIATR INFECT DIS J, V10, P883, DOI 10.1097/00006454-199112000-00001; LINKINS RW, 1994, ARCH PEDIAT ADOL MED, V148, P908, DOI 10.1001/archpedi.1994.02170090022002; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; STEHRGREEN PA, 1993, PUBLIC HEALTH REP, V108, P426; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1992, MMWR-MORBID MORTAL W, V40, P888; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1992, MMWR-MORBID MORTAL W, V41, P103; 1991, MMWR-MORBID MORTAL W, V40, P36; 1993, JAMA-J AM MED ASSOC, V269, P1817; 1992, MMWR-MORBID MORTAL W, V41, P1	16	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					626	630						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC853	8773635				2022-12-28	WOS:A1996VC85300029
J	Ekbom, A; Daszak, P; Kraaz, W; Wakefield, AJ				Ekbom, A; Daszak, P; Kraaz, W; Wakefield, AJ			Crohn's disease after in-utero measles virus exposure	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; INFECTION	Background An epidemiological association between Crohn's disease and measles virus exposure in early life has been suggested in case-control studies. Methods To determine absolute risk estimates for in-utero measles virus exposure and Crohn's disease, maternity charts for all 25000 deliveries at University Hospital, Uppsala, between 1940-49 were reviewed: four cases of measles infection in the mother during pregnancy were identified. The children and two of their mothers were interviewed and case records reviewed. Three offspring had undergone multiple intestinal resections; tissue from these cases were examined by routine histology, and for measles-virus nucleoprotein antigen by immunohistochemistry and immunogold electronmicroscopy. Findings Three of the four children had Crohn's disease. In each the disease was preceded by recurrent, antibiotic-resistant pneumonia. They had extensive ileal and colonic disease; two patients required intravenous feeding. The only offspring to have had measles as a child did not develop Crohn's disease. Measles virus antigen was detected in foci of granulomatous and lymphocytic inflammation in ail children with Crohn's disease. Interpretation The data indicate that exposure of mothers to measles virus in utero is a risk factor for Crohn's disease in their children. Exposure at this time may lead to persistent infection, or modify the response to infection in later life, leading to persistence of measles virus.	UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN; KINGSTON UNIV,DEPT LIFE SCI,SURREY,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND	Uppsala University; Uppsala University Hospital; Kingston University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Ekbom, A (corresponding author), UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,INFLAMMATORY BOWEL DIS STUDY GRP,S-75185 UPPSALA,SWEDEN.		daszak, peter/U-4588-2017	daszak, peter/0000-0002-2046-5695				AABY P, 1988, LANCET, V1, P516; BALZOLA F, IN PRESS ITALIAN J G; EKBOM A, 1990, AM J EPIDEMIOL, V132, P1111, DOI 10.1093/oxfordjournals.aje.a115754; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; KANGRO HO, 1990, GASTROENTEROLOGY, V98, P549, DOI 10.1016/0016-5085(90)90272-3; LEWIN J, 1995, GUT, V36, P564, DOI 10.1136/gut.36.4.564; LINDBERG E, 1991, SCAND J GASTROENTERO, V26, P459; MILLER E, 1991, INT J EPIDEMIOL, V134, P876; MIYAMOTO H, 1995, J GASTROENTEROL, V30, P28, DOI 10.1007/BF01211371; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; Thompson NP, 1996, BRIT MED J, V312, P95; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415	13	98	98	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					515	517		10.1016/S0140-6736(96)04429-7	http://dx.doi.org/10.1016/S0140-6736(96)04429-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757154				2022-12-28	WOS:A1996VD42700012
J	Middleton, BA; Stone, BM; Arendt, J				Middleton, BA; Stone, BM; Arendt, J			Melatonin and fragmented sleep patterns	LANCET			English	Letter									UNIV SURREY,SCH BIOL SCI,GUILDFORD GU2 5XH,SURREY,ENGLAND; MINIST DEF,DRA CTR HUMAN SCI,FARNBOROUGH,HANTS,ENGLAND	University of Surrey								Arendt J., 1995, MELATONIN MAMMALIAN; COLE RJ, 1992, SLEEP, V15, P461, DOI 10.1093/sleep/15.5.461; WEHR TA, 1991, J CLIN ENDOCR METAB, V73, P1276, DOI 10.1210/jcem-73-6-1276	3	40	40	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					551	552		10.1016/S0140-6736(05)64715-0	http://dx.doi.org/10.1016/S0140-6736(05)64715-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757173				2022-12-28	WOS:A1996VD42700060
J	Odawara, M; Tada, K; Akaza, H; Yamashita, K				Odawara, M; Tada, K; Akaza, H; Yamashita, K			Diabetes, hypertension, and manic episodes	LANCET			English	Article							HYPERPLASIA		UNIV TSUKUBA,INST CLIN MED,DEPT UROL,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba	Odawara, M (corresponding author), UNIV TSUKUBA,DEPT ENDOCRINOL & METAB,1-1-1 TENNODAI,TSUKUBA,IBARAKI 305,JAPAN.							AIBA M, 1991, AM J CLIN PATHOL, V96, P334, DOI 10.1093/ajcp/96.3.334; SMALS AGH, 1984, J CLIN ENDOCR METAB, V58, P25, DOI 10.1210/jcem-58-1-25; SOFFER LJ, 1961, AM J MED, V30, P129, DOI 10.1016/0002-9343(61)90069-9	3	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					518	518		10.1016/S0140-6736(96)04393-0	http://dx.doi.org/10.1016/S0140-6736(96)04393-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757155				2022-12-28	WOS:A1996VD42700013
J	Yuzaki, M; Forrest, D; Curran, T; Connor, JA				Yuzaki, M; Forrest, D; Curran, T; Connor, JA			Selective activation of calcium permeability by aspartate in Purkinje cells	SCIENCE			English	Article							CEREBELLAR CLIMBING FIBERS; ACID RECEPTOR CHANNELS; METHYL-D-ASPARTATE; CA2+ PERMEABILITY; GLUTAMATE; RAT; NEURONS; PERMEATION; NEUROTRANSMITTER; RELEASE	Glutamate and aspartate are endogenous excitatory amino acid neurotransmitters widely distributed in the mammalian central nervous system, Aspartate was shown to induce a large membrane current sensitive to N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists in Purkinje cells from mice lacking functional NMDA receptors (NR1(-/-)). This response was accompanied by high permeability to calcium, in contrast, no current was induced by aspartate in hippocampal neurons and cerebellar granule cells from NR1(-/-) mice, Several other glutamate receptor agonists failed to evoke this response. Thus, in Purkinje cells, aspartate activates a distinct response capable of contributing to synaptic plasticity through calcium permeability.	CUNY MT SINAI SCH MED, DEPT HUMAN GENET, NEW YORK, NY 10029 USA; LOVELACE INST, ALBUQUERQUE, NM 87108 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Lovelace Respiratory Research Institute	Yuzaki, M (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Curran, Thomas/AAE-7631-2019; Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Yuzaki, Michisuke/K-5328-2013; Curran, Tom/D-7515-2011	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Yuzaki, Michisuke/0000-0002-5750-3544; 	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJIMA A, 1991, NEUROSCI RES, V12, P281, DOI 10.1016/0168-0102(91)90117-H; BRORSON JR, 1994, J NEUROSCI, V14, P187; CREPEL F, 1983, BRAIN RES, V279, P311, DOI 10.1016/0006-8993(83)90200-7; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GILBERTSON TA, 1991, SCIENCE, V251, P1613, DOI 10.1126/science.1849316; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KIMURA H, 1985, J PHYSIOL-LONDON, V365, P103, DOI 10.1113/jphysiol.1985.sp015761; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MURASE K, 1990, BRAIN RES, V525, P84, DOI 10.1016/0006-8993(90)91323-9; NADI NS, 1977, J NEUROCHEM, V28, P661, DOI 10.1111/j.1471-4159.1977.tb10439.x; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PITZER KS, 1973, J PHYS CHEM-US, V77, P2300, DOI 10.1021/j100638a009; ROSEMUND C, 1992, J NEUROPHYSIOL, V68, P1901, DOI 10.1152/jn.1992.68.5.1901; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; VOLLENWEIDER FX, 1990, J NEUROCHEM, V54, P1533, DOI 10.1111/j.1471-4159.1990.tb01201.x; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WIKLUND L, 1982, SCIENCE, V216, P78, DOI 10.1126/science.6121375; YUZAKI M, 1992, J NEUROSCI, V12, P4253; Yuzaki M, 1996, J NEUROSCI, V16, P4651	25	34	36	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1996	273	5278					1112	1114		10.1126/science.273.5278.1112	http://dx.doi.org/10.1126/science.273.5278.1112			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688099				2022-12-28	WOS:A1996VD42800040
J	Chavis, P; Fagni, L; Lansman, JB; Bockaert, J				Chavis, P; Fagni, L; Lansman, JB; Bockaert, J			Functional coupling between ryanodine receptors and L-type calcium channels in neurons	NATURE			English	Article							CEREBELLAR GRANULE CELLS; PROTEIN-KINASE-C; GLUTAMATE RECEPTORS; CA2+ CHANNEL; DEPRESSION; INDUCTION; RELEASE; TOXIN	IN skeletal muscle, L-type Ca2+ channels act as voltage sensors to control ryanodine-sensitive Ca2+ channels in the sarcoplasmic reticulum(1). It has recently been demonstrated that these ryanodine receptors generate a retrograde signal that modifies L-type Ca2+-channel activity(2). Here we demonstrate a tight functional coupling between ryanodine receptors and L-type Ca2+ channel in neurons, In cerebellar granule cells, activation of the type-1 metabotropic glutamate receptor (mGluR1) induced a large, oscillating increase of the L-type Ba2+ current. Activation occurred independently of inositol 1,4,5-trisphosphate and classical protein kinases, but was mimicked by caffeine and blocked by ryanodine, The kinetics of this blockade were dependent on the frequency of Ba2+ current stimulation, Both mGluR1- and caffeine-induced increase in L-type Ca2+-channel activity persisted in inside-out membrane patches, In these excised patches, ryanodine suppressed both the mGluR1- and caffeine-activated L-type Ca2+ channels. These results demonstrate a novel mechanism for Ca2+-channel modulation in neurons.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Chavis, P (corresponding author), CNRS,UPR 9023,CCIPE,141 RUE CARDONILLE,F-34094 MONTPELLIER 05,FRANCE.		Chavis, Pascale/M-8312-2016	Chavis, Pascale/0000-0002-3038-1014; Lansman, Jeffry/0000-0002-8279-4064				CHAVIS P, 1994, J NEUROSCI, V14, P7067; CHAVIS P, 1995, NEUROPHARMACOLOGY, V34, P929, DOI 10.1016/0028-3908(95)00082-H; CHAVIS P, 1995, J NEUROSCI, V15, P135; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DEWAARD M, 1992, NEURON, V9, P497, DOI 10.1016/0896-6273(92)90187-I; FAGNI L, 1992, BRIT J PHARMACOL, V105, P973, DOI 10.1111/j.1476-5381.1992.tb09087.x; HALL KE, 1995, J NEUROSCI, V15, P6069; IRVING AJ, 1992, J PHYSIOL-LONDON, V456, P667, DOI 10.1113/jphysiol.1992.sp019360; KOHDA K, 1995, J NEUROPHYSIOL, V74, P2184, DOI 10.1152/jn.1995.74.5.2184; LAMBERT RC, 1995, J NEUROSCI, V15, P6014; LINDEN DJ, 1993, NEURON, V11, P1093, DOI 10.1016/0896-6273(93)90222-D; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MANZONI O, 1990, MOL PHARMACOL, V38, P1; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229; WHITHAM EM, 1991, EUR J PHARM-MOLEC PH, V206, P181, DOI 10.1016/S0922-4106(05)80017-3	19	271	275	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					719	722		10.1038/382719a0	http://dx.doi.org/10.1038/382719a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751443				2022-12-28	WOS:A1996VD33300051
J	Gossop, M; Griffiths, P; Powis, B; Williamson, S; Strang, J				Gossop, M; Griffiths, P; Powis, B; Williamson, S; Strang, J			Frequency of non-fatal heroin overdose: Survey of heroin users recruited in non-clinical settings	BRITISH MEDICAL JOURNAL			English	Article							DEPENDENCE				Gossop, M (corresponding author), NATL ADDICT CTR,DRUG TRANSIT STUDY,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				Darke S, 1996, ADDICTION, V91, P405, DOI 10.1111/j.1360-0443.1996.tb02289.x; GHODSE AH, 1977, BRIT MED J, V1, P1381, DOI 10.1136/bmj.1.6073.1381; GOSSOP M, 1995, ADDICTION, V90, P607, DOI 10.1111/j.1360-0443.1995.tb02199.x; GRIFFITHS P, 1993, ADDICTION, V88, P1617, DOI 10.1111/j.1360-0443.1993.tb02036.x; *NAT I DRUG AB, 1992, DHHS PUBL NAT I DRUG	5	140	143	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					402	402						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD206	8761230				2022-12-28	WOS:A1996VD20600028
J	Starzl, TE; Fung, JJ				Starzl, TE; Fung, JJ			The politics of grafting cadaver kidneys	LANCET			English	Editorial Material							RENAL-TRANSPLANTATION; UNRELATED DONORS; CELL-MIGRATION; ACCEPTANCE; CHIMERISM; SURVIVAL; SYSTEM				Starzl, TE (corresponding author), UNIV PITTSBURGH, INST TRANSPLANTAT, PITTSBURGH, PA 15213 USA.		FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441	NIDDK NIH HHS [R01 DK029961-19] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Chang RWS, 1996, LANCET, V348, P453, DOI 10.1016/S0140-6736(96)02051-X; DALESSANDRO AM, 1995, ANN SURG, V222, P353, DOI 10.1097/00000658-199509000-00012; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GUTTMANN RD, 1995, TRANSP CL IMMUN SFMM, V26, P235; HALASZ NA, 1993, CLIN TRANSPLANT, V7, P357; MCCARTNEY S, 1993, WALL STREET J   0401; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1989, TRANSPLANT P, V21, P3432; STARZL TE, 1995, TRANSPLANT P, V27, P57; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1970, ANN SURG, V172, P437, DOI 10.1097/00000658-197009000-00011; STARZL TE, 1987, JAMA-J AM MED ASSOC, V257, P3073, DOI 10.1001/jama.257.22.3073; STARZL TE, 1992, PUZZLE PEOPLE, P262; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; Terasaki PI, 1965, HISTO COMPATIBILITY, P83	16	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					454	455		10.1016/S0140-6736(96)03435-6	http://dx.doi.org/10.1016/S0140-6736(96)03435-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709788	Green Accepted			2022-12-28	WOS:A1996VC67300016
J	Pisacane, A; Sansone, R; Impagliazzo, N; Coppola, A; Rolando, P; DApuzzo, A; Tregrossi, C				Pisacane, A; Sansone, R; Impagliazzo, N; Coppola, A; Rolando, P; DApuzzo, A; Tregrossi, C			Iron deficiency anaemia and febrile convulsions: Case-control study in children under 2 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEIZURES		OSPED CASTELLAMMARE STABIA, DIV PEDIAT, NAPLES, ITALY		Pisacane, A (corresponding author), UNIV NAPLES, DIPARTIMENTO PEDIAT, VIA PANSINI 5, I-80131 NAPLES, ITALY.							CASSANO PA, 1990, AM J EPIDEMIOL, V132, P462, DOI 10.1093/oxfordjournals.aje.a115681; NELSON KB, 1990, ANN NEUROL, V27, P127, DOI 10.1002/ana.410270206; PARKS YA, 1989, ACTA PAEDIAT SC S361, V55, P71; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; WALTER T, 1989, PEDIATRICS, V84, P7	5	48	50	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1996	313	7053					343	343		10.1136/bmj.313.7053.343	http://dx.doi.org/10.1136/bmj.313.7053.343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760744	Green Published			2022-12-28	WOS:A1996VC30000022
J	Leung, S; Li, XX; Stark, GR				Leung, S; Li, XX; Stark, GR			STATs find that hanging together can be stimulating	SCIENCE			English	Editorial Material							TRANSCRIPTION FACTOR; GAMMA RECEPTOR; ACTIVATION				Leung, S (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195, USA.							DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUYER NB, 1995, J IMMUNOL, V155, P3472; HORVATH C, COMMUNICATION; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEUNG SY, UNPUB; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, IN PRESS MOL CELL BI; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; VINKEMEIER U, IN PRESS EMBO J; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	19	22	23	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					750	751		10.1126/science.273.5276.750	http://dx.doi.org/10.1126/science.273.5276.750			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8701326				2022-12-28	WOS:A1996VB42900027
J	Zhu, CM; Bogue, MA; Lim, DS; Hasty, P; Roth, DB				Zhu, CM; Bogue, MA; Lim, DS; Hasty, P; Roth, DB			Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates	CELL			English	Article							STRAND-BREAK-REPAIR; DEPENDENT PROTEIN-KINASE; COMBINED IMMUNE-DEFICIENCY; DNA END-BINDING; CELL RECEPTOR-GAMMA; PRE-B CELLS; KU-AUTOANTIGEN; MAMMALIAN-CELLS; SCID MICE; MOUSE THYMOCYTES	Ku is a heterodimeric DNA end binding complex composed of 70 and 86 kDa subunits. Here, we show that Ku86 is essential for normal V(D)J recombination in vivo, as Ku86-deficient mice are severely defective for formation of coding joints. Unlike severe combined immunodeficient (scid) mice, Ku8B-deficient mice are also defective for signal joint formation. Both hairpin coding ends and blunt full-length signal ends accumulate. Contrary to expectation, Ku86 is evidently not required for protection of either type of V(D)J recombination intermediate. Instead, V(D)J recombination appears to be arrested after the cleavage step in Ku86-deficient mice. We suggest that Ku86 may be required to remodel or disassemble DNA-protein complexes containing broken ends, making them available for further processing and joining.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Zhu, CM (corresponding author), BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030, USA.		Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555; Hasty, Paul/0000-0003-3046-0131	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36420] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Aldaz H, 1996, CELL, V85, P257, DOI 10.1016/S0092-8674(00)81102-2; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chen FQ, 1996, MUTAT RES-DNA REPAIR, V362, P9, DOI 10.1016/0921-8777(95)00026-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HENDRICKSON EA, 1991, MOL CELL BIOL, V11, P3155, DOI 10.1128/MCB.11.6.3155; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; KIENKER LJ, 1991, J IMMUNOL, V147, P4351; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; LEBER R, 1996, IN PRESS VET IMMUNOL; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LEWIS SM, 1994, P NATL ACAD SCI USA, V91, P1332, DOI 10.1073/pnas.91.4.1332; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIELKE C, 1995, TRENDS GENET, V11, P258, DOI 10.1016/S0168-9525(00)89069-1; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; Savilahti H, 1996, CELL, V85, P271, DOI 10.1016/S0092-8674(00)81103-4; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHULER W, 1990, EUR J IMMUNOL, V20, P545, DOI 10.1002/eji.1830200313; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STAUNTON JE, 1994, MOL CELL BIOL, V14, P3876, DOI 10.1128/MCB.14.6.3876; Steen SB, 1996, GENES CELLS, V1, P543; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	79	372	381	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					379	389		10.1016/S0092-8674(00)80111-7	http://dx.doi.org/10.1016/S0092-8674(00)80111-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756720	Bronze			2022-12-28	WOS:A1996VC30900006
J	Shields, PL; LowBeer, TS				Shields, PL; LowBeer, TS			Patients' awareness of adverse relation between Crohn's disease and their smoking: Questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							RECURRENCE		SELLY OAK HOSP,DEPT MED,BIRMINGHAM B29 6JD,W MIDLANDS,ENGLAND									COTTONE M, 1994, GASTROENTEROLOGY, V106, P643, DOI 10.1016/0016-5085(94)90697-1; LINDBERG E, 1992, GUT, V33, P779, DOI 10.1136/gut.33.6.779; PERSSON PG, 1990, GUT, V31, P1377, DOI 10.1136/gut.31.12.1377; SUTHERLAND LR, 1990, GASTROENTEROLOGY, V98, P1123, DOI 10.1016/0016-5085(90)90324-T	4	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					265	266		10.1136/bmj.313.7052.265	http://dx.doi.org/10.1136/bmj.313.7052.265			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704536	Green Published			2022-12-28	WOS:A1996VA90300025
J	Dick, TP; Ruppert, T; Groettrup, M; Kloetzel, PM; Kuehn, L; Koszinowski, UH; Stevanovic, S; Schild, H; Rammensee, HG				Dick, TP; Ruppert, T; Groettrup, M; Kloetzel, PM; Kuehn, L; Koszinowski, UH; Stevanovic, S; Schild, H; Rammensee, HG			Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; INTERFERON-GAMMA; 20S PROTEASOME; HOMOLOGOUS SUBUNITS; PROTEIN-DEGRADATION; 20-S PROTEASOME; PEPTIDES; ACTIVATOR; PURIFICATION	The eukaryotic 20S proteasome is known to associate with the IfN gamma-inducible regulator PA28. We analyzed the kinetics of product generation by 20S proteasomes with and without PA28. In the absence of PA28, the 20S proteasome rapidly generates peptides that have been cleaved only once, while internal fragments accumulate only slowly. In the presence of PA28, products generated by two flanking cleavages appear immediately as main products while the generation of single-cleavage products is strongly reduced. Kinetic data support a PA28-induced, coordinated double-cleavage mechanism. In particular, degradation of peptides derived from mouse cytomegalovirus pp89 and JAK1 kinase in the presence of PA28 leads to strongly enhanced production of the respective major histocompatibility complex ligands and potential precursors. These results show that PA28 profoundly alters the cleavage mechanism of the proteasome and appears to optimize the generation of dominant T-cell epitopes.	GERMAN CANC RES CTR,DEPT TUMORVIRUS IMMUNOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; HUMBOLDT UNIV BERLIN,FAC MED,INST BIOCHEM,D-10115 BERLIN,GERMANY; DIABET RES INST,D-40225 DUSSELDORF,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Humboldt University of Berlin			Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; DEVAL M, 1991, CELL, V66, P1145; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HARPUR AG, 1993, IMMUNOL LETT, V35, P235, DOI 10.1016/0165-2478(93)90188-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; Kuehn L, 1996, ARCH BIOCHEM BIOPHYS, V329, P87, DOI 10.1006/abbi.1996.0195; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, J BIOL CHEM, V267, P10515; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MOTT JD, 1994, J BIOL CHEM, V269, P31466; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; NIESIG A, 1995, J IMMUNOL, V154, P1273; Oldstone M B, 1994, Curr Top Microbiol Immunol, V189, P1; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	32	245	251	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					253	262		10.1016/S0092-8674(00)80097-5	http://dx.doi.org/10.1016/S0092-8674(00)80097-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706130	Bronze			2022-12-28	WOS:A1996UZ97200011
J	GalatiusJensen, S; Launbjerg, J; Mortensen, LS; Hansen, JF				GalatiusJensen, S; Launbjerg, J; Mortensen, LS; Hansen, JF			Sex related differences in short and long term prognosis after acute myocardial infarction: 10 year follow up of 3073 patients in database of first Danish verapamil infarction trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONFIRMED DIAGNOSIS; HEART-DISEASE; RISK-FACTORS; WOMEN; MORTALITY; SURVIVAL; MEN; MORBIDITY; GENDER; ENDOTHELIN	Objective-To re-examine the prevailing hypothesis that women fare worse than m Design-10 year follow up of all patients with confirmed acute myocardial infarction registered in the database of the Danish verapamil infarction trial in 1979-81. Setting-16 coronary care units, covering a fifth of the total Danish population. Patients-3073 consecutive patients with acute myocardial infarction, 738 (24%) women and 2335 (76%) men. Main outcome measures-Early mortality (before day 15). For patients alive on day 15: mortality, cause of death, admission with recurrent infarction, and mortality after reinfarction. Results-Early mortality increased significantly with age (P<0.0001) but was not significantly related to sex, with a 15 day mortality of 17% in women and 16% in men. Adjustment for age and sex simultaneously revealed a significant interaction (P=0.02) between these variables, with a greater increase with age in early mortality for men than for women (early mortality was equal for the two sexes at age 64 years). Ten year mortality in patients alive on day 15 was 58.8%. The overall age adjusted hazard ratio (95% confidence interval) for women versus men was 0.90 (0.80 to 1.01); 0.90 (0.78 to 1.04) for 10 year reinfarction (48.8%); and 0.98 (0.82 to 1.16) for 10 year mortality after reinfarction (82.3%). No difference in cause of death was found between the sexes. With a follow up of up to 10 years for patients alive on day 15 mortality, rate of reinfarction, and mortality after reinfarction increased with increasing age (P<0.0001). Conclusion-Sex by itself is not a risk factor after acute myocardial infarction.	UNI C, DANISH COMP CTR RES & EDUC, AARHUS, DENMARK; HVIDOVRE UNIV HOSP, DEPT CARDIOL, DK-2650 HVIDOVRE, DENMARK	University of Copenhagen	GalatiusJensen, S (corresponding author), NATL UNIV HOSP, RIGSHOSP, DEPT CARDIOL B, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BUENO H, 1995, CIRCULATION, V92, P1133, DOI 10.1161/01.CIR.92.5.1133; CHAMBERLAIN DA, 1988, LANCET, V1, P545; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; EDWARDS BS, 1991, AM J CARDIOL, V67, P782, DOI 10.1016/0002-9149(91)90545-V; EVERY NR, 1995, CIRCULATION, V92, P124; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HANSEN JF, 1984, EUR HEART J, V5, P516; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KARLSON BW, 1994, AM HEART J, V128, P477, DOI 10.1016/0002-8703(94)90620-3; LAUNBJERG J, 1993, CORONARY ARTERY DIS, V4, P195, DOI 10.1097/00019501-199302000-00010; LAUNBJERG J, 1991, AM HEART J, V122, P1270, DOI 10.1016/0002-8703(91)90565-Y; LAUNBJERG J, 1992, CARDIOLOGY, V80, P294, DOI 10.1159/000175015; LERMAN A, 1991, CIRCULATION, V83, P1808, DOI 10.1161/01.CIR.83.5.1808; MADSEN EB, 1984, AM J CARDIOL, V53, P47, DOI 10.1016/0002-9149(84)90682-9; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; NAYLOR CD, 1994, J AM COLL CARDIOL, V24, P1431, DOI 10.1016/0735-1097(94)90136-8; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; Rose GA, 1982, WHO MONOGRAPH SERIES; SAITO M, 1987, AM HEART J, V113, P891, DOI 10.1016/0002-8703(87)90049-4; THOMSEN BL, 1988, 885317 U COP STAT RE; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; WILCOX RG, 1988, LANCET, V2, P525; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702	35	27	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	1996	313	7050					137	140		10.1136/bmj.313.7050.137	http://dx.doi.org/10.1136/bmj.313.7050.137			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688773	Green Published			2022-12-28	WOS:A1996UY92100015
J	Rodgers, A; MacMahon, S; Gamble, G; Slattery, J; Sandercock, P; Warlow, C				Rodgers, A; MacMahon, S; Gamble, G; Slattery, J; Sandercock, P; Warlow, C			Blood pressure and risk of stroke in patients with cerebrovascular disease	BRITISH MEDICAL JOURNAL			English	Article									UNIV EDINBURGH,DEPT CLIN NEUROSCI,NEUROSCI TRIALS UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Rodgers, A (corresponding author), UNIV AUCKLAND,DEPT MED,CLIN TRIALS RES UNIT,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				CARLSSON A, 1993, STROKE, V24, P195, DOI 10.1161/01.STR.24.2.195; IRIE K, 1993, STROKE, V24, P1844, DOI 10.1161/01.STR.24.12.1844; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON S, 1993, J VASC MED BIOL, V4, P265; 1991, J NEUROL NEUROSUR PS, V54, P1044	5	186	196	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					147	147		10.1136/bmj.313.7050.147	http://dx.doi.org/10.1136/bmj.313.7050.147			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688776	Green Published			2022-12-28	WOS:A1996UY92100019
J	Schermeier, Q				Schermeier, Q			The view from Europe	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					349	350		10.1038/381349a0	http://dx.doi.org/10.1038/381349a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692277				2022-12-28	WOS:A1996UM40300065
J	Ewald, D; Li, MG; Efrat, S; Auer, G; Wall, RJ; Furth, PA; Hennighausen, L				Ewald, D; Li, MG; Efrat, S; Auer, G; Wall, RJ; Furth, PA; Hennighausen, L			Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen	SCIENCE			English	Article							SV40-TRANSFORMED CELLS; GENE-EXPRESSION; ONCOGENES; PROMOTER; PROTEIN; CANCER; GROWTH	The role of viral oncoprotein expression in the maintenance of cellular transformation was examined as a function of time through controlled expression of simian virus 40 T antigen (TAg), Expression of TAg in the submandibular gland of transgenic mice from the time of birth induced cellular transformation and extensive ductal hyperplasia by 4 months of age, The hyperplasia was reversed when TAg expression was silenced for 3 weeks, When TAg expression was silenced after 7 months, however, the hyperplasia persisted even though TAg was absent, Although the polyploidy of ductal cells could be reversed at 4 months of age, cells at 7 months of age remained polyploid even in the absence of TAg, These results support a model of time-dependent multistep tumorigenesis, in which virally transformed cells eventually lose their dependence on the viral oncoprotein for maintenance of the transformed state.	UNIV MARYLAND,SCH MED,DEPT MED,DIV INFECT DIS,BALTIMORE,MD 21201; INST HUMAN VIROL,BALTIMORE,MD 21201; ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461; KAROLINSKA INST,DEPT PATHOL & ONCOL,S-17176 STOCKHOLM,SWEDEN; ARS,USDA,BELTSVILLE,MD 20705; NIDDKD,BIOCHEM & METAB LAB,NIH,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; United States Department of Agriculture (USDA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Efrat, Shimon/0000-0001-5987-232X; Hennighausen, Lothar/0000-0001-8319-9841				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; ELSON A, 1995, ONCOGENE, V11, P181; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; FURTH PA, UNPUB; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; HENNINGHAUSEN L, UNPUB; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PASCALL JC, 1994, J MOL ENDOCRINOL, V12, P313, DOI 10.1677/jme.0.0120313; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TZENG YJ, 1993, ONCOGENE, V8, P1965; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x	21	202	206	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1384	1386		10.1126/science.273.5280.1384	http://dx.doi.org/10.1126/science.273.5280.1384			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703072				2022-12-28	WOS:A1996VF61000041
J	Yang, NN; Venugopalan, M; Hardikar, S; Glasebrook, A				Yang, NN; Venugopalan, M; Hardikar, S; Glasebrook, A			Identification of an estrogen response element activated by metabolites of 17 beta-estradiol and raloxifene	SCIENCE			English	Article							CARDIOVASCULAR RISK-FACTORS; POSTMENOPAUSAL WOMEN; BREAST-CANCER; RECEPTOR; GROWTH; GENE; BONE; TRANSCRIPTION; PROMOTER; CELLS	17 beta-Estradiol modulates gene transcription through the estrogen receptor and the estrogen response element in DNA. The human transforming growth factor-beta 3 gene was shown to be activated by the estrogen receptor in the presence of estrogen metabolites or estrogen antagonists, Activation was mediated by a polypurine sequence, termed the raloxifene response element, and did not require the DNA binding domain of the estrogen receptor, Interaction of the estrogen receptor with the raloxifene response element appears to require a cellular adapter protein, The observation that individual estrogens modulate multiple DNA response elements may explain the tissue-selective estrogen agonist or antagonist activity of compounds such as raloxifene.			Yang, NN (corresponding author), ELI LILLY & CO,LILLY CORP CTR,ENDOCRINE RES,MAIL DROP 0444,INDIANAPOLIS,IN 46285, USA.							ANDERSON JE, 1984, BIOL REGUL DEV, V3, P169; ARRICK BA, 1994, MOL CELL BIOL, V14, P619, DOI 10.1128/MCB.14.1.619; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; Draper MW, 1996, J BONE MINER RES, V11, P835; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHMAN J, 1981, J ENDOCRINOL S, V89, P59; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; GLASEBROOK AL, UNPUB; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; JONES CD, 1984, J MED CHEM, V27, P1057, DOI 10.1021/jm00374a021; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRAUS WL, 1993, ENDOCRINOLOGY, V132, P2371, DOI 10.1210/en.132.6.2371; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LIEBERMAN S, 1986, J ENDOCRINOL, V111, P519, DOI 10.1677/joe.0.1110519; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MACLUSKY NJ, 1981, J STEROID BIOCHEM, V15, P111, DOI 10.1016/0022-4731(81)90265-X; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NEDIVI E, 1992, J NEUROSCI, V12, P691; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; YOUNG MF, 1989, J BIOL CHEM, V264, P450	31	370	388	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1222	1225		10.1126/science.273.5279.1222	http://dx.doi.org/10.1126/science.273.5279.1222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703055				2022-12-28	WOS:A1996VE47600038
J	Abenhaim, L; Moride, Y; Brenot, F; Rich, S; Benichou, J; Kurz, X; Higenbottam, T; Oakley, C; Wouters, E; Aubier, M; Simonneau, G; Begaud, B				Abenhaim, L; Moride, Y; Brenot, F; Rich, S; Benichou, J; Kurz, X; Higenbottam, T; Oakley, C; Wouters, E; Aubier, M; Simonneau, G; Begaud, B			Appetite-suppressant drugs and the risk of primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FENFLURAMINE; INFECTION	Background Recently in France, primary pulmonary hypertension developed in a cluster of patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. Methods In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. Results The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used for a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. Conclusions The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since the use of anorexic drugs is expected to increase in the near future. (C) 1996, Massachusetts Medical Society.	MCGILL UNIV,CTR CLIN EPIDEMIOL & COMMUNITY STUDIES,MONTREAL,PQ H3T 1E2,CANADA; ANTOINE BECLERE HOSP,SERV PNEUMOL,CLAMART,FRANCE; UNIV ILLINOIS,DEPT SURG,CARDIOL SECT,CHICAGO,IL 60680; NCI,ROCKVILLE,MD; CHU LIEGE,INST PATHOL,PHARMACOL LAB,LIEGE,BELGIUM; UNIV SHEFFIELD,SECT RESP MED,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; HAMMERSMITH HOSP,DEPT CARDIOL,LONDON,ENGLAND; UNIV HOSP MAASTRICHT,DEPT PULMONOL,MAASTRICHT,NETHERLANDS; HOP XAVIER BICHAT,SERV PNEUMOL,PARIS,FRANCE; PELLEGRIN HOSP,CTR PHARMACOVIGILANCE,BORDEAUX,FRANCE	McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Liege; University of Sheffield; Imperial College London; Maastricht University; Maastricht University Medical Centre (MUMC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux	Abenhaim, L (corresponding author), SIR MORTIMER B DAVIS JEWISH HOSP,CTR CLIN EPIDEMIOL & COMMUNITY STUDIES,MONTREAL,PQ H3T 1E2,CANADA.		Wouters, Emiel/ABD-6200-2021; Simonneau, Gerald/ABE-6614-2020					ABENHAIM L, 1994, CHEST, V105, pS37; BRENOT F, 1993, BRIT HEART J, V70, P537; BRENOT F, 1994, CHEST, V105, pS33, DOI 10.1378/chest.105.2_Supplement.33S; COLLINS E, 1989, MED J AUSTRALIA, V150, P331, DOI 10.5694/j.1326-5377.1989.tb136497.x; DAWKINS KD, 1986, CHEST, V89, P383, DOI 10.1378/chest.89.3.383; DOUGLAS JG, 1981, BMJ-BRIT MED J, V283, P881, DOI 10.1136/bmj.283.6296.881; FAHLEN M, 1973, BRIT HEART J, V35, P824; GURTNER HP, 1985, COR VASA, V27, P160; HADENGUE A, 1991, GASTROENTEROLOGY, V100, P520, DOI 10.1016/0016-5085(91)90225-A; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; KLEIGER RE, 1976, CHEST, V69, P143, DOI 10.1378/chest.69.2.143; LANGLEBEN D, 1994, CHEST, V105, pS13, DOI 10.1378/chest.105.2_Supplement.13S; LEGOUX B, 1990, AM J MED, V89, P122, DOI 10.1016/0002-9343(90)90113-R; MASI AT, 1976, CHEST, V69, P451; MCDONNELL PJ, 1983, AM REV RESPIR DIS, V127, P437, DOI 10.1164/arrd.1983.127.4.437; MCMURRAY J, 1986, BRIT MED J, V293, P51, DOI 10.1136/bmj.293.6538.51-d; MICHELAKIS ED, 1995, AM J RESP CRIT CAR S, V151, pA725; NAEIJE R, 1995, AM J RESP CRIT CARE, V151, P692; OAKLEY CW, 1994, CHEST, V105, pS29, DOI 10.1378/chest.105.2_Supplement.29S; PETITPRETZ P, 1994, CIRCULATION, V89, P2722, DOI 10.1161/01.CIR.89.6.2722; POUWELS HMM, 1990, EUR RESPIR J, V3, P606; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; RUSSELL L A, 1992, American Review of Respiratory Disease, V145, pA717; SCHAIBERGER PH, 1993, CHEST, V104, P614, DOI 10.1378/chest.104.2.614	27	885	914	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					609	616		10.1056/NEJM199608293350901	http://dx.doi.org/10.1056/NEJM199608293350901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8692238				2022-12-28	WOS:A1996VD42500001
J	Markram, H; Tsodyks, M				Markram, H; Tsodyks, M			Redistribution of synaptic efficacy between neocortical pyramidal neurons	NATURE			English	Article							LONG-TERM POTENTIATION; TRANSMISSION; HIPPOCAMPUS; LTP	EXPERIENCE-dependent potentiation and depression of synaptic strength has been proposed to subserve learning and memory by changing the gain of signals conveyed between neurons(1,2). Here we examine synaptic plasticity between individual neocortical layer-5 pyramidal neurons, We show that an increase in the synaptic response, induced by pairing action-potential activity in pre- and postsynaptic neurons, was only observed when synaptic input occurred at low frequencies. This frequency-dependent increase in synaptic responses arises because of a redistribution of the available synaptic efficacy and not because of an increase in the efficacy. Redistribution of synaptic efficacy could represent a mechanism to change the content, rather than the gain, of signals conveyed between neurons.			Markram, H (corresponding author), WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL.		tsodyks, misha/J-4430-2013	Tsodyks, Misha/0000-0002-5661-4349				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BARNES CA, 1995, NEURON, V15, P751, DOI 10.1016/0896-6273(95)90166-3; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; JONES HC, 1987, J PHYSL LOND P, V64; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MARKRAM H, 1995, SOC NEUR ABSTR; MARKRAM H, 1995, EUROPEAN NEUROSCIENC; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STEVENS CF, 1993, NEURON S, V10, P55; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TEYLER TJ, 1984, BRAIN RES REV, V7, P15, DOI 10.1016/0165-0173(84)90027-4; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X	16	600	614	0	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					807	810		10.1038/382807a0	http://dx.doi.org/10.1038/382807a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752273				2022-12-28	WOS:A1996VE34700046
J	Ekbom, A; Hsieh, CC; Lipworth, L; Wolk, A; Ponten, J; Adami, HO; Trichopoulos, D				Ekbom, A; Hsieh, CC; Lipworth, L; Wolk, A; Ponten, J; Adami, HO; Trichopoulos, D			Perinatal characteristics in relation to incidence of and mortality from prostate cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; MUTATOR PHENOTYPE; PHYSICAL-ACTIVITY; BREAST-CANCER; BIRTH-WEIGHT; RISK; ESTROGENS; PREGNANCY; EPIDEMIOLOGY; VASECTOMY	Objective-To test the hypothesis that factors causing morbidity and mortality from prostate cancer may operate in utero. Design-Matched case-control study of singleton men born between 1874 and 1946 at one hospital. Setting-Uppsala University Hospital. Subjects-250 patients with prostate cancer and 691 controls, including 80 patients who died from prostate cancer and their 196 matched controls. Main outcome measures-Mother's age at menarche, parity, pre-eclampsia or eclampsia before delivery, age at delivery and socioeconomic status; case or control's birth length and weight, placental weight, prematurity derived from gestational age, and presence of jaundice. Results-Both pre-eclampsia (odds ratio 0, 95% confidence interval 0 to 0.71) and prematurity (0.31, 0.09 to 1.04) were inversely associated with incidence of prostate cancer. Among subjects born full term, placental weight, birth weight, and ponderal index (weight/height(3)) showed non-significant positive associations with prostate cancer incidence, and stronger associations with mortality. Conclusion-Prenatal exposures that are likely correlates of pregnancy hormones and other growth factors are important in prostate carcinogenesis and influence the natural course as well as the occurrence of this cancer.	UNIV UPPSALA, DEPT PATHOL, S-75185 UPPSALA, SWEDEN; UNIV MASSACHUSETTS, MED CTR, CTR CANC, WORCESTER, MA 01605 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, CTR CANC PREVENT, BOSTON, MA 02115 USA	Uppsala University; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Ekbom, A (corresponding author), UNIV UPPSALA, DEPT CANC EPIDEMIOL, S-75185 UPPSALA, SWEDEN.				NCI NIH HHS [T32 CA09001-19A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON SO, 1995, CANCER EPIDEM BIOMAR, V4, P187; ANDERSSON SO, 1993, BRIT J CANCER, V68, P97, DOI 10.1038/bjc.1993.293; BARRETTCONNOR E, 1990, CANCER RES, V50, P169; BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; *CANC REG, 1990, CAN INC SWED 1987; CHEVILLE JC, 1995, AM J SURG PATHOL, V19, P1068, DOI 10.1097/00000478-199509000-00011; COFFEY DS, 1981, UROLOGY, V17, P17; DAIKOKU NH, 1979, OBSTET GYNECOL, V54, P211; DRAFTA D, 1982, J STEROID BIOCHEM, V17, P689, DOI 10.1016/0022-4731(82)90572-6; EKBOM A, 1995, INT J CANCER, V61, P177, DOI 10.1002/ijc.2910610206; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GERHARD I, 1987, EUR J OBSTET GYN R B, V26, P313, DOI 10.1016/0028-2243(87)90129-8; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; GREENWALD P, 1982, CANC EPIDEMIOLOGY PR, P9138; HENDERSON BE, 1988, BRIT J CANCER, V57, P216, DOI 10.1038/bjc.1988.46; HSING AW, 1989, AM J EPIDEMIOL, V130, P829; HYNES RB, 1995, JNCI-J NATL CANCER I, V87, P629; JOHN EM, 1995, J NATL CANCER I, V87, P662, DOI 10.1093/jnci/87.9.662; KLOPPER A, 1975, J STEROID BIOCHEM, V6, P651, DOI 10.1016/0022-4731(75)90047-3; LIPWORTH L, 1995, EUR J CANCER PREV, V4, P7, DOI 10.1097/00008469-199502000-00002; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1994, CANCER RES, V54, P5059; LONG PA, 1979, AM J OBSTET GYNECOL, V135, P344, DOI 10.1016/0002-9378(79)90702-6; LUBCHENCO LO, 1966, PEDIATRICS, V37, P403; LUNDE AS, 1980, VITAL HLTH STATIST 2, V84, P5; MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; Petridou E, 1990, Epidemiology, V1, P247, DOI 10.1097/00001648-199005000-00011; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; ROSING U, 1984, GYNECOL OBSTET INVES, V18, P199, DOI 10.1159/000299081; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; ROSS RK, 1994, J NATL CANCER I, V86, P252, DOI 10.1093/jnci/86.4.252; ROTKIN ID, 1977, CANCER TREAT REP, V61, P173; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; THUNE I, 1994, CANCER CAUSE CONTROL, V5, P549, DOI 10.1007/BF01831383; TIBBLIN G, 1995, EPIDEMIOLOGY, V6, P423, DOI 10.1097/00001648-199507000-00017; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; TRICHOPOULOS D, 1995, EPIDEMIOLOGY, V6, P347; WANG XB, 1994, INT J EPIDEMIOL, V23, P119, DOI 10.1093/ije/23.1.119; WHITTEMORE AS, 1995, JNCI-J NATL CANCER I, V87, P652, DOI 10.1093/jnci/87.9.652; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8	47	86	86	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1996	313	7053					337	341		10.1136/bmj.313.7053.337	http://dx.doi.org/10.1136/bmj.313.7053.337			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760741	Green Published			2022-12-28	WOS:A1996VC30000019
J	Wardle, J; Armitage, J; Collins, R; Wallendszus, K; Keech, A; Lawson, A				Wardle, J; Armitage, J; Collins, R; Wallendszus, K; Keech, A; Lawson, A			Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration	BRITISH MEDICAL JOURNAL			English	Article							COA REDUCTASE INHIBITORS; LOW SERUM-CHOLESTEROL; DEPRESSIVE SYMPTOMS; MORTALITY; MEN	Objective-To evaluate the effects on mood of a substantial and prolonged reduction in total cholesterol concentration. Design-Randomised placebo controlled comparison of patients who had been allocated to receive simvastatin 20 mg or 40 mg daily versus those allocated matching placebo in a ratio of 2:1. Follow up at an average of 152 weeks after randomisation. Subjects-Men and women aged between 40 and 75 years at entry with blood total cholesterol of 3.5 mmol/l or greater, who were considered to be at higher than average risk of coronary heart disease based on medical history. Main outcome measures-The shortened profile of mood states questionnaire, reported use of psychotropic medication, and symptoms possibly related to mood. Results-Simvastatin reduced total cholesterol by 1.9 mmol/l (26.7%) at the time of follow up. Among all 621 patients randomised to simvastatin (414 patients) or placebo (207 patients) there were no significant differences in the use of psychotropic medication or in reports of symptoms possibly related to mood. Of these patients, 491 (334 simvastatin, 157 placebo) completed the mood questionnaire, and there were no significant differences between the treatment groups in total or subscale scores, even when patients with low baseline cholesterol concentrations or elderly subjects were considered separately. Conclusion-These results do not support the hypothesis that treatment to lower cholesterol concentration causes mood disturbance.	UNIV OXFORD,RADCLIFFE INFIRM,BRITISH HEART FDN,MED RES COUNCIL,ICRF CLIN TRIAL SERV UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Oxford	Wardle, J (corresponding author), UNIV LONDON UNIV COLL,IMPERIAL CANC RES FUND,HLTH BEHAV UNIT,LONDON WC1E 6BT,ENGLAND.			Wallendszus, Karl/0000-0003-0971-3026				BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; BRUNNER E, 1992, LANCET, V339, P1001; CURRAN SL, 1995, PSYCHOL ASSESSMENT, V7, P80, DOI 10.1037/1040-3590.7.1.80; DEALBERTO MJ, 1993, LANCET, V341, P435; DOWNS JR, 1993, JAMA-J AM MED ASSOC, V269, P3107, DOI 10.1001/jama.269.24.3107; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P507, DOI 10.1093/oxfordjournals.aje.a117465; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; IRIBARREN C, 1995, CIRCULATION, V92, P2396, DOI 10.1161/01.CIR.92.9.2396; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; KEECH A, 1994, EUR HEART J, V15, P355; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; McNair DM, 1981, PROFILE MOOD STATES; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; STEPTOE A, 1989, J PSYCHOSOM RES, V33, P537, DOI 10.1016/0022-3999(89)90061-5; STRANDBERG TE, 1993, LANCET, V341, P433, DOI 10.1016/0140-6736(93)93026-W; WEIDNER G, 1992, ANN INTERN MED, V117, P820, DOI 10.7326/0003-4819-117-10-820	20	75	75	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					75	78		10.1136/bmj.313.7049.75	http://dx.doi.org/10.1136/bmj.313.7049.75			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688757	Green Published			2022-12-28	WOS:A1996UX69800020
J	Kendall, MJ; Toescu, V; Wallace, DMA				Kendall, MJ; Toescu, V; Wallace, DMA			QED: Quick and early diagnosis	LANCET			English	Editorial Material											Kendall, MJ (corresponding author), QUEEN ELIZABETH HOSP,QUICK & EARLY DIAG UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.								0	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					528	529		10.1016/S0140-6736(96)03483-6	http://dx.doi.org/10.1016/S0140-6736(96)03483-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757158				2022-12-28	WOS:A1996VD42700016
J	Pless, IB				Pless, IB			Collisions with animals	LANCET			English	Editorial Material											Pless, IB (corresponding author), MCGILL UNIV,DEPT PAEDIAT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA.							Farrell TM, 1996, ARCH SURG-CHICAGO, V131, P377; HAYES P, 1995, DANGEROUS ELK    SEP; PLESS IB, 1996, INJURY PREVENTION, V2, P87; THOMPSON SJ, 1985, ERGONOMICS, V28, P1469, DOI 10.1080/00140138508963271	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					492	492		10.1016/S0140-6736(05)64668-5	http://dx.doi.org/10.1016/S0140-6736(05)64668-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757149				2022-12-28	WOS:A1996VD42700007
J	Holley, SA; Neul, JL; Attisano, L; Wrana, JL; Sasai, Y; OConnor, MB; DeRobertis, EM; Ferguson, EL				Holley, SA; Neul, JL; Attisano, L; Wrana, JL; Sasai, Y; OConnor, MB; DeRobertis, EM; Ferguson, EL			The Xenopus dorsalizing factor noggin ventralizes Drosophila embryos by preventing DPP from activating its receptor	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; TGF-BETA SUPERFAMILY; SHORT GASTRULATION; NEURAL INDUCTION; MESODERM INDUCTION; SPEMANN ORGANIZER; MARGINAL ZONE; THICK VEINS; I RECEPTORS; PATTERN	noggin is expressed in the Spemann organizer region of the Xenopus embryo and can promote dorsal cell fates within the mesoderm and neural development within the overlying ectoderm. Here, we show that noggin promotes ventral development in Drosophila, specifying ventral ectoderm and CNS in the absence of all endogenous ventral-specific zygotic gene expression. We utilize constitutively active forms of the dpp receptors to demonstrate that noggin blocks dpp signaling upstream of dpp receptor activation. These results suggest a mechanistic basis for the action of Spemann's organizer during Xenopus development and provide further support for the conservation of dorsal-ventral patterning mechanisms between arthropods and chordates.	UNIV CHICAGO,COMM DEV BIOL,CHICAGO,IL 60637; UNIV TORONTO,DEPT ANAT & CELL BIOL,TORONTO,ON M5S 1A8,CANADA; HOSP SICK CHILDREN,PROGRAM DEV BIOL,DIV GASTROENTEROL,TORONTO,ON M5G 1X8,CANADA; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92717	University of Chicago; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Irvine	Holley, SA (corresponding author), UNIV CHICAGO,DEPT MOL GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.		O'Connor, Michael B/C-9977-2014; Wrana, Jeffrey/F-8857-2013; Neul, Jeffrey/AAF-5324-2020	O'Connor, Michael B/0000-0002-3067-5506; Neul, Jeffrey/0000-0002-5628-5872; Ferguson, Edwin/0000-0003-4125-4253	NICHD NIH HHS [HD21503] Funding Source: Medline; NIGMS NIH HHS [GM47462, GM50838] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050838] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; Attisano L, 1996, MOL CELL BIOL, V16, P1066; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; DALE L, 1992, DEVELOPMENT, V115, P573; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Geoffroy Saint-Hilaire E., 1822, MEMOIRES DU MUSEUM D, V9, P89; GODSAVE SF, 1989, DEV BIOL, V134, P486, DOI 10.1016/0012-1606(89)90122-X; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JONES CM, 1992, DEVELOPMENT, V115, P639; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; New HV, 1991, CURR OPIN GENET DEV, V1, P196, DOI 10.1016/S0959-437X(05)80070-X; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PATEL NH, 1994, DROSOPHILA MELANOGAS, P446; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PICCOLO S, 1996, CELL, V86; RAY RP, 1991, DEVELOPMENT, V113, P35; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; SUZUKI A, 1995, DEV GROWTH DIFFER, V37, P581; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; ZIMMERMAN LB, 1996, CELL, V86; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	60	201	207	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					607	617		10.1016/S0092-8674(00)80134-8	http://dx.doi.org/10.1016/S0092-8674(00)80134-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752215	Bronze			2022-12-28	WOS:A1996VE23500011
J	Liu, R; Paxton, WA; Choe, S; Ceradini, D; Martin, SR; Horuk, R; MacDonald, ME; Stuhlmann, H; Koup, RA; Landau, NR				Liu, R; Paxton, WA; Choe, S; Ceradini, D; Martin, SR; Horuk, R; MacDonald, ME; Stuhlmann, H; Koup, RA; Landau, NR			Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection	CELL			English	Article							ERYTHROCYTE CHEMOKINE RECEPTOR; TYPE-1; DISEASE; GENE; FAMILY; REGION; PROGRESSION; REQUIREMENT; EXPRESSION; PHENOTYPE	Rare individuals have been multiply exposed to HIV-1 but remain uninfected. The CD4(+) T-cells of two of these individuals, designated EU2 and EU3, are highly resistant in vitro to the entry of primary macrophage-tropic virus but are readily infectable with transformed T-cell line adapted viruses. We report here on the genetic basis of this resistance. We found that EU2 and EU3 have a homozygous defect in CKR-5, the gene encoding the recently described coreceptor for primary HIV-1 isolates. These individuals appear to have inherited a defective CKR-5 allele that contains an internal 32 base pair deletion. The encoded protein is severely truncated and cannot be detected at the cell surface. Surprisingly, this defect has no obvious phenotype in the affected individuals. Thus, a CKR-5 allele present in the human population appears to protect homozygous individuals from sexual transmission of HIV-1. Heterozygous individuals are quite common (similar to 20%) in some populations. These findings indicate the importance of CKR-5 in HIV-1 transmission and suggest that targeting the HIV-1-CKR-5 interaction may provide a means of preventing or slowing disease progression.	BERLEX BIOSCI, DEPT IMMUNOL, RICHMOND, CA 94080 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET UNIT, CHARLESTOWN, MA 02129 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOL BIOL, NEW YORK, NY 10029 USA	Harvard University; Massachusetts General Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Liu, R (corresponding author), ROCKEFELLER UNIV, AARON DIAMOND AIDS RES CTR, 1230 YORK AVE, NEW YORK, NY 10016 USA.		paxton, william/R-9747-2019	Paxton, William/0000-0002-2654-5186; Paxton, William/0000-0001-5200-0801; Stuhlmann, Heidi/0000-0001-7217-768X	NCI NIH HHS [R01CA72149] Funding Source: Medline; NIAID NIH HHS [R01AI35522, R29AI36057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035522, R29AI036057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; COCCHI F, 1996, SCIENCE, V720, P1811; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HE JL, 1995, J VIROL, V69, P4587, DOI 10.1128/JVI.69.7.4587-4592.1995; HEXTER A, 1968, SCIENCE, V160, P436, DOI 10.1126/science.160.3826.436; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LENBURG ME, 1993, J VIROL, V67, P7238, DOI 10.1128/JVI.67.12.7238-7245.1993; LOCKE PA, 1993, SOMAT CELL MOLEC GEN, V19, P95, DOI 10.1007/BF01233958; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MACDONALD ME, 1991, AM J HUM GENET, V49, P723; MALLINSON G, 1995, BRIT J HAEMATOL, V90, P823, DOI 10.1111/j.1365-2141.1995.tb05202.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naylor SL, 1996, CYTOGENET CELL GENET, V72, P90, DOI 10.1159/000134170; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; TANZI R E, 1988, Genomics, V3, P129, DOI 10.1016/0888-7543(88)90143-7; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	45	2423	2550	1	140	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					367	377		10.1016/S0092-8674(00)80110-5	http://dx.doi.org/10.1016/S0092-8674(00)80110-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756719	Bronze			2022-12-28	WOS:A1996VC30900005
J	Roberts, JM				Roberts, JM			Preventing pre-eclampsia	LANCET			English	Editorial Material							PREGNANCY-INDUCED HYPERTENSION; PREECLAMPSIA				Roberts, JM (corresponding author), UNIV PITTSBURGH,MAGEE WOMENS RES INST,DEPT OBSTET & GYNAECOL,PITTSBURGH,PA 15213, USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				BAKER PN, 1994, OBSTET GYNECOL, V83, P745; Conde-Agudelo A, 1994, Obstet Gynecol Surv, V49, P210, DOI 10.1097/00006254-199403000-00027; FRIEDMAN SA, 1991, CLIN PERINATOL, V18, P661, DOI 10.1016/S0095-5108(18)30490-1; KYLE PM, 1995, AM J OBSTET GYNECOL, V173, P865, DOI 10.1016/0002-9378(95)90356-9; MACGILLIVRAY I, 1976, IS J MED SCI, V112, P500; Millar JGB, 1996, BRIT J OBSTET GYNAEC, V103, P421, DOI 10.1111/j.1471-0528.1996.tb09767.x; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					281	282		10.1016/S0140-6736(05)64469-8	http://dx.doi.org/10.1016/S0140-6736(05)64469-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709684				2022-12-28	WOS:A1996VA25000005
J	Santana, P; Pena, LA; HaimovitzFriedman, A; Martin, S; Green, D; McLoughlin, M; CordonCardo, C; Schuchman, EH; Fuks, Z; Kolesnick, R				Santana, P; Pena, LA; HaimovitzFriedman, A; Martin, S; Green, D; McLoughlin, M; CordonCardo, C; Schuchman, EH; Fuks, Z; Kolesnick, R			Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis	CELL			English	Article							NIEMANN-PICK DISEASE; ACTIVATED PROTEIN-KINASE; CELL-FREE SYSTEM; SIGNAL-TRANSDUCTION; DNA-DAMAGE; PARTIAL-PURIFICATION; NUCLEOTIDE-SEQUENCE; MAMMALIAN-CELLS; B PATIENTS; RAT-BRAIN	Stress is believed to activate sphingomyelinase to generate ceramide, which serves as a second messenger in initiating the apoptotic response. Conclusive evidence for this paradigm, however, is lacking. In the present study, we used a genetic approach to address this issue directly. We show that lymphoblasts from Niemann-Pick patients, which have an inherited deficiency of acid sphingomyelinase activity, fail to respond to ionizing radiation with ceramide generation and apoptosis. These abnormalities are reversible upon restoration of acid sphingomyelinase activity by retroviral transfer of human acid sphingomyelinase cDNA. Acid sphingomyelinase knockout mice also expressed defects in radiation-induced ceramide generation and apoptosis in vivo. Comparison with p53 knockout mice revealed that acid sphingomyelinase-mediated apoptosis and p53-mediated apoptosis are likely distinct and independent. These genetic models provide definitive evidence for the involvement of acid sphingomyelinase in one form of stress-induced apoptosis.	MEM SLOAN KETTERING CANC CTR,DEPT RADIAT ONCOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; MT SINAI SCH MED,DEPT HUMAN GENET,NEW YORK,NY 10029; LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,LA JOLLA,CA 92037	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; La Jolla Institute for Immunology	Santana, P (corresponding author), MEM SLOAN KETTERING CANC CTR,LAB SIGNAL TRANSDUCT,1275 YORK AVE,NEW YORK,NY 10021, USA.			Martin, Seamus/0000-0002-8539-3143; Santana-Delgado, Pino/0000-0002-4093-2692	NATIONAL CANCER INSTITUTE [R01CA057400] Funding Source: NIH RePORTER; NCI NIH HHS [CA57400, CA42385, CA52462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN DJ, 1992, INT J RADIAT BIOL, V62, P145, DOI 10.1080/09553009214551951; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADFORD JS, 1991, INT J RADIAT ONCOL, V21, P1457; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CIFONE MG, 1993, J EXP MED, V177, P1547; COLEMAN CN, 1993, RADIOTHER ONCOL, V28, P1; DEWEY WC, 1971, P NATL ACAD SCI USA, V68, P667, DOI 10.1073/pnas.68.3.667; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DOBROWSKY RT, 1993, ADV LIPID RES, V25, P91; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Fuks Z, 1995, Cancer J Sci Am, V1, P62; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALL EJ, 1994, INT J RADIAT ONCOL, V30, P1919; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, P9; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HURWITZ C, 1969, BIOPHYS J, V9, P607, DOI 10.1016/S0006-3495(69)86407-6; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JARVIS WD, 1995, CLIN CANCER RES, V2, P1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; LEVRAN O, 1991, J CLIN INVEST, V88, P806, DOI 10.1172/JCI115380; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARUYAMA EN, 1989, J NEUROCHEM, V52, P611, DOI 10.1111/j.1471-4159.1989.tb09163.x; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCMILLAN TJ, 1992, EUR J CANCER, V28A, P267, DOI 10.1016/0959-8049(92)90430-A; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611; RAO BG, 1976, J LIPID RES, V17, P506; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SEKI H, 1994, EUR J IMMUNOL, V24, P2914, DOI 10.1002/eji.1830241150; STEEL GG, 1989, INT J RADIAT BIOL, V56, P525, DOI 10.1080/09553008914551691; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUCHI M, 1992, P NATL ACAD SCI USA, V89, P3227, DOI 10.1073/pnas.89.8.3227; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; THOMPSON LH, 1991, MUTAT RES, V247, P213, DOI 10.1016/0027-5107(91)90017-I; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; YEDGAR S, 1976, BIOCHEMISTRY-US, V15, P2570, DOI 10.1021/bi00657a013; YEYATI PL, 1995, HUM GENE THER, V6, P975, DOI 10.1089/hum.1995.6.8-975; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	68	693	706	2	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					189	199		10.1016/S0092-8674(00)80091-4	http://dx.doi.org/10.1016/S0092-8674(00)80091-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706124	Bronze			2022-12-28	WOS:A1996UZ97200005
J	Arie, T				Arie, T			Caring for older people - Some legal aspects of mental capacity	BRITISH MEDICAL JOURNAL			English	Article								This article discusses some practical matters which arise when competence to make decisions is in question. Consent, testamentary capacity, powers of attorney, the Court of Protection, ''living wills,'' and research on people with dementia are briefly considered.			Arie, T (corresponding author), UNIV NOTTINGHAM,SCH MED,DEPT HLTH CARE ELDERLY,NOTTINGHAM NG7 2UH,ENGLAND.								0	12	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					156	158		10.1136/bmj.313.7050.156	http://dx.doi.org/10.1136/bmj.313.7050.156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688779	Green Published			2022-12-28	WOS:A1996UY92100027
J	Whincup, PH; Cook, DG; Adshead, F; Taylor, S; Papacosta, O; Walker, M; Wilson, V				Whincup, PH; Cook, DG; Adshead, F; Taylor, S; Papacosta, O; Walker, M; Wilson, V			Cardiovascular risk factors in British children from towns with widely differing adult cardiovascular mortality	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; BLOOD-PRESSURE; SOCIOECONOMIC-STATUS; GLUCOSE-TOLERANCE; BODY-MASS; CHILDHOOD; WEIGHT; GROWTH; BIRTH; FETAL	Objective-To examine whether cardiovascular risk factors differ in children from towns in England and Wales with widely differing adult cardiovascular death rates. Design-School based survey conducted during 1994 in 10 towns, five with exceptionally high adult cardiovascular mortality (standardised mortality ratio 131-143) and five with exceptionally low adult cardiovascular mortality (64-75). Towns were surveyed in high-low pairs. Subjects-3415 white children aged 8-11 years with physical measurements (response rate 75%), including 1287 with blood samples (response rate 64%), of whom 515 had blood samples taken 30 minutes after a glucose load. Results-Children in towns with high cardiovascular mortality were on average shorter than those in towns with low mortality (mean difference 1.2 cm; 95% confidence interval 0.3 to 2.1 cm; P = 0.02) and had a higher ponderal index (0.34 kg/m(3); 0.16 to 0.52 kg/m(3); P = 0.006). Mean systolic pressure was higher in high mortality towns, particularly after adjustment for height (2.0 mm Hg; 0.8 to 3.2 mm Hg; P = 0.009). Mean waist:hip ratio, total cholesterol concentration, and 30 minute post-load glucose measurements were similar in high and low mortality towns. The differences in height and blood pressure between high and low mortality towns were unaffected by standardisation for birth weight. Conclusions-The differences in height, ponderal index, and blood pressure between towns with high and low cardiovascular mortality, if persistent, may have important future public health implications. Their independence of birth weight suggests that the childhood environment rather than the intrauterine environment is involved in their development.	UNIV LONDON ST GEORGES HOSP, SCH MED,DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	St Georges University London	Whincup, PH (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND.		TAYLOR, STEPHANIE/GYV-4768-2022	Whincup, Peter/0000-0002-5589-4107; Cook, Derek/0000-0002-9723-5759; Papacosta, Olia/0000-0001-8781-6747; Taylor, Stephanie/0000-0001-7454-6354	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZAD K, 1994, ANN CLIN BIOCHEM, V31, P233, DOI 10.1177/000456329403100303; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Bennett N, 1995, HLTH SURVEY ENGLAND; BRUCE NG, 1990, J CLIN EPIDEMIOL, V43, P385, DOI 10.1016/0895-4356(90)90124-8; CHINN S, 1992, EUR J CLIN NUTR, V46, P489; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; FREEMAN W, 1990, ARCH DIS CHILD, V65, P78, DOI 10.1136/adc.65.1.78; FROHLICH ED, 1988, CIRCULATION, V77, pA502; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HAMMOND J, 1994, ARCH DIS CHILD, V70, P367, DOI 10.1136/adc.70.5.367; LAW CM, 1993, J EPIDEMIOL COMMUN H, V47, P255, DOI 10.1136/jech.47.4.255; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; *OFF POP CENS SURV, 1990, OFF POP CENS SURV DS, V9; *POL STUD I, 1994, URB TRENDS, V2; PRINEAS RJ, 1980, HYPERTENSION, V2, pI24, DOI 10.1161/01.HYP.2.4_Pt_2.I24; RAMSEY M, 1979, MED BIOL ENG COMPUT, V17, P11, DOI 10.1007/BF02440948; *SAS I, 1985, SAS US GUID; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1984, BRIT MED BULL, V40, P366, DOI 10.1093/oxfordjournals.bmb.a072006; VOORS AW, 1977, AM J EPIDEMIOL, V106, P101, DOI 10.1093/oxfordjournals.aje.a112439; WALKER M, 1989, INT J EPIDEMIOL, V18, P602, DOI 10.1093/ije/18.3.602; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WHINCUP PH, 1988, LANCET, V2, P890; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P164, DOI 10.1136/jech.46.2.164; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P396, DOI 10.1136/jech.46.4.396; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1991, THESIS U LONDON	38	49	51	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	1996	313	7049					79	84		10.1136/bmj.313.7049.79	http://dx.doi.org/10.1136/bmj.313.7049.79			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688758	Green Published			2022-12-28	WOS:A1996UX69800021
J	Schedl, A; Ross, A; Lee, M; Engelkamp, D; Rashbass, P; vanHeyningen, V; Hastie, ND				Schedl, A; Ross, A; Lee, M; Engelkamp, D; Rashbass, P; vanHeyningen, V; Hastie, ND			Influence of PAX6 gene dosage on development: Overexpression causes severe eye abnormalities	CELL			English	Article							HOMEOBOX-CONTAINING GENE; PAIRED BOX GENE; INSITU HYBRIDIZATION; WAARDENBURG SYNDROME; POINT MUTATION; NEURAL-TUBE; ANIRIDIA; MOUSE; DEFECTS; EXPRESSION	Aniridia in man and Small eye in mice are semidominant developmental disorders caused by mutations within the paired box gene PAX6. Whereas heterozygotes suffer from iris hypoplasia, homozygous mice lack eyes and nasal cavities and exhibit brain abnormalities. To investigate the role of gene dosage in more detail, we have generated yeast artificial chromosome transgenic mice carrying the human PAX6 locus. When crossed onto the Small eye background, the transgene rescues the mutant phenotype. Strikingly, mice carrying multiple copies on a wild-type background show specific developmental abnormalities of the eye, but not of other tissues expressing the gene. Thus, at least five different eye phenotypes are associated with changes in PAX6 expression. We provide evidence that not only reduced, but also increased levels of transcriptional regulators can cause developmental defects.			Schedl, A (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Schedl, Andreas/F-8823-2015; Schedl, Andreas/GOP-3427-2022; VAN HEYNINGEN, Veronica/GYE-0531-2022; van Heyningen, Veronica/B-8039-2008	Schedl, Andreas/0000-0001-9380-7396; van Heyningen, Veronica/0000-0003-0359-0141	Medical Research Council [MC_U127527199] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; Bateman J B, 1984, Int Ophthalmol Clin, V24, P87, DOI 10.1097/00004397-198402410-00008; BEEBE DC, 1986, T OPHTHAL SOC UK, V105, P123; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FALK RE, 1973, AM J MENT DEF, V77, P383; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1992, AM J HUM GENET, V51, P1286; GENISGAL.JM, 1966, NATURE, V210, P209, DOI 10.1038/210209a0; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HODGSON SV, 1980, J MED GENET, V17, P478, DOI 10.1136/jmg.17.6.478; HOGAN B, 1994, MANIPULATION MOUSE E; HOGAN BLM, 1988, DEVELOPMENT, V103, P115; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; LAMB BT, 1995, CURR OPIN GENET DEV, V5, P342, DOI 10.1016/0959-437X(95)80049-2; LAVEDAN C, 1989, CYTOGENET CELL GENET, V50, P70, DOI 10.1159/000132726; LURIE IW, 1994, BRIT J OPHTHALMOL, V78, P415, DOI 10.1136/bjo.78.5.415; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; PALMER CG, 1976, HUM GENET, V31, P219, DOI 10.1007/BF00296149; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PLAZA S, 1995, MOL CELL BIOL, V15, P892; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; READ AP, 1995, NAT GENET, V9, P333, DOI 10.1038/ng0495-333; SANCHEZ O, 1974, HUMANGENETIK, V22, P59, DOI 10.1007/BF00338135; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; SMITH DJ, 1995, GENOMICS, V27, P425, DOI 10.1006/geno.1995.1073; SPELEMAN F, 1991, CYTOGENET CELL GENET, V56, P129, DOI 10.1159/000133068; STROBEL RJ, 1980, AM J MED GENET, V7, P15, DOI 10.1002/ajmg.1320070105; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TON CCT, 1992, GENOMICS, V13, P251, DOI 10.1016/0888-7543(92)90239-O; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WALTHER C, 1991, DEVELOPMENT, V113, P1435	45	358	365	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					71	82		10.1016/S0092-8674(00)80078-1	http://dx.doi.org/10.1016/S0092-8674(00)80078-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689689	Bronze			2022-12-28	WOS:A1996UX93400009
J	Jiang, F; Kumar, RA; Jones, RA; Patel, DJ				Jiang, F; Kumar, RA; Jones, RA; Patel, DJ			Structural basis of RNA folding and recognition in an AMP-RNA aptamer complex	NATURE			English	Article							RIBOSOMAL-RNA; SELECTION; SEQUENCE; INVITRO; LOOPS; DNA	THE catalytic properties of RNA(1,2) and its well known role in gene expression and regulation are the consequence of its unique solution structures, Identification of the structural determinants of ligand recognition by]RNA molecules is of fundamental importance for understanding the biological functions of RNA, as well as for the rational design of RNA sequences with specific catalytic activities(3-6). Towards this latter end, Szostak et al(7,8) used in vitro selection techniques to isolate RNA sequences ('aptamers') containing a high-affinity binding site for ATP, the universal currency of cellular energy, and then used this motif to engineer ribozymes with polynucleotide kinase activity, Here we present the solution structure, as determined by multidimensional NMR spectroscopy and molecular dynamics calculations, of both uniformly and specifically C-13-, N-15-labelled 40-mer RNA containing the ATP-binding motif complexed with AMP, The aptamer adopts an L-shaped structure with two nearly orthogonal stems, each capped proximally by a G . G mismatch pair, binding the AMP ligand at their junction in a GNRA-like motif.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08855	Memorial Sloan Kettering Cancer Center; Rutgers State University New Brunswick			Jones, Roger A./GRY-0637-2022	Jones, Roger A./0000-0002-6835-6615				ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; Battiste JL, 1995, J BIOMOL NMR, V6, P375; Brunger A. T., 1992, X PLOR SYSTEM X RAY; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ELLINGTON A, 1990, NATURE, V346, P812; Fan P, 1996, J MOL BIOL, V258, P480, DOI 10.1006/jmbi.1996.0263; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KOLE R, 1981, BIOCHEMISTRY-US, V20, P1902, DOI 10.1021/bi00510a028; Koshland D E Jr, 1971, Harvey Lect, V65, P33; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4508; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; Pardi A, 1995, METHOD ENZYMOL, V261, P350; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; YE X, 1995, J CHEM BIOL, V2, P827	28	225	237	3	94	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					183	186		10.1038/382183a0	http://dx.doi.org/10.1038/382183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700212				2022-12-28	WOS:A1996UW67200055
J	Xu, QL; Alldus, G; Macdonald, R; Wilkinson, DG; Holder, N				Xu, QL; Alldus, G; Macdonald, R; Wilkinson, DG; Holder, N			Function of the Eph-related kinase rtk1 in patterning of the zebrafish forebrain	NATURE			English	Article							TYROSINE KINASE; BRAIN; INDUCTION; MESODERM	EARLY during its development, the vertebrate brain is subdivided into regions that have distinct fates and correlate with the expression domains of regulatory genes(1,2), but little is known about the cell-cell interactions that establish this spatial pattern. Candidates for regulating such interactions are the Eph-related receptor tyrosine kinases (RTKs) which have spatially restricted expression in the developing brain(2-6). These RTKs may mediate cell-contact-dependent signalling by interacting with membrane-bound ligands, and have been implicated in axon repulsion(8,9) and the segmental restriction of gene expression in the hindbrain(10), but nothing is known regarding their function in the rostral neural epithelium. Here we use a dominant-negative approach in the zebrafish embryo to interfere with the function of Rtk1, an Eph-related RTK expressed in the developing diencephalon. We find that expression of a truncated receptor leads to expansion of the eye field into diencephalic territory and loss of diencephalic structures, indicating a role for Rtk1 in patterning the developing forebrain.	UNIV LONDON KINGS COLL,RANDALL INST,DBRC,LONDON WC2B 5RL,ENGLAND; NATL INST MED RES,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND	University of London; King's College London; MRC National Institute for Medical Research				Wilkinson, David/0000-0001-6757-7080				ALLENDE ML, 1994, DEV BIOL, V166, P509, DOI 10.1006/dbio.1994.1334; ALVARADOMALLART RM, 1990, DEV BIOL, V139, P75, DOI 10.1016/0012-1606(90)90280-V; AMAYA E, 1991, CELL, V66, P256; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHUNG SH, 1975, NATURE, V258, P126, DOI 10.1038/258126a0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; NAKAMURA H, 1986, CELL DIFFER DEV, V19, P187, DOI 10.1016/0045-6039(86)90095-3; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PAPALOPULU N, 1995, PERSPECT DEV NEUROBI, V3, P39; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; RUBENSTEIN JLR, 1994, CURR TOP DEV BIOL, V29, P1, DOI 10.1016/S0070-2153(08)60546-3; SCHMITT EA, 1994, J COMP NEUROL, V344, P532, DOI 10.1002/cne.903440404; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WOO K, 1995, DEVELOPMENT, V121, P2595; XU QL, 1994, DEVELOPMENT, V120, P287; Xu QL, 1995, DEVELOPMENT, V121, P4005	28	109	111	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					319	322		10.1038/381319a0	http://dx.doi.org/10.1038/381319a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692269				2022-12-28	WOS:A1996UM40300055
J	Knowlton, BJ; Mangels, JA; Squire, LR				Knowlton, BJ; Mangels, JA; Squire, LR			A neostriatal habit learning system in humans	SCIENCE			English	Article							MULTIPLE MEMORY-SYSTEMS; FRONTAL-LOBE DAMAGE; EARLY PARKINSONS-DISEASE; CAUDATE-NUCLEUS LESIONS; MEDIAL TEMPORAL-LOBE; DOUBLE DISSOCIATION; IMPLICIT MEMORY; HUNTINGTONS-DISEASE; MAZE TASKS; HIPPOCAMPUS	Amnesic patients and nondemented patients with Parkinson's disease were given a probabilistic classification task in which they learned which of two outcomes would occur on each trial, given the particular combination of cues that appeared. Amnesic patients exhibited normal learning of the task but had severely impaired declarative memory for the training episode. In contrast, patients with Parkinson's disease failed to learn the probabilistic classification task, despite having intact memory for the training episode. This double dissociation shows that the limbic-diencephalic regions damaged in amnesia and the neostriatum damaged in Parkinson's disease support separate and parallel learning systems. In humans, the neostriatum (caudate nucleus and putamen) is essential for the gradual, incremental learning of associations that is characteristic of habit learning. The neostriatum is important not just for motor behavior and motor learning but also for acquiring nonmotor dispositions and tendencies that depend on new associations.	VET AFFAIRS MED CTR,SAN DIEGO,CA 92161; UNIV CALIF LOS ANGELES,DEPT PSYCHOL,LOS ANGELES,CA 90024; BAYCREST CTR GERIATR CARE,ROTMAN RES INST,N YORK,ON,CANADA; UNIV TORONTO,TORONTO,ON M6A 2E1,CANADA; UNIV CALIF SAN DIEGO,SCH MED,DEPT PSYCHIAT,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT NEUROSCI,LA JOLLA,CA 92093	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH024600, R01MH024600] Funding Source: NIH RePORTER; NIMH NIH HHS [MH24600] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BONDI MW, 1991, J CLIN EXP NEUROPSYC, V13, P339, DOI 10.1080/01688639108401048; Bondi MW, 1993, NEUROPSYCHOLOGY, V7, P89, DOI DOI 10.1037/0894-4105.7.1.89; BUTTERS N, 1990, B PSYCHONOMIC SOC, V28, P359; CHAO LL, 1995, NEUROREPORT, V6, P1605, DOI 10.1097/00001756-199508000-00005; ESTES WK, 1972, J AM STAT ASSOC, V67, P81; Fahn S, 1987, RECENT DEV PARKINSON; GABRIELI JDE, 1995, PSYCHOL SCI, V6, P76, DOI 10.1111/j.1467-9280.1995.tb00310.x; GOTHAM AM, 1988, BRAIN, V111, P229; Graybiel AM, 1995, CURR OPIN NEUROBIOL, V5, P733, DOI 10.1016/0959-4388(95)80100-6; HARRINGTON DL, 1990, J CLIN EXP NEUROPSYC, V12, P323, DOI 10.1080/01688639008400978; Heaton R.K., 1993, WISCONSIN CARD SORTI; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; KEANE MM, 1995, BRAIN, V118, P1129, DOI 10.1093/brain/118.5.1129; KNOPMAN D, 1991, NEUROPSYCHOLOGIA, V29, P245, DOI 10.1016/0028-3932(91)90085-M; Knowlton B J, 1994, Learn Mem, V1, P106; KNOWLTON BJ, IN PRESS NEUROPSYCHO; LEES AJ, 1983, BRAIN, V106, P257, DOI 10.1093/brain/106.2.257; Mangels JA, 1996, NEUROPSYCHOLOGY, V10, P32, DOI 10.1037/0894-4105.10.1.32; MATTIS S, 1976, GERIATRIC PSYCHIATRY; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; OSTERGAARD AL, 1994, Q J EXP PSYCHOL-A, V47, P331, DOI 10.1080/14640749408401115; OWEN AM, 1995, NEUROPSYCHOLOGY, V9, P126, DOI 10.1037/0894-4105.9.1.126; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; PACKARD MG, 1992, BEHAV NEUROSCI, V106, P439, DOI 10.1037/0735-7044.106.3.439; PACKARD MG, 1989, J NEUROSCI, V9, P1465; PAULSEN JS, 1993, NEUROPSYCHOLOGY, V7, P73; PERLMUTTER JS, 1985, NEUROLOGY, V35, P1127, DOI 10.1212/WNL.35.8.1127; POLICH J, 1993, ELECTROEN CLIN NEURO, V86, P408, DOI 10.1016/0013-4694(93)90136-J; REBER PJ, IN PRESS BEHAV NEURO; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SAINTCYR JA, 1992, NEUROPSYCHOLOGICAL D, P204; SALMON DP, 1995, CURR OPIN NEUROBIOL, V5, P184, DOI 10.1016/0959-4388(95)80025-5; SCATTON B, 1982, NEUROLOGY, V32, P1039, DOI 10.1212/WNL.32.9.1039; Schacter D. L., 1994, MEMORY SYSTEMS 1994; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SHANKS DR, 1994, BEHAV BRAIN SCI, V17, P367, DOI 10.1017/S0140525X00035032; SHIMAMURA AP, 1995, J COGNITIVE NEUROSCI, V7, P144, DOI 10.1162/jocn.1995.7.2.144; SHIMAMURA AP, 1988, J NEUROSCI, V8, P4400; SQUIRE L, UNPUB; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; SQUIRE LR, 1994, COGNITIVE NEUROSCIEN, P825; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; TAYLOR AE, 1990, BRAIN COGNITION, V13, P211, DOI 10.1016/0278-2626(90)90051-O; TEUBER HL, 1955, ANNU REV PSYCHOL, V9, P267; VRIEZEN ER, 1990, NEUROPSYCHOLOGIA, V28, P1283, DOI 10.1016/0028-3932(90)90044-O; WEISKRANTZ L, 1990, PHILOS T ROY SOC B, V329, P99, DOI 10.1098/rstb.1990.0154; WEISKRANTZ L, 1968, ANAL BEHAVIORAL CHAN, P415; WILLINGHAM DB, 1993, PSYCHOBIOLOGY, V21, P173; Wise SP, 1996, SEMIN NEUROSCI, V8, P39, DOI 10.1006/smns.1996.0006; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	58	1205	1214	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1399	1402		10.1126/science.273.5280.1399	http://dx.doi.org/10.1126/science.273.5280.1399			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VF610	8703077				2022-12-28	WOS:A1996VF61000046
J	Burns, A; Murphy, D				Burns, A; Murphy, D			Protection against Alzheimer's disease?	LANCET			English	Editorial Material							ESTROGEN REPLACEMENT THERAPY; OLDER WOMEN		INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	Burns, A (corresponding author), UNIV MANCHESTER,WITHINGTON HOSP,MANCHESTER M20 8LR,LANCS,ENGLAND.			Burns, Alistair/0000-0002-9837-0645				BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; GOULD E, 1990, J NEUROSCI, V10, P1286; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; ROBINSON D, 1994, J AM GERIATR SOC, V42, P919, DOI 10.1111/j.1532-5415.1994.tb06580.x	7	25	25	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					420	421		10.1016/S0140-6736(05)64533-3	http://dx.doi.org/10.1016/S0140-6736(05)64533-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709777				2022-12-28	WOS:A1996VC67300004
J	Geraghty, J				Geraghty, J			Adenomatous polyposis coli and translational medicine	LANCET			English	Editorial Material											Geraghty, J (corresponding author), EUROPEAN INST ONCOL,DEPT GEN SURG ONCOL,I-20141 MILAN 135,ITALY.							BESS MA, 1980, ARCH SURG-CHICAGO, V115, P460; BUSSEY HJR, 1985, BRIT J SURG, V72, pS29, DOI 10.1002/bjs.1800721318; NAGASE H, 1992, CANCER RES, V52, P4055; 1996, J CLIN ONCOL, V14, P1730	4	24	84	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					422	422		10.1016/S0140-6736(05)64535-7	http://dx.doi.org/10.1016/S0140-6736(05)64535-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709779				2022-12-28	WOS:A1996VC67300006
J	Laird, L; Dezateux, C; Anionwu, EN				Laird, L; Dezateux, C; Anionwu, EN			Neonatal screening for sickle cell disorders: What about the carrier infants?	BRITISH MEDICAL JOURNAL			English	Article							DRIED BLOOD SPECIMENS; NON-PATERNITY; DISEASE; HEMOGLOBINOPATHIES; PERCEPTIONS; DIAGNOSIS; GENETICS; CHILDREN; BLOTTERS; LIQUID		INST CHILD HLTH, DEPT EPIDEMIOL & BIOSTAT, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DEPT CLIN GENET & FETAL MED, LONDON WC1N 1EH, ENGLAND	University of London; University College London; University of London; University College London			Dezateux, Carol/A-3416-2009	Dezateux, Carol/0000-0001-9787-6276	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADJAYE N, 1989, ARCH DIS CHILD-FETAL, V64, P39, DOI 10.1136/adc.64.1_Spec_No.39; Anionwu EN, 1996, J ADV NURS, V23, P853; ANIONWU EN, 1993, RACE HLTH CONT BRITA, P76; ANIONWU EN, 1996, RES CULTURAL DIFFERE, P160; ANTLEY MA, 1973, J PSYCHOL, V83, P335, DOI 10.1080/00223980.1973.9915623; BALARAJAN R, 1993, ETHNICITY HLTH GUIDE; Ballas S K, 1994, J Med Screen, V1, P229; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BROCK DJH, 1991, LANCET, V338, P1151, DOI 10.1016/0140-6736(91)92013-R; Choiseul M, 1988, Health Visit, V61, P205; CLARKE A, 1994, J MED GENET, V31, P785, DOI 10.1136/jmg.31.10.785; *COMM ASS GEN RISK, 1994, ASS GEN RISKS IMPL H; COOLING H, 1986, BRIT MED J, V292, P958, DOI 10.1136/bmj.292.6525.958-a; DALBY S, 1995, J MED GENET, V32, P490, DOI 10.1136/jmg.32.6.490; DAVIES SC, 1994, INT CONGR SER, V1041, P195; EBOH W, 1995, BRIT J MIDWIFERY, V3, P189; GITHENS JH, 1990, AM J DIS CHILD, V144, P466, DOI 10.1001/archpedi.1990.02150280088018; GRIFFITHS PD, 1988, BRIT MED J, V296, P1583, DOI 10.1136/bmj.296.6636.1583; GROSSMAN LK, 1985, AM J DIS CHILD, V139, P241, DOI 10.1001/archpedi.1985.02140050035016; HAMPTON ML, 1974, AM J DIS CHILD, V128, P58, DOI 10.1001/archpedi.1974.02110260060010; HORN MEC, 1986, BRIT MED J, V292, P737, DOI 10.1136/bmj.292.6522.737; HURST D, 1989, PEDIATRICS, V83, P868; JINKS DC, 1989, HUM GENET, V81, P363, DOI 10.1007/BF00283692; Lorey Fred, 1994, European Journal of Human Genetics, V2, P262; MACINTYRE S, 1991, LANCET, V338, P869, DOI 10.1016/0140-6736(91)91513-T; MARKEL H, 1992, AM J MED, V93, P209, DOI 10.1016/0002-9343(92)90052-D; MARTEAU T, 1995, BRIT MED J, V311, P58, DOI 10.1136/bmj.311.6996.58c; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; Marteau TM, 1996, TROUBLED HELIX SOCIA, P123; MCCABE ERB, 1987, HUM GENET, V75, P213, DOI 10.1007/BF00281061; *NHS MAN EX, 1994, SICKL CELL AN; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; PAPADEA C, 1994, PEDIATRICS, V93, P427; PELIAS MZ, 1991, AM J MED GENET, V39, P347, DOI 10.1002/ajmg.1320390320; ROBERTS BE, 1988, CLIN LAB HAEMATOL, V10, P87; ROWLEY PT, 1989, PEDIATRICS, V83, P891; Science and Technology Committee, 1995, HUM GEN SCI ITS CONS; Sears David A., 1994, P381; Serjeant GR, 1992, SICKLE CELL DIS, P415; SHICKLE D, 1989, J MED GENET, V26, P109, DOI 10.1136/jmg.26.2.109; *SICKL CELL SOC, 1981, SICKL CELL DIS NEED; Sickle Cell Disease Guideline Panel, 1993, SICKL CELL DIS SCREE, V6; SMITH T, 1995, BRIT MED J, V311, P574, DOI 10.1136/bmj.311.7004.574a; *STAND MED ADV COM, 1994, SICKL CELL THAL OTH; STATHAM H, 1993, BRIT MED J, V306, P858, DOI 10.1136/bmj.306.6881.858-c; STEPHENS A, 1987, SICKLE CELL ANAEMIA, P11; WOOLDRIDGE EQ, 1988, SOC BIOL, V35, P123; *WORK PART PREN DI, 1989, PREN DIAGN GEN SCREE; ZEESMAN S, 1984, AM J MED GENET, V18, P769, DOI 10.1002/ajmg.1320180424; ZHANG YH, 1992, HUM GENET, V89, P311; 1987, BRIT MED J, V295, P1551	51	42	42	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					407	411						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761233				2022-12-28	WOS:A1996VD20600031
J	Bouwmeester, T; Kim, SH; Sasai, Y; Lu, B; DeRobertis, EM				Bouwmeester, T; Kim, SH; Sasai, Y; Lu, B; DeRobertis, EM			Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer	NATURE			English	Article							XENOPUS-LAEVIS EMBRYOS; HOMEO-BOX GENE; NEURAL INDUCTION; BLASTOPORE LIP; GASTRULATION; MESODERM; CLONING; DOMAIN; NOGGIN; AXIS	An abundant cDNA enriched in Spemann's organizer, cerberus, was isolated by differential screening. It encodes a secreted protein that is expressed in the anterior endomesoderm. Microinjection of cerberus mRNA into Xenopus embryos induces ectopic heads, and duplicated hearts and livers. The results suggest a role for a molecule expressed in the anterior endoderm in the induction of head structures in the vertebrate embryo.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869				ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; BLITZ IL, 1995, DEVELOPMENT, V121, P993; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DALE L, 1987, DEVELOPMENT, V99, P527; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GONT LK, 1993, DEVELOPMENT, V119, P991; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAUSEN P, 1991, EARLY DEV XENOPUS; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HOLTPRETER J., 1938, WILHELM RAUX ARCH ENTWICKLUNGSMECH ORGAN, V138, P522, DOI 10.1007/BF00573814; JONES CM, 1995, DEVELOPMENT, V121, P3651; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MOOS M, 1995, DEVELOPMENT, V121, P4239; NASCONE N, 1995, DEVELOPMENT, V121, P515; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Nieuwkoop P. D., 1950, Archives de Biologie Liege, V61, P113; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; PANNESE M, 1995, DEVELOPMENT, V121, P707; PASTEELS J., 1949, ARCH BIOL, V60, P235; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SASAI Y, IN PRESS EMBO J; SATER AK, 1990, DEVELOPMENT, V108, P461; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SIVE HL, 1989, CELL, V58, P170; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; VODICKA MA, 1995, DEVELOPMENT, V121, P3505; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; ZARAISKY AG, 1995, DEVELOPMENT, V121, P3839	48	617	647	1	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					595	601		10.1038/382595a0	http://dx.doi.org/10.1038/382595a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757128				2022-12-28	WOS:A1996VC30300043
J	Curnow, AW; Ibba, M; Soll, D				Curnow, AW; Ibba, M; Soll, D			tRNA-dependent asparagine formation	NATURE			English	Letter							TRANSFER-RNA-SYNTHETASE				Curnow, AW (corresponding author), YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,POB 6666,NEW HAVEN,CT 06520, USA.							Baron Christian, 1995, P529; BAYLEY ST, 1971, METHOD MOL BIOL, V1, P89; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; DOOLITTLE RF, 1995, P NATL ACAD SCI USA, V92, P2421, DOI 10.1073/pnas.92.7.2421; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GUPTA R, 1984, J BIOL CHEM, V259, P9461; Hong KW, 1996, EMBO J, V15, P1983, DOI 10.1002/j.1460-2075.1996.tb00549.x; JimenezSanchez A, 1995, J MOL EVOL, V41, P712; Kim SI, 1996, NUCLEIC ACIDS RES, V24, P2648, DOI 10.1093/nar/24.14.2648; SCHON A, 1988, BIOCHIMIE, V70, P391, DOI 10.1016/0300-9084(88)90212-X; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WHITE BN, 1972, CAN J BIOCHEM CELL B, V50, P600, DOI 10.1139/o72-082; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229	17	139	144	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					589	590		10.1038/382589b0	http://dx.doi.org/10.1038/382589b0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757127				2022-12-28	WOS:A1996VC30300034
J	Fink, GR; Halligan, PW; Marshall, JC; Frith, CD; Frackowiak, RSJ; Dolan, RJ				Fink, GR; Halligan, PW; Marshall, JC; Frith, CD; Frackowiak, RSJ; Dolan, RJ			Where in the brain does visual attention select the forest and the trees?	NATURE			English	Article							HUMANS; CORTEX; AREAS; ORGANIZATION; STIMULI; V2	THE perceptual world is organized hierarchically: the forest consists of trees, which in turn have leaves, Visual attention can emphasize the overall picture (global form) or the focal details of a scene (local components)(1). Neuropsychological studies have indicated that the left hemisphere is biased towards local and the right towards global processing, The underlying attentional and perceptual mechanisms are maximally impaired by unilateral lesions to the temporal and parietal cortex(2,3). We measured brain activity of normal subjects during two experiments using 'hierarchically' organized figures, In a directed attention task, early visual processing (prestriate) areas were activated: attention to the global aspect of the figures activated the right lingual gyrus whereas locally directed attention activated the left inferior occipital cortex. In a subsequent divided attention task, the number of target switches from local to global (and vice versa) covaried with temporal-parietal activation, The findings provide direct evidence for hemispheric specialization in global and local perception; furthermore, they indicate that temporal-parietal areas exert attentional control over the neural transformations occurring in prestriate cortex.	INST NEUROL,WELLCOME DEPT COGNIT NEUROL,LONDON WC1N 3BG,ENGLAND; RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND; RADCLIFFE INFIRM,UNIV DEPT CLIN NEUROL,NEUROPSYCHOL UNIT,OXFORD OX2 6HE,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON NW3 2PF,ENGLAND	University of London; University College London; Radcliffe Infirmary; University of Oxford; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Fink, Gereon R./AFW-9377-2022; Frackowiak, Richard/H-4383-2011; Fink, Gereon R./E-1616-2012; Frackowiak, Richard S/I-1809-2013; Halligan, Peter W/A-1669-2010; Frith, Chris D/A-2171-2009	Fink, Gereon R./0000-0002-8230-1856; Frackowiak, Richard/0000-0002-3151-822X; Fink, Gereon R./0000-0002-8230-1856; Halligan, Peter W/0000-0003-2784-6690; Frith, Chris D/0000-0002-8665-0690; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CLARKE S, 1994, EUR J NEUROSCI, V6, P725, DOI 10.1111/j.1460-9568.1994.tb00984.x; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; Friston K, 1995, HUM BRAIN MAPP, V2, P1; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; Hellige J. B., 1993, HEMISPHERIC ASYMMETR; MARSHALL JC, 1995, NATURE, V373, P521, DOI 10.1038/373521a0; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; POLSTER MR, 1994, CORTEX, V30, P487, DOI 10.1016/S0010-9452(13)80344-9; Rafal Robert, 1995, P625; ROBERTSON LC, 1988, J NEUROSCI, V8, P3757; ROBERTSON LC, 1991, COGNITIVE PSYCHOL, V23, P299, DOI 10.1016/0010-0285(91)90012-D; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SHIPP S, 1995, NEUROIMAGE, V2, P125, DOI 10.1006/nimg.1995.1015; SILBERSWEIG DA, 1993, J CEREBR BLOOD F MET, V13, P617, DOI 10.1038/jcbfm.1993.80; Talairach J., 1988, COPLANAR STEREOTAXIC; TIPPER SP, 1994, Q J EXP PSYCHOL-A, V47, P809, DOI 10.1080/14640749408401098	19	503	514	6	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					626	628		10.1038/382626a0	http://dx.doi.org/10.1038/382626a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VC303	8757132	Green Submitted			2022-12-28	WOS:A1996VC30300052
J	Sorensen, TIA				Sorensen, TIA			Which patients may be harmed by good treatments?	LANCET			English	Editorial Material							METAANALYSIS; CIRRHOSIS; TRIALS				Sorensen, TIA (corresponding author), UNIV COPENHAGEN HOSP,INST PREVENT MED,COPENHAGEN TRIAL UNIT,DK-2100 COPENHAGEN,DENMARK.							CHRISTENSEN E, 1985, GASTROENTEROLOGY, V88, P156, DOI 10.1016/S0016-5085(85)80148-7; Horwitz RI, 1996, J CLIN EPIDEMIOL, V49, P395, DOI 10.1016/0895-4356(95)00058-5; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; MOLLER S, 1992, J HEPATOL, V15, P184, DOI 10.1016/0168-8278(92)90034-M; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; 1974, NEW ENGL J MED, V291, P271	7	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					351	352		10.1016/S0140-6736(05)64988-4	http://dx.doi.org/10.1016/S0140-6736(05)64988-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709730				2022-12-28	WOS:A1996VB42600006
J	Hanahan, D; Folkman, J				Hanahan, D; Folkman, J			Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis	CELL			English	Review							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; PLATELET FACTOR-IV; TRANSGENIC MICE; TUMOR ANGIOGENESIS; PANCREATIC-ISLETS; FACTOR EXPRESSION; POTENT INHIBITOR; BREAST-CARCINOMA; CELL MOTILITY		CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Hanahan, D (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; Arbeit JM, 1996, CANCER SURV, V26, P7; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1996, IN PRESS ONCOGENE; AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BOUCK N, 1996, IN PRESS ADV CANC RE, V69; BREM S, 1976, CANCER RES, V36, P2807; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROUTYBOYE D, 1980, SCIENCE, V208, P516, DOI 10.1126/science.6154315; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BROWN LF, 1996, IN PRESS CONTROL ANG; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; CHRISTOFORI G, 1995, NAT GENET, V10, P496; CHRISTOFORI G, 1996, IN PRESS TUMOR ANGIO; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; COCKERILL GW, 1995, INT REV CYTOL, V159, P113, DOI 10.1016/S0074-7696(08)62106-3; COUSSENS LM, 1996, IN PRESS AM J PATH; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FERRARA N, 1991, ENDOCRINOLOGY, V129, P896, DOI 10.1210/endo-129-2-896; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1995, MOL BASIS CANC, P206; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; FROST P, 1995, CANCER METAST REV, V14, P77; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOTO F, 1993, LAB INVEST, V69, P508; Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; GUIDI AJ, 1994, J NATL CANCER I, V86, P614, DOI 10.1093/jnci/86.8.614; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HOBSON B, 1984, BRIT J CANCER, V49, P405, DOI 10.1038/bjc.1984.66; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Joukov V, 1996, EMBO J, V15, P290; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; LACEY M, 1986, NATURE, V322, P609, DOI 10.1038/322609a0; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NAIK P, 1994, MOL GENETICS CANC, P459; NELSON J, 1995, CANCER RES, V55, P3772; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PARANGI S, 1995, CANCER RES, V55, P6071; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SATO Y, 1990, BIOCHEM BIOPH RES CO, V172, P595, DOI 10.1016/0006-291X(90)90715-Y; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; SIDKY YA, 1987, CANCER RES, V47, P5155; SIPPOLATHIELE M, 1988, MOL CELL BIOL, V9, P925; SMITHMCCUNE KK, 1994, CANCER RES, V54, P800; STEIN I, 1995, MOL CELL BIOL, V15, P5363; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; TEICHER BA, 1992, CANCER RES, V52, P6702; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401	80	5535	5966	4	317	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					353	364		10.1016/S0092-8674(00)80108-7	http://dx.doi.org/10.1016/S0092-8674(00)80108-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756718	Bronze			2022-12-28	WOS:A1996VC30900004
J	Hyman, SE				Hyman, SE			Shaking out the cause of addiction	SCIENCE			English	Article											Hyman, SE (corresponding author), NIMH,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CAREW TJ, 1996, J PHARMACOL EXP THER, V16, P5; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; MALDONADO R, 1992, J PHARMACOL EXP THER, V261, P669; MALDONADO R, 1996, SCIENCE, V273, P658; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; NESTLER EJ, 1996, NEURON, V16, P901	8	27	28	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					611	612		10.1126/science.273.5275.611	http://dx.doi.org/10.1126/science.273.5275.611			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8701316				2022-12-28	WOS:A1996VA24900036
J	vonKries, R; Gobel, U; Hachmeister, A; Kaletsch, U; Michaelis, J				vonKries, R; Gobel, U; Hachmeister, A; Kaletsch, U; Michaelis, J			Vitamin K and childhood cancer: A population based case-control study in Lower Saxony, Germany	BRITISH MEDICAL JOURNAL			English	Article								Objective-To confirm or refute a possible association of parenteral vitamin K prophylaxis and childhood cancer. Design-Population based case-control study. Comparison of vitamin K exposure in children with leukaemia or other common tumours with two control groups. Setting-State of Lower Saxony (north western part of Germany); case recruitment from the German childhood cancer registry. Subjects-272 children with leukaemia, nephroblastoma, neuroblastoma, rhabdomyosarcoma, and tumours of the central nervous system diagnosed between 1 July 1988 and 30 June 1993; children were aged between 30 days and 15 years at diagnosis. 334 population based controls without diagnoses of cancer matched to the leukaemia cases for age and sex. Main exposure measures-Parenteral vitamin K prophylaxis (intramuscular and subcutaneous) versus oral and no vitamin K prophylaxis. Results-An association between parenteral vitamin K exposure and childhood cancer (leukaemias and other tumours combined) could not be confirmed (odds ratio 1.04, 95% confidence interval 0.74 to 1.48). For leukaemias the observed odds ratio was only 0.98 (0.64 to 1.50) (comparison of leukaemia cases with local controls 1.24 (0.68 to 2.25); state controls 0.82 (0.50 to 1.36)). These odds ratios remained almost unchanged when several potential confounders were considered in the logistic regression model. Conclusions-This population based study adds substantial evidence that there is no association between parenteral vitamin K and childhood cancer.	UNIV DUSSELDORF,KINDERKLIN,D-40225 DUSSELDORF,GERMANY; UNIV MAINZ,INST MED STAT & DOKUMENTAT,D-55131 MAINZ,GERMANY	Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz								DRAPER G, 1994, BRIT MED J, V308, P867, DOI 10.1136/bmj.308.6933.867; DRAPER GJ, 1992, BRIT MED J, V305, P709, DOI 10.1136/bmj.305.6855.709; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; KAATSCH P, 1995, EUR J CANCER, V31A, P993, DOI 10.1016/0959-8049(95)00091-7; KAATSCH P, IN PRESS CLIN PAEDIA; KALETSCH U, 1995, FALLKONTROLL STUDIE; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; MILLER RW, 1992, BMJ-BRIT MED J, V305, P1016, DOI 10.1136/bmj.305.6860.1016-c; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; PASSMORE SJ, 1993, BRIT MED J, V307, P1140, DOI 10.1136/bmj.307.6912.1140; *SAS I, 1992, P229 SAS STAT; SAS Institute, 1990, SAS STAT US GUID, V2; 1986, DTSCH ARZTEBLATT, V83, P3380	14	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					199	203		10.1136/bmj.313.7051.199	http://dx.doi.org/10.1136/bmj.313.7051.199			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696195	Green Published			2022-12-28	WOS:A1996VA12600024
J	Pontieri, FE; Tanda, G; Orzi, F; DiChiara, G				Pontieri, FE; Tanda, G; Orzi, F; DiChiara, G			Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs	NATURE			English	Article							CEREBRAL GLUCOSE-UTILIZATION; FREELY MOVING RATS	THE question of whether nicotine, the neuroactive compound of tobacco, is addictive has been open to considerable scientific and public discussion. Although it can serve as a positive reinforcer in several animal species, including man, nicotine is thought to be a weak reinforcer in comparison with addictive drugs such as cocaine and heroin(1,2), and has been argued to be habit forming but not addictive(3,4). Here we report that intravenous nicotine in the rat, at doses known to maintain self-administration, stimulates local energy metabolism, as measured by 2-deoxyglucose autoradiography, and dopamine transmission, as estimated by brain microdialysis, in the shell of the nucleus accumbens. These neurochemical and metabolic effects are qualitatively similar to those of other drugs, such as cocaine, amphetamine and morphine, which have strong addictive properties(5-7). Our results provide functional and neurochemical evidence that there are specific neurobiological commonalities between nicotine and addictive drugs.	UNIV CAGLIARI, DEPT TOXICOL, I-09126 CAGLIARI, ITALY; UNIV ROMA LA SAPIENZA, DEPT NEUROSCI, I-00185 ROME, ITALY; INM NEUROMED, POZILLI, IS, ITALY	University of Cagliari; Sapienza University Rome; IRCCS Neuromed			Di Chiara, Gaetano/I-7835-2013; Tanda, Gianluigi/B-3318-2009; Tanda, Gianluigi/Q-4976-2019; PONTIERI, FRANCESCO ERNESTO/K-4232-2018	Tanda, Gianluigi/0000-0001-9526-9878; Tanda, Gianluigi/0000-0001-9526-9878; PONTIERI, FRANCESCO ERNESTO/0000-0002-8693-8432; Orzi, Francesco/0000-0003-1048-4662				ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; CORRIGALL WA, 1991, ADV PHAR SC, P423; CRANE AM, 1989, BRAIN RES, V499, P87, DOI 10.1016/0006-8993(89)91137-2; DAMSMA G, 1989, EUR J PHARMACOL, V168, P368; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DICHIARA G, 1990, TRENDS PHARMACOL SCI, V11, P116, DOI 10.1016/0165-6147(90)90197-G; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; GRUNWALD F, 1987, BRAIN RES, V400, P232, DOI 10.1016/0006-8993(87)90622-6; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; HENNINGFIELD JE, 1995, PSYCHOPHARMACOLOGY, V117, P11, DOI 10.1007/BF02245089; IMPERATO A, 1986, EUR J PHARMACOL, V132, P337, DOI 10.1016/0014-2999(86)90629-1; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LONDON ED, 1988, J NEUROSCI, V8, P3920; MCNAMARA D, 1990, J CEREBR BLOOD F MET, V10, P48, DOI 10.1038/jcbfm.1990.7; ORZI F, IN PRESS EUR J PHARM; PAXINOS G, 1987, RAT BRAIN STEREOTAXI; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; PONTIERI FE, 1994, NEUROREPORT, V5, P2561, DOI 10.1097/00001756-199412000-00039; PORRINO LJ, 1993, PSYCHOPHARMACOLOGY, V112, P343, DOI 10.1007/BF02244931; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STOLERMAN IP, 1987, HDB PSYCHOPHARMACOLO, P421; SWEDBERG MDB, 1990, NICOTINE PSYCHOPHARM, P38; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147; Ungerstedt U, 1984, MEASUREMENT NEUROTRA, P81; WARBURTON DM, 1989, PHARM NICOTINE, P359; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	28	844	874	1	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					255	257		10.1038/382255a0	http://dx.doi.org/10.1038/382255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717040				2022-12-28	WOS:A1996UX79000050
J	Riek, R; Hornemann, S; Wider, G; Billeter, M; Glockshuber, R; Wuthrich, K				Riek, R; Hornemann, S; Wider, G; Billeter, M; Glockshuber, R; Wuthrich, K			NMR structure of the mouse prion protein domain PrP(121-231)	NATURE			English	Article							DISEASES	THE 'protein only' hypothesis(1) states that a modified form of normal prion protein triggers infectious neurodegenerative diseases, such as bovine spongiform encephalopathy (BSE), or Creutzfeldt-Jakob disease (CJD) in humans(2-4). Prion proteins are thought to exist in two different conformations(5): the 'benign' PrPC form, and the infections 'scrapie form', PrPSc. Knowledge of the three-dimensional structure of PrPC is essential for understanding the transition to PrPSc. The nuclear magnetic resonance (NMR) structure of the autonomously folding PrP domain comprising residues 121-231 (ref. 6) contains a two-stranded antiparallel beta-sheet and three alpha-helices. This domain contains most of the point-mutation sites that have been linked, in human PrP, to the occurrence of familial prion diseases(7). The NMR structure shows that these mutations occur within, or directly adjacent to, regular secondary structures, The presence of a beta-sheet in PrP(121-231) is in contrast with model predictions of an all-helical structure of PrPC (ref. 8), and may be important for the initiation of the transition from PrPC to PrPSc.	ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Billeter, Martin/A-8293-2010	Wider, Gerhard/0000-0001-9366-7645; Riek, Roland/0000-0002-6333-066X				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Cavanagh J., 1996, PROTEIN NMR SPECTROS; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; CORNELL, 1995, J AM CHEM SOC, V117, P5179; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HORNEMANN S, IN PRESS J MOL BIOL; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; STAHL N, 1991, FASEB J, V5, P2799, DOI 10.1096/fasebj.5.13.1916104; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; WEISSMANN C, 1995, NATURE, V375, P628, DOI 10.1038/375628a0; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; Wuthrich K, 1986, NMR PROTEINS NUCL AC	26	1022	1045	1	122	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					180	182		10.1038/382180a0	http://dx.doi.org/10.1038/382180a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700211				2022-12-28	WOS:A1996UW67200054
J	Rieder, HL				Rieder, HL			Repercussions of the Karonga prevention trial for tuberculosis control	LANCET			English	Editorial Material											Rieder, HL (corresponding author), INT UNION AGAINST TB & LUNG DIS,68 BLVD ST MICHEL,F-75006 PARIS,FRANCE.							[Anonymous], 1995, Wkly Epidemiol Rec, V70, P229; Baily G V, 1980, Indian J Med Res, V72 Suppl, P1; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; 1980, LANCET, V1, P73	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					4	4		10.1016/S0140-6736(05)64349-8	http://dx.doi.org/10.1016/S0140-6736(05)64349-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691932				2022-12-28	WOS:A1996UV92300004
J	Todd, G; Dunlop, K; McNaboe, J; Ryan, MF; Carson, D; Shields, MD				Todd, G; Dunlop, K; McNaboe, J; Ryan, MF; Carson, D; Shields, MD			Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate	LANCET			English	Article								Background Fluticasone propionate was introduced in 1993 in the UK as a potentially safer inhaled corticosteroid than those already in use. The efficacy and safely of fluticasone has been established at recommended doses of 200 mu g/day, but not at the higher doses that are often used. Methods Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder). Assessment of cortisol response was by insulin-induced hypoglycaemia in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one. Findings Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression. In one case the growth rate and cortisol response returned to normal 9 months after the fluticasone dose was reduced to 500 mu g/day. Interpretation When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.	ROYAL BELFAST HOSP SICK CHILDREN,BELFAST,ANTRIM,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT CHILD HLTH,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	Queens University Belfast	Todd, G (corresponding author), ANTRIM HOSP,BELFAST BT41 2RL,ANTRIM,NORTH IRELAND.							AYRES JG, 1995, EUR RESPIR J, V8, P579; Clark DJ, 1996, THORAX, V51, P262, DOI 10.1136/thx.51.3.262; DOGTEROM P, 1995, EUR RESPIR J, V8, P303; GRAHNEN A, 1995, THORAX, V50, P105; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; JOHNSTON DI, 1994, INVESTIGATIONS PAEDI, P52; LUNDBACK B, 1993, RESP MED, V87, P609, DOI 10.1016/S0954-6111(05)80264-1; MACKENZIE CA, 1993, EUR J PEDIATR, V152, P856, DOI 10.1007/BF02073387; RUSSELL G, 1994, THORAX, V49, P1185, DOI 10.1136/thx.49.12.1185; *SIX PART ASTHM MA, 1995, US NIH PUBL, P92; WALKER JM, 1995, CLIN PAEDIAT ENDOCRI, P786; WONG J, 1992, BRIT MED J, V304, P1414	12	131	134	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					27	29		10.1016/S0140-6736(96)03339-9	http://dx.doi.org/10.1016/S0140-6736(96)03339-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691927				2022-12-28	WOS:A1996UV92300012
J	Rousset, R; Desbois, C; Bantignies, F; Jalinot, P				Rousset, R; Desbois, C; Bantignies, F; Jalinot, P			Effects on NF-kappa B1/p105 processing of the interaction between the HTLV-1 transactivator tax and the proteasome	NATURE			English	Article							NF-KAPPA-B; THERMOPLASMA-ACIDOPHILUM; PRECURSOR P105; EXPRESSION; PROTEINS; PRODUCT; SUBUNIT; YEAST; GENE; LOCALIZATION	THE viral Tax protein, which is encoded by human T-cell leukaemia virus HTLV-I, activates nuclear translocation of the NF-kappa B/Rel transcription factors and relieves cytoplasmic sequestration of RelA and Rel by heterodimerizatian with NF-kappa B1/p105 (refs 1,2). Proleolytic maturation of this precursor protein is performed by the proteasome complex(3,4). Here we show that Tax binds specifically to two subunits of the 20S proteasome, HsN3 and HC9. This Interaction is weakened with HsN3 and last for HC9 when a mutant of Tax is substituted that is selectively defective for NF-kappa B activation. Immunoprecipitation shows that p105 binds weakly to HC9 and that this interaction is reinforced by Tax. No bridging function of Tax between p105 and HsN3 was observed. From these results, we propose that Tax accelerates the proteolytic maturation of p105 by favouring its anchorage to the proteasome.	ECOLE NORMALE SUPER LYON,CNRS,UMR 49,F-69364 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)			Rousset, Raphael/E-5908-2017; Morris, Christelle/M-8168-2014	Rousset, Raphael/0000-0002-4999-403X; Morris, Christelle/0000-0003-1575-4609				BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CRENON I, 1993, ONCOGENE, V8, P867; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; HIRAI H, 1992, ONCOGENE, V7, P1737; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOPP F, 1995, J MOL BIOL, V248, P264; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Miller J.H., 1972, EXPT MOL GENETICS; MUNOZ E, 1994, J VIROL, V68, P8035; NOTHWANG HG, 1994, BBA-GENE STRUCT EXPR, V1219, P361, DOI 10.1016/0167-4781(94)90060-4; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79	30	125	129	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					328	331		10.1038/381328a0	http://dx.doi.org/10.1038/381328a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692272				2022-12-28	WOS:A1996UM40300058
J	LeGall, JR; Klar, J; Lemeshow, S; Saulnier, F; Alberti, C; Artigas, A; Teres, D				LeGall, JR; Klar, J; Lemeshow, S; Saulnier, F; Alberti, C; Artigas, A; Teres, D			The logistic organ dysfunction system - A new way to assess organ dysfunction in the intensive care unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAILURE; SEVERITY; SEPSIS; MULTICENTER; INFECTION; PROGNOSIS; ILLNESS; SCORE	Objective.-To develop an objective method for assessing organ dysfunction among intensive care unit (ICU) patients on the first day of the ICU stay. Design and Setting.-Physiological variables defined dysfunction in 6 organ systems, Logistic regression techniques were used to determine severity levels and relative weights for the Logistic Organ Dysfunction (LOD) score and for conversion of the LOD score to a probability of mortality. Patients.-A total of 13152 consecutive admissions to 137 adult medical/surgical ICUs in 12 countries from the European/North American Study of Severity Systems. Outcome Measure.-Patient vital status at hospital discharge. Results.-The LOD System identified from 1 to 3 levels of organ dysfunction for 6 organ systems: neurologic, cardiovascular, renal, pulmonary, hematologic, and hepatic, From 1 to 5 LOD points were assigned to the levels of severity, and the resulting LOD scores ranged from 0 to 22 points, Model calibration was very good in the developmental and validation samples (P=.21 and P=.50, respectively), as was model discrimination (area under the receiver operating characteristic curves of 0.843 and 0.850, respectively). Conclusion.-The LOD System provides an objective tool for assessing severity levels for organ dysfunction in the ICU, a critical component in the conduct of clinical trials. Neurologic, cardiovascular, and renal dysfunction were the most severe organ dysfunctions, followed by pulmonary and hematologic dysfunction, with hepatic dysfunction the least severe. The LOD System takes into account both the relative severity among organ systems and the degree of severity within an organ system.	HOP ST LOUIS,INTENS CARE UNIT,F-75475 PARIS 10,FRANCE; UNIV MASSACHUSETTS,SCH PUBL HLTH,AMHERST,MA 01003; HOP CALMETTE,INTENS CARE UNIT,LILLE,FRANCE; CONSULTAT HOSP PARC TAULI,SERV MED INTENS,SABADELL,SPAIN; BAYSTATE MED CTR,DIV CRIT CARE,SPRINGFIELD,MA 01107; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Massachusetts System; University of Massachusetts Amherst; Universite de Lille - ISITE; CHU Lille; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Baystate Medical Center; Tufts University				antonio, artigas/0000-0002-8029-1017				CASTELLA X, 1995, CRIT CARE MED, V23, P1327, DOI 10.1097/00003246-199508000-00005; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; FRY DE, 1980, ARCH SURG-CHICAGO, V115, P136; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEBERT PC, 1993, CHEST, V104, P230, DOI 10.1378/chest.104.1.230; HOSMER DW, 1989, APPL LOGISTIC REGRES; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1989, MULTIPLE SYSTEMS ORG, P221; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1994, JAMA-J AM MED ASSOC, V272, P1049, DOI 10.1001/jama.272.13.1049; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MARSHALL JC, 1988, ARCH SURG-CHICAGO, V123, P309; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; RAUSS A, 1990, MED DECIS MAKING, V10, P155, DOI 10.1177/0272989X9001000302; SIBBALD WJ, 1995, CRIT CARE MED, V23, P394, DOI 10.1097/00003246-199502000-00027; STEVENS LE, 1983, ARCH SURG-CHICAGO, V118, P1190	17	578	601	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					802	810		10.1001/jama.276.10.802	http://dx.doi.org/10.1001/jama.276.10.802			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769590				2022-12-28	WOS:A1996VF21900027
J	Tollervey, D				Tollervey, D			Small nucleolar RNAs guide ribosomal RNA methylation	SCIENCE			English	Editorial Material											Tollervey, D (corresponding author), EUROPEAN MOL BIOL LAB,POSTFACH 102209,D-69012 HEIDELBERG,GERMANY.		Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772				AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; CAVAILLE JY, COMMUNICATION; Dunbar DA, 1996, RNA, V2, P324; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; NI JS, COMMUNICATION; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607	13	63	65	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1056	1057		10.1126/science.273.5278.1056	http://dx.doi.org/10.1126/science.273.5278.1056			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8711484				2022-12-28	WOS:A1996VD42800027
J	Daley, J; Delbanco, TL; Walzer, J				Daley, J; Delbanco, TL; Walzer, J			A 47-year-old woman with ductal carcinoma in situ, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Morrow M, 1996, JAMA-J AM MED ASSOC, V275, P61	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					491	491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691559				2022-12-28	WOS:A1996VA86300039
J	Jacobs, HS				Jacobs, HS			Controversies in management - Hormone replacement therapy for all? Universal prescription is desirable - Not for everybody	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; ESTROGEN				Jacobs, HS (corresponding author), MIDDLESEX HOSP,COBBOLD LABS,LONDON W1N 8AA,ENGLAND.		Jacobs, Howard/A-9845-2009					BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; JACOBS HS, 1992, BMJ-BRIT MED J, V305, P1403, DOI 10.1136/bmj.305.6866.1403; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; Stampfer Meir J., 1994, P223	9	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					351	352		10.1136/bmj.313.7053.351	http://dx.doi.org/10.1136/bmj.313.7053.351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760748	Green Published			2022-12-28	WOS:A1996VC30000026
J	Murphy, FA				Murphy, FA			The public health risk of animal organ and tissue transplantation into humans	SCIENCE			English	Editorial Material							XENOTRANSPLANTATION				Murphy, FA (corresponding author), UNIV CALIF DAVIS, SCH VET MED, DAVIS, CA 95616 USA.							Altman L. K. (, 1994, NY TIMES, pA1; Buchmeier M., 1995, ARCH VIROL, V10, P350; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; HOKE F, 1995, SCIENTIST, V9, P11; Institute of Medicine Committee on Xenograft Transplantation, 1996, XEN SCI ETH PUBL POL; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1462, DOI 10.1097/00007890-199405270-00011; Michler RE, 1996, EMERG INFECT DIS, V2, P64, DOI 10.3201/eid0201.960111; OBrien C, 1996, SCIENCE, V271, P1357; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	18	41	43	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					746	747		10.1126/science.273.5276.746	http://dx.doi.org/10.1126/science.273.5276.746			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8701323				2022-12-28	WOS:A1996VB42900024
J	Neutra, MR; Frey, A; Kraehenbuhl, JP				Neutra, MR; Frey, A; Kraehenbuhl, JP			Epithelial M cells: Gateways for mucosal infection and immunization	CELL			English	Review							SYSTEM		CHILDRENS HOSP, GL CELL BIOL LAB, BOSTON, MA USA; UNIV MUNSTER, CTR MOL BIOL INFLAMMAT, D-48149 MUNSTER, GERMANY; UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND; SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	Harvard University; Boston Children's Hospital; University of Munster; University of Lausanne; Swiss Institute Experimental Cancer Research	Neutra, MR (corresponding author), HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA.							ALLAN CH, 1993, GASTROENTEROLOGY, V104, P698, DOI 10.1016/0016-5085(93)91004-2; APODACA G, 1991, J CLIN INVEST, V87, P1877, DOI 10.1172/JCI115211; Baumler AJ, 1996, P NATL ACAD SCI USA, V93, P279, DOI 10.1073/pnas.93.1.279; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; CHOI WS, 1991, J VIROL, V65, P2875, DOI 10.1128/JVI.65.6.2875-2883.1991; ELDRIDGE JH, 1991, MOL IMMUNOL, V28, P287, DOI 10.1016/0161-5890(91)90076-V; FREY A, 1996, IN PRESS J EXP MED; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; MAURY J, 1995, EUR J BIOCHEM, V228, P323; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; MEKALANOS JJ, 1992, ADV EXP MED BIOL, V327, P43; MILLER CJ, 1992, AM J PATHOL, V141, P655; Neutra M.R., 1994, PHYSL GASTROINTESTIN, P975; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NEUTRA MR, 1994, INFECT GI TRACT, P163; NIBERT ML, 1991, J CLIN INVEST, V88, P727, DOI 10.1172/JCI115369; PERDOMO OJJ, 1994, J EXP MED, V180, P1307, DOI 10.1084/jem.180.4.1307; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; SANSONETTI PJ, 1991, REV INFECT DIS S4, V13, P285	20	424	444	1	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 9	1996	86	3					345	348		10.1016/S0092-8674(00)80106-3	http://dx.doi.org/10.1016/S0092-8674(00)80106-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756716	Bronze, Green Published			2022-12-28	WOS:A1996VC30900002
J	Nussenzweig, A; Chen, CH; Soares, VD; Sanchez, M; Sokol, K; Nussenzweig, MC; Li, GC				Nussenzweig, A; Chen, CH; Soares, VD; Sanchez, M; Sokol, K; Nussenzweig, MC; Li, GC			Requirement for Ku80 in growth and immunoglobulin V(D)J recombination	NATURE			English	Article							STRAND-BREAK-REPAIR; DEPENDENT PROTEIN-KINASE; DNA END-BINDING; CATALYTIC SUBUNIT; CELL-LINE; GENE; MICE; MUTANT; AUTOANTIGEN; SENSITIVITY	THE DNA-dependent protein kinase (DNA-PK) is a mammalian serine/threonine kinase that is implicated in the repair of DNA double-strand breaks(1-4), DNA replication(1,5), transcription(6-8), and V(D)J recombination(9-12). To determine the role of the DNA-binding subunit of DNA-PK in vivo, we targeted Ku80 in mice. In mutant mice, T and B lymphocyte development is arrested at early progenitor stages and there is a profound deficiency in V(D)J rearrangement. Although Ku80(-/-) mice are viable and reproduce, they are 40-60% of the size of littermate controls. Consistent with this growth defect, fibroblasts derived from Ku80(-/-) embryos showed an early loss of proliferating cells, a prolonged doubling time, and intact cell-cycle checkpoints that prevented cells with damaged DNA from entering the cell-cycle. The unexpected growth phenotype suggests a new and important link between Ku80 and growth control.	MEM SLOAN KETTERING CANC CTR,DEPT MED PHYS,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT RADIAT ONCOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,LAB MOL IMMUNOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,LAB ANIM RES CTR,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Nussenzweig, Michel/AAE-7292-2019					ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CARROLL AM, 1993, MOL CELL BIOL, V13, P3623; Chen FQ, 1996, MUTAT RES-DNA REPAIR, V362, P9, DOI 10.1016/0921-8777(95)00026-7; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; Errami A, 1996, MOL CELL BIOL, V16, P1519; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEIRICHSCHWAIGER H, 1994, MUTAT RES, V316, P37, DOI 10.1016/0921-8734(94)90006-X; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	29	551	564	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					551	555		10.1038/382551a0	http://dx.doi.org/10.1038/382551a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700231				2022-12-28	WOS:A1996VB25800054
J	Tian, GL; Huang, Y; Rommelaere, H; Vandekerckhove, J; Ampe, C; Cowan, NJ				Tian, GL; Huang, Y; Rommelaere, H; Vandekerckhove, J; Ampe, C; Cowan, NJ			Pathway leading to correctly folded beta-tubulin	CELL			English	Article							MICROTUBULE-MEDIATED PROCESSES; T-COMPLEX POLYPEPTIDE-1; FUNCTION IN-VIVO; CYTOPLASMIC CHAPERONIN; ALPHA-TUBULIN; PROTEIN; GROEL; SUBUNITS; RELEASE; TRANSLATION	We describe the complete beta-tubulin folding pathway. Folding intermediates produced via ATP-dependent interaction with cytosolic chaperonin undergo a sequence of interactions with four proteins (cofactors A, D, E, and C). The postchaperonin steps in the reaction cascade do not depend on ATP or GTP hydrolysis, although GTP plays a structural role in tubulin folding. Cofactors A and D function by capturing and stabilizing beta-tubulin in a quasi-native conformation. Cofactor E binds to the cofactor D-beta-tubulin complex; interaction with cofactor C then causes the release of beta-tubulin polypeptides that are committed to the native state. Sequence analysis identifies yeast homologs of cofactors D (cin1) and E (pac2), characterized by mutations that affect microtubule function.	NYU, MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA; STATE UNIV GHENT VIB, B-9000 GHENT, BELGIUM	New York University; Flanders Institute for Biotechnology (VIB); Ghent University			Ampe, Christophe/B-5534-2012					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ARCHER JE, 1995, CELL, V82, P425, DOI 10.1016/0092-8674(95)90431-X; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CLEVELAND DW, 1978, CELL, V15, P1021, DOI 10.1016/0092-8674(78)90286-6; DETRICH HW, 1978, BIOCHEMISTRY-US, V17, P3900, DOI 10.1021/bi00612a002; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; FARR GW, 1990, P NATL ACAD SCI USA, V87, P5041, DOI 10.1073/pnas.87.13.5041; FONTALBA A, 1993, J CELL SCI, V106, P627; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MURPHY DB, 1977, BIOCHEMISTRY-US, V16, P2598, DOI 10.1021/bi00631a004; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PACIUCCI R, 1994, BIOCHEM J, V301, P105, DOI 10.1042/bj3010105; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; STEARNS T, 1990, GENETICS, V124, P251; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; YAFFE MB, 1988, J BIOL CHEM, V263, P16023; YAFFE MB, 1989, J BIOL CHEM, V264, P19045; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZABALA JC, 1992, CELL MOTIL CYTOSKEL, V23, P222, DOI 10.1002/cm.970230306	43	228	236	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					287	296		10.1016/S0092-8674(00)80100-2	http://dx.doi.org/10.1016/S0092-8674(00)80100-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706133	hybrid			2022-12-28	WOS:A1996UZ97200014
J	Davies, RH				Davies, RH			A difficult case - Home ventilation of a child with motor and sensory neuropathy	BRITISH MEDICAL JOURNAL			English	Article											Davies, RH (corresponding author), GWYNEDD COMMUNITY HLTH TRUST,WOMEN & CHILDRENS BUSINESS UNIT HEADQUARTERS,CAERNARVON LL55 1BH,GWYNEDD,WALES.							KLEIN R, 1993, BRIT MED J, V307, P309, DOI 10.1136/bmj.307.6899.309	1	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					153	154		10.1136/bmj.313.7050.153	http://dx.doi.org/10.1136/bmj.313.7050.153			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688778	Green Published			2022-12-28	WOS:A1996UY92100022
J	Mattingly, RR; Macara, IG				Mattingly, RR; Macara, IG			Phosphorylation-dependent activation of the Ras-GRF/CDC25(Mm) exchange factor by muscarinic receptors and G-protein beta gamma subunits	NATURE			English	Article							NUCLEOTIDE-RELEASING-FACTOR; MAP KINASE; RAS; PATHWAY; TRANSFORMATION; FIBROBLASTS; STIMULATION; HYPERTROPHY; P21(RAS); CLONING	MUSCARINIC receptors activate Ras through a pathway distinct(1,2) from that mediated through translocation of the exchange factor mSos1 by receptor tyrosine kinases(3'4). Here we report that muscarinic receptors can activate another Ras exchange factor, CDC25(Mm), or p140(Ras-GRF) (refs 5,6). In NIH-3T3 cells expressing subtype 1 human muscarinic receptors (hm1), the agonist carbachol selectively increased the specific activity and phosphorylation state of epitope-tagged Ras-GRF. This stimulation nas reversed by protein phosphatase 1 (PP1), and prevented by transducin alpha-subunits. Carbachol treatment of neonatal rat brain explants increased Ras exchange factor activity and the phosphorylation state of endogenous Ras-GRF. In COS-7 cells, cotransfection of hm1 or hm2 receptors with Ras-GRF conferred carbachol-dependent increases in exchange-factor activity, whereas cotransfection with G protein beta gamma subunits caused a constitutive activation that was sensitive to PP1. These results demonstrate a G-protein-coupled mechanism for Ras activation, mediated by p140R(Ras-GRF).	UNIV VERMONT,COLL MED,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405; VERMONT COMPREHENS CANC CTR,BURLINGTON,VT 05405	University of Vermont	Mattingly, RR (corresponding author), UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT 05405, USA.							BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GRABER SG, 1992, J BIOL CHEM, V267, P13123; Guerrero C, 1996, ONCOGENE, V12, P1097; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HANLEY MR, 1989, NATURE, V340, P97, DOI 10.1038/340097a0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LINNEMANN D, 1989, DISSECTION TISSUE CU, P75; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATTINGLY RR, 1992, J BIOL CHEM, V267, P7470; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; THORBURN A, 1993, J BIOL CHEM, V268, P2244; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	30	155	157	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					268	272		10.1038/382268a0	http://dx.doi.org/10.1038/382268a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717044				2022-12-28	WOS:A1996UX79000054
J	Barlow, C; Hirotsune, S; Paylor, R; Liyanage, M; Eckhaus, M; Collins, F; Shiloh, Y; Crawley, JN; Ried, T; Tagle, D; WynshawBoris, A				Barlow, C; Hirotsune, S; Paylor, R; Liyanage, M; Eckhaus, M; Collins, F; Shiloh, Y; Crawley, JN; Ried, T; Tagle, D; WynshawBoris, A			Atm-deficient mice: A paradigm of ataxia telangiectasia	CELL			English	Article							WILD-TYPE P53; DOUBLE-STRAND BREAKS; CELL-CYCLE; P53-DEFICIENT MICE; GENE AMPLIFICATION; MOLECULAR ANALYSIS; GAMMA-IRRADIATION; DNA; RADIATION; TRANSLOCATION	A murine model of ataxia telangiectasia was created by disrupting the Atm locus via gene targeting. Mice homozygous for the disrupted Atm allele displayed growth retardation, neurologic dysfunction, male and female infertility secondary to the absence of mature gametes, defects in T lymphocyte maturation, and extreme sensitivity to gamma-irradiation. The majority of animals developed malignant thymic lymphomas between 2 and 4 months of age. Several chromosomal anomalies were detected in one of these tumors. Fibroblasts from these mice grew slowly and exhibited abnormal radiation-induced G1 checkpoint function. Atm-disrupted mice recapitulate the ataxia telangiectasia phenotype in humans, providing a mammalian model in which to study the pathophysiology of this pleiotropic disorder.	NATL INST HLTH,NATL CTR HUMAN GENOME RES,LAB GENE TRANSFER,BETHESDA,MD 20892; NATL INST HLTH,NATL CTR HUMAN GENOME RES,DIAGNOST DEV BRANCH,BETHESDA,MD 20892; NIMH,EXPTL THERAPEUT BRANCH,SECT BEHAV NEUROPHARMACOL,NATL INST HLTH,BETHESDA,MD 20892; NATL INST HLTH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; Tel Aviv University; Sackler Faculty of Medicine	Barlow, C (corresponding author), NATL INST HLTH,NATL CTR HUMAN GENOME RES,LAB GENET DIS RES,BETHESDA,MD 20892, USA.							ARTUSO M, 1995, ONCOGENE, V11, P1427; BAKER BS, 1972, GENETICS, V71, P255; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; Boder E, 1975, Birth Defects Orig Artic Ser, V11, P255; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CARBONARI M, 1990, NEW ENGL J MED, V322, P73, DOI 10.1056/NEJM199001113220201; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CLARKE AR, 1994, ONCOGENE, V9, P1767; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; COQUERELLE TM, 1987, INT J RADIAT BIOL, V51, P209, DOI 10.1080/09553008714550711; COX R, 1986, MOL BIOL MED, V3, P229; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; Harlow E., 1988, ANTIBODIES LAB MANUA; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HEPPELL A, 1988, HUM GENET, V79, P360; Hogan B, 1994, MANIPULATING MOUSE E; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIU N, 1994, INT J RADIAT BIOL, V66, pS115, DOI 10.1080/09553009414551941; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luna L.G., 1992, HISTOPATHOLOGICAL ME; METCALFE JA, 1991, CYTOGENET CELL GENET, V56, P91, DOI 10.1159/000133057; MEYN MS, 1995, CANCER RES, V55, P5991; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; PECKER I, 1996, IN PRESS GENOMICS; POWELL S, 1993, MUTAT RES, V294, P9, DOI 10.1016/0921-8777(93)90053-J; PURDIE CA, 1994, ONCOGENE, V9, P603; RABBITTS P, 1995, NAT GENET, V9, P369, DOI 10.1038/ng0495-369; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; SCHROCK E, 1996, IN PRESS SCIENCE; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; STERN MH, 1989, BLOOD, V74, P2076; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; TSUKADA T, 1993, ONCOGENE, V8, P3313; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	69	1203	1219	2	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					159	171		10.1016/S0092-8674(00)80086-0	http://dx.doi.org/10.1016/S0092-8674(00)80086-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689683	Bronze			2022-12-28	WOS:A1996UX93400017
J	DSouza, T; Dryer, SE				DSouza, T; Dryer, SE			A cationic channel regulated by a vertebrate intrinsic circadian oscillator	NATURE			English	Article							CHICK PINEAL CELLS; MELATONIN RHYTHM; PHOTOENDOCRINE TRANSDUCTION; CALCIUM INFLUX; CYCLIC-AMP; GLAND; LIGHT; GMP; PACEMAKER; CULTURE	SECRETORY cells of the chicken pineal gland exhibit light sensitive circadian rhythms in melatonin release that persist in vitro(1-12). Melatonin secretion is positively regulated by cyclic AMP and intracellular Ca2+ (refs 8, 10-15), Cyclic AMP analogues are more effective at stimulating melatonin secretion during the circadian night owing in part to increased Ca2+ influx at those times(12), However, this cannot be attributed to increased activity of L-type Ca2+ channels(12). Here we describe an unusual 40-pS cationic channel (I-LOT) in cultured chicken pineal cells that is permeable to Ca2+ and active in the night but not during the day, I-LOT is not voltage- or stretch-activated, it has a characteristically long open time, and its gating persists in excised inside-out patches in the absence of Ca2+ or cyclic nucleotides. Daily rhythms in I-LOT gating are also observed in previously entrained chicken pineal cells free-running under constant dark conditions. Nighttime I-LOT activity is not suppressed by brief Light pulses.	FLORIDA STATE UNIV, DEPT BIOL SCI, PROGRAM NEUROSCI, TALLAHASSEE, FL 32306 USA	State University System of Florida; Florida State University								DEGUCHI T, 1979, NATURE, V282, P94, DOI 10.1038/282094a0; DRYER SE, 1991, NATURE, V353, P756, DOI 10.1038/353756a0; DRYER SE, 1993, J COMP PHYSIOL A, V172, P271, DOI 10.1007/BF00216609; DSOUZA T, 1994, BRAIN RES, V656, P85, DOI 10.1016/0006-8993(94)91369-2; HARRISON NL, 1989, J NEUROSCI, V9, P2462; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; NIKAIDO SS, 1989, NEURON, V3, P609, DOI 10.1016/0896-6273(89)90271-7; NIKAIDO SS, IN PRESS BRAIN RES; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1989, BRAIN RES, V477, P14, DOI 10.1016/0006-8993(89)91389-9; ZATZ M, 1988, BRAIN RES, V463, P305; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X; ZATZ M, 1992, J BIOL RHYTHM, V7, P301, DOI 10.1177/074873049200700404; ZATZ M, 1988, BRAIN RES, V453, P51, DOI 10.1016/0006-8993(88)90142-4; ZATZ M, 1988, BRAIN RES, V450, P137, DOI 10.1016/0006-8993(88)91553-3; ZAWILSKA JB, 1990, NEUROSCI LETT, V118, P17, DOI 10.1016/0304-3940(90)90238-5	19	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	1996	382	6587					165	167		10.1038/382165a0	http://dx.doi.org/10.1038/382165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700206				2022-12-28	WOS:A1996UW67200049
J	Schipani, E; Langman, CB; Parfitt, AM; Jensen, GS; Kikuchi, S; Kooh, SW; Cole, WG; Juppner, H				Schipani, E; Langman, CB; Parfitt, AM; Jensen, GS; Kikuchi, S; Kooh, SW; Cole, WG; Juppner, H			Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MESSENGER RIBONUCLEIC-ACIDS; FOLLOW-UP; GENE; DYSPLASIA; TISSUES; PROTEIN	Background An activating mutation of the receptor for parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) was recently found in a patient with Jansen's metaphyseal chondrodysplasia, a rare form of short-limbed dwarfism associated with hypercalcemia and normal or low serum concentrations of the two hormones. To investigate this and other activating mutations and to refine the classification of this unusual disorder, we analyzed genomic DNA from six additional patients with Jansen's disease. Methods Exons encoding the PTH-PTHrP receptor were amplified by the polymerase chain reaction (PCR), and the products were analyzed by gel electrophoresis or direct nucleotide-sequence analysis. Nucleotide changes were confirmed by restriction-enzyme digestion of genomic DNA or the PCR products. Results The previously reported mutation, which changes a histidine at position 223 to arginine (H223R), was found in genomic DNA from three of the six patients but not in DNA from their healthy relatives or 45 unrelated normal subjects. A novel missense mutation that changes a threonine in the receptor's sixth membrane-spanning region to proline (T410P) was identified in another patient but not in 62 normal subjects. In two patients with radiologic evidence of Jansen's metaphyseal chondrodysplasia but less severe hypercalcemia, no receptor mutations were detected. In COS-7 cells expressing PTH-PTHrP receptors with the T410P or H223R mutation, basal cyclic AMP accumulation was four to six times higher than in cells expressing wild-type receptors. Conclusions The expression of constitutively active PTH-PTHrP receptors in kidney, bone, and growth-plate chondrocytes provides a plausible genetic explanation for mineral-ion abnormalities and metaphyseal changes in patients with Jansen's disease. (C) 1996, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,DEPT MED,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CHILDRENS SERV,BOSTON,MA 02114; NORTHWESTERN UNIV,SCH MED,PEDIAT NEPHROL & MINERAL METAB UNIT,CHICAGO,IL; CHILDRENS MEM HOSP,CHICAGO,IL 60614; HENRY FORD HOSP,BONE & MINERAL RES LAB,DETROIT,MI 48202; FUKUSHIMA MED COLL,FUKUSHIMA,JAPAN; HOSP SICK CHILDREN,DEPT ORTHOPAED SURG & ENDOCRINOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,TORONTO,ON M5S 1A1,CANADA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Henry Ford Health System; Henry Ford Hospital; Fukushima Medical University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto					PHS HHS [R01 46718] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAMERON JAP, 1954, J BONE JOINT SURG BR, V36, P622, DOI 10.1302/0301-620X.36B4.622; CHARROW J, 1984, AM J MED GENET, V18, P321, DOI 10.1002/ajmg.1320180216; de Haas W H, 1969, J Bone Joint Surg Br, V51, P290; Frame B, 1980, PEDIAT DIS RELATED C, P269; GORDON SL, 1976, PEDIATRICS, V58, P556; GRAM PB, 1959, J BONE JOINT SURG AM, V41, P951, DOI 10.2106/00004623-195941050-00015; Holthusen W, 1975, Pediatr Radiol, V3, P137, DOI 10.1007/BF01006898; IWAMOTO M, 1994, J BIOL CHEM, V269, P17245; Jaffe HL, 1972, METABOLIC DEGENERATI, P222; Jansen M, 1934, Z ORTHOP CHIR, V61, P253; Jikko A, 1996, ENDOCRINOLOGY, V137, P122, DOI 10.1210/en.137.1.122; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KESSEL D, 1992, PEDIATR RADIOL, V22, P470, DOI 10.1007/BF02013518; KIKUCHI S, 1976, J BONE JOINT SURG BR, V58, P102, DOI 10.1302/0301-620X.58B1.1270485; KRUSE K, 1993, EUR J PEDIATR, V152, P912, DOI 10.1007/BF01957529; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; Lee KC, 1996, AM J PHYSIOL-RENAL, V270, pF186, DOI 10.1152/ajprenal.1996.270.1.F186; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LENZ WD, 1969, BIRTH DEFECTS, V5, P71; Rao DS, 1979, VITAMIN D BASIC RES, P1173; REED A, 1990, J PEDIATR-US, V116, P574, DOI 10.1016/S0022-3476(05)81605-1; REN Q, 1994, J BIOL CHEM, V269, P1566; REN Q, 1993, J BIOL CHEM, V268, P16483; SCHIPANI E, 1994, HUM MOL GENET, V3, P1210, DOI 10.1093/hmg/3.7.1210-a; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; SILVERTHORN KG, 1987, PEDIATR RADIOL, V17, P119, DOI 10.1007/BF02388087; TIAN J, 1993, AM J NEPHROL, V13, P210, DOI 10.1159/000168620; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; WEIR E, 1995, J BONE MINER RES, V10, pS157; WYSOLMERSKI JJ, 1995, DEVELOPMENT, V121, P3539	33	192	194	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					708	714		10.1056/NEJM199609053351004	http://dx.doi.org/10.1056/NEJM199609053351004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH266	8703170				2022-12-28	WOS:A1996VH26600004
J	Gelb, BD; Shi, GP; Chapman, HA; Desnick, RJ				Gelb, BD; Shi, GP; Chapman, HA; Desnick, RJ			Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency	SCIENCE			English	Article							MOLECULAR-CLONING; PROTEINASE-INHIBITORS; TISSUE DISTRIBUTION; CYSTEINE PROTEASE; TOULOUSE-LAUTREC; BONE-RESORPTION; OSTEOCLASTOMAS; LOCALIZATION; COLLAGEN; CELLS	Pycnodysostosis, an autosomal recessive osteochondrodysplasia characterized by osteosclerosis and short stature, maps to chromosome 1q21. Cathepsin K, a cysteine protease gene that is highly expressed in osteoclasts, localized to the pycnodysostosis region. Nonsense, missense, and stop codon mutations in the gene encoding cathepsin K were identified in patients. Transient expression of complementary DNA containing the stop codon mutation resulted in messenger RNA but no immunologically detectable protein. Thus, pycnodysostosis results from gene defects in a lysosomal protease with highest expression in osteoclasts. These findings suggest that cathepsin K is a major protease in bone resorption, providing a possible rationale for the treatment of disorders such as osteoporosis and certain forms of arthritis.	MT SINAI SCH MED,DIV PEDIAT CARDIOL,NEW YORK,NY 10029; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gelb, BD (corresponding author), MT SINAI SCH MED,DEPT HUMAN GENET,BOX 1203,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NHLBI NIH HHS [R01 HL44816] Funding Source: Medline; NIDDK NIH HHS [R01 DK31775, R37 DK34045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031775, R37DK034045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREN L., 1962, ACTA CHIR SCAND, V124, P496; BISHOP DF, 1982, J BIOL CHEM, V256, P1307; BLAIR HC, 1993, CLIN ORTHOP RELAT R, V294, P7; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; DEBARI K, 1995, CALCIFIED TISSUE INT, V56, P566, DOI 10.1007/BF00298591; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674; FREY JB, 1995, NAT GENET, V10, P128, DOI 10.1038/ng0695-128; Gelb BD, 1996, HUM GENET, V98, P141, DOI 10.1007/s004390050177; GELB BD, 1995, NAT GENET, V10, P235, DOI 10.1038/ng0695-235; GELB BD, UNPUB; GOTO T, 1994, HISTOCHEMISTRY, V101, P33, DOI 10.1007/BF00315829; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; LI YP, 1995, J BONE MINER RES, V10, P1197; MAROTEAUX P, 1962, PRESSE MED, V70, P999; MAROTEAUX P, 1965, J AMER MED ASSOC, V191, P715, DOI 10.1001/jama.1965.03080090029007; MAROTEAUX P, 1993, PRESSE MED, V22, P1635; MUNGER JS, 1995, BIOCHEM J, V311, P299, DOI 10.1042/bj3110299; POLYMEROPOULOS MH, 1995, NAT GENET, V10, P238, DOI 10.1038/ng0695-238; SHI GP, 1992, J BIOL CHEM, V267, P7258; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SHI GP, 1994, J BIOL CHEM, V269, P11530; TEZUKA K, 1994, J BIOL CHEM, V269, P1106	30	792	821	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1236	1238		10.1126/science.273.5279.1236	http://dx.doi.org/10.1126/science.273.5279.1236			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703060				2022-12-28	WOS:A1996VE47600043
J	Valaskovic, GA; Kelleher, NL; McLafferty, FW				Valaskovic, GA; Kelleher, NL; McLafferty, FW			Attomole protein characterization by capillary electrophoresis mass spectrometry	SCIENCE			English	Article							MULTIPLY-CHARGED IONS; ELECTROSPRAY-IONIZATION; LARGE BIOMOLECULES; LARGE MOLECULES; SENSITIVITY; PEPTIDES; SPECTRA; IDENTIFICATION; CELLS	Electrospray ionization with an ultralow flow rate (less than or equal to 4 nanoliters per minute) was used to directly couple capillary electrophoresis with tandem mass spectrometry for the analysis and identification of biomolecules in mixtures. A Fourier transform mass spectrometer provided full spectra (>30 kilodaltons) at a resolving power of approximate to 60,000 for injections of 0.7 x 10(-18) to 3 x 10(-18) mole of 8- to 29-kilodalton proteins with errors of <1 dalton in molecular mass. Using a crude isolate from human blood, a value of 28,780.6 daltons (calculated, 28,780.4 daltons) was measured for carbonic anhydrase, representing 1 percent by weight of the protein in a single red blood cell. Dissociation of molecular ions from 9 x 10(-18) mole of carbonic anhydrase gave nine sequence-specific fragment ions, more data than required for unique retrieval of this enzyme from the protein database.	CORNELL UNIV,BAKER LAB,DEPT CHEM,ITHACA,NY 14853	Cornell University					NIGMS NIH HHS [08-T2GM07273, GM16609] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016609, R37GM016609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; CURL RF, 1988, SCIENCE, V242, P1017, DOI 10.1126/science.242.4881.1017; EMMETT MR, 1994, J AM SOC MASS SPECTR, V5, P605, DOI 10.1016/1044-0305(94)85001-1; EWING AG, 1992, ACCOUNTS CHEM RES, V25, P440, DOI 10.1021/ar00022a002; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FISHMAN HA, 1995, P NATL ACAD SCI USA, V92, P7877, DOI 10.1073/pnas.92.17.7877; Flaming K.T., 1986, ADV MICROPIPETTE TEC; FOSKETT JK, 1990, NONINVASIVE TECHNIQU, V9; Herman B., 1990, OPTICAL MICROSCOPY B, V1st; Hofstadler SA, 1996, RAPID COMMUN MASS SP, V10, P919, DOI 10.1002/(SICI)1097-0231(19960610)10:8<919::AID-RCM597>3.0.CO;2-8; HOFSTADLER SA, 1993, J AM CHEM SOC, V115, P6983, DOI 10.1021/ja00068a070; JORGENSON JW, 1983, SCIENCE, V222, P266, DOI 10.1126/science.6623076; KARGER BL, 1995, ANNU REV BIOPH BIOM, V24, P579, DOI 10.1146/annurev.bb.24.060195.003051; KELLEHER NL, 1995, J AM SOC MASS SPECTR, V6, P981, DOI 10.1016/1044-0305(95)00584-Z; KENNEDY RT, 1989, SCIENCE, V246, P57, DOI 10.1126/science.2675314; LINDSKOG S, 1960, BIOCHIM BIOPHYS ACTA, V39, P218, DOI 10.1016/0006-3002(60)90156-6; LITTLE DP, IN PRESS J AM CHEM S; LOO JA, 1991, ANAL CHEM, V63, P2488, DOI 10.1021/ac00021a018; LOO JA, 1994, ANAL CHEM, V66, P3659, DOI 10.1021/ac00093a020; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MCLAFFERTY FW, 1994, ACCOUNTS CHEM RES, V27, P379, DOI 10.1021/ar00047a009; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; Pennell R.B., 1974, RED BLOOD CELL, V1, P93; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAKMANN B, 1983, SINGLE CHANNEL RECOR; SAUER K, 1995, METHOD ENZYMOL, V246, P1; SENKO MW, 1995, J AM SOC MASS SPECTR, V6, P52, DOI 10.1016/1044-0305(94)00091-D; SENKO MW, 1995, J AM SOC MASS SPECTR, V6, P229, DOI 10.1016/1044-0305(95)00017-8; SMITH RD, 1993, ANAL CHEM, V65, pA574, DOI 10.1021/ac00061a001; SPEIR JP, 1995, J MASS SPECTROM, V30, P39, DOI 10.1002/jms.1190300108; VALASKOVIC GA, 1995, ANAL CHEM, V67, P3802, DOI 10.1021/ac00116a030; Valaskovic GA, 1996, RAPID COMMUN MASS SP, V10, P825; WAHL JH, 1993, ELECTROPHORESIS, V14, P448, DOI 10.1002/elps.1150140170; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; YEUNG ES, 1994, ACCOUNTS CHEM RES, V27, P409, DOI 10.1021/ar00048a004	36	327	333	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1199	1202		10.1126/science.273.5279.1199	http://dx.doi.org/10.1126/science.273.5279.1199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703047				2022-12-28	WOS:A1996VE47600030
J	Faix, J; Steinmetz, M; Boves, H; Kammerer, RA; Lottspeich, F; Mintert, U; Murphy, J; Stock, A; Aebi, U; Gerisch, G				Faix, J; Steinmetz, M; Boves, H; Kammerer, RA; Lottspeich, F; Mintert, U; Murphy, J; Stock, A; Aebi, U; Gerisch, G			Cortexillins, major determinants of cell shape and size, are actin-bundling proteins with a parallel coiled-coil tail	CELL			English	Article							HEAVY-CHAIN GENE; DICTYOSTELIUM WILD-TYPE; CROSS-LINKING PROTEINS; ALPHA-ACTININ; CYTOSKELETAL PROTEINS; CRYSTAL-STRUCTURE; MONOCLONAL-ANTIBODIES; BINDING PROTEINS; CAPPING PROTEIN; BETA-SPECTRIN	Cortexillins I and II of D. discoideum constitute a novel subfamily of proteins with actin-binding sites of the alpha-actinin/spectrin type. The C-terminal halves of these dimeric proteins contain a heptad repeat domain by which the two subunits are joined to form a two-stranded, parallel coiled coil, giving rise to a 19 nm tail. The N-terminal domains that encompass a consensus actin-binding sequence are folded into globular heads. Cortexillin-linked actin filaments form preferentially anti-parallel bundles that associate into meshworks. Both cortexillins are enriched in the cortex of locomoting cells, primarily at the anterior and posterior ends. Elimination of the two isoforms by gene disruption gives rise to large, flattened cells with rugged boundaries, portions of which are often connected by thin cytoplasmic bridges. The double-mutant cells are multinucleate owing to a severe impairment of cytokinesis.	UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel	Faix, J (corresponding author), MAX PLANCK INST BIOCHEM, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.		Steinmetz, Michel O/AAA-3349-2022	Steinmetz, Michel O/0000-0001-6157-3687; Kammerer, Richard/0000-0003-4570-5197				AEBI U, 1987, J ELECTRON MICR TECH, V7, P29, DOI 10.1002/jemt.1060070104; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER A, 1994, J MOL BIOL, V242, P683, DOI 10.1006/jmbi.1994.1617; BRETSCHER A, 1980, J CELL BIOL, V86, P335, DOI 10.1083/jcb.86.1.335; BRINK M, 1990, J CELL BIOL, V111, P1477, DOI 10.1083/jcb.111.4.1477; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; CLAVIEZ M, 1986, J CELL SCI, V86, P69; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EASON R, 1986, CENTRIFUGATION PRACT, P251; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FECHHEIMER M, 1984, J BIOL CHEM, V259, P4514; FINKELSTEIN AV, 1977, BIOPOLYMERS, V16, P497, DOI 10.1002/bip.1977.360160303; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HOFMANN A, 1993, FEBS LETT, V328, P71, DOI 10.1016/0014-5793(93)80968-Z; HOFMANN A, 1994, THESIS U BAYREUTH BA; HU RJ, 1992, J BIOL CHEM, V267, P18715; HUMBEL BM, 1992, SCANNING MICROSCOPY, V6, P817; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LUNA EJ, 1990, DEV GENET, V11, P328, DOI 10.1002/dvg.1020110503; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; PACAUD M, 1987, J CELL SCI, V88, P81; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PRASSLER J, 1995, THESIS TECHNICAL U M; RAYMONDDENISE A, 1993, MOL BIOCHEM PARASIT, V59, P123, DOI 10.1016/0166-6851(93)90013-N; REES MK, 1967, J BIOL CHEM, V242, P4449; SCHINDL M, 1995, BIOPHYS J, V68, P1177, DOI 10.1016/S0006-3495(95)80294-8; SCHLEICHER M, 1992, NEW BIOL, V4, P461; STPIERRE B, 1993, BIOCHIM BIOPHYS ACTA, V1173, P107, DOI 10.1016/0167-4781(93)90254-B; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; WALLRAFF E, 1986, EMBO J, V5, P61, DOI 10.1002/j.1460-2075.1986.tb04178.x; WALLRAFF E, 1991, METHOD ENZYMOL, V196, P334; WEBER I, 1995, J CELL SCI, V108, P1519; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WEIJER CJ, 1984, J CELL SCI, V70, P111; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; WITKE W, 1993, J CELL BIOL, V121, P599, DOI 10.1083/jcb.121.3.599; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	68	148	151	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 23	1996	86	4					631	642		10.1016/S0092-8674(00)80136-1	http://dx.doi.org/10.1016/S0092-8674(00)80136-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752217	Bronze			2022-12-28	WOS:A1996VE23500013
J	Arason, VA; Kristinsson, KG; Sigurdsson, JA; Stefansdottir, G; Molstad, S; Gudmundsson, S				Arason, VA; Kristinsson, KG; Sigurdsson, JA; Stefansdottir, G; Molstad, S; Gudmundsson, S			Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STREPTOCOCCUS-PNEUMONIAE; ANTIBIOTIC-RESISTANCE; ICELAND; SPAIN	Objective-To study the correlation of antimicrobial consumption with the carriage rate of penicillin resistant and multiresistant pneumococci in children. Design-Cross sectional and analytical prevalence study. Setting-Five different communities in Iceland. Main outcome measure-Prevalence of nasopharyngeal carriage of penicillin resistant pneumococci in children aged under 7 years in relation to antibiotic use as determined by information from parents, patient's records, and total sales of antimicrobials from local pharmacies in four study areas. Results-Total antimicrobial sales for children (6223 prescriptions) among the four areas for which data were available ranged from 9.6 to 23.2 defined daily doses per 1000 children daily (1.1 to 2.6 courses yearly per child). Children under 2 consumed twice as much as 2-6 year olds (20.5 v 10.9 defined daily doses per 1000 children daily). Nasopharyngeal specimens were obtained from 919 children, representing 15-38% of the peer population groups in the different areas. Pneumococci were carried by 484 (52.7%) of the children, 47 (9.7%) of the isolates being resistant to penicillin or multiresistant. By multivariate analysis age (<2 years), area (highest antimicrobial consumption), and individual use of antimicrobials significantly influenced the odds of carrying penicillin resistant pneumococci. By univariate analysis, recent antimicrobial use (two to seven weeks) and use of co-trimoxazole were also significantly associated with carriage of penicillin resistant pneumococci. Conclusions-Antimicrobial use, with regard to both individual use and total antimicrobial consumption in the community, is strongly associated with nasopharyngeal carriage of penicillin resistant pneumococci in children. Control measures to reduce the prevalence of penicillin resistant pneumococci should include reducing the use of antimicrobials in community health care.	LANDSPITALINN UNIV HOSP, DEPT MICROBIOL, IS-101 REYKJAVIK, ICELAND; BORGARSPITALINN REYKJAVIK CITY HOSP, MICROBIOL LAB, IS-108 REYKJAVIK, ICELAND; HOOR HLTH CTR, S-24330 HOOR, SWEDEN; LANDSPITALINN, DEPT INTERNAL MED, IS-101 REYKJAVIK, ICELAND	Landspitali National University Hospital	Arason, VA (corresponding author), UNIV ICELAND, SOLVANGUR HLTH CTR, DEPT FAMILY MED, IS-220 HAFNARFJORDUR, ICELAND.			Sigurdsson, Johann Agust/0000-0002-5646-6411				APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; Bro F, 1986, Scand J Prim Health Care, V4, P101, DOI 10.3109/02813438609014811; GESLIN P, 1992, CLIN INFECT DIS, V15, P95, DOI 10.1093/clinids/15.1.95; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HOSMER DW, 1989, APPLIED LOGISTIC REG, P83; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; Kristinsson KG, 1995, MICROB DRUG RESIST, V1, P121, DOI 10.1089/mdr.1995.1.121; KRISTINSSON KG, 1992, LANCET, V339, P1606, DOI 10.1016/0140-6736(92)91868-9; KRONVALL G, 1973, J MED MICROBIOL, V6, P187, DOI 10.1099/00222615-6-2-187; KUNIN CM, 1990, PRINCIPLES PRACTICE, P427; LINARES J, 1992, CLIN INFECT DIS, V15, P99, DOI 10.1093/clinids/15.1.99; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; MIETTINEN OS, 1976, AM J EIDEMIOL, V104, P425; MOLSTAD S, 1992, Scandinavian Journal of Primary Health Care, V10, P16, DOI 10.3109/02813439209014029; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; *NORD LAK, 1993, NLN PUBL, V34; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; Ruoff Kathryn L., 1995, P299; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; SWENSON JM, 1986, J CLIN MICROBIOL, V24, P749, DOI 10.1128/JCM.24.5.749-752.1986; *WHO, 1992, AN THER CHEM ACT CLA; Woods Gail L., 1995, P1327	26	412	418	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	1996	313	7054					387	391						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761224				2022-12-28	WOS:A1996VD20600022
J	Miller, PM; Plant, M				Miller, PM; Plant, M			Drinking, smoking, and illicit drug use among 15 and 16 year olds in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine patterns of self reported drinking, smoking, and illicit drug use among a representative United Kingdom sample of people born in 1979. Design-Cross sectional, single phase survey based on a stratified cluster sample of 70 United Kingdom secondary schools during March and April 1995. Pupils completed a 406 item standardised questionnaire under examination conditions. Setting-United Kingdom state and private secondary schools. Subjects-7722 pupils aged 15 and 16. Main outcome measures-Reported use of alcohol, tobacco, and illicit drugs. Results-Almost all the pupils had drunk alcohol, 36% (2772/7689) had smoked cigarettes in the past 30 days, and 42.3% (3264/7722) had at some time used illicit drugs, mainly cannabis. 43% (1546/3546) of boys and 38% (1529/4009) of girls had tried cannabis, Higher levels of smoking were associated with poorer school performance (20.4% (783/3840) with average performance v 44.1% (214/486) with below average performance, F = 79.06, P<0.01), Levels of drug use in 15 and 16 year olds in 1995 were higher in Scotland than in England, Wales, or Northern ireland. Conclusions-Drug experimentation was high among 15 and 16 year olds, and use of cannabis was particularly high among smokers. Cigarette smoking was more common among girls than boys.			Miller, PM (corresponding author), UNIV EDINBURGH,DEPT PSYCHIAT,ALCOHOL & HLTH RES GRP,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND.							Aldridge J., 1995, DRUGS FUTURES CHANGI; ANDERSON J, 1995, ALCOHOL TOBACCO ILLI; *FIF HLTH RES, 1996, REP STUD YOUNG PEOPL; GODDARD E, 1996, TEENAGE DRINKING 199; *HOM OFF, 1995, 1994 HOM OFF; *HOM OFF, 1995, 1993 HOM OFF; *IOW STAT U, 1989, MAN PEC; JOHNSTON LD, 1994, SURVEYING STUDENT DR; LORETTO WA, 1994, DRUG-EDUC PREV POLIC, V1, P143, DOI 10.3109/09687639409017379; MAY C, 1992, ALCOHOL ALCOHOLISM, V27, P109; Plant M., 1992, RISK TAKERS ALCOHOL; RUDAT K, 1992, TOMORROWS YOUNG ADUL; Rudat K, 1992, TODAYS YOUNG ADULTS	13	160	163	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					394	397						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761226				2022-12-28	WOS:A1996VD20600024
J	Yuan, ZM; Huang, YY; Whang, Y; Sawyers, C; Weichselbaum, R; Kharbanda, S; Kufe, D				Yuan, ZM; Huang, YY; Whang, Y; Sawyers, C; Weichselbaum, R; Kharbanda, S; Kufe, D			Role for c-Abl tyrosine kinase in growth arrest response to DNA damage	NATURE			English	Article							RETINOBLASTOMA PROTEIN; INHIBITION; BINDING; P53	THE c-Abl protein tyrosine kinase is activated by certain DNA-damaging agents', and its overexpression causes arrest in the G1 phase of the cell cycle by a mechanism dependent on the tumour-suppressor protein p53 (refs 2-4). Here we investigate the possible role of c-Abl in growth arrest induced by DNA damage. Transient transfection experiments using wild-type or inactivated c-Abl show that both induce expression of p21, an effector of p53, but only wild-type c-Abl downregulates the activity of the cyclin-dependent kinase Cdk2 and causes growth arrest. Exposure to ionizing radiation of cells that stably express active or inactive c-Abl is associated with induction of c-Abl/p53 complexes and p21 expression. However, cells expressing the dominant-negative c-Abl mutant and cells lacking the c-abl gene are impaired in their ability to downregulate Cdk2 or undergo G1 arrest in response to ionizing radiation. We also show that expression of c-Abl kinase in p21(-/-), but not in p53(-/-), cells results in downregulation of Cdk2. Our results suggest that c-Abl kinase contributes to the regulation of growth arrest induced by ionizing radiation by a p53-dependent, p21-independent mechanism.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Chicago			Whang, Young/AAK-7435-2021; Sawyers, Charles/G-5327-2016	Whang, Young/0000-0002-1621-6661				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARTEK J, 1992, ONCOGENE, V7, P101; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOGA A, 1995, ONCOGENE, V11, P791; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MATTIONI T, 1995, ONCOGENE, V10, P1325; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041	18	214	222	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					272	274		10.1038/382272a0	http://dx.doi.org/10.1038/382272a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717045				2022-12-28	WOS:A1996UX79000055
J	Fahey, TP; Peters, TJ				Fahey, TP; Peters, TJ			What constitutes controlled hypertension? Patient based comparison of hypertension guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; MANAGEMENT; CLUSTER; TRIALS	Objectives-To investigate and quantify the extent to which variations in guidelines influence assessment of control of hypertension. Design-Cross sectional study. Selected patients had hypertension assessed as controlled or uncontrolled with guidelines from New Zealand, Canada, the United States, Britain, and the World Health Organisation. Setting-18 general practices in Oxfordshire. Subjects-876 patients with diagnosed hypertension and taking antihypertensive drugs. Main outcome measures-Proportion of patients with controlled hypertension according to each set of guidelines. Results-The proportion of patients with controlled hypertension varied from 17.5% to 84.6% with the different guidelines after adjustment for the sampling method. All five sets of guidelines agreed on the classification for 31% (277) of the patients. The New Zealand guidelines calculate an absolute risk of a cardiovascular event. When this was taken as the standard half of the patients with uncontrolled hypertension by the United States criteria would be treated unnecessarily and 31% of those classified as having controlled hypertension by the Canadian guidelines would be denied beneficial treatment. Conclusions-Hypertension guidelines are inconsistent in their recommendations and need to make clear the absolute benefits and risks of treatment.			Fahey, TP (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.		Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783; Peters, Tim/0000-0003-2881-4180				ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; [Anonymous], 1991, JAMA, V265, P3255; Armitage P., 1987, STAT METHODS MED RES; COLLINS R, 1994, TXB HYPERTENSION, P1156; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DONNER A, 1994, AM J EPIDEMIOL, V140, P279, DOI 10.1093/oxfordjournals.aje.a117247; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; EGGER M, 1995, J HYPERTENS, V13, P813, DOI 10.1097/00004872-199507000-00014; EVANS JBT, 1995, BRIT J GEN PRACT, V45, P15; FAHEY T, 1995, J PUBLIC HEALTH MED, V17, P57; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Grol R, 1992, Qual Health Care, V1, P184, DOI 10.1136/qshc.1.3.184; GROVER SA, 1995, BRIT MED J, V310, P975, DOI 10.1136/bmj.310.6985.975; GROVER SA, 1995, JAMA-J AM MED ASSOC, V274, P801, DOI 10.1001/jama.274.10.801; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HOES AW, 1995, J HYPERTENS, V13, P805; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; LEVY D, 1995, LANCET, V346, P1112, DOI 10.1016/S0140-6736(95)91792-6; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; MYERS MG, 1989, CAN MED ASSOC J, V140, P1141; Payer L., 1988, MED CULTURE VARIETIE; SACKETT DL, 1994, BMJ-BRIT MED J, V309, P755, DOI 10.1136/bmj.309.6957.755; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; SWALES JD, 1994, LANCET, V344, P380; SWALES JD, 1993, J HYPERTENS, V11, P899, DOI 10.1097/00004872-199309000-00003; ZANCHETTI A, 1993, BMJ-BRIT MED J, V307, P1541, DOI 10.1136/bmj.307.6918.1541	30	80	80	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	1996	313	7049					93	96		10.1136/bmj.313.7049.93	http://dx.doi.org/10.1136/bmj.313.7049.93			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688763	Green Published			2022-12-28	WOS:A1996UX69800026
J	Grewal, SIS; Klar, AJS				Grewal, SIS; Klar, AJS			Chromosomal inheritance of epigenetic states in fission yeast during mitosis and meiosis	CELL			English	Article							MATING-TYPE REGION; SWITCHING GENE SWI6; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTIONAL STATES; MEIOTIC RECOMBINATION; EXPRESSION; LOCI; CASSETTES; CHROMATIN; METHYLATION	Inheritance of the active and inactive states of gene expression by individual cells is crucial for development. In fission yeast, mating-type region consists of three loci called mat1, mat2, and mat3. Transcriptionally silent mat2 and mat3 loci are separated by a 15 kb interval, designated the K-region, and serve as donors of information for transcriptionally active mat1 interconversion. In a strain carrying replacement of 7.5 kb of the K-region with the ura4 gene, we discovered that ura4 silencing and efficiency of mating-type switching were covariegated and were regulated by an epigenetic mechanism. Genetic analyses demonstrated that epigenetic states were remarkably stable not only in mitosis but also in meiosis and were linked to the mating-type region. This study indicates that different epigenetic states are heritable forms of chromatin organization at the mat region.			Grewal, SIS (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, GENE REGULAT & CHROMOSOME BIOL LAB, FREDERICK, MD 21702 USA.			Grewal, Shiv/0000-0002-4552-9261	OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-46000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; ANTEQUERA F, 1984, J BIOL CHEM, V259, P8033; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BEACH DH, 1984, EMBO J, V3, P603, DOI 10.1002/j.1460-2075.1984.tb01855.x; BENDER J, 1995, CELL, V83, P725, DOI 10.1016/0092-8674(95)90185-X; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BRUTNELL TP, 1994, GENETICS, V138, P213; COLOT V, 1995, GENETICS, V141, P1299; EGEL R, 1984, CURR GENET, V8, P199, DOI 10.1007/BF00417816; EGEL R, 1989, CURR GENET, V15, P407, DOI 10.1007/BF00376796; EISSENBERG JC, 1995, CHROMATIN STRUCTURE, P147; EKWALL K, 1994, GENETICS, V136, P53; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; KLAR AJS, 1991, GENETICS, V129, P1033; KLAR AJS, 1992, MOL CELLULAR BIOL YE, P745; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; McClintock B, 1987, DISCOVERY CHARACTERI; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PATTERSON GI, 1993, GENETICS, V135, P881; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; SABL JF, 1992, AM J HUM GENET, V50, P1171; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SINGER MJ, 1995, GENE SILENCING HIGHE, P165; THON G, 1993, GENETICS, V134, P1045; THON G, 1992, GENETICS, V131, P287; THON G, 1994, GENETICS, V138, P29; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604	39	194	199	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					95	101		10.1016/S0092-8674(00)80080-X	http://dx.doi.org/10.1016/S0092-8674(00)80080-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689692	Bronze			2022-12-28	WOS:A1996UX93400011
J	Liu, XS; Kim, CN; Yang, J; Jemmerson, R; Wang, XD				Liu, XS; Kim, CN; Yang, J; Jemmerson, R; Wang, XD			Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c	CELL			English	Article							MITOCHONDRIAL-DNA; BCL-2 PROTEIN; DEATH; GENE; LOCALIZATION; DEFICIENCY; CLEAVAGE; ENCODES; CED-3	A cell-free system based on cytosols of normally growing cells is established that reproduces aspects of the apoptotic program in vitro. The apoptotic program is initiated by addition of dATP. Fractionation of cytosol yielded a 15 kDa protein that is required for in vitro apoptosis. The absorption spectrum and protein sequence revealed that this protein is cytochrome c. Elimination of cytochrome c from cytosol by immunodepletion, or inclusion of sucrose to stabilize mitochondria during cytosol preparation, diminished the apoptotic activity. Adding back cytochrome c to the cytochrome c-depleted extracts restored their apoptotic activity. Cells undergoing apoptosis in vivo showed increased release of cytochrome c to their cytosol, suggesting that mitochondria may function in apoptosis by releasing cytochrome c.	EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; UNIV MINNESOTA, SCH MED, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA	Emory University; University of Minnesota System; University of Minnesota Twin Cities				Wang, Xiaodong/0000-0001-9885-356X				BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; DEJONG D, 1994, CANCER RES, V54, P256; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; EEARI M, 1995, EMBO J, V14, P5201; EVANS MJ, 1988, P NATL ACAD SCI USA, V85, P9625, DOI 10.1073/pnas.85.24.9625; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GODAY A, 1985, BIOCHEM PHARMACOL, V34, P3561, DOI 10.1016/0006-2952(85)90734-8; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; HAYAKAWA M, 1993, MOL CELL BIOCHEM, V119, P95, DOI 10.1007/BF00926859; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, PHILOS T R SOC B, V345, P243, DOI 10.1098/rstb.1994.0100; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JEMMERSON R, 1991, EUR J IMMUNOL, V21, P143, DOI 10.1002/eji.1830210122; JEMMERSON R, 1991, P NATL ACAD SCI USA, V88, P4428, DOI 10.1073/pnas.88.10.4428; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WAKADE AR, 1995, J BIOL CHEM, V270, P17986, DOI 10.1074/jbc.270.30.17986; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	48	4227	4453	12	238	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					147	157		10.1016/S0092-8674(00)80085-9	http://dx.doi.org/10.1016/S0092-8674(00)80085-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689682	Bronze			2022-12-28	WOS:A1996UX93400016
J	Hartwig, WC; Cartelle, C				Hartwig, WC; Cartelle, C			A complete skeleton of the giant South American primate Protopithecus	NATURE			English	Article								A COMPLETE Skeleton of a large-bodied New World monkey has been found in Pleistocene cave deposits in the Brazilian state of Bahia. It demonstrates an unprecedented combination of body size, locomotor and cranial morphology. Skeletal features indicate an animal of approximately 25 kg, more than twice the mass of any living South American monkey. We refer the specimen to Protopithecus brasiliensis Lund, 1838, a large Pleistocene primate originally represented by only a proximal femur and distal humerus(1-4). The skeleton resembles species of two distinct New World monkey lineages. The cranium is modified for an enlarged vocal sac typical of living howler monkeys(5-7), and the postcranium includes suspensory and brachiating components of locomotion as seen in living spider and woolly spider monkeys(8). This skeleton confirms that adaptive diversity in neotropical primates was greater in the recent past, and that current interpretations of how their distinctive adaptations evolved should be revised.	UNIV FED MINAS GERAIS,INST GEOCIENCIAS,BELO HORIZONT,MG,BRAZIL; GEORGE WASHINGTON UNIV,DEPT ANTHROPOL,WASHINGTON,DC 20052	Universidade Federal de Minas Gerais; George Washington University								CARTELLE C, 1994, ACTA GEOL LEOPOLD, V17, P411; CARTELLE C, 1993, NEOTROPICAL PRIMATES, V1, P8; Erikson, 1963, S ZOOL SOC LOND, V10, P135; Fleagle JG, 1988, PRIMATE ADAPTATION E; HARTWIG WC, 1995, J HUM EVOL, V28, P189, DOI 10.1006/jhev.1995.1013; HARTWIG WC, 1996, HIST PHIL LIFE SCI, V17, P3; LUND PW, 1838, DET KONG DANSKE VIDE, V8, P61; Martin PS, 1984, QUATERNARY EXTINCTIO; MENDEL F, 1976, FOLIA PRIMATOL, V26, P36, DOI 10.1159/000155728; PERES CA, 1994, J HUM EVOL, V26, P245, DOI 10.1006/jhev.1994.1014; ROSENBERGER AL, 1989, J HUM EVOL, V18, P717, DOI 10.1016/0047-2484(89)90102-4; Ruff C., 1990, P119; SCHON MA, 1971, FOLIA PRIMATOL, V15, P117, DOI 10.1159/000155371; Schon Ybarra MA, 1976, S DEV BAS, P664; YBARRA MAS, 1984, AM J PHYS ANTHROPOL, V63, P65, DOI 10.1002/ajpa.1330630109	15	65	68	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					307	311		10.1038/381307a0	http://dx.doi.org/10.1038/381307a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UM403	8692267				2022-12-28	WOS:A1996UM40300052
J	Battiste, JL; Mao, HY; Rao, NS; Tan, RY; Muhandiram, DR; Kay, LE; Frankel, AD; Williamson, JR				Battiste, JL; Mao, HY; Rao, NS; Tan, RY; Muhandiram, DR; Kay, LE; Frankel, AD; Williamson, JR			alpha helix-RNA major groove recognition in an HIV-1 Rev peptide RRE RNA complex	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; IMMUNODEFICIENCY-VIRUS TAT; CHEMICAL-SHIFT INDEX; NMR-SPECTROSCOPY; CRYSTAL-STRUCTURE; BINDING-SITE; RESPONSIVE ELEMENT; MESSENGER-RNA; SIDE-CHAIN; BASE-PAIRS	The solution structure of a human immunodeficiency virus type-1 (HIV-1) Rev peptide bound to stem-loop IIB of the Rev response element (RRE) RNA was solved by nuclear magnetic resonance spectroscopy. the Rev peptide has an alpha-helical conformation and binds in the major groove of the RNA near a purine-rich internal loop. Several arginine side chains make base-specific contacts, and an asparagine residue contacts a G . A base pair. The phosphate backbone adjacent to a G . G base pair adopts an unusual structure that allows the peptide to access a widened major groove. The structure formed by the two purine-purine base pairs of the RRE creates a distinctive binding pocket that the peptide can use for specific recognition.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; UNIV TORONTO,DEPT MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT CHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,PROT ENGN CTR EXCELLENCE,TORONTO,ON M5S 1A8,CANADA; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Massachusetts Institute of Technology (MIT); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of California System; University of California San Francisco			Williamson, James R/B-2891-2009; Rao, Nageswara/H-8707-2019; Williamson, James/AAL-2104-2021	Williamson, James R/0000-0002-8772-468X; Williamson, James/0000-0002-8772-468X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039589, R01GM053320] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39589, GM-53320, GM-08344] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Battiste JL, 1995, J BIOMOL NMR, V6, P375; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BATTISTE JL, UNPUB; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNGER AT, 1992, X PLOR USER MANUAL V; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GRONENBORN AM, 1994, J BIOMOL NMR, V4, P455; Harada K, 1996, NATURE, V380, P175, DOI 10.1038/380175a0; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; LOGAN TM, 1992, FEBS LETT, V314, P413, DOI 10.1016/0014-5793(92)81517-P; LYU PC, 1993, BIOCHEMISTRY-US, V32, P421, DOI 10.1021/bi00053a006; MILHOLLEN MA, UNPUB; MONTELIONE GT, 1992, J AM CHEM SOC, V114, P10974, DOI 10.1021/ja00053a051; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P201; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; PRITCHARD CE, 1994, NUCLEIC ACIDS RES, V22, P2592, DOI 10.1093/nar/22.13.2592; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; YEN R, 1995, P NATL ACAD SCI USA, V92, P5282; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	48	537	546	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1547	1551		10.1126/science.273.5281.1547	http://dx.doi.org/10.1126/science.273.5281.1547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703216				2022-12-28	WOS:A1996VG59700040
J	Barker, LF; Shulman, NR; Roderick, MD; Hirschman, RJ; Ratner, F; Diefenbach, WCL; Geller, HM				Barker, LF; Shulman, NR; Roderick, MD; Hirschman, RJ; Ratner, F; Diefenbach, WCL; Geller, HM			Transmission of serum hepatitis (Reprinted from JAMA, vol 211, pg 1509, 1970)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint								There is evidence that transmission of serum hepatitis is associated with transmission of virus-like particles, approximately 20 my in diameter, containing the Australia or serum hepatitis (SH) antigen, which is currently referred to as the hepatitis associated antigen (HAA). Virus-like particles containing HAA were in the following materials, inoculation of which produced serum hepatitis: (1) a pool of human plasma, (2) serum obtained during the acute phase of hepatitis from a recipient of the plasma pool, (3) a preparation of human thrombin, and (4) serum from a proved hepatitis carrier. The HAA appeared in the serum samples of 61 individuals inoculated with these materials; serum hepatitis developed in 38 of them. Inoculation of dilutions of the plasma pool showed that serum hepatitis can be transmitted by materials containing HAA in amounts too low to be detected by current techniques.	DIV BIOL STAND,BETHESDA,MD; NIAMD,BETHESDA,MD; NIH,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA								BARKER L F, 1970, Journal of the American Medical Association, V211, P1509, DOI 10.1001/jama.211.9.1509; BARKER LF, 1969, J IMMUNOL, V102, P1529; BAYER ME, 1968, NATURE, V218, P1057, DOI 10.1038/2181057a0; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; BLUMBERG BS, 1968, B NEW YORK ACAD MED, V44, P1566; BLUMBERG BS, 1969, P NATL ACAD SCI USA, V62, P1108, DOI 10.1073/pnas.62.4.1108; GILES JP, 1969, NEW ENGL J MED, V281, P119, DOI 10.1056/NEJM196907172810302; GOCKE DJ, 1969, LANCET, V2, P248; GOCKE DJ, 1969, LANCET, V1, P1055; HIRSCHMAN RJ, 1969, J AMER MED ASSOC, V208, P1667, DOI 10.1001/jama.208.9.1667; LONDON WT, 1969, ANN INTERN MED, V70, P55, DOI 10.7326/0003-4819-70-1-55; MURRAY R, 1955, JAMA-J AM MED ASSOC, V157, P8, DOI 10.1001/jama.1955.02950180010003; MURRAY R, 1955, Bull N Y Acad Med, V31, P341; MURRAY R, 1954, JAMA-J AM MED ASSOC, V154, P1072, DOI 10.1001/jama.1954.02940470024005; NEEFE JR, 1954, JAMA-J AM MED ASSOC, V154, P1066, DOI 10.1001/jama.1954.02940470018004; OKOCHI K, 1968, VOX SANG, V15, P374, DOI 10.1111/j.1423-0410.1968.tb04078.x; PORTER JE, 1953, JAMA-J AM MED ASSOC, V153, P17, DOI 10.1001/jama.1953.02940180019006; PRINCE AM, 1968, P NATL ACAD SCI USA, V60, P814, DOI 10.1073/pnas.60.3.814; SHULMAN NR, 1969, SCIENCE, V165, P304, DOI 10.1126/science.165.3890.304	19	15	15	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					841	844		10.1001/jama.276.10.841	http://dx.doi.org/10.1001/jama.276.10.841			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769597				2022-12-28	WOS:A1996VF21900037
J	Marks, C; Marks, JD				Marks, C; Marks, JD			Phage libraries - A new route to clinically useful antibodies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									SAN FRANCISCO GEN HOSP,DEPT ANESTHESIA,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco								HOOGENBOOM HR, 1992, IMMUNOL REV, V130, P41, DOI 10.1111/j.1600-065X.1992.tb01520.x; MARKS JD, 1992, J BIOL CHEM, V267, P16007; RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2; SCHIER R, IN PRESS J MOL BIOL; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	5	72	77	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					730	733		10.1056/NEJM199609053351008	http://dx.doi.org/10.1056/NEJM199609053351008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH266	8703174				2022-12-28	WOS:A1996VH26600008
J	Hyams, KC; Wignall, FS; Roswell, R				Hyams, KC; Wignall, FS; Roswell, R			War syndromes and their evaluation: From the US Civil War to the Persian Gulf War	ANNALS OF INTERNAL MEDICINE			English	Review							POSTTRAUMATIC-STRESS-DISORDER; CHRONIC FATIGUE SYNDROME; OPERATION-DESERT-STORM; MITRAL-VALVE PROLAPSE; PRIMARY-CARE; NEUROCIRCULATORY ASTHENIA; DACOSTAS SYNDROME; VIETNAM VETERANS; SYMPTOMS; HEALTH	Purpose: To better understand the health problems of veterans of the Persian Gulf War by analyzing previous war-related illnesses and identifying possible unifying factors. Data Source: English-language articles and books on war-related illnesses published since 1863 that were located primarily through a manual search of bibliographies. Data Extraction: Publications were assessed for information on the clinical characteristics of war-related illnesses and the research methods used to evaluate such illnesses. Data Synthesis: Poorly understood war syndromes have been associated with armed conflicts at least since the U.S. Civil War. Although these syndromes have been characterized by similar symptoms (fatigue, shortness of breath, headache, sleep disturbance, forgetfulness, and impaired concentration), no single recurring illness that is unrelated to psychological stress is apparent. However, many types of illness were found among evaluated veterans, including well-defined medical and psychiatric conditions, acute combat stress reaction, post-traumatic stress disorder, and possibly the chronic fatigue syndrome. No single disease is apparent, but one unifying factor stands out: A unique population was intensely scrutinized after experiencing an exceptional, life-threatening set of exposures. As a result, research efforts to date have been unable to conclusively show causality, have been subject to reporting bias, and have lacked similar control populations. In addition to research limitations, war syndromes have involved fundamental, unanswered questions about the importance of chronic somatic symptoms and the factors that create a personal sense of ill health. Conclusion: Until we can better understand what constitutes health and illness in all adult populations, we risk repeated occurrences of unexplained symptoms among veterans after each war.	USN, MED RES UNIT 2, APO, AP 96520 USA; DEPT VET AFFAIRS, VISN 8, BAY PINES, FL 33504 USA	United States Department of Defense; United States Navy	Hyams, KC (corresponding author), USN, MED RES INST, 12300 WASHINGTON AVE, ROCKVILLE, MD 20852 USA.			Roswell, Robert/0000-0003-4358-6534				Abrahams A, 1917, LANCET, V1, P442; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ARCHIBALD HC, 1965, ARCH GEN PSYCHIAT, V12, P475; ARMFIELD F, 1994, MIL MED, V159, P739, DOI 10.1093/milmed/159.12.739; BAKER DB, 1988, ARCH ENVIRON HEALTH, V43, P325; BARSKY AJ, 1988, NEW ENGL J MED, V318, P414, DOI 10.1056/NEJM198802183180705; BARSKY AJ, 1995, JAMA-J AM MED ASSOC, V274, P1931, DOI 10.1001/jama.274.24.1931; BEACH P, 1995, FEDERAL PRACTITIONER, V12, P9; BEACH P, 1995, FEDERAL PRACTITIONER, V12, P15; BEALE P, 1994, BRIT MED J, V308, P1574, DOI 10.1136/bmj.308.6943.1574c; BOGEN G, 1979, JAMA-J AM MED ASSOC, V242, P2391, DOI 10.1001/jama.1979.03300220011002; BOYLE CA, 1989, EPIDEMIOL REV, V11, P1; BROWN D, 1994, WASHINGTON POST 0725, pA9; BROWN D, 1994, WASHINGTON POST 0724, pA1; BROWN D, 1994, WASHINGTON POST 0724, pA19; COATE BD, 1995, 123 ANN M AM PUBL HL, P2198; COHEN ME, 1972, MIL MED, V137, P142; COHEN ME, 1948, ARCH INTERN MED, V81, P260, DOI 10.1001/archinte.1948.00220210014002; Cohn AE, 1919, AM J MED SCI, V158, P453, DOI 10.1097/00000441-191910000-00001; COPE H, 1994, LANCET, V344, P864, DOI 10.1016/S0140-6736(94)92833-9; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P1559, DOI 10.1001/jama.271.20.1559; Cotton T, 1915, BRIT MED J, V1915, P722; COWAN D, 1995, 123 ANN M AM PUBL HL, P2198; Culpin M, 1920, LANCET, V2, P184; Da Costa JM., 1871, AM J MED SCI, V61, P17; DALESSIO DJ, 1978, JAMA-J AM MED ASSOC, V239, P1401, DOI 10.1001/jama.239.14.1401; DECOUFLE P, 1992, AM J EPIDEMIOL, V135, P312, DOI 10.1093/oxfordjournals.aje.a116285; DEFRAITES RF, 1992, INV SUSP OUTBR UNKN; *DEP VET AFF, 1995, FED ACT REL HLTH PER; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; EGENDORF A, 1981, LEGACIES VIETNAM COM, V4; EITREM R, 1990, AM J TROP MED HYG, V43, P207, DOI 10.4269/ajtmh.1990.43.207; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; ETTEDGUI E, 1985, PSYCHIAT CLIN N AM, V8, P89; FRANK JD, 1946, AM J PSYCHIAT, V102, P631, DOI 10.1176/ajp.102.5.631; Fraser F R, 1940, Edinb Med J, V47, P451; FRIEDMAN MJ, 1981, PSYCHOSOMATICS, V22, P931; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GLASS AJ, 1954, AM J PSYCHIAT, V110, P725, DOI 10.1176/ajp.110.10.725; Goldberg J, 1992, Ann Epidemiol, V2, P841, DOI 10.1016/1047-2797(92)90078-5; Grant RT, 1925, HEART-J STUD CIRC, V12, P121; GREEN GM, 1994, JAMA-J AM MED ASSOC, V272, P391, DOI 10.1001/jama.1994.03520050071033; Grinker RR, 1945, MEN STRESS, P82; HAMMOND EC, 1964, AM J PUBLIC HEALTH N, V54, P11, DOI 10.2105/AJPH.54.1.11; HAMMOND WA, 1883, TREATISE INSANITY ME, P411; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; HOLDEN C, 1979, SCIENCE, V205, P770, DOI 10.1126/science.111351; HORTON R, 1994, LANCET, V343, P1150, DOI 10.1016/S0140-6736(94)90245-3; HOWELL JD, 1985, MED HIST S, V5, P34; Hume WE, 1918, LANCET, V1, P529; HYAMS KC, 1995, CLIN INFECT DIS, V20, P1497, DOI 10.1093/clinids/20.6.1497; IMBODEN JB, 1961, ARCH INTERN MED, V108, P393, DOI 10.1001/archinte.1961.03620090065008; IMBODEN JB, 1959, ARCH INTERN MED, V103, P406, DOI 10.1001/archinte.1959.00270030037004; JARCHO S, 1959, AM J CARDIOL, V4, P809, DOI 10.1016/0002-9149(59)90130-4; JARCHO S, 1966, AM J CARDIOL, V18, P892, DOI 10.1016/0002-9149(66)90436-X; KANG HK, 1995, 123 ANN M AM PUBL HL, P2198; KAPLAN C, 1988, J GEN INTERN MED, V3, P177, DOI 10.1007/BF02596128; KATON W, 1984, COMPR PSYCHIAT, V25, P208, DOI 10.1016/0010-440X(84)90009-9; KENTSMITH DK, 1986, MIL MED, V151, P89, DOI 10.1093/milmed/151.2.89; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KLUZNIK JC, 1986, AM J PSYCHIAT, V143, P1443; Kroenke K, 1994, Arch Fam Med, V3, P774; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; LABBATE LA, 1992, HOSP COMMUNITY PSYCH, V43, P831; LATE M, 1996, UD MED           APR, V32, P25; LATE M, 1996, US MED           APR, V32, P1; Lewis T., 1940, SOLDIERS HEART EFFOR; LEWIS T, 1919, SOLDIERS HEART EFFOR; LEWIS T, 1918, MIL SURG, V42, P409; LINDY JD, 1992, PSYCHOTHER PSYCHOSOM, V57, P180, DOI 10.1159/000288596; LITZ BT, 1992, J TRAUMA STRESS, V5, P131, DOI 10.1007/BF00976818; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MACILWAIN C, 1995, NATURE, V373, P92, DOI 10.1038/373092a0; Mackenzie J, 1916, BRIT MED J, V1916, P117, DOI 10.1136/bmj.1.2873.117; Maclean W C, 1867, Br Med J, V1, P161; MACLIWAINE JE, 1918, J ROY ARMY MED CORPS, V30, P357; MCALLISTER B, 1994, WASHINGTON POST 0725, pA1; MILNER IB, 1994, JAMA-J AM MED ASSOC, V271, P661, DOI 10.1001/jama.1994.03510330039024; Mott FW, 1916, LANCET, V1, P331; *NAT AC PR, 1995, HLTH CONS SERV PERS; *NAT AC PR, 1994, VET AG OR HLTH EFF H; *NAT AC PR, 1995, EV US DEP DEF PERS G; Newham D, 1979, Physiotherapy, V65, P52; NIXON PGF, 1993, J ROY COLL PHYS LOND, V27, P377; *OFF ASS SECR DEF, 1996, COMPR CLIN EV PROGR; *OFF UND DEF ACQ T, 1994, REP DEF SCI BOARD TA; Parkinson J, 1916, LANCET, V2, P133; PAUL O, 1987, BRIT HEART J, V58, P306; Penman AD, 1996, MIL MED, V161, P1; PERCONTE ST, 1993, MIL MED, V158, P516, DOI 10.1093/milmed/158.8.516; PETERS DC, 1863, AM MED TIMES, V6, P75; *PRES ADV COMM GUL, 1996, INT REP; QUIN NE, 1982, MIL MED, V147, P728, DOI 10.1093/milmed/147.9.728; REVELL T, 1995, BRIT MED J, V310, P1073, DOI 10.1136/bmj.310.6986.1073a; ROBINSON A, 1995, CAN MED ASSOC J, V152, P944; ROHT LH, 1985, AM J EPIDEMIOL, V122, P418, DOI 10.1093/oxfordjournals.aje.a114123; Ross M C, 1993, Arch Psychiatr Nurs, V7, P265; ROY MJ, 1994, FEDERAL PRACTITIONER, V11, P13; ROY MJ, 1994, FED PRACTITIONER, V11, P22; Rudolf RD, 1916, CAN MED ASSOC J, V6, P796; RUDZKI SJ, 1984, MED J AUSTRALIA, V141, P766, DOI 10.5694/j.1326-5377.1984.tb113262.x; RYANWENGER NM, 1992, MIL MED, V157, P447, DOI 10.1093/milmed/157.9.447; Salmon T, 1929, NEUROPSYCHIATRY, V10; SHALEV A, 1990, PSYCHOSOMATICS, V31, P197, DOI 10.1016/S0033-3182(90)72195-0; SILER JF, 1928, COMMUNICABLE OTHER D, V9; SOLOMON Z, 1987, J PSYCHOSOM RES, V31, P131, DOI 10.1016/0022-3999(87)90108-5; SOLOMON Z, 1992, FAM PROCESS, V31, P289, DOI 10.1111/j.1545-5300.1992.00289.x; SOLOMON Z, 1988, BEHAV MED, V14, P179, DOI 10.1080/08964289.1988.9935143; SOUTHWICK SM, 1993, AM J PSYCHIAT, V150, P1524; STRAUS SE, 1994, J INFECT DIS, V170, P1, DOI 10.1093/infdis/170.1.1; STRAUS SE, 1991, REV INFECT DIS, V13, pS2; STRETCH RH, 1995, MIL MED, V160, P131, DOI 10.1093/milmed/160.3.131; Sutker P.B., 1991, PSYCHOL ASSESSMENT J, V3, P520, DOI DOI 10.1037/1040-3590.3.4.520; SUTKER PB, 1994, J TRAUMA STRESS, V7, P159; SUTKER PB, 1991, AM J PSYCHIAT, V148, P67; SUTKER PB, 1993, J SOC ISSUES, V49, P33, DOI 10.1111/j.1540-4560.1993.tb01180.x; Venning JA, 1919, BRIT MED J, V1919, P337; VERBRUGGE LM, 1987, MED CARE, V25, P539, DOI 10.1097/00005650-198706000-00008; WESSELY S, 1995, LANCET, V345, P1333, DOI 10.1016/S0140-6736(95)92537-6; Wood P, 1941, BRIT MED J, V1941, P805; Wood P, 1941, BRIT MED J, V1941, P767; Wood P, 1941, BMJ-BRIT MED J, V1941, P845, DOI 10.1136/bmj.1.4196.845; WOOLEY CF, 1976, CIRCULATION, V53, P749, DOI 10.1161/01.CIR.53.5.749; WOOLEY CF, 1985, AM J CARDIOL, V55, P1107, DOI 10.1016/0002-9149(85)90755-6; Writer JV, 1996, JAMA-J AM MED ASSOC, V275, P118, DOI 10.1001/jama.275.2.118; 1922, BRIT MED J, V1, P68; 1996, ARCH INTERN MED, V155, P262; 1988, JAMA-J AM MED ASSOC, V259, P2715; 1996, LANCET, V347, P341; 1995, MMWR-MORBID MORTAL W, V44, P443	133	268	274	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					398	405		10.7326/0003-4819-125-5-199609010-00007	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE079	8702091				2022-12-28	WOS:A1996VE07900007
J	Paltiel, O				Paltiel, O			Atonement	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Paltiel, O (corresponding author), HADASSAH UNIV HOSP, DEPT SOCIAL MED, POB 12000, IL-91120 JERUSALEM, ISRAEL.								0	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					416	417		10.7326/0003-4819-125-5-199609010-00010	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702094				2022-12-28	WOS:A1996VE07900010
J	Rosse, WF				Rosse, WF			Epidemiology of PNH	LANCET			English	Editorial Material							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; APLASTIC-ANEMIA				Rosse, WF (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710, USA.							DACIE J V, 1972, Series Haematologica, V5, P3; FUJIOKA S, 1989, ACTA HAEMATOL JAPON, V52, P1386; Graham ML, 1996, BRIT J HAEMATOL, V92, P707, DOI 10.1046/j.1365-2141.1996.365901.x; Gull WW, 1866, GUYS HOSP REP, V12, P381; HAM TH, 1938, NEW ENGL J MED, V217, P915; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; KRUATRACHUE M, 1978, BRIT J HAEMATOL, V39, P267, DOI 10.1111/j.1365-2141.1978.tb01097.x; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P2336; SCHUBERT J, 1994, BLOOD, V83, P2323; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T	10	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					560	560		10.1016/S0140-6736(05)64792-7	http://dx.doi.org/10.1016/S0140-6736(05)64792-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774563				2022-12-28	WOS:A1996VF18600004
J	Lee, SL; Sadovsky, Y; Swirnoff, AH; Polish, JA; Goda, P; Gavrilina, G; Milbrandt, J				Lee, SL; Sadovsky, Y; Swirnoff, AH; Polish, JA; Goda, P; Gavrilina, G; Milbrandt, J			Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1)	SCIENCE			English	Article							GONADOTROPIN-RELEASING-HORMONE; RAT PITUITARY-CELLS; GENE-EXPRESSION; BETA-SUBUNIT; TRANSGENIC MICE; GROWTH; RECEPTOR; PROTEIN; DNA; NUCLEAR	The immediate-early transcription factor NGFl-A (also called Egr-1, zif/268, or Krox-24) is thought to couple extracellular signals to changes in gene expression, Although activins and inhibins regulate follicle-stimulating hormone (FSH) synthesis, no factor has been identified that exclusively regulates luteinizing hormone (LH) synthesis. An analysis of NGFl-A-deficient mice derived from embryonic stem cells demonstrated female infertility that was secondary to LH-beta deficiency. Ovariectomy led to increased amounts of FSH-beta but not LH-beta messenger RNA, which suggested a pituitary defect. A conserved, canonical NGFl-A site in the LH-beta promoter was required for synergistic activation by NGFl-A and steroidogenic factor-1 (SF-1). NGFl-A apparently influences female reproductive capacity through its regulation of LH-beta transcription.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [CA53524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA053524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beamer W. G., 1983, The mouse in biomedical research. Volume III. Normative biology, immunology, and husbandry, P165; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLAYTON RN, 1991, MOL CELL ENDOCRINOL, V80, P193, DOI 10.1016/0303-7207(91)90156-M; CLAYTON RN, 1993, HUM REPROD, V8, P29, DOI 10.1093/humrep/8.suppl_2.29; DALKIN AC, 1993, ENDOCRINOLOGY, V132, P1297, DOI 10.1210/en.132.3.1297; DAY ML, 1990, J BIOL CHEM, V265, P15253; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JAMESON L, 1984, J BIOL CHEM, V259, P5474; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; KIM KE, 1990, MOL CELL ENDOCRINOL, V74, P101, DOI 10.1016/0303-7207(90)90112-L; LALA DS, 1995, STEROIDS, V60, P10, DOI 10.1016/0039-128X(94)00002-T; Lee S. A., UNPUB; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; RUGH R, 1990, MOUSE ITS REPRODUCTI, P7; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SAADE G, 1989, ENDOCRINOLOGY, V124, P1744, DOI 10.1210/endo-124-4-1744; SAADE G, 1989, J MOL ENDOCRINOL, V2, P213, DOI 10.1677/jme.0.0020213; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; WATSON MA, 1990, DEVELOPMENT, V110, P173; WEISS J, 1992, ENDOCRINOLOGY, V130, P415, DOI 10.1210/en.130.1.415; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	31	418	423	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1219	1221		10.1126/science.273.5279.1219	http://dx.doi.org/10.1126/science.273.5279.1219			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703054				2022-12-28	WOS:A1996VE47600037
J	Anderson, RM; Donnelly, CA; Ferguson, NM; Woolhouse, MEJ; Watt, CJ; Udy, HJ; MaWhinney, S; Dunstan, SP; Southwood, TRE; Wilesmith, JW; Ryan, JBM; Hoinville, LJ; Hillerton, JE; Austin, AR; Wells, GAH				Anderson, RM; Donnelly, CA; Ferguson, NM; Woolhouse, MEJ; Watt, CJ; Udy, HJ; MaWhinney, S; Dunstan, SP; Southwood, TRE; Wilesmith, JW; Ryan, JBM; Hoinville, LJ; Hillerton, JE; Austin, AR; Wells, GAH			Transmission dynamics and epidemiology of BSE in British cattle	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; SCRAPIE; SHEEP; OPTIMIZATION; MICE; PRP; VARIABLES; GENE	A comprehensive analysis of the bovine spongiform encephalopathy (BSE) epidemic in cattle in Great Britain assesses past, present and future patterns in the incidence of infection and disease, and allows a critical appraisal of different culling policies for eradication of the disease.	UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA; CENT VET LAB, ADDLESTONE KT15 3NB, SURREY, ENGLAND; INST ANIM HLTH, COMPTON NG20 7NN, BERKS, ENGLAND	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Anderson, RM (corresponding author), UNIV OXFORD, DEPT ZOOL, CTR EPIDEMIOL INFECT DIS, OXFORD OX1 3PS, ENGLAND.		Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093; Anderson, Roy/0000-0002-9528-3175; Donnelly, Christl/0000-0002-0195-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; Asher D M, 1976, Ann Clin Lab Sci, V6, P84; BACCHETTI P, 1993, STAT SCI, V8, P82, DOI 10.1214/ss/1177010994; *BOV SPONG ENC ORD, 1988, 1039 BOV SPONG ENC O; BROOKMEYER R, 1988, J AM STAT ASSOC, V83, P301, DOI 10.2307/2288844; Caughley G, 1980, ANAL VERTEBRATE POPU; DAWSON M, 1991, CURRENT TOPICS VET M, P25; *DEP AGR FISH SCOT, 1981, 1980 1989 DEP AGR FI; *DEP AGR FISH SCOT, 1975, 1974 1979 DEP AGR FI; DICKINSON AG, 1974, J COMP PATHOL, V84, P19, DOI 10.1016/0021-9975(74)90023-1; Dickinson AG., 1979, SLOW TRANSMISSIBLE D, P13; DORRELL S, 1996, COMMUNICATION   0320; ESSLEMONT RJ, 1995, DAISY; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; Foster JD, 1996, VET REC, V138, P546, DOI 10.1136/vr.138.22.546; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; HALL JG, 1986, RUMINANT IMMUNE SYST; HOINVILLE LJ, 1995, VET REC, V136, P312, DOI 10.1136/vr.136.13.312; HUNTER N, 1994, VET REC, V135, P400, DOI 10.1136/vr.135.17.400; HUNTER N, 1989, VET REC, V124, P364, DOI 10.1136/vr.124.14.364; Jacobs D. A. H., 1977, STATE ART NUMERICAL; KIMBERLIN RH, 1993, INTERVIROLOGY, V35, P208, DOI 10.1159/000150311; KIMBERLIN RH, 1988, CIBA F SYMP, V135, P37; KIMBERLIN RH, 1994, ANN NY ACAD SCI, V724, P210, DOI 10.1111/j.1749-6632.1994.tb38911.x; KIRKPATRICK S, 1984, J STAT PHYS, V34, P975, DOI 10.1007/BF01009452; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Madge D. S., 1975, MAMMALIAN ALIMENTARY; *MAFF, 1989, REP WORK PART BOV SP; MARTIN T, 1991, P EUR SOC VET VIR SE, P148; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; MCKINLEY MP, 1989, NEUROLOGY, V39, P1319, DOI 10.1212/WNL.39.10.1319; MIDDLETON DJ, 1993, VET REC, V132, P545, DOI 10.1136/vr.132.22.545; *MILK MARK BOARD N, 1991, MONTHL STAT MILK REC; *MIN AGR FISH FOOD, 1992, 1991 1994 AGR CENS S; *MIN AGR FISH FOOD, 1975, 1974 1989 MIN AGR FI; *MIN AGR FISH FOOD, 1996, SPONG ENNC GREAT BRI; OUTRAM GW, 1973, NATURE, V241, P536, DOI 10.1038/241536a0; PRESS WH, 1992, NUMEICAL RECIPES C; Prusiner SB, 1996, SEMIN VIROL, V7, P159, DOI 10.1006/smvy.1996.0021; RICHARDS MS, 1993, P SOC VET EP PREV ME, P70; *SCOTT OFF EC, 1991, 1990 1994 SCOTT OFF; *SPONG ENC ADV COM, 1995, TRANSM SPONG ENC SUM; Stekel DJ, 1996, NATURE, V381, P119, DOI 10.1038/381119a0; VANDERBILT D, 1984, J COMPUT PHYS, V56, P259, DOI 10.1016/0021-9991(84)90095-0; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLS GAH, 1994, VET REC, V135, P40, DOI 10.1136/vr.135.2.40; WILESMITH JW, 1992, VET REC, V130, P90, DOI 10.1136/vr.130.5.90; WILESMITH JW, 1994, PHILOS T R SOC B, V343, P357, DOI 10.1098/rstb.1994.0029; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; WILESMITH JW, 1993, VET REC, V132, P300, DOI 10.1136/vr.132.12.300; WILESMITH JW, UNPUB NATURE; WILESMITH JW, SERONO S; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; 1996, PROGRAMME ERADICATE	55	496	513	1	62	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 29	1996	382	6594					779	788		10.1038/382779a0	http://dx.doi.org/10.1038/382779a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752271				2022-12-28	WOS:A1996VE34700038
J	Perrimon, N				Perrimon, N			Serpentine proteins slither into the wingless and hedgehog fields	CELL			English	Review							DROSOPHILA; ENCODES				Perrimon, N (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,200 LONGWOOD AVE,BOSTON,MA 02115, USA.			Perrimon, Norbert/0000-0001-7542-472X				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; DIMINGUEZ M, 1996, SCIENCE, V272, P1621; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; ORSULIC S, 1996, IN PRESS J CELL BIOL; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	20	68	84	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					513	516		10.1016/S0092-8674(00)80124-5	http://dx.doi.org/10.1016/S0092-8674(00)80124-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752205	Bronze			2022-12-28	WOS:A1996VE23500001
J	Beltman, FW; Heesen, WF; Kok, RHJ; Smit, AJ; May, JF; deGraeff, PA; Havinga, TK; Schuurman, FH; vanderVeur, E; Lie, KI; MeyboomdeJong, B				Beltman, FW; Heesen, WF; Kok, RHJ; Smit, AJ; May, JF; deGraeff, PA; Havinga, TK; Schuurman, FH; vanderVeur, E; Lie, KI; MeyboomdeJong, B			Predictive value of ambulatory blood pressure shortly after withdrawal of antihypertensive drugs in primary care patients	BRITISH MEDICAL JOURNAL			English	Article							THERAPY	Objective-To determine whether ambulatory blood pressure eight weeks after withdrawal of antihypertensive medication is a more sensitive measure than seated blood pressure to predict blood pressure in the long term. Design-Patients with previously untreated diastolic hypertension were treated with antihypertensive drugs for one year; these were withdrawn in patients with well controlled blood pressure, who were then followed for one year. Setting-Primary care. Subjects-29 patients fulfilling the criteria for withdrawal of antihypertensive drugs. Main outcome measures-Sensitivity, specificity, and positive and negative predictive value of seated and ambulatory blood pressure eight weeks after withdrawal of antihypertensive drugs. Results-Eight weeks after withdrawal of medication, mean diastolic blood pressure returned to the pretreatment level on ambulatory measurements but not on seated measurements. One;year after withdrawal of medication, mean diastolic blood pressure had returned to the pretreatment revel both for seated and ambulatory blood pressure. For ambulatory blood pressure, the sensitivity and the positive predictive value eight weeks after withdrawal of medication were superior to those for seated blood pressure; specificity and negative predictive value were comparable for both types of measurement. Receiver operating characteristic curves showed that the results were not dependent on the cut off vales that were used. Conclusion-Ambulatory blood pressure eight weeks after withdrawal of antihypertensive drugs predicts long term blood pressure better than measurements made when the patient is seated.	UNIV GRONINGEN HOSP,DEPT CARDIOL,NL-9700 RB GRONINGEN,NETHERLANDS; GRONINGEN HYPERTENS SERV,GEN PRACTITIONERS LAB,NL-9713 EC GRONINGEN,NETHERLANDS	University of Groningen	Beltman, FW (corresponding author), UNIV GRONINGEN,DEPT GEN PRACTICE,ANT DEUSINGLAAN 4,NL-9713 AW GRONINGEN,NETHERLANDS.							APPEL LJ, 1993, ANN INTERN MED, V118, P867, DOI 10.7326/0003-4819-118-11-199306010-00008; DORFMAN DD, 1969, J MATH PSYCHOL, V6, P487, DOI 10.1016/0022-2496(69)90019-4; FLETCHER AE, 1988, J HYPERTENS, V6, P431, DOI 10.1097/00004872-198806000-00001; METZ CE, 1986, INVEST RADIOL, V21, P720, DOI 10.1097/00004424-198609000-00009; SCHMIEDER RE, 1990, CARDIOVASC DRUG THER, V4, P1487, DOI 10.1007/BF02026496; STAESSEN J, 1990, J HYPERTENS, V8, pS57; STAESSEN JA, 1993, J HYPERTENS, V11, P1289; STANTON A, 1992, HYPERTENSION, V19, P93, DOI 10.1161/01.HYP.19.1.93	8	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					404	406						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761232				2022-12-28	WOS:A1996VD20600030
J	Fuchs, SC; Victora, CG; Martines, J				Fuchs, SC; Victora, CG; Martines, J			Case-control study of risk of dehydrating diarrhoea in infants in vulnerable period after full weaning	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OTITIS-MEDIA; YOUNG-CHILDREN; BRAZIL; DISEASES; DEATHS	Objectives-To investigate risk factors for dehydrating diarrhoea in infants, with special interest in the weaning period. Design-Case-control study. Setting-Metropolitan area of Porto Alegre, Brazil. Subjects-Cases were 192 children aged 0-23 months hospitalised with acute diarrhoea and moderate to severe dehydration. Controls were 192 children matched for age and neighbourhood who did not have diarrhoea in the previous week. Main outcome measures-Associations between dehydrating diarrhoea and child's age, type of milk consumed, time since breast feeding stopped, and breast feeding status. Results-In infants aged <12 months the risk of dehydrating diarrhoea was significantly higher in the first 9 months of life (P<0.001), and in those aged 12-23 months the risk was again greater in younger children (12-17 months) (P = 0.03). The type of milk consumed before start of diarrhoea episode was strongly associated with dehydration independent of socioeconomic, environmental, maternal reproductive, demographic, and health services factors. Compared with infants exclusively breast fed, bottle fed infants were at higher risk (odds ratio (95% confidence interval) for cow's milk 6.0 (1.8 to 19.8), for formula milk 6.9 (1.4 to 33.3)). Compared with those still breast feeding, children who stopped in the previous two months were more likely to develop dehydrating diarrhoea (odds ratio 8.4 (2.4 to 29.6)). This risk decreased with time since breast feeding stopped. Conclusion-These results confirm the protective effect of breast feeding and suggest there is a vulnerable period soon after breast feeding is stopped, which may be of relevance for developing preventive strategies.	UNIV FED PELOTAS, SCH MED, MESTRADO EPIDEMIOL, PELOTAS, RS, BRAZIL; WHO, DIARRHOEAL DIS CONTROL PROGRAMME, GENEVA, SWITZERLAND	Universidade Federal de Pelotas; World Health Organization	Fuchs, SC (corresponding author), UNIV FED RIO GRANDE SUL, SCH MED, DEPT SOCIAL MED, R RAMIRO BARCELOS 2600, SALA 415, BR-90035003 PORTO ALEGRE, RS, BRAZIL.		Fuchs, Sandra C/T-2670-2019; Victora, Cesar Gomes/Y-2455-2019; Victora, Cesar G/D-4476-2013	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180				ANIANSSON G, 1994, PEDIATR INFECT DIS J, V13, P183, DOI 10.1097/00006454-199403000-00003; BARAHAVIT Z, 1980, INFECT IMMUN, V29, P417; BARROS FC, 1990, 3 POP COUNC; BLACK RE, 1989, AM J EPIDEMIOL, V129, P785, DOI 10.1093/oxfordjournals.aje.a115193; Breslow N, 1980, STATISTICAL METHODS, V32; DUNCAN B, 1993, PEDIATRICS, V91, P867; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; GIUGLIANI ERJ, 1992, ACTA PAEDIATR, V81, P484, DOI 10.1111/j.1651-2227.1992.tb12279.x; GLASS RI, 1989, ACTA PAEDIATR SCAND, P131; HANSON LA, 1985, PEDIATRICS, V75, P172; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; LODINOVAZADNIKOVA R, 1991, PEDIATR RES, V29, P396, DOI 10.1203/00006450-199104000-00013; MAHMOOD DA, 1989, B WORLD HEALTH ORGAN, V67, P701; NARAYANAN I, 1989, ACTA PAEDIATR SCAND, P126; SASSEN ML, 1994, AM J OTOLARYNG, V15, P351, DOI 10.1016/0196-0709(94)90134-1; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; VICTORA CG, 1989, AM J EPIDEMIOL, V129, P1032, DOI 10.1093/oxfordjournals.aje.a115207; VICTORA CG, 1994, PEDIATRICS, V93, P977; VICTORA CG, 1992, B WORLD HEALTH ORGAN, V70, P467; VICTORA CG, 1987, LANCET, V2, P319; World Health Organization, 1991, WHOCDDSER9114	22	27	28	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	1996	313	7054					391	394						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761225	Green Published			2022-12-28	WOS:A1996VD20600023
J	Haynes, RB; McKibbon, KA; Kanani, R				Haynes, RB; McKibbon, KA; Kanani, R			Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications	LANCET			English	Review							SCHIZOPHRENIC-PATIENTS; IMPROVE COMPLIANCE; HYPERTENSION; PUBLICATION; STRATEGIES; MANAGEMENT; DETECT	Background Low adherence of patients to prescribed, self-administered medical interventions is ubiquitous. Low adherence limits the benefits of current medical care. Efforts to assist patients to follow treatments might improve the efficiency of care and substantially enhance benefits. Our objective was to summarise the results of randomised controlled trials (RCTs) of interventions to help patients follow prescriptions for medications. Methods A previous systematic review was updated through computerised searches in Medline, International Pharmaceutical Abstracts, Psychinfo, and HSTAR online databases; bibliographies in articles on patient adherence; articles in the reviewers' personal collections; and contact with authors. Articles were judged of interest if they reported original data concerning an unconfounded RCT of an intervention to improve adherence with prescribed medications, with one or more measure of medication adherence, one or more measure of treatment outcome, at least 80% follow-up of each group studied, and, for longterm treatments, at least 6 months of follow-up for studies with positive initial findings. Information on study design features, interventions and controls, and findings were extracted by one reviewer (RK) and checked by the other two reviewers. Findings 1553 relevant citations and abstracts were screened, 252 full text articles were reviewed in detail, and 13 RCTs met all criteria. The studies were too disparate in clinical problems, adherence interventions, measures and reporting of adherence, and the clinical outcomes studied to warrant meta-analysis. Seven of 15 interventions were associated with improvements in adherence and six interventions led to improvements in treatment outcomes. For short-term treatments, one study showed an effect on adherence and outcome of counselling and written information. The interventions that were effective for long term care were complex, including various combinations of more convenient care, information, counselling, reminders, self-monitoring, reinforcement, family therapy, and other forms of additional supervision or attention. Even the most effective interventions did not lead to substantial improvements in adherence. Interpretation Although adherence and treatment outcomes can be improved by certain-usually complex-interventions, full benefits of medications cannot be realised at currently achievable levels of adherence. It is time that additional efforts be directed towards developing and testing innovative approaches to assist patients to follow treatment prescriptions.			Haynes, RB (corresponding author), MCMASTER UNIV, HLTH SCI CTR, HLTH INFORMAT RES UNIT, 3H7, 1200 MAIN ST W, HAMILTON, ON L8N 3Z5, CANADA.			Haynes, Robert Brian/0000-0002-1453-3196				BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAIRD MG, 1984, CLIN INVEST MED, V7, P95; BASS MJ, 1986, CAN MED ASSOC J, V134, P1247; BECKER LA, 1986, J FAM PRACTICE, V22, P357; COLCHER IS, 1972, J AMER MED ASSOC, V222, P657, DOI 10.1001/jama.222.6.657; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Gordis L, 1979, COMPLIANCE HLTH CARE, P23; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HAYNES RB, 1976, LANCET, V1, P1265; HAYNES RB, 1987, PATIENT EDUC COUNS, V10, P155, DOI 10.1016/0738-3991(87)90095-4; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; HAYNES RB, 1982, HYPERTENSION, V4, P415; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; HOWLAND JS, 1990, J FAM PRACTICE, V31, P62; JOHNSON AL, 1978, CAN MED ASSOC J, V119, P1034; LOGAN AG, 1981, HYPERTENSION, V3, P211, DOI 10.1161/01.HYP.3.2.211; LOGAN AG, 1979, LANCET, V2, P1175; MACHARIA WM, 1992, JAMA-J AM MED ASSOC, V267, P1813, DOI 10.1001/jama.267.13.1813; PETERSON GM, 1984, EPILEPSIA, V25, P412, DOI 10.1111/j.1528-1157.1984.tb03436.x; SACKETT DL, 1975, LANCET, V1, P1205; Sackett DL, 1979, COMPLIANCE HLTH CARE; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; STRANG J S, 1981, Psychopharmacology Bulletin, V17, P87; XIONG W, 1994, BRIT J PSYCHIAT, V165, P239, DOI 10.1192/bjp.165.2.239; ZHANG ML, 1994, BRIT J PSYCHIAT, V165, P96, DOI 10.1192/S0007125000293045	26	468	485	0	36	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1996	348	9024					383	386						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709739				2022-12-28	WOS:A1996VB42600015
J	Khan, WA; Bennish, ML; Seas, C; Khan, EH; Ronan, A; Dhar, U; Busch, W; Salam, MA				Khan, WA; Bennish, ML; Seas, C; Khan, EH; Ronan, A; Dhar, U; Busch, W; Salam, MA			Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139	LANCET			English	Article							DOUBLE-BLIND TRIAL; TETRACYCLINE; FURAZOLIDONE; THERAPY; ADULTS	Background Effective antimicrobial therapy can reduce the duration and volume of cholera diarrhoea by half, However, such treatment is currently limited by Vibrio cholerae resistance to the drugs commonly prescribed for cholera, and by the difficulties involved in the administration of multi-drug doses under field conditions, Because of its favourable pharmacokinetics we thought it likely that single-dose ciprofloxacin would be effective in the treatment of cholera. Methods In this double-blind study treatment was either a single 1 g oral dose of ciprofloxacin plus doxycycline placebo, or a single 300 mg oral dose of doxycycline plus ciprofloxacine placebo. 130 moderately or severely dehydrated men infected with V cholerae 01 and 130 infected with V cholerae 0139 were randomly assigned treatment. Patients stayed in hospital for 5 days. We measured fluid intake and stool volume every 6 h, and a sample of stool for culture was obtained daily. The primary outcome measures were clinical success-the cessation of watery stool within 48 h; and bacteriological success-absence of V cholerae from cultures of stool after study day 2. Findings Among patients infected with V cholerae 01, treatment was clinically successful in 62 (94%) of 66 patients who received ciprofloxacin and in 47 (73%) of 64 who receive doxycycline (difference 21% [95% CI 8-33]); the corresponding proportions with bacteriological success were 63 (95%) and 44 (69%) (27% [14-39]). Among patients infected with V cholerae 0139, treatment was successful in 54 (92%) of 59 patients who ciprofloxacin and in 65 (92%) of 71 who received doxycycline (<1% [-9 to 9]), and bacteriologically successful in 58 (98%) and 56 (79%), respectively (19% [9-30]). Total volume of watery stool did not differ significantly between ciprofloxadin-group and doxycycline-group patients infected with either V cholerae 01 or 0139. All but one of the V cholerae 01 and all of the 0139 isolates were susceptible in vitro to doxycycline, whereas 48 (37%) of the V cholerae 01 isolates and none of the 0139 isolates were resistant to tetracycline. Treatment clinically failed in 14 (52%) of 27 doxycycline-treated patients infected with a tetracycline-resistant V cholerae 01 strain, compared with three (8%) of 37 patients infected with a tetracycline-susceptible strain (44% [23-65]). Interpretation Single-dose ciprofloxacin is effective in the treatment of cholera caused by V cholerae 01 or 0139 and is better than single-dose doxycycline in the eradication of V cholerae from stool. Single-dose ciprofloxacin may also be the preferred treatment in areas where tetracycline-resistant V cholerae are common. In V cholerae, in-vitro doxycycline susceptibilities are not a useful indicator of the in-vivo efficacy of the drug.	TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DEPT PEDIAT, BOSTON, MA 02111 USA; INT CTR DIARRHOEAL DIS RES, DHAKA 1000, BANGLADESH; UNIV PERUANA CAYETANO HEREDIA, INST MED TROP ALEXANDER VON HUMBOLDT, LIMA, PERU; ROYAL NEWCASTLE HOSP, CTR CLIN EPIDEMIOL & BIOSTAT, NEWCASTLE, NSW 2300, AUSTRALIA; BAYER AG, PHARMA RES CTR, D-5600 WUPPERTAL, GERMANY	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; International Centre for Diarrhoeal Disease Research (ICDDR); Universidad Peruana Cayetano Heredia; University of Newcastle; Bayer AG				Seas, Carlos/0000-0001-7067-9141				ALAM AN, 1990, BRIT MED J, V300, P1619, DOI 10.1136/bmj.300.6740.1619; [Anonymous], 1995, Lancet, V345, P339; Bennish Michael L., 1994, P229; Bennish Michael L., 1995, P1499; BHATTACHARYA SK, 1990, ANTIMICROB AGENTS CH, V34, P939, DOI 10.1128/AAC.34.5.939; DE S, 1976, B WORLD HEALTH ORGAN, V54, P177; DEPAOLA A, 1988, APPL ENVIRON MICROB, V54, P1861, DOI 10.1128/AEM.54.7.1861-1863.1988; DHAR U, 1996, IN PRESS T R SOC TRO; DUPONT HL, 1993, T ROY SOC TROP MED H, V87, P31, DOI 10.1016/0035-9203(93)90534-W; GOTUZZO E, 1995, CLIN INFECT DIS, V20, P1485, DOI 10.1093/clinids/20.6.1485; GREENOUGH WB, 1964, LANCET, V1, P355; ISLAM MR, 1987, GUT, V28, P1029, DOI 10.1136/gut.28.8.1029; KHAN WA, 1995, T ROY SOC TROP MED H, V89, P103, DOI 10.1016/0035-9203(95)90675-4; MHALU FS, 1984, LANCET, V2, P82; MURRAY BE, 1986, REV INFECT DIS, V8, pS172; RABBANI GH, 1989, ANTIMICROB AGENTS CH, V33, P1447, DOI 10.1128/AAC.33.9.1447; RABBANI GH, 1991, ANTIMICROB AGENTS CH, V35, P1864, DOI 10.1128/AAC.35.9.1864; SACK DA, 1978, ANTIMICROB AGENTS CH, V14, P462, DOI 10.1128/AAC.14.3.462; SALAM MA, 1988, J PEDIATR-US, V113, P901, DOI 10.1016/S0022-3476(88)80029-5; SCHAAD UB, 1995, PEDIATR INFECT DIS J, V14, P1, DOI 10.1097/00006454-199501000-00001; SCHOLL H, 1987, J CHROMATOGR-BIOMED, V416, P321, DOI 10.1016/0378-4347(87)80515-7; Vincent S., 1989, THEORY APPL MICROBIO; *WHO, 1991, WHOCDDSER804REV2; YAMAMOTO T, 1995, ANTIMICROB AGENTS CH, V39, P241, DOI 10.1128/AAC.39.1.241; 1995, WKLY EPIDEMIOL REC, V70, P201	25	51	57	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 3	1996	348	9023					296	300		10.1016/S0140-6736(96)01180-4	http://dx.doi.org/10.1016/S0140-6736(96)01180-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709688				2022-12-28	WOS:A1996VA25000009
J	Smee, PH				Smee, PH			Controversies in management - Should insurance companies have access to patients' medical records? Denying access would do more harm than good	BRITISH MEDICAL JOURNAL			English	Article											Smee, PH (corresponding author), ASSOC BRITISH INSURERS,LONDON EC2V 7HQ,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					287	287		10.1136/bmj.313.7052.287	http://dx.doi.org/10.1136/bmj.313.7052.287			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704545	Green Published			2022-12-28	WOS:A1996VA90300035
J	Wasan, HS; Goodlad, RA				Wasan, HS; Goodlad, RA			Fibre-supplemented foods may damage your health	LANCET			English	Editorial Material							CHAIN FATTY-ACIDS; DIETARY FIBER; CELL-DIVISION; GERM-FREE; CANCER; COLON		IMPERIAL CANC RES FUND, HISTOPATHOL UNIT, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	Wasan, HS (corresponding author), IMPERIAL CANC RES FUND, CANC GENET LAB, LONDON WC2A 3PX, ENGLAND.			Wasan, Harpreet/0000-0002-6268-2030; Goodlad, Robert/0000-0002-7660-4287				ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BURKITT DP, 1969, LANCET, V2, P1229, DOI 10.1016/S0140-6736(69)90757-0; Goodlad R. A., 1995, P97; GOODLAD RA, 1989, GUT, V30, P820, DOI 10.1136/gut.30.6.820; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HEATON KW, 1990, ROY SOC CH, V83, P3, DOI 10.1533/9781845698195.1.3; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; KRIPKE SA, 1989, JPEN-PARENTER ENTER, V13, P109, DOI 10.1177/0148607189013002109; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; PELL JD, 1995, GASTROENTEROLOGY, V108, P1745, DOI 10.1016/0016-5085(95)90136-1; Peterson K, 1996, SCIENCE, V271, P441; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; ROBERFROID MB, 1993, ROY SOC CH, P255, DOI 10.1533/9781845698256.5.255; SAKATA T, 1984, Q J EXP PHYSIOL CMS, V69, P639, DOI 10.1113/expphysiol.1984.sp002850; THOMAS RD, 1995, ENVIRON HEALTH PERSP, V103, P45, DOI 10.2307/3432344	18	53	54	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					319	320		10.1016/S0140-6736(96)01401-8	http://dx.doi.org/10.1016/S0140-6736(96)01401-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709694				2022-12-28	WOS:A1996VA25000016
J	Wise, R				Wise, R			Global paradox	LANCET			English	Editorial Material											Wise, R (corresponding author), CITY HOSP NHS TRUST,DUDLEY RD,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							Ford CW, 1996, ANTIMICROB AGENTS CH, V40, P1508, DOI 10.1128/AAC.40.6.1508; SLEE AM, 1987, ANTIMICROB AGENTS CH, V31, P1791, DOI 10.1128/AAC.31.11.1791; *WHO, 1996, 1996 WORLD HEALTH; 1996, ECONOMIST       0525, P17	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					282	282		10.1016/S0140-6736(05)64470-4	http://dx.doi.org/10.1016/S0140-6736(05)64470-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709685				2022-12-28	WOS:A1996VA25000006
J	Salmeron, JM; Oldroyd, GED; Rommens, CMT; Scofield, SR; Kim, HS; Lavelle, DT; Dahlbeck, D; Staskawicz, BJ				Salmeron, JM; Oldroyd, GED; Rommens, CMT; Scofield, SR; Kim, HS; Lavelle, DT; Dahlbeck, D; Staskawicz, BJ			Tomato Prf is a member of the leucine-rich repeat class of plant disease resistance genes and lies embedded within the Pto kinase gene cluster	CELL			English	Article							SELF-INCOMPATIBILITY LOCUS; CLADOSPORIUM-FULVUM; BRASSICA-OLERACEA; PROTEIN; CLONING; ARABIDOPSIS; RECEPTOR; SENSITIVITY; DROSOPHILA; EXPRESSION	In tomato, resistance to Pseudomonas syringae pv. tomato (Pst) strains expressing the avirulence gene avrPto requires the presence of at least two host genes, designated Pto and Prf. Here we report that Prf encodes a protein with leucine-zipper, nucleotide-binding, and leucine-rich repeat motifs, as are found in a number of resistance gene products from other plants. prf mutant alleles (4) were found to carry alterations within the Prf coding sequence. A genomic fragment containing Prf complemented a prf mutant tomato line both for resistance to Pst strains expressing avrPto and for sensitivity to the insecticide Fenthion. Prf resides in the middle of the Pto gene cluster, 24 kb from the Pto gene and 500 bp from the Fen gene.	UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA; CIBA GEIGY CORP, AGR BIOTECHNOL, RES TRIANGLE PK, NC 27709 USA; NATL SCI FDN, CTR ENGN PLANTS RESISTANCE AGAINST PATHOGENS, DAVIS, CA 95616 USA	University of California System; University of California Berkeley; National Science Foundation (NSF)			Scofield, Steven/C-3868-2016; Oldroyd, Giles/ABD-8143-2021; Oldroyd, Giles/ABA-7501-2020	Oldroyd, Giles/0000-0002-5245-6355; 				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; BOYES DC, 1993, MOL GEN GENET, V236, P369, DOI 10.1007/BF00277135; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CARLAND FM, 1993, MOL GEN GENET, V239, P17, DOI 10.1007/BF00281596; Dangl J L, 1994, Curr Top Microbiol Immunol, V192, P99; DANLG J, 1995, CELL, V80, P383; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LATEROTT H, 1995, TOMATO GENET RES COO, V35, P6; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MARTIN GB, 1993, MOL PLANT MICROBE IN, V6, P26, DOI 10.1094/MPMI-6-026; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; Pitblado R. E., 1983, Canadian Journal of Plant Pathology, V5, P251; REARDON JT, 1987, GENETICS, V115, P323; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; RYALS J, 1995, P NATL ACAD SCI USA, V92, P4202, DOI 10.1073/pnas.92.10.4202; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STOTZ HU, 1994, PLANT MOL BIOL, V25, P607, DOI 10.1007/BF00029600; SUDUPAK MA, 1993, GENETICS, V133, P119; SUN TP, 1992, PLANT CELL, V4, P119, DOI 10.1105/tpc.4.2.119; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	41	439	479	0	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					123	133		10.1016/S0092-8674(00)80083-5	http://dx.doi.org/10.1016/S0092-8674(00)80083-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689679	hybrid			2022-12-28	WOS:A1996UX93400014
J	Fine, PEM; Ponnighaus, JM; Warndorff, DK; Gruer, PJK; Oxborrow, S; Pharoah, PDP; Lucas, SB; McDougall, AC; Jenkins, PA; Chavula, D; Msiska, G; Msosa, E; Munthali, M; Mwamondwe, B; Ngoma, D; Nkhosa, P; Phiri, H; Simfukwa, M; Chihana, A; Kawaonja, D; Malema, S; Mwinuka, V; Mkandawire, P; Nyasulu, S; Tegha, H; Kalambo, M; Kileta, S; Simwaka, M; Bliss, L; Saul, J; Maine, N; Sterne, JAC; Glynn, JR; Bell, D; Clayton, D; Pike, MC; Cree, I; Desikan, K; Gupte, MD; Jacobson, RR; Nyangulu, DS; Darbyshire, J; Peto, R				Fine, PEM; Ponnighaus, JM; Warndorff, DK; Gruer, PJK; Oxborrow, S; Pharoah, PDP; Lucas, SB; McDougall, AC; Jenkins, PA; Chavula, D; Msiska, G; Msosa, E; Munthali, M; Mwamondwe, B; Ngoma, D; Nkhosa, P; Phiri, H; Simfukwa, M; Chihana, A; Kawaonja, D; Malema, S; Mwinuka, V; Mkandawire, P; Nyasulu, S; Tegha, H; Kalambo, M; Kileta, S; Simwaka, M; Bliss, L; Saul, J; Maine, N; Sterne, JAC; Glynn, JR; Bell, D; Clayton, D; Pike, MC; Cree, I; Desikan, K; Gupte, MD; Jacobson, RR; Nyangulu, DS; Darbyshire, J; Peto, R			Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi	LANCET			English	Article							NORTHERN MALAWI; HIV-INFECTION; DIAGNOSIS	Background Repeat BCG vaccination is standard practice in many countries for prevention of tuberculosis and leprosy, but its effectiveness has not been evaluated. The addition of Mycobacterium leprae antigens to BCG might improve its effectiveness against leprosy. A double-blind, randomised, controlled trial to evaluate both these procedures was carried out in Karonga District, northern Malawi, where a single BCG vaccine administered by routine health services had previously been found to afford greater than 50% protection against leprosy, but no protection against tuberculosis. Methods Between 1986 and 1989, individuals lacking a BCG scar were randomly assigned BCG alone (27 904) or BCG plus killed M leprae (38 251). Individuals with a BCG scar were randomly allocated placebo (23 307), a second BCG (23 456), or BCG plus killed M leprae (8102). Incident cases of leprosy and tuberculosis were ascertained over the subsequent 5-9 years. Findings 139 cases of leprosy were identified by May, 1995; 93 of these were diagnostically certain, definitely postvaccination cases. Among scar-positive individuals, a second BCG vaccination gave further protection against leprosy (about 50%) over a first BCG vaccination. The rate ratio for all diagnostically certain, definitely postvaccination cases, all ages, was 0.51 (95% CI 0.25-1.03, p=0.05) for BCG versus placebo. This benefit was apparent in all subgroups, although the greatest effect was among individuals vaccinated below 15 years of age (RR=0.40 [95% CI 0.15-1.01], p=0.05). The addition of killed M leprae did not improve the protection afforded by a primary BCG vaccination. The rate ratio for BCG plus killed M leprae versus BCG alone among scar-negative individuals was 1.06 (0.62-1.82, p=0.82) for all ages, though 0.37 (0.11-1.24, p=0 09) for individuals vaccinated below 15 years of age. 376 cases of postvaccination pulmonary tuberculosis and 31 of glandular tuberculosis were ascertained by May, 1995. The rate of diagnostically certain tuberculosis was higher among scar-positive individuals who had received a second BCG (1.43 [0.88-2.35], p=0.15) than among those who had received placebo and there was no evidence that any of the trial vaccines contributed to protection against pulmonary tuberculosis. Interpretation In a population in which a single BCG vaccination affords 50% or more protection against leprosy, but none against tuberculosis, a second vaccination can add appreciably to the protection against leprosy, without providing any protection against tuberculosis.	LEPRA, CHILUMBA, MALAWI; UCL HOSP, SCH MED, LONDON, ENGLAND; SLADE HOSP, OXFORD, ENGLAND; UKPHLS, MYCOBACTERIUM REFERENCE LAB, CARDIFF, S GLAM, WALES; UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, MERSEYSIDE, ENGLAND; MRC, BIOSTAT UNIT, LONDON W1N 4AL, ENGLAND; RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND; INST OPHTHALMOL, LONDON, ENGLAND; MAHATHMA GANDHI INST MED SCI, WARDHA, MAHARASHTRA, INDIA; INDIAN COUNCIL MED RES, AVADI, INDIA; US PHS, HANSENS DIS CTR, CARVILLE, LA USA; MINIST HLTH, LILONGWE, MALAWI; MRC, HIV CLIN TRIALS UNIT, LONDON, ENGLAND; IMPERIAL CANC RES FUND, MRC, BHF, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; Liverpool School of Tropical Medicine; University of Liverpool; MRC Biostatistics Unit; Radcliffe Infirmary; University of Oxford; University of London; University College London; Mahatma Gandhi Institute of Medical Sciences, Sevagram; Indian Council of Medical Research (ICMR); United States Public Health Service; Medical Research Council Clinical Trials Unit; University of Oxford	Fine, PEM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND.		Pharoah, Paul/V-6658-2019; Sterne, Jonathan/Z-3106-2019	Pharoah, Paul/0000-0001-8494-732X; Sterne, Jonathan/0000-0001-8496-6053				BAGSHAWE A, 1989, B WORLD HEALTH ORGAN, V67, P389; Bloom Barry R., 1994, P531; BOERRIGTER G, 1993, LEPROSY REV, V64, P227; Breslow N. E., 1987, STATISTICAL METHODS, VII; CONVIT J, 1992, LANCET, V339, P446, DOI 10.1016/0140-6736(92)91056-E; FINE PEM, 1992, INT J LEPROSY, V60, P71; FINE PEM, 1988, T ROY SOC TROP MED H, V82, P810, DOI 10.1016/0035-9203(88)90003-X; FINE PEM, 1986, INT J LEPROSY, V54, P614; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; LWIN K, 1985, B WORLD HEALTH ORGAN, V63, P1069; Murray C.J, 1994, GLOBAL COMP ASSESSME; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; PONNIGHAUS JM, 1991, INT J LEPROSY, V59, P221; PONNIGHAUS JM, 1987, INT J LEPROSY, V55, P454; PONNIGHAUS JM, 1994, INT J LEPROSY, V62, P10; PONNIGHAUS JM, 1991, LANCET, V337, P1039, DOI 10.1016/0140-6736(91)92697-Z; PONNIGHAUS JM, 1993, LEPROSY REV, V64, P338; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; SEPULVEDA RL, 1992, TUBERCLE LUNG DIS, V73, P372, DOI 10.1016/0962-8479(92)90043-J; SPRINGETT VH, 1994, TUBERCLE LUNG DIS, V75, P227, DOI 10.1016/0962-8479(94)90013-2; STANLEY SJ, 1981, J HYG CAMB, V87, P235; Sterne JAC, 1995, INT J EPIDEMIOL, V24, P1211, DOI 10.1093/ije/24.6.1211; STERNE JAC, 1995, J INFECT DIS, V172, P543, DOI 10.1093/infdis/172.2.543; Tripathy S P, 1983, Ann Natl Acad Med Sci, V19, P11; Wade H., 1960, INT J LEPR, V28, P179; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WELTMAN AC, 1993, AIDS, V7, P149, DOI 10.1097/00002030-199302000-00001; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; 1980, INDIAN J MED RES S, V72, P1; 1995, WHO WKLY EPIDEMIOL R, V70, P229; 1995, WHO WKLY EPIDEMIOL R, V70, P221	31	307	317	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					17	24						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691924				2022-12-28	WOS:A1996UV92300010
J	Honour, JW				Honour, JW			Testing for drug abuse	LANCET			English	Editorial Material											Honour, JW (corresponding author), UCL, DIV MOL PATHOL, LONDON W1N 8AA, ENGLAND.								0	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					41	43		10.1016/S0140-6736(96)05336-6	http://dx.doi.org/10.1016/S0140-6736(96)05336-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV923	8691934				2022-12-28	WOS:A1996UV92300016
J	Waldo, AL; Camm, AJ; deRuyter, H; Friedman, PL; MacNeil, DJ; Pauls, JF; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP				Waldo, AL; Camm, AJ; deRuyter, H; Friedman, PL; MacNeil, DJ; Pauls, JF; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP			Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction	LANCET			English	Article							CLINICAL-TRIALS; ARRHYTHMIC EVENTS; SUDDEN-DEATH; RISK; CLASSIFICATION; MORBIDITY; SURVIVAL; PLACEBO; THERAPY; ISOMERS	Background Left ventricular dysfunction after myocardial infarction is associated with an increased risk of death. Other studies have suggested that a potassium-channel blocker might reduce this risk with minimal adverse effects. We investigated whether d-sotalol, a pure potassium-channel blocker with no clinically significant beta-blocking activity, could reduce all-cause mortality in these high-risk patients. Methods Patients with a left ventricular ejection fraction of 40% or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (>42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily. Findings After 3121 of the planned 6400 patients had been recruited, the trial was stopped. Among 1549 patients assigned d-sotalol, there were 78 deaths (5.0%) compared with 48 deaths (3 1%) among the 1572 patients assigned placebo (relative risk 165 [95% CI 1.15-2.36], p=0.006). Presumed arrhythmic deaths (relative risk 1.77 [1.15-2.74], p=0.008) accounted for the increased mortality. The effect was greater in patients with a left ventricular ejection fraction of 31-40% than in those with lower (less than or equal to 30%) ejection fractions (relative risk 4.0 vs 1.2, p=0.007). Interpretation Among the 1549 patients evaluated, administration of d-sotalol was associated with increased mortality, which was presumed primarily to be due to arrhythmias. The prophylactic use of a specific potassium-channel blocker does not reduce mortality, and may be associated with increased mortality in high-risk patients after myocardial infarction.	CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; UNIV LONDON ST GEORGES HOSP, SCH MED, LONDON, ENGLAND; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, PRINCETON, NJ 08543 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV MICHIGAN, ANN ARBOR, MI 48109 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV PAVIA, I-27100 PAVIA, ITALY	Case Western Reserve University; St Georges University London; Bristol-Myers Squibb; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; Baylor College of Medicine; University of Pavia			Schwartz, Peter J/J-4267-2016	Schwartz, Peter J/0000-0003-0367-1048				[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1991, Circulation, V84, P1831; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; COX DR, 1972, J R STAT SOC B, V34, P187; DEMETS DL, 1987, STAT MED, V6, P753, DOI 10.1002/sim.4780060706; DEMETS DL, 1980, BIOMETRIKA, V67, P651; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; GOMOLL AW, 1986, EUR J PHARMACOL, V132, P123, DOI 10.1016/0014-2999(86)90597-2; GREENE HL, 1989, AM J CARDIOL, V63, P1, DOI 10.1016/0002-9149(89)91065-5; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; JOHNSTON GD, 1985, BRIT J CLIN PHARMACO, V20, P507, DOI 10.1111/j.1365-2125.1985.tb05109.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATO R, 1986, J AM COLL CARDIOL, V7, P116, DOI 10.1016/S0735-1097(86)80268-6; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LYNCH JJ, 1985, AM HEART J, V109, P949, DOI 10.1016/0002-8703(85)90234-0; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MALLIANI A, 1969, AM J PHYSIOL, V217, P703, DOI 10.1152/ajplegacy.1969.217.3.703; MOSS AJ, 1979, CIRCULATION, V60, P998, DOI 10.1161/01.CIR.60.5.998; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; MYERBURG RJ, 1992, CIRCULATION, V85, P2; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; ODEMUYIWA O, 1991, AM J CARDIOL, V68, P434, DOI 10.1016/0002-9149(91)90774-F; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PODRID PJ, 1987, AM J CARDIOL, V59, pE38, DOI 10.1016/0002-9149(87)90200-1; PRIORI SG, 1995, CARDIAC ARRHYTHMIA M, P951; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROSEN MR, 1991, EUR HEART J, V12, P1112; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; SCHWARTZ PJ, 1994, EUR HEART J, V15, P620, DOI 10.1093/oxfordjournals.eurheartj.a060557; SCHWARTZ PJ, 1994, CIRCULATION, V89, P2892; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; STEINBERG JS, 1992, AM J CARDIOL, V69, P13, DOI 10.1016/0002-9149(92)90669-P; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; VANOLI E, 1995, J CARDIOVASC PHARM, V26, P847, DOI 10.1097/00005344-199512000-00001; VANOLI E, 1995, J AM COLL CARDIOL, V25, P1609, DOI 10.1016/0735-1097(95)00046-7; VANOLI E, 1993, EUR HEART J SUPPL, V14, P92; WALDO AL, 1995, AM J CARDIOL, V75, P1023, DOI 10.1016/S0002-9149(99)80717-6; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	43	941	964	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1996	348	9019					7	12		10.1016/S0140-6736(96)02149-6	http://dx.doi.org/10.1016/S0140-6736(96)02149-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691967				2022-12-28	WOS:A1996UV92300008
J	Horton, B				Horton, B			Flexibility the key for neuroscientists	NATURE			English	Article																			0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					347	349		10.1038/381347a0	http://dx.doi.org/10.1038/381347a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692276				2022-12-28	WOS:A1996UM40300064
J	Sullivan, RB; Watanabe, M; Whitcomb, ME; Kindig, DA				Sullivan, RB; Watanabe, M; Whitcomb, ME; Kindig, DA			The evolution of divergences in physician supply policy in Canada and the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-EDUCATION; GONE	The size, geographic distribution, and specialty mix of the US physician workforce continue to interest American health policy analysts. Evidence suggests that the United States is on the verge of a serious oversupply of physicians, particularly nongeneralist physicians. Canada faces some of the same problems in physician supply, cost, and distribution as does the United States. Unlike the American states, however, the Canadian provinces, which have responsibility for financing health care, have in recent years made changes in their physician workforce policies that address these problems. Of particular note, Canadian provinces have developed policies that limit medical school enrollments, adjust the specialty training mix to better accord with needs, and establish physician practice location incentives. This article proceeds on the assumption that historical and contemporary similarities between medical care systems in Canada and the United States make comparisons between them potentially valuable. It offers a historical perspective on the evolution of workforce planning in the 2 countries and identifies 3 periods of policy development. It also compares and contrasts the relative size and specialty composition of the Canadian and US workforces and discusses how Canadian initiatives have diverged from American policy. Unless the United States devises its own coordinated workforce strategy, it will have considerable difficulty limiting physician workforce growth and influencing specialization and distribution in the future.	UNIV WISCONSIN,SCH MED,DEPT PREVENT MED,MADISON,WI 53706; UNIV CALGARY,FAC MED,DEPT MED,CALGARY,AB,CANADA; ASSOC AMER MED COLL,WASHINGTON,DC 20036	University of Wisconsin System; University of Wisconsin Madison; University of Calgary; Association of American Medical Colleges	Sullivan, RB (corresponding author), UNIV WISCONSIN,DEPT HIST MED,SCH MED,1420 MED SCI CTR,1300 UNIV AVE,MADISON,WI 53706, USA.							*AM MED ASS, 1974, PHYS CHAR DISTR US; [Anonymous], [No title captured]; *ASS CAN MED COLL, 1994, CAN MED ED STAT 1994, V16, P12; *ASS CAN MED COLL, 1995, CAN MED ED STAT 1995, V17; BARER ML, 1995, PHYSICIAN EXPENDITUR, V6, P27; BARER ML, 1995, PHYSICIAN EXPENDITUR, V6, P13; BARER ML, 1991, 917 MCMAST U CTR HLT, pCH3; *BUR CENS, 1996, 1995 STAT ABSTR US, P8; *CAN I HLTH INF, 1995, 1994 DAT; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; *COMM US PHYS SUPP, 1996, NAT PHYS WORKF OPT B, P4; *COMM US PHYS SUPP, 1996, NAT PHYS WORKF OPT B, P5; *COUNC GRAD MED ED, 1992, IMPR ACC HLTH CAR PH, P4; *COUNC GRAD MED ED, 1994, 4 COUNC GRAD MED ED, P11; *COUNC GRAD MED ED, 1995, 7 COUNC GRAD MED ED, P13; CROWLEY AE, 1985, JAMA-J AM MED ASSOC, V254, P1565, DOI 10.1001/jama.254.12.1565; CROWLEY AE, 1984, JAMA-J AM MED ASSOC, V252, P1525; CROWLEY AE, 1982, JAMA-J AM MED ASSOC, V248, P3245; Evans R.G, 1976, CAN PUBLIC POL, V2, P147; *FED PROV TERR MIN, 1994, C FED PROV TERR MIN; *GOV CAN, 1971, 1968 1971 ANN DEM ST; *GRAD MED ED NAT A, 1980, REP GRAD MED NAT ADV, P3; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; Hall EM, 1980, COMPETENCE PROCESS M; *HLTH WELF CAN, 1993, HLTH PERS CAN; JUDEK S, 1964, MED MANPOWER CANADA, P1; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KINDIG DA, 1989, HEALTH AFFAIR, V8, P63, DOI 10.1377/hlthaff.8.2.63; LOMAS J, 1986, MEDICARE MATURITY AC, P221; MCPHEDRAN NT, 1993, CANADIAN MED SCH 2 C, P23; *MED SOC STAT OFF, B MED SOC STAT OFF D, V1; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; MULLAN F, 1992, MILBANK Q, V70, P381, DOI 10.2307/3350065; *NAT COMM PHYS MAN, 1975, REQ PHYS CAN; *NAT COORD COMM PO, 1994, NAT ACT PLAN CAN PHY; NEWHOUSE JP, 1982, JAMA-J AM MED ASSOC, V247, P2392, DOI 10.1001/jama.247.17.2392; PETERSEN ES, 1981, JAMA-J AM MED ASSOC, V246, P2913; *PEW HLTH PROF COM, 1995, CRIT CHAL REV HLTH P, P2; PRIEST L, 1993, TORONTO STAR    0219, pA12; *PROV TERR MIN HLT, 1992, C PROV TERR MIN HLTH; Rivo ML, 1996, NEW ENGL J MED, V334, P892, DOI 10.1056/NEJM199604043341405; RYTEN E, 1986, PHYSICIAN MANPOWER C; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SCHWARTZ WB, 1980, NEW ENGL J MED, V303, P1032, DOI 10.1056/NEJM198010303031803; SINGER AM, 1995, ANN STAT REPORT; Taylor Malcolm G., 1990, INSURING NATL HLTH C; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P1133, DOI 10.1001/jama.268.9.1133; WATANABE M, 1994, CLIN INVEST MED, V17, P256; WATANABE M, 1993, PHYSICIANS CANADA, V3, P1; [No title captured]; 1968, JAMA-J AM MED ASSOC, V206, P1987; 1993, ACAD MED, V68, P1	52	18	18	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					704	709						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769549				2022-12-28	WOS:A1996VE23300009
J	Braitman, LE; Davidoff, F				Braitman, LE; Davidoff, F			Predicting clinical states in individual patients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							REGRESSION-MODELS; RISK	A probability model expresses the relation between the presence of clinical findings (input or independent variables) and the probability that a clinical state will occur (the dependent variable); for example, it expresses the probability that a disease is present or will develop or the probability that an outcome state will be reached. Probability models are developed by using selected study groups. Although these models are most often used to make predictions for groups of patients, they can also predict clinical states for individual patients. The following seven criteria provide a basis for the critical appraisal of probability models. In particular, physicians can use these criteria to decide when a specific probability model should be used to make a prediction in an individual patient. Five of the criteria are concerned with the applicability of a model to a particular patient: 1) the comparability of the patient and the study group used to develop the model; 2) the congruence between the clinical state of interest to patient and physician and the model's outcome; 3) the availability of all input variables where and when the prediction is to be made; 4) the usefulness of a quantitative estimate of the predicted clinical state; and 5) the degree of uncertainty in the probability estimate. The other two criteria are concerned with how well the probability model ''works'': 6) the fit of probabilities calculated from the model to the outcomes actually observed and 7) the model's ability to discriminate between outcome states relative to chance and to other, more traditional, prediction methods. We illustrate the use of these criteria by applying them, in the form of questions, to a convenient, tabular version of a model that estimates a patient's chances of surviving for 10 years after having definitive surgical therapy for primary cutaneous melanoma.	ALBERT EINSTEIN HEALTHCARE NETWORK, OFF RES & TECHNOL DEV, PHILADELPHIA, PA 19141 USA; AMER COLL PHYSICIANS, PHILADELPHIA, PA 19106 USA	Yeshiva University; American College of Physicians								Agresti A., 1996, INTRO CATEGORICAL DA; AGRESTI A, 1996, INTRO CATEGORICAL DA, P71; AGRESTI A, 1996, INTRO CATEGORICAL DA, P110; BRAITMAN LE, 1988, ANN INTERN MED, V108, P296, DOI 10.7326/0003-4819-108-2-296; Bursztajn HJ, 1981, MED CHOICES MED CHAN; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Collett D., 1991, MODELLING BINARY DAT; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; DAVIS W, 1987, STAT METHODS CANC RE, P69; DAVIS W, 1987, STAT METHODS CANC RE; DIACONIS P, 1983, SCI AM, V248, P116, DOI 10.1038/scientificamerican0583-116; Efron B., 1994, MONOGRAPHS STAT APPL; EFRON B, 1993, INTRO BOOTSTRAP, P247; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HORWITZ L, 1980, STAT SOCIAL CHANGE, P20; HOSMER DW, 1991, AM J PUBLIC HEALTH, V81, P1630, DOI 10.2105/AJPH.81.12.1630; Ingelfinger JA, 1983, BIOSTATISTICS CLIN M; Kleinbaum DG, 1994, LOGISTIC REGRESSION; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; Liao, 1994, INTERPRETING PROBABI; LINDSEY JK, 1995, INTRO STAT MODELLING; Mooney CZ, 1993, BOOTSTRAPPING NONPAR, DOI DOI 10.4135/9781412983532; MOSTELLER F, 1977, DATA ANAL REGRESSION, P37; Mosteller F., 1968, HDB SOC PSYCHOL, V2, P80; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RUTTIMANN UE, 1994, CRIT CARE CLIN, V10, P19, DOI 10.1016/S0749-0704(18)30142-8; Schuchter L, 1996, ANN INTERN MED, V125, P369, DOI 10.7326/0003-4819-125-5-199609010-00003	28	124	128	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					406	412		10.7326/0003-4819-125-5-199609010-00008	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702092				2022-12-28	WOS:A1996VE07900008
J	Walter, JH				Walter, JH			Two ''new'' treatable inherited biosynthetic disorders	LANCET			English	Editorial Material											Walter, JH (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,WILLINK BIOCHEM GENET UNIT,MANCHESTER M27 4HA,LANCS,ENGLAND.							Isbrandt D, 1995, BBA-GENE STRUCT EXPR, V1264, P265, DOI 10.1016/0167-4781(95)00184-0; Jaeken J, 1996, ARCH DIS CHILD, V74, P542, DOI 10.1136/adc.74.6.542; STOCKLER S, 1994, PEDIATR RES, V36, P409; STOCKLER S, 1996, AM J HUM GENET, V59, P914	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					558	559		10.1016/S0140-6736(05)64790-3	http://dx.doi.org/10.1016/S0140-6736(05)64790-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774561				2022-12-28	WOS:A1996VF18600002
J	Cutler, S; Ghassemian, M; Bonetta, D; Cooney, S; McCourt, P				Cutler, S; Ghassemian, M; Bonetta, D; Cooney, S; McCourt, P			A protein farnesyl transferase involved in abscisic acid signal transduction in Arabidopsis	SCIENCE			English	Article							GUARD-CELLS; GENE-EXPRESSION; PLASMA-MEMBRANE; RAS PROTEINS; ACTIVATION; CALCIUM; YEAST; FARNESYLTRANSFERASE; ISOPRENYLATION; PHOSPHATASE	The hormone abscisic acid (ABA) modulates a variety of developmental processes and responses to environmental stress in higher plants. A collection of mutations, designated era, in Arabidopsis thaliana that confer an enhanced response to exogenous ABA includes mutations in the Era1 gene, which encodes the beta subunit of a protein farnesyl transferase. In yeast and mammalian systems, farnesyl transferases modify several signal transduction proteins for membrane localization. The era1 mutants suggest that a negative regulator of ABA sensitivity must be acted on by a farnesyl transferase to function.	UNIV TORONTO, DEPT BOT, TORONTO, ON M5S 3B2, CANADA	University of Toronto			Cutler, Sean R/D-6617-2011					BASKIN JM, 1971, CAN J BOT, V50, P277; BLATT MR, 1990, NATURE, V346, P766, DOI 10.1038/346766a0; CASEY PJ, 1995, BIOCHEM SOC T, V23, P161, DOI 10.1042/bst0230161; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; Cutler S. J., UNPUB; FINKELSTEIN RR, 1994, PLANT J, V5, P765, DOI 10.1046/j.1365-313X.1994.5060765.x; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; IRVING HR, 1992, P NATL ACAD SCI USA, V89, P1790, DOI 10.1073/pnas.89.5.1790; Koornneef M., 1994, ARABIDOPSIS, VVolume 27, P313; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; RANDALL SK, 1993, PLANT CELL, V5, P433, DOI 10.1105/tpc.5.4.433; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; SHIRLEY BW, 1992, PLANT CELL, V4, P333, DOI 10.1105/tpc.4.3.333; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; YANG ZB, 1993, PLANT PHYSIOL, V101, P667, DOI 10.1104/pp.101.2.667; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.arplant.39.1.439	27	321	340	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1996	273	5279					1239	1241		10.1126/science.273.5279.1239	http://dx.doi.org/10.1126/science.273.5279.1239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703061				2022-12-28	WOS:A1996VE47600044
J	Kasid, U; Suy, S; Dent, P; Ray, S; Whiteside, TL; Sturgill, TW				Kasid, U; Suy, S; Dent, P; Ray, S; Whiteside, TL; Sturgill, TW			Activation of Raf by ionizing radiation	NATURE			English	Article							MAP KINASE-KINASE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; GROWTH-FACTORS; PROTOONCOGENE; SENSITIVITY; PHOSPHATASE	THE critical pathways through which ionizing radiation induces malignant transformation and cell death are not well defined. Raf-1, a cytoplasmic serine-threonine protein kinase, mediates the transmission of mitogenic signals initiated at the cell membrane to the nucleus, resulting in the activation of transcription factors that regulate cell growth and proliferation(1,2). Moreover, Raf-1 overexpression and activation increases the survival response of mammalian cells to the toxic effects of ionizing radiation by an as-yet unknown mechanism (refs 3, 4 and V. Soldatenkov et al.; manuscript submitted), Somewhat analogous to mitogen-induced signalling, radiation stimulates protein-tyrosine kinase(s) and transcription factors(5,6). No direct biochemical link has been established, however, between radiation-stimulated protein tyrosine phosphorylation and downstream signals. Here we report a series of radiation-responsive events in which protein-tyrosine phosphorylation is followed by membrane recruitment, then tyrosine phosphorylation and activation of Raf-1 in vivo. Our results show that radiation-stimulated protein-tyrosine kinase(s) modify Raf-1, and implicate Raf-1 in the ionizing-radiation signal-transduction pathway.	GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; UNIV VIRGINIA,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV PITTSBURGH,PITTSBURGH CANC INST,DEPT PATHOL,PITTSBURGH,PA 15261	Georgetown University; Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Kasid, U (corresponding author), GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT RADIAT MED,WASHINGTON,DC 20007, USA.							CHAE HP, 1993, CANCER RES, V53, P447; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HEO DS, 1989, CANCER RES, V49, P5167; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1995, EMBO J, V14, P3169; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WITTE L, 1989, CANCER RES, V49, P5066; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	29	149	156	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					813	816		10.1038/382813a0	http://dx.doi.org/10.1038/382813a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752275				2022-12-28	WOS:A1996VE34700048
J	Swinbanks, D				Swinbanks, D			Japan shuns radishes after 'possible link' to E-coli	NATURE			English	News Item																		1996, NATURE, V382, P290	1	19	19	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					567	567		10.1038/382567b0	http://dx.doi.org/10.1038/382567b0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757116	Bronze			2022-12-28	WOS:A1996VC30300008
J	Callaghan, JJ; Daley, J; Pottenger, L				Callaghan, JJ; Daley, J; Pottenger, L			A 76-year-old woman considering total hip replacement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							OSTEO-ARTHRITIS; COST-EFFECTIVENESS; OSTEOARTHRITIS; KNEE; ARTHROPLASTY		UNIV IOWA,COLL MED,IOWA CITY,IA	University of Iowa								ARNOLDI CC, 1971, ACTA ORTHOP SCAND, V42, P357, DOI 10.3109/17453677108989056; BARRACK RL, 1992, J BONE JOINT SURG BR, V74, P385, DOI 10.1302/0301-620X.74B3.1587883; BLOUNT WP, 1956, J BONE JOINT SURG AM, V38, P695, DOI 10.2106/00004623-195638030-00023; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BROOKS PM, 1982, J RHEUMATOL, V9, P3; Chang RW, 1996, JAMA-J AM MED ASSOC, V275, P858, DOI 10.1001/jama.275.11.858; CHARNLEY J, 1972, Journal of Bone and Joint Surgery British Volume, V54, P61; COLLINS DH, 1953, J BONE JOINT SURG BR, V35, P518, DOI 10.1302/0301-620X.35B4.518; CROFT P, 1990, AM J EPIDEMIOL, V132, P514, DOI 10.1093/oxfordjournals.aje.a115687; CUSHNAGHAN J, 1991, ANN RHEUM DIS, V50, P8, DOI 10.1136/ard.50.1.8; DANIELSSON LG, 1964, ACTA ORTHOP SCAND S, V55, P1; DEQUEKER J, 1985, CLIN RHEUM DIS, V11, P271; DIEPPE P, 1993, BRIT J RHEUMATOL, V32, P595; DIEPPE P, 1993, OSTEOARTHRITIS, P399; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; EHRLICH GE, 1975, JAMA-J AM MED ASSOC, V232, P157, DOI 10.1001/jama.232.2.157; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012; HARRISON MHM, 1953, J BONE JOINT SURG BR, V35, P598, DOI 10.1302/0301-620X.35B4.598; JOHNSTON RC, 1990, J BONE JOINT SURG AM, V72A, P161, DOI 10.2106/00004623-199072020-00002; JOHNSTON RC, 1970, CLIN ORTHOPAEDICS, V72, P205; KAVANAGH BF, 1989, J BONE JOINT SURG AM, V71A, P1496, DOI 10.2106/00004623-198971100-00007; KAVANAGH BF, 1985, CLIN ORTHOP RELAT R, V193, P133; LAUPACIS A, 1993, J BONE JOINT SURG AM, V75A, P1619, DOI 10.2106/00004623-199311000-00006; LAUPACIS A, 1994, J ARTHROPLASTY, V9, P48; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; LEQUESNE M, 1970, PRESSE MED, V78, P1435; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; LIANG MH, 1991, NEW ENGL J MED, V325, P125, DOI 10.1056/NEJM199107113250210; LLOYDROBERTS GC, 1953, J BONE JOINT SURG BR, V35, P627, DOI 10.1302/0301-620X.35B4.627; MCCOY TH, 1988, ORTHOP CLIN N AM, V19, P467; MULROY W, 1996, J BONE JOINT SURG AM, V77, P1836; NEWMAN NM, 1985, LANCET, V2, P11; PERRY GH, 1972, ANN RHEUM DIS, V31, P440, DOI 10.1136/ard.31.6.440; REVELL PA, 1988, ANN RHEUM DIS, V47, P300, DOI 10.1136/ard.47.4.300; SCHULTE KR, 1993, J BONE JOINT SURG AM, V75A, P961, DOI 10.2106/00004623-199307000-00002; SIEFERT MH, 1969, ANN RHEUM DIS, V28, P325; SOLOMON L, 1976, J BONE JOINT SURG BR, V58, P176, DOI 10.1302/0301-620X.58B2.932079; SULLIVAN PM, 1994, J BONE JOINT SURG AM, V76A, P863, DOI 10.2106/00004623-199406000-00010; SUMMERS MN, 1988, ARTHRITIS RHEUM, V31, P204, DOI 10.1002/art.1780310208; WILSON MG, 1990, MAYO CLIN PROC, V65, P1214, DOI 10.1016/S0025-6196(12)62745-1; [No title captured]; [No title captured]; 1995, JAMA-J AM MED ASSOC, V273, P1950	44	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					486	491						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691558				2022-12-28	WOS:A1996VA86300038
J	Teale, C				Teale, C			Caring for older people - Money problems and financial help .4.	BRITISH MEDICAL JOURNAL			English	Article								Older people make up the largest low income group in the United Kingdom. This article gives an overview of financial help available for older people, including general information, such as pensions and low income benefits, and also particular support for those with disabilities, such as attendance allowance and assistance with residential or nursing home fees. Advice on an individual's entitlements is available from the Benefits Agency and, particularly for those with disabilities, from social workers.			Teale, C (corresponding author), SEACROFT HOSP,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND.								0	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					288	290		10.1136/bmj.313.7052.288	http://dx.doi.org/10.1136/bmj.313.7052.288			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704546	Green Published			2022-12-28	WOS:A1996VA90300036
J	Wei, Y; Lukashev, M; Simon, DI; Bodary, SC; Rosenberg, S; Doyle, MV; Chapman, HA				Wei, Y; Lukashev, M; Simon, DI; Bodary, SC; Rosenberg, S; Doyle, MV; Chapman, HA			Regulation of integrin function by the urokinase receptor	SCIENCE			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; SMOOTH-MUSCLE CELLS; ROUS-SARCOMA VIRUS; ADHESION; EXPRESSION; INHIBITOR; VITRONECTIN; FIBROBLASTS; CANCER; DEGRADATION	Integrin function is central to inflammation, immunity, and tumor progression. The urokinase-type plasminogen activator receptor (uPAR) and integrins formed stable complexes that both inhibited native integrin adhesive function and promoted adhesion to vitronectin via a ligand binding site on uPAR. Interaction of soluble uPAR with the active conformer of integrins mimicked the inhibitory effects of membrane uPAR. Both uPAR-mediated adhesion and altered integrin function were blocked by a peptide that bound to uPAR and disrupted complexes. These data provide a paradigm for regulation of integrins in which a nonintegrin membrane receptor interacts with and modifies the function of activated integrins.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, S SAN FRANCISCO, CA 94080 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Roche Holding; Genentech; Novartis					NHLBI NIH HHS [HL 02768, HL44712] Funding Source: Medline; NICHD NIH HHS [HD 26732] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BIANCHI E, 1994, CANCER RES, V54, P861; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BODARY SC, UNPUB; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; BURCHILL SA, 1994, BIOESSAYS, V16, P225, DOI 10.1002/bies.950160403; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; CONFORTI G, 1994, BLOOD, V83, P994; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FONG S, UNPUB; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LI H, 1994, J BIOL CHEM, V269, P8153; LI R, 1995, J CELL BIOL, V129, P1143, DOI 10.1083/jcb.129.4.1143; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; RAO NK, 1995, J CLIN INVEST, V96, P465, DOI 10.1172/JCI118057; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; SCHLECHTE W, 1989, CANCER RES, V49, P6064; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SIMON DI, 1993, BLOOD, V82, P2414; SIMON DI, IN PRESS BLOOD; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; SKINNER MP, 1994, AM J PATHOL, V145, P1070; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; TIVERON MC, 1994, J CELL SCI, V107, P1783; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WANG N, 1995, AM J PHYSIOL-CELL PH, V268, pC1062, DOI 10.1152/ajpcell.1995.268.4.C1062; WEBER MJ, 1977, CELL, V10, P45, DOI 10.1016/0092-8674(77)90138-6; WEI Y, 1994, J BIOL CHEM, V269, P32380; XUE W, 1994, J IMMUNOL, V152, P4630; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	52	692	716	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1996	273	5281					1551	1555		10.1126/science.273.5281.1551	http://dx.doi.org/10.1126/science.273.5281.1551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703217				2022-12-28	WOS:A1996VG59700041
J	Ormo, M; Cubitt, AB; Kallio, K; Gross, LA; Tsien, RY; Remington, SJ				Ormo, M; Cubitt, AB; Kallio, K; Gross, LA; Tsien, RY; Remington, SJ			Crystal structure of the Aequorea victoria green fluorescent protein	SCIENCE			English	Article							CHROMOPHORE; MUTATIONS; PROGRAM	The green fluorescent protein (GFP) from the Pacific Northwest jellyfish Aequorea victoria has generated intense interest as a marker for gene expression and localization of gene products, The chromophore, resulting from the spontaneous cyclization and oxidation of the sequence -Ser(65) (or Thr(65))-Tyr(66)-Gly(67)-, requires the native protein fold for both formation and fluorescence emission. The structure of Thr(65) GFP has been determined at 1.9 angstrom resolution, The protein fold consists of an 11-stranded beta barrel with a coaxial helix, with the chromophore forming from the central helix. Directed mutagenesis of one residue adjacent to the chromophore, Thr(203), to Tyr or His results in significantly red-shifted excitation and emission maxima.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST 0647, LA JOLLA, CA 92093 USA; AURORA BIOSCI, LA JOLLA, CA 92037 USA; UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Oregon; University of Oregon								BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; *DAR LAB SCI ENG R, 1979, CCP4 SUIT PROGR PROT; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; Dopf J, 1996, GENE, V173, P39, DOI 10.1016/0378-1119(95)00692-3; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; INOUYE S, 1994, FEBS LETT, V351, P211, DOI 10.1016/0014-5793(94)00859-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MINOR W, 1993, XDISPLAYF; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305; MORISE H, 1974, BIOCHEMISTRY-US, V13, P2656, DOI 10.1021/bi00709a028; OTWINOWSKI Z, 1991, DATA COLLECTION PROC, P56; PEROZZO MA, 1988, J BIOL CHEM, V263, P7713; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; RAO BDN, 1980, BIOPHYS J, V32, P630, DOI 10.1016/S0006-3495(80)84999-X; SanPietro R. M., 1993, PHOTOCHEM PHOTOBIOL, V57, p63s; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; STEIGEMANN W, 1974, THESIS TU MUNICH; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Ward W.W., 1979, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V4, P1; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WARD WW, 1982, PHOTOCHEM PHOTOBIOL, V35, P803, DOI 10.1111/j.1751-1097.1982.tb02651.x; Ward WW., 1981, BIOLUMINESCENCE CHEM, DOI 10.1016/b978-0-12-208820-9.50035-5; YANG F, IN PRESS NATURE BIOT	39	1824	1939	19	604	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1996	273	5280					1392	1395						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703075				2022-12-28	WOS:A1996VF61000044
J	Popkin, BM; SiegaRiz, AM; Haines, PS				Popkin, BM; SiegaRiz, AM; Haines, PS			A comparison of dietary trends among racial and socioeconomic groups in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PATTERNS; WOMEN; CHOLESTEROL; ADULTS; HEALTH	Background There may be dietary differences among racial and socioeconomic groups in the United States. Methods Using data from a representative sample of adults, we compared dietary trends among blacks and whites of varying socioeconomic status. We developed comparable measures of diet and of the consumption of macronutrients and food groups for 6061 participants in the 1965 Nationwide Food Consumption Surveys, 16,425 in the 1977-1978 Nationwide Food Consumption Surveys, and 9920 in the 1989-1991 Continuing Survey of Food Intake by Individuals (all conducted by the U.S. Department of Agriculture). The primary outcome was the score (range, 0 to 16) on the Diet Quality Index, a composite of eight food-and-nutrient-based recommendations from the National Academy of Sciences. A score of 4 or less was considered to indicate a relatively more healthful diet, and a value of 10 or more a relatively less healthful diet. Results Overall dietary quality improved in all groups, from a mean Diet Quality Index score of 7.4 in 1965 to 6.4 in 1989-1991. in 1965, blacks of low socioeconomic status and, to a lesser extent, whites of low socioeconomic status had better diets than whites of high socioeconomic status. By the 1989-1991 survey, the differences among racial and socioeconomic groups had narrowed. In 1965, 9.3 percent of whites of low socioeconomic status, 16.4 percent of blacks of low socioeconomic status, and 4.7 percent of whites of high socioeconomic status had mean scores of 4 or less. In the 1989-1991 survey, the respective percentages were 19.9, 23.5, and 20.0. Fat consumption decreased in all groups. The consumption of fruits and vegetables varied little over time, except for an increase among blacks of medium and high socioeconomic status. The consumption of grains and legumes increased over time among whites of medium and high socioeconomic status and declined among blacks of low socioeconomic status. Conclusions In 1965, there were large differences among groups in dietary quality, with whites of high socioeconomic status eating the least healthful diet, as measured by the index, and blacks of low socioeconomic status the most healthful. By the 1989-1991 survey, the diets of all groups had improved and were relatively similar. (C) 1996, Massachusetts Medical Society.	UNIV N CAROLINA, DEPT NUTR, CHAPEL HILL, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill			Popkin, Barry/T-6633-2019					BLOCK G, 1988, AM J PUBLIC HEALTH, V78, P1150, DOI 10.2105/AJPH.78.9.1150; GUENTHER PM, 1994, J AM DIET ASSOC, V94, P270, DOI 10.1016/0002-8223(94)90367-0; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KUCZMARSKI RJ, 1992, AM J CLIN NUTR, V55, P495; KUMANYIKA SK, 1993, ANN INTERN MED, V119, P650, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00005; National Research Council (US) Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; PATTERSON BH, 1990, AM J PUBLIC HEALTH, V80, P1443, DOI 10.2105/AJPH.80.12.1443; PATTERSON RE, 1994, J AM DIET ASSOC, V94, P57, DOI 10.1016/0002-8223(94)92042-7; PATTERSON RE, 1994, PREV MED, V23, P453, DOI 10.1006/pmed.1994.1062; POPKIN BM, 1989, AM J CLIN NUTR, V49, P1307, DOI 10.1093/ajcn/49.6.1307; POPKIN BM, 1992, AM J CLIN NUTR, V55, P823, DOI 10.1093/ajcn/55.4.823; POPKIN BM, 1989, AM J AGR ECON, V71, P949, DOI 10.2307/1242671; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	19	235	239	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					716	720		10.1056/NEJM199609053351006	http://dx.doi.org/10.1056/NEJM199609053351006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VH266	8703172	Green Published			2022-12-28	WOS:A1996VH26600006
J	Seifer, SD; Troupin, B; Rubenfeld, GD				Seifer, SD; Troupin, B; Rubenfeld, GD			Changes in marketplace demand for physicians - A study of medical journal recruitment advertisements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORKFORCE; REQUIREMENTS	Objective.-To measure trends in marketplace demand for physicians in different specialties. Methods.-Retrospective review of physician recruitment advertisements appearing in the September issues of 7 medical journals in 1984, 1987, 1990, 1993, and 1995. Main Outcome Measure.-Number of advertised positions in each of the studied specialties. Results.-Steep declines in the number of advertised positions for specialist physicians over the past 5 years were consistently observed with the exception of pediatric specialists. The most dramatic changes occurred in the number of internal medicine specialist positions, which declined by 75% since 1990. For physicians as a whole, there were 4 specialist positions for every generalist position advertised in 1990; by 1995, this ratio dropped to 1,8, Family medicine exhibited continuous growth in the number of advertised positions, more than doubling during the period studied, Conclusions.-Our data suggest a recent decline in marketplace demand for physicians, particularly those in specialist fields, Among generalists, demand for internists and pediatricians appears to be flat or declining, while demand for family physicians is rising. Ongoing analysis of these advertisements will provide timely information about the demand for physicians in a rapidly changing health care system.	UNIV WASHINGTON,HARBORVIEW MED CTR,DIV PULM & CRIT CARE MED,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MED EDUC,CTR MED EDUC RES,SEATTLE,WA 98104; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SHARP GROSSMONT FAMILY MED RESIDENCY PROGRAM,LA MESA,CA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco					AHRQ [2T32HS000044-18] Funding Source: Federal RePORTER; AHRQ HHS [T32 HS00044] Funding Source: Medline	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAHAM K, 1987, BROOKINGS PAPERS EC, V0001, P00207; BODENHEIMER TS, 1995, UNDERSTANDING HLTH P; CLAWSON DK, 1993, ROLE PHYSICIAN ASSIS; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; *COUNC GRAD MED ED, 1994, 4 COUNC GRAD MED ED; *COUNC GRAD MED ED, 1995, 6 COUNC GRAD MED ED; FEIL EC, 1993, JAMA-J AM MED ASSOC, V269, P2659, DOI 10.1001/jama.269.20.2659; FEIN E, 1995, NY TIMES        1016, pA1; HAWKINS J, 1994, JAMA-J AM MED ASSOC, V272, pE832; LOHR KN, 1996, NATIONS PHYSICIAN WO; *MED GROUP MAN ASS, 1994, PHYS COMP PROD SURV; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; PRESTON NL, 1977, HELP WANTED INDEX TR; SEIFER SD, 1995, ACAD MED, V70, P854, DOI 10.1097/00001888-199510000-00002; SEIFER SD, 1994, 103HR940854P00001 US; STILLMAN AE, 1995, NEW ENGL J MED, V333, P1086, DOI 10.1056/NEJM199510193331618; TARLOV AR, 1995, JAMA-J AM MED ASSOC, V274, P1558, DOI 10.1001/jama.274.19.1558; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; WIENER JP, 1993, MED CARE REV, V50, P411; 1993, NEW ENGLAND J MED; 1993, ACAD MED, V68, P1	23	56	56	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					695	699		10.1001/jama.276.9.695	http://dx.doi.org/10.1001/jama.276.9.695			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769547				2022-12-28	WOS:A1996VE23300007
J	Tanaka, N; Ishihara, M; Lamphier, MS; Nozawa, H; Matsuyama, T; Mak, TW; Aizawa, S; Tokino, T; Oren, M; Taniguchi, T				Tanaka, N; Ishihara, M; Lamphier, MS; Nozawa, H; Matsuyama, T; Mak, TW; Aizawa, S; Tokino, T; Oren, M; Taniguchi, T			Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage	NATURE			English	Article							TRANSCRIPTION FACTOR IRF-1; CYCLIN-DEPENDENT KINASES; APOPTOSIS; INDUCTION; ARREST; CELLS; P21; CHECKPOINT; INHIBITORS; ACTIVATION	NORMALLY growing cells promptly cease DNA synthesis when exposed to genotoxic stresses, such as radiation, and this cell-cycle arrest prevents the accumulation of mutations(1,2). The transcription factor interferon regulatory factor (IRF)-1 is essential for the regulation of the interferon system(3-5), inhibits cell growth, and manifests tumour-suppressor activities(6,7). Here we show that mouse embryonic fibroblasts (EFs) lacking LRF-1 are deficient in their ability to undergo DNA-damage-induced cell-cycle arrest. A similar phenotype has been observed in EFs lacking the tumour suppressor p53 (refs 8, 9), although the expression of IRF-1 and p53 are independent of one another. Furthermore, we show that transcriptional induction of the gene encoding p21 (WAF1, CIP1)(10-12), a cell-cycle inhibitor, by gamma-irradiation is dependent on both p53 and IRF-1, and that the p21 promoter is activated, either directly or indirectly, by both in a transient cotransfection assay. These two tumour-suppressor transcription factors therefore converge functionally to regulate the cell cycle through the activation of a common target genes.	NARA INST SCI & TECHNOL,NARA 6301,JAPAN; RES DEV CORP JAPAN,PRECURSORY RES PROGRAM EMBRYON SCI & TECHNOL,KYOTO 61902,JAPAN; ONTARIO CANC INST,AMGEN INST,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT IMMUNOL & MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 860,JAPAN; UNIV TOKYO,INST MED SCI,MOL MED LAB,MINATO KU,TOKYO 108,JAPAN; WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Kumamoto University; University of Tokyo; Weizmann Institute of Science	Tanaka, N (corresponding author), UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,HONGO 7-3-1,TOKYO 113,JAPAN.		Tokino, Takashi/AAI-9887-2021	Tanaka, Nobuyuki/0000-0002-6373-2220				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	297	305	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					816	818		10.1038/382816a0	http://dx.doi.org/10.1038/382816a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752276				2022-12-28	WOS:A1996VE34700049
J	Zwaal, RR; Ahringer, J; vanLuenen, HGAM; Rushforth, A; Anderson, P; Plasterk, RHA				Zwaal, RR; Ahringer, J; vanLuenen, HGAM; Rushforth, A; Anderson, P; Plasterk, RHA			G proteins are required for spatial orientation of early cell cleavages in C. elegans embryos	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; BETA-GAMMA-DIMERS; SIGNAL-TRANSDUCTION; VULVAR INDUCTION; GENE-EXPRESSION; ALPHA-SUBUNITS; DIVISION AXES; GTP-BINDING; POLARITY; SPINDLE	Heterotrimeric G proteins are signal-transducing molecules activated by seven transmembrane domain receptors. In C. elegans, gpb-1 encodes the sole G beta subunit; therefore, its inactivation should affect all heterotrimeric G protein signaling. When maternal but no zygotic gpb-1 protein (GPB-1) is present, development proceeds until the first larval stage, but these larvae show little muscle activity and die soon after hatching. When, however, the maternal contribution of GPB-1 is also reduced, spindle orientations in early cell divisions are randomized. Cell positions in these embryos are consequently abnormal, and the embryos die with the normal number of cells and well-differentiated but abnormally distributed tissues. These results indicate that maternal G proteins are important for orientation of early cell division axes, possibly by coupling a membrane signal to centrosome position.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706	University of Cambridge; MRC Laboratory Molecular Biology; University of Wisconsin System; University of Wisconsin Madison	Zwaal, RR (corresponding author), NETHERLANDS CANC INST,DIV MOL BIOL,PLESMANLAAN 121,NL-1066 CX AMSTERDAM,NETHERLANDS.			van Luenen, Henri/0000-0002-5584-7968; Ahringer, Julie/0000-0002-7074-4051	NCRR NIH HHS [5 R01 RR10082-02] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR010082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BRENNER S, 1974, GENETICS, V77, P71; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; DRUBIN DG, 1996, CELL, V84, P401; ETAMADMOGHADAM B, 1995, CELL, V83, P743; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HERMAN RK, 1976, GENETICS, V83, P91; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; HODGKIN J, 1979, GENETICS, V91, P67; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KOGA M, 1995, DEVELOPMENT, V121, P2655; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LIN CT, 1992, LAB INVEST, V67, P770; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MELLO C, 1995, CAENORHABDITIS ELEGA, P452; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; RUSHFORTH AM, 1993, MOL CELL BIOL, V13, P902, DOI 10.1128/MCB.13.2.902; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SILVA IF, 1990, J MOL BIOL, V215, P483, DOI 10.1016/S0022-2836(05)80160-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VANDERVOORN L, 1990, J MOL BIOL, V213, P17, DOI 10.1016/S0022-2836(05)80118-4; White J, 1996, CELL, V84, P195, DOI 10.1016/S0092-8674(00)80974-5; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	55	132	134	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					619	629		10.1016/S0092-8674(00)80135-X	http://dx.doi.org/10.1016/S0092-8674(00)80135-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752216	Bronze			2022-12-28	WOS:A1996VE23500012
J	Dickinson, TA; White, J; Kauer, JS; Walt, DR				Dickinson, TA; White, J; Kauer, JS; Walt, DR			A chemical-detecting system based on a cross-reactive optical sensor array	NATURE			English	Article							PATTERN-RECOGNITION ANALYSIS; NILE-RED; ELECTRONIC NOSE; OLFACTORY-BULB; ODOR; VAPORS; MIXTURES; DISCRIMINATION; SALAMANDER; RESPONSES	THE vertebrate olfactory system has long been recognized for its extraordinary sensitivity and selectivity for odours. Chemical sensors have been developed recently that are based on analogous distributed sensing properties(1-4), but although an association between artificial devices and the olfactory system has been made explicit in some previous studies(4,5) none has incorporated comparable mechanisms into the mode of detection. Here we describe a multi-analyte fibre-optic sensor modelled directly on the olfactory system, in the sense that complex, time-dependent signals from an array of sensors provide a 'signature' of each analyte, In our system, polymer-immobilized dye molecules on the fibre tips give different fluorescent response patterns (including spectral shifts, intensity changes, spectral shape variations(6) and temporal responses) on exposure to organic vapours, depending on the physical and chemical nature (for example, polarity, shape and size) of both the vapour and the polymer, We use video images of temporal responses of the multi-fibre tip as the input signals to train a neural network for vapour recognition, The system is able to identify individual vapours at different concentrations with great accuracy. 'Artificial noses' such as this should have wide potential application, most notably in environmental and medical monitoring.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155; TUFTS UNIV,SCH MED,DEPT NEUROSCI,BOSTON,MA 02111	Tufts University; Tufts University								BARNARD SM, 1991, ENVIRON SCI TECHNOL, V25, P1301, DOI 10.1021/es00019a012; CAREY W, 1988, ANAL CHEM, V60, P2801; CAREY WP, 1987, ANAL CHEM, V59, P1529, DOI 10.1021/ac00138a010; DABAN JR, 1991, ANAL BIOCHEM, V199, P162, DOI 10.1016/0003-2697(91)90084-7; DEYE JF, 1990, ANAL CHEM, V62, P615, DOI 10.1021/ac00205a015; FREUND MS, 1995, P NATL ACAD SCI USA, V92, P2652, DOI 10.1073/pnas.92.7.2652; GARDNER JW, 1994, SENSOR ACTUAT B-CHEM, V18, P211; GRATE JW, 1991, ANAL CHEM, V63, P1719, DOI 10.1021/ac00017a013; GREENSPAN P, 1993, INT J BIOCHEM, V25, P987, DOI 10.1016/0020-711X(93)90111-Q; HAMILTON KA, 1989, J NEUROPHYSIOL, V62, P609, DOI 10.1152/jn.1989.62.3.609; HATFIELD JV, 1994, SENSOR ACTUAT B-CHEM, V18, P221, DOI 10.1016/0925-4005(94)87086-1; HILDEBRAND JG, 1995, P NATL ACAD SCI USA, V92, P67, DOI 10.1073/pnas.92.1.67; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KAUER JS, 1977, J PHYSIOL-LONDON, V272, P495, DOI 10.1113/jphysiol.1977.sp012056; Lakowicz J. R., 1982, PRINCIPLES FLUORESCE; LUNDSTROM I, 1991, NATURE, V352, P47, DOI 10.1038/352047a0; MEREDITH M, 1978, J GEN PHYSIOL, V71, P615, DOI 10.1085/jgp.71.6.615; ORELLANA G, 1995, ANAL CHEM, V67, P2231, DOI 10.1021/ac00109a050; PERSAUD K, 1982, NATURE, V299, P352, DOI 10.1038/299352a0; POSCH HE, 1988, TALANTA, V35, P89, DOI 10.1016/0039-9140(88)80044-4; REVIAL MF, 1982, CHEM SENSES, V7, P175, DOI 10.1093/chemse/7.2.175; RONOT C, 1993, SENSOR ACTUAT B-CHEM, V11, P375, DOI 10.1016/0925-4005(93)85277-H; ROSEPEHRSSON SL, 1988, ANAL CHEM, V60, P2801, DOI 10.1021/ac00175a032; RUVINOV SB, 1995, J BIOL CHEM, V270, P6357, DOI 10.1074/jbc.270.11.6357; SARDZEWSKI R, 1908, TALANTA, V35, P95; STETTER JR, 1986, ANAL CHEM, V58, P860, DOI 10.1021/ac00295a047; THUNDAT T, 1995, ANAL CHEM, V67, P519, DOI 10.1021/ac00099a006; VAUTHEY E, 1993, CHEM PHYS LETT, V216, P530, DOI 10.1016/0009-2614(93)90138-Q; White J, 1996, ANAL CHEM, V68, P2191, DOI 10.1021/ac9511197; ZELL A, 1994, STUTTGART NEURAL NET; ZELLERS ET, 1995, ANAL CHEM, V67, P1092, DOI 10.1021/ac00102a012	31	332	372	2	141	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					697	700		10.1038/382697a0	http://dx.doi.org/10.1038/382697a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751439				2022-12-28	WOS:A1996VD33300043
J	Schiffmann, R				Schiffmann, R			Niemann-Pick disease type C - From bench to bedside	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIPOPROTEIN-DERIVED CHOLESTEROL; INTRACELLULAR-TRANSPORT; CULTURED FIBROBLASTS; STORAGE; ESTERIFICATION; ACCUMULATION; SPECTRUM				Schiffmann, R (corresponding author), NINCDS, DEV & METAB BRANCH,NIH,BLDG 10,ROOM 3D03, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; CARSTEA ED, 1993, P NATL ACAD SCI USA, V90, P2002, DOI 10.1073/pnas.90.5.2002; CROCKER AC, 1958, MEDICINE, V37, P1, DOI 10.1097/00005792-195802000-00001; CROCKER AC, 1961, J NEUROCHEM, V7, P69, DOI 10.1111/j.1471-4159.1961.tb13499.x; FINK JK, 1989, NEUROLOGY, V39, P1040, DOI 10.1212/WNL.39.8.1040; HIGGINS JJ, 1992, NEUROLOGY, V42, P2286, DOI 10.1212/WNL.42.12.2286; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Mieli-Vergani G, 1991, Gut, VSuppl, pS123, DOI 10.1136/gut.32.Suppl.S123; MORRIS MD, 1982, AM J PATHOL, V108, P150; Niemann A., 1914, JB KINDERHEILKD, V79, P1; PATTERSON MC, 1993, NEUROLOGY, V43, P61, DOI 10.1212/WNL.43.1_Part_1.61; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PENTCHEV PG, 1984, J BIOL CHEM, V259, P5784; PIN I, 1990, ARCH FR PEDIATR, V47, P373; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; SOKOL J, 1988, J BIOL CHEM, V263, P3411; SUZUKI K, 1995, ACTA NEUROPATHOL, V89, P227; VANIER MT, 1991, BIOCHIM BIOPHYS ACTA, V1096, P328, DOI 10.1016/0925-4439(91)90069-L; Vanier MT, 1996, AM J HUM GENET, V58, P118	23	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					561	564		10.1001/jama.276.7.561	http://dx.doi.org/10.1001/jama.276.7.561			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709406				2022-12-28	WOS:A1996VC10100033
J	Boisaubin, EV				Boisaubin, EV			Treatment for obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							TRIAL				Boisaubin, EV (corresponding author), UNIV TEXAS,MED BRANCH,DEPT MED,GALVESTON,TX 77550, USA.							ADKINSON RL, 1994, AM J CLIN NUTR, V60, P153; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BRAY GA, 1979, NATL I HLTH PUBLICAT; GOLDSTEIN DJ, 1994, INT J OBESITY, V18, P129; OCONNOR HT, 1995, INT J OBESITY, V19, P181; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; 1996, AM MED NEWS     0603, P14; [No title captured]	9	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					445	445						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691540				2022-12-28	WOS:A1996VA86300010
J	Pais, P; Pogue, J; Gerstein, H; Zachariah, E; Savitha, D; Jayprakash, S; Nayak, PR; Yusuf, S				Pais, P; Pogue, J; Gerstein, H; Zachariah, E; Savitha, D; Jayprakash, S; Nayak, PR; Yusuf, S			Risk factors for acute myocardial infarction in Indians: A case-control study	LANCET			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; INSULIN RESISTANCE; ADIPOSE-TISSUE; MORTALITY; DESCENT; LONDON; WOMEN; MEN; LIPOPROTEIN	Background South Asians who have settled overseas and Chose in urban India have an increased risk of ischaemic heart disease (IHD). Reasons for this increased risk are unclear. Most studies have been based on migrants to western nations. so their findings may not apply to most south Asians, who live in their own countries, Therefore, we assessed the relative importance of risk factors for IHD among South Asians in Bangalore, India. Methods We conducted a prospective hospital-based case-control study of 200 Indian patients with a first acute myocardial infarction (AMI) and 200 age and sex matched controls. We recorded prevalence of the following risk factors for IHD: diet, smoking, alcohol use. socioeconomic status, waist to hip ratio (WHR), blood glucose, serum insulin, oral glucose tolerance test, and lipid profile. Findings The most important predictor of AMI was current smoking (odds ratio [OR] 3.6, p<0.001) of cigarettes or beedis (a local form of tobacco), with individuals who currently smoked 10 or more per day having an OR of 6.7 (p<0.001). History of hypertension and of overt diabetes mellitus were also independent risk factors (OR 2.69 [p=0.001] and 2.64 [p=0.004]. respectively). Among all individuals, fasting blood glucose was a strong predictor of risk over the entire range, including al values usually regarded as normal (OR adjusted for smoking, hypertension, and WHR 1.62 for 1 SD increase, p<0.001). Abdominal obesity (as measured by WHR) was also a strong independent predictor across the entire range of measures (OR adjusted for smoking, hypertension, and blood glucose 2.24 for 1 SD increase; p<0.001). Compared with individuals with no risk factors, individuals with multiple risk factors had greatly increased risk of AMI leg, OR of 10.6 far the group with smoking and elevated glucose), Lipid profile was not associated with AMI. In univariate analyses, higher socioeconomic (income) status (OR 0.32, p=0.005 highest vs lowest: OR 0.75 middle vs lowest) and vegetarianism (OR=0.55, p=0.006), seemed to be protective. The impact of vegetarianism was closely correlated with blood glucose and WHR. Interpretation Smoking cessation, treatment of hypertension. and reduction in blood glucose and central obesity (perhaps through dietary modification) may be important in preventing IHD in Asian Indians.	MCMASTER UNIV,DIV CARDIOL,HAMILTON,ON L8L 2X2,CANADA; MCMASTER UNIV,DIV ENDOCRINOL,HAMILTON,ON L8L 2X2,CANADA; HAMILTON GEN HOSP,HAMILTON CIV HOSP,RES CTR,HAMILTON,ON L8L 2X2,CANADA; ST JOHNS MED COLL,EPIDEMIOL RES & TRAINING CTR,DEPT MED,BANGALORE 560034,KARNATAKA,INDIA; ST JOHNS MED COLL,EPIDEMIOL RES & TRAINING CTR,DEPT CARDIOL,BANGALORE 560034,KARNATAKA,INDIA	McMaster University; McMaster University; McMaster University; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College			Gerstein, Hertzel C/B-1235-2013; Gerstein, Hertzel/ABB-8781-2020	Gerstein, Hertzel C/0000-0001-8072-2836; Gerstein, Hertzel/0000-0001-8072-2836; Yusuf, Salim/0000-0003-4776-5601				BECKLES GLA, 1986, LANCET, V1, P1298; CEREMUZYNSKI L, 1981, CIRC RES, V48, P767, DOI 10.1161/01.RES.48.6.767; CHADHA SL, 1992, INDIAN J MED RES-B, V96, P115; CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424; DHAWAN J, 1991, BRIT HEART J, V66, P81; ENAS EA, 1992, AM J CARDIOL, V70, P945, DOI 10.1016/0002-9149(92)90744-J; FARMER JA, 1992, HEART DISEASE, P1125; FRAYN KN, 1992, CLIN SCI, V82, P1, DOI 10.1042/cs0820001; GORE JM, 1984, AM J CARDIOL, V54, P722, DOI 10.1016/S0002-9149(84)80197-6; GUPTA R, 1994, BRIT MED J, V307, P1332; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; KVIST H, 1988, AM J CLIN NUTR, V48, P1351, DOI 10.1093/ajcn/48.6.1351; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEIDIG GA, 1994, AM J CARDIOL, V74, P47, DOI 10.1016/0002-9149(94)90490-1; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; MCKEIGUE PM, 1989, CLIN EPIDEMIOL, V42, P579; MCKEIGUE PM, 1994, CORONARY HEART DISEA; MILLER GJ, 1989, INT J EPIDEMIOL, V18, P808, DOI 10.1093/ije/18.4.808; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; RAMCHANDRAN A, 1988, BRIT MED J, V297, P587; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REDDY S, 1992, ATHEROSCLEROSIS, V95, P223, DOI 10.1016/0021-9150(92)90025-C; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SARVOTHAM SG, 1968, CIRCULATION, V37, P939, DOI 10.1161/01.CIR.37.6.939; SEEDAT YK, 1990, S AFR MED J, V78, P447; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; THOMAS I, 1986, ATHEROSCLEROSIS, V61, P99, DOI 10.1016/0021-9150(86)90068-7; VETTER NJ, 1974, LANCET, V1, P284; 1986, LANCET, V1, P1307	33	198	205	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					358	363		10.1016/S0140-6736(96)02507-X	http://dx.doi.org/10.1016/S0140-6736(96)02507-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709733				2022-12-28	WOS:A1996VB42600009
J	Ball, S; Guan, HP; James, M; Myers, A; Keeling, P; Mouille, G; Buleon, A; Colonna, P; Preiss, J				Ball, S; Guan, HP; James, M; Myers, A; Keeling, P; Mouille, G; Buleon, A; Colonna, P; Preiss, J			From glycogen to amylopectin: A model for the biogenesis of the plant starch granule	CELL			English	Review									IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011; INRA,CTR RECH AGROALIMENTAIRES,F-44316 NANTES 03,FRANCE; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Iowa State University; INRAE; Michigan State University	Ball, S (corresponding author), UNIV SCI & TECH LILLE FLANDRES ARTOIS,CTR NATL RECH SCI,UNITE MIXTE RECH 111,CHIM BIOL LAB,F-59655 VILLENEUVE DASCQ,FRANCE.			Myers, Alan/0000-0002-9619-4692; Ball, Steven/0000-0003-1629-1650; Mouille, Gregory/0000-0002-5493-754X				Correns C, 1901, BIBLIOTHECA BOT, V53, P1; ERLANDER S. R., 1958, ENZYMOLOGIA, V19, P273; Geddes R., 1985, POLYSACCHARIDES, V3, P283; GUAN HP, 1995, P NATL ACAD SCI USA, V92, P964, DOI 10.1073/pnas.92.4.964; IMBERTY A, 1988, J MOL BIOL, V20, P2634; JAMES MG, 1995, PLANT CELL, V7, P417, DOI 10.1105/tpc.7.4.417; JENKINS JPJ, 1993, STARCH-STARKE, V45, P417; MADDELEIN ML, 1994, J BIOL CHEM, V269, P25150; MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0; MOUILLE G, 1996, IN PRESS PLANT CELL; NAKAMURA Y, 1996, IN PRESS PHYSL PLANT; Nelson O, 1995, Physiol Mol Biol, V46, P475; OOSTERGETEL GT, 1993, CARBOHYD POLYM, V21, P7, DOI 10.1016/0144-8617(93)90110-P; PAN D, 1984, PLANT PHYSIOL, V74, P324, DOI 10.1104/pp.74.2.324; Sumner J.B., 1944, ARCH BIOCH, V4, P433	15	334	382	2	68	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					349	352		10.1016/S0092-8674(00)80107-5	http://dx.doi.org/10.1016/S0092-8674(00)80107-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756717	Bronze			2022-12-28	WOS:A1996VC30900003
J	Trauger, JW; Baird, EE; Dervan, PB				Trauger, JW; Baird, EE; Dervan, PB			Recognition of DNA by designed ligands at subnanomolar concentrations	NATURE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; DOUBLE-HELICAL DNA; COVALENT PEPTIDE DIMERS; MINOR-GROOVE; ZINC FINGERS; BINDING SPECIFICITY; 2-DIMENSIONAL NMR; DISTAMYCIN; SELECTION; MOTIF	SMALL molecules that specifically bind with high affinity to any predetermined DNA sequence in the human genome would be useful tools in molecular biology and potentially in human medicine. Simple rules have been developed to control rationally the sequence specificity of minor-groove-binding polyamides containing N-methylimidazole and N-methylpyrrole amino acids. Two eight-ring pyrrole-imidazole polyamides differing in sequence by a single amino acid bind specifically to respective six-base-pair target sites which differ in sequence by a single base pair. Binding is observed at subnanomolar concentrations of ligand. The replacement of a single nitrogen atom with a C-H regulates affinity and specificity by two orders of magnitude, The broad range of sequences that can be specifically targeted with pyrrole-imidazole polyamides, coupled with an efficient solid-phase synthesis methodology, identify a powerful class of small molecules for sequence-specific recognition of double-helical DNA.			Trauger, JW (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.							Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CHEN YH, 1994, J AM CHEM SOC, V116, P6995, DOI 10.1021/ja00095a001; CHO JY, 1995, P NATL ACAD SCI USA, V92, P10389, DOI 10.1073/pnas.92.22.10389; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DWYER TJ, 1993, J AM CHEM SOC, V115, P9900, DOI 10.1021/ja00075a005; FOX KR, 1984, NUCLEIC ACIDS RES, V12, P9271, DOI 10.1093/nar/12.24.9271; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEIERSTANGER BH, 1993, J AM CHEM SOC, V115, P4474, DOI 10.1021/ja00064a009; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P3055, DOI 10.1021/bi00176a039; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; IVERSON BL, 1987, NUCLEIC ACIDS RES, V15, P7823, DOI 10.1093/nar/15.19.7823; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Maxam A M, 1980, Methods Enzymol, V65, P499; MRKSICH M, 1994, J AM CHEM SOC, V116, P3663, DOI 10.1021/ja00087a088; MRKSICH M, 1993, J AM CHEM SOC, V115, P9892, DOI 10.1021/ja00075a004; MRKSICH M, 1995, J AM CHEM SOC, V117, P3325, DOI 10.1021/ja00117a002; MRKSICH M, 1993, J AM CHEM SOC, V115, P2572, DOI 10.1021/ja00060a004; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; MRKSICH M, 1994, J AM CHEM SOC, V116, P7983, DOI 10.1021/ja00097a004; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; PELTON JG, 1990, J AM CHEM SOC, V112, P1393, DOI 10.1021/ja00160a016; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; WADE WS, 1993, BIOCHEMISTRY-US, V32, P11385, DOI 10.1021/bi00093a015	30	383	407	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					559	561		10.1038/382559a0	http://dx.doi.org/10.1038/382559a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700233				2022-12-28	WOS:A1996VB25800056
J	Pell, J; Pell, A; Morrison, C; Blatchford, O; Dargie, H				Pell, J; Pell, A; Morrison, C; Blatchford, O; Dargie, H			Retrospective study of influence of deprivation on uptake of cardiac rehabilitation	BRITISH MEDICAL JOURNAL			English	Article									STOBHILL GEN HOSP,DEPT CARDIOL,GLASGOW G21 3UW,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT CARDIOL,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow	Pell, J (corresponding author), GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW G1 1ET,LANARK,SCOTLAND.							DAVEYSMITH G, 1990, BRIT MED J, V301, P373; McLoone P., 1994, CARSTAIRS SCORES SCO; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; Tunstall-Pedoe H, 1986, Health Bull (Edinb), V44, P153	5	64	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					267	268		10.1136/bmj.313.7052.267	http://dx.doi.org/10.1136/bmj.313.7052.267			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704538	Green Published			2022-12-28	WOS:A1996VA90300027
J	Roosevelt, G; Sheehan, K; GruppPhelan, J; Tanz, RR; Listernick, R				Roosevelt, G; Sheehan, K; GruppPhelan, J; Tanz, RR; Listernick, R			Dexamethasone in bronchiolitis: A randomised controlled trial	LANCET			English	Article							VIRAL BRONCHIOLITIS; INFANTS; ALBUTEROL	Background Although corticosteroids are commonly prescribed in the treatment of bronchiolitis, there is no evidence on the efficacy of these drugs in this disorder, We designed a randomised, double-blind, prospective study to assess the efficacy of dexamethasone in infants with bronchiolitis who require hospital management. Methods Infants younger than 12 months who had been admitted to hospital for an initial episode of wheezing, were randomly allocated intramuscular dexamethasone (1 mg/kg daily) or placebo, every 24 h for three doses. We excluded infants who were younger than 4 weeks, who required admission to the intensive care unit, or who had a history of congenital heart disease, mechanical ventilation, or supplemental oxygen use. We assessed infants on admission and every 12 h thereafter-vital signs were taken, severity of accessory muscle use and wheezing were measured by a clinical severity score, and pulse oximetry in room air was done. Our primary endpoints were the time to resolution of symptoms-defined as the number of assessments needed to reach oxygen saturation of more than 95% while receiving no supplemetal oxygen, an accessory muscle score of 0, a wheeze score of 0 or 1, and resumption of normal feeding-and duration of oxygen therapy. Follow-up assessments were made 10-14 days after discharge by telephone. We used a proportional-hazards model for our survival analysis. Findings 197 infants presented with bronchiolitis that required inpatient management. 75 were not enrolled (31 no consent, 28 no approach made, 16 transferred elsewhere). Of the 122 enrolled, four were excluded (clinical deterioration, diagnosis of cystic fibrosis, previous intubation, did not receive all study treatment). There were no differences between the dexamethasone (n=65) and placebo-treated infants in demographic factors, exposure to tobacco smoke, duration of illness, presence of respiratory syncytial virus (RSV) antigen, respiratory rate, or severity score. More dexamethasone-treated patients had an initial oxygen saturation of 95% or less (51 [79%] dexamethasone vs 31 [59%] placebo, p=0.02). There were no differences in duration of oxygen therapy (p=0.74) or time to resolution of symptoms (p=0.22). Stratification for presence of RSV antigen or family history of atopy did not affect the results. Interpretation Our findings do not support the use of dexamethasone in the treatment of bronchiolitis in infants.	CHILDRENS MEM HOSP,NO MED SCH,DEPT PEDIAT,DIV GEN ACAD PEDIAT,CHICAGO,IL 60614	Ann & Robert H. Lurie Children's Hospital of Chicago	Roosevelt, G (corresponding author), CHILDRENS MEM HOSP,DIV PEDIAT EMERGENCY MED,2300 CHILDRENS PLAZA,CHICAGO,IL 60614, USA.			Sheehan, Karen/0000-0003-3901-8534				*ABB LAB, 1989, TEST PACK RSV IMM CA; ARNOLD J, 1992, NELSON TXB PEDIAT, P1075; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; CHALMERS TC, 1990, PEDIATRICS, V85, P366; DABBOUS IA, 1966, PEDIATRICS, V37, P477; GADOMSKI AM, 1994, PEDIATRICS, V93, P907; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; KHINE H, 1996, ARCH PEDIAT ADOLES S, V150, P63; KORPPI M, 1993, AM J DIS CHILD, V147, P628, DOI 10.1001/archpedi.1993.02160300034017; LEER JA, 1969, AM J DIS CHILD, V117, P495, DOI 10.1001/archpedi.1969.02100030497001; NAHATA MC, 1994, J CLIN PHARM THER, V19, P117, DOI 10.1111/j.1365-2710.1994.tb01122.x; *NAT ASTHM ED PROG, 1991, 913042 NIH, P113; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; *SAN PAST DIAGN, 1993, KALL RSV MICR EIA; SCHUH S, 1990, J PEDIATR-US, V117, P633, DOI 10.1016/S0022-3476(05)80706-1; SHAW KN, 1991, AM J DIS CHILD, V145, P151, DOI 10.1001/archpedi.1991.02160020041012; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; SPRINGER C, 1990, PEDIATR PULM, V9, P181, DOI 10.1002/ppul.1950090311; SUSSMAN S, 1964, PEDIATRICS, V34, P851; TAL A, 1983, PEDIATRICS, V71, P13; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325	21	133	136	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					292	295		10.1016/S0140-6736(96)02285-4	http://dx.doi.org/10.1016/S0140-6736(96)02285-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709687				2022-12-28	WOS:A1996VA25000008
J	Visscher, PK; Vatter, RS; Camazine, S				Visscher, PK; Vatter, RS; Camazine, S			Removing bee stings	LANCET			English	Article							HYPERSENSITIVITY; VENOM	Background Conventional advice on immediate treatment of honey-bee stings has emphasised that the sting should be scraped off, never pinched. The morphology of the sting suggested little basis for this advice, which is likely to slow down removal of the sting. Methods The response to honey-bee stings was assayed with a measurement of the size of the resulting weal. Injection of known quantities of venom showed that this measurement is a good indicator of envenomisation. Findings Weal size, and thus envenomisation, increased as the time from stinging to removal of the sting increased, even within a few seconds. There was no difference in response between stings scraped or pinched off after 2 s. Interpretation These data suggest that advice to patients on the immediate treatment of bee stings should emphasise quick removal, without concern for the method of removal.	PENN STATE UNIV,DEPT ENTOMOL,STATE COLL,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Visscher, PK (corresponding author), UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521, USA.		Camazine, Scott/T-2604-2017					Free J. B., 1987, PHEROMONES SOCIAL BE; GODDARD J, 1993, PHYSICIANS GUIDE ART, P349; MOSBACH H, 1995, CLIN TOXICOLOGY ANIM, P81; MULFINGER L, 1992, J MED ENTOMOL, V29, P325, DOI 10.1093/jmedent/29.2.325; RICHES HRC, 1989, BEE WORLD, V70, P12, DOI 10.1080/0005772X.1989.11098980; RICHES HRC, 1982, BEE WORLD, V63, P7, DOI 10.1080/0005772X.1982.11097849; Schmidt J. O., 1992, HIVE HONEY BEE, P1209; Snodgrass R.E., 1956, ANATOMY HONEY BEE, P334	8	61	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					301	302		10.1016/S0140-6736(96)01367-0	http://dx.doi.org/10.1016/S0140-6736(96)01367-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709689				2022-12-28	WOS:A1996VA25000010
J	Rother, RP; Squinto, SP				Rother, RP; Squinto, SP			The alpha-galactosyl epitope: A sugar coating that makes viruses and cells unpalatable	CELL			English	Review							RNA TUMOR-VIRUSES; HUMAN-SERUM; RETROVIRUS INACTIVATION; COMPLEMENT; ANTIBODY; GLYCOPROTEIN; PRIMATES; LYSIS				Rother, RP (corresponding author), ALEXION PHARMACEUT,DEPT MOL DEV,NEW HAVEN,CT 06511, USA.							BARBACID M, 1980, P NATL ACAD SCI-BIOL, V77, P1617, DOI 10.1073/pnas.77.3.1617; BARTHOLOMEW RM, 1978, J EXP MED, V147, P844, DOI 10.1084/jem.147.3.844; COOPER NR, 1976, J EXP MED, V144, P970, DOI 10.1084/jem.144.4.970; CORNETTA K, 1990, HUM GENE THER, V1, P15, DOI 10.1089/hum.1990.1.1-15; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; DONAHUE RE, 1992, J EXP MED, V176, P1125, DOI 10.1084/jem.176.4.1125; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; HAMADEH RM, 1995, INFECT IMMUN, V63, P4900, DOI 10.1128/IAI.63.12.4900-4906.1995; Purcell DFJ, 1996, J VIROL, V70, P887, DOI 10.1128/JVI.70.2.887-897.1996; REPLK PM, 1994, J GEN VIROL, V75, P1177; Rollins SA, 1996, HUM GENE THER, V7, P619, DOI 10.1089/hum.1996.7.5-619; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; RUSSELL DW, 1995, HUM GENE THER, V6, P635, DOI 10.1089/hum.1995.6.5-635; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0; WELSH RM, 1977, J IMMUNOL, V118, P348	19	80	85	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					185	188		10.1016/S0092-8674(00)80090-2	http://dx.doi.org/10.1016/S0092-8674(00)80090-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706123	Bronze			2022-12-28	WOS:A1996UZ97200004
J	Barbosa, MDFS; Nguyen, QA; Tchernev, VT; Ashley, JA; Detter, JC; Blaydes, SM; Brandt, SJ; Chotai, D; Hodgman, C; Solari, RCE; Lovett, M; Kingsmore, SF				Barbosa, MDFS; Nguyen, QA; Tchernev, VT; Ashley, JA; Detter, JC; Blaydes, SM; Brandt, SJ; Chotai, D; Hodgman, C; Solari, RCE; Lovett, M; Kingsmore, SF			Identification of the homologous beige and Chediak-Higashi syndrome genes	NATURE			English	Article							PROTEIN SECONDARY STRUCTURE; POLYMORPHONUCLEAR LEUKOCYTES; STRUCTURE PREDICTION; DOWN-REGULATION; CAP FORMATION; KINASE-C; MOUSE; MICE; CONCANAVALIN; MUTATION	VESICULAR transport to and from the lysosome and late endosome is defective in patients with Chediak-Higashi syndrome (CHS) and in mutant beige (bg) mice(1-4). CHS and bg cells have giant, perinuclear vesicles with characteriscs of late endosomes and lysosomes that arise from dysregulated homotypic fusion(3-5). CHS and bg lysosomes also exhibit compartmental missorting of proteins, such as elastase, glucuronidase and cathepsin G(2,3,6,7) Lyst, a candidate gene for bg, was identified by direct complementary DNA selection from a yeast artificial chromosome (YAC) clone containing a 650-kilobase segment of the bg-critical region on mouse chromosome 13. Lyst is disrupted by a 5-kilobase deletion in bg(11J) mice, and Lyst messenger RNA is markedly reduced in bg(2J) homozygotes. The homologous human gene, LYST, is highly conserved with mouse Lyst, and contains a frame-shift mutation at nucleotides 117-118 of the coding domain in a CHS patient. Thus bg mice and human CHS patients have homologous disorders associated with Lyst mutations. Lyst encodes a protein with a carboxy-terminal prenylation motif and multiple potential phosphorylation sites. Lyst protein is predicted to form extended helical domains, and has a region of sequence similar to stathmin, a coiled coil phosphoprotein thought to act as a relay integrating cellular signal response coupling(8-10).	UNIV FLORIDA,DEPT MED,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT PATHOL,GAINESVILLE,FL 32610; UNIV FLORIDA,CTR MAMMALIAN GENET,GAINESVILLE,FL 32610; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; GLAXO WELLCOME MED RES CTR,CELL BIOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND; GLAXO WELLCOME MED RES CTR,ADV TECHNOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND; GLAXO WELLCOME MED RES CTR,INFORMAT UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University; Vanderbilt University; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline				Hodgman, Charlie/0000-0001-5862-8296; Kingsmore, Stephen/0000-0001-7180-2527; kingsmore, stephen/0000-0002-3758-4631	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U19HD077693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039824] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI039824, P01 AI039824-050002] Funding Source: Medline; NICHD NIH HHS [U19 HD077693] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAETZ K, 1995, J IMMUNOL, V154, P6122; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BLUME RS, 1972, MEDICINE, V51, P247, DOI 10.1097/00005792-197207000-00001; BRANDT EJ, 1975, J CELL BIOL, V67, P774, DOI 10.1083/jcb.67.3.774; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; CLARKE SA, REV BIOCH, V61, P355; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; GALLIN JI, 1974, BLOOD, V43, P201, DOI 10.1182/blood.V43.2.201.201; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GRIBRAT JF, 1987, J MOL BIOL, V198, P425; Holcombe R F, 1994, Immunodeficiency, V5, P131; ITO M, 1989, BIOCHEM BIOPH RES CO, V160, P433, DOI 10.1016/0006-291X(89)92451-0; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KINGSMORE SF, IN PRESS MAMM GENOME; KINGSMORE SF, IN PRESS J INVEST ME; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; OLIVER JM, 1975, NATURE, V253, P471, DOI 10.1038/253471a0; OLIVER JM, 1976, J CLIN INVEST, V57, P1239, DOI 10.1172/JCI108392; PEROU CM, 1993, SOMAT CELL MOLEC GEN, V19, P459, DOI 10.1007/BF01233251; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; RODER J, 1979, NATURE, V278, P451, DOI 10.1038/278451a0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SATO A, 1990, J LEUKOCYTE BIOL, V48, P377, DOI 10.1002/jlb.48.5.377; SAXENA RK, 1982, NATURE, V295, P240, DOI 10.1038/295240a0; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; SWANK RT, 1978, AM J PATHOL, V92, P755; WILLINGHAM MC, 1981, EXP CELL RES, V136, P157, DOI 10.1016/0014-4827(81)90047-1; ZHAO HQ, 1994, LAB INVEST, V71, P25	30	383	404	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					262	265		10.1038/382262a0	http://dx.doi.org/10.1038/382262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717042	Green Accepted			2022-12-28	WOS:A1996UX79000052
J	Fitzmaurice, DA; Bradley, CP; Salter, R; Slater, AE				Fitzmaurice, DA; Bradley, CP; Salter, R; Slater, AE			Evidence used to formulate guidelines on managing asthma did not include costs	BRITISH MEDICAL JOURNAL			English	Letter											Fitzmaurice, DA (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Bradley, Colin/0000-0002-3595-9567				AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; DOWIE J, 1996, HEALTH CARE ANAL, V1, P1; DREPAUL BA, 1989, CLIN TRIALS J, V26, P335; VANDERPALEN J, 1995, THORAX, V50, P1183, DOI 10.1136/thx.50.11.1183; 1996, BRIT MED J, V312, P762	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1996	313	7049					113	114		10.1136/bmj.313.7049.113c	http://dx.doi.org/10.1136/bmj.313.7049.113c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688733	Green Published			2022-12-28	WOS:A1996UX69800069
J	Fox, PT; Ingham, RJ; Ingham, JC; Hirsch, TB; Downs, JH; Martin, C; Jerabek, P; Glass, T; Lancaster, JL				Fox, PT; Ingham, RJ; Ingham, JC; Hirsch, TB; Downs, JH; Martin, C; Jerabek, P; Glass, T; Lancaster, JL			A PET study of the neural systems of stuttering	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN-BRAIN; LOCALIZATION; IMAGES	THE cause of stuttering is unknown(1). Failure to develop left-hemispheric dominance for speech is a long-standing theory(1) although others implicate the motor system more broadly(2), often postulating hyperactivity of the right (language nondominant) cerebral hemisphere(3). As knowledge of motor circuitry has advanced(4), theories of stuttering have become more anatomically specific, postulating hyperactivity of premotor cortex, either directly(5) or through connectivity with the thalamus and basal ganglia(6), Alternative theories target the auditory(7) and speech productions(8,9) systems. By contrasting stuttering with fluent speech using positron emission tomography combined with chorus reading to induce fluency, we found support for each of these hypotheses, Stuttering induced widespread over-activations of the motor system in both cerebrum and cerebellum, with right cerebral dominance. Stuttered reading lacked left-lateralized activations of the auditory system, which are thought to support the self-monitoring of speech, and selectively deactivated a frontal-temporal system implicated in speech production, Induced fluency decreased or eliminated the overactivity in most motor areas, and largely reversed the auditory-system underactivations and the deactivation of the speech production system. Thus stuttering is a disorder affecting the multiple neural systems used for speaking.	UNIV TEXAS, HLTH SCI CTR, DEPT RADIOL, SAN ANTONIO, TX 78284 USA; UNIV CALIF SANTA BARBARA, DEPT SPEECH & HEARING SCI, SANTA BARBARA, CA 93106 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Santa Barbara	Fox, PT (corresponding author), UNIV TEXAS, HLTH SCI CTR, RES IMAGING CTR, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.		Fox, Peter/B-4725-2010; Lancaster, Jack L/F-2994-2010	Fox, Peter/0000-0002-0465-2028; 				ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Bloodstein O., 1995, HDB STUTTERING; CARUSO AJ, 1991, INT CONGR SER, V950, P101; CORDES AK, 1995, J SPEECH HEAR RES, V38, P33, DOI 10.1044/jshr.3801.33; Fairbanks G, 1954, J SPEECH HEAR DISORD, V19, P133, DOI 10.1044/jshd.1902.133; FOX PT, 1985, J NEUROPHYSIOL, V54, P348, DOI 10.1152/jn.1985.54.2.348; FOX PT, 1984, J CEREBR BLOOD F MET, V4, P329, DOI 10.1038/jcbfm.1984.49; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FRISTON KJ, 1991, P ROY SOC B-BIOL SCI, V244, P101, DOI 10.1098/rspb.1991.0057; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; GRAFTON ST, 1994, ANN NEUROL, V36, P3, DOI 10.1002/ana.410360103; INGHAM RJ, 1993, J SPEECH HEAR RES, V36, P1168, DOI 10.1044/jshr.3606.1168; INGHAM RJ, 1979, J SPEECH HEAR RES, V22, P784, DOI 10.1044/jshr.2204.784; INGHAM RJ, 1984, STUTTERING BEHAV; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; Pardo Jose V., 1993, Human Brain Mapping, V1, P57, DOI 10.1002/hbm.460010107; PERKINS WH, 1991, J SPEECH HEAR RES, V34, P734, DOI 10.1044/jshr.3404.734; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; Stromsta C., 1986, ELEMENTS STUTTERING; Talairach J., 1988, COPLANAR STEREOTAXIC; Van Riper C., 1955, STUTTERING CHILDREN, P199; Webster WG, 1993, NEUROPSYCHOLOGY STUT, P73; Wingate M. E., 1988, STRUCTURE STUTTERING; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; YEUDALL LT, 1985, SEMINARS SPEECH LANG, V6, P197; ZIMMERMANN G, 1980, J SPEECH HEAR RES, V23, P122, DOI 10.1044/jshr.2301.122; ZIMMERMANN G, 1984, NATURE TREATMENT STU, P131	30	326	337	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					158	162		10.1038/382158a0	http://dx.doi.org/10.1038/382158a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UW672	8700204				2022-12-28	WOS:A1996UW67200047
J	Gerald, C; Walker, MW; Criscione, L; Gustafson, EL; BatzlHartmann, C; Smith, KE; Vaysse, P; Durkin, MM; Laz, TM; Linemeyer, DL; Schaffhauser, AO; Whitebread, S; Hofbauer, KG; Taber, RI; Branchek, TA; Weinshank, RL				Gerald, C; Walker, MW; Criscione, L; Gustafson, EL; BatzlHartmann, C; Smith, KE; Vaysse, P; Durkin, MM; Laz, TM; Linemeyer, DL; Schaffhauser, AO; Whitebread, S; Hofbauer, KG; Taber, RI; Branchek, TA; Weinshank, RL			A receptor subtype involved in neuropeptide-Y-induced food intake	NATURE			English	Article							PROTEIN-COUPLED RECEPTOR; PEPTIDE-YY; GENE; EXPRESSION; CLONING; BINDING	NEUROPEPTIDE Y (NPY) is a powerful stimulant of food intake and is proposed to activate a hypothalamic 'feeding' receptor distinct from previously cloned Y-type receptors(1). This receptor was first suggested to explain a feeding response to NPY and related peptides, including NPY2-36, that differed from their activities at the Y1 receptor(2), Here we report the expression cloning of a novel Y-type receptor from rat hypothalamus, which we name Y5, The complementary DNA encodes a 456-amino-acid protein with less than 35% overall identity to known Y-type receptors, The messenger RNA is found primarily in the central nervous system, including the paraventricular nucleus of the hypothalamus. The extent to which selected peptides can Inhibit adenylate cyclase through the Y5 receptor and stimulate food intake in rats correspond well, Our data support the idea that the Y5 receptor is the postulated 'feeding' receptor, and may provide a new method for the study and treatment of obesity and eating disorders.	CIBA GEIGY LTD,DIV PHARMACEUT,METAB RISK FACTOR DEPT,CH-4002 BASEL,SWITZERLAND	Novartis	Gerald, C (corresponding author), SYNAPT PHARMACEUT CORP,215 COLL RD,PARAMUS,NJ 07652, USA.							BALASUBRAMANIAM A, 1994, J MED CHEM, V37, P811, DOI 10.1021/jm00032a015; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; BARD JA, 1995, Patent No. 17906; BLOMQVIST AG, 1995, BBA-GENE STRUCT EXPR, V1261, P439, DOI 10.1016/0167-4781(95)00051-H; COX HM, 1995, BRIT J PHARMACOL, V116, P2673, DOI 10.1111/j.1476-5381.1995.tb17225.x; DURKIN MM, 1995, MOL BRAIN RES, V33, P7, DOI 10.1016/0169-328X(95)00101-W; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GERALD C, 1995, EMBO J, V14, P2806, DOI 10.1002/j.1460-2075.1995.tb07280.x; GERALD C, 1995, Patent No. 21245; HARRIGAN MT, 1991, MOL ENDOCRINOL, V5, P1331, DOI 10.1210/mend-5-9-1331; HERZOG H, 1993, J BIOL CHEM, V268, P6703; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; KRAUSE J, 1992, MOL PHARMACOL, V41, P817; KRSTENANSKY JL, 1989, P NATL ACAD SCI USA, V86, P4377, DOI 10.1073/pnas.86.12.4377; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LARSEN PJ, 1993, EUR J NEUROSCI, V5, P1622, DOI 10.1111/j.1460-9568.1993.tb00231.x; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; Rimland JM, 1996, MOL PHARMACOL, V49, P387; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; RUDOLF K, 1994, EUR J PHARMACOL, V271, pR11, DOI 10.1016/0014-2999(94)90822-2; SCHWARTZ TW, 1983, GASTROENTEROLOGY, V85, P1411; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309	28	807	841	0	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					168	171		10.1038/382168a0	http://dx.doi.org/10.1038/382168a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700207				2022-12-28	WOS:A1996UW67200050
J	FritzWolf, K; Schnyder, T; Wallimann, T; Kabsch, W				FritzWolf, K; Schnyder, T; Wallimann, T; Kabsch, W			Structure of mitochondrial creatine kinase	NATURE			English	Article							FORMS OCTAMERIC STRUCTURES; MUSCLE; SITE; CRYSTALLIZATION; CRYSTALS	CREATINE kinase (CK; EC 2.7.3.2), an enzyme important for energy metabolism in cells of high and fluctuating energy requirements, catalyses the reversible transfer of a phosphoryl goup from phosphocreatine to ADP(1-3). We have solved the structure of the octameric mitochondrial isoform, Mi(b)-CK, which is located in the intermembrane compartment and along the cristae membranes. Mi(b)-CK consumes ATP produced in the mitochondria for the production of phosphocreatine, which is then exported into the cytosol for fast regeneration of ATP by the cytosolic CK isoforms. The octamer has 422 point-group symmetry, and appear as a cube of side length of 93 Angstrom with a channel 20 Angstrom wide extending along the four-fold axis. Positively charged amino acids at the four-fold faces of the octamer possible interact with negatively charged mitochondrial membranes. Each monomer consists of a small alpha-helical domain and a large domain containing an eight-stranded antiparallel beta-sheet flanked by seven alpha-helices. The conserved residues of the CK family form a compact cluster that covers the active site between the domains.	MAX PLANCK INST MED RES,BIOPHYS ABT,D-69028 HEIDELBERG,GERMANY; ETH ZURICH,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich			Wallimann, Theo/C-6047-2008	Wallimann, Theo/0000-0003-4957-5836				BRUNGER AT, 1992, X PLOR VERSION 3 1; BUECHTER DD, 1992, J BIOL CHEM, V267, P2173; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1204, DOI 10.1021/bi00508a023; GROSS M, 1995, BIOCHEMISTRY-US, V34, P6660, DOI 10.1021/bi00020a011; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; HOSSLE JP, 1988, BIOCHEM BIOPH RES CO, V151, P408, DOI 10.1016/0006-291X(88)90608-0; JAMES P, 1990, FEBS LETT, V273, P139, DOI 10.1016/0014-5793(90)81069-Z; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KALDIS P, 1994, BIOCHEMISTRY-US, V33, P952, DOI 10.1021/bi00170a014; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; MILNERWH.EJ, 1971, BIOCHEM J, V122, P727, DOI 10.1042/bj1220727; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P19935; ROJO M, 1991, J BIOL CHEM, V266, P20290; ROSEVEAR PR, 1981, BIOCHEMISTRY-US, V20, P6155, DOI 10.1021/bi00524a038; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16942; SCHNYDER T, 1991, J BIOL CHEM, V266, P5318; SCHNYDER T, 1990, J MOL BIOL, V216, P809, DOI 10.1016/S0022-2836(99)80002-3; SCHNYDER T, 1991, J CELL BIOL, V112, P95, DOI 10.1083/jcb.112.1.95; SCHNYDER T, 1994, J STRUCT BIOL, V112, P136, DOI 10.1006/jsbi.1994.1015; SCHNYDER T, 1988, J BIOL CHEM, V263, P16954; TAYLOR JS, 1969, P NATL ACAD SCI USA, V64, P219, DOI 10.1073/pnas.64.1.219; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VASAK M, 1979, BIOCHEMISTRY-US, V18, P5050, DOI 10.1021/bi00590a004; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WATTS DC, 1973, ENZYMES, V8, P383; WYSS M, 1993, BIOCHEMISTRY-US, V32, P10727, DOI 10.1021/bi00091a025	30	257	267	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					341	345		10.1038/381341a0	http://dx.doi.org/10.1038/381341a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692275				2022-12-28	WOS:A1996UM40300061
J	Zecevic, D				Zecevic, D			Multiple spike-initiation zones in single neurons revealed by voltage-sensitive dyes	NATURE			English	Article							POTENTIALS; DENDRITES; GANGLION	THE primary function of the nerve cell is to process electrical signals. Over the past fifteen years(1) there has beers renewed Interest in the detailed spatial analysis of signalling in individual neurons owing to experimental evidence that the regional electrical properties of neurons are complex. Thus the behaviour of many nerve cells cannot be understood on the basis of microelectrode measurements from the soma. Regional electrical properties of neurons have been studied using sharp microelectrode(1) and patch-electrode(2,3) recordings from neuronal processes, high-resolution multisite optical recordings of Ca2+ concentration changes(4,5), and by using models to predict the distribution of membrane potential in the entire neoronal arborization(6). Additional direct evidence about electrical signalling in neuronal processes in situ tan now he obtained by recording membrane potential changes using voltage-sensitive dyes(7,21). Here I demonstrate the existence of multiple action potential trigger zones in separate regions of the neuronal arborization of an indentified molluscan neuron.			Zecevic, D (corresponding author), YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.		Zecevic, Dejan/A-9824-2008	Zecevic, Dejan/0000-0002-8917-5784				ANTIC S, 1995, J NEUROSCI, V15, P1392; Cohen L B, 1986, Soc Gen Physiol Ser, V40, P71; COHEN LB, 1978, REV PHYSIOL BIOCH P, V83, P35, DOI 10.1007/3-540-08907-1_2; COMBES D, 1993, J PHYSIOL-LONDON, V460, P581, DOI 10.1113/jphysiol.1993.sp019488; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; GRINVALD A, 1987, BIOPHYS J, V51, P643, DOI 10.1016/S0006-3495(87)83389-1; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GUPTA RK, 1981, J MEMBRANE BIOL, V58, P123, DOI 10.1007/BF01870975; HEITLER WJ, 1978, J EXP BIOL, V76, P63; HUGUENARD JR, 1994, J SOC NEUR ABSTR, V20, P1527; KANDEL ER, 1965, J PHYSL, V183, P269; KOGAN A, 1995, BRAIN RES, V700, P235, DOI 10.1016/0006-8993(95)00956-Q; KORN H, 1971, BRAIN RES, V27, P169, DOI 10.1016/0006-8993(71)90379-9; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MIDTGAARD J, 1993, J NEUROPHYSIOL, V70, P2455, DOI 10.1152/jn.1993.70.6.2455; REGEHR W, 1993, NEURON, V11, P145, DOI 10.1016/0896-6273(93)90278-Y; ROSS WN, 1984, J NEUROSCI, V4, P659; ROSS WN, 1993, JPN J PHYSIOL, V43, pS83; SALZBERG BM, 1993, JPN J PHYSIOL, V43, pS37; STUART G, 1994, NEURON, V13, P703, DOI 10.1016/0896-6273(94)90037-X; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TAUC L, 1962, J GEN PHYSIOL, V45, P1077, DOI 10.1085/jgp.45.6.1077; TAUC L., 1963, JOUR GEN PHYSIOL, V46, P533; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Wu J.-Y., 1993, FLUORESCENT LUMINESC, P389; ZECEVIC D, 1989, J NEUROSCI, V9, P3681	26	81	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1996	381	6580					322	325		10.1038/381322a0	http://dx.doi.org/10.1038/381322a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692270				2022-12-28	WOS:A1996UM40300056
J	Spina, M; MerloPich, E; Chan, RKW; Basso, AM; Rivier, J; Vale, W; Koob, GF				Spina, M; MerloPich, E; Chan, RKW; Basso, AM; Rivier, J; Vale, W; Koob, GF			Appetite-suppressing effects of urocortin, a CRF-related neuropeptide	SCIENCE			English	Article							CORTICOTROPIN-RELEASING-FACTOR; FACTOR-RECEPTOR; FUNCTIONAL EXPRESSION; EXPLORATORY-BEHAVIOR; FACTOR ANTAGONIST; BETA-ENDORPHIN; RAT-BRAIN; STRESS; SECRETION; PITUITARY	The neuropeptide corticotropin-releasing factor (CRF) is well known to act on the central nervous system in ways that mimic stress and result in decreases in exploration, increases in sympathetic activity, decreases in parasympathetic outflow, and decreases in appetitive behavior. Urocortin, a neuropeptide related to CRF, binds with high affinity to the CRF(2) receptor, is more potent than CRF in suppressing appetite, but is less potent than CRF in producing anxiety-like effects and activation. Doses as low as 10 nanograms injected intracerebroventricularly were effective in decreasing food intake in food-deprived and free-feeding rats. These results suggest that urocortin may be an endogenous CRF-like factor in the brain responsible for the effects of stress on appetite.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, NEURONAL STRUCT & FUNCT LAB, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Salk Institute; Salk Institute					FIC NIH HHS [1 F05 TW05262] Funding Source: Medline; NIDDK NIH HHS [DK 26741] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW005262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, SEMIN NEUROSCI; ANTONI FA, 1990, J ENDOCRINOL, V125, P175, DOI 10.1677/joe.0.1250175; BALDWIN HA, 1991, PSYCHOPHARMACOLOGY, V103, P227, DOI 10.1007/BF02244208; BERRIDGE CW, 1989, PHARMACOL BIOCHEM BE, V34, P517, DOI 10.1016/0091-3057(89)90551-0; BRITTON KT, 1986, LIFE SCI, V39, P1281, DOI 10.1016/0024-3205(86)90189-X; BRITTON KT, 1985, PSYCHOPHARMACOLOGY, V86, P170, DOI 10.1007/BF00431704; BURTON MJ, 1981, BRIT J PHARMACOL, V72, P621, DOI 10.1111/j.1476-5381.1981.tb09142.x; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P2167, DOI 10.1210/en.137.5.2167; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; EAVES M, 1985, PEPTIDES, V6, P923, DOI 10.1016/0196-9781(85)90323-7; FISHER LA, 1983, REGUL PEPTIDES, V5, P153, DOI 10.1016/0167-0115(83)90123-4; FISHER LA, 1989, AM J PHYSIOL, V256, pH949, DOI 10.1152/ajpheart.1989.256.4.H949; GOSNELL BA, 1983, PHARMACOL BIOCHEM BE, V19, P771, DOI 10.1016/0091-3057(83)90078-3; GRINKER JA, 1980, PHARMACOL BIOCHEM BE, V12, P265, DOI 10.1016/0091-3057(80)90367-6; HEINRICHS SC, 1992, PEPTIDES, V13, P879, DOI 10.1016/0196-9781(92)90044-4; HEINRICHS SC, 1993, BRAIN RES, V611, P18, DOI 10.1016/0006-8993(93)91771-J; HEINRICHS SC, 1992, BRAIN RES, V581, P190, DOI 10.1016/0006-8993(92)90708-H; HENKE PG, 1991, DIGEST DIS SCI, V36, P1633, DOI 10.1007/BF01296409; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; KRAHN DD, 1986, BRAIN RES BULL, V17, P285, DOI 10.1016/0361-9230(86)90233-9; Lederis K., 1985, Recent Progress in Hormone Research, V41, P553; LENZ HJ, 1985, AM J PHYSIOL, V249, pR85; LEVINE AS, 1983, NEUROPHARMACOLOGY, V22, P337, DOI 10.1016/0028-3908(83)90249-6; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; MENZAGHI F, 1994, J PHARMACOL EXP THER, V269, P564; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; PERRIN MH, 1993, ENDOCRINOLOGY, V133, P3058, DOI 10.1210/en.133.6.3058; PICH EM, 1993, PSYCHONEUROENDOCRINO, V18, P495; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; RIVIER C, 1982, ENDOCRINOLOGY, V110, P272, DOI 10.1210/endo-110-1-272; SPINA ME, UNPUB; SUTTON RE, 1982, NATURE, V297, P331, DOI 10.1038/297331a0; TAKAHASHI LK, 1989, BEHAV NEUROSCI, V103, P648, DOI 10.1037/0735-7044.103.3.648; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V	40	513	519	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1561	1564		10.1126/science.273.5281.1561	http://dx.doi.org/10.1126/science.273.5281.1561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703220				2022-12-28	WOS:A1996VG59700044
J	Borhani, NO; Mercuri, M; Borhani, PA; Buckalew, VM; CanossaTerris, M; Carr, AA; Kappagoda, T; Rocco, MV; Schnaper, HW; Sowers, JR; Bond, MG				Borhani, NO; Mercuri, M; Borhani, PA; Buckalew, VM; CanossaTerris, M; Carr, AA; Kappagoda, T; Rocco, MV; Schnaper, HW; Sowers, JR; Bond, MG			Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS) - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; B-MODE ULTRASOUND; CAROTID ATHEROSCLEROSIS; CALCIUM-ANTAGONISTS; DESIGN-FEATURES; RISK-FACTORS; HYPERTENSION; MORTALITY; REPRODUCIBILITY; MORBIDITY	Objective.-To compare the rate of progression of mean maximum intimal-medial thickness (IMT) in carotid arteries, using quantitative B-mode ultrasound imaging, during antihypertensive therapy with isradipine vs hydrochlorothiazide. Design.-Randomized, double-blind, positive-controlled trial. Setting.-Nine medical center clinics. Population.-A total of 883 patients with baseline mean+/-SD systolic and diastolic blood pressure (SBP and DBP, respectively) of 149.7+/-16.6 and 96.5+/-5.1 mm Hg, age of 58.5+/-8.5 years, and maximum IMT of 1.17+/-0.20 mm. Interventions.-Twice daily doses of isradipine (2.5-5.0 mg) or hydrochlorothiazide (12.5-25 mg). Main Outcome Measure (Primary End Point).-Rate of progression of mean maximum IMT in 12 carotid focal points over 3 years. Results.-There was no difference in the rate of progression of mean maximum IMT between isradipine and hydrochlorothiazide over 3 years (P=.68). There was a higher incidence of major vascular events (eg, myocardial infarction, stroke, congestive heart failure, angina, and sudden death) in isradipine (n=25; 5.65%) vs hydrochlorothiazide (n=14; 3.17%) (P=.07), and a significant increase in nonmajor vascular events and procedures (eg, transient ischemic attack, dysrhythmia, aortic valve replacement, and femoral popliteal bypass graft) in isradipine (n=40; 9.05%) vs hydrochlorothiazide (n=23; 5.22%) (P=.02). At 6 months, mean DBP decreased by 13.0 mm Hg in both groups, and mean SEP decreased by 19.5 mm Hg in hydrochlorothiazide and 16.0 mm Hg in isradipine (P=.002); the difference in SBP between the 2 groups persisted throughout the study but did not explain the increased incidence of vascular events in patients treated with isradipine. Conclusion.-The rate of progression of mean maximum IMT in carotid arteries, the surrogate end point in this study, did not differ between the 2 treatment groups. The increased incidence of vascular events in patients receiving isradipine compared with hydrochlorothiazide is of concern and should be studied further.	BOWMAN GRAY SCH MED,NEPHROL SECT,DEPT INTERNAL MED,WINSTON SALEM,NC 27157; UNIV CALIF DAVIS,SCH MED,DIV CARDIOVASC MED,DAVIS,CA 95616; UNIV CALIF DAVIS,SCH MED,DEPT INTERNAL MED,DAVIS,CA 95616; UNIV NEVADA,SCH MED,DEPT FAMILY & COMMUNITY MED,RENO,NV 89557; BOWMAN GRAY SCH MED,DIV VASC ULTRASOUND RES,WINSTON SALEM,NC 27157; HEART RES INST,CLIN TRIALS UNIT,MIAMI,FL; CIRCULATORY DIS CTR,AUGUSTA,GA; SCI APPLICAT CO INC,BIRMINGHAM,AL; PREVENT CARDIOL INC,BIRMINGHAM,AL; WAYNE STATE UNIV,DIV ENDOCRINOL METAB & HYPERTENS,DETROIT,MI	Wake Forest University; Wake Forest Baptist Medical Center; University of California System; University of California Davis; University of California System; University of California Davis; Nevada System of Higher Education (NSHE); University of Nevada Reno; Wake Forest University; Wake Forest Baptist Medical Center; Wayne State University								APPLEGATE WB, 1991, AM J HYPERTENS, V4, pS114, DOI 10.1093/ajh/4.2.114S; BOND MG, 1989, AM J MED, V86, P33; BOND MG, 1991, J CARDIOVASC PHAR S4, V17, P87; BORHANI NO, 1992, J CARDIOVASC PHAR S3, V19, P16; BORHANI NO, 1991, J CARDIOVASC PHAR S3, V18, P15; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; CHOBANIAN AV, 1987, J HYPERTENS       S4, V5, P43; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; Dahlof B, 1993, Blood Press, V2, P136, DOI 10.3109/08037059309077541; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P133; FURBERG CD, 1993, AM J HYPERTENS, V6, pS24, DOI 10.1093/ajh/6.3.24S; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; FURBERG CD, 1989, AM J MED, V86, P37, DOI 10.1016/0002-9343(89)90188-5; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; INSULL W, 1990, PATHOBIOLOGY HUMAN A, P662; KIRKENDALL W M, 1988, American Journal of Medicine, V84, P32, DOI 10.1016/0002-9343(88)90185-4; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MERCURI M, 1993, J CARDIOVASC DIAGN P, V11, P241; MERCURI M, 1994, J HYPERTENS       S3, V12, pS134; POLAK JF, 1993, RADIOLOGY, V188, P363, DOI 10.1148/radiology.188.2.8327679; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; RILEY WA, 1992, STROKE, V23, P1062, DOI 10.1161/01.STR.23.8.1062; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Ruzicka Marcel, 1995, P2815; SALONEN JT, 1989, ANN MED, V21, P227, DOI 10.3109/07853898909149939; *SAS I INC, 1992, P229 SAS I INC, P21; STAESSEN J, 1993, J HUM HYPERTENS, V7, P265; VANDENBERG EK, 1988, AM J CARDIOL, V61, P1102, DOI 10.1016/0002-9149(88)90134-8; WATERS D, 1991, CIRCULATION, V84, P2598, DOI 10.1161/01.CIR.84.6.2598; WEINSTEIN DB, 1989, AM J HYPERTENS, V2, P205, DOI 10.1093/ajh/2.3.205; WEINSTEIN DB, 1987, AM J CARDIOL, V59, pB163, DOI 10.1016/0002-9149(87)90097-X; Zanchetti A, 1995, J HYPERTENS, V13, pS35, DOI 10.1097/00004872-199512002-00006; 1992, BRIT MED J, V304, P405; 1991, JAMA-J AM MED ASSOC, V265, P3255	39	402	412	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					785	791		10.1001/jama.276.10.785	http://dx.doi.org/10.1001/jama.276.10.785			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769587				2022-12-28	WOS:A1996VF21900024
J	Begg, C; Cho, M; Eastwood, S; Horton, R; Moher, D; Olkin, I; Pitkin, R; Rennie, D; Schulz, KF; Simel, D; Stroup, DF				Begg, C; Cho, M; Eastwood, S; Horton, R; Moher, D; Olkin, I; Pitkin, R; Rennie, D; Schulz, KF; Simel, D; Stroup, DF			Improving the quality of reporting of randomized controlled trials - The CONSORT statement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL JOURNALS; CLINICAL-TRIALS; SAMPLE-SIZE; ARTICLES; BIAS		MEM SLOAN KETTERING CANC CTR,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021; UNIV PENN,CTR BIOETH,PHILADELPHIA,PA 19104; UNIV CALIF SAN FRANCISCO,DEPT NEUROL SURG,SAN FRANCISCO,CA 94143; LANCET,LONDON,ENGLAND; UNIV OTTAWA,DEPT MED,OTTAWA,ON K1N 6N5,CANADA; UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY HLTH,OTTAWA,ON K1N 6N5,CANADA; STANFORD UNIV,DEPT STAT,STANFORD,CA 94305; OBSTET & GYNECOL,LOS ANGELES,CA; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC 27705	Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; University of California System; University of California San Francisco; University of Ottawa; University of Ottawa; Stanford University; Centers for Disease Control & Prevention - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Moher, David/0000-0003-2434-4206				ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; EVANS M, 1984, ARCH SURG-CHICAGO, V119, P109; FLETCHER RH, 1979, NEW ENGL J MED, V301, P180, DOI 10.1056/NEJM197907263010403; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GARDNER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1355, DOI 10.1001/jama.263.10.1355; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GARDNER MJ, 1989, STATISTICS CONFIDENC, P101; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GOTZSCHE PC, 1989, CONTROLLED CLIN TRIA, V10, P356; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KARLOWSKI TR, 1975, JAMA-J AM MED ASSOC, V231, P1038, DOI 10.1001/jama.231.10.1038; LEE YJ, 1991, STAT MED, V10, P1595, DOI 10.1002/sim.4780101011; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P182; RENNIE D, 1995, JAMA-J AM MED ASSOC, V273, P1054, DOI 10.1001/jama.273.13.1054; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 1996, BRIT MED J, V312, P742; TADDIO A, 1994, CAN MED ASSOC J, V150, P1611; WILLIAMS JW, 1995, JAMA-J AM MED ASSOC, V273, P1015, DOI 10.1001/jama.273.13.1015; 1987, ANN INTERN MED, V106, P598; 1995, JAMA-J AM MED ASSOC, V273, P776; 1994, JAMA-J AM MED ASSOC, V272, P1926; 1994, ANN INTERN MED, V121, P894	33	2919	3019	2	88	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					637	639		10.1001/jama.276.8.637	http://dx.doi.org/10.1001/jama.276.8.637			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC853	8773637				2022-12-28	WOS:A1996VC85300031
J	Young, B; Runge, JW; Waxman, KS; Harrington, T; Wilberger, J; Muizelaar, JP; Boddy, A; Kupiec, JW				Young, B; Runge, JW; Waxman, KS; Harrington, T; Wilberger, J; Muizelaar, JP; Boddy, A; Kupiec, JW			Effects of pegorgotein on neurologic outcome of patients with severe head injury - A multicenter, randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONJUGATED SUPEROXIDE-DISMUTASE; CEREBRAL ISCHEMIA-REPERFUSION; SCALE; COMA	Objective.-To evaluate outcome of patients with severe closed head injury treated with pegorgotein, a scavenger of oxygen-derived free radicals. Design.-Randomized, parallel, placebo-controlled, third-party-blind, multicenter trial, with a blinded, multicenter follow-up protocol. Setting.-Twenty-nine centers in the United States. Patients.-A total of 463 patients with severe closed head injury and a Glasgow Coma Scale score of 8 or less after resuscitation and stabilization. Interventions.-Patients received a single intravenous dose of placebo, 10 000 U/kg of pegorgotein, or 20 000 U/kg of pegorgotein within 8 hours after injury. Outcome Measures.-The primary endpoint was the Glasgow Outcome Scale (GOS) score at 3 months after brain injury with GOS data trichotomized into good, fair, or poor outcome. Secondary efficacy endpoints included the Disability Rating Scale (DRS) and mortality. A secondary analysis was performed using GOS scores dichotomized into favorable and unfavorable outcomes. In a follow-up protocol at 6 months, GOS and DRS scores were again determined. Results.-Of 463 patients randomized, 162 received placebo; 149, pegorgotein 10 000 U/kg; and 152, pegorgotein 20 000 U/kg. Treatment groups were comparable with respect to demographic characteristics, mechanism of injury, and time to treatment. Pegorgotein was well tolerated at both dose levels. At month 3, the trichotomized analysis found no significant statistical difference in neurologic outcome between the pegorgotein and the placebo groups. Although differences were not statistically significant, there were more favorable outcomes and no increase in the number of deaths or vegetative states among the patients given pegorgotein, more subjects had good or favorable outcomes with the 10 000-U/kg dose than with the 20 000-U/kg dose or placebo, and less disability was observed with the 10 000-U/kg dose than with either the 20 000-U/kg dose or placebo. No differences in mortality rate or cause of death were found between the 10 000-U/kg and placebo groups at either month 3 or month 6. The only statistically significant difference between the groups was a decreased incidence of adult respiratory distress syndrome in the 10 000-U/kg group as compared with the placebo group (P<.015). Conclusions-in this clinical trial of 463 patients with severe head injury, no statistically significant difference in neurologic outcome or mortality was observed between patients treated with pegorgotein and those receiving placebo.	CAROLINAS MED CTR, DEPT EMERGENCY MED, CHARLOTTE, NC 28203 USA; SANTA BARBARA COTTAGE HOSP, SANTA BARBARA, CA USA; BARROW NEUROL INST, DEPT NEUROSURG, PHOENIX, AZ 85013 USA; ALLEGHENY GEN HOSP, PITTSBURGH, PA 15212 USA; WAYNE STATE UNIV, DEPT NEUROSURG, DETROIT, MI USA; SANOFI WINTHROP INC, SANOFI RES DIV, MALVERN, PA USA	Carolinas Medical Center; Santa Barbara Cottage Hospital; Barrow Neurological Institute; Allegheny General Hospital; Wayne State University; Sanofi-Aventis	Young, B (corresponding author), UNIV KENTUCKY, ALBERT B CHANDLER MED CTR,DEPT SURG,COLL MED, DIV NEUROSURG, 800 ROSE ST, LEXINGTON, KY 40536 USA.							ABRAMSON NS, 1990, ANN EMERG MED, V19, P781, DOI 10.1016/S0196-0644(05)81703-2; BRIGHAM KL, 1991, KLIN WOCHENSCHR, V69, P1004, DOI 10.1007/BF01645147; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CROSS CE, 1990, ADV EXP MED BIOL, V264, P435; HALL ED, 1993, RES P ARNMD, V71, P81; HE YY, 1993, AM J PHYSIOL, V265, pH252, DOI 10.1152/ajpheart.1993.265.1.H252; JENNETT B, 1975, LANCET, V1, P480; LEFF JA, 1993, AM J PHYSIOL, V265, pL501, DOI 10.1152/ajplung.1993.265.5.L501; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE G, 1974, LANCET, V2, P81; VANASBECK BS, 1989, RESUSCITATION, V18, pS63, DOI 10.1016/0300-9572(89)90054-3	14	138	139	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					538	543		10.1001/jama.276.7.538	http://dx.doi.org/10.1001/jama.276.7.538			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709402				2022-12-28	WOS:A1996VC10100029
J	Fallowfield, L				Fallowfield, L			Quality of quality-of-life data	LANCET			English	Editorial Material							ADVANCED BREAST-CANCER				Fallowfield, L (corresponding author), UCL, SCH MED, CRC, COMMUN & COUNSELLING RES CTR, MORTIMER ST, LONDON W1P 7PL, ENGLAND.			Fallowfield, Lesley/0000-0003-0577-4518				[Anonymous], 1995, LANCET, V1, P1; COATES A, 1992, J CLIN ONCOL, V10, P1833, DOI 10.1200/JCO.1992.10.12.1833; COATES A, 1983, EUR J CANCER CLIN ON, V19, P1633, DOI 10.1016/0277-5379(83)90096-2; COOK DJ, 1993, J CLIN EPIDEMIOL, V46, P529, DOI 10.1016/0895-4356(93)90125-K; FALLOWFIELD LJ, 1995, ACTA ONCOL, V34, P689, DOI 10.3109/02841869509094050; FRASER SCA, 1993, BRIT J CANCER, V67, P341, DOI 10.1038/bjc.1993.62; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; SKINNER HA, 1983, J CONSULT CLIN PSYCH, V51, P267, DOI 10.1037/0022-006X.51.2.267; Weinberger M, 1996, J CLIN EPIDEMIOL, V49, P135, DOI 10.1016/0895-4356(95)00556-0	9	41	42	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					421	422		10.1016/S0140-6736(05)64534-5	http://dx.doi.org/10.1016/S0140-6736(05)64534-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709778				2022-12-28	WOS:A1996VC67300005
J	Macias, MJ; Hyvonen, M; Baraldi, E; Schultz, J; Sudol, M; Saraste, M; Oschkinat, H				Macias, MJ; Hyvonen, M; Baraldi, E; Schultz, J; Sudol, M; Saraste, M; Oschkinat, H			Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide	NATURE			English	Article							NMR-SPECTROSCOPY; IDENTIFICATION; DYSTROPHIN; RESONANCE; MODULES; SITE	THE WW domain is a new protein module with two highly conserved tryptophans that binds proline-rich peptide motifs in vitro. It is present in a number of signalling and regulatory proteins, often in several copies(1-3). Here we investigate the solution structure of the WW domain of human YAP65 (for Yes kinase-associated protein) in complex with proline-rich peptides containing the core motif PPxY (ref. 4). The structure of the domain with the bound peptide GTPPPPYTVG is a slightly curved, three-stranded, antiparallel beta-sheet. Two prolines pack against the first tryptophan, forming a hydrophobic buckle on the convex side of the sheet. The concave side has three exposed hydrophobic residues (tyrosine, tryptophan and leucine) which form the binding site for the ligand, A non-conserved isoleucine in the amino-terminal flanking region covers a hydrophobic patch and stabilizes the WW domain of human YAP65 irt vitro. The structure of the WW domain differs from that of the SH3 domain and reveals a new design for a protein module that uses stacked aromatic surface residues to arrange a binding site for proline-rich peptides.	EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; FORSCHUNGSINST MOL PHARMAKOL, D-10315 BERLIN, GERMANY; MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	European Molecular Biology Laboratory (EMBL); Icahn School of Medicine at Mount Sinai			Macias, Maria J/K-3898-2014; baraldi, elena/I-7863-2012	Macias, Maria J/0000-0002-6915-963X; baraldi, elena/0000-0001-9496-0093; Oschkinat, Hartmut/0000-0002-4384-9544				ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BRUNGER AT, 1992, X PLOR 3 1 MANUAL; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HOFMANN K, 1995, FEBS LETT, V358, P153, DOI 10.1016/0014-5793(94)01415-W; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OTTING G, 1989, J MAGN RESON, V85, P586, DOI 10.1016/0022-2364(89)90249-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	27	362	371	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1996	382	6592					646	649		10.1038/382646a0	http://dx.doi.org/10.1038/382646a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757138				2022-12-28	WOS:A1996VC30300058
J	Isner, JM; Pieczek, A; Schainfeld, R; Blair, R; Haley, L; Asahara, T; Rosenfield, K; Razvi, S; Walsh, E; Symes, JF				Isner, JM; Pieczek, A; Schainfeld, R; Blair, R; Haley, L; Asahara, T; Rosenfield, K; Razvi, S; Walsh, E; Symes, JF			Clinical evidence of angiogenesis after arterial gene transfer of phVEGF(165) in patient with ischaemic limb	LANCET			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; PROTEIN SECRETION; TIME-COURSE; IN-VIVO; RABBIT; MODEL; EXPRESSION; CELLS	Background Preclinical findings suggest that intra-arterial gene transfer of a plasmid which encodes for vascular endothelial growth factor [VEGF) can improve blood supply to the ischaemic limb, We have used the method in a patient. Methods Our patient was the eighth in a dose-ranging series, She was aged 71 with an ischaemic right leg. We administered 2000 mu g human plasmid phVEGF(165) that was applied to the hydrogel polymer coating of an angioplasty balloon. By inflating the balloon, plasmid DNA was transferred to the distal popliteal artery. Findings Digital subtraction angiography 4 weeks after gene therapy showed an increase in collateral vessels at the knee, mid-tibial, and ankle levels, which persisted at a 12-week view. Intra-arterial doppler-flow studies showed increased resting and maximum flows (by 82% and 72%, respectively). Three spider angiomas developed on the right foot/ankle about a week after gene transfer; one lesion was excised and revealed proliferative endothelium, the other two regressed. The patient developed oedema in her right leg, which was treated successfully. Interpretation Administration of endothelial cell mitogens promotes angiogenesis in patients with limb ischaemia.	TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,DEPT BIOMED RES,BOSTON,MA 02111; TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,DEPT RADIOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,DEPT SURG,BOSTON,MA 02111	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	Isner, JM (corresponding author), TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,DEPT MED,BOSTON,MA 02135, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053354, R37HL053354, R01HL050692] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 02824, HL 53354, HL 50692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAHARA T, IN PRESS CIRCULATION; BAUTERS C, 1994, AM J PHYSIOL, V36, pH1263; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FELDMAN LJ, 1995, J CLIN INVEST, V95, P2662, DOI 10.1172/JCI117968; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; INGO F, 1995, DEV BIOL, V171, P399; ISNER JM, 1995, CIRCULATION, V91, P2687, DOI 10.1161/01.CIR.91.11.2687; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LOSORDO DW, 1994, CIRCULATION, V89, P785, DOI 10.1161/01.CIR.89.2.785; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RIESSEN R, 1993, HUM GENE THER, V4, P749, DOI 10.1089/hum.1993.4.6-749; ROSENFIELD K, 1993, INTERVENTIONAL CARDI, P1153; TAKASHITA S, IN PRESS LAB INVEST; TAKESHITA S, 1993, CIRCULATION, V88, P476; TAKESHITA S, 1995, AM J PATHOL, V147, P1649; TAKESHITA S, 1994, LAB INVEST, V71, P387; TISCHER E, 1991, J BIOL CHEM, V266, P11947; UNGER EF, 1994, AM J PHYSIOL, V266, pH1588, DOI 10.1152/ajpheart.1994.266.4.H1588; WHITE FC, 1992, CIRC RES, V71, P1490, DOI 10.1161/01.RES.71.6.1490	24	802	930	0	32	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					370	374		10.1016/S0140-6736(96)03361-2	http://dx.doi.org/10.1016/S0140-6736(96)03361-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709735				2022-12-28	WOS:A1996VB42600011
J	DiLaurenzio, L; WysockaDiller, J; Malamy, JE; Pysh, L; Helariutta, Y; Freshour, G; Hahn, MG; Feldmann, KA; Benfey, PN				DiLaurenzio, L; WysockaDiller, J; Malamy, JE; Pysh, L; Helariutta, Y; Freshour, G; Hahn, MG; Feldmann, KA; Benfey, PN			The SCARECROW gene regulates an asymmetric cell division that is essential for generating the radial organization of the Arabidopsis root	CELL			English	Article							PLANT GENES; TRANSCRIPTION; EXPRESSION; THALIANA; PROTEINS; MERISTEM; MARKERS	In the Arabidopsis root meristem, initial cells undergo asymmetric divisions to generate the cell lineages of the root. The scarecrow mutation results in roots that are missing one cell layer owing to the disruption of an asymmetric division that normally generates cortex and endodermis. Tissue-specific markers indicate that a heterogeneous cell type is formed in the mutant. The deduced amino acid sequence of SCARECROW (SCR) suggests that it is a member of a novel family of putative transcription factors. SCR is expressed in the cortex/endodermal initial cells and in the endodermal cell lineage. Tissue-specific expression is regulated at the transcriptional level. These results indicate a key role for SCR in regulating the radial organization of the root.	NYU, DEPT BIOL, NEW YORK, NY 10003 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA; UNIV ARIZONA, DEPT PLANT SCI, TUCSON, AZ 85721 USA	New York University; University System of Georgia; University of Georgia; University of Arizona			Helariutta, Yrjo/AAE-8149-2020; Hahn, Michael/AHC-5847-2022	Helariutta, Yrjo/0000-0002-7287-8459; Hahn, Michael/0000-0003-2136-5191	NIGMS NIH HHS [R01-GM43778] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043778] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AESCHBACHER RA, 1995, GENE DEV, V9, P330, DOI 10.1101/gad.9.3.330; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENFEY PN, 1993, DEVELOPMENT, V119, P57; BERRY JO, 1985, MOL CELL BIOL, V5, P2238, DOI 10.1128/MCB.5.9.2238; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DOLAN L, 1993, DEVELOPMENT, V119, P71; Esau K., 1977, Anatomy of seed plants.; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Freshour G, 1996, PLANT PHYSIOL, V110, P1413, DOI 10.1104/pp.110.4.1413; HEIDECKER G, 1986, ANNU REV PLANT PHYS, V37, P439, DOI 10.1146/annurev.arplant.37.1.439; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HURST HC, 1994, PROTEIN PROFILE, V1, P123; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; JARVIS P, 1994, PLANT MOL BIOL, V24, P685, DOI 10.1007/BF00023565; JOHNSON PF, 1993, J NUTR BIOCHEM, V4, P386, DOI 10.1016/0955-2863(93)90069-9; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KNOX JP, 1990, PLANTA, V181, P512, DOI 10.1007/BF00193004; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Maniatis T., 1982, MOL CLONING; MAYER U, 1993, DEVELOPMENT, V117, P149; MeloOliveira R, 1996, P NATL ACAD SCI USA, V93, P4718, DOI 10.1073/pnas.93.10.4718; MOGEN BD, 1990, PLANT CELL, V2, P1261; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; PUHLMANN J, 1994, PLANT PHYSIOL, V104, P699, DOI 10.1104/pp.104.2.699; SCHERES B, 1995, DEVELOPMENT, V121, P53; TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213	31	764	812	5	108	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					423	433		10.1016/S0092-8674(00)80115-4	http://dx.doi.org/10.1016/S0092-8674(00)80115-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756724	hybrid			2022-12-28	WOS:A1996VC30900010
J	Li, ZW; Deutscher, MP				Li, ZW; Deutscher, MP			Maturation pathways for E-coli tRNA precursors: A random multienzyme process in vivo	CELL			English	Article							TRANSFER-RNA PRECURSORS; ESCHERICHIA-COLI; 3' TERMINUS; EXORIBONUCLEASES; ORGANIZATION; TRANSCRIPT; VIABILITY; GENES; K-12; PH	tRNA maturation consists of the specific removal of precursor sequences from both the 5' and 3' termini of an initial RNA transcript. How this is accomplished has heretofore not been ascertained in any system. Using Northern analysis of RNA isolated from a variety of RNase-deficient E. coli strains, we have identified the processing intermediates that accumulate in the absence of specific processing nucleases. From this information we have established the maturation pathways for 12 different E. coli tRNAs including the specific role of each of the relevant RNases in the process. The surprising conclusion from this work is that tRNA maturation is a stochastic process that lacks a defined order and that can proceed with a variety of alternative 3' processing nucleases.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06030	University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1987, MOL BIOL RNA NEW PER, P3; Altman Sidney, 1995, P67; AN G, 1980, GENE, V12, P13; BASL M, 1991, NUCLEIC ACIDS RES, V19, P5863; BIKOFF EK, 1975, J BIOL CHEM, V250, P6240; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; CUDNY H, 1980, P NATL ACAD SCI-BIOL, V77, P837, DOI 10.1073/pnas.77.2.837; DEUTSCHE.MP, 1974, J BACTERIOL, V118, P621, DOI 10.1128/JB.118.2.621-627.1974; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; Deutscher Murray P., 1995, P51; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; FOURNIER MJ, 1985, MICROBIOL REV, V49, P379, DOI 10.1128/MMBR.49.4.379-397.1985; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; KELLY KO, 1992, J BIOL CHEM, V267, P16015; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; LI ZW, 1994, J BIOL CHEM, V269, P6064; REUVEN NB, 1993, FASEB J, V7, P143, DOI 10.1096/fasebj.7.1.8422961; ROSSI J, 1981, CELL, V26, P305, DOI 10.1016/0092-8674(81)90199-9; SCHEDL P, 1976, CELL, V8, P581, DOI 10.1016/0092-8674(76)90226-9; SEKIYA T, 1979, J BIOL CHEM, V254, P5802	25	156	157	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					503	512		10.1016/S0092-8674(00)80123-3	http://dx.doi.org/10.1016/S0092-8674(00)80123-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756732	hybrid			2022-12-28	WOS:A1996VC30900018
J	Molenaar, M; vandeWetering, M; Oosterwegel, M; PetersonMaduro, J; Godsave, S; Korinek, V; Roose, J; Destree, O; Clevers, H				Molenaar, M; vandeWetering, M; Oosterwegel, M; PetersonMaduro, J; Godsave, S; Korinek, V; Roose, J; Destree, O; Clevers, H			XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos	CELL			English	Article							WINGLESS SIGNALING PATHWAY; HMG-BOX; ALPHA-ENHANCER; EXPRESSION CLONING; CYTOPLASMIC DOMAIN; ACTIVATION DOMAIN; SPEMANN ORGANIZER; CELL-ADHESION; E-CADHERIN; GENE	XTcf-3 is a maternally expressed Xenopus homolog of the mammalian HMG box factors Tcf-1 and Lef-1 The N-terminus of XTcf-3 binds to beta-catenin. Microinjection of XTcf-3 mRNA in embryos results in nuclear translocation of beta-catenin. The beta-catenin-XTcf-3 complex activates transcription in a transient reporter gene assay, while XTcf-3 by itself is silent. N-terminal deletion of XTcf-3 (Delta N) abrogates the interaction with beta-catenin, as well as the consequent transcription activation. This dominant-negative Delta N mutant suppresses the induction of axis duplication by microinjected Delta-catenin. It also suppresses endogenous axis specification upon injection into the dorsal blastomeres of a 4-cell-stage embryo. We propose that signaling by beta-catenin involves complex formation with XTcf-3, followed by nuclear translocation and activation of specific XTcf-3 target genes.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Molenaar, M (corresponding author), UNIV UTRECHT HOSP,DEPT IMMUNOL,POB 85500,NL-3508 GA UTRECHT,NETHERLANDS.		Korinek, Vladimir/G-6348-2014	Korinek, Vladimir/0000-0002-9777-4664; Roose, Jeroen/0000-0003-4746-2811				BEUMER TL, 1995, TRENDS GENET, V11, P9, DOI 10.1016/S0168-9525(00)88978-7; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; CASTROP J, 1992, NUCLEIC ACIDS RES, V20, P611, DOI 10.1093/nar/20.3.611; CASTROP J, 1992, EUR J IMMUNOL, V22, P1327; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GAO ZM, 1994, ONCOGENE, V9, P573; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Huelsken Joerg, 1994, Journal of Cell Biology, V127, P2061; Joore J, 1996, MECH DEVELOP, V55, P3, DOI 10.1016/0925-4773(95)00481-5; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SOKOL SY, 1995, DEVELOPMENT, V121, P3487; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VEENSTRA GJC, 1995, MECH DEVELOP, V50, P103, DOI 10.1016/0925-4773(94)00328-K; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	41	1575	1638	1	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					391	399		10.1016/S0092-8674(00)80112-9	http://dx.doi.org/10.1016/S0092-8674(00)80112-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756721	Green Submitted, Bronze			2022-12-28	WOS:A1996VC30900007
J	Smith, PG; Cousens, SN				Smith, PG; Cousens, SN			Is the new variant of Creutzfeldt-Jakob disease from mad cows?	SCIENCE			English	Editorial Material											Smith, PG (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				ALLEN IV, 1993, BR MED B, V49; BRADLEY R, 1993, BRIT MED BULL, V49, P932, DOI 10.1093/oxfordjournals.bmb.a072654; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; *MIN AGR FOOD FISH, 1989, REP WORK PART BOV SP; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	6	5	5	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					748	748		10.1126/science.273.5276.748	http://dx.doi.org/10.1126/science.273.5276.748			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8701324				2022-12-28	WOS:A1996VB42900025
J	Lavender, H				Lavender, H			Controversies in management - Should insurance companies have access to patients' medical records? Access should be denied	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-DISORDERS; UNITED-STATES; COMMUNITY; AREA				Lavender, H (corresponding author), FALMOUTH RD GRP PRACTICE,LONDON SE1 4JW,ENGLAND.							ANDERSON R, 1995, BRIT MED J, V311, P5, DOI 10.1136/bmj.311.6996.5; BARQUERO JLV, 1981, BRIT J PSYCHIAT, V139, P328, DOI 10.1192/bjp.139.4.328; BARQUERO JLV, 1987, PSYCHOL MED, V17, P227; BEBBINGTON P, 1981, PSYCHOL MED, V11, P561, DOI 10.1017/S0033291700052879; FREELING PR, 1992, HDB AFFECTIVE DISORD; *GEN MED COUNC, 1995, DUT DOCT; HODIAMONT P, 1987, PSYCHOL MED, V17, P495, DOI 10.1017/S0033291700025058; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; WEISSMAN MM, 1978, ARCH GEN PSYCHIAT, V35, P1304	9	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					286	287		10.1136/bmj.313.7052.286	http://dx.doi.org/10.1136/bmj.313.7052.286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VA903	8704544	Green Published			2022-12-28	WOS:A1996VA90300034
J	Alcedo, J; Ayzenzon, M; VonOhlen, T; Noll, M; Hooper, JE				Alcedo, J; Ayzenzon, M; VonOhlen, T; Noll, M; Hooper, JE			The Drosophila smoothened gene encodes a seven-pass membrane protein, a putative receptor for the hedgehog signal	CELL			English	Article							SEGMENT-POLARITY GENE; KINASE-A; CELL FATE; WINGLESS TRANSCRIPTION; TRANSMEMBRANE DOMAINS; LARVAL CUTICLE; NERVOUS-SYSTEM; IMAGINAL DISKS; PATCHED GENE; ZYGOTIC LOCI	smoothened(smo) is a segment polarity gene required for correct patterning of every segment in Drosophila. The earliest defect in smo mutant embryos is loss of expression of the Hedgehog-responsive gene wingless between 1 and 2 hr after gastrulation. Since smo mutant embryos cannot respond to exogenous Hedgehog (Hh) but can respond to exogenous Wingless, the Smo product functions in Hh signaling. Smo acts downstream of or in parallel to Patched, an antagonist of the Hh signal. The smo gene encodes an integral membrane protein with characteristics of G protein-coupled receptors and shows homology to the Drosophila Frizzled protein. Based on its predicted physical characteristics and on its position in the Hh signaling pathway, we suggest that smo encodes a receptor for the Hh signal.	UNIV COLORADO, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Alcedo, J (corresponding author), UNIV ZURICH, INST MOL BIOL 2, CH-8057 ZURICH, SWITZERLAND.			Alcedo, Joy/0000-0002-5279-6640	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045396, R01GM045396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FORBES AJ, 1993, DEVELOPMENT, P115; FREI E, 1985, EMBO J, V4, P979, DOI 10.1002/j.1460-2075.1985.tb03727.x; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; Harlow E., 1988, ANTIBODIES LAB MANUA; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HIDALGO A, 1990, DEVELOPMENT, V110, P291; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1991, GENE DEV, V5, P265, DOI 10.1101/gad.5.2.265; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LIMBOURGBOUCHON B, 1991, DEVELOPMENT, V112, P417; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Maniatis T., 1982, MOL CLONING; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; PIRROTTA V, 1988, VECTORS SURVEY MOL C; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; PREAT T, 1993, GENETICS, V135, P1047; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Small S, 1991, CURR OPIN GENET DEV, V1, P255, DOI 10.1016/S0959-437X(05)80079-6; STJOHNSTON D, 1992, CELL, V68, P201; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; VANDENHEUVEL M, 1993, DEVELOPMENT, P105; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang YS, 1996, J BIOL CHEM, V271, P4468; WILDER EL, 1995, DEVELOPMENT, V121, P477; YOFFE KB, 1995, DEV BIOL, V170, P636, DOI 10.1006/dbio.1995.1243; ZHANG Y, 1994, DEVELOPMENT, V120, P1151; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	86	474	513	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1996	86	2					221	232		10.1016/S0092-8674(00)80094-X	http://dx.doi.org/10.1016/S0092-8674(00)80094-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706127	Bronze			2022-12-28	WOS:A1996UZ97200008
J	Kang, JM; Rebek, J				Kang, JM; Rebek, J			Entropically driven binding in a self-assembling molecular capsule	NATURE			English	Article							HOST-GUEST COMPLEXATION	THE encapsulation of molecules within larger molecular or supramolecular cages (see ref. 1 for examples) brings about many interesting phenomena, among them the stabilization of reactive intermediates(2), new forms of stereoisomerism(3), and templating of the cage itself 4,5. Here we describe a self-assembling hydrogen-bonded molecular capsule that encapsulates guest molecules in a reversible, apparently entropy-driven process, giving rise to unusual temperature dependence of the formation process. The positive entropy of formation-at first sight unexpected-seems to be the result of the fact that more than one solvent molecule is included in the 'bare' cage, making their replacement by a single large molecule (here adamantane or ferrocene) entropically favourable.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								CANCEILL J, 1989, ANGEW CHEM INT EDIT, V28, P1246, DOI 10.1002/anie.198912461; CHAPMAN RG, 1995, J AM CHEM SOC, V117, P9081, DOI 10.1021/ja00140a031; CHAPMAN RG, 1994, J AM CHEM SOC, V116, P369, DOI 10.1021/ja00080a042; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; CRAM DJ, 1992, J AM CHEM SOC, V114, P7748, DOI 10.1021/ja00046a022; CRAM DJ, 1992, NATURE, V356, P29, DOI 10.1038/356029a0; CRAM DJ, 1992, J AM CHEM SOC, V114, P7765, DOI 10.1021/ja00046a023; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; LINDSEY JS, 1991, NEW J CHEM, V15, P153; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; MOCK WL, 1989, J ORG CHEM, V54, P5302, DOI 10.1021/jo00283a024; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; PETERSON BR, 1995, TETRAHEDRON, V51, P401, DOI 10.1016/0040-4020(94)00905-A; SEARLE MS, 1995, J CHEM SOC PERK T 2, P141, DOI 10.1039/p29950000141; Shimizu KD, 1995, P NATL ACAD SCI USA, V92, P12403, DOI 10.1073/pnas.92.26.12403; TIMMERMAN P, 1994, ANGEW CHEM INT EDIT, V33, P2345, DOI 10.1002/anie.199423451; WALTER CJ, 1993, J CHEM SOC CHEM COMM, P458, DOI 10.1039/c39930000458	17	201	203	2	50	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					239	241		10.1038/382239a0	http://dx.doi.org/10.1038/382239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717037				2022-12-28	WOS:A1996UX79000044
J	Ortiz, Z; Tugwell, P				Ortiz, Z; Tugwell, P			Raised ESR in polymyalgia rheumatica no longer a sine qua non?	LANCET			English	Editorial Material							GIANT-CELL ARTERITIS; MANAGEMENT				Ortiz, Z (corresponding author), OTTAWA GEN HOSP,DEPT MED,OTTAWA,ON K1H 8LG,CANADA.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556				AYOUB WT, 1985, AM J MED, V79, P309, DOI 10.1016/0002-9343(85)90309-2; BYRON M, 1983, OXFORD TXB MED, P27; CHUANG T, 1985, ANN INTERN MED, V97, P672; COHEN MD, 1990, RHEUM DIS CLIN N AM, V16, P325; ELLIS ME, 1983, ANN RHEUM DIS, V42, P168, DOI 10.1136/ard.42.2.168; HAMILTON CR, 1971, MEDICINE, V50, P1, DOI 10.1097/00005792-197101000-00001; Helfgott SM, 1996, ARTHRITIS RHEUM, V39, P304, DOI 10.1002/art.1780390220; JONES JG, 1981, ANN RHEUM DIS, V40, P1, DOI 10.1136/ard.40.1.1; SUEIRO JLF, 1994, ARTHRITIS RHEUM S9, V37, P410; ZLONIS M, 1993, CLIN LAB MED, V13, P787, DOI 10.1016/S0272-2712(18)30408-6	10	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					4	5		10.1016/S0140-6736(05)64350-4	http://dx.doi.org/10.1016/S0140-6736(05)64350-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691933				2022-12-28	WOS:A1996UV92300005
J	Delbanco, TL; Daley, J; Walzer, J				Delbanco, TL; Daley, J; Walzer, J			A 47-year-old man with chronic depression, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Goodwin F, 1996, JAMA-J AM MED ASSOC, V275, P479	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					822	822		10.1001/jama.276.10.822	http://dx.doi.org/10.1001/jama.276.10.822			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769593				2022-12-28	WOS:A1996VF21900030
J	Brook, WJ; Cohen, SM				Brook, WJ; Cohen, SM			Antagonistic interactions between Wingless and decapentaplegic responsible for dorsal-ventral pattern in the Drosophila leg	SCIENCE			English	Article							SEGMENT-POLARITY GENE; PROTEIN-KINASE-A; IMAGINAL DISKS; SIGNAL-TRANSDUCTION; EXPRESSION; HEDGEHOG; COMPARTMENTS; MELANOGASTER; AXIS; APPENDAGE	Subdivision of the limb primordia of Drosophila into anterior and posterior compartments triggers cell interactions that pattern the legs and wings. A comparable compartment-based mechanism is used to pattern the dorsal-ventral axis of the wing. Evidence is presented here for a mechanism based on cell interaction, rather than on compartment formation, that distinguishes dorsal from ventral in the leg. Mutual repression by Wingless and Decapentaplegic signaling systems generates a stable regulatory circuit by which each gene maintains its own expression in a spatially restricted domain. Compartment-independent patterning mechanisms may be used by other organisms during development.	EUROPEAN MOL BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROOK WJ, 1993, DEVELOPMENT, V117, P1287; BROOK WJ, UNPUB; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COHEN B, 1993, DEVELOPMENT, V117, P597; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WILDER EL, 1995, DEVELOPMENT, V121, P477; ZECCA M, 1995, DEVELOPMENT, V121, P2265	42	276	279	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1373	1377		10.1126/science.273.5280.1373	http://dx.doi.org/10.1126/science.273.5280.1373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703069				2022-12-28	WOS:A1996VF61000038
J	Barzansky, B; Jonas, HS; Etzel, SI				Barzansky, B; Jonas, HS; Etzel, SI			Educational programs in US medical schools, 1995-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								We present herein data on US medical education programs and describe how medical schools are adapting to a changing health care environment. The data mainly derive from the 1995-1996 Liaison Committee on Medical Education Medical School Questionnaire, which had a 100% response rate. The data indicate that in the 1995-1996 academic year there were 91 451 full-time faculty members in basic science and clinical departments, a 1.6% increase from 1994-1995. In clinical departments, major increases occurred in emergency medicine (a 10.6% increase in full-time faculty) and family medicine (a 13.5% increase). Applicants for the class entering in 1995 numbered 46591, an increase of 2.7% from 1994; however, the number of first-time applicants decreased slightly (0.6%). Of the 17 357 applicants accepted, 2179 (12.6%) were members of underrepresented minority groups. Health system changes are affecting medical school clinical affiliations. During the past 2 years, 42 schools saw a merger, acquisition, or closure involving medical school-owned or medical school-affiliated hospitals used for core clinical clerkships. At 15 sites, this change affected the distribution of students across clinical sites. In 1995-1996, 40 medical schools or their universities owned a health maintenance organization or other managed care organization, 93 schools contracted with a managed care organization to provide primary care services, and 96 schools contracted with managed care to provide specialty services. During the past year, 57 schools acquired primary care physician practices, and 70 started primary care clinics in the community.	AMER MED ASSOC,DEPT RES & DATA ANAL,CHICAGO,IL 60610	American Medical Association	Barzansky, B (corresponding author), AMER MED ASSOC,DIV UNDERGRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							*ASS AM MED COLL, 1996, TRENDS US MED SCH AP; Blumenthal D, 1996, HEALTH AFFAIR, V15, P200, DOI 10.1377/hlthaff.15.2.200; Randlett RR, 1996, ACAD MED, V71, P697, DOI 10.1097/00001888-199606000-00028; RANDOLPH L, 1996, PHYSICIAN CHARACTERI	4	30	30	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					714	719		10.1001/jama.276.9.714	http://dx.doi.org/10.1001/jama.276.9.714			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769551				2022-12-28	WOS:A1996VE23300011
J	Krakower, JY; Ganem, JL; Jolly, P				Krakower, JY; Ganem, JL; Jolly, P			Review of US medical school finances, 1994-1995	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Krakower, JY (corresponding author), ASSOC AMER MED COLL,SECT OPERAT STUDIES,2450 N ST NW,WASHINGTON,DC 20037, USA.							GANEM JL, 1995, JAMA-J AM MED ASSOC, V274, P723	1	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1996	276	9					720	724		10.1001/jama.276.9.720	http://dx.doi.org/10.1001/jama.276.9.720			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE233	8769552				2022-12-28	WOS:A1996VE23300012
J	Pettersson, J; Nordfelth, R; Dubinina, E; Bergman, T; Gustafsson, M; Magnusson, KE; WolfWatz, H				Pettersson, J; Nordfelth, R; Dubinina, E; Bergman, T; Gustafsson, M; Magnusson, KE; WolfWatz, H			Modulation of virulence factor expression by pathogen target cell contact	SCIENCE			English	Article							YERSINIA-PSEUDOTUBERCULOSIS; EPITHELIAL-CELLS; FUNCTIONAL CONSERVATION; SALMONELLA-TYPHIMURIUM; POLARIZED TRANSFER; SHIGELLA-FLEXNERI; IPA INVASINS; SECRETION; PROTEINS; ENTEROCOLITICA	Upon contact with the eukaryotic cell, Yersinia pseudotuberculosis increased the rate of transcription of virulence genes (yop), as determined by in situ monitoring of light emission from individual bacteria expressing luciferase under the control of the yopE promoter, The microbe-host interaction triggered export of LcrQ, a negative regulator of Yop expression, via the Yop-type III secretion system. The intracellular concentration of LcrQ was thereby lowered, resulting in increased expression of Yops. These results suggest a key role for the type III secretion system of pathogenic bacteria to coordinate secretion with expression of virulence factors after physical contact with the target cell.	LINKOPING UNIV,DEPT MED MICROBIOL,S-58185 LINKOPING,SWEDEN	Linkoping University	Pettersson, J (corresponding author), UMEA UNIV,DEPT MOL & CELL BIOL,S-90187 UMEA,SWEDEN.			Magnusson, Karl-Eric/0000-0002-7809-8437				BERGMAN T, 1994, J BACTERIOL, V176, P2619, DOI 10.1128/JB.176.9.2619-2626.1994; Cornelis G., 1992, SGM S, V49, P231; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; FORSBERG A, 1987, MICROB PATHOGENESIS, V2, P123, DOI 10.1016/0882-4010(87)90104-5; FORSBERG A, 1991, MOL MICROBIOL, V5, P977, DOI 10.1111/j.1365-2958.1991.tb00773.x; FORSBERG A, 1993, INFECT AGENT DIS, V2, P275; Forsberg Ake, 1994, Trends in Microbiology, V2, P14, DOI 10.1016/0966-842X(94)90339-5; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HERMANT D, 1995, MOL MICROBIOL, V17, P781, DOI 10.1111/j.1365-2958.1995.mmi_17040781.x; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; Milton DL, 1996, J BACTERIOL, V178, P1310, DOI 10.1128/jb.178.5.1310-1319.1996; NORDFELTH R, UNPUB; OLSSON O, 1988, MOL GEN GENET, V215, P1, DOI 10.1007/BF00331295; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; RIMPILAINEN M, 1992, J BACTERIOL, V174, P3355, DOI 10.1128/jb.174.10.3355-3363.1992; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; ROSQVIST R, 1986, MICROB PATHOGENESIS, V1, P229, DOI 10.1016/0882-4010(86)90047-1; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; STRALEY SC, 1993, MOL MICROBIOL, V8, P1005, DOI 10.1111/j.1365-2958.1993.tb01644.x; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x	26	331	336	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1231	1233		10.1126/science.273.5279.1231	http://dx.doi.org/10.1126/science.273.5279.1231			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703058				2022-12-28	WOS:A1996VE47600041
J	Richman, AD; Uyenoyama, MK; Kohn, JR				Richman, AD; Uyenoyama, MK; Kohn, JR			Allelic diversity and gene genealogy at the self-incompatibility locus in the solanaceae	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; LYCOPERSICON-PERUVIANUM; POPULATION-GENETICS; PAPAVER RHOEAS; S-ALLELES; NATURAL-POPULATIONS; SOLANUM-CHACOENSE; POLYMORPHISM; RIBONUCLEASE; VARIABILITY	The self-incompatibility (S) locus of flowering plants offers an example of extreme polymorphism maintained by balancing selection. Estimates of recent and long-term effective population size (N-e) were determined for two solanaceous species by examination of S-allele diversity. Estimates of recent N-e in two solanaceous species differed by an order of magnitude, consistent with difference in the species' ecology. In one species, the evidence was consistent with historical population restriction despite a large recent N-e. In the other, no severe bottleneck was indicated over millions of years. Bottlenecks are integral to founder-event speciation, and loci that are subject to balancing selection can be used to evaluate the frequency of this mode of speciation.	DUKE UNIV,DEPT ZOOL,DURHAM,NC 27708	Duke University	Richman, AD (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.			Uyenoyama, Marcy/0000-0001-8249-1103	NIGMS NIH HHS [GM 37841] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AI YJ, 1992, PLANT MOL BIOL, V19, P523, DOI 10.1007/BF00023404; AI YJ, 1990, SEX PLANT REPROD, V3, P130, DOI 10.1007/BF00198857; CHUNG IK, 1994, PLANT MOL BIOL, V26, P757, DOI 10.1007/BF00013760; CLARK AG, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P79; CLARK AG, 1991, P NATL ACAD SCI USA, V88, P9823, DOI 10.1073/pnas.88.21.9823; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; Emerson S, 1939, GENETICS, V24, P524; FELSENSTEIN J, 1993, PHYLIP 3 5; HINATA K, 1995, GENETICS, V140, P1099; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; IDE H, 1991, FEBS LETT, V284, P161, DOI 10.1016/0014-5793(91)80675-S; IOERGER TR, 1990, P NATL ACAD SCI USA, V87, P9732, DOI 10.1073/pnas.87.24.9732; IOERGER TR, 1991, SEX PLANT REPROD, V4, P81; JOST W, 1991, EUR J BIOCHEM, V198, P1, DOI 10.1111/j.1432-1033.1991.tb15978.x; KAUFMANN H, 1991, MOL GEN GENET, V226, P457, DOI 10.1007/BF00260659; KHEYRPOUR A, 1990, SEX PLANT REPROD, V3, P88, DOI 10.1007/BF00198851; KLEIN D, 1993, NATURE, V364, P330, DOI 10.1038/364330a0; KLEIN J, 1993, J MED PRIMATOL, V22, P57; Kumar S, 1993, MOL EVOLUTIONARY GEN; LANE MD, 1993, HEREDITY, V71, P596, DOI 10.1038/hdy.1993.184; LAWRENCE MJ, 1993, HEREDITY, V71, P581, DOI 10.1038/hdy.1993.182; LEVIN DA, 1993, HEREDITY, V71, P193, DOI 10.1038/hdy.1993.124; LEWIS D, 1951, HEREDITY, V5, P399, DOI 10.1038/hdy.1951.39; MANTEL N, 1974, BIOMETRICS, V30, P355; NEI M, 1989, MOL BIOL EVOL, V6, P290; ODONNELL S, 1993, HEREDITY, V71, P591, DOI 10.1038/hdy.1993.183; OLMSTEAD RG, 1994, SYST BIOL, V43, P467, DOI 10.2307/2413546; PAXMAN GJ, 1963, GENETICS, V48, P1029; RICHMAN AD, 1995, HEREDITY, V75, P405, DOI 10.1038/hdy.1995.153; RICHMAN AD, IN PRESS HEREDITY; ROYO J, 1994, P NATL ACAD SCI USA, V91, P6511, DOI 10.1073/pnas.91.14.6511; ROYO J, 1994, PLANT PHYSIOL, V105, P751, DOI 10.1104/pp.105.2.751; SABAELLEIL MK, 1994, PLANT MOL BIOL, V24, P571, DOI 10.1007/BF00023555; TAKAHATA N, 1990, P NATL ACAD SCI USA, V87, P2419, DOI 10.1073/pnas.87.7.2419; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TAKAHATA N, 1990, P NATL ACAD SCI USA, V87, P1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UYENOYAMA MK, 1995, GENETICS, V139, P975; VEKEMANS X, 1994, GENETICS, V137, P1157; WRIGHT S, 1960, BIOMETRICS, V16, P61, DOI 10.2307/2527956; Wright S, 1939, GENETICS, V24, P538; XU BB, 1990, MOL GEN GENET, V224, P341, DOI 10.1007/BF00262427; YOKOYAMA S, 1982, HEREDITY, V48, P299, DOI 10.1038/hdy.1982.35	44	133	134	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1212	1216		10.1126/science.273.5279.1212	http://dx.doi.org/10.1126/science.273.5279.1212			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703052				2022-12-28	WOS:A1996VE47600035
J	McKalip, DM; Gudeman, SK				McKalip, DM; Gudeman, SK			Intraventricular rupture of a cerebral abscess	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											McKalip, DM (corresponding author), UNIV N CAROLINA,CHAPEL HILL,NC 27599, USA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					639	639		10.1056/NEJM199608293350906	http://dx.doi.org/10.1056/NEJM199608293350906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8692239				2022-12-28	WOS:A1996VD42500006
J	Macdonald, W; Newnham, J; Gurrin, L; Evans, S				Macdonald, W; Newnham, J; Gurrin, L; Evans, S			Effect of frequent prenatal ultrasound on birthweight: Follow up at 1 year of age	LANCET			English	Letter									UNIV WESTERN AUSTRALIA,KING EDWARD MEM HOSP WOMEN,TVW TELETHON INST CHILD HLTH RES,PERTH,WA 6009,AUSTRALIA; UNIV WESTERN AUSTRALIA,KING EDWARD MEM HOSP WOMEN,WOMENS & INFANTS RES FDN,PERTH,WA 6009,AUSTRALIA	King Edward Memorial Hospital; Telethon Kids Institute; University of Western Australia; King Edward Memorial Hospital; University of Western Australia			Study, Raine/K-4517-2013					Evans S, 1996, EARLY HUM DEV, V45, P203, DOI 10.1016/0378-3782(96)01728-8; HAMILL PVV, 1977, DHEW PHS PUBLICATION; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H	3	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					482	482		10.1016/S0140-6736(05)64587-4	http://dx.doi.org/10.1016/S0140-6736(05)64587-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709817				2022-12-28	WOS:A1996VC67300066
J	Katoh, J; Tsuchiya, K; Sato, W; Nakajima, M; Iida, Y				Katoh, J; Tsuchiya, K; Sato, W; Nakajima, M; Iida, Y			Cimetidine and immunoreactivity	LANCET			English	Letter							CARDIOPULMONARY BYPASS				Katoh, J (corresponding author), YAMANASHI CENT HOSP,DEPT CARDIOVASC SURG,KOFU,YAMANASHI 400,JAPAN.							LYDYARD P, 1996, IMMUNOLOGY, P2; MARKEWITZ A, 1993, J THORAC CARDIOV SUR, V105, P15, DOI 10.1016/S0022-5223(19)33842-5; MATSUMOTO S, 1995, LANCET, V346, P115, DOI 10.1016/S0140-6736(95)92136-2; NGUYEN DM, 1992, ANN THORAC SURG, V53, P611, DOI 10.1016/0003-4975(92)90319-Y; SAHASRABUDHE DM, 1987, J IMMUNOL, V138, P2760	5	12	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					404	405		10.1016/S0140-6736(05)65021-0	http://dx.doi.org/10.1016/S0140-6736(05)65021-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709749				2022-12-28	WOS:A1996VB42600042
J	Ramsay, LE; Haq, IU; Jackson, PR; Yeo, WW; Pickin, DM; Payne, JN				Ramsay, LE; Haq, IU; Jackson, PR; Yeo, WW; Pickin, DM; Payne, JN			Targeting lipid-lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table	LANCET			English	Article							HEART-DISEASE; RISK		SHEFFIELD CTR HLTH & RELATED RES, MED CARE RES UNIT, SHEFFIELD, S YORKSHIRE, ENGLAND; SHEFFIELD HLTH, DEPT PUBL HLTH, SHEFFIELD, S YORKSHIRE, ENGLAND	University of Sheffield	Ramsay, LE (corresponding author), ROYAL HALLAMSHIRE HOSP, DEPT MED & PHARMACOL, SECT CLIN PHARMACOL & THERAPEUT, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND.		Payne, Nick/A-3073-2010	Yeo, Wilfred/0000-0001-9554-5203				GROVER SA, 1995, JAMA-J AM MED ASSOC, V274, P801, DOI 10.1001/jama.274.10.801; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; HAQ IU, IN PRESS CLIN SCI; PEDERSEN TR, 1994, LANCET, V344, P1383; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	5	122	123	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1996	348	9024					387	388		10.1016/S0140-6736(96)05516-X	http://dx.doi.org/10.1016/S0140-6736(96)05516-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709740				2022-12-28	WOS:A1996VB42600016
J	Stevenson, RD				Stevenson, RD			Stress-related growth failure	LANCET			English	Editorial Material											Stevenson, RD (corresponding author), UNIV VIRGINIA,SCH MED,KLUGE CHILDRENS REHABIL CTR & RES INST,CHARLOTTESVILLE,VA 22903, USA.							POWELL GF, 1967, NEW ENGL J MED, V276, P1279, DOI 10.1056/NEJM196706082762302; POWELL GF, 1967, NEW ENGL J MED, V276, P1271, DOI 10.1056/NEJM196706082762301	2	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					348	348		10.1016/S0140-6736(05)64984-7	http://dx.doi.org/10.1016/S0140-6736(05)64984-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709726				2022-12-28	WOS:A1996VB42600002
J	MacAuley, D				MacAuley, D			Fortnightly review - Drugs in sport	BRITISH MEDICAL JOURNAL			English	Article							ANABOLIC-STEROID USE; BODY-BUILDERS; ADOLESCENTS; GAMES; ABUSE; PERFORMANCE; PREVALENCE		BRITISH JOURNAL SPORTS MED,LONDON WC1H 9JR,ENGLAND									BERGLUND B, 1987, INT J SPORTS MED, V8, P231, DOI 10.1055/s-2008-1025661; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; CATLIN DH, 1987, CLIN CHEM, V33, P319; CHAN SC, 1991, CLIN CHEM, V37, P1289; DELBEKE FT, 1995, INT J SPORTS MED, V16, P66, DOI 10.1055/s-2007-972966; ELASHOFF JD, 1991, ANN INTERN MED, V115, P387, DOI 10.7326/0003-4819-115-5-387; KICMAN AT, 1994, CLIN CHEM, V40, P2084; KOMOROSKI EM, 1992, AM J DIS CHILD, V146, P823, DOI 10.1001/archpedi.1992.02160190055019; KRUSE P, 1986, J APPL PHYSIOL, V61, P417, DOI 10.1152/jappl.1986.61.2.417; Lombardo JA, 1996, BRIT J SPORT MED, V30, P82, DOI 10.1136/bjsm.30.2.82; MCKILLOP G, 1987, SCOT MED J, V32, P39, DOI 10.1177/003693308703200204; PARK JS, 1991, J SPORT MED PHYS FIT, V31, P303; Perry H M, 1992, Br J Sports Med, V26, P259; RAYNAUD E, 1992, LANCET, V340, P1468, DOI 10.1016/0140-6736(92)92657-2; RICKERT VI, 1992, CLIN PEDIATR, V31, P723, DOI 10.1177/000992289203101206; SCARPINO V, 1990, LANCET, V336, P1048, DOI 10.1016/0140-6736(90)92502-9; *SPORTS COUNC, 1995, DOP CONTR UK SURV EX; *SPORTS COUNC DOP, 1994, SUGG FURTH READ; *SPORTS COUNC DOP, 1994, INT OL COMM ACCR LAB; *SPORTS COUNC DOP, 1994, INT OL COMM DOP CLAS; *SPORTS COUNC DOP, 1995, GUID ALL MED; *SPORTS COUNC DOP, 1993, UK LEG DOP SUBST; *SPORTS COUNC DOP, 1993, AN STER; *SPORTS COUNC DOP, 1996, 1995 96 SPORTS COUNC; SPRIET LL, 1995, INT J SPORT NUTR, V5, pS84, DOI 10.1123/ijsn.5.s1.s84; TERNEY R, 1990, AM J DIS CHILD, V144, P99, DOI 10.1001/archpedi.1990.02150250111046; TRICKER R, 1989, J DRUG EDUC, V19, P313, DOI 10.2190/EGT5-4YWD-QX15-FLKK; VANDERMERWE PJ, 1992, S AFR MED J, V82, P151; WHITEHEAD R, 1992, J FAM PRACTICE, V35, P401; WINDSOR R, 1989, MED SCI SPORT EXER, V21, P494	30	10	10	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					211	215		10.1136/bmj.313.7051.211	http://dx.doi.org/10.1136/bmj.313.7051.211			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696200	Green Published			2022-12-28	WOS:A1996VA12600030
J	PerezMartin, J; deLorenzo, V				PerezMartin, J; deLorenzo, V			ATP binding to the sigma(54)-dependent activator XyIR triggers a protein multimerization cycle catalyzed by UAS DNA	CELL			English	Article							INTEGRATION HOST FACTOR; TRANSCRIPTIONAL REGULATOR XYLR; RHIZOBIUM-MELILOTI DCTD; AMINO-TERMINAL DOMAIN; ESCHERICHIA-COLI; RNA-POLYMERASE; PSEUDOMONAS-PUTIDA; TOL PLASMID; AROMATIC-COMPOUNDS; TRUNCATED FORM	The events that take place at the prokaryotic enhancer of the Po promoter of Pseudomonas putida prior to the engagement of the sigma(54)-RNA polymerase (sigma(54)-RNAP) have been studied in vitro. ATP hydrolysis by XylR, the cognate regulator of the system, is preceded by the multimerization of XylR at the enhancer, which is itself triggered by the sole allosteric effect of ATP binding to the protein. Since ADP is unable to support multimerization, ATP hydrolysis might be followed by a return to the nonmultimerized state. This notion is supported further by the properties of mutant proteins that seem to be frozen, in either the nonmultimerized or the multimerized state, respectively. These results support a cyclic mechanism of ATP-dependent association/dissociation of XylR at the promoter UAS that precedes any involvement of the polymerase in transcription initiation.	CSIC,CTR INVEST BIOL,E-28049 MADRID,SPAIN; CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Perez-Martin, Jose/K-5117-2014	Perez-Martin, Jose/0000-0001-9849-7382; de Lorenzo, Victor/0000-0002-6041-2731				ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; AUSTIN S, 1990, EUR J BIOCHEM, V187, P353, DOI 10.1111/j.1432-1033.1990.tb15312.x; AUSTIN S, 1994, J BIOL CHEM, V269, P18141; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; DELGADO A, 1994, J BIOL CHEM, V269, P8059; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; HOOPER S, 1994, J BIOL CHEM, V269, P19597; HOOPER S, 1995, J BACTERIOL, V177, P2798; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; LEE HS, 1993, P NATL ACAD SCI USA, V90, P2266, DOI 10.1073/pnas.90.6.2266; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; LEE JH, 1994, J BIOL CHEM, V269, P20401; MARQUES S, 1993, MOL MICROBIOL, V9, P923, DOI 10.1111/j.1365-2958.1993.tb01222.x; Maxam A M, 1980, Methods Enzymol, V65, P499; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PerezMartin J, 1996, J MOL BIOL, V258, P562, DOI 10.1006/jmbi.1996.0269; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; PEREZMARTIN J, 1995, J BACTERIOL, V177, P3758, DOI 10.1128/jb.177.13.3758-3763.1995; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P9392, DOI 10.1073/pnas.92.20.9392; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGTH S, 1988, CELL, V62, P945; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; SHINGLER V, 1994, J BACTERIOL, V176, P1555, DOI 10.1128/jb.176.6.1555-1560.1994; SHINGLER V, 1995, MOL MICROBIOL, V17, P505, DOI 10.1111/j.1365-2958.1995.mmi_17030505.x; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; WEBB MR, 1992, PHILOS T ROY SOC B, V336, P19, DOI 10.1098/rstb.1992.0039; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; XIAO YX, 1994, J BACTERIOL, V176, P1025, DOI 10.1128/JB.176.4.1025-1036.1994	55	75	75	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					331	339		10.1016/S0092-8674(00)80104-X	http://dx.doi.org/10.1016/S0092-8674(00)80104-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706137	Bronze			2022-12-28	WOS:A1996UZ97200018
J	Barker, S				Barker, S			Brain science benefits from budget plan	NATURE			English	News Item																		1995, NATURE, V378, P227	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					105	105		10.1038/382105a0	http://dx.doi.org/10.1038/382105a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700193	Bronze			2022-12-28	WOS:A1996UW67200015
